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PREFACE
Allergic diseases are affecting the lives of more than one billion people worldwide. With an epidemic 
rise during the last 60 years, their prevalence is expected to reach up to 4 billion in 2050s. Because of 
immense numbers of affected individuals, the general public confronts huge direct and indirect costs 
with major effects on macroeconomics due to health-care, loss of productivity and absenteeism of 
patients. Unfortunately, high number of unmet needs due to missing scientific knowledge in disease 
mechanisms, prevention, patient care, and social determinants remain to be resolved.
To tackle this huge global health problem, we as the EAACI decided to develop the “Global Atlas of Al-
lergy” as a follow up of our “Global Atlas of Asthma” which was launched last year. With this Atlas, we 
aimed to gather evidence to call attention to the burden of allergic diseases; to warrant their recog-
nition as a main concern in national health strategies; to reveal their priority for research; to describe 
environmental factors; to evaluate the best ways to prevent and control allergies; to provide guidance 
on how to overcome barriers; to alert the political bodies to ensure global management approaches.
The EAACI Global Atlas of Allergy contains 139 chapters written by 183 authors with 274 illustra-
tions and 100 tables. It is developed as a desktop reference for multisectoral usage covering all as-
pects of allergic diseases from allergens, epidemiology, risk factors and molecular and cellular mecha-
nisms to their management, major current problems in allergies and associated  diseases, prevention 
and control of allergic diseases. In addition, the Atlas will offer an educational tool and a desktop 
reference for medical students, allied health workers, primary care physicians, medical industry, pol-
icy makers, patient organizations and specialists dealing with allergies and co-morbid diseases. We 
would like to thank all of the authors for their contributions.
Cezmi A. Akdis
Ioana Agache
Editors
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s • The term “Allergy” was first coined on July 24, 1906 as 
“specifically altered reactivity of the organism
• Today, we define allergy as an immunologically-mediated and 
allergen-specific hypersensitivity
• Allergies can be seen in almost every organ, most commonly in 
the skin and the mucous membranes
• Allergology is the science regarding allergic diseases and their 
differential diagnoses and mechanisms
The term “Allergy” was born on 
July 24, 1906 in the Münchener 
Medizinische Wochenschrift as 
“specifically altered reactivity of 
the organism”. Today, we define al-
lergy as immunological hypersen-
sitivity that can lead to a variety 
of different diseases via different 
pathomechanisms and thus differ-
ent approaches in diagnosis, ther-
apy and prevention can be taken. 
(Table 1). Several misconceptions 
can be delineated (Table 2). 
Allergology is the science regard-
ing allergic diseases and their 
differential diagnoses and mech-
anisms. It requires clinical experi-
ence in allergic diseases, basic un-
derstanding of the immune system 
in physiology and pathology and 
finally extensive knowledge of en-
vironmental factors in eliciting or 
modulating allergic reactions.
Allergy is not a disease itself, but 
a mechanism leading to disease. 
In clinical practice, allergy mani-
fests in form of various different 
conditions such as anaphylaxis, 
urticaria, angioedema, allergic rhi-
noconjunctivitis, allergic asthma, 
serum sickness, allergic vasculitis, 
hypersensitivity pneumonitis, at-
opic dermatitis (eczema), contact 
dermatitis and granulomatous 
Johannes Ring  
Technische Universität München  
München, Germany
WHAT IS ALLERGY1
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What is allergy
Figure 1 The word “allergy” first appeared on July 24, 1906 in the Münchener 
Medizinische Wochenschrift in an essay written by Clemens von Pirquet, a 
pediatrician from Vienna. (Reproduced with permission from Ring J: Allergy in 
Practice. Springer Berlin, Heidelberg, New York, 2005.)
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What is allergy
Figure 2 Classification of environmentally related health these disorders. (Reproduced with permission from Ring J: Allergy 
in Practice. Springer Berlin, Heidelberg, New York, 2005.)
reactions, as well as the colorful 
spectrum of food- or drug – in-
duced hypersensitivity reactions. 
Allergies can be seen in almost 
every organ. Most commonly, 
however, it is the skin and the mu-
cous membranes that are involved 
since they represent the frontier 
between the individual organism 
and its environment.
Allergy often starts in the first 
three months of life but very 
rarely at birth, although there is a 
strong genetic background. Aller-
gy in some cases does not persist 
over life-time; it starts and some 
patients may out grow their al-
lergic disease spontaneously. We 
should study these patients in-
tensively, who spontaneously lose 
their allergy. Many allergic diseas-
es have a chronic course, but there 
are ways to cure. Allergic diseases 
can be influenced by psychological 
processes in a positive or in a neg-
ative way. 
KEY REFERENCES
1. Bergmann KC, Ring J. History of Al-
lergy. Basel:Karger, 2014 – in press.
2. Johansson SGO, Bieber C, Dahl R, 
Friedmann PS, Lanier BQ, Lockey 
RF et al. Revised nomenclature for 
allergy for global use: Report of the 
nomenclature committee of the 
World Allergy Organization. J Al-
lergy Clin Immunol 2004; 113: 832-
836.
3. Ring J. Allergy in Practice. Berlin: 
Springer, 2005.
4. Adkinson NF, Bochner BS, Burks 
AW, Busse WW, Holgate ST, Le-
manske LF, O’Hehir RE. Middleton’s 
Allergy Principles and Practice. 
8th edition. Philadelphia: Elsevier 
2014.
5. Ring J, Akdis C, Behrendt H, Lauen-
er RP, Schäppi G, Akdis M et al. 
Davos declaration: allergy as a glob-
al problem. Allergy 2012;67:141-
143.
TABLE 1
Definitions of terms frequently used in allergy
Sensitivity Normal response to a stimulus
Hypersensitivity Abnormally strong response to a stimulus
Sensitation Development of increased sensitivity after repeated 
contact
Allergy Immunologically mediated hypersensitivity leading to 
disease
Anaphylaxis severe, life-threatening, generalized or systemic 
hypersensitivity reaction
TABLE 2
The most common misconceptions 
of allergy
• natural reaction
• a symptom or sign (e.g. rhinitis)
• incompatibility of toxic/irritant 
substances (e.g. tobacco smoke)
• psychological aversion
• incurable
Enviroment-induced disease
Toxicity  
of a substance
Hypersensitivity 
of the individuum
non- 
immune
immune 
mediated
Irritation, 
Intoxication, 
chronic 
damage
AllergyIntolerance
Psycho- 
neurogenic 
reaction
Idio- 
syncrasy
4Global atlas oF allerGy
se
c
t
io
n
 a
 - 
A
lle
rg
y 
 - 
fr
o
m
 g
en
et
ic
s 
to
 m
ec
h
an
is
m
s • In 1921, Prausnitz and Küstner demonstrated passive 
sensitization of the skin, since then referred to as the PK-test
• In the 1960’s K. and T. Ishizaka published several articles 
describing an antiserum that could block the PK-test indicating 
that it reacted with regain
• In 1965 S.G.O. Johansson in Uppsala detected in the serum of a 
myeloma patient an M-component that could not be identified as 
any of the 4 known immunoglobulin classes
• The discovery of IgE and the understanding of the IgE-mediated 
inflammation, allergic asthma and rhino-conjunctivitis, food 
allergy and eczema has had a significant impact on diagnosis and 
treatment of allergy 
Allergic asthma and rhinitis were 
already recognized in the 19th 
century, but the mechanisms be-
hind the diseases were not under-
stood. In 1919 Ramirez noticed 
that blood transfusion could trans-
fer allergic asthma and passively 
sensitize the recipient. In 1921, 
Prausnitz and Küstner demon-
strated passive sensitization of 
the skin, since then referred to as 
the PK-test.
The search for reagin, the factor 
in plasma causing the positive PK-
test, was unsuccessful for about 
45 years and some rather confus-
ing proposals were published, e.g. 
identifying reagin as IgA. In the 
1960’s K. and T. Ishizaka published 
several articles describing an an-
tiserum that could block the PK-
test indicating that it reacted with 
reagin. They referred to this anti-
serum as anti-γE. Not surprisingly 
considering the very low serum 
concentration of IgE, they did not 
succeed in isolating their γE.
In 1965 S.G.O. Johansson in 
Uppsala detected in the serum of a 
myeloma patient an M-component 
that could not be identified as any 
of the 4 known immunoglobulin 
classes. Working with H. Bennich, 
the unique immunological and 
physicochemical characteristics 
S.G.O. Johansson  
Karolinska Institute 
Stockholm, Sweden
THE DISCOVERY OF IgE2
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The discovery of IgE
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of the new immunoglobulin, pro-
visionally labelled IgND after the 
initials of the patient, were docu-
mented and published. Very small 
amounts of IgND did, in dose-re-
sponse, block the PK-test and the 
active structure was located in the 
Fc-fragment. A sensitive radio-im-
muno assay was developed for 
IgND. Extremely low serum con-
centrations, in the order of a few 
nanograms per ml, were found in 
healthy individuals but, interest-
ingly, 10-100 fold higher levels 
were found in allergic individuals.
Purified IgND was sent to the 
Ishizakas in 1967 and was found 
to react with their anti-γE. In Feb-
ruary 1968 the WHO Internation-
al Reference Centre in Lausanne, 
where studies on IgND had been 
performed for some months, in-
vited the two groups to a meeting 
to review comparative laboratory 
studies of IgND and γE, resulting 
in the publication of the official re-
port on the fifth immunoglobulin 
class, IgE.
The discovery of IgE has had a 
significant impact on the diagno-
sis and management of allergic 
disease, enabling clinicians to dif-
ferentiate between IgE-mediated 
allergic diseases and other hyper-
sensitivity reactions, and to man-
age allergic diseases according 
to their underlying mechanisms. 
Tests became available that al-
lowed a more simple and reliable 
diagnosis covering a very broad 
spectrum of allergens. The char-
acterization and standardization 
of allergen preparations for clini-
cal diagnosis and allergen specific 
immunotherapy, ASIT, improved 
although there is still much to do 
in this area. An injectable mon-
oclonal anti-IgE is now available 
that eliminates IgE and has an im-
portant role in the management 
of severe allergic asthma, severe 
food allergy and chronic urticaria.
KEY REFERENCES
1. Ramirez MA. Horse asthma fol-
lowing blood transfusion. JAMA 
1919;73:984.
2. Prausnitz C, Küstner H. “Studien 
über die Ueberempfindlichkeit”, 
Zentralbl Bakteriol 1921;86:160–
169.
3. Ishizaka K, Ishizaka T. Identifica-
tion of γE-antibodies as a carri-
er of reaginic activity. J Immunol 
1967;99:1187.
4. Johansson SGO, Bennich H. Im-
munological studies of an atypical 
(myeloma) immunoglobulin. Immu-
nology 1967;13:381-394.
5. Stanworth DR, Humphrey JH, Ben-
nich H, Johansson SGO. Specific 
inhibition of the Praunitz-Küstner 
reaction by an atypical human my-
eloma protein. Lancet 1967;2:330-
332.
6. Bennich H, Ishizaka K, Johans-
son SGO, Rowe DS, Stanworth 
DR, Terry WD. Immunoglobulin 
E, a new class of human immuno-
globulins. Bull World Health Organ 
1968;38:151-152.
Figure 1 From left L. Wide, H. Bennich and S.G.O. Johansson presenting RAST in 1974.
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producing IgE antibodies is called a primary sensitizer
• Pro-allergenic properties of a protein cannot be separated from 
the individual being exposed or from the context of exposure
• Several structural and functional properties have been identified 
that contribute to allergenicity 
• There is not a single common denominator for allergenicity
Patients with type I allergy make 
IgE antibodies against some, but 
not against all environmental or 
dietary proteins they are exposed 
to. In fact, most allergens belong 
to a rather limited number of pro-
tein families. 
Can we identify common struc-
tural or functional properties of 
proteins that turn them into al-
lergens? Before answering this 
question, it is important to clearly 
define what an allergen is. An ab-
solute prerequisite for a molecule 
to be designated an allergen is for 
it to bind specific IgE antibodies. 
Not every protein fulfilling that 
requirement is however also ca-
pable of instructing the immune 
system to start producing these 
IgE antibodies, i.e. of being a pri-
mary sensitizer (Figure 1). Clear 
examples of allergens not able to 
do so are those in fruits, nuts and 
vegetables that are cross-reactive 
with the major birch pollen Bet v 
1. Their allergenicity is dependant 
on their structural (and functional) 
similarity to their “parent” mole-
cule Bet v 1, the primary sensitizer. 
The more intriguing question is 
however, what determines wheth-
er a protein is capable of being the 
primary sensitizer. The answer to 
this question is complex, because 
Ronald van Ree  
Academic Medical Center 
Amsterdam, The Netherlands
ALLERGENS – STRUCTURE 
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Allergens – structure and function
potential endogenous pro-aller-
genic properties of a protein can-
not be seen in isolation from the 
individual being exposed and from 
the context of exposure, which 
includes timing and dose of expo-
sure, and the presence of co-fac-
tors that may act as pro-allergenic 
or anti-allergenic adjuvants (Fig-
ure 2). 
With that in mind, are there com-
mon endogenous structural or 
functional properties that deter-
mine allergenicity? Glycosylation 
per se has often been mentioned 
as marker for allergenicity, but 
convincing evidence for such a 
general claim cannot be found. 
Some properties of proteins, in-
cluding specific types of glycosyla-
tion and binding of lipids, seem to 
determine their role as allergens 
via interaction with the innate 
immune system. Many known al-
lergens are indeed lipid binding 
proteins (e.g. Bet v 1 and homo-
logues, house dust mite group 2 
allergens, lipocalins of pets, plant 
lipid transfer proteins), and some 
are glycoproteins (e.g. peanut Ara 
h 1 and grass pollen Phl p 1). Their 
lipid ligands and conjugated gly-
cans have been shown to interact 
with pathogen recognition recep-
tors such as Toll-like receptors and 
C-type lectins on antigen-present-
ing cells, thereby skewing the im-
mune systems towards Th2-type 
responses and IgE production 
(Figure 3). In addition, protease 
activity such as of the cysteine 
protease Der p 1 has been shown 
to drive Th2 inflammation. It is 
important to note that all these in-
nate Th2-skewing properties may 
also turn other proteins without 
these pro-allergenic properties 
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ous exposure. 
In summary, several structural and 
functional properties have been 
identified that contribute to aller-
genicity, but it is safe to say that 
there is not a single common de-
nominator for allergenicity.
KEY REFERENCES
1. Chapman MD, Pomés A, Breitened-
er H, Ferreira F. Nomenclature and 
structural biology of allergens. J Al-
lergy Clin Immunol 2007;119:414-
420.
2. Vieths S, Scheurer S, Ballmer-We-
ber B. Current understanding 
of cross-reactivity of food aller-
gens and pollen. Ann N Y Acad Sci 
2002;964:47-68.
3. Thomas WR. Innate affairs of aller-
gens. Clin Exp Allergy 2013;43:152-
163.
4. Chapman MD, Wünschmann S, 
Pomés A. Proteases as Th2 ad-
juvants. Curr Allergy Asthma Rep 
2007;7:363-367.
Figure 1 Panel A illustrates the minimum requirements for a molecule to be designated as an allergen: it binds IgE 
antibodies Panel B and C depict the two identities an allergen can have: it can itself act as primary sensitizer (orange in 
panel B and C), or it cannot and binds IgE only based on cross-reactivity with the primary sensitizer (blue in panel C).
Allergens – structure and function
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Figure 2 Sensitization is a complex interplay of the individual exposed (inherited risk of becoming allergic), the timing 
of exposure (earlier in life the immune system is more susceptible to sensitization but also to induction of tolerance), the 
dose (high early life exposure may skew towards tolerance), the context of exposure (environmental exposures such as 
pollution, microbes, parasites, diet, lifestyle) and endogenous properties of the protein.
Figure 3 Allergens can interact via various mechanisms with dendritic cells skewing them towards a DC2 phenotype, 
which in turn skews adaptive immunity towards Th2 and IgE production.
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• The innate immune system plays a fundamental role in shaping 
the response to potentially allergenic proteins
• Allergic sensitization, a multifactorial process, is influenced by a 
protein’s biological and molecular features and by the interaction 
pathway/s with the immune system
• Proteins interact with Toll-like-, C-type lectin-, NOD-like-, and 
protease-activated receptors (present on epithelial cells and 
dendritic cells) or with surfactant proteins (present in soluble 
form) to manifest their allergenicity
• Lipids (directly bound by allergens, present in the allergen 
source, or originating from microbial contaminations) modulate 
the immune response of predisposed individuals by interacting 
with the innate immune system
Allergens interact with various 
parts of the innate immune sys-
tem which plays a fundamental 
role in shaping adaptive immune 
responses (Figure 1). The innate 
immune system comprises sever-
al cell types that express pattern 
recognition receptors (PRRs). 
PRRs recognize pathogen- or 
damage-associated molecular 
patterns (PAMPs, DAMPs) which 
frequently accompany allergens.
MEMBRANE-ASSOCIATED, 
CYTOPLASMIC AND SOLUBLE 
PRRS
Toll-like receptors (TLR) are a 
conserved family of PRRs. The al-
lergens Der p 2 (house-dust mite), 
Fel d 1 (cat), and Can f 6 (dog) 
bind lipopolysaccharide (LPS) and 
interact with TLR4, shifting the 
LPS-response curve to a Th2-in-
ducing range. Bacterial contami-
nations present on pollen, shown 
for ryegrass and Parietaria, are 
responsible for triggering TLR2, 
TLR4 and TLR9 signaling. C-type 
lectin receptors contain carbohy-
drate recognition domains that 
bind glycosylated allergens and 
trigger pathways that determine 
T-cell polarization. Ara h 1 (pea-
nut), Der p 1 (house dust mite) 
and Can f 1 (dog) interact with 
the C-type lectin receptor DC-
Heimo Breiteneder  
Medical University of Vienna 
Vienna, Austria
MECHANISMS OF 
ALLERGENICITY OF 
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Mechanisms of allergenicity of allergens
SIGN; Ara h 1, Der p 1 and 2, Fel d 
1, Can f 1 and Bla g 2 (cockroach) 
with the mannose receptor. Pro-
tease-activated receptors (PARs) 
signal in response to extracelluar 
proteases. Allergens of house dust 
mite (Der p 1, -3, -9) and mold (Pen 
c 13) activate PAR-2 and induce IL-
25 and thymic stromal lymphopoi-
etin (TSLP).
NOD-like receptors (NLRs) sense 
cytoplasmic PAMPs and DAMPs. 
Some NLRs are core components 
of inflammasomes, protein com-
plexes involved in generating the 
pro-inflammatory cytokines IL-
1β and IL-18. Inflammasomes are 
triggered by Der p 1, Api m 4 (bee), 
and Ambrosia artemisiifolia pollen 
extracts.
Surfactant associated proteins 
(SP), found in the alveoli of the 
lungs, bind inhaled glycosylat-
ed allergens via a carbohydrate 
recognition domain. Der p 1 and 
Der f 1 degrade SP-A resulting in 
increased degranulation of mast 
cells and basophils triggered by 
these allergens.
CELLS OF THE INNATE IMMUNE 
SYSTEM
Epithelial cells function as phys-
ical barrier whose tight junction 
proteins are degraded by proteas-
es including Der p 1 and Act d 1 
10
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(kiwi). Following allergen contact, 
epithelial cells produce TSLP, IL-
25 and IL-33 and instruct dendrit-
ic cells to induce Th2 responses. 
Dendritic cells bridge innate and 
adaptive immunity and polarize 
the T helper cell response (5). Po-
larization towards a Th2 response 
in dendritic cell-T cell co-cultures 
has been shown for Bet v 1 (birch 
pollen) and Pru p 3 (peach) when 
cells were derived from allergic 
donors. Invariant natural killer T 
cells (iNKTs) recognize lipids pre-
sented by CD1d (6). They secrete 
IL-4, -5 and -13 when presented 
lipids from Brazil nut or sphingo-
myelin from milk. Co-delivery of 
certain lipids and potentially aller-
genic proteins determine the out-
come of the sensitization process.
KEY REFERENCES
1. Thomas WR. Innate affairs of aller-
gens. Clin Exp Allergy 2013;43:152-
163.
2. Dai X, Sayama K, Tohyama M, Shi-
rakata Y, Hanakawa Y, Tokumaru S 
et al. Mite allergen is a danger signal 
for the skin via activation of inflam-
masome in keratinocytes. J Allergy 
Clin Immunol 2011;127:806-814.
3. Dombrowski Y, Peric M, Koglin 
S, Kaymakanov N, Schmezer 
V, Reinholz M et al. Honey bee 
(Apis mellifera) venom induces 
AIM2 inflammasome activation 
in human keratinocytes. Allergy 
2012;67:1400-1407.
4. Varga A, Budai MM, Milesz S, 
Bácsi A, Tőzsér J, Benkő S. Rag-
weed pollen extract intensifies 
lipopolysaccharide-induced prim-
ing of NLRP3 inflammasome in 
human macrophages. Immunology 
2013;138:392-401.
5. Hammad H, Lambrecht BN. Den-
dritic cells and airway epithelial cells 
at the interface between innate and 
adaptive immune responses. Allergy 
2011;66:579-587.
6. Brennan PJ, Brigl M, Brenner MB. 
Invariant natural killer T cells: an 
innate activation scheme linked to 
diverse effector functions. Nat Rev 
Immunol 2013;13:101-17.
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Figure 1 Simplified model of innate immune mechanisms activated by allergens. Examples are given for interactions 
of allergens with Toll-like receptors (TLRs) via binding by the allergen or co-delivery of bacterial compounds (LPS: 
lipopolysaccharide. LTA: lipoteichoic acid); with C-type lectin receptors via carbohydrate moieties present on allergens; 
with protease-activated receptor (PAR) 2 via the allergens’ proteolytical activity; and with inflammasome complexes 
(2-4). In addition, the presentation of lipids from the allergen source by CD1d to invariant natural killer T cells, which 
enhances sensitization or in some cases even drives it, is shown.
Mechanisms of allergenicity of allergens
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• Members of the same protein family may share IgE and T cell 
epitopes, which can cause allergic reactions by cross-reactivity
• Shared IgE epitopes between inhalant allergens and food 
allergens can induce an immediate IgE-mediated reaction 
confined to the oral cavity, known as the oral allergy syndrome
• Cross-reactivity at the T cell level represents one of the 
mechanisms of worsening of atopic eczema in birch-pollen 
allergic patients
• Immunological cross-reactivity is explored as a possible cure 
for allergy, by inducing cross-reactive regulatory T cells and/or 
cross-reactive blocking IgG4 antibodies
Allergens belong to a relatively low 
number of different protein fami-
lies according to intrinsic features, 
e.g. similar amino acid sequenc-
es and/or 3-dimensional folding. 
Members of the same protein fami-
ly may share IgE and T cell epitopes, 
which by cross-reactivity can cause 
allergic reactions. In this context, 
birch pollen-related food allergy 
has been well studied. This special 
form of food allergy affects more 
than 70% of birch pollen-allergic 
patients and is one of the most fre-
quent food allergies in adults. 
Bet v 1, the single major birch pol-
len allergen belongs to the patho-
genesis-related protein family 10 
and homologous molecules are 
present in various foods, e.g. Mal d 
1 in apple, Pru av 1 in cherry, Gly m 
4 in soy and Ara h 8 in peanut. Al-
though these proteins derive from 
plant species non-related to birch 
trees, their primary and tertiary 
structures are highly homologous 
with Bet v 1. 
Bet v 1 contains mainly confor-
mational IgE-epitopes, as destruc-
tion of its 3-dimensional structure 
leads to a dramatic reduction of 
its IgE-binding capacity. Due to 
similar protein folding, Bet v 1 - 
homologs contain surface patch-
es forming epitopes that may be 
Barbara Bohle  
Medical University of Vienna 
Vienna, Austria 
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Allergens and cross-reactivity
recognized by Bet v 1 - specific IgE 
antibodies (Figure 1A). Although 
not all IgE-epitopes are shared, 
Bet v 1 - related food allergens 
contain sufficient epitopes to 
achieve cross-linkage of IgE bound 
to the surface of mast cells and 
basophils. In most cases, this in-
duces the oral allergy syndrome, 
an immediate IgE-mediated re-
action confined to the oral cavity. 
Destruction of the 3-dimensional 
protein structure, e.g. by gastroin-
testinal degradation or heat pro-
cessing, reduces IgE cross-reac-
tivity, which explains why cooked 
foods containing Bet v 1-related 
proteins usually are tolerated by 
birch pollen-allergic patients. 
Cross-reactivity at the T cell level 
depends on amino acid sequence 
homologies. After uptake by anti-
gen-presenting cells, allergens are 
degraded into short linear pep-
tides, which are then loaded onto 
MHC class II molecules to be pre-
sented to T cells (Figure 1B). Pro-
teins with homologous amino acid 
sequences are processed in analog 
fashion resulting in similar pep-
tides. These activate cross-reac-
tive T cells to proliferate and pro-
duce cytokines. Clinically, T cell 
activation by Bet v 1-related food 
allergens may result in a worsen-
ing of atopic eczema in birch pol-
len-allergic patients.
The analysis of the immune mech-
anisms underlying birch pollen-re-
lated food allergy has markedly 
12
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contributed to our understanding 
how immunological cross-reac-
tivity can induce allergy. Birch 
pollen-related food allergy is now 
currently investigated as a disease 
model to elucidate whether immu-
nological cross-reactivity can cure 
allergy, e.g. by cross-reactive reg-
ulatory T cells and/or cross-reac-
tive blocking IgG4 antibodies. 
KEY REFERENCES
1. Radauer C, Bublin M, Wagner S, 
Mari A, Breiteneder H. Allergens 
are distributed into few protein 
families and possess a restricted 
number of biochemical functions. J 
Allergy Clin Immunol 2008;121:847-
852.
2. Bohle B, Zwolfer B, Heratizadeh A, 
Jahn-Schmid B, Antonia YD, Alter 
M et al. Cooking birch pollen-relat-
ed food: divergent consequences 
for IgE- and T cell-mediated reac-
tivity in vitro and in vivo. J Allergy 
Clin Immunol 2006;118:242-249.
3. Dall’Antonia F, Gieras A, Deva-
naboyina SC, Valenta R, Keller W. 
Prediction of IgE-binding epitopes 
by means of allergen surface com-
parison and correlation to cross-re-
activity. J Allergy Clin Immunol 
2011;128:872-879. 
4. Jahn-Schmid B, Radakovics A, 
Luttkopf D, Scheurer S, Vieths S, 
Ebner C et al. Bet v 1142-156 is the 
dominant T-cell epitope of the ma-
jor birch pollen allergen and impor-
tant for cross-reactivity with Bet v 
1-related food allergens. J Allergy 
Clin Immunol 2005;116:213-219.
TLLRAVESYLLAHSDAYN GLFKLI ESYLKDHPDAYN
IL-4
IL-5
IL-13
Bet v 1 Mal d 1
Bet v 1
Pru av 1
A
B
N NC C
Figure 1 A. Homologous conformational epitopes cause IgE cross-reactivity. A putative IgE epitope defined on Bet v 
1 and Pru av 1, the Bet v 1-homolog in cherry is shown in green (3). Protein models (pdb 1BV1 and 1E09, respectively) 
are displayed using Polyview3D. B. Homologous linear epitopes cause T cell cross-reactivity. Proteins with similar amino 
acid sequences (indicated as red and green lines) are processed in a similar manner by antigen-presenting cells leading 
to the generation of linear peptides. The highly cross-reactive C-terminal immunodominant T cell epitope of Bet v 1 and 
the homolog peptide of Mal d 1 are shown (4). Identical amino acid residues are highlighted in bold, similar residues are 
underlined. T cell activation by either epitope induces proliferation and cytokine production.
Allergens and cross-reactivity
13
Global atlas oF allerGy
se
c
t
io
n
 a
 - A
llergy  - fro
m
 gen
etics to
 m
ech
an
ism
s 
• Many house dust mite proteins elicit IgE antibody synthesis, but 
for most the titres are low
• The group 1,2 and probably the newly recognized group 23 
allergens are the major allergens for Dermatophagoides species 
• As found for D. pteronyssinus, the group 4, 5, 7 and 21 allergens 
are quantitatively the next most important, or mid-tier, allergens
• Blomia tropicalis is an important source of allergens in some 
tropical and subtropical regions with the major specificities Blo 
t 5 and Blo t 21
• Mite proteases other than the group 1 allergens induce only low 
levels of sensitisation and very few allergens from other sources 
are cysteine proteases
House dust mites are the most 
ubiquitous source of indoor al-
lergens inducing allergies, highly 
associated with asthma. They are 
of paramount importance in all 
but the few regions of the world, 
where they do not survive due to 
aridness, extreme cold or high al-
titude. 
IgE binding studies have found 
that while a wide range of mite 
proteins can elicit antibodies most 
induce low or sporadically de-
tectable titres (Table 1). Taking D. 
pteronyssinus as the exemplar, only 
3 allergens bind IgE from most 
people at high titre, Der p 1&2 and 
the recently recognized Der p 23. 
The allergens Der p 4, 5, 7 and 21 
each elicit IgE antibodies in 30-
50% of mite-allergic subjects and 
collectively, and sometimes indi-
vidually, induce titres of a magni-
tude considered important for the 
induction of disease. The group 
1&2 allergens can be readily de-
tected in dust and proprietary 
house dust mite extracts made 
from mites cultured in optimized 
allergen-producing conditions. 
The distribution of other allergens 
in the environment is largely un-
known and frequently cannot be 
detected in proprietary extracts. 
The evolutionary conservation of 
Wayne R. Thomas  
University of Western Australia 
Perth, Australia
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House dust mite allergens
the amino-acid sequence of tropo-
myosin group 10 makes them a po-
tential source of cross reactivity 
with allergens from a wide range 
of species. In most regions of the 
world, however, they only induce 
IgE in about 10% of mite-allergic 
subjects. There are possible ex-
ceptions mentioned in uncorrobo-
rated reports from Zimbabwe and 
Japan showing high titre binding, 
suggesting regional importance. In 
another example of a regional ef-
fect, aboriginals in northern Aus-
tralia do not have IgE to Der p 1, 2 
or 10, but instead have high titres 
to the amylase, Der p 4. The profile 
of allergens responsible for sensi-
tisation, thus might vary from the 
studies conducted in urban tem-
perate regions. 
The main species that cause al-
lergic sensitisation are D. ptero-
nyssinus and D. farinae. The most 
abundant, D. pteronyssinus (Figure 
1), is essentially the only species 
found in Australasia and the Unit-
ed Kingdom and mixed species 
are found elsewhere except for D. 
farinae-rich regions of central and 
northern Korea, northern Italy 
and high-latitude areas of east-
ern USA, where mites are found 
in low abundance. The allergens 
from these species cross react 
extensively so species-specificity 
cannot be determined by skin test. 
The possibility that the biochemi-
14
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cal functions of the allergens might 
help promote their allergenicity 
has been mooted especially the 
cysteine protease activity of Der 
p 1, the lipopolysaccharide bind-
ing activity of Der p 2 and the chi-
tin-binding of Der p 23, but this re-
mains unproven. Blomia tropicalis a 
glycyphagoide mite found with D. 
pteronyssinus in some tropical and 
subtropical environments pro-
vides another source of allergens 
where Blo t 5 and Blo t 21 are the 
most important allergens and Blo t 
2 is a minor specificity.
KEY REFERENCES
1. Thomas WR. House dust allergy 
and immunotherapy. Hum Vaccin 
Immunother 2012;8:1469-1478.
2. Thomas WR, Hales BJ, Smith WA. 
House dust mite allergens in asth-
ma and allergy. Trends Mol Med 
2010;16:321-328.
3. Weghofer M, Grote M, Resch Y, 
Casset A, Kneidinger M, Kopec J et 
al. Identification of Der p 23, a peri-
trophin-like protein, as a new major 
Dermatophagoides pteronyssinus 
allergen associated with the peri-
trophic matrix of mite fecal pellets. 
J Immunol 2013;190:3059-3067. 
4. Thomas WR. Geography of house 
dust mite allergens. Asian Pac J Al-
lergy Immunol 2010;28:211-224.
5. Casset A, Mari A, Purohit A, Resch 
Y, Weghofer M, Ferrara R, et al. 
Varying allergen composition and 
content affects the in vivo aller-
genic activity of commercial Der-
matophagoides pteronyssinus 
extracts. Int Arch Allergy Immunol 
2012;159:253-262.
6. Thomas WR. Innate affairs of al-
lergens. Clin Exp Allergy 2013;43: 
152-163.
TABLE 1
Known important house dust mite allergens
Species Allergen Biochemical Category
D. pteronyssinus Der p 1 cysteine protease Major
Der p 2 ML Lipid binding Major
Der p 23 peritrophin Major
Der p 4 amylase Mid tier
Der p 5 unknown Mid tier
Der p 7 LPS/BPI family Mid tier
Der p 21 Der p 5-related Mid tier
D. farinae Der f 1 cysteine protease Major
Der f 2 ML Lipid binding Major
Other not investigated not investigated
B. tropicalis Blo t 5 unknown Major
Blo t 21 Blo t 5-related Major
Blo t 7 LPS/BPI family Mid tier
The table lists allergens shown to have IgE-binding titres expected to make significant 
contributions to the total anti-house dust mite titres. 
LPS/BPI: lipopolysaccharide binding/bacterial permeability increasing protein
Figure 1  Stereomicroscopic 
view of Dermatophagoides 
pteronyssinus on fabric cover. Scale: 
mites are 0.3 mm long. Attribution: 
Gilles San Martin from Namur, 
Belgium (By Gilles San Martin from 
Namur, Belgium (House dust mites  
Uploaded by Jacopo Werther) [CC-BY-
SA-2.0], via Wikimedia Commons.)
House dust mite allergens
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• Exposure to pet allergens is ubiquitous in every-day life
• 10-15% of the population in affluent areas show pet allergen 
specific IgE
• Allergy to pets is among the most common cause of asthma 
and polysensitisation to several pets a risk factor for severe 
problematic asthma
• Allergen-specific immunotherapy for cat is efficacious, while 
extracts from dog and horse needs improvement
Pets of mammalian origin are com-
mon in society and kept for social, 
recreational or occupational rea-
sons. In the United States alone 
the number of dog and cat own-
ers is estimated to be 77.5 and 
93.6 million, respectively. Pets are 
among the most common causes 
of allergy: scattered information 
suggests to 10-15% of the popu-
lation in affluent countries. Sen-
sitization is thought to depend on 
seeding of airborne particles from 
the pelt, saliva or urine. Upon in-
halation and mucosal uptake these 
particles induce IgE antibodies 
Hans Grönlund  
Karolinska Institutet 
Stockholm, Sweden
PET ALLERGENS3e
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Pet allergens
Figure 1  Traditionally allergens 
from pets are extracted from the hair. 
There is a growing awareness that 
other sources, such as saliva (Can f 
2) or urine (Can f 5) may contribute 
critically to the IgE profile of in dog 
allergic patients. 
to many identified components, 
Table 1, however there are many 
more to be identified. Allergy to 
pets is a risk factor for symptoms 
of asthma, rhinoconjunctivitis and 
eczema and in some areas is con-
sidered the most common cause of 
childhood asthma.
To date eight cat (Felis domesti-
cus), six dog (Canis familiaris), four 
horse (Equus caballus) and addi-
tional allergens from less common 
sources have been identified, Ta-
ble 1. The major allergens in cat, 
dog and horse extracts are Fel d 
1, Can f 1 and Equ c 1, with serum 
IgE-reactivity in allergic patients 
of about 95, 50 and 75%, respec-
tively. However their proportions 
may vary between different ge-
ographic regions. The serum IgE 
profile in cat allergy is dominated 
by Fel d 1, whereas the profile in 
dog and horse is more complex. Fel 
d 1 is a secretoglobin glycoprotein 
composed of 10-20% carbohy-
drates, which has been suggested 
to increase allergenicity via man-
nose receptor uptake. Yet another 
mechanism by which Fel d 1 exerts 
its allergenicity is via signaling 
through the innate Toll-like recep-
tors 4 and 2.
Polysensitization between pets 
is extensive and a risk factor for 
severe asthma. The most prom-
inent group of cross-reactive al-
lergens is the lipocalin family, in-
cluding e.g. cat Fel d 4, horse Equ 
c 1, dog Can f 6 and rat Rat n 1. 
A second cross-reactive cluster 
are serum albumins, responsible 
for the pork-cat syndrome, a rare 
phenomenon that can lead to se-
vere reactions. IgE to the galac-
tose- α1,3- galactose carbohydrate 
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TABLE 1
Current list of characterized allergens from pets (www.allergen.org) 
Animal Allergen Protein 
Family
Source MW 
(kDa)
Sensitized 
(%) 
Cat Fel d 1 Secretoglobin Saliva 30-38 80-95
Fel d 2 Albumin
Dander, Sera, 
Urine
68 20-35
Fel d 3 Cystatin Dander 11 10
Fel d 4 Lipocalin Saliva 20 63
Fel d 5 IgA Saliva, Serum 28, 64 38
Fel d 6 IgM Saliva, Serum 28, 94
Fel d 7 Lipocalin Saliva 18 38
Fel d 8 Latherin Saliva 24 19
Dog Can f 1 Lipocalin Saliva, Dander 22-25 45-55
Can f 2 Lipocalin Saliva, Dander 22-27 20-30
Can f 3 Albumin
Dander, Sali-
va, Serum
69 15-35
Can f 4 Lipocalin Saliva, Dander 18 15-30
Can f 5 Kallikrein Urine 28 70
Can f 6 Lipocalin Dander 27, 29 38
Horse
Equ c 1 Lipocalin Dander, Saliva 22 76
Equ c 2§ Lipocalin Dander 16 50
Equ c 3 Albumin
Dander, Meat, 
Sera
65 18
Equ c 4 Latherin Dander, Saliva 17-19
Equ c 5 Latherin Dander 17
Guinea-
pig
Cav p 1§ Lipocalin Dander, Urine 20 70-87
Cav p 2 Lipocalin Dander, Tears 17-19 55-65
Cav p 3 Lipocalin Saliva 18-19 54
Rabbit
Ory c 1§ Lipocalin Dander, Saliva 17-18
Ory c 2§ Lipocalin Dander, Saliva 21
Ory c 3 Secretoglobin Dander, Saliva 18-19 77
Rat Rat n 1 Lipocalin Urine 17-21 66
Pet allergens
moiety, present in ticks bites, 
helminths and mammals, but 
not humans, has convincingly 
been shown to induce severe 
reactions after treatment with 
certain biopharmaceuticals 
and furthermore was linked to 
red meat food allergy.
The accuracy of pet allergy 
diagnostics and success of im-
munotherapy depends largely 
on the quality of the allergen 
source and the allergy profile 
of the patient. Thus, specific 
immunotherapy of patients 
with IgE sensitization to cat 
has proven efficacious, while 
specific immunotherapy of 
dog and horse allergy are not 
equally established.
KEY REFERENCES
1. Portnoy J, Kennedy K, Sub-
lett J, Phipatanakul W, Mat-
sui E, Barnes C et al. Envi-
ronmental assessment and 
exposure control: a practice 
parameter--furry animals. 
Ann Allergy Asthma Immunol 
2012;108:223.e1-15.
2. Brunekreef B1, Von Muti-
us E, Wong G, Odhiambo J, 
García-Marcos L, Foliaki S; 
ISAAC Phase Three Study 
Group. Exposure to cats 
and dogs, and symptoms of 
asthma, rhinoconjunctivitis, 
and eczema. Epidemiology 
2012;23:742-750.
3. Nilsson OB, van Hage M, 
Grönlund H. Mammalian-de-
rived respiratory allergens - 
Implications for diagnosis and 
therapy of individuals aller-
gic to furry animals. Methods 
2014;66:86-95.
4. Zuberbier T, Bachert C, 
Bousquet PJ, Passalacqua G, 
Walter Canonica G, Merk H 
et al. GA² LEN/EAACI pock-
et guide for allergen-specific 
immunotherapy for allergic 
rhinitis and asthma. Allergy 
2010;65:1525-1530. 
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Figure 2  A) Saliva (n=14) from different dogs and breeds show variable allergen expression by IgE immunoblot using 
a pool of dog allergic patients. Molecular marker, left lane (Reproduced with permission from Polovic N, Wadén K, Binnmyr 
J, et al. Dog saliva – an important source of dog allergens. Allergy, 2013;68:585-92, with permission from Willey Blackwell.). B) 
Variability in protein content of dog dander extracts commercially available for skin prick test. Left hand lane in-house 
extract control, right hand side molecular markers (Reproduced with permission from Curin M, Reininger R, Swoboda I, et 
al. Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog 
allergens. Int Arch Allergy Immunol 2011;154:258–263; with permission from Karger Publishers.)
A B
Pet allergens
rFel d1
(kUA/L)
1000
100
10
1
0.35
10000.35 1 10 100
Cat dander extract (kUA/L)
Figure 3  As opposed to dog and horse dander, one allergen, Fel d 1 (y-axis), is dominating in cat dander extracts (x-axis) 
as illustrated by IgE correlation analysis of 100 cat sensitized subjects using ImmunoCAP system (Reproduced with 
permission from Grönlund H, Adédoyin J, Reininger R et al. Higher immunoglobulin E antibody levels to recombinant Fel d 1 in cat-
allergic children with asthma compared with rhinoconjunctivitis. Clin Exp Allergy. 2008 ;38:1275-81, with permission from Willey 
Blackwell.) 
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found among Fagales, Oleaceae, and Cupressaceae plants, which 
are widely distributed worldwide
• Bet v 1-like proteins, Ole e 1- like proteins, and pectate lyases/
polygalacturonases represent the major pollen allergens of 
Fagales, Oleaceae, and Cupressaceae, respectively
• Bet v 1-like allergens are responsible for allergic cross-reactions 
among Fagales pollen and various fruits and vegetables, a clinical 
condition referred to as oral allergy syndrome
• Ole e 1-like allergens and pectate lyases/polygalacturonases are 
responsible for extensive IgE cross-reactivity between Oleaceae 
and Cupressaceae plants, respectively
GEOGRAPHICAL 
DISTRIBUTION AND CLINICAL 
RELEVANCE
Trees belonging to the Fagales, 
Oleaceae, and Cupressaceae com-
prise the clinically most relevant 
sources of allergenic pollen in 
many regions around the world. 
This approach to the classification 
of allergenic trees according to 
their phylogeny provides useful 
guidance both for their geograph-
ical distribution and typical flow-
ering seasons (Figure 1). Thus, Fa-
gales trees are widely distributed 
within the temperate climate zone 
of the Northern hemisphere and 
predominantly flower in spring. 
Oleaceae trees grow in the Medi-
terranean areas as well as in oth-
er parts of the temperate climate 
zone. Their flowering season vary 
according to regions, ranging from 
early January to June. Cupres-
saceae plants are widely distrib-
uted in parts of Europe, Asia and 
Northern America, with pollina-
tion periods occurring between 
January and April, depending on 
the region. Figure 2 shows sensiti-
zation rates to representative tree 
pollen allergen sources in four-
teen European countries.
FAGALES POLLEN ALLERGENS
Fagales pollen allergies are mainly 
TREE POLLEN 
ALLERGENS3f
Ke y  m e ssag e s
Tree pollen allergens
elicited by the Bet v 1-like aller-
gens, which belong to the family 
10 of plant pathogenesis-related 
proteins. Besides cross-reactiv-
ity between Fagales trees, Bet v 
1 sensitization often leads to al-
lergic reactions to various fruits 
and vegetables due to homolo-
gous proteins found in certain 
plant families, including Rosaceae, 
Apiacea, and Fabaceae (Figure 
3). Furthermore, pan-allergens 
belonging to the families of calci-
um-binding proteins and profilin 
contribute to the extensive food 
and pollen cross-reactive patterns 
observed among Fagales-sensi-
tized patients.
OLEACEAE POLLEN ALLERGENS
Ole e 1-like glycoproteins repre-
sent the major allergen of aller-
genic Oleaceae trees, including 
olive, ash, and privet (Table 1). It 
has been shown that exposure to 
high loads of olive pollen can lead 
to increased sensitization rates 
to minor allergens (lipid-transfer 
proteins, 1,3-beta-glucanase) and 
correlates with more severe aller-
gic symptoms, including asthma.
CUPRESSACEAE POLLEN 
ALLERGENS
The major pollen allergens from 
Cupressaceae trees (e.g. cypress, 
mountain cedar, Japanese cedar) 
belong to the family of pectate 
Fatima Ferreira Gabriele Gadermaier Michael Wallner
University of Salzburg 
Salzburg, Austria
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Betula ssp Quercus ssp
Fraxinus ssp
Cryptomeria ssp Juniperus ssp
Olea ssp
Figure 1  Word maps showing the distribution of trees causing respiratory allergic reactions. Representative members 
of the Fagales family (Betula and Quercus), the Oleaceae family (Olea and Fraxinus), and the Cupressaceae family 
(Cryptomeria and Juniperus) are depicted in the maps as density of registered data (increasing density from yellow to 
orange) within the Global Biodiversity Information Facility (www.gbif.org), a free and open access data infrastructure 
funded by governments.
Tree pollen allergens
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Figure 2 Sensitization (colored) 
and clinically relevant sensitization 
rates (striped) to tree pollen allergens 
from the GA2LEN skin test study II. 
Patients (n=3034) referred to allergy 
clinics in 14 European countries 
were diagnosed using skin prick test 
extracts of birch, olive and cypress. 
In Northern and central European 
countries, a high prevalence to 
birch pollen was observed while 
reactivity to cypress was generally 
low. Sensitization to olive was most 
abundant in Switzerland and Greece 
suggesting an involvement of cross-
reactive ash-tree pollen. The majority 
of sensitized patients (66%-75%) 
displayed clinical symptoms to the 
allergen elicitor. (Reproduced with 
permission from Burbach GJ, Heinzerling 
LM, Edenharter G, et al. GA(2)LEN 
skin test study II: clinical relevance 
of inhalant allergen sensitizations in 
Europe.Allergy 2009,64:1507-1515, 
with permission from Willey Blackwell.)
lyases and polygalacturonases. 
Natural purified Cupressaceae 
allergens display extensive IgE 
cross-reactivity, which is partly 
due to the presence of cross-reac-
tive carbohydrate determinants. 
In addition, the overlap of flower-
ing period with winter flu seasons 
complicates the clinical diagnosis 
of Cupressacea pollen allergies.
CONCLUSION
The major allergens of Fagales, 
Oleaceae, and Cupressaceae be-
long to distinct families of pro-
teins, and thus represent ideal 
tools for molecule-based diagno-
sis and therapy of tree pollen al-
lergies.
KEY REFERENCES
1. Mothes N, Valenta R. Biology of 
tree pollen allergens. Curr Allergy 
Asthma Rep 2004;4:384-390.
2. Radauer C, Breiteneder H. Pol-
len allergens are restricted to 
few protein families and show 
distinct patterns of species dis-
tribution. J Allergy Clin Immunol 
2006;117:141–147.
3. Villalba M, Rodriguez R, Batane-
ro E. The spectrum of olive pollen 
allergens. From structures to di-
agnosis and treatment. Methods 
2013;66:44-54.
4. Charpin D, Calleja M, Lahoz C, Pi-
chot C, Waisel Y. Allergy to cypress 
pollen. Allergy 2005;60:293-301.
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Tree pollen allergens
Tree pollen allergens Cross-reactive allergens
Fagales pollen 
allergens
Oleaceae 
pollen 
allergens
Cupressaceae 
pollen allergens
Pollen Fruits Vegetables Other
MAJOR ALLERGENS
B
et
 v
 1
-r
el
at
ed
 p
ro
te
in
s
Alder (Aln g 1)
Birch (Bet v 1)
Hornbeam (Car 
b 1)
Chestnut (Cas 
s 1)
Hazel (Cor a 1)
Beech (Fag s 1)
Hophornbeam 
(Ost c 1)
Oak (Que a 1)
Gold kiwi (Act c 8)
Kiwi (Act d 8)
Kiwi (Act d 11)
Peanut (Ara h 8)
Strawberry (Fra a 1)
Apple (Mal d 1)
Apricot (Pru ar 1)
Sweet cherry (Pru av 1)
Peach (Pru p 1)
Pear (Pyr c 1)
Red raspberry (Rub i 1)
Celery (Api 
g 1)
Carrot (Dau 
c 1)
Tomato 
(Sola l 4)
Hazelnut (Cor 
a 1)
Soy (Gly m 4)
Mung bean (Vig 
r 1)
Bet v 1-associated 
oral allergy syndrome
O
le
 e
 1
-r
el
at
ed
p
ro
te
in
s
Ash (Fra e 1)
Privet (Lig v 1)
Lilac (Syr v 1)
Sweet beet (Beta v 1)
Pigweed (Che a 1)
Privet (Lig v 1)
Rye grass (Lol p 11)
Timothy grass (Phl p 11)
English plantain (Pla l 1)
Russian thistle (Sal k 5)
P
ec
ta
te
 ly
as
es Japanese cypress (Cha o 1)
Japanese cedar (Cry j 1)
Cypress (Cup a 1)
Common cypress (Cup s 1)
Mountain cedar (Jun a 1)
Eastern red cedar (Jun v 1)
Ragweed (Amb a 1)
Mugwort (Art v 6)
P
o
ly
- 
ga
la
ct
u
ro
n
as
es Japanese cypress (Cha o 2)
Japanese cedar (Cry j 2)
Mountain cedar (Jun a 2)
English plane tree (Pla a 2)
English plane tree (Pla a 2)
MINOR ALLERGENS
P
ro
fil
in
s
Birch (Bet v 2) Olive (Ole e 2) Ragweed (Amb a 8)
Redroot pigweed (Ama r 2)
Mugwort (Art v 4)
Sweet beet (Beta v 2)
Turnip (Bra r 5)
Pigweed (Che a 2)
Bermuda grass (Cyn d 12)
Sunflower (Hel a 2)
Annual mercury (Mer a 1)
Wall pellitory (Par j 3)
Timothy grass (Phl p 12)
Date palm (Pho d 2)
Russian thistle (Sal k 4)
Maize (Zea m 12)
Kiwi (Act d 9)
Pineapple (Ana c 1)
Peanut (Ara h 5)
Sweet orange (Cit s 2)
Melon (Cuc m 2)
Strawberry (Fra a 4)
Litchi (Lit c 1)
Apple (Mal d 4)
Banana (Mus a 1)
Sweet cherry (Pru av 4)
Peach (Pru p 4)
Pear (Pyr c 4)
Celery (Api 
g 4)
Bell pepper 
(Cap a 2)
Carro (Dau 
c 4)
Tomato 
(Sola l 1)
Hazelnut (Cor 
a 2)
Saffron crocus 
(Cro s 2)
Soy (Gly m 3)
Latex (Hev b 8)
Barley (Hor v 12)
Rice (Ory s 12)
Almond (Pru 
du 4)
Yellow mustard 
(Sin a 4)
Wheat (Tri a 12)
P
o
lc
al
ci
n
s
Alder (Aln g 4)
Birch (Bet v 3)
Birch (Bet v 4)
Olive (Ole e 3)
Olive (Ole e 8)
Lilac (Syr v 3)
Prickly juniper (Jun o 4) Ragweed (Amb a 9)
Ragweed (Amb a 10)
Mugwort (Art v 5)
Pigweeed (Che a 3)
Bermuda grass (Cyn d 7)
Wall pellitory (Par j 4)
Timothy grass (Phl p 7)
O
th
er
 m
in
o
r 
al
le
rg
en
s
Birch (Bet v 6)
Hazel (Cor a 6)
Birch (Bet v 7)
Olive (Ole e 4)
Olive (Ole e 5)
Olive (Ole e 6)
Olive (Ole e 7)
Olive (Ole e 9)
Olive (Ole e 10)
Olive (Ole e 11)
Common cypress (Cup s 3)
Mountain cedar (Jun a 3)
Eastern red cedar (Jun v 3)
Prickly juniper (Jun a 4)
Figure 3 Major and minor allergens identified in pollen from 
Fagales, Oleaceae, and Cupressaceae trees. Cross-reactive 
allergens identified in other allergen sources are shown in the 
left panel. IgE cross-reactivity between Bet v 1-like proteins 
found in pollen, fruits, and vegetables can cause a clinical 
condition referred to as Oral Allergy Syndrome.
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seasonal inhalant allergies worldwide
• Grass group 1 and 5 allergens represent highly cross-reactive 
and potent major allergens, group 5 present only in temperate 
climate grasses (Pooideae)
• Depending on climate and region, global sensitization rates to 
grass pollen vary between 1% to 30% of the general population
• Strong evidence supports specific immunotherapy with grass 
pollen extracts
BOTANICAL RELATIONSHIP
Grasses are ubiquitous plants in 
most parts of the world. The grass 
family (Poaceae) includes >600 
genera and >11,000 recognized 
species with a wide distribution. 
Over 95% of allergy-relevant 
grass species belong to three sub-
families; Pooideae, Chloridoideae 
and Panicoideae (Figure 1 and 2). 
GLOBAL DISTRIBUTION
Depending on climate and geogra-
phy, grass pollens represent major 
contributors of airborne allergens 
during spring as well as summer. 
They grow on all continents and 
represent 25% to 35% of the 
earth´s vegetation. Pooideae dom-
inate temperate climate zones; 
Chlorodoideae cover the North 
American, African and Australian 
continents and Panicoideae grow 
in tropical and subtropical envi-
ronments of Asia, Australia, Africa 
and South America (Figure 3). 
ALLERGENS OF GRASS POLLEN
Grass pollen allergens are grouped 
according to their protein struc-
ture and function (Table 1). They 
are named according to the offi-
cial nomenclature (www.allergen.
org), i.e.: Phl p 1 = grass group 1 al-
lergen from Phleum pratense (tim-
othy grass). Ten designated groups 
GRASS POLLEN 
ALLERGENS3g
Ke y  m e ssag e s
Grass pollen allergens 
consist of major (>50% sensitiza-
tion rate, SR) and minor allergens 
(<50% SR). Due to their abun-
dance and potency, grass group 
1 and 5 allergens are considered 
immunodominant major Pooideae 
pollen allergens (Figure 4). While 
group 5 allergens are restricted 
to the Pooideae subfamily, group 
1 allergens are present through-
out the subfamilies of Poaceae. In 
contrast, pan-allergens profilin 
(group 12) and polcalcin (group 7) 
contribute to ubiquitous cross-re-
activity between grass, tree and 
weed pollen in 10 – 15% of grass 
pollen sensitized subjects. Present 
concepts of homologous allergen 
groups, are based on similar bio-
chemical composition, homology 
and immune cross-reactivity re-
flecting in most cases their close 
taxonomic relationship and have 
been adopted by the European 
Medicines Agency (EMA). 
CLINICAL ALLERGY BASED ON 
SENSITIZATIONS
Sensitizations to grass pollen al-
lergens, indicated by grass pollen 
allergen (extract) positive skin 
test or specific IgE, reflect regional 
plant distribution and pollen ex-
posure. Population based sensiti-
zation rates are mainly available 
for Europe and the US and vary 
considerably between and within 
countries (Figure 5). Grass pollen 
allergy is a global problem (Figure 
5c). At least half of grass pollen 
allergen sensitized subjects will 
suffer from symptoms of allergic 
rhinoconjunctivitis and/or bron-
chial asthma, particularly during 
the warm seasons in moderate cli-
mate regions. 
Jörg Kleine-Tebbe  
Allergy & Asthma Center Westend 
Berlin, Germany
Janet Davies  
The University of Queensland 
Brisbane, Australia
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Poaceae Bambusoideae Oryzeae
Arundinoideae Arundineae
Panicoideae
Chlorideae
Pooideae
Paniceae
Andropogoneae
Poeae
Aveneae
Bromeae
Triticeae
Oryza
Phragmites
Cynodon
Paspalum
Sorghum
Zea
Dactylis
Festuca
Lolium
Poa
Anthoxanthum
Avena
Holcus
Phleum
Bromus
Hordeum
Secale
Triticum
Chloridoideae
(Rice)
(Common reed)
(Bermuda grass)
(Bahia grass)
(Johnson grass)
(Corn, maize)
(Orchard grass)
(Meadow fescue)
(Perennial rye)
(Kentucky bluegrass)
(Sweet vernal grass)
(Cultivated oat)
(Velvet grass)
(Timothy grass)
(Smooth brome grass)
(Barley)
(Cultivated rye)
(Wheat)
Family Subfamily Tribe Genus Common name (US)
Figure 1  Pictures of different grass species and their pollen : a - Timothy grass (Phleum pratense), subfamily Pooideae; 
b-Bermuda grass (Cynodon dactylon), subfamily Chloridoideae; c - Bahia grass (Paspalum notatum), subfamily Panicoideae.
Figure 2  Taxonomy of grasses (important subfamilies within colored boxes). Overlapping circles (colored lines) indicate 
partial cross-reactivity between neighboring subfamilies (modified from (2), (4) and (10)).
Grass pollen allergens 
a b
c
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Figure 3 Global distribution of selected grass species (10): a- Timothy grass 
(Phleum pratense), subfamily Pooideae; b-Bermuda grass (Cynodon dactylon), sub-
family Chloridoideae; c-Bahia grass (Paspalum notatum), subfamily Panicoideae.
DIAGNOSIS AND TREATMENT
Positive skin prick tests and ele-
vated specific serum IgE to grass 
pollen preparations indicate al-
lergic sensitizations, being clini-
cally relevant only in case of cor-
responding symptoms. Measuring 
IgE to major allergens (i.e. Phl p 1 
and 5) increases analytical spec-
ificity for temperate grass pol-
len allergy, particularly in case of 
sensitizations to cross-reactive 
pollen-panallergens. Specific im-
munotherapy is most successfully 
applied for at least three years by 
subcutaneous injections or sublin-
gual home use of droplets or tab-
lets with monopreparations of one 
grass species, but also grass mixes 
(mainly Pooideae), with or without 
adjuvants. 
Acknowledgement: We kindly 
acknowledge Andreas Nandy 
(Allergopharma, Reinbek, Germa-
ny),  Jonas Lidholm and Kerstin Wall 
(ThermoFisher, Uppsala, Sweden) 
for additional information and 
helpful suggestions. 
KEY REFERENCES
1. Esch RE. Grass pollen allergens. 
In: Lockey RF, Ledford DK, ed-
itors. Allergens and Allergen 
Immunotherapy. 4th Edition ed: 
Informa Healthcare, New York; 
2008. p. 107-126.
2. Andersson K, Lidholm J. Charac-
teristics and immunobiology of 
grass pollen allergens. Int Arch Al-
lergy Immunol 2003;130:87-107. 
3. Hrabina M, Peltre G, van Ree R, 
Moingeon P. Grass pollen allergens. 
Clin Exp Allergy Rev 2008;8:7-11. 
4. Gangl K, Niederberger V, Va-
lenta R. Multiple grass mixes as 
opposed to single grasses for 
allergen immunotherapy in al-
lergic rhinitis. Clin Exp Allergy 
2013;43:1202-1216. 
5. Lorenz AR, Lüttkopf D, May S, 
Scheurer S, Vieths S. The princi-
ple of homologous groups in reg-
ulatory affairs of allergen prod-
ucts--a proposal. Int Arch Allergy 
Immunol 2009;148:1-17. 
6. European Medicines Agen-
cy (EMA). Guideline on aller-
gen products:production and 
quality issues. (EMEA/CHMP/
BWP/304831/2007) 2009. 
7. Newson RB, van Ree R, Forsberg 
B, Janson C, Lotvall J, Dahlen SE 
et al. Geographical variation in 
the prevalence of sensitization to 
common aeroallergens in adults: 
the GA2LEN survey. Allergy 
2014;69:643-651. 
8. Salo PM, Arbes SJ Jr, Jaramillo R, 
Calatroni A, Weir CH, Sever ML, 
et. al Prevalence of allergic sen-
sitization in the United States: 
Results from the National Health 
and Nutrition Examination Sur-
vey (NHANES) 2005-2006. J Al-
lergy Clin Immunol 2014 (in press). 
9. Davies JM. Grass pollen aller-
gens globally; the contribution of 
subtropical grasses to burden of 
allergic respiratory diseases. Clin 
Exp Allergy 2014;44:790-801.
10. Simon BK, Clayton WD, Harman 
KT, Vorontsova M, Brake I, Healy 
D and Alfonso Y.  2011. Grass-
World, http://grassworld.mys-
pecies.info/ (Accessed April 25, 
2014).
Grass pollen allergens 
a
b
c
25
Global atlas oF allerGy
se
c
t
io
n
 a
 - A
llergy  - fro
m
 gen
etics to
 m
ech
an
ism
s 
TABLE 1
Grass pollen allergen groups
Allergen 
group
Biochemical 
function
Molecular-
weight [kDa]
Member in 
Phleum pratense
Features
IgE 
reactivity
1 β-expansin 27 - 35 Phl p 1 Glycoprotein, major grass pollen allergen, 
produced by every grass species
>90% 
85-99%
2 Unknown 11 Phl p 2
highly homologous to group 3 and 
C-terminal portion of group 1 allergens
35 - 50% 
40-60 %
3 Unknown 11 - 14 Phl p 3
highly homologous to group 2 and 
C-terminal portion of group 1 allergens
35 - 70% 
57-67 %
4
Oxidoreduc-
tase
50 - 60 Phl p 4
Glycoprotein, Berberine bridge enzyme 
family member, plant pathogen response 
system
50 - 75% 
45 - 88%
5 Unknown 27 - 35 Phl p 5
found in Pooideae grass species, associated 
with submicronic cytoplasmic starch 
particles
65 - 85% 
50 - 88 %
6 Unknown 12 - 13 Phl p 6
homologous to internal group 5 sequences, 
only in Anthoxanthum odoratum, Phleum 
pratense and Poa pratensis
60 - 70% 
45 - 70%
7 Polcalcin, Ca
++- 
binding protein 
8 - 12 Phl p 7 Panallergen, dimer assembly in grass 
pollen, broad pollen-related crossreactivity
5 - 35% 
2 - 12%
11
Ole e 1-related 
protein
16 - 20 Phl p 11
Glycoprotein, similar structure to pollen 
allergens from olive tree pollen (Ole e 1) 
and lamb´s quarter (Che a 1)
18 - 56%
12 Profilin 13 - 14 Phl p 12 Panallergen, highly conserved, broad pollen 
and plant food-related crossreactivity
10 - 40%
9 - 32%
13
Polygalacturo-
nase
45 - 60 Phl p 13 Glycoprotein, susceptible to protease 
degradation
30 - 40% 
36 - 56 %
Modified from (1). Due to their taxonomic and biochemical relationship, many grasses contain similar allergens grouped accor-
ding to shared amino acid sequences. Specific allergens from timothy grass (Phleum pratense, see middle column) are given as 
examples of the listed grass allergen groups. 
Group 
5
Group 
1
Group 
4
Group 
2/3
Group 
13Group 
11
Group 
7Group 
10
Group 
12
Low High
Low
High
50%
40% Potency 
(mean IgE level)
Prevalence
Figure 4  Involvement of 
grass pollen allergens in patient 
sensitization (3).
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Figure 5  Sensitization rates to grass pollen (Pooideae) in Europe (a: modified from (7)), to Ryegrass (b) and Bermuda 
grass (c ) in the US (b and c: modified from (8)) and to Johnson, Bahia and Bermuda grass pollen elsewhere (d: limited 
information, modified from (9)).
b
d
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AR, allergic rhinitis, 
GPA, grass pollen allergic
Southern USA 
▲ 57% AR (429)
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61%  AR (54) 
Zimbabwe 
50.4%  AR (341) 
Australia (GPA, 48)
▼77%
▲81%
84%
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12.5%, (AR/A, 48)
52% (GPA, 133) 
Taiwan (AR, 419)
▼ 10%, 
 2.1%
Thailand (AR, 100)
▼21%, 
▲16% 
17% 
Malaysia (A, 100)
20.5%,
▲6.5%
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• The major weeds families inducing allergic rhinitis are the 
Amaranthaceae, the Asteraceae and the Urticaceae
• Cross-reactivity between family members is frequent
• In most temperate regions the weeds pollen season is August 
and September, but climate change can be associated with a 
lengthening of the pollination period
Weeds can be defined as un-
wanted plants; as such, they may 
be very variable in form. While 
many are herbaceous, some have 
greater or lesser woody stocks, 
for example the sagebrushes, Ar-
temisia tridentata and A. frigida. 
Some are prostrate and hug the 
ground, while others, such as giant 
ragweed, Ambrosia trifida, may be 
over 3 meters high. Herbaceous 
varieties may be annuals or per-
ennials. Weeds found in numerous 
botanical families can be inducers 
of allergic rhinitis and asthma, but 
a few families stand out with the 
majority of aeroallergen sources. 
Amaranthaceae contains the pig-
weeds (Amaranthus), saltbush-
es (Atriplex), and tumbleweeds 
(Salsola, Kochia, Bassia) as well as 
other chenopod weeds (Cheno-
podium). The latter three groups 
were earlier placed in a separate 
family, Chenopodiaceae. More 
recent systematics has, however, 
redefined this group as a subfam-
ily of Amaranthaceae. The major 
tumbleweeds of the North Amer-
ican Great Plains are Russian 
thistle (Salsola kali) and burning 
bush (Kochia scoparia): both are 
introduced plants. Other species 
of Salsola and Bassia are common 
throughout the Middle East. The 
Atriplex saltbushes are common 
Richard W. Weber  
National Jewish Medical & Research Center 
Denver, USA
WEED POLLEN 
ALLERGENS3h
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Weed pollen allergens
in arid floristic zones. Redroot 
pigweed (A. retroflexus) is a ubiq-
uitous cosmopolitan weed, found 
throughout temperate regions of 
the globe. Allergenic cross-reac-
tivity is very strong amongst the 
Atriplex weeds, and likewise be-
tween the Amaranthus species ex-
amined; cross-reactivity between 
other chenopod weeds is present 
but more variable.
Asteraceae (previously known as 
Compositae) is the largest family 
of flowering plants (Angiosper-
mae), and contains several noto-
rious inducers of pollinosis. The 
genus Ambrosia contains all the 
ragweeds, including several re-
classified from the discarded ge-
nus Franseria. The four major rag-
weed (Artemisia) species are giant 
(A. trifida) (Figure 1), short (A. ar-
temisiifolia) (Figure 2), western (A. 
psilostachya), and false (A. acanthi-
carpa). These are all North Ameri-
can natives, but most of them have 
been introduced into Europe, and 
have rapidly expanded across the 
Balkans, Ukraine, and into Poland. 
In most temperate regions the pol-
len season is August and Septem-
ber. Cross-allergenicity is strong 
amongst the major ragweed spe-
cies. Other important members of 
Asteraceae are in the genus Arte-
misia, the sages. There are about a 
dozen species found in the United 
States. The most prevalent in east-
ern U.S. and Europe is mugwort 
(A. vulgaris). Fringed sagebrush (A. 
frigida) is a common groundcover 
in the Siberian steppes. Cross-re-
activity is very strong between Ar-
temisia species.
Urticaceae includes two members 
of significance: pellitory (Parietar-
ia) (figure 3) and nettle (Urtica). 
Pellitory is a major seasonal aer-
oallergen of the Mediterranean 
Basin. Climate change is associat-
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ed with a lengthening of its pollen 
season to about ten months.
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Figure 1 a - Giant sagebrush (Artemisia); b - short ragweed; c- pellitory (Parietaria).
Weed pollen allergens
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• Differences in sensitization to food allergens across different 
geographic regions have been particularly observed for plant 
food allergens
• 65% of plant food allergens are part of four protein families/
superfamilies: the prolamin, cupin, Bet v 1 and profilin family
• In Europe, the prevalence of IgE to foods significantly correlates 
with the prevalence of sensitization to birch-pollen-associated 
allergens Bet v 1 and Bet v 2
• Food allergic patients from Mediterranean countries show a 
higher sensitization rate to profilin and non-specific lipid transfer 
proteins compared to Central, Western or Eastern Europe
Depending on the route of sen-
sitization, immediate-type food 
hypersensitivities are either a 
result of reactivity to food aller-
gens through the gastrointesti-
nal tract (class I allergens) or the 
result of secondary sensitization 
to cross-reactive food allergens 
mainly due to primary sensitiza-
tion to homologous pollen aller-
gens via the respiratory tract (class 
II allergens, Figure 1). Class I aller-
gens are often resistant to heat, 
degradation and digestion. Class II 
allergens are mainly labile and eas-
ily degradable. According to these 
characteristics the clinical mani-
festation is influenced by the type 
of allergens to which an individual 
is sensitized. The class I allergens 
have a higher potential to induce 
severe reactions compared to the 
easily degradable class II food al-
lergens, which induce often symp-
toms restricted to the oral cavity. 
Due to such reasons, great efforts 
have been made in the last few 
years to identify and characterize 
individual food allergen molecules 
in the most prevalent allergenic 
foods (http://www.allergen.org/; 
http://www.allergome.org/; http://
www.meduniwien.ac.at/allergens/
allfam/) and to compare sensiti-
zation patterns between different 
geographic regions.
Barbara Ballmer-Weber  
University Hospital Zürich 
Zürich, Switzerland
FOOD ALLERGENS3i
Ke y  m e ssag e s
Food allergens
More than 65% of plant food al-
lergens are members of just four 
protein families/superfamilies: 
the prolamin, cupin, Bet v 1 and 
profilin family (Table 1). Animal 
derived food allergens mainly be-
long to three protein families: the 
tropomyosins, parvalbumins and 
caseins. 
At school age, adolescence and 
adulthood cross-reactive food al-
lergy is dominating. According to 
new epidemiologic data sensitiza-
tion to the respective food aller-
gens is heavily dependent on the 
exposure and sensitization to in-
halant allergens. In a recent study 
including adult participants from 
eight European centres the preva-
lence of IgE to foods ranged from 
6.6% (Iceland) to 23.6% (Switzer-
land) and was significantly corre-
lated with the prevalence of sensi-
tization to birch-pollen-associated 
allergens Bet v 1 and Bet v 2 (pro-
filin), whereas IgE sensitization to 
non-pollen-related plant allergens 
were more evenly distributed. 
These results confirmed the find-
ings from studies evaluating the 
sensitisation pattern to food aller-
gens across Europe. Sensitization 
rates to the Bet v 1 homologous 
proteins in apple (Mal d 1), kiwi 
(Act d 8), carrot (Dau c 1) or ha-
zelnut (Cor a 1) were significantly 
higher in countries with high birch 
pollen exposure such the Neth-
erlands, Austria, Northern Italy, 
Switzerland and Denmark com-
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Figure 1 Homology between the major birch pollen allergen Bet v 1 and homologous food protein. High structural 
homology between the major birch pollen allergen Bet v 1 (top) and homologous food protein (here as an example the 
cherry allergen Pru av 1, bottom) explains the phenomenon of cross-sensitization between birch pollen and plant foods 
and the high prevalence of sensitization to foods in birch pollen exposed regions of Europe.
TABLE 1
Most important protein families for plant food allergies
Protein 
family
Prolamin Cupin Profilin Bet v 1 Thaumatin-like 
protein
Biochemical 
structure
2S albumin nsLTP
7S-globulin 
vicilin
11S-globulin 
legumin
function
storage 
protein
plant 
defense
storage 
protein
storage 
protein
actin 
binding
pathogen 
resistance 
PR-10
pathogen 
resistance PR-5
examples of 
foods
peanut, soy, 
tree nuts, 
sesame, 
mustard
Rosaceae 
fruits, 
nuts, 
seeds, 
vegetables
peanut, soy, 
pea, lentil, 
nuts, sesame
peanut, soy, 
nuts
all plant 
foods
Rosaceae 
fruits, 
nuts, 
legumes, 
vegetables
cherry, apple, 
peach, tomato, 
orange, grape, 
kiwi, bell 
pepper
Food allergens
31
Global atlas oF allerGy
se
c
t
io
n
 a
 - A
llergy  - fro
m
 gen
etics to
 m
ech
an
ism
s 
Figure 2 Sensitization pattern to kiwi allergens. Sensitization pattern to kiwi allergens Act d 1 (Actinidin), Act d 5 
(Kiwellin), Act d 8 (Bet v 1 homologous protein), Act d 9 (Profilin) and Act d 10 (non-specific LTP) in four European regions 
(northern: Iceland; central/western: France, northern Italy, Switzerland, The Netherlands, United Kingdom; eastern: 
Bulgaria, Poland, Czech Republic, Lithuania, southern: Spain, Greece). Patients from Iceland were mainly sensitized to 
Act d 1 (32%), those from western/central and eastern Europe to Act d 8 (58% and 44%, respectively), and those from 
southern Europe to Act d 9 (profilin, 31%) and Act d 10 (non-specific LTP, 22%) (Le et al., J Allergy Clin Immunol 2013).
Food allergens
pared to that observed in Medi-
terranean countries such as Spain 
or Greece (Figure 2: sensitization 
pattern to kiwifruit allergens 
across Europe). Spanish and Greek 
patients, however, showed a high-
er sensitization rate to profilin and 
non-specific Lipid transfer protein 
(LTP). A similar association of sen-
sitisation to pollen from the Betu-
laceae family, particular alder, and 
the development of fruit allergy 
was observed in Japan. Sensitiza-
tion to food LTP is highly prevalent 
in Mediterranean countries and 
associated with a higher rate of 
systemic reactions. Also in China 
sensitization to peach LTP, Pru p 3, 
was associated with a high rate of 
systemic reactions. 
Differences in the sensitization 
pattern were also demonstrated 
for children with peanut allergy 
from three different geographic 
regions. Spanish patients were 
mainly sensitised to non-specific 
LTP (Ara h 9), Swedish patients to 
the Bet v 1 homologous allergen 
Ara h 8 and US patients to the 
storage proteins in peanut Ara h 1, 
Ara h 2 and Ara h 3. 
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s • 12 molecular allergens of honey bee venom, and five of Vespula 
venom are known and have been sequenced
• Use of molecular allergens has improved testing of venom-
specific IgE antibodies 
• Further research on the clinical role of individual molecular 
insect venom allergens is needed
• Allergen components of the venoms should be available for 
routine testing
INSECTS
For allergic sting reactions, main-
ly social Aculeatae are important 
elicitors. Social insects have de-
veloped a division of labour with 
sterile females forming a work-
ing class. Female workers have a 
stinger by which venom is injected 
during a sting into the skin. Within 
the Aculeatae, Vespidae (vespids), 
Apidae (bees), and Formidaceae 
(ants) are social insects (Figures 
1 and 2). Vespidae are divided into 
the subfamilies Polistinae and Ves-
pinae. The latter contains three 
genera: Vespula, Dolichovespula 
and Vespa. 
INSECT VENOMS
Insect venoms contain a complex 
mixture of toxic proteins and pep-
tides, of which some may induce 
IgE-mediated sensitisation. Today, 
12 molecular allergens of hon-
ey bee venom, and 5 of Vespula 
venom are known and have been 
sequenced (Table 1). For some of 
these allergens, isoforms have 
been detected. 
Major allergens are characterized 
by the fact that there is corre-
sponding specific IgE-antibodies 
(sIgE) in the blood of the majority 
of allergic patients. Major aller-
gens are probably more important 
than minor allergens in terms of 
Franziska Ruëff  
Ludwig-Maximilian University  
Munich, Germany
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Venom allergens
eliciting an allergic reaction. Mi-
nor allergens may also induce sIgE, 
however, this occurs in a small 
percentage of venom allergic pa-
tients.
Phospholipase A2, hyaluronidase, 
and acid phosphatase are the ma-
jor bee venom allergens. Major 
allergens of Vespula venom are 
Phospholipase A1, Hyaluronidase, 
and Antigen 5. Some allergens of 
Vespula and bee venom share mi-
nor to moderate sequence iden-
tity and show a corresponding 
cross-reactivity. However, the 
closer is the taxonomic relation-
ship of insects the greater is the 
overlap of biochemical structures 
of molecular venom allergens. 
Honey bee venom allergens show 
more cross-reactivity with bumble 
bee allergens compared to aller-
gens of the venoms from Vespula 
Figure 1 a - Apidae (bee); b- 
Vespidae (vespids).
a
b
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species. Venom allergens from 
Polistinae or Dolichovespula are 
more related to Vespula venoms.
In-vITRO DIAGNOSTICS OF 
VENOM SENSITIZATION
Demonstration of venom-specific 
sensitization is essential for diag-
nosing an insect venom allergy and 
is also a prerequisite to select the 
proper venom for immunothera-
py. To identify venom-specific IgE 
in human blood, insect venoms 
are in use since the seventies. In 
the late eighties, purified allergens 
were produced. Today, one recom-
binant allergen component of hon-
ey bee venom (Api m 1) and two of 
Vespula venom (Ves v 1 and 5) are 
available for routine diagnostics. 
It is assumed that in the near fu-
ture more molecular compounds 
will be available to identify venom 
sIgE. 
In contrast to certain food al-
lergies, where the sensitization 
patterns were found to be associ-
ated with mild or severe allergic 
reactions and can be used for risk 
assessment, for venom allergy, 
the clinical relevance of a certain 
pattern of venom sIgE remains un-
clear. 
Testing sIgE to single venom al-
lergens is of major importance for 
improving sensitivity and specific-
ity of in-vitro diagnostics. Using 
recombinant allergens improved 
the value of assays testing sIgE to 
the whole venom. 
Another problem for the diagnosis 
of insect venom allergy is the dou-
ble positivity although presuma-
bly the patient only suffers from 
one allergy. Double positivity may 
be due to true double allergy, to 
cross reactivity between allergen 
compounds of honey bee and Ves-
pula venoms, and to sensitization 
to widespread cross-reactive car-
bohydrate determinants (CCD), 
which are present in many aller-
gen sources from plants and ani-
mals. The latter, however, usually 
do not act as allergens. Allergen 
compounds, which are free from 
CCD improve the specificity of in 
vitro testing.
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TABLE 1
Most important protein families for plant food allergies
Allergen Name / Function
Molecular weight 
(KDa)
Percent of 
dry weight
Honey bee venom allergens
Api m 1 Phospholipase A2* 16 12
Api m 2 Hyaluronidase* 39 2
Api m 3 Acid phosphatase 43 1-2
Api m 4 Melittin* 3 50
Api m 5 Dipeptidylpeptidase IV 100 <1
Api m 6 8 1-2
Api m 7 CUB serine protease 39 ?
Api m 8 Carboxylesterase 70 ?
Api m 9 Serine carboxypeptidase 60 ?
Api m 10
Icarapin variant 2, car-
bohydrate-rich protein
50- <1
Api m 11 Major royal jelly protein 
50 (deglycosylated 
form)
?
Api m 12 Vitellogenin 200 ?
Vespula venom allergens
Ves v 1 Phospholipase A1* 34 6-14
Ves v 2 Hyaluronidase* 28 1-3
Ves v 3 Dipeptidylpeptidase IV 100 ?
Ves v 5 Antigen 5* 23 5-10
Ves v 6 Vitellogenin 200 ?
(IUIS Allergen Nomenclature Sub-Committee. www.allergen.org). Major allergens are 
indicated by an asterix (*)
Venom allergens
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• Allergen panels contribute to improve in vitro diagnosis of allergy
• While some allergens rather induce mild symptoms, others are 
known to be linked with severe symptoms (marker allergens) 
• Depending on environmental exposure and dietary habits IgE 
recognition patterns may vary in different patients groups
In the recent past, great efforts 
have been undertaken to charac-
terise allergens. This in turn has 
revolutionized in vitro diagnosis, 
by determining the range of cross 
reactivities and establishing aller-
gen panels. Of special interest is 
the identification of marker aller-
gens: allergens that tend to induce 
rather severe symptoms versus 
allergens that rather account for 
mild symptoms. 
It is only a minority of proteins 
that exert allergenic activity. To 
date allergens can be assigned to 
2% of all known protein families. 
According to allergen databases, 
the dominating protein families 
among animal-derived food aller-
gens are tropomyosins, parvalbu-
mins and caseins. Similarly, pro-
lamins, cupins and PR10 proteins 
are the 3 most important plant 
protein families (Table 1). 
ANIMAL-DERIVED FOOD 
ALLERGENS 
Tropomyosins are highly con-
served eukaryotic proteins with a 
typical coiled-coil structure that 
are necessary for regulating mus-
cle contraction. So far, allergenic 
tropomyosins have been identi-
fied from e-vertebrates, highly 
cross-reactive among crustaceans 
and mollusks, as well as inhalant 
Karin Hoffmann-Sommergruber  
Medical University of Vienna 
Vienna, Austria
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Emerging allergens
allergens from mites and cock-
roaches.
Parvalbumins share an EF-hand 
domain binding Ca2+ and thus are 
involved in signaling pathways or 
Ca2+ transport. These major food 
allergens were identified from 
fish and amphibians, but not from 
higher vertebrates. 
Caseins are a major heterogenous 
protein fraction in mammalian 
milk displaying a random-coiled 
structure. They function as Ca2+ 
binders and allergenic caseins and 
are highly cross-reactive among 
mammalian species. 
So far sensitization to carbohy-
drates has been regarded as of 
low clinical importance in allergic 
diseases. However, recently, aller-
gic reactions to alpha-gal epitopes 
were observed in meat allergy. 
Previous administration of mono-
clonal antibody doses induced the 
sensitization event. This highlights 
that alternative exposures have 
to be considered if new and unex-
pected cases of allergies occur.
PLANT-DERIVED FOOD 
ALLERGENS
The non-specific lipid transfer 
proteins (LTP) and the 2S albumins 
belong to the prolamin superfam-
ily. Both types of proteins display 
a rigid tertiary structure and are 
resistant to enzymatic and ther-
mal treatment. Non-specific-LTPs 
are involved in plant defense, and 
are relevant allergens in various 
fruits, nuts and pollens. 2S albu-
mins are seed storage proteins 
and together with the proteins 
from the cupin superfamily they 
represent important allergens in 
seeds and nuts, usually evoking 
severe symptoms in patients. The 
PR10 proteins, involved in plant 
defense, are present in pollen as 
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well as in plant food, usually evok-
ing mild oral symptoms. Eventual-
ly, they can induce severe symp-
toms as in soy allergy. 
In conclusion, a number of aller-
gens are now available for compo-
nent-resolved in vitro diagnosis. 
Analysis of their physicochemical 
features, especially their 3D struc-
ture contributes to our under-
standing of protein stability, range 
of cross reactivity and changes in 
allergenicity during thermal or en-
zymatic treatment. 
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TABLE 1
Overview of 3 most important plant and animal food allergen protein 
families 
Protein su-
perfamily 
Protein 
family 
Biological 
function
Molecular 
mass (kDa)
Allergens 
known from 
Structure 
Animal food allergens
Tropomyosin
Muscle 
contraction
36-38 Crustaceans, 
molluscs
PDB: 1C1G
Parvalbumin 
Ca2+ 
binding 
12
Fish, 
amphibians
PDB:1B8R
Casein
Ca2+ 
binding
20-30
Mammalian 
milk
Not available
Plant food allergens
Prolamin 
superfamily
2S 
Albumin
Seed 
storage 
15-17 Peanut, tree 
nuts, seeds
PDB: 1PNB
ns-LTP
Plant 
defense
7-9 Plant food
PDB: 2B5S
Cupin 
superfamily 
7/8S 
globulin
Seed 
storage
150-190 Legumes, 
nuts, seeds
PDB: 3SMH
11S 
globulin
Seed 
storage
60 Peanut, tree 
nuts, seeds
PDB:3FZ3
PR10
Plant 
defense
17 Plant food
PDB: 2BKO
(ns-LTP – non-specific Lipid transfer protein; PR10 – pathogenesis related protein 
family 10; structures retrieved from pdb)
Emerging allergens
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s • Pollen exposure varies between geographical regions
• The same amount of olive pollen releases 12-fold variable 
amounts of Ole e 1, 10-fold differences in Bet v 1 is documented 
for birch pollen, while Phl p 5 from grass pollen can show even 
higher variations 
• Pollen allergen release potency is not geographically fixed and 
changes between years
• Pollen allergen release potency is determined in the week before 
pollination by two simultaneous competing ripening processes: 
anther development and individual pollen ripening
Allergies to pollen are the most 
frequent type 1 allergies, surpass-
ing the prevalence of allergies to 
house dust mite. Their prevalence 
have been increasing since dec-
ades and an end is not in sight.
Pollen is a natural product and 
shows a large geographical and 
climatic variability. Indeed, natural 
variability is so large that a simple 
prediction of pollen load depend-
ing on the year long experience is 
not possible. This has led to the im-
plementation of pollen monitoring 
networks.
GEOGRAPHIC FACTORS AND 
POLLEN ExPOSURE
Few pollen monitoring networks 
exist worldwide (Figure 1). In addi-
tion, rotorod samplers are used in 
USA, while Hirst-type pollen traps 
are frequent in Europe making 
quantitative comparison between 
continents challenging. 
However, similar results emerge: 
pollen exposure varies substan-
tially. For Europe, according to a 
20-year average, birch pollen is 
the dominant pollen with 2-times 
higher counts than grass pollen 
in almost all reported locations. 
Between locations, a 10-fold dif-
ference of pollen load was noted 
(Figure 2). 
Jeroen Buters  
Technische Universität München and Helmholtzzentrum  
Munich, Germany
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Pollen allergens and geographical factors
Climate change is reported to 
influence pollen season for the 
starting date and for the intensi-
ty for early blooming species. The 
natural yearly variability in pollen 
exposure is large, making the ef-
fect of climate change difficult to 
predict. An elongation of the birch 
pollen season was reported only 
in a few random places. Pollen 
exposure is mostly dependent on 
short-term local weather, making 
on the spot monitoring an essen-
tial instrument in determining ex-
posure.
GEOGRAPHICAL FACTORS AND 
POLLEN POTENCY
Pollens are natural products and 
like wine and strawberries their 
“quality” depends on the climatic 
conditions at source, which var-
ies with the geographical location. 
The amount of allergen released 
per pollen is variable between 
years, locations and even days. In 
a EU-wide project (www.hialine.
eu) the allergen release potency 
for olive, birch and grass pollen 
was analyzed with standardized 
methods. Across Europe, pollen 
potency varied 12-fold for olive 
pollen, 10-fold for birch pollen 
and even more for grass pollen. 
Also, potency of pollen from olive 
and birch depended on the origin 
of emission as potency is deter-
mined by weather at the place of 
emission, not at the place of meas-
uring the pollen. Within Germany, 
a constant 3-fold gradient of birch 
pollen potency is observed, with 
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southern pollen being more po-
tent that northern pollen. In the 
same line, olive pollen from Spain 
released 5 times more Ole e 1 than 
Portugese olive pollen.
The difference in pollen potency 
could be due to two competing rip-
ening processes: allergen expres-
sion in pollen increases from zero 
in the week before pollination to 
high numbers upon pollination 
(ripening of Bet v 1). Concomitant-
ly the anthers ripen too, and will 
release pollen when they are ripe 
and weather is suitable. Thus, bad 
weather can result in late opening 
of anthers and consequently long 
ripening periods for the allergen, 
resulting in more potent pollen. 
CONCLUSION
All investigated aeroallergens:pol-
len from birch, olive and grass, but 
also from cat, dog and horse vary 
at least 10-fold in allergen release 
within the same species. We ex-
pect the same for other sources.
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Figure 1 Pollen monitoring networks across the world. Current pollen monitoring sites running for more than 6 years. 
Three different types of pollen counters are in use worldwide: Rotorod, Durham and Hirst-type traps. This makes pollen 
counts difficult to compare. Data from Europe were provided by U. Berger, European Aerobiology Network (EAN), 
Medical University Vienna, from USA by Jerome Schultz (AAAAI), from Russia by E. Severova, from Japan by R. Kishikawa, 
from South Africa by D. Byrman, from Israel by A. Eshel, from Saudi Arabia by H. Syed, from Azores by Rui Brandao, from 
Canada by F. Coates and from Australia by Janet Davies. For some countries data was not available.
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Figure 2 Pollen distribution and pollen potency across Europe. Size of the circles represents quantitative differences in 
the pollen index, colors represent different pollen species (families). Bar graphs represent the amount of allergen released 
per pollen (potency) for the indicated locations. 
v 1 Allergen from Birch Pollen: 
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• The early development of memory T and B cell responses and IgE 
production represent the sensitization phase of allergic reaction
• IL-4 and IL-13 are essential to induce class switching to IgE in B 
cells and for the production of allergen-specific IgE antibodies 
• Cross-linking of the IgE-FcεRI complexes on basophils and mast 
cells and subsequent release of anaphylactogenic mediators is 
responsible for the immediate hypersensitivity reaction
• Effector T and B cell and eosinophil infiltration of the affected 
tissues is controlled by a chemokine network
• Type 2 innate lymphoid cells play a role in eosinophilic inflammation 
in mouse models and are observed in nasal polyp tissue in humans
• There is strong evidence on the defective allergen tolerance 
mechanisms by T and B regulatory cells 
• Epithelial barrier is leaky in asthma, chronic rhinosinusitis and 
atopic dermatitis
• Different disease endotypes show different dominant molecular 
mechanisms, biomarkers and therapy response to biologicals
The immune system forms an in-
teractive network with tissues and 
makes its decisions on the basis of 
signals coming from resident tissue 
cells, infectious agents, commensal 
bacteria and almost any environ-
mental agents. The immunologic 
basis of allergic diseases (Table 1) 
is observed in two phases: sensiti-
zation and development of mem-
ory T and B cell responses and IgE 
production and effector functions 
related to tissue inflammation, tis-
sue injury, tissue remodeling and 
chronicity in asthma, atopic derma-
titis (AD) and allergic rhinitis (AR). 
Different disease endotypes may 
become apparent with different 
dominant molecular mechanisms, 
related biomarkers and response 
to biological therapy.
In the sensitization phase, during 
the development of allergic dis-
eases, effector Th2 cells produce 
IL-4, IL-5, and IL-13. IL-4 and IL-
13 induce class switching to the 
ε immunoglobulin heavy chain 
in B cells and the production of 
allergen-specific IgE antibodies 
(Figure 1). Innate lymphoid cells 
(ILC2) also provide Th2 cytokines. 
Allergen-specific IgE binds to the 
high-affinity FcεRI on the surface 
of mast cells and basophils, thus 
leading to the patient’s sensitiza-
Cezmi A. Akdis  
Swiss Institute of Allergy and Asthma Research  
Davos, Switzerland
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The underlying mechanisms in allergy
tion. In the effector phase, when 
a new encounter with the allergen 
causes cross-linking of the IgE-
FcεRI complexes on sensitized ba-
sophils and mast cells, they are ac-
tivated and subsequently release 
anaphylactogenic mediators that 
are responsible for the immediate 
hypersensitivity reaction.
Defective epithelial barrier func-
tion has been demonstrated for 
bronchial epithelial cells in the 
asthmatic lung, epithelial cells 
in the sinus tissue of chronic rhi-
nosinusitis (CRS) patients as well 
as keratinocytes in the skin of AD 
patients. Recent studies suggest 
that tissue integrity is disturbed 
and allows penetration of aller-
gens, bacterial toxins and other 
particles through the epidermis, 
the lung and sinus epithelium, 
where they may activate the im-
mune system leading to severe 
chronic inflammation in these dis-
eases. Activation of the epithelial 
cells and release of IL-25, IL-31, 
IL-33 and TSLP contribute to type 
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The underlying mechanisms in allergy 
TABLE 1
Cellular and molecular events in allergic inflammation
• Epithelial barrier defect in the skin and affected mucosas
• Epithelial cell activation and their proinflammatory cytokines and 
chemokine production that induces inflammation and contributes to Th2 
response: TNF-α, IL-13, IL-25, IL-31, IL-33, TSLP
• Chemokine release attracting Th2 cells and eosinophils 
• Epithelial apoptosis and shedding in AD and asthma: IFN-γ, TNF-α, IL-32
• Innate lymphoid cell type 2 response: IL5, IL13
• Th2 response: IL-4, IL-5, IL-13,
• Eosinophilia: IL-5, IL-25, IL-33
• Local and systemic IgE production: IL-4, IL-13 
• Cross-linking of IgE receptor FcεRI on the surface of mast cells and baso-
phils and their degranulation
• Smooth muscle, myofibroblasts activation,  bronchial hyperreactivity in 
asthma: IL-4, IL-9, IL-13, IL-25, IL-33 
• Angiogenesis in chronic inflammation: VEGF, IL-32
• Survival and reactivation of migrating inflammatory cells and their inter-
action with resident tissue cells and other inflammatory cells: IL-2, IL-4 
• Activation of other effector T cell subsets, such as Th9, Th17 and Th22 
cells and their contribution to mucus production, tissue inflammation and 
regeneration.
Th2
IgE
production 
by plasma cells
naive
B cell
IgM
IL-4
IL-13
memory
B cell
IgE class 
switching
memory
B cell
IgE
IgE+ memory 
B cell
expansion 
allergens
IgE
degranulation
basophil
B cell epitopes
FcεRI
Vasoactive amins
(histamine)
Lipid mediators
(PGD2, PAF
LTC4, LTD4, LTE4)
Cytokines
(IL-3, IL-4, IL-5, IL-13)
Chemokines
type 1 hypersensitivity
Figure1
Akdis
ILC2
Figure 1 In the sensitization phase 
allergen-specific IgE antibodies 
are produced and bind to the 
high-affinity FcεRI on the surface 
of mast cells and basophils, thus 
leading to the patient’s sensitization. 
When a new encounter with the 
allergen causes cross-linking of the 
IgE-FcεRI complexes on sensitized 
basophils and mast cells, they release 
anaphylactogenic mediators that 
are responsible for the immediate 
hypersensitivity reaction.
2 responses of T cells and innate 
lymphoid cells (Figure 2). These 
cytokines play a role in the pro-
duction of allergen-specific IgE, 
eosinophilia, permissiveness of 
endothelium for the recruitment 
of inflammatory cells to inflamed 
tissues, production of mucus and 
decreased threshold of contrac-
tion of smooth muscle cells. 
The discovery of ILCs has changed 
our perception of T cells as the 
major cytokine-secreting effec-
tors of immunity and made us 
aware of completely unappreci-
ated innate immune cell sources 
of effector cytokines. Particularly 
type 2 ILCs can contribute to Th2 
type inflammation similar to Th2 
cells in mouse models. Th1 cells 
also efficiently contribute to the 
effector phase in allergic diseases 
with their role in apoptosis of the 
epithelium in asthma and AD.
In recent years, induction of im-
mune tolerance has become a 
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The underlying mechanisms in allergy
Figure 2 Pathogenic mechanisms in allergic inflammation. Epithelial leakiness and activation and their proinflammatory 
cytokines and chemokines (TNF-α, IL-13, TSLP, IL-31, IL-33) production induces inflammation and contributes to Th2 re-
sponse. Highly activated epithelial cells undergo apoptosis and shedding takes place. Chemokines are essential players for 
the recruitment of inflammatory cells, which is followed by survival and reactivation of migrating inflammatory cells and 
their interaction with resident tissue cells and other inflammatory cells. Innate lymphoid cells (ILC2) play a role in T and 
B cell activation and recruitment and are early providers of Th2 and T cell recruitment cytokines. Th2 type of an immune 
environment is characterized by IL-4, IL-5, IL-9, IL-13, IL-25, IL-33 production coming from Th2 cells and tissue cells. Eosin-
ophilia is induced by IL-5, IL-25, IL-33. Local and systemic IgE production takes place in allergic patients with the involve-
ment of IL-4, IL-13. Other effector T cell subsets, such as Th9, Th17 and Th22 cells also play partial roles in inflammation, 
mucus production and tissue healing. Smooth muscle, myofibroblasts activation and bronchial hyperreactivity is related 
to IL-4, IL-9, IL-13, IL-25, IL-33. Several chemokines, and arachidonic acid pathway molecules and other small molecules 
play roles in the inflammatory cell recruitment and further augmentation of the inflammatory cascades. 
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prime target for prevention and 
treatment strategies for allergic 
diseases. Immune tolerance to 
allergens can be defined as estab-
lishment of a long-term clinical 
tolerance against allergens, which 
immunologically implies changes 
in memory type allergen-specific 
T and B cell responses as well as 
mast cell and basophil activation 
thresholds that do not cause al-
lergic symptoms anymore (Figure 
3). T and B regulatory cells and 
production of allergen-specific 
IgE-blocking IgG4 isotype anti-
bodies play an essential role in 
allergen tolerance. Similar mech-
anisms of immune tolerance take 
place in high dose allergen ex-
posed bee-keepers and cat owners 
(who do not develop allergy), after 
allergen-specific immunotherapy, 
and in individuals who naturally 
outgrow allergic diseases.
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Figure 3 Concept development 
in T cell tolerance in allergy and 
autoimmunity. After the discovery 
of Th1 and Th2 cell subsets in 1986, 
it was thought that Th1 cells play a 
role in infections and autoimmunity 
and Th2 cells in allergic disease. Both 
subsets were considered to have 
reciprocal roles in counter regulating 
each other. After the introduction 
of Treg cells, it was demonstrated 
that although there is reciprocal 
regulation between individual Th cell 
subsets, Treg cells play a major role in 
the induction of    immune tolerance 
in allergy, autoimmunity, organ 
transplantation, cancer, pregnancy, 
chronic infections.
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• Bronchial epithelial cells and skin keratinocytes play an important 
role in asthma and atopic dermatitis
• Type 2 innate lymphoid cells are essential for asthma progression
• Dendritic cell subsets may play both pro and anti-inflammatory 
roles
• Epithelial cells, dendritic cells and innate lymphoid cells play a 
crucial role during the chronic phase of the allergic inflammation 
by producing pro-inflammatory cytokines and chemokines that 
attract other inflammatory cells to affected tissues
• Non-antigen specific innate immunity serves as the bridge to 
adaptive immune responses
While the underlying inflamma-
tion in allergic asthma, allergic 
rhinitis and atopic dermatitis is 
thought to result from the activity 
of Th2 cells, the innate (non-anti-
gen specific) response to these in-
sults provides key triggers for the 
initiation of the chronic inflamma-
tion. 
Innate immune responses begin 
with sensing of insults by airway 
and skin epithelial cells. Non-spe-
cific antigen recognition by epi-
thelial cells occurs via pattern rec-
ognition receptors (PRR), which 
include both soluble (collectins) 
and cellular [Toll-like receptors 
(TLR)] PRRs. Soluble PRRs recog-
nize the carbohydrate moieties 
of microbes and can activate the 
complement cascade, initiating 
inflammatory responses. Cellular 
PRRs are better known for their 
interaction with pathogen-associ-
ated molecular patterns (PAMPs). 
Although TLRs are best known for 
binding to products of microbes 
and viruses, allergens also inter-
act with TLRs (e.g., house dust 
mite protein, Der p2 with TLR4). 
Binding of TLRs and other cellular 
PRRs triggers the production of 
interferon (IFN) and pro-inflam-
matory cytokines and chemok-
ines. Both type I and type III IFN 
Michael n. Teng Richard F. Lockey
University of South Florida  
Tampa, USA
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production are important for 
antiviral defense. Airway epithe-
lial cells from subjects with asth-
ma have decreased levels of IFN 
production after viral infection, 
suggesting that IFN may play a 
protective role in preventing viral 
asthma exacerbations. Production 
of pro-inflammatory cytokines / 
chemokines (e.g., TNFα, IL-1, IL-6, 
IL-25, IL-33, TSLP) from epithelial 
cells is the result of PRR activation 
of NFκB. 
Epithelial cells responding to aller-
gen insult also produce IL-25, IL-33 
and thymic stromal lymphopoietin 
(TSLP) (Figure 1). These cytokines 
have downstream effects on in-
nate and adaptive immune cells. In 
particular, type 2 innate lymphoid 
cells (ILC2, Neucytes) are impor-
tant for asthma pathogenesis. 
ILC2 are derived from a common 
lymphoid progenitor and related 
to NK and RORγt innate lymphoid 
cells (Figure 2). ILC2 respond to IL-
25, IL-33, and TSLP stimulation by 
producing high levels of “Th2-type” 
cytokines (i.e., IL-5, -9, and -13) 
upon stimulation. These cytokines 
can then activate eosinophils (via 
IL-5, -13) and mast cells (via IL-9) 
as well as B and T lymphocytes 
(Figure 1). In addition, secretion 
of IL-13 induces mucus produc-
tion, smooth muscle contractility, 
and alternative activation of alve-
olar macrophages, which leads to 
amplification of IL-33 production. 
ILC2 also secrete amphiregulin, 
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which may be involved in airway 
remodeling. TSLP also drives the 
maturation of immature lung den-
dritic cells (DC) to conventional 
DC capable of presenting antigen 
to T cells. These allergen-activat-
ed DC then initiate the adaptive 
immune responses characteristic 
of atopic airway disease.
In summary, innate immunity plays 
a key role in initiating asthma. Rec-
ognition of insults by AEC leads 
to activation of ILC2, which pro-
duce Th2-type cytokines, and DC, 
which stimulate allergen-specific 
CD4+ T cell responses is necessary 
for asthma progression. 
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Figure 1 Innate immune response in asthma. Exposure to allergens or viruses 
induces innate immune responses in airway epithelial cells. Viral infection in-
duces type I and type III interferon (IFN) responses. Epithelial cells also secrete 
IL-25, IL-33, and TSLP, which activate type 2 innate lymphoid cells (ILC2) and 
dendritic cells (DC). ILC2 cells produce “Th2-like” cytokines (e.g., IL-5, IL-9, and 
IL-13). These cytokines then active eosinophils, mast cells, and goblet cells to 
cause disease. ILC2 also produce amphiregulin (Areg) to induce airway remod-
eling. Activated DC traffic to lymphoid organs to initiate T cell responses to the 
allergens/viruses to further disease pathogenesis. Adapted from ref. 3.
Figure 2 Differentiation of ILC2 cells. ILC precursors (ILCP) are derived from 
the common lymphoid progenitor (CLP) cells in an Id2-dependent process. ILCP 
are further differentiated into RORγt, NK, and ILC2 cells through the activities 
of transcription factors (GATA3, RORα) and cytokines (IL-7, IL-15). CLP cells 
also differentiate into Th2 cells through thymic maturation. ILC2 and Th2 cells 
secrete an overlapping set of cytokines. Adapted from ref. 3.
Innate immune response in allergy
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• Dendritic cells are one of the first immune cells that come into 
contact with allergens at mucosal surfaces and can sample 
luminal antigens directly by extending dendrites across the 
epithelial barrier
• In the lymph node they report on the type of antigen encountered 
and subsequently induce CD4 T helper cell differentiation and 
CD8 T cell activation and transfer some of their encountered 
antigens to B cells
• Lung and skin DCs also play a crucial role during the chronic 
phase of the allergic inflammation, by producing chemokines 
that attract other inflammatory cells to inflamed tissues
• Unraveling how DCs induce and maintain Th2 immunity will 
provide new selective therapeutics targets for allergic diseases
The adaptive immune response 
to allergens is characterized by a 
humoral arm (production of IgE 
by B lymphocytes), and a cellular 
arm (CD8 and CD4 T lymphocytes 
that respond to the allergen in the 
context of MHCI and MHCII mol-
ecules). Before adaptive immuni-
ty is induced to environmental or 
food allergens, the allergen must 
get through the natural barriers of 
the body (skin, mucus membranes) 
and reach the cells of the immune 
system that are recirculating in 
the lymph nodes (LN). Dendritic 
cells (DCs) are one of the first im-
mune cells that come into contact 
with allergens at mucosal surfac-
es. In the lungs, intestine and skin, 
DCs sit at the basolateral side of 
Bart n. Lambrecht  
Gent University,  
Gent, Belgium
DENDRITIC CELLS6
Ke y  m e ssag e s
Dendritic cells
epithelial cells and can sample lu-
minal antigens directly by extend-
ing dendrites across the epithelial 
barrier (Figure 1). 
After antigen uptake, DCs migrate 
to the draining LN and present the 
processed antigen to naïve T cells, 
leading to clonal expansion and 
differentiation of antigen-specific 
T cells (Figure 2). Dendritic cells 
arriving in the LN report on the 
type of pathogen or allergen that 
has been encountered in the pe-
riphery, and they subsequently 
induce CD4 T helper cell differen-
tiation (Figure 3), CD8 T cell acti-
vation and transfer some of their 
encountered antigens to B cells. 
DCs originating from the lungs 
of house dust mite (HDM) al-
lergen-exposed mice are neces-
sary and sufficient to induce Th2 
sensitization to HDM. Lung and 
skin DCs also play a crucial role 
during the chronic phase of the 
allergic response, by producing 
chemokines that attract other in-
flammatory cells back to periph-
eral tissues (Figure 2). In addition, 
allergen-specific IgE and IgG1, 
through stimulation of FcεRI and 
FcγRIII respectively, target aller-
gens to DCs thus boosting Th2 
immunity further. During both 
sensitization and challenge, DCs 
closely communicate with neigh-
Figure 1  Dendritic cells across the 
epithelial barrier.
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Dendritic cells 
Figure 2 Role of dendritic cells in inflammation and T-cell polarisation.
Figure 3 Factors that affect T-cell differentiation.
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boring epithelial cells. Triggering 
of pattern recognition receptors 
on epithelial cells like the Toll-like 
receptor 4 or protease activated 
receptors by allergens leads to the 
production of epithelial-derived 
chemokines and cytokines (Fig-
ure 4) that recruit DCs and that 
program the DCs to induce Th2 
immune responses. Epithelial cells 
and other innate immune cells also 
make endogenous danger signals 
like uric acid, ATP and High Mobili-
ty Group Box 1 (HM-GB1) that can 
have the same effect on DCs. 
Patients with atopic dermatitis, al-
lergic rhinitis and asthma have in-
creased numbers of activated DCs 
armed with IgE in the inflamed 
tissues. Not surprisingly, target-
ing the function of DCs in allergy 
constitutes a therapeutic avenue. 
However, eliminating the function 
of DCs completely would also in-
duce immunodeficiency, and it is 
much more important to unravel 
how DCs induce and maintain Th2 
immunity selectively, to find new 
therapeutics for allergy.
KEY REFERENCES
1. Lambrecht BN, Hammad H. Lung 
dendritic cells in respiratory viral 
infection and asthma : from protec-
tion to immunopathology Ann Rev 
Immunol 2012;30:243-270.
2. Plantinga M, Guilliams M, Van-
heerswynghels M, Deswarte K, 
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cyte-derived CD11b(+) dendritic 
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2013;38:322-335.
3. Lambrecht BN, Hammad H. The 
airway epithelium in asthma. Nat 
Med 2012;18:684-692.
4. Hammad H, Chieppa M, Perros F, 
Willart MA, Germain RN, Lambre-
cht BN. House dust mite allergen 
induces asthma via Toll-like recep-
tor 4 triggering of airway structural 
cells. Nat Med 2009;15:410-416.
5. Kool M, Willart MA, van Nimwegen 
M, Bergen I, Pouliot P, Virchow JC 
et al. An unexpected role for uric 
acid as an inducer of T helper 2 cell 
immunity to inhaled antigens and 
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540.
Th2
Dendritic cells
Figure 4 The interaction of dendritic cells and epitelial cells drives the inflammatory process.
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by secreting various cytokines or cell-to-cell contact and thus, 
regulate innate and adaptive immune responses and maintain 
immune homeostasis
• NK cells express subsets similar to T helper cells, such as NK1, 
NK2 and NK regulatory cells
• Understanding the mechanisms enrolled in the development of 
allergic diseases are essential to develop strategies for treatment 
and prevention 
• Recent developments in NK cell subsets support their role in 
allergic diseases
Besides the heterogeneity of asth-
ma pathogenesis, current knowl-
edge underlines the dominance 
of a subgroup with Th2-like im-
mune response and eosinophil-
ia. However allergic asthma may 
additionally involve innate, T cell 
independent immune responses. 
Several different populations of 
innate lymphoid cells (ILC), in-
cluding natural killer (NK) cells, γδ 
T cells, and CD1-restricted NK1 
cells have been previously impli-
cated in the regulation of immune 
responses in the respiratory tract.
NK cells are innate lymphocytes, 
which are a first line of defense 
against infection and cancer. The 
airways are a major route of en-
try of many important pathogens 
into the body and the ability of 
NK cells to respond rapidly to 
infection suggests an important 
role for these cells in acute pul-
monary infection. Recent devel-
opments in our understanding 
of NK cell subsets support their 
role in allergic diseases that may 
contribute to allergen-specific 
Th1 or Th2 cell generation as well 
induction or suppression of IgE. 
The in vivo and in vitro existence 
of human NK cell subsets, simi-
lar to Th1 and Th2 cells, with dis-
tinct cytokine patterns as IFN-γ 
Günnur Deniz  
Istanbul University 
Istanbul, Turkey
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Natural killer cells and natural killer-T cells
secreting and IFN-non-secreting 
NK cells strongly support this 
concept (Figure 1). The IFN-γ se-
creting NK subset showed a typ-
ical Th1-like cytokine pattern. In 
contrast, the IFN-γ-non-secreting 
NK subset was composed of IL-
4, IL-5 and IL-13-producing NK 
cells. These results demonstrate 
that circulating NK cells retain 
effector subsets in humans with 
distinct cytokine profiles and may 
display different inflammatory 
properties. In addition, it has been 
reported that patients with aller-
gic rhinitis had a higher percent-
age and cytotoxicity of NK cells 
compared to nonatopic patients. 
The mean percentage of IL-4- and 
IL-13-secreting NK cells were sig-
nificantly higher, while IFN-γ+ NK 
cells were not significantly lower 
in allergic rhinitis patients com-
pared to nonatopic controls. Since 
NK cells are important cells in in-
nate immunity and the initiation 
of immune responses, their differ-
ent cytokine patterns may be im-
portant in changing the cytokine 
milieu and the induction of T cell 
deviation.
Natural killer-T (NK-T) cells are 
unique CD1d-restricted T cells 
with NK cell surface markers. 
These cells may play an important 
role in the pathogenesis of asthma. 
Invariant NK-T cells and not con-
ventional MHC class II-restricted 
CD4+ T cells were found predomi-
nant in the lungs and bronchoalve-
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olar lavage fluid of allergic asthma. 
Although CD1d-restricted NK-T 
cells might play a role in modulat-
ing the asthmatic phenotype, they 
are not the critical drivers of the 
asthmatic response and at most 
play a modulatory role.
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NK 
NK1
IL-12, IL-18
NK22
IFN-γ
IL-5, IL-13
IL-10, TGF-β
IL-22
Suppression of  IgE
production
Protection of 
epithelial cell bariers
NK2
NKreg
IL-4
IL-2
IL-23
Suppression of  IgE
production
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production
Figure 1 NK cells are divided into four different subsets according to their cytokine secretion. NK cells have been 
detected in close contact to dendritic cells. NK cells grown in IL-12 and IL-18 (NK1) produce IFN-γ and inhibit IgE 
production, whereas NK cells grown in IL-4 (NK2) produce IL-5 and IL-13 and stimulate IgE production. NK reg cells 
produce IL-10 and TGF-β and suppress IgE production. IL-22 secreting NK22 subset might have a role in the protection 
of epithelial cell barriers. (Reprinted from J Allergy Clin Immunol, 132/3, Deniz G,van de Veen W, Akdis M. Natural  killer cells in 
patients with allergic diseases, 527-35, Copyright 2013, with permission from Elsevier.) 
Natural killer cells and natural killer-T cells
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s • Innate lymphoid cells (ILCs) have lymphoid morphology, but lack 
rearranged antigen receptors and myeloid and dendritic cell 
markers
• ILCs are derived from a committed ILC precursor 
• Group 1 ILCs (ILC1s) release INF-γ, but not Th2 and Th17 
cytokines under the  influence of IL-12 and IL-18
• Group 2 ILCs (ILC2s) may play a role in allergic diseases and 
eosinophilic inflammation by releasing the Th2 cytokines IL-
5, IL-9 and IL-13, when stimulated with IL-25, IL-33 and thymic 
stromal lymphopoietin
• Group 3 ILCs (ILC3s) may play a role in some chronic allergic 
diseases by releasing the Th17 cytokines IL-17 and IL-22 
DEFINITION AND ONTOGENY
Innate lymphoid cells (ILCs) are the 
cells having lymphoid morphology, 
but lacking recombination acti-
vating gene (RAG)-dependent re-
arranged antigen receptors. They 
also lack myeloid and dendritic 
cell markers (Lineage – (Lin-)). Ac-
cording to these definition, natural 
killer (NK) cells and lymphoid tis-
sue-inducer (LTi) cells are included 
into the ILC population. NK cells 
mediate initial immune responses 
against viruses and cancer cells. 
LTi cells are essential for the for-
mation of lymph nodes. 
ILCs can be divided into three 
groups. Group 1 ILCs (ILC1s) are 
defined by their capacity to pro-
duce Th1 cytokine IFNγ and the 
inability to produce Th2 cell- and 
TH17 cell-associated cytokines. 
They develop under the influence 
of IL-12 and IL-18. Group 2 ILCs 
(ILC2s) are capable of producing 
Th2 cytokines (IL-5, IL-9 and IL-13) 
in response to epithelium-derived 
cytokines IL-25, IL-33 and thym-
ic stromal lymphopoietin (TSLP). 
Group 3 ILCs (ILC3s) can produce 
Th17 cytokines IL-17 and/or IL-22 
in the presence of IL-1β and IL-23. 
Some ILC3s express the natural 
cytotoxicity triggering receptor 
(NCR) NKp46 (NCR+ ILC3s). The 
NCR+ ILC3s can produce IL-22, 
Hirohisa Saito  
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but not IL-17, while NCR-- ILC3s 
are capable of producing IL-17, 
but not IL-22. However, it should 
be noted that some NCR--ILC3s 
can also produce IL-22. Recently, 
it was suggested that ILCs are de-
rived from a committed ILC pre-
cursor, which is developmentally 
unrelated to NK and LTi cells. 
ROLE OF ILCS IN ALLERGY
ILC2s include Lin- SCA1+ natural 
helper cells found in fat-associat-
ed lymphoid clusters, Lin-SCA1+ 
nuocytes and Lin-SCA1- innate 
helper 2 cells derived from lymph 
nodes of IL-25 and/or IL-33-inject-
ed or N. brasiliensis-infected mice. 
ILC2s are important in host resist-
ance against nematodes. Although 
Th2 cells are a major source of 
type 2 cytokines during asthmatic 
and allergic reactions, ILC2s also 
contribute to disease pathology, 
especially where IL-25, IL-33 and 
TSLP are released by inflamed and 
damaged epithelia. Human ILC2s 
have similar properties with their 
murine counterparts. In addition, 
human ILC2s express CRTh2 (che-
moattractant receptor-homolo-
gous molecule expressed on Th2 
cells) on their surface.
IL-17-producing ILC3s play a role 
in neutrophilic inflammation in a 
particular endotype of asthma via 
production of IL-1β by macrophag-
es stimulated with damage-associ-
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Figure 1 Ontogeny of innate lymphoid cells (ILCs). A committed ILC precursor (ILCP) having a high level of 
transcriptional factor PLZF (2) can give rise to ILC1s, ILC2s and ILC3s, but not to LTi cells and NK cells, which originate 
from a α4β7+ common progenitor shared with the three ILC lineages. Development of ILC2s depends on the transcription 
factors Gfi1, GATA3 and RORα. ILC3s require the transcription factor RORγt for their development and function. 
Although NCR+ ILC3s can give rise to ILC1s if stimulated with IL-12 and IL-18, the differentiation pathway of ILC1s is not 
fully understood yet. 
Innate lymphoid cells
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Figure 2 The role of ILCs in allergy. Epithelial tissues can release IL-25, IL-33 and TSLP in response to protease allergens 
such as house dust mites or papain, DAMPs, PAMPs and TH2 cytokines. In response to the epithelium-derived cytokines 
ILC2s can release IL-13, which induces inflammation and remodeling (such as goblet cell hyperplasia) in the tissue, and IL-
5, which can induce eosinophilic inflammation. ILC3s release IL-17, which can induce neutrophilic inflammation, and IL-22, 
which inhibits the release of ILC2-activating cytokines. 
ated molecular patterns (DAMPs) 
and/or pathogen-associated mo-
lecular patterns (PAMPs). The 
expression of the IL-10 family 
cytokine IL-22, which is capable 
of being released from ILC3s, LTi 
cells or Th17 cells, is increased in 
chronic allergic inflammation in 
the lung and skin. IL-22 inhibits 
the production of ILC2-activating 
cytokines, IL-25 and IL-33.
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Innate lymphoid cells and allergy
53
Global atlas oF allerGy
se
c
t
io
n
 a
 - A
llergy  - fro
m
 gen
etics to
 m
ech
an
ism
s 
• Mast cells develop in essentially all tissues from precursors that 
circulate in the blood
• Mast cells are major sources of histamine and other products 
(mediators) that contribute to anaphylaxis and other allergic 
disorders
• Mast cells can be rapidly activated (within minutes) to release 
mediators when allergens are recognized by IgE antibodies 
bound to IgE receptors (FcεRI) on the cells’ surface
• Mast cells also can be activated to release mediators by many 
agents that act independently of IgE 
• Mast cells can have beneficial roles in enhancing resistance to 
animal venoms and in host defense against certain parasites
WHAT ARE MAST CELLS?
In humans and other vertebrates, 
mast cells reside in virtually all 
tissues, often close to epithelial 
surfaces (e.g., the skin, respira-
tory system, and gastrointesti-
nal tract) and near blood vessels, 
nerves, smooth muscle cells and 
fibroblasts. Mast cell precursors 
are generated in the bone mar-
row, circulate in the blood, and 
then enter the tissues where they 
complete their maturation, be-
coming cells with many prominent 
cytoplasmic granules (Figure 1A 
& C). These granules are storage 
sites for mast cell products (often 
called “mediators”) that, when re-
leased by the cell, have powerful 
effects on other cell types. Mast 
cell granules contain most of the 
body’s histamine and virtually all 
of its heparin, as well as a variety 
of proteases (Table 1). When mast 
cells are “activated” (i.e., stimulat-
ed to release their products), they 
release histamine, heparin and 
proteases by “degranulation” (Fig-
ure 1B & D), and they also secrete 
many other mediators that are not 
stored, but are synthesized by the 
activated cells, including leukot-
rienes, prostaglandins, cytokines, 
chemokines and peptide growth 
factors (Table 1). Mast cell num-
bers can increase in tissues at sites 
Stephen J. Galli  
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Mast cells
of allergic diseases or parasite in-
fections, and in other settings.
HOW CAN MAST CELLS BE 
ACTIVATED TO RELEASE THEIR 
PRODUCTS?
Mast cells express on their sur-
face hundreds of thousands of 
high affinity receptors (FcεRI) that 
strongly bind the Fc portion of IgE 
antibodies. Individual mast cells 
can bind IgEs which recognize 
any of a variety of different aller-
gens derived from pollens, foods, 
dust mites, medicines, etc. Such 
mast cells can be activated when 
they encounter any antigens that 
cross-link two adjacent IgE mole-
cules, which results in aggregation 
of the IgE-bound FcεRIs, signaling 
the cells to release their products 
(Figure 1B & D). Mast cells also can 
be activated independently of IgE, 
e.g., by products of microorgan-
isms, certain neuropeptides, and 
compounds present in animal ven-
oms (Table 2).
When large numbers of mast cells 
are rapidly activated by the sys-
temic distribution of an allergen 
in subjects who have IgE recog-
nizing that allergen, anaphylaxis 
can occur within minutes. Such 
IgE-dependent anaphylaxis is ab-
sent or markedly diminished in 
mice genetically lacking mast cells 
(even though they have basophils, 
another bone marrow-derived cell 
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Figure 1 (A, C) A resting mast cell 
(shown in a transmission electron 
micrograph in A and as a cartoon in C) 
contains many cytoplasmic granules 
(indicated by arrows in A) and has 
allergen-specific IgE (yellow symbols 
in C) bound to FcεRI receptors (green 
symbols in C) on its surface (B, D). 
When allergen (red symbols in D) is 
recognized by adjacent IgE antibodies 
bound to the mast cell’s FcεRI 
receptors, this aggregates the FcεRIs 
on the cell’s surface, activating the mast 
cell to release its granule contents at 
points where the granules fuse with 
the plasma membrane (indicated by 
arrows in a transmission electron 
micrograph in B and as a cartoon in D). 
Such activated mast cells also secrete 
newly synthesized products that are 
not stored in the granules. (Modified 
from Fig. 9.44 in Parham P. The Immune 
System. 3rd edition, Copyright 2009 
from The Immune System by Parham. 
Reproduced by permission of Garland 
Science/Taylor & Francis LLC. The 
electron micrographs in A & B are 
courtesy of Ann M. Dvorak.) 
TABLE 1
Mast Cell Products
Products Biological effects*
Stored preformed in 
granules and secreted 
upon activation (in 
minutes)
Histamine
• Increases vascular permeability and blood vessel dilatation
• Contracts airway smooth muscle
• Causes itching and pain
• Influences immune responses and the function of some nerves
Heparin
• Anticoagulant 
• Required for storage of other products in granules
Proteases (e.g., 
tryptase, chymase, 
carboxypeptidase 
A3)
• Degrade certain proteins and peptides, including components of 
animal venoms
• Regulate tissue remodeling
• Converts angiotensin I to angiotensin II (chymase)
Synthesized and se-
creted upon activation 
(beginning in minutes 
for lipid mediators, 
extending over hours 
for peptide products†)
Lipid mediators 
(e.g., leukotrienes, 
prostaglandins)
• Regulate migration and function of leukocytes 
• Increase vascular permeability
• Induce constriction or dilatation of blood vessels (depending on 
the type of mediator)
• Contract or relax smooth muscle (airways, gastrointestinal tract)
• Enhance mucus secretion
Cytokines, chemok-
ines, peptide growth 
factors
• Many effects on other cells (both leukocytes and tissue structural 
cells) that can promote or suppress inflammation and/or tissue re-
modeling
* Only some of the many biological effects of these products are listed.
† Some of these can be present in granules and therefore also can be released rapidly upon mast cell activation.
Mast cells
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TABLE 2
Mechanisms of mast cell activation*
Activation mechanisms† Settings in which this occurs Comments
Cross-linking of IgE bound to mast cell 
surface FcεRI by multivalent antigen 
recognized by the IgE
Anaphylaxis, allergic rhinitis, 
atopic dermatitis, allergic 
asthma, some types of urti-
caria
The site of mast cell activation depends on the 
site of exposure to the antigen; in anaphylaxis, 
there is systemic distribution of the offending 
antigen throughout the body.
Reaction of microbial products or 
products of damaged or dead cells 
with receptors (Toll-like receptors or 
other pattern recognition receptors) 
on the mast cell surface or inside the 
mast cell
Various types of viral or bac-
terial infections; diverse set-
tings in which cell damage or 
cell death occurs
Exposure of mast cells to some of these prod-
ucts cells can influence how the mast cells re-
spond to other activation signals, such as IgE 
and antigen.
Reaction of endogenous peptides 
with receptors for those peptides on 
the mast cell surface
Various disease processes or 
mechanisms of host defense 
that maintain health
Endogenous peptides that can activate some 
types of mast cells include certain neuropep-
tides, endothelin-1, and products of comple-
ment activation (C3a, C5a).
Reaction of exogenous peptides with 
receptors on the mast cell surface 
that recognize such peptides
Envenomation by venomous 
reptiles
Some of these venom peptides are structur-
ally similar to endogenous peptides that can 
also activate mast cells; mast cell proteases 
released when the activated mast cells de-
granulate can degrade and thereby reduce the 
toxicity of some components of the venoms.
* In addition to mechanisms that activate mast cells, certain stimuli can diminish the extent of mast cell activation.
† Mast cells activated by IgE and specific antigen can release many or all of the products listed in Table 1. By contrast, other acti-
vation mechanisms can result in the relatively selective release of granule-stored products (e.g., in response to certain peptides) or 
cytokines, chemokines and growth factors (e.g., in response to certain microbial products).
type that can bind IgE), showing 
that mast cells importantly con-
tribute to this acute, catastroph-
ic and potentially fatal reaction. 
Through effects of released mast 
cell products on inflammation 
and structural cells in the affected 
tissues (Table 1), IgE-dependent 
mast cell activation can contribute 
to late phase reactions (that devel-
op hours after allergen exposure) 
and to the features of chronic al-
lergic inflammation (e.g., in allergic 
asthma). 
DO MAST CELLS CONTRIBUTE 
TO HEALTH, OR ONLY TO 
DISEASE?
From an evolutionary perspective, 
mast cells did not develop in order 
to cause disease. Likely beneficial 
roles of mast cells include enhanc-
ing host resistance to some par-
asites and other pathogens and 
enhancing innate and acquired re-
sistance to certain animal venoms. 
Mast cells also have the potential 
to limit the pathology associated 
with certain innate or acquired 
immune responses through the 
production of mediators with an-
ti-inflammatory or immunosup-
pressive effects.
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owing to their small numbers and phenotypic similarity to mast 
cells
• The finding that basophils secrete large quantities of Th2 
cytokines (IL-4 and IL-13) ended the long-held view of basophils 
as minor relatives of mast cells with little function
• Basophils normally circulate in the blood, and are recruited to 
affected tissues in various allergic disorders, including allergic 
rhinitis, chronic urticaria, atopic dermatitis, and asthma
• Recent development of analytical tools in mouse models has 
identified pivotal and nonredundant roles for basophils in a 
variety of immune responses, including allergy
Basophils are the least abundant 
granulocytes, and represent less 
than 1% of peripheral blood leuko-
cytes. They were first document-
ed by Paul Ehrlich more than 100 
years ago, but their functional sig-
nificance remained enigmatic for a 
long time. Basophils share certain 
features with tissue-resident mast 
cells, including the presence of ba-
sophilic granules in the cytoplasm, 
the surface expression of IgE re-
ceptor (FcεRI), and the release of 
chemical mediators in response 
to various stimuli (Table 1). There-
fore, they have often erroneously 
been considered as minor and re-
dundant relatives or precursors of 
tissue-resident mast cells. Indeed, 
in clinical settings, basophils have 
been used, as surrogates of less 
accessible tissue mast cells, for the 
in vitro quantification of immedi-
ate-type response to allergens in 
allergic patients.
Basophils circulate in the periph-
eral blood, and are rarely present 
in peripheral tissues under home-
ostatic conditions, in contrast to 
mast cells. The half-life of circu-
lating basophils is estimated at 
approximately 2 days, while mast 
cells survive for months in periph-
eral tissues. Although these differ-
ences suggest that basophils and 
Hajime Karasuyama  
Tokyo Medical and Dental University 
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mast cells may play distinct roles 
in vivo, no definitive evidence for 
it has been provided until recently. 
Basophils release preformed his-
tamine, newly synthesized leukot-
riene C4, and Th2 cytokines (IL-4 
and IL-13), all of which are involved 
in allergic reactions. Indeed, baso-
phils have been demonstrated to 
infiltrate affected tissues in var-
ious allergic disorders, including 
allergic rhinitis, chronic urticaria, 
atopic dermatitis, and asthma. 
However, the overwhelming influx 
TABLE 1
Difference between basophils and mast cells
Basophils Mast cells
Place of birth bone marrow bone marrow
Place of maturation bone marrow peripheral tissues
Anatomical localization peripheral blood peripheral tissues
Life span short (several days) long (weeks or months)
Proliferation capability - +
57
Global atlas oF allerGy
se
c
t
io
n
 a
 - A
llergy  - fro
m
 gen
etics to
 m
ech
an
ism
s 
of eosinophils in these responses 
has long overshadowed the signif-
icance of basophil infiltration and 
it has remained uncertain whether 
basophils play a crucial role or are 
just redundant with mast cells.
Recent development of analyti-
cal tools for basophil function in 
vivo, including basophil-deficient 
mice, has identified pivotal and 
nonredundant roles for basophils 
in a variety of immune responses 
in mouse models, such as allergic 
reactions (allergic rhinitis, chronic 
cutaneous allergic inflammation, 
systemic anaphylaxis, and eosin-
ophilic esophagitis), autoimmun-
ity (lupus nephritis), protective 
immunity against infections with 
parasites (ticks and intestinal hel-
minths), and regulation of innate 
and acquired immunity (gener-
ation of Th2 cells and M2-type 
macrophages, and enhancement 
of humoral immunity) (Figure 1). 
Of note, the number of basophils 
recruited to affected tissues of 
model mice is much smaller than 
that of eosinophils, as observed in 
allergic patients, suggesting that 
basophils may also play key roles 
in the development and exacerba-
tion of human allergic disorders in 
spite of their paucity. Therefore, 
basophils and their products could 
be promising targets for the treat-
ment of allergic disorders.
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Figure 1 Previously unappreciated roles of basophils revealed by mouse studies.
Basophils 
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• Eosinophilia in allergic diseases is largely mediated by IL-5-
producing T cells
• Eosinophils can cause organ dysfunction by both cytotoxicity 
and fibrosis
• Specific anti-eosinophil therapies have been shown to be 
effective in asthma
Eosinophils are terminally differ-
entiated granulocytic effector 
cells that produce and store bio-
logically active molecules, includ-
ing cytotoxic proteins, lipid medi-
ators, chemotactic peptides, and 
cytokines. They are considered as 
multifunctional cells able to mod-
ulate both innate and adaptive 
immunity (Fig. 1). Eosinophils are 
generated in the bone marrow 
under the influence of eosinopoie-
tins (IL-3, IL-5, GM-CSF), released 
to peripheral blood upon matura-
tion, and mainly reside in the he-
matopietic and lymphatic organs, 
such as the bone marrow, spleen, 
lymph nodes, and thymus. The 
normal eosinophil blood count 
ranges from 50 to 500 x 109/L. 
Eosinophil numbers can increase 
in various inflammatory reactions, 
including allergic diseases. Several 
proposals for the classification of 
eosinophil-related disorders have 
been published. In allergic diseas-
es, eosinophilia is largely mediat-
ed by IL-5 - producing T cells.
Clinical observations point to a 
potential role of eosinophils in the 
pathogenesis of allergic diseases. 
Eosinophil numbers in blood and 
eosinophil tissue infiltration of-
ten correlate with the severity of 
the disease. Therefore, therapies 
Hans-Uwe Simon  
University of Bern 
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that reduce eosinophil numbers 
are usually effective in allergic dis-
eases. Moreover, the numbers of 
eosinophils in sputum have been 
shown to predict the success of 
anti-eosinophil therapies in asth-
matic patients. For example, tai-
loring of asthma treatment based 
on sputum eosinophils is effective 
in decreasing asthma exacerba-
tions.
The exact role of eosinophils in 
the pathogenesis of allergic dis-
eases is currently a topic of inten-
sive research. In asthma, eosin-
ophil-derived cytotoxic proteins 
and reactive oxygen species have 
been shown to damage bronchial 
epithelial cells, leading to a bar-
rier defect. Eosinophils are also a 
source of lipid mediators, such as 
leukotriene C4 and platelet-ac-
tivating factor, which can cause 
bronchoconstriction. Moreover, 
eosinophils can amplify T helper 
2 immune reactions by the gener-
ation of cytokines. A role for eo-
sinophils in experimental asthma 
has been demonstrated in eosino-
phil-deficient mice, which demon-
strated reduced T cell recruitment 
and mucus production, as well as 
reduced bronchial hyperreactivity.
Eosinophils also play a role in tis-
sue repair and remodeling pro-
cesses. Specific anti-eosinophil 
treatment by using anti-IL-5 an-
tibodies was associated with re-
duced fibrosis in allergic asthma 
and eosinophilic esophagitis. The 
peribronchial fibrosis was also 
reduced in experimental asthma 
induced in eosinophil-deficient 
mice. Therefore, eosinophils can 
contribute to organ dysfunction 
by both cytotoxicity and fibrosis.
59
Global atlas oF allerGy
se
c
t
io
n
 a
 - A
llergy  - fro
m
 gen
etics to
 m
ech
an
ism
s 
KEY REFERENCES
1. Simon D, Simon HU. Eosinophilic 
disorders. J Allergy Clin Immunol 
2007;119:1291-1300.
2. Valent P, Klion AD, Horny HP, Rou-
fosse F, Gotlib J, Weller PF et al. 
Contemporary consensus propos-
al on criteria and classification of 
eosinophilic disorders and related 
syndromes. J Allergy Clin Immunol 
2012;130:607-612.
3. Radonjic-Hoesli S, Simon HU. 
Novel targeted therapies for eo-
sinophil-associated diseases and 
allergy. Ann Rev Pharmacol Toxicol 
2014;55:in press.
4. Rosenberg HF, Dyer KD, Foster PS. 
Eosinophils: changing perspectives 
in health and disease. Nat Rev Im-
munol 2013;13:9-22.
IL-5
GM-CSF
IL-3
Bone 
marrow Blood Tissue
Activation
Granule proteins
DNA
ROS
Immune regulation
Remodeling
Killing of pathogens
&
tissue damage
Cytokines
Lipid mediators
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Figure 1 Tissue infiltration and role of eosinophils in diseases. (A) Eosinophils originate from multipotent and lineage-
restricted hematopoietic progenitor cells. They mature in the bone marrow under the influence of eosinophilopoietic 
cytokines (IL-3, IL-5, and GM-CSF). Mature eosinophils are released in the peripheral blood and can infiltrate 
inflammatory tissues as it occurs in allergic diseases. At sites of inflammation, eosinophils are activated and their 
apoptosis is delayed (reviewed by Geering B, Stoeckle C, Conus S, Simon HU. Living and dying for inflammation: 
neutrophils, eosinophils, basophils. Trends Immunol 2013;34:398-409). Under non-inflammatory conditions, eosinophils 
undergo apoptosis without infiltration of organs outside the hematopoietic and lymphatic systems. (B) An example of 
eosinophil tissue infiltration: Eosinophil infiltration of the dermis in a patient with drug allergy. The tissue section was 
stained with hematoxylin and eosin (original magnification x63). (C) Eosinophils are multifunctional cells. Following 
activation of eosinophils, they release granule proteins and reactive oxygen species (ROS), which are able to kill 
pathogens, but also tissue cells possibly causing organ dysfunction. Eosinophils additionally release mitochondrial DNA, 
which forms together with granule proteins eosinophil extracellular traps (reviewed by Simon D, Simon HU, Yousefi 
S. Extracellular DNA traps in allergic, infectious, and autoimmune diseases. Allergy 2013;68:409-416). By releasing 
cytokines and lipid mediators, eosinophils are further involved in immune regulation and remodeling events.
Eosinophils
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regularly 
• Allergic symptoms correlate with T cell activation particularly of 
the Th2 type
• T cells do also react to allergens in asymptomatic patients and 
may mediate allergen tolerance by active immune suppression
IMMUNE MEMORY - GOOD 
AGAINST BUGS, BAD FOR 
ALLERGIC AND AUTOIMMUNE 
DISEASES
The potency of the immune mem-
ory is assumed to be a key event 
in the evolution that allowed the 
success of larger organisms over 
smaller sized creatures and gen-
erated longer-lived organisms. 
However, the ability to remember 
pathogens has also its downsides.
A key feature of allergy is that 
the symptoms occur again every 
season. This is similar to the im-
munologic feature that memoriz-
es determinants on pathogens or 
other harmless structures such 
as autoantigens or allergens. The 
inappropriate immune response 
caused by dysregulation of the im-
munologic tolerance is underlying 
autoimmune and allergic diseases. 
Both memory and immune toler-
ance are mediated by T lympho-
cytes, which recognize immu-
nogenic structures by the T-cell 
receptor (TCR). This receptor is 
characterized by a very high varia-
bility that is generated by multiple 
gene-segment cassettes that are 
alternatively rearranged to gen-
erate a final gene product. Further 
variation is introduced by a flexi-
ble fusion process that increases 
Carsten B. Schmidt-Weber  
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variability and, thus, an extend-
ed repertoire of TCRs that cover 
most determinants of our environ-
ment is generated. Apart from the 
sophisticated structure of TCRs, 
the activation and differentiation 
of these cells is integrating mul-
tiple signals from the tissue, the 
immune system and the external 
environment. This integration pro-
cess involves antigen-presenting 
cells (APC) that need to digest the 
environmental allergen/antigen 
and present it in a molecule with 
similar high diversity as the TCR. 
Major histocompatibility com-
plexes, (MHC) bring the digested 
peptides to the surface of the APC 
and also deliver additional signals 
that are essential for the activa-
tion or deactivation of T cells. The 
successful activated T cell will di-
vide and after the termination of 
an immune response some cells 
(memory cells) will remain. These 
memory cells are able to quickly 
expand and reproduce an immune 
response that has been proven to 
be successful. It is anticipated that 
the generation of memory cells is 
underlying successful immuniza-
tions (vaccination) against infec-
tious agents. Hyposensitisation 
by allergen-specific immunother-
apy (AIT) may also be governed by 
memory populations.
DECISION MAKING IN THE 
IMMUNE SYSTEM 
The decision making process is 
subject of immunology research 
and has the intention to solve the 
“black box” of immune tolerance 
mechanisms. The goals are to 
prevent the loss of immune tol-
erance by means of public health 
initiatives (e.g. pollution control, 
dietary advices etc.), to increase 
effectiveness of specific immuno-
therapy and similar vaccination 
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strategies and to develop new 
therapies that prevent severe tis-
sue damage as it occurs in the gut, 
skin and airways. The decision of 
the immune system is reflected by 
the T lymphocyte activity, mainly 
by their secreted mediators, in-
terleukins (IL). Interleukins are 
typically of the “Th2”-type includ-
ing IL-4, IL-5 and IL-13, whereas 
autoimmune or pathogen-trigged 
T cells usually express “Th1- or 
Th17-type” IL’s and interferons 
(IFN) such as IFN-γ or IL-17. IL-4 
produced by T cells is essential for 
the production of IgE, the diagnos-
tic key parameter in the detection 
of allergies. The interleukins have 
various functions and are charac-
terizing the regulatory impact of 
T cells on other immune cells and 
on tissue cells. The exploration 
of T cell mediated signals on tis-
sue cells is just beginning and it is 
already revealed that T cells can 
directly mediate tissue pathology 
such as epithelial damage or colla-
gen deposition (Figure 1).
TERMINATING IMMUNE 
RESPONSES
This holds particularly true for 
the immune system. T regulatory 
(Treg) cells represent a key discov-
ery that falls into this category, as 
they are actively suppressing oth-
er immune cells particularly Th1, 
-2 and-17 cells. In fact, healthy 
individuals are showing immune 
activation in vitro, suggesting that 
mechanisms exist that keep these 
processes under asymptomatic 
control. Novel immune regulato-
ry T cell phenotypes are hypothe-
sized to mediate anti-inflammato-
ry signals also to tissue cells. AIT is 
assumed to generate Treg cells and 
future research and novel phar-
maceutical strategies are aiming 
to reinforce these mechanisms in 
order to re-construct immune tol-
erance under minimal influence on 
anti-pathogen responses.
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Figure 1 Different T cell phenotypes arise from naïve (resting, not antigen-experienced T cells) upon activation by 
antigen-presenting cells and by decision cytokines (not shown). The figure highlights a variety of responding cells both of 
the immune system as well as from non-immune (mesenteric) origin.
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contribute to the pathophysiology of a wide range of allergic 
diseases
• CD4+ Th2 cells that produce IL-4 and express CD40L orchestrate 
the IgE-switch and differentiation of B cells
• The recently described B regulatory cells inhibit over-activated 
immune responses
• Elucidating mechanisms regulating the bifurcation of B cell 
responses into B regulatory versus IgE-producing cells holds 
promise for therapeutic interventions
B cells are crucial in allergic dis-
eases by virtue of their production 
of allergen-specific IgE antibodies, 
which play a key role in instigat-
ing immediate hypersensitivity 
reactions and contribute to the 
pathophysiology of a wide range 
of allergic diseases ranging from 
asthma, atopic dermatitis, food 
and drug allergy, amongst others. 
IgE-production by B cells entails 
class-switch recombination at the 
immunoglobulin heavy chain locus 
into the IgE heavy chain (Cε). CD4+ 
Th2 cells that produce IL-4 and 
express CD40L orchestrate the 
differentiation of IgE-switched B 
cells. It has been suggested that 
there are two pathways for IgE 
production after secondary expo-
sure to antigen. 
The first involves the differen-
tiation of IgE-switched plasma 
cells from IgG1+ precursors by 
sequential switching from Cγ1 
to Cε, leading to the production 
of high affinity IgE antibodies by 
somatic hypermutation (affinity 
maturation). The second pathway 
involves the direct differentiation 
of IgE+ memory B cells generated 
during the primary immune re-
sponse into plasma cells, leading 
to a robust recall IgE antibody re-
sponse. The relative contribution 
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of each pathway to the generation 
of disease-promoting pathogenic 
IgE antibodies remains to be es-
tablished (Figure 1). 
The highly variable correlation be-
tween the levels of allergen-spe-
cific IgE antibodies and suscepti-
bility to anaphylaxis indicates that 
other factors, such as IgG antibod-
ies, have profound influences on 
IgE-mediated responses. Immuno-
therapy to aeroallergens has been 
shown to stimulate the production 
of allergen-specific IgG1 and IgG4 
antibodies, that protect against 
disease by inhibiting allergen in-
teraction with FcεRI-bound IgE on 
mast cells and basophils, thus pre-
venting their degranulation.
Recently, much attention has been 
given to regulatory B (Breg) cells 
that inhibit over-activated im-
mune responses. Several groups 
have proposed that a reduction 
in Breg cells worsens symptoms 
of allergic disease such as contact 
hypersensitivity and anaphylax-
is. Breg cells are characterized by 
their production of the negative 
regulatory cytokines, IL-10 and 
TGF-β. An increased number of 
IL-10-producing B cells has been 
found in S. mansoni worm infection 
and the in vivo transfer of these 
cells prevents recipient mice from 
anaphylaxis. Breg cells proliferate 
when stimulated with the milk an-
tigen casein in milk tolerant but 
not in milk allergic patients. Akdis 
and colleagues recently found in-
creased suppressive IL10+ Breg 
Azza Abdel-Gadir Talal Chatila
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cells in non-allergic beekeepers 
undergoing allergen-specific im-
munotherapy and high-dose ven-
om exposure. They revealed that 
Breg cells are specifically devel-
oping into IgG4-producing plasma 
cells (Figure 2). Thus, elucidating 
mechanisms regulating the bi-
furcation of B cell responses into 
Breg versus IgE producing cells 
holds promise for therapeutic in-
terventions. 
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Figure 1 Pathways for the generation of memory B cells. The interaction of 
Th2 cells with allergen-specific B cells may lead to switching into either IgE+ or 
IgG1+ memory B cells. The former would differentiate directly to IgE+ plasma 
cells upon recall responses, while the latter would first undergo switching from 
Cγ1 to Cε before further differentiating into plasma cells.
Figure 2 Opposing actions of IgE and IgG4 in allergic responses. Allergen-
specific IgG4, generated during immunotherapy, blocks the interaction of 
allergens to IgE and abrogates IgE-dependent effector responses. Regulatory 
B cells may promote tolerance by differentiating into allergen-specific IgG4-
producing plasma cells.
B cells
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• IgE antibodies are synthesized and secreted by allergen-specific 
B cells that have undergone heavy-chain class switching to IgE 
and differentiated into IgE-secreting plasma cells 
• IgE binds to FcεRI on mast cells and antigen (in this case allergen)-
presenting cells to sensitize the cells for allergen activation
• The immediate symptoms of allergy are caused by the release 
of potent physiological mediators produced by the allergen-
activated mast cells, while the activated antigen-presenting cells 
indirectly induce new allergen-specific B cells to produce more IgE 
• Allergen immunotherapy can generate allergen-specific antibo-
dies of IgG and IgA classes to compete with IgE for allergens
Immunoglobulin E (IgE) is one of 
five antibody classes, IgM, IgD, 
IgG, IgA and IgE, in mammals (Fig-
ure 1). There are four subclasses 
of IgG (IgG1-4) and two of IgA 
(IgA1, IgA2), making a total of 9 
nine different classes including 
the subclasses in humans. 
Every person can produce an anti-
body to recognize virtually any po-
tential antigen by a combination of 
mechanisms. The initial repertoire 
of IgMs generated in the bone 
marrow by “V(D)J” gene recombi-
nation and junctional nucleotide 
variation is highly diverse and is 
further adapted by antigen stimu-
lation of the B cells in the immune 
response. This results in cell prolif-
eration and the formation of ger-
minal centers in lymphoid tissues, 
where they undergo two process-
es: somatic hypermutation (SHM) 
and class switch recombination 
(CSR). SHM introduces point mu-
tations in the antigen-binding 
sites, which may increase or de-
crease affinity for antigen result-
ing in selection of high-affinity 
mutants that compete for antigen 
in a process called affinity matu-
ration. CSR replaces the constant 
region of the heavy-chain with one 
of another class encoded in a tan-
dem array downstream from the 
VDJ sequence in the expressed 
IMMUNOGLOBULIN E AND 
OTHER ANTIBODIES IN 
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Immunoglobulin E and other antibodies in allergy
immunoglobulin gene (Figure 2). 
This changes the antibody class 
and the way it is able to engage dif-
ferent effector cells in the immune 
response. Germinal center reac-
tions may also occur in the target 
organs of allergy.
Antibodies of the IgE class are 
central to the allergic response 
(Figure 3). They are synthesized 
and secreted by IgE-expressing 
B cells that have differentiated 
into IgE-secreting plasma cells. 
IgEs bind to mast cells and anti-
gen-presenting cells bearing the 
high-affinity IgE receptor, FcεRI, to 
sensitize the cells for allergen ac-
tivation. Allergen-activated mast 
cells release the physiologically 
potent molecules that cause the 
symptoms of allergy. The activat-
ed antigen-presenting cells stim-
ulate T helper 2 (Th2) cells, which 
in turn induce the production of 
more allergen-specific antibodies 
in a positive feedback loop primed 
by allergen.
Antibodies of the same or cross-re-
acting specificity, but another an-
tibody class can compete with IgE 
for antigen binding to prevent or 
suppress the allergic response. 
This may occur in specific allergen 
immunotherapy, which stimulates 
a modified Th2 response, causing 
a massive up-regulation of IgG4 
and IgA2. Some of these antibod-
ies may recognize the allergen and 
Hannah Gould Yih-Chih Chan
King’s College London 
London, United Kingdom
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Figure 1 All five antibody classes 
have the same basic “immunoglobu-
lin” structure with two heavy- and two 
light-chains, each with variable-re-
gions (white) containing the anti-
gen-combining site and class-specific 
constant-regions shown in different 
colors. The distinctive ε constant re-
gion of the IgE heavy-chain is shown in 
green. Carbohydrates attached to the 
protein are depicted as small purple 
circles. The different constant-regions 
are encoded in a tandem array in the 
germ line immunoglobulin heavy-
chain gene locus on human chromosome 14, downstream from the heavy-chain variable-region of the expressed heavy-
chain gene.
Figure 2 Class switch recombination 
is required to express IgE. The immu-
noglobulin heavy-chain locus contains 
the rearranged variable (VDJ) region 
linked to a transcriptional enhancer 
(E) and a series of three elements re-
quired for expression of the complete 
heavy-chain, an “intervening” exon (I), 
a switch region (S) and a constant re-
gion (C). During class switch recombi-
nation the VDJ, I and proximal part of 
S are recombined with the distal part 
of S within another germ line gene 
cassette (I, S, and C distinguished by 
Greek letters corresponding to the 
newly expressed antibody class). The 
intervening sequence is deleted and 
the ends join to form a circle. Prior 
to recombination, specific cytokines 
stimulate germ line gene transcrip-
tion from the I exon promoters of the 
two genes that subsequently undergo 
recombination. The germ line gene 
transcript corresponding to the gene 
to be expressed helps to instigate the 
subsequent recombination. The I exon 
promoter in the switch circle, now 
attached to the previously expressed 
gene, remains transiently active, producing a circle transcript whose sequences can be used to identify the genes that re-
combined. The new immunoglobulin gene in the shortened chromosome is expressed from the VDJ promoter, leading to 
the synthesis of the immunoglobulin heavy-chain mRNA and protein. The light-chain is unchanged after heavy-chain re-
combination. 
compete with IgE. It is thought 
that immune deviation to IgG4 
and IgA2 allergen specificities 
may contribute to the success of 
specific allergen immunotherapy 
(Figure 4). 
KEY REFERENCES
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Figure 3 IgE binds very tightly to 
mast cells and antigen-presenting 
cells through its high-affinity 
receptor, FcεRI. Specific allergen 
crosslinking of the IgE-receptor 
complex on mast cells induces cell 
degranulation with the release of 
mediators leading to the allergic 
response and also the production 
of IL-4 and IL-13 and expression of 
CD40L by the antigen-presenting 
cells and mast cells. These cytokines 
lead to B cell proliferation and further 
switching to IgE in B cells expressing 
other isotypes in a positive feedback 
loop, resulting the generation of even 
more IgE. 
Figure 4 Natural exposure to 
allergens may induce allergen-
specific IgE production in sensitive 
individuals by stimulation of antigen-
presenting cells in a T helper 2 (Th2) 
immune response. This IgE sensitizes 
effector cells (mast cells, basophils 
and eosinophils) and the generation 
of allergen-specific IgE by B cells. 
Exposure to high-doses of allergens 
through immunotherapy induces IL-
10/IL27 release from dendritic cells 
leading to suppression of the Th2 by 
deviation of T cell differentiation into 
the T helper 1 cell and T regulatory 
(Treg) cell pathways. The resultant 
cytokines, IFN-γ IL-12, IL-10 and 
TGF-β lead to the generation of 
allergen-specific IgG4 and IgA2 
antibodies that compete with IgE for 
allergens.
Immunoglobulin E and other antibodies in allergy
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• Staphylococcus aureus is a major trigger of atopic dermatitis and 
may contribute to severity of rhinosinusitis and asthma
• S. aureus exacerbates allergic diseases by secreting virulence 
factors such as superantigens and alpha toxin
• Staphylococcal virulence factors alter host responses to 
allergens and microbes 
• Th2 skin immune responses and filaggrin deficiency increases 
the propensity of atopic skin to become colonized and infected 
with S. aureus
Atopic dermatitis (AD) is the most 
common chronic skin disease in the 
general population. It often pre-
sents during early childhood and 
is the prelude to development of 
food allergy, asthma and allergic 
rhinitis. A majority of AD patients 
have a systemic and skin direct-
ed Th2 immune response lead-
ing to allergen sensitization and 
increased skin colonization with 
Staphylococcus aureus (S. aureus). 
These patients also have a defect 
in the terminal differentiation of 
their skin keratinocytes leading to 
reduced expression of skin barrier 
Donald Y. M. Leung  
National Jewish Health 
Denver, USA
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Role of superantigens in allergic diseases
proteins such as filaggrin, and de-
creased expression of antimicro-
bial peptides needed for skin host 
defense against invading bacteria 
and viruses. Reduced barrier func-
tion is due to a combination of gene 
mutations encoding skin barrier 
proteins such as filaggrin with the 
downregulation of epithelial dif-
ferentiation protein levels induced 
by Th2-type cytokines and IL-22. 
Loss of filaggrin has been linked to 
enhanced allergen penetration into 
the skin, increased S. aureus growth 
and S. aureus infection (Figure 1). 
Staphylococcus aureus triggers and 
maintains skin inflammation in AD 
via the production of virulence fac-
tors, such as superantigens and al-
pha toxin (Figure 2). 
Superantigens are potent poly-
clonal T cell activators that also 
stimulates cytokine release from 
antigen-presenting cells (Figure 
3). Evidence supporting a role for 
superantigens in AD include the 
observation that most AD pa-
tients make IgE antibodies direct-
ed against superantigens found 
on their skin and the presence of 
these IgE antibodies to superan-
tigens correlate with skin disease 
severity. Basophils and skin mast 
cells from patients with anti-su-
perantigen IgE release histamine 
on exposure to superantigens, but 
not in response to superantigens 
to which they have no specific 
IgE. Importantly, the superanti-
gen, staphylococcal enterotoxin B 
(SEB), can induce eczematoid skin 
changes when applied to the skin. 
After stimulation by SEB, T reg-
ulatory cells lose their immuno-
Figure 1 Child with atopic dermati-
tis superinfected with superantigen 
secreting Staphylococcus aureus. 
(Reprinted from J Allergy Clin Immu-
nol, 125/1, Boguniewicz M, Leung DY. 
Recent insights into atopic dermatitis 
and implications for management of in-
fectious complications, 4-13, Copyright 
2010, with permission from Elsevier.)
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suppressive activity, suggesting a 
novel mechanism by which super-
antigens could augment T-cell ac-
tivation and skin inflammation in 
patients with AD. Superantigens 
also selectively induce T cells to 
become corticosteroid resistant 
and to secrete IL-31, a highly pru-
ritogenic cytokine that induces ec-
zema in animal models. 
Treatment of AD patients should 
focus on skin barrier repair with 
Figure 2 Virulence factor production by S. aureus (Reprinted from J Allergy Clin 
Immunol, 125/1, Schlievert PM, Strandberg KL, Lin YC, Peterson ML, Leung DYM. 
Secreted virulence factor comparison between methicillin-resistant and methicillin-
sensitive Staphylococcus aureus, and its relevance to atopic dermatitis, 39-49, 
Copyright 2010, with permission from Elsevier.)
Figure 3 Model comparing activation of CD4+ T cells and macrophages by the 
superantigen, SEB, compared with antigenic peptide activation of the same cells. 
In comparison to peptide activation, SEB causes polyclonal T cell stimulation. 
(Reprinted from J Allergy Clin Immunol, 125/1, Schlievert PM, Strandberg KL, Lin YC, 
Peterson ML, Leung DYM. Secreted virulence factor comparison between methicillin-
resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic 
dermatitis, 39-49, Copyright 2010, with permission from Elsevier.)
reduction of skin inflammation. 
AD patients with S. aureus infec-
tion should receive antibiotics as 
this may reduce the severity of 
their skin disease. Together, these 
observations fulfill Koch’s postu-
lates and support a role for staph-
ylococcal superantigens in AD. 
There is also increasing data sug-
gesting that in certain clinical sit-
uations, S. aureus may contribute 
to severity of rhinosinusitis and 
asthma, by augmenting the airway 
inflammation and promoting pol-
yclonal local IgE formation, and 
by inducing corticosteroid resist-
ance.
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• Cytokines act as messengers of the immune system with other 
cells of the body
• Various groups of cytokines are responsible for the sensitisation 
to an allergen and for eliciting the allergic inflammation.
• There are sensing cytokines, T cell instructing cytokines, effector 
cytokines, resolving cytokines and chemokines
• The integrated actions of the cytokines in development, 
elicitation and eventually resolving the inflammation is called the 
cytokine network of allergy
Cytokines are soluble proteins or 
peptides that act as the hormones 
- messengers - of the immune sys-
tem and between other cells of the 
body. They confer cell-to-cell com-
munication which may take place 
between adjacent cells (juxtacrine) 
or cells in different organs of the 
body (para- or endocrine). A cy-
tokine signal is delivered via a re-
ceptor on the surface of a cell, and 
since different cells may express 
the same receptor, a cytokine can 
have several functions (pleiotropy) 
depending on the target cell. Also 
a target cell may have receptors 
for several similar cytokines al-
lowing for redundancy. 
There are more than 100 de-
scribed cytokines and their names 
are not easy to cope with, since no 
unified nomenclature exists. Some 
are named after where they were 
first found and/or their function, 
such as thymic stromal lymphopoi-
etin (TSLP), others after the first 
function identified, like Granulo-
cyte-Macrophage Colony Stimu-
lating Factor (GM-CSF), and some 
may even have several names giv-
en to them by different research 
groups. An attempt to unify the 
nomenclature has been made by 
the word interleukin - meaning 
messengers between white blood 
Lars K. Poulsen  
National University Hospital 
Copenhagen, Denmark
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Cytokines in allergy
cells - followed by a number, but 
more and similar molecules have 
been discovered, so instead of just 
interleukin-1 (IL-1), we now have 
IL-1α, IL-1β and IL-1RA (= Interleu-
kin 1 Receptor Antagonist). 
Various groups of cytokines are 
responsible for the different 
phases of the allergic sensitization 
(building up the allergic immune 
response) and elicitation (reactions 
upon exposure to an allergen):
The sensing cytokines: IL-33, IL-25, 
TSLP. These are released from 
the epithelial cells of the mucous 
membranes and signals to the al-
lergen-presenting dendritic cells 
to take up incoming allergens and 
bring them to the lymph nodes.
The T-cell instructing cytokines will 
instruct undifferentiated T helper 
(CD4+) cell to develop into dif-
ferent kinds of cells, each of them 
equipped for different kinds of im-
mune response: IL-12 and γ-inter-
feron will produce T helper cells 
type 1 (Th1) that helps fighting 
bacteria and viruses, IL-4 leads to 
Th2 cells which fights large mul-
ticellular parasites like worms, 
but unfortunately also create the 
allergic immune response. Oth-
er Th-cell types such as Th17 
(believed to be active in fighting 
bacterial or fungal infections, but 
unfortunately also involved in au-
toimmune diseases), and T regu-
latory (dampening the inflamma-
tion) also exists.
T-cell effector cytokines in allergy 
are the cytokines by which Th-
cells exerts their action: Th2 cells 
release IL-4 and IL-13 which in-
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structs B-cells to produce the al-
lergy antibody IgE, IL-5 that stim-
ulates the bone marrow to form 
the eosinophilic granulocyte, and 
IL-9 that together with IL-13 cre-
ates the allergic inflammation e.g. 
in the lung as is the case in asthma.
The resolving cytokines such as 
IL-10 and Transforming Growth 
Factor (TGF-β) comprise a small 
but important group of cytokines 
that down-regulates the allergic 
inflammation, restoring the home-
ostasis of the immune system.
Chemokines is a special group of 
cytokines that attract leukocytes 
to the site of inflammation, and 
the immune system uses these to 
move leukocytes in the tissues, 
when they have left the blood-
stream.
The integrated actions of the cy-
tokines in development, elicita-
tion and eventually resolving the 
inflammation is called the cytokine 
network of allergy. Since several of 
these cytokines play a profound 
role in allergy, many attempts are 
being made to use this therapeu-
tically by the so-called biological 
therapeutics where cytokine ac-
tions are antagonized.
KEY REFERENCES
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Cytokines in allergy
Figure 1 The complex interplay of cytokines in allergic inflammation: red - sensing cytokines; green - T-cell instructing 
cytokines; violet - T-cell effector cytokines; blue - Resolving cytokines; pink - Chemokines.
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• Cell migration in the immune system is a highly regulated, 
multi-step process involving adhesion molecules, chemotactic 
factors and their receptors and is necessary for the homeostatic 
immune surveillance as well as for the coordinated recruitment 
of inflammatory cells at sites of inflammation
• Chemokines represent a superfamily of small proteins that 
regulate immune cell trafficking and the recruitment and 
activation of specific leukocyte cell types to sites of inflammation
• Chemokines are divided in four subclasses – CC, CXC, CX3C 
and C – and activate cell targets through class-specific seven-
transmembrane chemokine receptors
• Dysregulation of the chemokine system plays a crucial role in 
chronic inflammatory diseases, metabolic disorders, cancer and 
aging
• Antagonism of chemokine receptors has so far shown partial 
success as therapeutic strategy, and is now assisted by research 
toward more specific downstream regulatory pathways 
modulating the chemokine network
The immune system relies on a 
tightly regulated migration pro-
cess for the ordered compart-
mentalization of immune cells 
within the lymphoid organs, for 
implementation of the homeo-
static immune surveillance as well 
as for an appropriate response to 
environmental insults through 
innate and adaptive effector re-
sponses. Circulating leukocytes 
and tissue-dwelling immune cells 
proceed from hematopoietic to 
vascular compartments and into 
tissue sites through receptor-me-
diated, multi-step processes in-
volving many classes of traffick-
ing molecules, including adhesion 
molecules (selectins and integrins) 
with their counterligands and che-
moattractants, either lipid-derived 
or belonging to the chemokine su-
perfamily. It is the combinatorial 
nature of the diverse patterns of 
expression and activation of these 
molecules and their receptors on 
immune and structural cells, to-
gether with their modulation in 
response to environmental clues, 
as in case of inflammatory or tu-
morigenic settings, that ultimately 
provides a high level of specificity 
in cellular trafficking.
Chemokines constitute a su-
perfamily of small polypeptides, 
CELL MIGRATION AND 
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whose first identified member, 
CXCL8, was initially characterized 
by its potent and specific leukocyte 
chemoattractant activity – hence 
the name, derived from ‘chemot-
actic cytokines’. Chemokines are 
divided into the CXC, CC, CX3C 
and C subfamilies based on the 
number and spacing of conserved 
cysteine residues. They bind to the 
seven-transmembrane, G-protein 
coupled receptors that are specif-
ic for each subclass, with multiple 
members sharing the same recep-
tor (Table 1). The ensuing signal-
ing involves multiple and diverse 
pathways that are highly recep-
tor-, cell type- and context-specif-
ic and produce diverse functional 
outcomes. Among these, the con-
trol of immune cell trafficking in 
homeostasis and the regulation of 
leukocyte recruitment, phenotype 
and activation in innate and adap-
tive immune responses remains 
a defining and pivotal function of 
Cristiana Stellato  
University of Salerno 
Salerno, Italy
Gilda varricchi  
University of Naples 
Federico II, Italy
Gianni Marone  
University of Naples 
Federico II, Italy
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TABLE 1
Nomenclature of Chemokine Families and Paired Receptors 
Standard 
name
Chromo-
some
Human  
ligand
Chemokine 
receptor(s)
Standard 
name
Chromo-
some
Human  
ligand
Chemokine 
receptor(s)
CxC-chemokines CCL3L3 17q21.1 LD78β CCR1, CCR5 (CD195)
CXCL1 4q21.1 GROα/MGSAα CXCR2>CXCR1 CCL4 17q12 MIP-1β CCR5 (CD195)
CXCL2 4q21.1 GROβ/MIP-2α CXCR2 CCL4L1 17q12 LAG-1 CCR5 (CD195)
CXCL3 4q21.1 GROβ/MIP-2β CXCR2 CCL4L2 17q12 CCL4L CCR5 (CD195)
CXCL4 4q21.1 Platelet Factor-4 CXCR3 (CD183) CCL5 17q12 RANTES CCR1, CCR3, CCR5 (CD195)
CXCL4L1 4q12-q21 PF4V1 CXCR3 (CD183) CCL6*
CXCL5 4q21.1 ENA-78 CXCR2 CCL7 17q11.2 MCP-3 CCR1, CCR2, 
CCR3
CXCL6 4q21.1 GCP-2 CXCR1,CXCR2 CCL8 17q11.2 MCP-2 CCR3, CCR5 (CD195)
CXCL7 4q21.1 NAP-2 CXCR2 CCL9*
CXCL8 4q21.1 IL-8 CXCR1,CXCR2 CCL10*
CXCL9 4q21.1 MIG CXCR3 (CD183) CCL11 17q11.2 Eotaxin CCR3
CXCL10 4q21.1 IP-10 CXCR3 (CD183) CCL12*
CXCL11 4q21.1 I-TAC CXCR3 (CD183) CCL13 17q11.2 MCP-4 CCR2, CCR3
CXCL12 10q11.21 SDF-1α/β CXCR4 (CD184) CCL14 17q12 HCC-1 CCR1, CCR5 (CD195)
CXCL13 4q21.1 BCLC CXCR5 CCL15 17q12 HCC-2 CCR1, CCR3
CXCL14 5q31.1 BRAK CXCR4 (CD184) CCL16 17q12 HCC-4 CCR1, CCR2
CXCL15* CCL17 16q13 TARC CCR4
CXCL16 17p13 SR-PSOX CXCR6 CCL18 17q12 PARC Unknown
CXCL17 19q13.2 DMC Unknown CCL19 9p13.3 ELC CCR7 (CD197)
C-chemokines CCL20 2q36.3 MIP-3α, LARC CCR6
XCL1 1q24.2 Lymphotactin/α XCR1 CCL21 9p13.3 SLC CCR7 (CD197)
XCL2 1q24.2 Lymphotactin/β XCR1 CCL22 16q13 MDC CCR4
Cx
3
C-chemokines CCL23 17q12 MPIF-1 CCR1
CX
3
CL1 16q13 Fractalkine CX
3
CR1 CCL24 7q11.23 Eotaxin-2 CCR3
CC-chemokines CCL25 19p13.3 TECK CCR9
CCL1 17q11.2 I-309 CCR3 CCL26 7q11.23 Eotaxin-3 CCR3
CCL2 17q11.2 MCP-1 CCR2 CCL27 9p13.3 CTACK CCR10
CCL3 17q12 MIP-1α CCR1, CCR5 (CD195) CCL28 5p12 MEC CCR3/CCR10
CCL3L1 17q21.1 LD78β CCR1, CCR5 (CD195)
*No human ortholog described
Modified from Bachelerie et al., Pharmacol. Rev. 66: 1-79, 2014, with update on Pubmed Library and Genebank.
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Figure 1 . The association of CC and CXC chemokines (CCL and CXCL indicated by outer arrows, member numbers 
listed in the outer gray circle) and their receptors (listed in pink circle below ) to a selection of diseases, gained from 
animal models and from data obtained in human samples and in clinical trials.  Abbreviations: Sep, Sepsis; RA, Rheumatoid 
arthritis; T, Transplant; IBD, Inflammatory Bowel Disease; Onc, Oncology; SLE, Systemic Lupus; MS, Multiple Sclerosis; 
Ath Scl, Atherosclerosis; COPD: Chronic Obstructive Pulmonary Disease; AMD, Acute macular degeneration; NP, 
Neuropathic pain; Asth, Asthma; At. Derm, Atopic dermatitis; Hep, Hepatitis; Panc, Pancreatitis; Pso, Psoriasis; GVHD, 
Graft vs Host disease. (Reprinted with permission from Garin and Proudfoot, Exp. Cell. Res. 317: 602-612, 2011.)
Cell migration and chemokines
the chemokine superfamily. The 
key role of chemokines in chronic 
inflammatory diseases is now firm-
ly established (Figure 1). In these 
contexts, the CXC and CC sub-
classes, though with overlaps, seg-
regate their control over different 
cell types, with CXC members act-
ing on effector functions relevant 
in diseases characterized by neu-
trophilic, Th1- and Th-17-driven 
responses, such as COPD, multiple 
sclerosis, Crohn’s disease and spe-
cific phenotypes of severe asthma; 
while CC chemokines shape leu-
kocyte trafficking and function in 
Th2-dependent, eosinophil-rich 
inflammatory processes such as 
allergic asthma, early-stage atopic 
dermatitis, eosinophilic gastroin-
testinal diseases (Figure 2). Among 
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Figure 2 Involvement of chemokines and chemokine receptors in the inflammatory response present in bronchial asthma 
and COPD . In asthma, dendritic- and epithelial-derived chemokines elicited by the inhaled allergens recruit and activate 
Th2 cells and eosinophils through CCR4 and CCR3, respectively, contributing to the generation of an IgE-mediated inflam-
matory response. In COPD, chemokines released from lung epithelial cells and macrophages following exposure to cigarette 
smoke and/or pollutants generate a neutrophilic/monocytic-enriched infiltrate driven by Th1/Th17 cells that contributes to 
the inflammatory response and determins lung structural damage. (Reprinted by permission from Macmillan Publishers Ltd: Nat 
Rev Immunol, Barnes PJ, Immunology of asthma and chronic obstructive pulmonary disease, 8,183-192, copyright 2008.)
Asthma
COPD
Cell migration and chemokines
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the CC chemokines, CCL2/Mono-
cyte Chemoattractant Protein-1 
(MCP-1) is a non-redundant, po-
tent regulator of monocytes, ba-
sophils and dendritic cells and par-
ticipates to the Th2 polarization 
of memory T cells. The CX3C and 
the C subfamilies are represented 
by a single member, CX3CL1/frac-
talkine, which is the only cell mem-
brane-associated chemokine, and 
lymphotactin, respectively.
Chemokines’ range of regulatory 
competences has been widened 
over the last decades, as almost 
all cell types, including structural 
cells such as fibroblasts, endothe-
lial and epithelial cells, as well as 
tumor cells have been found to 
express regulated profiles of func-
tional chemokine receptors. By 
regulating cell proliferation, differ-
entiation and apoptosis functions, 
and – either directly or indirectly 
– controlling angiogenesis and ex-
tracellular matrix remodeling, the 
chemokine system is also central 
to cancer-related inflammation, 
angiogenesis, tumor cell survival 
and invasiveness, and is critically 
involved in the step-wise process 
of wound healing.
Inhibition of leukocyte recruit-
ment is a major mechanism of glu-
cocorticoids’ anti-inflammatory 
action and a major goal for novel 
therapies selectively targeting 
specific recruitment pathways. 
Antagonism of chemokine-me-
diated functions offers major 
challenges, partly due to member 
redundancy in each subclass, but 
mostly to the complexity of the 
control of their expression, which 
spans from transcriptional to post-
translational and extracellular ma-
trix-dependent mechanisms, that 
are diversely affected in specific 
disease settings. Antagonism of 
single chemokine receptors has 
so far shown only partial success 
as therapeutic strategy, and is 
now flanked by research toward 
more specific downstream regu-
latory pathways modulating the 
chemokine network.
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Cell migration and chemokines
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s • The phylogenetically ancient complement activation system is 
activated in the lungs of asthmatic individuals 
• Several environmental triggers of asthma including allergens, air 
pollutants, cigarette smoke, and viruses activate the complement 
system and mediate Th2-driven immune responses
• Genetic polymorphisms in the C3 and C3aR1 genes are 
associated with susceptibility to the development of asthma in 
children and adults
• Modification of complement activation pathways may provide a 
novel strategy for the treatment of asthma
Asthma is thought to arise as a 
result of aberrant T helper type 2 
(Th2)-polarized immune respons-
es to innocuous environmental al-
lergens, however the mechanisms 
driving these aberrant immune re-
sponses remain elusive. As a phy-
logenetically ancient immune sys-
tem, the complement activation 
system, is a sophisticated network 
of soluble and membrane-bound 
proteins. It has evolved to recog-
nize “danger or pattern-associated 
molecular patterns” expressed by 
foreign organisms through “hard-
wired” pattern recognition recep-
tors (PRRs). Activation of these 
PRRs culminates in the generation 
of C3 and the production of two 
pro-inflammatory anaphylatoxins, 
C3a and C5a, which induce inflam-
mation and the membrane attack 
complex, which lyses foreign cells. 
The anaphylatoxins C3a and C5a 
are potent pro-inflammatory me-
diators that bind to specific cell 
surface receptors and regulate 
many processes observed in asth-
ma including leukocyte activation, 
smooth muscle contraction, and 
mucus secretion.
Consistent with a role for C3-C3a 
in asthma, exposure to a variety of 
environmental triggers of asthma 
in animal models has been shown 
Marsha Wills-Karp  
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Complement-mediated regulation of the allergic response
to directly activate complement 
at the airway surface. Genetic de-
letion of C3 in animal models has 
been shown to protect against the 
development of allergen-, pollut-
ant-, and RSV-induced asthmat-
ic responses and Th2 cytokine 
production suggesting that C3a 
production at the airway surface 
serves as a common pathway for 
the induction of Th2-mediated 
inflammatory responses thereby 
driving and/or exacerbating the 
disease (Figure 1, 2, 3). The exact 
mechanisms by which C3 regu-
lates allergic responses are un-
known, but current evidence sug-
gests that C3a can both enhance 
antigen uptake by antigen-pre-
senting cells, thereby enhancing 
sensitization to allergens, and ini-
tiate recruitment and activation of 
various inflammatory cells asso-
ciated with asthma pathogenesis 
(Figure 4).
In humans, segmental allergen 
provocation resulted in a signifi-
cant increase in C3a levels in the 
bronchoaveolar lavage of asth-
matics, with no change in healthy 
volunteers. This differential pro-
duction of C3a between individu-
als with asthma and those without 
asthma suggest that there may be 
alterations in the genetic control 
of the production of, the activation 
of, or the response to various com-
plement components that may un-
derlie susceptibility to asthma. In-
deed, associations between single 
nucleotide polymorphisms (SNPs) 
in the C3 gene and atopic asthma 
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Figure 1 Allergen-induced asthma is C3 dependent. A) The effect of C3 deficiency on airway hyperresponsiveness 
(AHR) in anesthetized C3−/− and C3+/+ mice. AHR was assessed 24 hrs after the last challenge and is expressed as the 
provocative concentration of ACh (in micrograms per gram) that increased baseline airway resistance 200% (PC
200
). B) 
IL-4- and IFN-γ-producing cells in the lungs from C3−/− (■) and C3+/+ littermates (□) were quantitated 24 h after the last Ag 
challenge. (Reproduced from Drouin SM, Corry DB, Kildsgaard J, Wetsel RA. 167:4141-4145, Copyright 2001 with permission 
from the American Association of Immunologists.).
Figure 2 Air pollution exposure-induced airway hyperresponsiveness is C3-dependent. Lung sections from PM-exposed 
mice were stained with anti-C3 mAb (A) or (B) isotype control antibodies. Specific C3 staining is observed in the airway 
epithelial layer. C) Airway responsiveness (APTI) to acetylcholine stimulation is significantly reduced in C3-deficient mice 
after particulate matter (PM) exposure as compared to PM-exposed wildtype mice. (P < 0.05). (Reproduced from American 
Journal of Respiratory Cell and Molecular Biology, the official journal of the American Thoracic Society, Walters DM, Breysse PN, 
Schofield B, et al., 27, 413-418, Copyright 2002 with permission from American Thoracic Society). 
Figure 3 Respiratory syncytial virus-induced airway hyperresponsiveness is C3-dependent. Airway hyperresponsiveness 
in wildtype and C3- and B cell-deficient mice challenged with RSV 7 days after immunization with formalin-fixed RSV. (A) 
B6129F2 WT (C3+/+) and C3 deficient (C3−/−), and (B) C57BL/10 (B+/+) and B10 μMT (B−/−) mice. AHR to acetylcholine 
challenge is defined by the time-integrated rise in peak airway pressure. (Reproduced from Journal of Experimental Medicine, 
Polack FP, Teng MN, Collins PL, et al., 196, 859-65, Copyright 2002 with permission from The Rockefeller University Press).
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have been reported in children 
and adults. Interestingly, the fre-
quency of these SNPs is high, sug-
gesting that these polymorphisms 
may have conferred evolutionary 
advantage in the past and perhaps 
in protection from parasitic infec-
tions. 
Although we are in the initial stag-
es of understanding the role of 
complement pathways in asthma 
pathogenesis, one may postulate 
that changes in the activation of 
specific complement components 
due to differences in exposure 
to different environmental trig-
gers or to genetic alterations in 
complement family genes or the 
convergence of both of these fac-
tors may play an important role in 
susceptibility to the development 
of allergic diseases. Further inves-
tigations into the mechanisms by 
which C3a modules allergic asth-
ma may offer novel therapeutic 
approaches for the treatment of 
asthma. 
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Figure 4 Complement activation pathways regulate Th2-mediated immune responses. Following airway exposure to a 
variety of environmental triggers of asthma in genetically susceptible individuals, C3 is produced and secreted by airway 
epithelial cells lining the airways. C3 is cleaved into its active form, C3a, presumably by proteases either contained in the 
allergens or produced by the epithelium. C3a then binds to its receptor, C3aR1 on antigen presenting cells, enhancing 
uptake of antigen by these cells. Antigen-loaded APCs then drive the differentiation of naïve T cells to Th2 cells. Th2 
cytokines in turn recruit and active the effector cells of the allergic response, eosinophils and mast cells. During the 
effector phase of the response, C3a can bind its receptor on these effector cells enhancing their recruitment and 
activation. Growth factors and bronchoactive substances from these cells lead to increased airway smooth muscle growth 
and contractile capacity. 
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• Lipid mediators regulate both the physiological status and 
inflammation in the airways
• Cysteinyl leukotrienes and prostaglandin D
2
 are the best studied 
inflammatory mediators of hypersensitivity and allergic disorders
• Other lipid mediators, like pro-inflammatory eoxins and anti-
inflammatory lipoxins also participate in allergic reaction
• A class of phospholipid and ceramide mediators interact with 
immune response in allergy
Since the discovery that bron-
choconstriction and edema can 
be mediated by cysteinyl leukot-
rienes, lipid mediators attracted 
much attention in allergology. The 
biological effect of a lipid media-
tor is determined by its receptor 
affinity and intracellular signal 
transduction, and receptors dif-
fer in their specificity and cellular 
distribution. Lipid mediators of 
inflammation are difficult to study 
due to their complex metabolism, 
chemical similarities and rapid in-
activation. Their levels in airways 
can be measured in bronchial or 
nasal lavage, induced sputum or 
exhaled breath condensate, while 
systemic production can be as-
sessed in urine. 
Regulation of the airways tonus, 
secretion or inflammation involves 
numerous mediators (Figures 1 
and 2). Respiratory epithelium 
produces prostaglandin E
2 
(PGE
2
), 
secreted to the apical surface. It 
has been recently demonstrated 
that excessive PGE
2
 can impair 
phagocytic clearance of solid par-
ticles by alveolar macrophages. A 
decreased number of carbon par-
ticles in alveolar macrophages and 
increased systemic production of 
PGE
2
 metabolites were report-
ed in children with asthma. Res-
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piratory epithelium also secretes 
15-hydroxyeicosapentaenoic acid 
(15-HETE) to its basal surface. 
Upon stimulation with Th2 cy-
tokines (IL-4, IL-13), the asthmat-
ic respiratory epithelium under-
goes mucous cell metaplasia with 
amplication of the production of 
15-HETE. 15-HETE can be metab-
olized to eoxins, isomers of cystei-
nyl leukotrienes. The concentra-
tion of eoxins (EXC
4
, EXD
4 
and 
EXE
4
) is increased together with 
cysteinyl leukotrienes in children 
with asthma. Moreover, EXD
4
 and 
EXE
4
 leves correlate with bronchi-
al hyperreactivity .
One of the asthma phenotypes 
is characterized by an overpro-
duction of cysteinyl leukotrienes. 
These asthmatics have hypersen-
sitivity to non-steroidal anti-in-
flammatory drugs and chronic 
rhinosinusitis. Patients with aspi-
rin-exacerbated respiratory dis-
ease (AERD) overproduce pros-
taglandin D
2
, but this finding is 
also present in other eosinophilic 
phenotypes of asthma. During an 
aspirin provocation test, bron-
choconstriction is mediated by a 
further increase in the local and 
systemic production of cysteinyl 
leukotrienes, a unique feature of 
this disease.
The integrity of the lung function 
is maintained by PGE
2
, which in-
hibits inflammation at physiologi-
cal concentrations. PGE
2
 can pro-
mote tissue injury in high doses. 
Other lipid mediators are released 
by activated cells only. They act 
as highly bioactive autacoids ca-
pable of chemoattraction of neu-
trophils (12-HETE, leukotriene B
4
) 
Lipid mediators of hypersensitivity and inflammation
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Lipid mediators of hypersensitivity and inflammation
or eosinophils and lymphoid cells 
(PGD
2
). Some can provide termi-
nation signals for inflammation 
(lipoxins, resolvins, protectins) 
and their biosynthesis requires 
cell interaction . Bioactive oxylip-
Figure 1 Main classes of inflammatory lipid mediators in the airways are 
cysteinyl leukotrienes, eoxins and prostaglandins. Platelet activating factor and 
ceramides are also released during allergic reaction.
Figure 2 Lipid mediators are produced in airways by structural and 
inflammatory cells. In general, tissue infiltrating inflammatory cells produce 
pro-inflammatory mediators, while structural ones produce anti-inflammatory 
mediators. Excessive production of lipid mediators by respiratory epithelial 
cells and alveolar macrophages also promotes inflammation.
ins are also generated from poly-
unsaturated fatty acids by reactive 
oxygen species in a non-enzymatic 
reaction. A separate class of lipid 
mediators are phospholipids and 
ceramides. Platelet-activating fac-
tor, a phosphatydylcholine ether 
of alkyl-acetyl glicerol is the most 
potent mediator of anaphylaxis 
and bronchoconstriction. Cer-
amides are abundant constituents 
of the cell membrane mediating 
apoptosis. Lipid mediators can 
bridge inflammation with the cel-
lular immune response in allergic 
disorders.
KEY REFERENCES
1. Brugha RE, Mushtaq M, Round T, 
Gadhvi DH, Dundas I, Gaillard E, et 
al. Carbon in airway macrophages 
from children with asthma. Thorax 
2014 in press.
2. Jakieła B, Gielicz A, Plutecka H, 
Hubalewska M, Mastalerz L, Bo-
chenek G, et al. Eicosanoid bio-
synthesis during mucocilliary and 
mucous metaplastic differentia-
tion of bronchial epithelial cells. 
Prostaglandins Other Lipid Mediat 
2013;106:116-23. 
3. Sachs-Olsen C, Sanak M, Lang AM, 
Gielicz A, Movinckel P, Lødrup 
Carlsen KC, et al. Eoxins: a new 
inflammatory pathway in child-
hood asthma. J Allergy Clin Immunol 
2010;126:859-867.
4. Sanak M, Gielicz A, Bochenek G, 
Kaszuba M, Niżankowska-Mogil-
nicka E, Szczeklik A. Targeted eicos-
anoid lipidomics of exhaled breath 
condensate provide a distinct pat-
tern in the aspirin-intolerant asth-
ma phenotype. J Allergy Clin Immu-
nol 2011;127:1141-1147.
5. Haworth O, Levy BD. Endogenous 
lipid mediators in the resolution of 
airway inflammation. Eur Respir J 
2007;30:980-950.
6. Vadas P, Gold M, Perelman B, Liss 
GM, Lack G, Blyth T, et al. Plate-
let-activating factor, PAF acetylhy-
drolase, and severe anaphylaxis. N 
Engl J Med 2008;358:28-35.
81
Global atlas oF allerGy
se
c
t
io
n
 a
 - A
llergy  - fro
m
 gen
etics to
 m
ech
an
ism
s 
• Non-resolving inflammation underlies the pathogenesis of 
allergic diseases
• Resolution of inflammation is an active, finely orchestrated and 
complex process
• Resolution of inflammation involves anti-inflammatory, immune 
regulatory, cell death and lipid mediator-related mechanisms 
• ω3-derived specialized proresolving lipid mediators (SPMs) 
such as protectins, resolvins and maresins are key mediators of 
inflammation resolution
• Allergic diseases are associated with defects in the generation of 
SPMs 
• Synthetic SPMs or compounds triggering their production are 
promising therapeutics for the treatment of allergic diseases
Persistent non-resolving inflam-
mation underlies the pathogen-
esis of allergic diseases including 
rhinitis and asthma, and deter-
mines both the intensity of the 
symptoms and the chronicity of 
the disease. Yet, the mechanisms 
controlling resolution of inflam-
mation have only recently started 
to become elucidated.
Resolution is an active and highly 
orchestrated process of similar 
complexity to the onset and pro-
gression of inflammation. It starts 
early in the inflammatory re-
sponse and involves the induction 
of anti-inflammatory/regulatory 
networks aiming at terminating 
pro-inflammatory signalling, and 
biosynthetic circuits triggering the 
production of specialized prore-
solving lipid mediators (SPMs) 
essential for return to homeosta-
sis. The relative balance between 
pro-inflammatory, anti-inflamma-
tory and proresolving respons-
es, influenced by environmental 
exposures and lifestyle factors, 
eventually determines whether 
the inflammatory response will 
persist or terminate. 
Central to the resolution of inflam-
mation are bioactive lipids derived 
from ω3 and ω6 polyunsaturated 
fatty acids (PUFA). The early oxy-
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genation of arachidonic acid into 
prostaglandins and leukotrienes 
that occurs during the initiation of 
an inflammatory response is fol-
lowed by the generation of lipox-
ins, lipids with anti-inflammatory 
and proresolving properties, in 
a process termed ‘lipid mediator 
class switching’. As the inflam-
matory response progresses, the 
production of additional SPMs 
derived from ω3 PUFAs such as 
protectins, resolvins and mares-
ins ensues (Figure 1). These act in 
a stereospecific manner through 
G protein-coupled receptors to 
reverse vasodilation and suppress 
leukocytic cell infiltration, de-acti-
vate inflammatory cells, promote 
apoptotic cell and tissue debris 
clearance, and repair damaged tis-
sue, altogether leading to the res-
toration of homeostasis. 
Notably, ω3-derived SPMs also 
possess antimicrobial function. 
PD1 is induced by antiviral TLRs 
and exhibits potent antiviral ac-
tivity, while several resolvins and 
protectins enhance antibacterial 
defences. This has significant im-
plications for the role of lipid me-
diators in allergic disease exacer-
bations, which are often triggered 
by infections. The biosynthesis of 
SPMs is dependent on lipoxygen-
ase-5 and lipoxygenase-12,15, 
Lipid mediators in resolution of allergic inflammation
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Figure 2 Proresolving activities of ω3/ω6 polyunsaturated fatty acid (PUFA)-derived bioactive lipids in respiratory 
allergies. Specialized proresolving lipid mediators (SPMs) are generated in response to viral infection, Toll-like receptor 
(TLR) stimulation or type 2 inflammation. SPMs act in concert to reverse vasodilation, prevent leukocytic cell infiltration, 
de-activate inflammatory cells including Th2 cells and innate lymphoid cells (ILCs), upregulate macrophage efferocytic 
function and antimicrobial defences, promote clearance of apoptotic cells and debris, and repair damaged tissue, 
eventually restoring homeostasis. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; EOS, 
eosinophil; MAC, macrophage; NEU, neutrophil. (Adapted from Andreakos E. Asthma exacerbations: a molecular dichotomy 
between antiviral and pro-inflammatory responses revealed.;EMBO Mol Med. 2012;4(12):1231-3. Reprinted with permission 
under the Creative Common Attribution License or equivalent.)
Lipid mediators in resolution of allergic inflammation
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Figure 1 Generation of eicosanoids and specialized proresolving lipid mediators as inflammation progresses. As the 
inflammatory response proceeds, the production of additional proresolving lipids derived from ω3 PUFAs such as 
protectins, resolvins and maresins ensues. These act in an orchestrated manner to terminate inflammation and ensure the 
transition to homeostasis.
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Lipid mediators in resolution of allergic inflammation
key enzymes that carry out the 
oxygenation of PUFAs. Substrate 
availability, temporal expression 
and activation of these and other 
key enzymes ultimately determine 
which SPMs will be produced, 
where and when.
There is emerging evidence that 
SPMs are essential for the reso-
lution of allergic inflammation. 
Lipoxin A4 (LXA4) has been found 
in nasal secretions of patients with 
allergic rhinitis or chronic rhinosi-
nusitis, as well as bronchoalveolar 
lavage and exhaled breath con-
densate of patients with asthma, 
and low LXA4 levels have been 
linked to the severity of the dis-
ease. LXA4 has also has been 
shown to inhibit IL-13 production 
by human innate lymphoid cells 
and resolve allergic inflammation 
in rodents. Similarly, protectin D1 
(PD1) has been detected in ex-
haled breath condensate from pa-
tients with asthma, and low PD1 
levels have been observed during 
acute exacerbations. PD1 and re-
solvins D1 and E1 have been fur-
ther used to promote resolution of 
allergic airway inflammation in ex-
perimental mouse models. On the 
basis of current data, SPMs can 
affect multiple processes during 
an allergic response as depicted in 
Figure 2. In conclusion, although 
it its early days, the field of res-
olution of inflammmation raises 
expectations for the application 
of SPMs or substances triggering 
their production for the treatment 
of allergic diseases. 
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s • The epithelium in chronic asthma resembles a chronic wound 
with impaired barrier function 
• This manifests as enhanced susceptibility to injury by viruses, 
pollutants and allergens and aberrant repair to sustain 
inflammation and remodelling
• Recapitulation of morphogenetic epithelial growth and 
transcription factors suggest persistent activation of the 
epithelial mesenchymal trophic unit (EMTU)
• A new approach to prevention and treatment might aim to 
increase airway resilience rather than focusing on suppressing 
inflammation once present
• Inadequate epithelial tight junction assembly has been demon-
strated in asthma, atopic dermatitis and chronic rhinosinusitis
Asthma is a disorder largely re-
stricted to the conducting airways 
characterised by episodic bron-
choconstriction superimposed on 
a background of airway hypere-
sponsiveness and is generally re-
sponsive to bronchodilator drugs. 
Airway inflammation is another 
characteristic of asthma which, to 
a variable extent, is responsive to 
corticosteroids and often associ-
ated with allergy. 
This concept of allergy driving an 
IgE, mast cell and eosinophilic in-
flammation in asthma has been 
heavily underpinned by involve-
ment of the Th2 subtype of T cells 
capable of releasing an array of cy-
tokines and chemokines linked to 
the allergic cascade.
However, this simplistic approach 
has not been rewarded by thera-
peutics targeting individual com-
ponents of the allergic cascade, 
which while identifying selective 
subgroups of “responders”, has 
not provided a ubiquitous series 
of treatments where “one size 
fits all”. These less than encour-
aging findings raise the question 
whether the current Th2 model 
for asthma adequately explains 
the disease in its very wide range 
of manifestations.
Stephen T. Holgate  
University of Southampton 
Southampton, UK
ALLERGY AND THE 
EPITHELIAL BARRIERS21
Ke y  m e ssag e s
Allergy and the epithelial barriers
ACTIVATION OF THE 
EPITHELIAL MESENCHYMAL 
TROPHIC UNIT
In addition to inflammation, the 
pathology of asthma is dominat-
ed by structural changes includ-
ing epithelial damage and mucous 
metaplasia, angiogenesis, smooth 
muscle proliferation and angio-
genesis. In 2000, we proposed that 
these structural features were 
the consequence of the airways 
resembling a chronic wound in 
which epithelial damage is accom-
panied by aberrant production 
of growth factors and mediators 
that not only drive remodelling, 
but also sustain chronic inflamma-
tion (Figure 1). We referred to this 
interaction as activation of the 
epithelial mesenchymal trophic 
unit (EMTU) since many of the sig-
nalling mechanisms are similar to 
those engaged in lung morphogen-
esis in the developing foetal lung. 
ENHANCED SUSCEPTIBILITY 
OF THE ASTHMATIC 
EPITHELIUM TO INJURY
The airways in chronic asthma 
are more susceptible to injury as 
revealed by the majority of novel 
genes discovered by GWAS being 
preferentially expressed in the 
epithelium. There is also strong 
genetic and gene expression evi-
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Figure 1  Schematic representation of the activated epithelial mesenchymal trophic unit (EMTU) in active asthma. 
Increased susceptibility of the epithelium to environmental injury such as biologically active allergens, respiratory viruses 
and pollutants together with a delayed repair response leads to the secretion of a range of growth factors, cytokines and 
chemokines that both drive airway wall remodelling and sustain chronic airway inflammation. (From Holgate S.T. Arshad 
SH, Roberts GC, Howarth PH et al. A new look at the pathogenesis of asthma. Clin Sci. 2009; Reprinted with permission under the 
Creative Common Attribution License or equivalent.)
dence that anti-oxidant pathways 
in the asthmatic airways are de-
fective leading to enhanced tissue 
damage on exposure to viruses 
and pollutants. Even under basal 
conditions, the asthmatic epithe-
lium shows enhanced expression 
of biomarkers of apoptosis (e.g. 
caspases, P85 fragment of PARP) 
indicating loss of resilience.
Asthmatic airways, both in chil-
dren and adults, are more vulner-
able to common and usually innoc-
uous respiratory viruses such as 
rhinoviruses (RVs) adenoviruses 
and coronaviruses. When infect-
ed with major or minor subclass 
RVs, asthmatic epithelial cells fail 
to eliminate the virus adequately 
leading to enhanced replication, 
shedding and cytotoxic cell death 
with pro-inflammatory media-
tor release. Such a mechanism 
explains viral exacerbations of 
asthma, the relatively weak effect 
of corticosteroids and the mixed 
neutrophilic/eosinophilic inflam-
matory profile. The primary defect 
appears to be in the first step of 
induction of the anti-viral protec-
tive cytokines interferons (IFNs) 
β and λ after ds viral RNA binds 
to microsomal TLR3 (Figure 2). At 
least part of this defect can be ac-
counted for by the enhanced basal 
production of TGFβ to reduce 
SMAD3 phosphorylation and in-
crease nuclear inhibitory signals 
provided by SOCS1 and 3. Since 
exogenous IFNβ could restore de-
fective anti-viral defence to asth-
matic epithelium in vitro, inhaled 
IFNβ could be a novel therapeutic 
for severe exacerbations. Indeed, 
when administered at the first 
sign of a common cold in severe 
asthma inhaled IFNβ1α given dai-
ly for 14 days almost abolishes the 
post-viral exacerbation in parallel 
with maintaining biomarkers of 
anti-viral defence in respiratory 
secretions.
THE ASTHMATIC EPITHELIUM 
DISPLAYS IMPAIRED HEALING
The epithelium also contributes 
to persistence of asthma through 
enhancing remodelling pathways 
in the form of aberrant epithelial 
repair. Over expression of the epi-
dermal growth factor (EGF) family 
of receptors and their phosphoryl-
ation in the asthmatic epithelium 
increases in proportion to disease 
severity and is not accompanied by 
appropriate proliferative respons-
es as a consequence of mobilisa-
tion of cell cycle inhibitors such as 
P21
waf to the epithelial nuclei where 
they inhibit cell cycling. The net 
result of this is delayed epithelial 
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Figure 2  In 
chronic asthma, 
there is a defect 
innate immunity at 
the level of defec-
tive production of 
interferons when 
toll-like recep-
tors such as TLR3, 
TLR5 and TLR7 be-
come activated by 
viral nucleic acids 
as the first step in 
triggering an an-
ti-viral response. 
This results in 
virus survival, 
replication and 
eventual cytotoxic 
destruction of ep-
ithelial cells with 
release of inflam-
matory mediators 
that contribute to 
exacerbations. The 
defect appears to 
be in Step 1 of the 
anti-viral cascade 
involving defective interferon regulatory factor (IRF) 3 signalling to the interferon genes with low production of IFN induc-
tion, reduced signalling via the common IFN receptor and, therefore, reduced IRF7 amplification of the antiviral cascade in 
Step 2. The IRF7 pathway itself remains intact. For this reason a small amount of exogenous IFNβ acting via the common 
IFN receptor can restore a full anti-viral response as shown in the left bottom panel. It is upon this principle that inhaled 
IFNb1ais being developed for the prevention/treatment of severe asthma exacerbations. (From Holgate S.T. Arshad SH, Rob-
erts GC, Howarth PH et al. A new look at the pathogenesis of asthma. Clin Sci. 2009; Reprinted with permission under the Creative 
Common Attribution License or equivalent).
healing following environmental 
insults and enhanced pro-fibrotic, 
myogenic and angiogenic growth 
factor production such as TGFβ 
PDGFs, IGFs, FGFs and VEGFs to 
drive structural remodelling (5). 
The epithelium of asthmatic chil-
dren displays similar characteris-
tics and when grown as a monolay-
er and physically injured displays 
slower and incomplete restitution 
suggesting that the abnormality is 
intrinsic to the asthmatic epitheli-
um irrespective of age.
INADEQUATE EPITHELIAL 
TIGHT JUNCTION ASSEMBLY IN 
ASTHMA
There is increasing evidence that 
the epithelial barrier function is 
persistently deranged in asthma 
at the level of junctional integrity. 
The defective barrier function in 
asthmatic epithelium persists in 
differentiated epithelial cell cul-
tures following repeated passage 
indicating an intrinsic abnormality 
linked to enhanced mucous meta-
plasia, reduced cilia-genesis and 
reduced innate immune respon-
siveness. Increased permeability 
is enhanced by T cell interactions 
within the epithelium as well as 
the actions of “biologically active” 
allergens (e.g. proteases), viral in-
fection and pollutant exposure, 
all of which perturb tight junction 
functions. 
IS ASTHMA A DISORDER OF 
EPITHELIAL SENSING OF THE 
INHALED ENVIRONMENT?
Such a “pro-asthmatic” epithelium 
may have its origin in the way the 
epithelium senses the inhaled en-
vironment, with altered sensitiv-
ity being predetermined through 
altered expression of transcrip-
tion factors involved in foetal lung 
morphogenesis such as SPDEF 
increase secondary to FoxA2 and 
NKX2-1 (TTF-1) decrease. Path-
way analyses have now shown 
that in addition to regulating the 
“set point” for epithelial mucus 
production, the same transcrip-
tion factors are also implicated in 
orchestrating innate immune de-
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fence (including IFN responses to 
viral infection) and inflammatory 
pathways such as those leading to 
Th2-type allergic responses (Fig-
ure 3). 
This leads to the overall conclu-
sion that the different asthma sub-
types have their origin in the way 
the airway epithelium “reads” the 
environment and translates this 
along discrete pathways to vari-
able disease manifestations and 
responses to interventions.
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Figure 3 Schematic representation of the role of epithelial transcription factors involved in morphogenesis of the foetal 
lung such as SPDEF, FoxA2 and TTF1 interacting with key transcription factors of the allergic cascade such as STAT6 in 
driving mucous metaplasia and orchestrating both chronic Th2-type inflammation and tissue remodelling. In asthma, the 
‘set’ point for responding to environmental insults is altered to reduce airway resilience and augment the chronic wound 
scenario depicted in figure 1 and on the right side of the above figure. (Reproduced with permission from Holgate S.T. The 
sentinel role of the airway epithelium in asthma pathogenesis. Immunol Rev 2011; 242: 205-219, with permission from Willey 
Blackwell.).
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and generate peptides from precursor proteins. However, 
both proteases and protease inhibitors can be active players in 
inflammation 
• Proteases can be endogenous and exogenous. Almost all inhalant 
allergens such as pollens, mites and fungi have protease activity.
• Proteases exert their activity through Protease Activated 
Receptors, PAR 1-4, which are highly relevant in asthma and 
other allergic diseases
• Proteases disrupt tight junctions between the cells, can 
penetrate into the tissue and directly activate the cells apart 
from the classical flow of immunological mechanisms
Proteases are composed of a 
group of molecules with diverse 
physiological and pathological ef-
fects. The human body is equipped 
with a variety of protease inhib-
itors that counteract and thus 
control the activity of proteases. 
However, these protease inhibi-
tors can be active participants of 
inflammation. 
Proteases are naturally present in 
all organisms. Depending on their 
catalytically active site, they are 
termed as serine, cysteine, aspar-
tic and metalloproteases. Endog-
enous proteases are produced 
by inflammatory cells, most im-
portantly by mast cells (chymase, 
tryptase), neutrophils (cathep-
sin, elastase) and epithelial cells 
(thrombin). Almost all allergens in-
cluding house dust mites, pollens, 
fungi and cockroach and many 
bacteria, such as staphylococcus 
aureus, and viruses such as rhino-
virus and influenza have signifi-
cant protease activities. 
Physiologically, proteases func-
tion as digestive enzymes, gen-
erate active peptides from their 
precursors and drive innate im-
munity against multicellular or-
ganisms such as parasites, which 
are too large to be phagocytosed. 
They also participate in patholog-
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Epithelial proteases and allergic diseases
ical processes including allergic 
diseases (Table 1).
The action of proteases can be me-
diated through Protease Activat-
ed Receptors (PAR) 1-4. They are 
G protein-coupled receptors and 
are present almost on all cell types. 
PAR-dependent action of proteas-
es results in: increased release of 
pro-inflammatory cytokines by 
epithelial cells, endothelial cells, 
inflammatory cells, keratinocytes 
and fibroblasts; enhancement of 
IgE production; angiogenesis; in-
creased cell migration, infiltration 
and degranulation of inflamma-
tory cells; proliferation and con-
traction of airway smooth muscle 
cells; proliferation and activation 
of goblet cells and increased mu-
cous production (Figure 1). 
Some activities of proteases are 
PAR-independent and are ba-
sically a function of exogenous 
proteases. They increase pro-in-
flammatory cytokine production 
by airway epithelial cells, activate 
eosinophils and increase mucus 
production. 
Their highly relevant activity for 
allergic diseases is the effect of 
proteases on epithelial tight junc-
tions and adhesion molecules. 
Through their ability to disrupt 
occludin and claudin molecules 
and to activate MMP9 (which ac-
tivates other cellular proteases), 
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proteases can penetrate through 
the intracellular junctions in the 
mucosal epithelial barrier and ep-
idermis. This allows the penetra-
tion of the allergenic molecules 
into the tissues, where they can 
exert their protease as well as im-
mune stimulating activities. This 
recently emerging concept raises 
the intriguing possibility that pro-
tease activities of the allergens 
may be critical not only for the 
maintenance of tissue inflamma-
tion observed in allergic diseases, 
but may also be important in the 
inception of allergic diseases. In 
addition, this initial penetration 
may be subsequently followed by 
the stimulation of a variety of cell 
types without the classical IgE and 
other cellular immune mechanism.
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TABLE 1
Proteases in inflammation
Source Protease Mode of action Actions
Exogeneous Pollens
Fungi
Mites
Cockroach
Hymenoptera
Bacteria
Viruses
PAR dependent
PAR independ-
ent
Disruption of tight junctions
Disruption of barrier function
Th-2 adjuvants 
Secretion of pro-inflamma-
tory cytokines
Promotion of IgE synthesis
Activation of 
epithelial cells
keratinocytes
inflammatory cells
airway smooth muscle
Endogenous Thrombin
Plasmin
Tyrptase
Chymase
Plasmin
Kallikrein
Trypsin 
Elastase
Cathepsin G
Mostly PAR 
dependent
Activation of
Endothelial cells
Epithelial cells
Keratinocytes
Fibroblasts
Airway smooth muscle
All inflammatory cells
Glandular secretion
Figure 1 The action of proteases mediated trough Protease Activated 
Receptors (PAR).
Epithelial proteases and allergic diseases
airway smoth muscle
mast cell
eosinophil
PAR
endothelium neutrophil
exogenous protease
endogenous  protease
PAR
Stimulation of 
epithelium
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receiving allergen-specific immunotherapy (AIT) and high dose 
allergen exposure models such as beekeepers and cat owners
• Early basophil and mast cell desensitisation is the first event of 
immune tolerance to allergens
• Induction of allergen-specific T regulatory (reg) cells 
characterized by the expression of multiple suppressor factors; 
CD25, CTLA-4, PD1, RUNX, HR2, IL-10 and TGF-beta is essential
• Induction of IL-10-producing Breg cells after high dose Ag 
exposure and AIT was described, together with increased 
allergen-specific IgG4 production, which is specifically confined 
to IL-10-producing Breg cells
• Decreased eosinophil, mast cell and basophil migration and 
activation in the affected tissues also occurs during allergen 
tolerance
Allergy is characterized by dom-
inant allergen-specific Th2 re-
sponses, and consequent IgE in-
duction. Many factors influence 
the pathophysiology of allergic 
diseases, including genetic sus-
ceptibility, route/time/dose of 
allergen exposure, structural fea-
tures of the allergen and microbial 
exposure.
The immunoregulatory mecha-
nisms that can mediate tolerance 
towards allergens in humans have 
been subject to intensive research 
during the last decades. These 
mechanisms have been studied in 
allergic patients receiving aller-
gen-specific immunotherapy (AIT) 
as well as in healthy individuals, 
who are exposed to high-doses 
of allergens, such as beekeepers 
and cat owners. These human in 
vivo models have demonstrated 
that the mechanisms leading to 
peripheral tolerance to allergens 
include early desensitization of 
mast cells and basophils, induc-
tion of T regulatory (reg) and Breg 
cells, regulation of allergen-spe-
cific immunoglobulin production 
and interference with migration 
and activation of eosinophils, mast 
cell and basophils in the allergic 
tissues.
Treg and Breg cells play a key role 
MECHANISMS OF IMMUNE 
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in the induction and maintenance 
of tolerance towards allergens. 
These cells produce immunoreg-
ulatory cytokines such as IL-10 
and TGF-β. TGF-β is a pleiotropic 
cytokine that has a wide range of 
functions including suppression 
of B and T cell proliferation and 
differentiation, as well as control 
of airway inflammation and air-
way remodeling. IL-10 is a key an-
ti-inflammatory cytokine, which 
inhibits effector T cell activation 
directly through suppression of 
co-stimulatory pathways in T 
cells, and indirectly through sup-
pression of antigen-presentation 
capacity of DCs. IL-10 also sup-
presses mast cell and eosinophil 
activation, thereby interfering 
with early and late phase allergic 
responses. Both Treg and Breg 
cells contribute to IgG4 produc-
tion and suppression of IgE pro-
duction. Inducible IL-10-produc-
ing B regulatory 1 (Br1) cells are 
skewed towards the production of 
anti-inflammatory IgG4 antibod-
ies. These cells may play a role in 
tolerance induction to allergens, 
as an increase in the frequency of 
IL-10-producing B cells specific for 
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the bee venom allergen phospholi-
pase A2 was observed in bee ven-
om allergic patients, who received 
AIT.
The susceptibility of mast cells 
and basophils to allergen-induced 
degranulation is reduced already 
after the first injection of AIT. This 
may be the result of subclinical lev-
els of degranulation of these cells 
caused by allergen, leading to the 
increased activation thresholds 
observed during in vitro measure-
ments. Furthermore, rapid up-reg-
ulation of histamine receptor 
(HR) 2 was observed in basophils 
during the first 6 hours of venom 
immunotherapy. HR2 triggering 
could suppress FcεRI-mediated 
basophil degranulation. Histamine 
can be released from mast cells 
and basophils that are activated 
during AIT and can regulate T cell 
responses as well. HR2 negatively 
regulates both Th1 and Th2-type 
responses. Therefore, HR2 ap-
pears to be a key mediator in the 
suppression of Th2 responses and 
induction of tolerance towards al-
lergens. Intensive research in the 
area is essential to fully uncover 
the molecular pathways of aller-
gen tolerance.
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IL-3 
IL-4 
IL-5 
IL-9
IL-4
IL-13
IL-10
IL-10
TGF-β
TRegBr1
mast cell basophil
Direct and indirect suppressive effects on 
mast cells, basophils and eosinophils
eosinophil
B cell
Th2
IgG4 production
IgG4 production
Suppression of Th2 cell 
homing to tissues
Endothelial cells Figure 1 Role of Treg and Breg 
cells in the suppression of allergic 
inflammation. Treg cells and their 
cytokines mainly IL-10 and TGF-β 
suppress Th2 type immune responses 
and control allergic diseases in 
many ways. Black arrows show the 
regulatory and suppressive effects 
of Treg cells on: B cells by inducing 
IgG4 and IgA and suppressing IgE; on 
Th2 cell by suppressing proliferation 
and homing to tissues; on mast cells, 
basophils and eosinophils via direct 
and indirect suppressive effects; 
and on epithelial cell activation and 
proinflammatory properties by 
direct and indirect suppression. In 
addition, Br1 cells, which produce 
IL-10 suppress effector T cells and 
contribute to IgG4 synthesis.
Mechanisms of immune regulation in allergy
92
Global atlas oF allerGy
se
c
t
io
n
 a
 - 
A
lle
rg
y 
 - 
fr
o
m
 g
en
et
ic
s 
to
 m
ec
h
an
is
m
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pathogenesis of allergic diseases and other inflammatory 
diseases
• The axon reflex participates in the acute inflammatory response 
in rhinitis or asthma and is aggravated in asthmatic patients, due 
to a high degree of neuronal plasticity
• Increased neurotrophin levels were described in the asthmatic 
patients where they play a critical role in maintaining eosinophilia 
and Th2 driven inflammation, mast cell activation and enhance 
IgE production by B cells 
• There is an urgent need for the development of biomarkers 
assessing the state of neurogenic dysregulation in asthmatic 
patients together with the development of novel therapeutic 
approaches aiming to re-establish the neurogenic homeostasis 
The pathophysiology of asthma 
is complex and heterogeneous 
showing inter- as well as intra-in-
dividual variability. In addition to 
the profound dysregulation in in-
nate and adaptive immune func-
tions, dysbalanced neurogenic re-
sponses substantially contribute 
to the disease (Figure 1).
Airway hyper-responsiveness is 
considered a hallmark of asth-
ma. The contractility of airway 
smooth muscle cells is controlled 
by several types of neurons in-
cluding sympathetic (adrenergic), 
parasympathetic (cholinergic) and 
non-adrenergic, non-cholinergic 
(NANC) neurons. These types of 
neurons are part of the complex 
innervation network of the air-
ways and the lung.
Neurons control lung function via 
the axon reflex (Figure 2). This is 
best described for sensory neu-
rons, which pick up stimulatory 
signals in the airways and transmit 
them via the sensory neurons to 
the central nervous system (CNS). 
Stimuli able to excite these neu-
rons include unspecific pollutants 
such as tobacco smoke particles, 
ozone and NO2 as well as signals 
driven from microbes and aller-
gens. Cell damage caused by viral 
infection and replication is an im-
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Figure 1 Neurotrophins contribute to bi-directional communication between 
nervous and immune system.
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portant trigger of the axon reflex. 
Efferent signals are sent back 
from the cell body of the neurons 
to the lung periphery. Within the 
cell bodies, neuropeptides are 
produced and stored. Afferent 
firing of the neurons triggers not 
only the production, but also the 
retrograde transport of these 
neuropeptides back to the site of 
irritation and activation. These 
locally released peptides (includ-
ing tachykinins, neurokinins and 
others) play an important role in 
mediating acute pro-inflammato-
ry events such as vasodilatation, 
recruitment of inflammatory cells, 
activation of mast cells and eosin-
ophils and others. Therefore, the 
axon reflex is one important exam-
ple of how neurons actively par-
ticipate in the acute inflammatory 
response in rhinitis or asthma.
Figure 2 Neurogenic inflammation – The axon reflex.
Figure 3 Neurotrophins and receptors. 
Neuro-immune regulation of allergic inflammation
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The axon reflex is aggravated in 
asthmatic patients, due to a high 
degree of neuronal plasticity ob-
served in many chronic diseases. 
The development of the peripher-
al neuronal network, the state of 
activation, and the differentiation 
of neurons and various subtypes 
is tightly controlled by another 
group of mediators termed neuro-
trophins (Figure 3). Neurotrophins 
belong to a family of mediators, 
which control neuronal functions 
and exert also important effector 
mechanisms on many other cells 
including immune cells. The pro-
totype of the neurotrophin family 
is the nerve growth factor (NGF). 
The brain-derived neurotrophic 
factor (BDNF) and other mem-
bers of this family have also been 
extensively studied. Neurotro-
phins signal through two different 
types of receptors, the pan-neu-
rotrophin-receptor p75 and the 
high-affinity neurotrophin recep-
tors TRKA, B and C. These recep-
tors are also expressed at various 
degrees and extend on cells of the 
innate and the adaptive immune 
system.
An important step forward in bet-
ter understanding the neurogenic 
component in asthma was the de-
scription of increased neurotro-
phin levels in asthmatic patients 
(observed in sputum, BAL, tissue, 
blood). Further mechanistic stud-
ies carried out both in human and 
mice models further revealed that 
NGF and BDNF play a critical role 
in maintaining eosinophilia and 
Th2-driven inflammation, mast 
cell activation, while enhancing 
IgE production by B cells. There-
fore, neurotrophins are consid-
ered major players in the overall 
maintenance of an already existing 
inflammatory response (Table 1).
There is an urgent need for the 
development of better diagnostic 
tools to assess the state of neu-
rogenic dysregulation in asthmat-
ic patients. The development of 
novel biomarkers should go hand 
in hand with the development 
of novel therapeutic approaches 
aiming to re-establish neurogenic 
homeostasis in this disease.
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TABLE 1
The family of NGF and its receptors in bronchial asthma
  augmentation of TH-2 inflammation (NGF, p75)
  anti-apoptic signals (NGF, BDNF, p75)
• eosinophils
• pulmonary plasma cells
  acute broncho-constiction (NGF, p75)
  neuronal control of airway hyperresponsiveness (BDNF)
  epithelial wound healing
Neuro-immune regulation of allergic inflammation
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• The upper and lower airways are often diseased together
• A high percentage of young children with asthma are sensitized 
to inhalant allergens
• There is an increased risk of developing late-onset asthma in 
chronic rhinosinusitis patients
• These patients are often non-atopic, but express IgE to 
staphylococcal enterotoxins
• Apart from inhalant allergens, staphylococcal enterotoxin–
specific IgE is related to asthma
It is well established that the up-
per and lower airways are linked 
together, we therefore, call them 
“United Airways”. The develop-
ment of asthma mostly begins 
early in life time, and asthma man-
ifests before the age of 16 years; 
usually, this early-onset asthma 
is preceded by rhinitis symptoms. 
Over 80% of young children with 
asthma are allergen sensitized, 
and atopy in this age group in-
creases disease morbidity. Addi-
tionally, atopy plays a critical role 
in the inception of asthma attacks 
in this age group, in particular dur-
ing viral infection. Also in later life, 
rhinitis is a powerful predictor of 
asthma, and atopy significantly in-
creases the risk for asthma devel-
opment in late-onset asthma. 
A recent Europe-wide epidemio-
logic study on the prevalence of 
chronic rhinosinusitis (CRS), a dis-
ease manifesting in the nose and 
paranasal sinuses, confirmed the 
well-known association between 
allergic rhinitis and early-onset 
asthma, but also demonstrated a 
clearly increased risk of suffering 
from late-onset asthma in CRS 
patients. Thus, whereas younger 
patients with asthma frequently 
complain of allergic rhinitis symp-
toms, older patients with asthma 
Claus Bachert  
University of Ghent 
Ghent, Belgium
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often suffer from sinus disease 
with symptoms such as nasal ob-
struction, loss of smell and facial 
pain/headache. CRS can be differ-
entiated into CRS without nasal 
polyps (CRSsNP) and with nasal 
polyps (CRSwNP), based on symp-
toms (loss of smell is typical for 
CRSwNP, headache and facial pain 
are typical for CRSsNP), nasal en-
doscopy (presence of bilateral na-
sal polyps) and CT scanning. From 
those phenotypes, CRSwNP has 
a clearly increased risk of asthma 
comorbidity in Caucasian popula-
tions. 
Allergic airway disease is charac-
terized by the mucosal synthesis 
of IgE molecules, which arm den-
dritic cells and mast cells. These 
armed cells upon contact with 
the allergen, release specific me-
diators and cytokines. With the 
Th2 cells being prominent, an eo-
sinophilic type of inflammation is 
orchestrated, which involves key 
interleukins (ILs) such as IL-4 and 
IL-5. Very similar mechanisms, 
although patients with CRSwNP 
often are non-atopic, also prevail 
in late-onset asthmatics with si-
nus disease. Among the group of 
nasal polyps, especially the IL-5 
positive endotype, predominantly 
showing an eosinophilic inflamma-
tion, bears a high risk of asthma 
comorbidity (up to 70%). In these 
patients, serum total IgE often 
is increased, independent of the 
atopic status of the patient. IgE 
antibodies to Staphylococcus au-
reus superantigens (SE-IgE) can 
be detected in a large proportion 
of these patients in the upper air-
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Figure 1 The association (relative risk ratio with 95% confidence interval) of early- and late-onset asthma with nasal 
allergies (early-onset) and chronic rhinosinusitis (late-onset). (Reproduced with permission from Jarvis D, Newson R, Lotvall 
J,et al. Asthma in adults and its association with chronic rhinosinusitis: The GA2LEN survey in Europe. Allergy 2012;67:91-98, 
with permission from Willey Blackwell)
Figure 2 Classification tree for 
comorbid asthma in patients with 
nasal polyps: SE-IgE positivity 
(categorical classifying determinant) 
is associated with a significantly 
increased risk to suffer from co-
morbid asthma. (Reprinted from J 
Allergy Clin Immunol, 126/5, Bachert 
C, Zhang N, Holtappels G,Presence 
of IL-5 protein and IgE-antibodies to 
staphylococcal enterotoxins in nasal 
polyps is associated with co-morbid 
asthma, 962-968, Copyright 2010, with 
permission from Elsevier.)
United airways and immune regulation
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Figure 3 Multiple correspondence analyses factor map with 95% confidence 
ellipses situating relationships between parameters and disease severity. SE 
IgE is situated near severe asthma, whereas GP and HDM IgEs are situated 
near non-severe asthma. (Reprinted from J Allergy Clin Immunol, 130/2, Bachert 
C,van Steen K, Zhang N,Specific IgE against Staphylococcus aureus enterotoxins: an 
independent risk factor for asthma, 376-381, Copyright 2012, with permission from 
Elsevier.)
Figure 4 Odds ratios for asthma presence for each of the tertiles of serum 
SE-IgE in a pan-European study involving app. 3000 patients. The concentration 
of SE-IgE is significantly associated with an increased risk of suffering from 
asthma (Reproduced with permission from Tomassen P, Jarvis D, Newson R, et al. 
Staphylococcus aureus enterotoxin specific IgE and its association with asthma in 
the general population: a GA²LEN. Study. Allergy 2013;68:1289-97, with permission 
from Willey Blackwell.) 
ways, but also with increasing se-
verity of asthma in serum. SE-IgE 
antibodies are significantly asso-
ciated with severe asthma, oral 
corticosteroid use and hospitali-
zations within the last 12 months, 
and lung function parameters. 
As well as IgE antibodies to in-
halant allergens, SE-IgE antibod-
ies are also associated with an 
increased risk of asthma in the 
general European population, ac-
cording to a recent epidemiolog-
ic study investigating more than 
55000 patients. Local IgE there-
fore needs to be recognized as an 
important mediator of disease of 
the airways. 
United airways and immune regulation
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Controls
SE-IgE Neg
HDM-IgE Neg
GP-IgE Neg
Severe
SE-IgE Pos
HDM-IgE Pos
GP-IgE Pos
-1.0 -0.5 0.0 0.5 1.0
-1.0
-0.5
0.0
0.5
1.0 Diagnostic tools in asthma should 
include questions on nasal and si-
nus symptoms, blood eosinophils, 
total IgE and specific IgE abs to 
inhalant allergens and SEs also in 
non-atopic subjects. The treat-
ment of the upper airways in these 
patients might furthermore sup-
port the management of the lower 
airways, and therefore should be 
part of the individual therapeutic 
strategy. 
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s • Epidemiological and genetic research has provided firm evidence 
for the existence of genetic determinants of atopic diseases with 
reported heritability estimates of up to 80%
• Atopic diseases are complex, polygenic traits, influenced by 
multiple disease genes
• Results from studies using high density association mapping 
suggest that epithelial events and innate immune function are 
major drivers of pathogenesis
• The detection of molecular interactions between susceptibility 
genes and environmental triggers over time and the elucidation 
of epigenetic factors as potentially underestimated source of 
hidden heritability will be major tasks for the next years
Atopic diseases (eczema, asthma, 
rhinitis) affect an increasing num-
ber of individuals worldwide and 
represent a major global health 
problem. Epidemiological and ge-
netic research has provided firm 
evidence for the existence of ge-
netic determinants of atopic dis-
eases with reported heritability 
estimates of up to 80% (Figure 1). 
Atopic diseases are typical com-
plex, polygenic traits, which are 
thought to be influenced by mul-
tiple disease genes. As for other 
complex traits, the identification 
of these genes is hampered by 
considerable phenotype and locus 
heterogeneity, incomplete pene-
trance and interaction with most-
ly unknown non-genetic factors, 
as well as by the yet incompletely 
understood interrelation of these 
diseases with each other and with 
intermediate traits like IgE. Only 
recently, it has become possible 
to systematically unravel the poly-
genic etiology of complex human 
diseases by high density associa-
tion mapping, which has allowed 
a breakthrough in the definition 
of disease genes with an unprec-
edented richness of findings and 
a surprisingly high degree of re-
producibility. For allergic diseases, 
results from such studies suggest 
that epithelial events, e.g. heredi-
Stephan Weidinger  
University Hospital Schleswig-Holstein 
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tary alterations of structural pro-
teins and innate immune function 
are major drivers of pathogenesis. 
With the exception of few sin-
gle loci exerting large effects on 
some phenotypes, e.g. filaggrin 
null mutations on atopic dermati-
tis (Figure 2), the majority of loci 
displays rather modest effects 
when considered in isolation, and 
the despite impressive progress in 
the field, only a small proportion 
of the total heritability is yet ex-
plained by known risk variants. It 
is further becoming clear that ge-
netic risk factors overlap between 
traditional entities rather than 
providing direct discriminators 
suggesting shared and potentially 
intermediate molecular mecha-
nisms of immune mechanisms and 
inflammation and illustrating the 
need for a more accurate classifi-
cation of allergic diseases based 
on their phenotypic and molecu-
lar basis (Figure 3). Of note, the 
observed increase in prevalence 
of atopic diseases is not primar-
ily genetic, but rather due to the 
dramatic changes of environmen-
tal conditions and modern health 
hazards that trigger a genetic 
vulnerability into action. The de-
tection of molecular interactions 
between susceptibility genes and 
environmental triggers over time 
and the elucidation of epigenetic 
factors as potentially underesti-
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Figure 2 The strong association of low-frequency FLG null mutations with atopic dermatitis is one of the most robust 
genotype-phenotype linkages observed in complex human genetic disorders, and illustrates the importance of epithelial 
barrier defects in the development of allergic disease.
Figure 1 A genetic predisposition to the development of asthma, allergic rhinitis, and atopic dermatitis (AD) has been 
confirmed by numerous epidemiological studies with the strongest evidence delivered by twin studies, which show a 
distinctly higher concordance rate among monozygotic twins as compared to dizygotic twin pairs (for AD: 0.72-0.77 vs 
0.15-0.23), and segregation analyses, which suggest that genetic factors account for more than 80% of the variance in the 
susceptibility to AD.
Genetics of allergy
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Figure 3 The majority of established risk loci for atopic dermatitis are also implicated in the development of other 
immune mediated-diseases with both agonistic and antagonistic effects.
mated source of this hidden her-
itability will be major tasks for the 
next years.
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• Epigenetic modifications result in changes in the expression 
of genetic material and can occur by three processes: DNA 
methylation, histone modification or microRNA mediated changes 
• Like genetics, epigenetic marks are inherited with each cell 
division and can persist through generations and may account in 
part for the increased prevalence of allergic disease
• Genes in immune cells responsible for disease can be 
epigenetically modified by variables such as environmental 
exposures, diet, and the microbiome 
• Identical twins with discordant asthmatic status have been 
shown to have different epigenetic marks on key immunologic 
genes in their genome
Epigenetics is the study of herit-
able changes in gene activity that 
are not caused by changes in the 
DNA sequence (Figure 1). These 
include modifications to the struc-
ture supporting the DNA called 
histones. Histone modification 
(adding or removing acetyl groups) 
determines DNA packaging and 
the cell’s ability to access and read 
the associated sequence. DNA can 
also be modified directly by adding 
a methyl group to cytosine bases, 
which may restrict access to the 
DNA for transcription into mRNA. 
Finally, gene expression can be 
regulated at the post-transcrip-
tional level by microRNAs, which 
can further modify mRNA tran-
scripts and histones to alter the 
expression of genes (Figure 2). 
Many environmental factors are 
thought to regulate gene expres-
sion through these mechanisms 
and studies are ongoing to identify 
specific exposures and pathways 
of effect (Figure 3). One of the 
main characteristics of epigenetic 
changes is that it is passed on to 
daughter cells with each cell divi-
sion so it may have a long lasting 
effect on cell function. 
The importance of epigenetics in 
determining allergic phenotype 
was illustrated in identical twin 
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studies, in which one twin suf-
fered from asthma and the other 
did not. Asthmatic twins were 
found to exhibit DNA methyla-
tion patterns that differed from 
their healthy counterpart. Most 
notably, they had increased meth-
ylation and decreased expression 
of the FOXP3 gene, which is im-
portant for the anti-inflammatory 
function of T regulatory cells. Ad-
ditionally, they showed decreased 
function of non-allergic effector T 
cells through methylation of the 
IFN-gamma gene.
Furthermore, there is evidence 
that some epigenetic marks can be 
transmitted from parents to chil-
dren trans-generationally, with 
cumulative effect over multiple 
generations (Figure 4). This is par-
ticularly relevant when consider-
ing the epidemiology of allergic dis-
ease, which seems to be amplified 
with subsequent generations. At 
the population level, allergic sen-
sitization seems to have occurred 
in waves. The first wave was char-
acterized by allergic rhinitis and 
asthma in industrialized countries 
(US, UK, Australia), more than 50 
years ago. The second wave is now 
food allergy. Interestingly, devel-
oping countries are currently just 
seeing the first wave. This implies 
that factors such as pollution, diet, 
and lifestyle may be driving epige-
netic changes in different parts of 
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HAT    HDACTET  DNMT ATP-dependent
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Figure 1 Different epigenetic 
mechanisms determine a 
gene’s active vs silenced state. 
DNA methylation involves 
adding a methyl group DNA 
base cytosine (red circle). 
This prevents gene access 
to transcription factors and 
promotes other epigenetic 
changes. Histones, which are 
large molecules that act as a scaffold for DNA strands, can be modified on 
their tails. Modification such as histone acetylation (green stars) can favour 
histone molecules to spread apart, allowing for an open DNA structure called 
euchromatin. Other histone modifications have been shown to favour a very 
condensed state (heterochromatin) in which DNA transcription is impossible. 
Chromatin remodelling is an active process that requires the intervention 
of various ATP-dependent enzymes. (HAT = Histone acetyltransferase; 
TET = Ten-eleven translocation dioxygenase; DNMT = DNA 
methyltransferase; HDAC = Histone deacetylase).
miRNA duplex
Blocked 
protein 
synthesis
mRNA 
degradation
RNA-induced silencing complex
ribosome
mRNA
Figure 2 MicroRNA (miRNA) is transcribed from eukaryotic DNA with RNA 
polymerase to form a double-stranded structure. Further processing of the 
miRNA results in a structure with other proteins essential to miRNA’s function, 
shown here as the three blue geometric shapes.  This complex is called an 
RNA-induced silencing complex, or RISC.  The RISC will bind to complementary 
mRNA sequences and has 2 modes of action: one, it can occlude and prevent 
translation of the mRNA into functional proteins; two, it can recruit other 
proteins to degrade the bound mRNA.
the world that are skewing people 
towards an allergic phenotype. 
Epigenetics is an exciting and ex-
panding field of asthma and allergy 
research that provides new insight 
into our understanding of these 
complex syndromes, and possibly 
useful biomarkers for diagnosis 
and characterization of various al-
lergic sub-phenotypes. 
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Figure 3 Environmental factors such as 
pollution, food, agriculture and microbiota 
have been shown to have significant impli-
cations on early immune programming and 
development. Prenatal exposure to these 
elements is postulated to cause epigenetic 
changes to genes and signaling pathways 
of fetal immunity that may have lasting 
effects during the child’s life.
Trans-generational Amplification Hypothesis
Figure A
Figure B
Figure 4 Figure A depicts a trans-
generational model of atopic disease 
predisposition that is solely based on 
environmental stressors. This model 
predicts that environmental pressure 
directly correlates with an increase in 
baseline genetic risk for disease only for 
generations that lived during the changed 
environment. Figure B illustrates an 
epigenetic transgenerational inheritance 
model wherein a change in environment 
not only increases baseline risk for disease 
but also induces epigenetic changes in 
subsequent generations as shown in 
animal models. This could lead to an 
amplification of the atopic disease that 
lasts up to two generations after return to 
normal environment. 
Epigenetics of allergy
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significant outcomes, including response to treatment, pushed 
towards the development of the concept of phenotypes and 
endotypes
• There are several benefits of using endotypes such as stratified 
treatment and better characterization of subjects in genetic and 
epidemiologic studies and clinical trials for drug development
• Several endotypes can be described for asthma, rhinitis and 
chronic rhinosinusitis based on the mechanisms of inflammation, 
driving cause, genetic factors, tissue-related factors and 
response to treatment
• Translation of biomarkers into pathway-specific diagnostic 
tests is essential and should guide the design of future clinical 
trials, incorporating both longitudinal and mechanism-tailored 
endpoints
• Stratified treatment should be endotype-, biomarker- and 
outcome-driven
The heterogeneity of allergic 
diseases in relation to clinically 
significant outcomes, including 
response to treatment, has been 
established beyond any doubt. 
However, current guidelines ig-
nore disease heterogeneity and 
causal pathways, leading to unsuc-
cessful clinical “bulk” trials or con-
tradictory results in epidemiologic 
and genetic surveys.
In the beginning, disease pheno-
types describing clinical and mor-
phologic characteristics as well 
as unique responses to treatment 
have been developed to address 
the complexities of the disease. 
Phenotypes are clinically rele-
vant observable characteristics 
in terms of presentation, triggers, 
and treatment response, but do 
not necessarily relate to or give 
insights into the underlying patho-
logical mechanism. For most of the 
allergic diseases heterogeneous 
and mechanisms of the disease-re-
lated metabolic, inflammatory, 
immunological, and remodeling 
pathways have been described, 
and defined as a disease endotype. 
There are several benefits of en-
dotyping in a clinical setting (Fig-
ure 1). In addition, aligning mouse 
models to human endotypes is a 
more relevant approach to the un-
ENDOTYPES OF 
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derstanding of pathophysiological 
mechanisms of allergic disease.
New and expensive biological 
therapies for allergic diseases are 
emerging that are highly effica-
cious only for a selected group of 
patients. The response to targeted 
interventions in allergic disease 
may vary among individuals or for 
the same individual in relation to 
outcome measures (dissociated 
effect). Therefore, targeted treat-
ment should be both biomark-
er-driven and outcome-driven 
(Figure 2).
The ideal biomarker should be 
pathway-specific, reproducible, 
easily measurable, and affordable. 
Biomarker research is increasingly 
shifting towards multidimensional 
approaches, in which the clinical 
value of a combination of various 
markers is studied. Translation of 
biomarkers into pathway-specific 
diagnostic tests is essential and 
should guide the design of future 
large clinical trials, incorporating 
both longitudinal and mechanism 
Ioana Agache  
Transylvania University 
Brasov, Romania
Cezmi A. Akdis  
Swiss Institute of Allergy and Asthma 
Research, Davos, Switzerland
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In epidemiological trials: subgrouping of asthma cohorts using 
endotypes may better determine the incidence, prevalence, morbidity, 
mortality and health-care resources utilisation related to asthma.
In genetical studies: relating endotypes to genes may 
yield more specific associations.
In drug-related trials: refining inclusion criteria using endotypes may 
identify patient subgroups with particular benefit from 
existing as well as new treatments. This could result in a 
substantial improvement  in asthma care.
It is anticipated that in the future endotype-tailored treatment 
(stratified medicine) could lead to measurable improvement in the 
optimization of care of individual cases and hopefully result in an 
improvement in health care costs by applying specific treatments 
only to those who will benefit from it.
Figure 1 Potential advantages of endotyping. (Reproduced with permission from Agache I, Akdis C, Jutel M, Virchow JC, 
Untangling asthma phenotypes and endotypes. Allergy. 2012;67:835-46, with permission from Willey Blackwell.)
Response to a targeted antiasthmatic drug
Genetic and epigenetic 
background
Immune-inflammatory 
pathway
Remodeling phenotype 
(ASM, epithelium)
Efficacy at the target site 
of the drug formulation
inter- and intraindividual 
differences in response 
(dissociated effect)
biomarker
driven treatmen
outcome
driven treatment
Figure 2 Response to targeted treatment in asthma. (Reproduced from Agache IO. From phenotypes to endotypes to asthma 
treatment. Curr Opin Allergy Clin Immunol. 2013 Jun;13:249-56.)
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tailored endpoints. The selection 
of outcome measures is difficult, 
as it must reflect the mechanistic 
intervention and should be rele-
vant for both the population as a 
whole and for the particular indi-
vidual. 
While endotype-driven thera-
peutic strategies are becoming 
increasingly successful in asthma, 
only feeble attends were made for 
other allergic diseases. In addition, 
the issues related to the dissociat-
ed effect and drug efficacy at the 
target site remain unresolved.
For asthma the “Th2 high” and 
“Th2 low” endotypes are well rec-
ognized and used to ascribe spe-
cific treatment. Several subtypes 
of the Th2-high and Th2-low en-
dotypes can be described based 
on the main operating molecular 
mechanism (Table 1).
Applying the same model to al-
lergic and non-allergic rhinitis 
could prove as successful in pro-
moting personalized approaches, 
especially for the severe forms of 
the disease. The well recognized 
link between rhinitis and asthma 
should be integrated and tackled 
within the framework provided by 
endotypes. 
Rhinitis endotypes can be defined 
in relation to the background in-
flammation or in terms of treat-
ment responsiveness. The follow-
ing endotypes can be proposed 
for allergic rhinitis: eosinophilic 
or Th2 (IL-4/IL-13) inflammation; 
steroid-responsive, anti IgE re-
sponsive, anti IL-5 responsive, 
anti IL-4/IL-13 responsive. For 
non-allergic rhinitis the defini-
tion of endotypes (eosinophilic or 
neutrophilic inflammation, steroid 
responsive or resistant) should 
include the driving cause: supe-
rantigens, local IgE production, 
autoantibodies. In the same line a 
TABLE 1
Th2 high and Th2 low asthma endotypes
Endotype Biomarker
Th2 high IgE driven (atopic 
and non-atopic)
Total serum IgE
IgE on DC
Sputum total or specific IgE
IL-4/IL-13 driven Serum periostin 
Sputum IL-13 
IL-4 rc α SNPs
IL-5/eotaxin driven Sputum/blood eosinophils
FeNO
Eotaxin 2
PGD2 driven ?
Aspirin intolerant Sputum/urine leukotrienes and 
prostaglandins
Mast cell/IL-9 driven) ?
Eosinophilic obese 
asthma
Sputum IL-5
Submucosal eosinophils
Asthmatic 
granulomatosis (Th1 
driven)
Eosinophilic inflammation 
Corticosteroid resistance
? Autoimmunity markers
Innate immune 
response driven
TSLP
IL-33/ST-2
Th2 low Neutrophilic (Th17/
IL-8/purinergic 
inflammation driven)
Sputum neutrophilia
Low IgE
Low eosinophils
High reversibility 
Paucigranulocytic 
(EMTU driven)
No inflammation (sputum/bronchial 
biopsies)
Prominent remodeling
Small airways 
disease
Flow, resistance, ventilation heterogeneity
Alveolar inflammation
Microbioma Non-eosinophilic exacerbation-prone 
asthma 
PCR evidence of infections
Innate IR driven BAL/sputum TNF-α
Non-eosinophilic 
obese asthma
L-Arg/ADMA
Abbreviations:
ADMA = asymmetric dimethyl arginine; BAL = broncho-alveolar lavage; EMTU = 
epithelium-mesenchyme trophic unit; FeNO = fractional exhaled nitric oxide; L-Arg 
= L-arginine; PCR = polymerase chain reaction; SNPs = single-nucleotide polymor-
phisms
Endotypes of allergic diseases
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PRACTALL document described 
several endotypes for chronic rhi-
nosinusitis (CRS) characterized 
by differences in responsiveness 
to treatment, including topical 
intranasal corticosteroids and bi-
ological agents, such as anti–IL-5 
and anti-IgE mAb (Figure 2). Some 
of the described CRS endotypes 
were based on different biomark-
ers linked to underlying mecha-
nisms.
Atopic dermatitis (AD) is a chron-
ic inflammatory skin disease with 
complex genetic and immunolog-
ical mechanisms. Several endo-
types can be proposed according 
to the inflammatory background 
such as Th2/IL-22/periostin high 
or Th17/Th1 high or in relation to 
the expression of fillagrin, MATT 
or vitamin D pathway genes muta-
tions. For the Th2 type AD serum 
periostin is related to disease se-
verity. Targeting both the inflam-
matory-immune dysregulated 
pathways or the barrier defect 
holds future promise. Several new 
targets such as toll-like recep-
tors, type 2 innate lymphoid cells 
and tight junction proteins are 
emerging. Promising new thera-
peutic agents in the near future 
are sphinganin, cannabinoids and 
highly targeted monoclonal anti-
bodies.
For food allergy phenotypes 
prove useful for predicting severe 
reactions. Different phenotypes 
of children with cow’s milk allergy 
can be distinguished by casein- 
and milk-specific IgE levels, milk 
specific basophil reactivity, and 
milk SPT mean wheal diameters. 
In another study IL-25 was found 
highly elevated only in children 
with a clinical response to peanut, 
suggesting a role for IL-25 in the 
pathogenesis of peanut allergy 
and as a biomarker of a severe at-
opic phenotype.
For drug allergy several pheno-
types were described for the hy-
persensivity to non-steroidal an-
ti-inflammatory drugs (NSAIDS): 
aspirin-exacerbated respiratory 
disease, aspirin-exacerbated cuta-
neous disease, multiple NSAID-in-
duced urticaria/angioedema, 
single NSAID-IgE reactions and 
single NSAID T cell responses, 
which differ in terms of the path-
ogenic pathways involved, as well 
as the mediators released after 
provocation tests.
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diseases
• Animal models are particularly useful for identifying novel 
cellular and molecular immunological mechanisms of allergy
• No single animal model completely recreates all the aspects of an 
allergic response
Animal models have been devel-
oped for almost all types of aller-
gic disease such as asthma, allergic 
rhinitis, food allergy, anaphylax-
is, atopic dermatitis and allergic 
conjunctivitis. These models are 
important to examine the mech-
anism of the disease, the activity 
of a variety of genes and cellular 
pathways, define the role of en-
vironmental factors (such as the 
microbiota), predict the safety of 
new drugs before being used in 
clinical studies, define the patho-
genic pathways and suggest new 
therapeutic options. The correct 
animal model should reflect the 
disease pathophysiology as close-
ly as possible and new models are 
essential for the development of 
new therapies. 
Laboratory mice do not usually 
spontaneously develop allergies 
and a range of sensitization and 
challenge protocols have been 
developed. The number of sensiti-
zations and challenges is decisive 
for the development of acute or 
chronic forms of these models. The 
nature of the allergic disease and 
inflammatory response is directly 
influenced by the genetic back-
ground of the mice, the allergen, 
type of the sensitization and chal-
lenge protocol and contamination 
Remo Frei Liam O’Mahony
 Swiss Institute of Allergy and Asthma Research 
Davos, Switzerland
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of the allergen with substances 
(e.g. LPS), which stimulate the in-
nate immune response. Certain 
protocols require the combina-
tion of allergen with an adjuvant, 
for example aluminium hydroxide 
(ALOH3, Alum), which is one of the 
preferred adjuvants in respiratory 
allergy models. The sensitization, 
challenge and analysis parameters 
of murine allergy models are sum-
marized in Figure 1.
Although murine models of aller-
gy provide important insights into 
the disease mechanisms, there 
are some limitations that should 
be considered. In addition to the 
genetic and physiological differ-
ences between humans and mice, 
there are also limitations due to 
complexity of this disease. In oth-
er words, mice do not develop al-
lergy. One can replicate important 
components of the disease, but no 
single model accurately models all 
the features of allergy. This is very 
important to take into account 
when choosing the correct model 
to address the specific experimen-
tal question. For example, chronic 
exposure models are required to 
examine many of the structural 
changes associated with allergic 
responses within the airways. 
Notwithstanding the limitations 
of these models, several studies 
carried out in animal models have 
given important clues that explain 
the pathophysiological conditions 
related to the disease status. For 
instance, the role of Th2 type cy-
tokines and T regulatory cells in 
the pathogenesis of allergy have 
been particularly well-studied in 
animal models.
Human clinical studies remain the 
gold standard for determining the 
clinical efficacy of new therapeu-
tic approaches. Murine models 
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will continue to provide important 
mechanistic clues, while improved 
models may extend our under-
standing of the basic mechanisms 
for examining new therapeutic op-
tions.
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Figure 1 Overview of the experimental steps commonly used in allergy models. Allergy mouse models typically comprise 
a sensitization, a challenge, and an analyses phase. After sensitization, allergic responses are provoked, depending on 
the model, by oral application (food allergy), by inhalation (respiratory allergy), or by skin contact (skin allergy) with the 
allergen. The severity and mechanisms of the allergic response are determined using a variety of technologies, focused on 
the relevant model organs or using functional assessments such as lung function testing or ear thickness measurements.
Animal models of allergic disease

Section B
EPIDEMIOLOGY AND RISK FACTORS 
* The allergy epidemic
* Natural history of allergy
* Birth cohorts
* Environmental risk factors for allergy: outdoor/
indoor pollution and climate change
* Measuring exposure to environmental airborne 
allergens
* Environmental risk factors for allergy: food 
* Environmental risk factors for asthma:  home 
environment
* Environmental risk factors for allergy: working 
environment
* Risk factors for childhood asthma:  viral infection and 
allergic sensitization
* Environmental risk factors for allergy: helminth 
infections 
* Perinatal immune development and its role in atopy 
development
* Perinatal risk and protective factors for allergic 
diseases
* The role of microbiome
112
Global atlas oF allerGy
se
c
t
io
n
 b
 - 
E
p
id
em
io
lo
gy
 a
n
d
 r
is
k 
fa
ct
o
rs
 
• In countries undergoing the epidemiological transition phase, 
allergies appear first among the richest, but soon affect the 
middle class and finally the disadvantaged
• Food allergies are emerging as a “second wave” of the allergy 
epidemic and they persist more frequently
• Epidemiological studies suggest that a high “antigenic burden” 
in early life, provided by infections and nutrition, can properly 
“educate” the immune system and prevent childhood allergic 
diseases
• A reduced “antigenic burden” implies a reduced stimulation of 
the immune system and contributes, in genetically predisposed 
individuals, to dysregulated immune response leading to allergy
• The discovery of the lifestyle factors promoting allergy 
susceptibility will inspire primary prevention strategies to revert 
the allergy epidemic trend
The growing worldwide burden 
of allergic rhinitis, asthma and at-
opic eczema has been properly 
defined as the “allergy epidemic”. 
During the last two centuries, this 
phenomenon has characterized 
countries undergoing their epide-
miological transition phase. Res-
piratory allergies (allergic rhinitis 
and asthma) appeared first among 
the richest, then spread within the 
middle class and finally affected 
also the disadvantaged. Following 
a similar pattern, respiratory aller-
gies and atopic eczema are nowa-
days on the rise in middle income 
countries, especially in the urban 
areas (Figure 1). 
More recently, food allergies are 
clearly becoming more prevalent 
in westernized populations (Fig-
ure 2). This “second wave” of the 
allergy epidemic is already gen-
erating a heavy burden on health 
systems not well prepared to face 
this new challenge. The increasing 
prevalence of food allergies is as-
sociated with fatal anaphylaxis in 
children and adolescents. 
A decline of microbial diversity 
was proposed since the late nine-
ties as a major cause of the allergy 
epidemic. This area of the hygiene 
hypothesis, now defined “biodiver-
sity hypothesis”, has found specific 
support in several epidemiological 
studies: 1) respiratory allergies are 
inversely related to the number of 
different foodborne infections; 2) 
a lower diversity of the gut micro-
bial flora in the first week of life 
is associated with atopic eczema 
at 18 months (Figure 3); 3) the 
probability of developing asthma 
in farming children is inversely re-
lated to the range of exposure to 
environmental bacteria and fungi.
Two recent studies have coher-
ently shown that reduced food 
diversity in infants’ diet is associ-
ated with atopic sensitization and 
allergic diseases later in childhood 
(Figure 4). A sufficiently high “an-
tigenic burden” in early life, provid-
ed by infections and nutrition, is 
therefore necessary to properly 
“educate” the immune system and 
to prevent childhood allergic dis-
eases. 
Current knowledge is a good basis 
to identify the allergy protective 
factors and to inspire primary and 
secondary prevention strategies 
to revert the allergy epidemic 
trend. Allergy prevention based 
on the administration of probiot-
ics to pregnant mothers and to in-
Paolo Maria Matricardi  
Charité Medical University  
Berlin, Germany
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The allergy epidemic
Figure 1 The spread of hay fever and allergic asthma according to socio-economic status and westernization level. 
(Reproduced with permission from Annals of Allergy, Asthma & Immunology, Vol. 89(S1). Matricardi PM, Bouygue GR, Tripodi S. 
Inner-city asthma and the hygiene hypothesis, 69–74. Copyright Elsevier 2002.)
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Figure 2 Observed and predicted 
values for the prevalence of food IgE 
sensitization in 20- to 54-year-olds 
in European cities. (reprinted from 
Allergy, Vol. 69. Burney PGJ et al. 
The prevalence of food sensitization 
among European adults. pp. 365–71. 
Copyright 2014 (Reproduced with 
permission from Burney PGJ, Potts J, 
Kummeling I, et al. The prevalence of 
food sensitization among European 
adults. Allergy, 2014 69: 365–71, with 
permission from Willey Blackwell.)
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fants provided unfortunately con-
flicting and still debated results. 
Other strategies under investiga-
tion include the safe administra-
tion of oral or intranasal bacterial 
extracts and earlier introduction 
of foods. 
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Figure 4 Association of increasing diversity of food introduced within the first 
year of life with (A) asthma and (B) food allergy among 856 children who partici-
pated in a birth cohort study, Protection Against Allergy Study in Rural Envi-
ronments/EFRAIM. The figure shows the diversity score with all different food 
items for the entire study population. The solid lines represents the predicted 
value of (A) asthma or (B) food allergy, as a function of the score, and dashed 
lines represent the corresponding CI. The y-axis is the linear logit of (A) asthma 
or (B) food allergy, and the values are centered on 0 (50/50 odds) and extended 
to both positive and negative values. All models are adjusted for farmer, center, 
duration of breast-feeding, parents with allergy, maternal education, sex, and 
siblings. (Reprinted from J Allergy Clin Immunol, 133/4, Roduit C, Frei R, Depner M 
et al. Increased food diversity in the first year of life is inversely associated with aller-
gic diseases, 1056-1064, Copyright 2014, with permission from Elsevier.)
The allergy epidemic
Figure 3 Shannon-Wiener index after T-RFLP of 16S rDNA with AluI for 
cutting and TTGE, respectively, generated from the fecal microbiota of 1-week-
old infants that at 18 months had atopic eczema or stayed healthy. For each 
group, median and 10th, 25th, 75th, and 90th percentiles are shown. *For 
T-RFLP, P<.01 and for TTGE, P<.05 (Reprinted from J Allergy Clin Immunol, 121/1, 
Wang M, Karlsson C, Olsson C, et al. Reduced diversity in the early fecal microbiota 
of infants with atopic eczema, 129-134, Copyright 2008, with permission from 
Elsevier.)
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• Atopic eczema (dermatitis) is usually the first manifestation of 
an atopic disease. Not all children with infantile eczema show a 
sensitisation to food allergens and will develop classical allergy
• Sensitisation to foods precedes sensitisation to inhalant 
allergens. Persistent sensitisation before and after 3 years of age 
is a risk factor for school age asthma
• Early infantile eczema, early sensitisation during the first 3 years 
of life and atopic family history are predictors of allergic airway 
disease and persistence of asthma until puberty 
• Children with infantile eczema often lose their symptoms until 
school age, although early onset is more frequently associated 
with persistence until puberty compared to children with later 
onset of the disease
• Remission of allergic asthma occurs not frequently up to the age 
of 20 years
Allergy is common in children, 
adolescents and adults. Epidemi-
ological studies like the German 
MAS (Multicentre Allergy Study) 
showed age-related typical man-
ifestations of atopic and allergic 
diseases. In the “Atopic March” 
infantile eczema and food allergy 
precede the onset of allergic air-
way disease (rhinitis and asthma). 
However, there are individu-
als with isolated allergic airway 
disease (for example hay fever) 
starting later in life at school age 
without any signs of other atopic 
disease during infancy and pre-
school age. Equally, there are chil-
dren with infantile eczema with-
out any signs of food or inhalant 
allergy. Furthermore, remission 
and relapse of disease entities are 
possible at any time.
Studies on the molecular pattern 
of sensitisation to pollen allergens 
showed a preclinical phase, where 
sensitization (IgE antibodies in 
serum) to certain molecules of an 
allergen source (grass or birch) 
precedes symptoms. The likeli-
hood of clinical allergy increases 
with the number of molecules rec-
ognized by IgE.
ATOPIC ECZEMA
The incidence of atopic eczema 
Susanne Lau  
Charité Medical University 
Berlin, Germany
NATURAL HISTORY OF 
ALLERGY2
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Natural history of allergy
and food allergy to cow`s milk, 
hen`s egg, wheat and soy is high-
est during the first 2 years of life 
in childhood, however, there is a 
second peak of new onset of atop-
ic eczema in puberty for females. 
Two third of young children with 
infantile eczema will lose their 
symptoms up to the age of three 
years. However, those children de-
veloping atopic eczema later in life 
(after the age of 5 years) are more 
likely to outgrow their eczema 
compared to those children, who 
had an earlier onset of disease 
(during the first year of life).
ASTHMA
In the German MAS cohort, the 
prevalence of asthma is 4% at 6 
years of age and more prevalent 
in boys and 9% at age 20 years. 
The incidence of allergic asthma 
is highest during preschool and 
early school age (Figure 1). There 
is a second peak for new onset 
of asthma in females at puberty. 
Atopic family history is a major 
risk factor for the development 
of asthma (Figure 2). 29% of the 
German MAS cohort children 
with complete follow-up showed 
wheezing episodes during the 
116
Global atlas oF allerGy
se
c
t
io
n
 b
 - 
E
p
id
em
io
lo
gy
 a
n
d
 r
is
k 
fa
ct
o
rs
 
first three years of life (early 
wheezers). 9% started wheezing 
between the age of 3 to 6 years 
(late wheezers) and another 9% 
started wheezing after 6 years 
of age (very late wheezers). Early 
persistent wheezers (early start 
of wheezing before 3 years of age, 
wheezing also after 6 years of age) 
showed the highest rates of atopy. 
In this group, early atopic eczema, 
parental atopy and early sensitiza-
tion (<3 years of age), especially to 
perennial allergens, turned out to 
be the major risk factors for per-
sistence of asthma/wheeze at age 
11-13 years.
IGE SENSITISATION TO 
ALLERGENS
The first allergens recognized by 
the immune system in terms of 
IgE production are food allergens. 
The most frequent food allergens 
inducing IgE-mediated sensitiza-
tion are hen`s egg, cow`s milk and 
peanut. Although, sensitisation to 
inhalant allergens like cat, house 
dust mite and pollen allergens can 
be present already during the first 
3 years of life, in most of the chil-
dren the clinical relevance is ob-
served later, at school age.
Atopy (sensitisation) in general is 
a risk factor for asthma at school 
age (Figure 3).
Figure 1 Incidence of asthma in the German MAS  cohort. (From Matricardi PM, Illi S, Grüber C,et al. Wheezing in childhood: 
incidence, longitudinal patterns and factors predicting persistence. Eur Resp J 2008; 32:585-92; Reprinted with permission under 
the Creative Common Attribution License or equivalent.)
Figure 2 Family history for asthma and cumulative incidence of allergic diseases in offsprings. (Reprinted from J Allergy 
Clin Immunol, 133/4, Grabenhenrich LB, Gough H, Reich A, et al. Early-life determinants of asthma from birth to age 20 years: A 
German birth cohort study, 979-988, Copyright 2014, with permission from Elsevier.) 
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Figure 3 Prevalence of current wheeze from birth to age 13 years in children 
with any wheezing episode at schoolage (5-7 years) stratified for atopy at school 
age. (Reprinted from The Lancet, 368, Illi S, von Mutius E,  Lau S, et al, Perennial 
allergen sensitisation early in life and chronic asthma in children: a birth cohort study, 
763-770, Copyright 2006, with permission from Elsevier.)
Children with sensitization to any 
allergen before the age of 3 years 
and sensitization to inhalant al-
lergens have an increased risk for 
asthma at school age (Figure 4).
ALLERGIC RHINITIS
There is a constant rise for the in-
cidence and prevalence of allergic 
rhinitis (AR) from preschool and 
early school age until puberty.
Allergic rhinitis until the age of 5 
years was found to be a risk factor 
for subsequent wheezing onset 
with an adjusted relative risk of 
3.79 (p<0.001). This association 
was not attributable to the type 
of sensitization, the severity of 
sensitization or atopic dermatitis 
during the first 2 years of life. On 
a population level 41.5% (95% 
CI: 20.0-61.3) of all new cases 
of wheezing was attributable to 
preceding AR. Neither AR until 
the age of 2 years nor non-aller-
gic rhinitis until the age of 5 years 
were significantly associated with 
wheezing onset in childhood.
The first manifestation of AR oc-
curs in preschool children, where 
it is a risk factor for subsequent 
wheezing onset. Preschool chil-
dren with rhinitis might thus ben-
efit from early assessment of al-
lergic sensitization to identify the 
children at high risk of developing 
wheezing. 
ALLERGIC RHINITIS: 
SENSITISATION TO AERO-
ALLERGENS
The 12-month prevalence of sen-
sitization to indoor or outdoor al-
lergens in the German MAS cohort 
rose with each time point of as-
sessment, reaching almost 60% of 
all boys and a third of all girls at the 
age of 13 years (in children with 
one or two allergic parents). Chil-
dren from non-allergic parents 
were less sensitized compared to 
Figure 4 Prevalence of asthma and asthmatic symptoms at 7 years of age, 
stratified for sensitization patterns and bronchial hyper-responsiveness (BHR). 
* p< 0.05; ** p<0.001. (Reprinted from J Allergy Clin Immunol, 108/5, Illi S, von 
Mutius E, Lau S, et al. The pattern of atopic sensitization is associated with the 
development of asthma in childhood, 709-714, Copyright 2001, with permission 
from Elsevier.)
Sensitisation to indoor allergens 
(house dust mite and pets) is asso-
ciated with allergic asthma.
School children with sensitisation 
to perennial allergens (house dust 
mite, cat dander) being highly ex-
posed to these allergens early in 
life are at risk to have impaired 
lung function at school age com-
pared to children without sensi-
tisation or with sensitisation and 
low exposure to indoor allergens 
during the first year of life.
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Figure 5 Probability of wheezing onset stratified by the 4 rhinitis phenotypes (allergic rhinitis, non-allergic rhinitis, 
atopy without rhinitis and control group) .at the ages of 2 and 5 years. (Reprinted from J Allergy Clin Immunol, 126/6, Rochat 
MK, Illi S, Ege MJ, et al. Allergic rhinitis as a predictor for wheezing onset in school-aged children, 1170-1175, Copyright 2010, 
with permission from Elsevier.)
those with allergic parents. Irre-
spective of parental allergy status 
the number of boys sensitized to 
aero-allergens was approximate-
ly twice the number of sensitized 
girls at age 13 years. 
At the age of 13 years, 91% out 
of the 35 children with “severe 
persistent” AR (ARIA) were sensi-
tized to at least one aero-allergen, 
whereas this proportion was only 
70% among the 56 children with 
“mild persistent” AR (p=0.015). 
This difference was similar at the 
age of 10 years, although over-
all slightly less children with AR 
were sensitized (p=0.033). Among 
the asymptomatic children 18% 
(32/175) were sensitized to at 
least one common aero-allergen 
at the age of 13 years, compared 
to 24% (49/289) at the previous 
time point of assessment at the 
age of 10 years.
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• Allergic diseases generally start early in life, thus birth cohorts are 
essential for elucidating disease mechanisms and natural course 
and evidence-based strategies for prevention and management
• Birth cohort studies have been instrumental in demonstrating the 
existence of a gene-environment interaction in the development 
of allergy and in identifying children at risk for allergy
• Several consortia (STELAR, MeDALL, EuroPreval/iFAM, EAGLE) 
bring together a number of ongoing birth cohort studies to 
facilitate data sharing
In contrast to most other complex 
diseases (for example diabetes or 
hypertension), allergic diseases 
generally start early in life. There-
fore, the best way to study aller-
gies is to recruit new born babies 
and follow them as they grow (so-
called birth cohort). Birth cohorts 
overcome problems related to the 
lack of accuracy (or completeness) 
of the recollections when patients 
are asked about the events, which 
occurred many years ago. Such 
studies permit careful longitudinal 
assessment of symptoms, sensiti-
zation status, physician diagnoses 
and medication usage, and objec-
tive measures such as lung func-
tion. 
Allergies are heritable, but despite 
lots of effort, we have had limited 
success identifying what genes are 
important, and this has yet to im-
pact on patient care. Many factors 
in the environment contribute to 
the development of allergies (for 
example diet, immunizations, an-
tibiotics, pets and tobacco smoke), 
but we don’t know how to modify 
the environment to reduce the 
risks. In birth cohorts, environ-
mental exposures can be meas-
ured to allow the study of complex 
gene-environment interactions. 
Birth cohort studies have been in-
Adnan Custovic  
University of Manchester 
Manchester, UK
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Birth cohorts
strumental in demonstrating the 
existence of a gene-environment 
interaction in the development of 
allergy, which helped to explain 
the disparities in genetic associ-
ation studies in different settings 
around the world. 
Several consortia bring together 
a number of ongoing birth cohort 
studies to facilitate data sharing. 
For example, the UK Study Team 
for Early Life Asthma Research 
(STELAR) brings together the net-
work of all UK-based birth cohorts 
designed to study allergies with 
the experts in machine learning 
and epidemiologically-orient-
ed health informatics.  Similarly, 
EU-funded MeDALL (Mechanisms 
of the Development of ALLergy)1 
and EuroPreval/iFAM2 projects 
bring together thousands of chil-
dren taking part in different birth 
cohorts across the continent, and 
will facilitate the generation of 
critically important knowledge on 
the mechanisms of initiation of 
allergy. Birth cohorts in The EArly 
Genetics and Lifecourse Epide-
miology (EAGLE) Consortium are 
extensively collaborating to inves-
tigate the genetic basis of allergy 
and asthma-related phenotypes in 
childhood. 
Numerous early breakthroughs 
have already been made. The on-
going birth cohort studies offer 
the best chance of identification 
of children at increased risk of al-
lergy. This is the first and crucially 
important step towards the de-
velopment of the evidence-based 
strategies for prevention of al-
lergy development, and stratified 
120
Global atlas oF allerGy
se
c
t
io
n
 b
 - 
E
p
id
em
io
lo
gy
 a
n
d
 r
is
k 
fa
ct
o
rs
 
(personalised) management of 
allergies (Figure 1). Existing birth 
cohorts of individuals now at 
various ages, from childhood to 
adulthood, should be considered 
a treasure, and every effort should 
be made to maintain long-term 
funding for such large efforts.
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Figure 1 Longitudinal data collected over a number of years in birth cohort studies are a foundation for utilisation of the 
power of novel state-of the art data analysis techniques to build complex models to describe different types of allergic 
diseases. In doing so, we will understand the basic biological mechanisms that underlie the different allergies, and identify 
novel targets for future drug therapies.
Birth cohorts
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• Allergy is an environmental disease as the most common and 
earliest onset chronic non-communicable disease 
• Life-style and civilization related risk factors for allergy are 
encountered both indoors and outdoors
• Allergy-relevant indoor air pollutants include environmental 
tobacco smoke and  volatile organic compounds
• Anthropogenic environmental factors influence pollen 
allergenicity indirectly via their effects on pollen-producing 
plants
• Climate change-related effects contribute to an increased 
allergen burden in outdoor air
• The growing evidence of man-made environmental risk factors 
for allergy highlights the importance of prevention strategies for 
improving public health
Allergic diseases are a heavy so-
cio-economic burden worldwide. 
There is a deficit in public aware-
ness, education and training and an 
urgent need for efficient preven-
tion strategies. The rising trend in 
allergies has been associated with 
changes in life-style, such as im-
proved hygiene measures, smaller 
family sizes and control of infec-
tions, which, taken together, result 
in an “under-challenged” immune 
system. On the other hand, life-
style changes include the exposure 
to potentially harmful – indoor and 
outdoor – environmental pollut-
ants suspected to keep our immune 
system in a constant state of alarm. 
How does this fit together?
INDOOR RISK FACTORS
In the western civilization, most 
individuals spend a considerable 
part of their lives indoors. Indoor 
exposure to mite, molds, chemi-
cals and inhaled particles can elicit 
and/or exacerbate allergic diseas-
es. The best assessed among the 
indoor pollutants are volatile or-
ganic compounds (VOCs) and en-
vironmental tobacco smoke (ETS), 
which is a mixture of VOCs, carbon 
monoxide and solid particles. In 
LINA (Lifestyle and environmen-
tal factors and their Influence on 
Newborns Allergy risk) birth co-
ENVIRONMENTAL RISK FACTORS 
FOR ALLERGY: OUTDOOR/INDOOR 
POLLUTION AND CLIMATE CHANGE
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Environmental risk factors for allergy: outdoor/indoor pollution and climate change
hort subgroup, prenatal and early 
life exposure to environmental 
tobacco smoke was positively cor-
related with circulating eosinophil 
and basophil precursors in cord 
blood, indicating allergy-promot-
ing effects on susceptible children. 
In a murine allergic asthma model, 
long-term exposure to VOCs emit-
ted from polyvinylchloride (PVC) 
flooring increased acute and 
chronic allergic lung inflammation.
OUTDOOR RISK FACTORS
A high degree of traffic and urban-
ization are hallmarks of Western 
civilization. A recent meta-analy-
sis of prospective, multi-center tri-
als did not find any clear associa-
tion of modeled traffic-related air 
pollution and allergic sensitization 
in children (Figures 1 and 2). Other 
studies do show associations of ex-
posure to diesel exhaust particles 
(DEP), NO2, ozone and particulate 
matter (PM), with asthma, allergic 
rhinitis or sensitization to aeroal-
lergens. These conflicting results 
illustrate how exposure and con-
founding factors, e.g. genetic pre-
disposition, lifestyle and nutrition 
interact closely in switching from 
health to disease (Figure 3). Apart 
from direct effects of outdoor pol-
Stefanie Gilles Claudia Traidl-Hoffmann
Technical University of Munich 
Augsburg, Germany
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Figure 1 Modification induced by anthropogenic pollutants to pollen allergens.
Figure 2 Climate change impact on the ecosystem of pollen-producing plants.
Environmental risk factors for allergy: outdoor/indoor pollution and climate change
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lutants on humans, pollen-produc-
ing plants are themselves subject 
to modification by anthropogenic 
pollutants (Figures 1 and 2). We 
recently identified ambient ozone 
as a major factor influencing al-
lergen content and adjuvant lipid 
composition of birch pollen. This 
illustrates how anthropogenic 
environmental factors, via their 
effect on the allergen carrier, can 
indirectly influence the health of 
allergic patients.
CLIMATE CHANGE RELATED 
RISKS
Global warming is associated 
with elevated CO2 levels and pro-
longed vegetation periods. This, 
in turn, causes prolonged flower-
ing seasons, which might increase 
the load of allergenic pollen. The 
aggressive spreading of allergen-
ic neophytes, such as Ambrosia 
artemisiifolia, in southeastern and 
parts of middle Europe already 
led to de novo sensitizations in 
the exposed populations. Moreo-
ver, exposure to Ambrosia pollen 
might induce symptoms even in 
mugwort-sensitized patients due 
to the high degree in inter-species 
cross-reactivity.
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Figure 3 The complex interplay 
between host and environmental 
factors leading to allergic diseases: 
anthropogenic factors can act direct 
increasing susceptibility in genetic 
predisposed individuals or indirect 
by modifying/potentiating other 
biogenic factors. 
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• Precise assessments of allergen concentrations is needed to 
define the exposure thresholds inducing sensitization, symptoms 
and exacerbations of allergic diseases
• The risks of respiratory allergy or elicitation of symptoms may be 
decreased by reducing exposure
• Control measures should be based on monitoring of allergen 
exposure performed according to well-defined and validated 
methods
A key factor for the development 
of respiratory allergy is the con-
tact between the respiratory or-
gan and inhaled air containing the 
allergens. Airborne allergens can 
be found in a variety of sources 
(Table 1). The risks of respiratory 
allergy or elicitation of symptoms 
may be decreased by reducing ex-
posure. Control measures should 
be based on allergen exposure 
monitoring performed accord-
ing to well-defined and validated 
methods.
To measure exposure to airborne 
allergens, it is imperative to report 
the presence of the sources of al-
lergens (mite counts, presence of 
pets), because allergen levels can 
stay high when there are no sourc-
es or their number is low. 
The choice of optimal procedures 
depends on the setting and ob-
jectives of allergen monitoring 
(Figure 1): epidemiological (pop-
ulation) studies on exposure-re-
sponse relation, intervention 
studies, diagnosis and follow-up of 
individual patients, hazard identi-
fication for disease clusters, iden-
tification of cases of “new allergy”, 
as part of routine monitoring or of 
a health surveillance program.
Indoor airborne allergen levels 
may be assessed in settled dust or 
Isabella Annesi-Maesano  
French Institute of Health and Medical Research 
and UPMC Sorbonne Universités 
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Measuring exposure to environmental airborne allergens
in an air sample. A dust sample is 
collected from the bed, carpet or 
sofa by vacuuming a square yard 
area of the bed/carpet/sofa per 
2 minutes with a vacuum clean-
er with a collection device. The 
presence of allergens is quantified 
with an ELISA test. Recently, an 
alternative wipe sampling method 
has been implemented to collect 
allergens from floor dust, where 
allergens are measured by a re-
al-time quantitative PCR meth-
odology. However, methods using 
settled dust might not provide ac-
curate measurements of inhaled 
allergens. To measure airborne 
allergens in the air, a technique 
has been developed that involves 
collecting an integrated total 
suspended particulate sample 
through an impactor. Extracts of 
air samples are then analyzed by a 
modified ELISA using an amplifica-
tion of the generated colorimetric 
signal.
The prevalent outdoor allergens 
are pollens and molds. Usually, 
pollen and mold counts are as-
sessed,and not their derived aller-
gens. 
A pollen count is nothing more 
than a measurement of how much 
pollen is in the air. It is expressed 
in terms of a concentration of pol-
len in the air in a specific area at 
a certain point in time. The exact 
measure is grains of pollen per cu-
bic meter over a 24 hour period. 
Mold counts, like pollen counts, 
are a measurement of how many 
mold spores are in the air in a 
certain area at any given point in 
time. Monitoring pollen and mold 
counts on a daily basis during the 
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TABLE 1
Common airborne allergens and possible reaction(s)
Allergens Where, when
Pollen
Lpl p 1, Phl p5, Cyn d1, Amb a 
1, Bet v ...
Outdoors
Spring/summer/autumn 
Mold
Alt 1, Cla 1 ...
Both indoors (perennial) and outdoors 
(seasonal) .
Indoors, molds can be found in any moist, 
dark place. Outdoors, mold results from 
vegetation degradation. 
Mold floats easily in the air.
House Dust mite (HDM)
Dermatophagoïdespteronyssi-
nus (European HDM), Dermato-
phagoïdes farina (American 
HDM), Blomia tropiclais. 
Derp 1, Derf 1, Blo...
Indoor
Found in house dust, mattresses, bedding, 
upholstered furniture, carpets and cur-
tains
HDM feed on shedded flakes of skin 
HDM thrive in warm and humid environ-
ments.
Pets Indoor
Major allergens are proteins secreted by 
oil glands in the animals' skin and shedded 
in dander as well as saliva proteins, which 
sticks to the fur when the animal licks it-
self. Urine is also a source of allergens. 
When the substance carrying the aller-
gens dries they become airborne
Cat (Feld1), Dog (Can1)
Hamster, squirrel,rabbit
Indoor/occupational
Urine is the major source of allergens from 
these animals.
Pests
Urine is the major source of allergens from 
these animals.Mouse, rat, 
(Mus m1, Rat 1)
Cockroach
Blatella germanica 
(German cockroach) (Bla g 1)
Tiny protein particles shed or excreted by-
cockroaches
Measuring exposure to environmental airborne allergens
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seasons when they are present is 
one of the most proactive steps to 
control asthma and allergies.Pol-
len and mold counts are collected 
using a special sampling trap that 
is typically placed on a rooftop 
several stories above the ground 
(Figure 2). The device has a sticky 
surface that collects grains of pol-
len and mold spore from the air. 
Specific pollen and mold are rec-
ognized using an electronic micro-
scope. 
Recent data have shown that pol-
len and mold counts do not repre-
sent allergen exposure. Air can be 
sampled for pollen and mold aller-
gens with a high-volume cascade 
impac to requipped with stages 
for particulate matter (PM)>10 
μm, 10 μm>PM>2.5 μm, and 2.5 
μm>PM>0.12 μm. Allergenis de-
termined with specific ELISA.
Precise assessment of allergen 
concentrations is needed to define 
the exposure thresholds inducing 
sensitization, symptoms and exac-
erbations of allergic diseases. 
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Definition of objectives and setting  
Exposure assessment strategy  
Sampling methods  
Procedure  
Allergen quantification  
Results in view of monitoring  
Figure 1 Stepwise selection process of methods and tools of allergen 
assessment (modified from ref. 1)
Figure 2 Pollen and mold assessment: A: pollen trap; B and E: ELISA 
measurement; C and D:microscopic evaluation of pollens and molds.
Measuring exposure to environmental airborne allergens
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• Environmental risk factors that may influence food allergy, 
together with atopy, include the “hygiene hypothesis”, vitamin D 
insufficiency, reduced consumption of healthful dietary fats and 
antioxidants, and obesity
• Theories suggesting early infant ingestion of food allergens as a 
risk for allergy have been substantially disprove
• Early infant avoidance of food allergens could be a risk factor 
for allergy due to bypassing oral tolerance during a period of 
sensitizing cutaneous exposure
• Food allergy is the result of a complex interaction of genetic, 
immunologic and environmental influences, indicating a 
challenge for identifying effective prevention strategies
The prevalence of food allergy 
appears to have increased.  Envi-
ronmental factors must account 
for the apparent rise, not genetic 
predisposition.  An over-arching 
effect may be the immune dys-
regulation attributable to the 
“hygiene hypothesis”.  Additional 
theories to explain increased ato-
py, with food allergy as a bystand-
er, include vitamin D insufficiency 
attributable to greater use of sun-
screens and less time outdoors, 
reduced consumption of healthful 
omega-3-polyunsaturated fatty 
acids and antioxidants, and in-
creased obesity, which may repre-
sent an inflammatory state. How-
ever, for environmental influence 
on food allergy in particular, the 
role of exposure to food proteins 
becomes relevant.
Probably as a response to early 
studies suggesting that infants ex-
posed to whole cow milk proteins 
were at higher risk of milk aller-
gy compared to those receiving 
breast milk or hypoallergenic for-
mula, among other observations, 
various expert panels and profes-
sional organizations suggested 
avoidance of allergens for infants 
at risk.  Some guidelines included 
allergen avoidance during preg-
nancy and lactation. The goal was 
Scott H. Sicherer  
Icahn School of Medicine  
New York, USA
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Environmental risk factors for allergy: food
to prevent exposure to food aller-
gens for a presumed immature and 
allergy-prone immune system.  
However, mounting studies sug-
gest that extended avoidance of 
food allergens may be a risk factor 
for food allergies, rather than pre-
ventative. Why would this be? One 
possibility is that earlier exposure 
allows for oral tolerance. For ex-
ample, in a study of the rate of pea-
nut allergy among Jewish children 
in the United Kingdom compared 
to Israel, there was a ten-fold high-
er rate of allergy in the UK, where 
early peanut consumption was 
comparatively very low (Figure 1). 
Timing of ingestion may only be 
part of the story. Non-ingestion 
routes of exposure may be strong-
ly sensitizing: for example, despite 
ingestion of raw fruits, many per-
sons develop pollen-food related 
syndrome caused by inhalation 
of food-homologous proteins in 
pollens, bypassing oral tolerance. 
Similarly, it was suggested that 
topical exposure, especially via in-
flamed skin, i.e., atopic dermatitis, 
during abstinence from oral expo-
sure could be a sensitizing route 
bypassing oral tolerance (Figure 
2). Additional evidence is the ob-
servation that household con-
sumption rates of peanut, particu-
larly messy products that increase 
environmental exposure, are a risk 
factor for peanut allergy, especial-
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ly if the infant has not ingested 
peanut early. Prior recommenda-
tions to avoid food allergens dur-
ing pregnancy, breastfeeding and 
for children during weaning have 
been substantially rescinded, al-
though counter-examples remain 
(Figure 3) and more studies are 
needed. Ultimately, the environ-
mental and genetic determinants 
of food allergy are complex, pre-
senting a challenge for identifying 
prevention strategies (Figure 4).  
KEY REFERENCES 
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sumption as a risk factor for the 
development of peanut allergy. J Al-
lergy Clin Immunol 2009;123:417-
423.
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AH, Pongracic JA. Primary preven-
tion of allergic disease through nu-
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Figure 1 Earlier consumption of 
peanut was associated with a lower 
rate of peanut allergy. A - Prevalence 
of peanut allergy in children 
4-18 years; B - Peanut protein 
consumption 8-14 month; United 
Kingdom n=5171; Israel n= 5615. 
(Data from Du Toit G, Katz Y, Sasieni P, 
Mesher D, Maleki SJ, Fisher HR et al. 
Early consumption of peanuts in infancy 
is associated with a low prevalence of 
peanut allergy. J Allergy Clin Immunol 
2008; 122(5):984-91. Reprinted from 
J Allergy Clin Immunol, 129/5, Lack G. 
Update on risk factors for food allergy, 
1187-1197, Copyright 2012, with 
permission from Elsevier.)
Figure 2 Cutaneous exposure to a 
food allergen, especially to inflamed 
skin, may be a sensitizing route. With 
a concomitant lack of oral exposure 
to induce tolerance, the effect could 
be promoting food allergy. (Reprinted 
from J Allergy Clin Immunol, 129/5, 
Lack G. Update on risk factors for food 
allergy, 1187-1197, Copyright 2012, 
with permission from Elsevier.) 
Environmental risk factors for allergy: food
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Figure 3 Although some studies suggest maternal ingestion of allergens during pregnancy or lactation does not increase 
the risk of sensitization/food allergy, there remains some controversy and more studies are needed. Here, a study of 
high risk infants suggests higher maternal ingestion of peanut during pregnancy is related to higher peanut IgE antibody 
levels in early infancy (P trend < 0.001). (Reprinted from J Allergy Clin Immunol, 126/6, Sicherer SH, Wood RA, Stablein D, 
et al. Maternal consumption of peanut during pregnancy is associated with peanut sensitization in atopic infants, 1191-1197, 
Copyright 2010, with permission from Elsevier.)
Figure 4 A complex interplay of genetic, immunologic and environmental influences likely conspires to result in food 
allergy, here with peanut as an example. (Reprinted from J Allergy Clin Immunol, 120/3, Sicherer SH, Sampson HA. Peanut 
allergy: emerging concepts and approaches for an apparent epidemic, 491-503, Copyright 2007, with permission from Elsevier.)
Environmental risk factors for allergy: food
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• During the last half of the 20th century, the perennial indoor 
allergens progressively increased in importance and became the 
primary allergens related asthma worldwide
• While the individual’s home is an important site of exposure, it 
is now clear that exposure to indoor allergens in other homes 
or schools can play an important role in sensitization and in 
symptoms
• Comparing sensitization of children with asthma in different 
communities makes it clear that the community prevalence of a 
particular allergen may be as important as the specific levels in 
the child’s home
• Although dust mites are ubiquitous in damp climates, they may be 
completely absent in ultra-dry environments such as Norbotten 
in Sweden and apartments in Chicago
THE RISE IN INDOOR LIVING 
AND THE RISE IN ASTHMA
The dramatic rise in electronic in-
door entertainment from 1950 to 
2000 paralleled the rise in asth-
ma among children.  The resulting 
changes in lifestyle led to both a 
major increase in time spent in-
doors and progressive “improve-
ments” in homes.  These changes 
not only allowed accumulation 
of allergens in fitted carpets, so-
fas, bedding, etc. but in humid cli-
mates allowed abundant growth 
of dust mites.  Over this same pe-
riod, almost all studies have shown 
strong associations between sen-
sitization to indoor allergens and 
asthma in children over 5 years old 
and young adults (Table 1).
ExPOSURE IN THE HOME AND 
IN THE COMMUNITY AS A 
CAUSE OF SENSITIZATION
Children spend up to 95% of their 
time at home, at school or in other 
enclosed spaces.   Initially it was 
assumed that the home had to be 
the primary site of sensitization; 
however, two findings have con-
fused the simple message.
1. Studies designed to avoid expo-
sure to dust mite carried out in 
Manchester and Sydney have 
not succeeded in preventing 
sensitization to this allergen. 
Thomas A.E. Platts-Mills  
University of Virginia 
Charlottesville, USA
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Environmental risk factors for asthma:  home environment
The explanation for that find-
ing appears to be that relevant 
exposure to mite allergens can 
occur in other houses.  In cities 
in the UK or coastal Australia 
most other houses in the com-
munity will contain mites.  In 
Northern Sweden or Chicago, 
very few children become aller-
gic to mites because the houses 
are too dry for mite growth.
2. Many but not all studies on cat 
exposure have found less sensi-
tization to cats among children 
with higher exposure (Figure 1). 
For cat allergens, it is now clear 
that Fel d 1 on dander particles 
is present in schools and homes 
without a cat.  Thus, exposure 
of children without a cat is suffi-
cient to cause sensitization.
RELATIONSHIP OF 
SENSITIZATION TO ASTHMA
Although sensitization to indoor 
allergens is strongly associated 
with asthma this relationship is 
not simple.  Sensitization as judged 
by skin prick tests is common in 
non-asthmatic children and also 
may be common in rural villages in 
Africa or Ecuador, where none of 
the children have allergic asthma. 
However, one of the striking fea-
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tures of asthma among children 
and adults in westernized or post 
hygiene societies is that titers of 
IgE antibodies to mite, cockroach, 
cat and Alternaria may be very 
high i.e. ≥30 IU/ml.  We have seen 
highly significant association be-
tween the titer of IgE antibodies 
to mite or cat and the severity of 
asthma (Figure 2).  Furthermore, 
studying children in Costa Rica, 
we found a strong association be-
tween the titer of IgE antibodies 
to mite and the impact of commu-
nity acquired rhinovirus infection 
on wheezing (Figure 2).
CONCLUSIONS
The increase in asthma has been 
documented as “wheezing” in 
ISAAC, as use of inhalers, or as 
presentation with acute asthma 
either to ED or hospital.  In each 
of these settings, evaluation of 
sensitization has shown a strong 
correlation between asthma and 
the perennial and predominantly 
indoor allergens.  In rural settings 
in Africa, Ecuador, Nepal, etc., sen-
sitization as judged by skin prick 
tests may be present, but wheez-
ing is more likely to correlate with 
evidence of Ascaris or other par-
asitic infections.  In recent stud-
ies, in Costa Rica, New Zealand, 
Ghana, Ecuador and Norbotten, 
TABLE 1
The allergens related to asthma
Source Particles Allergen MW (kDa) Structure
 
Dust mite
Der p 1 25
Der p 2 16
Der p 10 33
Der p 11 102
Cockroach Frass
Bla g 1 47
Bla g 2 39
Bla g 4 21
Bla g 5 23
Cat
Fel d 1 10
Fel d 2 69
Fel d 4 10
Cat IgA 200†
Alternaria
Alt a 1 17
Alt a 2 22
Alt a 3 14
Grass
Lol p 1 17*
The allergens related to asthma are predominantly in the molecular weight range 15 KD to 50 KD, and most of the major allergens 
are present as a significant proportion (>10%) of the extracts used for skin testing or in vitro assays (www.allergen.org)  However, 
the sources of cat, mite, cockroach or mold allergens generally do not become airborne, and the allergens themselves are too large 
to be volatile because the saturated vapor pressure of molecules >10,000 MW approaches zero.  Thus all relevant exposure is 
in the form of particles.  The aerodynamic properties of the particles determine how long they remain airborne and their volume 
decides how much allergen they can carry (5).
†Glycosylated with alpha-gal; *Glycosylated with MUXF3
Environmental risk factors for asthma:  home environment
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there is consistent evidence that 
the western model of asthma re-
lates to higher titers of IgE anti-
bodies to one or more of the per-
ennial allergens.  Thus, overall we 
have a model where, increased 
time spent indoors in overheat-
ed and under ventilated buildings 
leads to sensitization to the pre-
dominant allergen in the commu-
nity, which may be derived from 
mites, cockroaches, or animal dan-
der. The major rise in prevalence 
of asthma in children is most likely 
to be due to the combination of in-
creased exposure to indoor aller-
gen and the associated sedentary 
lifestyle.
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Figure 1 Prevalence of sensitization to cat allergens and of IgG antibodies 
to Fel d 1 for six groups of middle school children (age 11 years) with a wide 
range of concentrations of Fel d 1 in the dust from their homes.  In the highest 
exposure groups, the prevalence of IgG  to  Fel d 1 was higher while the 
prevalence of sensitization was significantly lower.  (Reprinted from The Lancet, 
357, Platts-Mills T,Vaughan J, Squillace S, et al.  Sensitisation, asthma, and a modified 
Th2 response in children exposed to cat allergen: a population-based cross-sectional 
study, 752-756, Copyright 2001, with permission from Elsevier.)
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Figure 2 Probability of current wheeze based on increasing titers of IgE 
antibodies to D. pteronyssinus in children with negative tests for rhinovirus 
by using real time PCR (A) compared to children with positive test results for 
rhinovirus (B). (Reprinted from J Allergy Clin Immunol, 129/6, Soto-Quiros M, Avila 
L, Platts-Mills TA, et al,  High titers of IgE antibody to dust mite allergen and risk for 
wheezing among asthmatic children infected with rhinovirus., 1499-1505, Copyright 
2012, with permission from Elsevier.)
Environmental risk factors for asthma:  home environment
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• Sensitizers (high and low molecular weight allergens, HMW, 
LMW) and irritants may lead to work-related respiratory 
disease.  There is overlap between the different categories of 
eliciting agents. Sensitizers may also have irritating properties. 
Irritants may lead to new onset occupational disease, but also to 
worsening of pre-existing disease
• The level of exposure is considered as the key factor for the 
development of occupational rhinitis and asthma
• Atopy is a risk factor for the development of IgE-mediated 
sensitization to HMW allergens. However, the presence of atopy 
cannot be used to identify and exclude susceptible workers
• The influence of smoking on development of occupational allergy 
may dependent on the specific allergens involved
Environmental agents  at the work 
place may lead to several aller-
gic and non-allergic conditions. 
Occupational rhinitis or asthma, 
but also occupational chronic 
cough may develop upon expo-
sure to agents at work.  Sensitizing 
agents - in most cases high molec-
ular weight (HMW) allergens, and 
sometimes low molecular weight 
(LMW) allergens – may induce an 
IgE mediated allergic reaction, re-
sponsible for allergic occupational 
rhinitis and asthma. Less frequent-
ly, single or multiple exposures to 
irritants will lead to non-allergic 
irritant-induced occupational rhi-
nitis or asthma.  Apart from these 
occupational diseases caused by 
work, environmental stimuli at 
work may also lead to worsening 
of pre-existent rhinitis, asthma or 
cough (work exacerbated rhinitis, 
asthma or cough). Figure 1 shows 
examples of allergens and stim-
uli responsible for the different 
work-related disorders. Chronic 
cough at work can be considered 
as a separate work-related disor-
der. Table 1 shows the occupations 
and causes of work-related chron-
ic cough. There is some overlap 
between the different categories 
of eliciting agents. Sensitizers may 
also have irritating properties. Ir-
ritants may lead to occupational 
Roy Gert van Wijk  
Erasmus Medical Center  
Rotterdam, Netherlands
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Environmental risk factors for allergy: working environment
disease, but also to worsening of 
pre-existing disease.
The level of exposure is consid-
ered as the key factor for the de-
velopment of occupational disor-
ders. The risk increases with high 
exposure. Less is known of the 
impact of exposure pattern (dura-
tion, continuous or intermittent, 
peak exposures).  
Apart from exposure, host factors 
may determine the risk of occupa-
tional rhinitis and asthma. Atopy is 
a risk factor for the development 
of IgE-mediated sensitization to 
HMW allergens in the working en-
vironment, and to a lesser extent 
for development of occupational 
rhinitis or asthma. The presence 
of atopy, however cannot be used 
to identify and exclude suscepti-
ble workers. Smoking has been as-
sociated with some work-related 
allergies such as allergies to bell 
peppers and platinum salts, but not 
in others. Possibly, the influence of 
smoking on development of occu-
pational allergy dependents on the 
specific allergens involved.  Finally, 
genetic factors may be associated 
with increased susceptibility to oc-
cupational asthma.
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TABLE 1
Causal agents of work related chronic cough
Occupation Agents
Miners Methylmethacrylate
Cement and glass bottle production Aliphatic polyamines
Construction workers Grain and flour mills
Farming workers Spices
Food industry Dust due to World Trade Center 
collapseMushroom factory
Wood industry Vapor Gases Dusts Fumes
Dental technicians Cattle and swine confinement farms
Fire-fighters Cleaning products
Bakery Second-hand smoking
Mechanic and repair jobs Reproduced with permission from Mosca-
to G, Pala G, Cullinan P,et al. EAACI Posi-
tion Paper on assessment of cough in the 
workplace. Allergy 2014; 69: 292–304, 
with permission from Willey Blackwell.
Spice factory
Greenhouse
Cleaners
Environmental risk factors for allergy: working environment
Work-related 
rhinitis or asthma
Occupational 
rhinitis or asthma
Work exacerbated 
rhinitis or asthma
Agents most frequesntly 
reported
Gases and mists
Fumes
Inorganic dusts, fibres
Organic aerosols
Organic chemicals
Physical stimuli
Non-allergic 
Irritant-induced rhinits or asthma
Commonly reported agents 
with irritating properties
Isocyanates
Cleaning agents
Chlorine
Metam sodium
Ammonia
Diesel exhaust
Solvents
Sulfur dioxide
Dinitrogen tetraoxide
Allergic occupational 
rhinits or asthma
HMW allergens
Flour dust
Enzymes
Latex
Proteins from animals
Proteins from fish, crustaceans 
shelfish
Pollen and other proteins
LMW allergens
Persufate
Metals (salts): chromium, nickel, 
platinum
Isocynates
Acid anhydrides
Acrylates
Soldering flux (colophony)
Uncertain components
Wood dust (red celar, oak, iroko)
Figure 1 Causes of work-related 
rhinitis or asthma.
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• Preschool viral wheezing illnesses are risk factor for the 
development of childhood asthma, with human rhinovirus (HRV) 
having the greatest impact
• Aeroallergen sensitization in the first two to three years of life 
further increases the risk of developing asthma in children, who 
have viral-induced wheezing
• Rhinovirus wheezing illnesses may lead to asthma development 
through two pathways, dependent and independent on allergic 
sensitization 
Asthma is the most prevalent 
chronic disease of childhood. Giv-
en its significant health as well as 
socioeconomic burden, investiga-
tors around the world have sought 
to define environmental and ge-
netic factors that contribute to 
asthma inception in early life. One 
important environmental factor 
demonstrable in multiple studies 
has been respiratory tract infec-
tions. From a genetics perspective, 
atopy  and genetic variation at the 
17q21 locus (that appears to be 
independent of atopy), are risk 
factors for asthma development. 
Interestingly, both appear to be 
dependent, at least in part, on an-
tecedent preschool human rhino-
virus (HRV) wheezing illnesses. 
EARLY CHILDHOOD 
RESPIRATORY VIRAL 
INFECTION AND ASTHMA IN 
CHILDHOOD
Although early childhood respira-
tory syncytial viral (RSV) infec-
tions have been documented to 
contribute to future asthma risk, 
recent advances in molecular diag-
nostic testing have enabled inves-
tigators to establish a relationship 
between HRV wheezing illnesses 
and asthma. In an evaluation of a 
high risk birth cohort, Jackson et 
al. found that infection with HRV 
RISK FACTORS FOR CHILDHOOD 
ASTHMA:  VIRAL INFECTION AND 
ALLERGIC SENSITIZATION
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Risk factors for childhood asthma:  viral infection and allergic sensitization
in the first three years of life was 
the virus most significantly asso-
ciated with the development of 
asthma at age 6 years (Figure 1). 
Mechanisms responsible for these 
developments are currently being 
intensely evaluated. Wark et al. 
found that cells from asthmatic pa-
tients had decreased production of 
both type I and III interferons, two 
important cytokines in the host’s 
innate immune response to viral 
infections. Recently, Caliskan and 
colleagues demonstrated that al-
lelic variation at a highly replicable 
genetic locus for asthma was asso-
ciated with significant asthma risk 
only in children who wheezed with 
HRV (not RSV) infections in early 
life. Since genes contained within 
this locus have functions that in-
volve calcium membrane flux and 
the unfolded protein response, 
it is possible that alterations in 
these pathways may further in-
fluence host immune response to 
viral infections at critical times in 
the lung development. Recently, 
infections with HRV-C have been 
noted to be associated with more 
significant clinical illnesses that 
may be of even greater severity in 
atopic children. 
COMBINED VIRAL INFECTION 
AND AEROALLERGEN 
SENSITIZATION
The relationship of atopy with the 
subsequent development of asth-
ma is widely recognized.  Aeroal-
lergen sensitization in the first 2 
to 3 years of life has been report-
ed to be a risk factor for the sub-
sequent development of asthma. 
Frederick J. Rubner Robert F. Lemanske Jr.
University of Wisconsin 
Madison, Wisconsin
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The development of multiple early 
sensitizations increases not only 
the risk of developing childhood 
asthma, but its clinical severity in 
terms of hospital admission rates 
as well. 
Preschool viral wheezing illness-
es and the development of aller-
gic sensitization can both inde-
pendently increase asthma risk. 
The presence of both can further 
influence the development of 
asthma, as demonstrated by data 
generated independently in two 
high-risk birth cohorts. In one of 
the high-risk birth cohort, aeroal-
lergen sensitization without doc-
umented preschool RV wheezing 
increased asthma risk by age six 
years (OR = 3.4) (Figure 2). If both 
RV wheezing and aeroallergen 
sensitization were present at age 
three, the risk of developing asth-
ma by age 6 years was substantial-
ly increased (OR = 80). 
Jackson et al. longitudinally eval-
uated which development occurs 
first: allergic sensitization predis-
posing to viral-induced wheez-
ing, or the reverse. Using a four 
stage statistical model, the study 
found that allergic sensitization 
is more likely to precede viral-in-
duced wheezing. Moreover, HRV 
wheezing illnesses were the most 
likely infections accounting for 
this temporal developmental se-
quence.  Allergic sensitization may 
increase lower airways inflamma-
tion and symptoms based on the 
ability of IgE receptor numbers 
and bridging to be associated with 
reduced dendritic cell production 
of type I and type III interferons 
with decreased viral host defense 
(Figure 3). 
INFLUENCE OF HRV WHEEZING 
ILLNESSES INDEPENDENT OF 
ATOPY
Genome-wide association studies 
of childhood asthma risk have re-
vealed a high susceptibility locus 
on chromosome 17q21. Genetic 
variation in this 17q21 region has 
been associated with increased 
childhood asthma risk but not 
with atopy. Caliskan and col-
leagues demonstrated that this 
association is in fact limited only 
to children who had HRV wheez-
ing illnesses in the first three years 
of life.3  Importantly, this geno-
type-attributable increased risk 
is totally independent of allergic 
sensitization (atopy). 
CONCLUSION
At least two distinct mechanistic 
pathways may predispose chil-
dren to asthma (Figure 4), both 
dependent on antecedent HRV 
wheezing illnesses. The first path-
way, termed 17q21, appears to be 
dependent on an asthma suscepti-
bility locus and totally independ-
ent of the presence of allergic sen-
sitization. The second pathway, 
termed FcεRI, is dependent on 
the development of allergic sensi-
tization. Continued evaluation of 
mechanisms responsible for these 
pathways hopefully will provide 
insight into disease treatment and 
prevention strategies.
KEY REFERENCES
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Figure 1 In an a high risk birth cohort infection with 
HRV in the first three years of life was the virus most 
significantly associated with the development of asthma at 
age 6 years.
Figure 2 Aeroallergen sensitization without documented 
preschool RV wheezing increases asthma risk by age six 
years. If both RV wheezing and aeroallergen sensitization 
are present at age three, the risk of developing asthma by 
age 6 years is substantially increased.
Risk factors for childhood asthma:  viral infection and allergic sensitization
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Hypothesis: Allergy Inhibits Innate Immune 
Responses Through Fc RI 
Cross-linking of Fc RI  
More frequent and severe virus-induced wheezing 
Prolonged inflammation 
Possible airway remodeling and/or loss of lung function 
PBMCs 
HRV 
Type I & Type III IFN Type I & Type III IFN 
Allergen 
Expression of Fc RI 
(Durrani et al, JACI 130:489, 2012) 
Figure 3 The process of allergic sensitization may influence innate immune 
responses to human rhinovirus (HRV) infection. Incubation of peripheral blood 
mononuclear cells (PBMCs) with HRV without cross linking of the high affinity 
receptor for IgE antibody (FcεRI) (left panel) results in decreased production 
of type I and type III interferons (IFN). Following cross-linking of this receptor 
(right panel) this decrease is further reduced. 
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Figure 4 Two distinct mechanistic pathways dependent on antecedent HRV 
wheezing illnesses predispose children to asthma. The first pathway, termed 
17q21, appears to be dependent on an asthma susceptibility locus and totally 
independent of the presence of allergic sensitization. The second pathway, 
termed FcεRI, is dependent on the development of allergic sensitization. 
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• In developing countries, large differences exist in the prevalence 
of allergies between rural and urban areas as well as between 
high and low socioeconomic status (SES) groups within urban 
areas
• Helminth infections, which are ubiquitous in rural areas and 
among low-SES urban dwellers, drive T-helper 2  (Th2) responses 
• High levels of total IgE and allergen-specific IgE are seen in 
helminth-infected subjects, but these do not translate into skin 
reactivity or clinical symptoms
• Regulatory network induced by helminths and helminth-induced 
IgE cross-reactivity prevent the translation of Th2 responses 
into allergic disorders
• Allergen-specific IgE has limited diagnostic value for allergic 
disease in helminth-endemic areas
Over 1 billion people worldwide 
are infected with parasitic worms. 
Most of these individuals are 
found in tropical regions of the 
world, where such infections are 
linked to poverty and rural living. 
Both helminths and allergens are 
potent inducers of T helper 2 (Th2) 
responses that lead to high levels 
of immunoglobulin (Ig) E, tissue 
eosinophilia, mast cells as well as 
the secretion of Th2 cytokines 
such as interleukin (IL)-4, IL-5, IL-9 
and IL-13.
Despite the similar immunologi-
cal profiles associated with both 
helminths and allergies, there is 
little overlap in the geographical 
distribution of these two health 
problems. Moreover, in develop-
ing countries, among urban popu-
lations of high socioeconomic sta-
tus (SES), improved hygiene and 
fewer infections have been linked 
to an increase in allergic disor-
ders. Indeed, a number of studies 
have found a negative association 
between helminth infections and 
allergic disorders among rural and 
low SES urban populations within 
these countries (Figure 1).
Mechanistically, chronic helminth 
infections have been shown to in-
duce an immune regulatory net-
work in the host characterized by 
ENVIRONMENTAL RISK 
FACTORS FOR ALLERGY: 
HELMINTH INFECTIONS 
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regulatory T and B cells, alterna-
tively activated macrophages and 
modified dendritic cells (Figure 2). 
This leads to an anti-inflammato-
ry environment that prevents the 
down-stream effector phase of 
Th2 responses associated with al-
lergic disorders. However, the tim-
ing and duration of helminth infec-
tion are key, since infections early 
in life and/or chronic infections are 
more effective in down-modulat-
ing allergic disease. In addition, 
the species of helminth is also 
an important determinant in the 
modulation of allergic disorders.
Another mechanism that might 
explain the inverse association 
between helminth infection and 
allergy may involve helminth-in-
duced IgE cross-reactivity. Cur-
rent helminth infections are as-
sociated with increased levels 
of allergen-specific IgE that do 
not translate into skin reactivity 
or clinical symptoms (Figure 3). 
Moreover, this helminth-induced 
IgE appears to be of low affinity 
and does not lead to mast cell de-
granulation.
In fact, in developing countries, 
strong correlations are observed 
between allergen-specific IgE and 
symptoms of allergy among urban 
Abena 
S. Amoah
Firdaus 
Hamid
Hermelijn 
H. Smits
Maria 
Yazdanbakhsh
Leiden University Medical Center, Leiden, The Netherlands
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populations of high SES. However, 
in rural populations as well as ur-
ban low SES groups, helminth-in-
duced IgE cross-reactivity and 
regulatory networks may prevent 
the translation of allergen-specific 
IgE into skin reactivity or allergic 
symptoms (Figure 4). Therefore, 
allergen-specific IgE has limited 
diagnostic value for allergic dis-
ease in helminth-endemic areas. 
Future studies taking an interna-
tional perspective will be essential 
for our understanding of environ-
mental risk factors and underlying 
mechanisms to develop new treat-
ments that can halt the allergy ep-
idemic worldwide.
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Figure 1 Allergy field research in a helminth-endemic area on Flores Island, 
Indonesia. The study showed an inverse association between current helminth 
infection and skin prick test positivity to house dust mite in a semi-urban 
population. (From Hamid F, Wiria AE, Wammes LJ, Kaisar MM, Djuardi Y, 
Versteeg SA, Wahyuni S, van Ree R, Sartono E, Supali T, Yazdanbakhsh M. Risk 
Factors Associated with the Development of Atopic Sensitization in Indonesia. 
PLoS One. 2013 19;8(6) :e67064).
Glycoconjugates
IL-10
TGFβ
CD1d
Effector
T cells
Breg
cells
Figure 2 Helminths and their products induce an immune regulatory network 
in the host characterized by regulatory T (Tregs), regulatory B cells (Bregs), 
alternatively activated macrophages (AAMΦ) and modified dendritic cells 
(immature dendritic cells [iDC] and regulatory dendritic cells [DCreg]).
Environmental risk factors for allergy: helminth infections
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Figure 3 Differences in the prevalence of mite sensitization when measured as IgE or as SPT among 5-16 year olds 
from three populations living in Ghana (urban and more rural areas of the Greater Accra region which is undergoing 
rapid urbanization) and on two Islands in Indonesia (semi-urban and rural parts of Flores Island as well as among high 
SES and low SES subjects living in an urban centre of Sulawesi Island). The data presented are from Hamid F, Wiria AE, 
Wammes LJ, Kaisar MM, Djuardi Y, Versteeg SA, Wahyuni S,van Ree R, Sartono E, Supali T, Yazdanbakhsh M. Risk Factors 
Associated with the Development of Atopic Sensitization in Indonesia. PLoS One. 2013 19;8(6) :e67064 as well as 
unpublished data from field studies in Ghana and Sulawesi, Indonesia.
i. Groups with chronic helminth infection ii. Groups with no helminth infections
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Figure 4 (i) In developing countries, the regulatory network induced by helminths and helminth-induced IgE cross-
reactivity prevent the translation of Th2 responses into allergic disorders among groups with chronic helminth infections. 
(ii) In the same countries, among groups with no helminth infections, specific IgE translates into skin prick test positivity 
and allergy symptoms from field studies in Ghana and Sulawesi, Indonesia).
Environmental risk factors for allergy: helminth infections
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• programming of long-term sensitization versus tolerance to 
allergens occurs in early life against a background of functional 
immaturity within the immune system
• slow postnatal maturation of immune functions increases 
sensitization risk
• multiple cell types within the innate and adaptive immune system 
exhibit slow maturation kinetics in children, who subsequently 
develop atopy
• postnatal maturation is driven by microbial signals, particularly 
from gut commensals
• the trajectory for postnatal immune development is partially 
present in utero, driven via signals present in the maternal 
environment, including microbial exposures
Interest in the role of immune de-
velopment as a risk factor for ato-
py was first stimulated by exper-
imental studies on the sequelae 
of de novo exposure of immuno-
logically naïve animals to aeroal-
lergen.  Such exposure triggered 
an initial “default” response com-
prising low-level Th2-immunity, 
including specific IgE production, 
which was eventually terminated 
by emergence of specific T-regu-
latory cells (Tregs) that induced a 
state of long-lived immunological 
tolerance, protecting the animals 
against sensitization at subse-
quent re-exposures. These find-
ings served to focus human stud-
ies on the etiology of atopy on the 
life period (infancy), during which 
the naïve immune system first en-
counters allergens. A number of 
resultant observations attest to 
the validity of this approach:
(i) data from birth cohorts (Fig 1) 
demonstrate an initial induc-
tion of aeroallergen-specific 
IgE in both atopic and non at-
opic children during infancy, 
preceding subsequent stabi-
lization of “tolerized” versus 
“sensitized” immunopheno-
types, as the immune system 
progressively programs alter-
nate forms of T-cell memory;
Patrick G. Holt  
 Telethon Kids Institute, The University of Western Australia and Queensland 
Children’s Medical Research Institute, The University of Queensland 
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(ii) the rate of postnatal matu-
ration of Th-cell functional 
competence (as measured 
by capacity to generate “bal-
anced” Th1/Th2 cytokine re-
sponses) is slower in children 
at high risk for allergy devel-
opment;
(iii) subsequent studies have ex-
tended the range of cell types 
manifesting atopic risk-asso-
ciated developmental defi-
ciencies to additional popu-
lations within the innate and 
adaptive immune system in-
cluding monocytes, dendritic 
cells and Tregs.
Following the advent of the Hy-
giene Hypothesis in the late 
1980s, interest has progressively 
increased in the role of the gut mi-
crobiome as the “driver” of postna-
tal development of immunocom-
petence. Recent findings suggest 
a link between postnatal devel-
opment of immunity to organisms 
within the respiratory microbiome 
and risk for atopic asthma. 
Since many of these functional 
deficiencies are already evident in 
cord blood the trajectory for post-
natal immune maturation seems at 
least partially preset before birth. 
Observations stemming from 
the “farm barn” studies in Europe 
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have identified TLR-dependent 
microbial signaling to innate 
immune cells in the maternal 
decidua as the potential mecha-
nism: this may result in stabiliza-
tion of the immunological milieu 
in the placenta, contributing to 
protection of the integrity of the 
local vasculature responsible for 
delivering nutrients to the fetus, 
thus optimizing in utero growth 
and development (Figure 2). 
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Figure 1 Postnatal development of sensitization versus tolerance to house 
dust mite (HDM). Fluctuations in HDM-specific IgE titers in individual children 
who were not (left) or were (right) sensitized at age 5 years. The dotted line 
indicates the 0.35 kU/L sensitization threshold. Note “cycling” of IgE production, 
particularly in non atopics, reflecting underlying competitive interactions 
between regulatory and helper T-cell populations. ( Holt et al 2010 originally 
published in J Allergy Clin Immunol 125(3), 645-651. Reprinted under Rightslink Lic 
No 3346780104940.)
Figure 2 Proposed mechanisms by which maternal exposure to bacteria 
protects against allergies in offspring. A multi-step process may be involved: (i) 
initial mild-to-moderate inflammation in the lungs induced by aerosol exposure 
to microbe-containing dust; (ii) resultant cytokine signals translocate from lung 
to placenta via the bloodstream, where they attenuate local TLR expression and 
modulate resident myeloid cell functions; (iii) circulating cytokines enter the 
maternal bone marrow, where they “program” myeloid precursors that subse-
quently traffic to the decidua to replenish resident myeloid populations and 
influence the local inflammatory milieu. (Reproduced with permission from Patrick 
G. Holt, et al. Soothing signals: transplacental transmission of resistance to asthma 
and allergy. J Exp Med. 2009;206(13):2861-2864.)
Perinatal immune development and its role in atopy development
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• The development and phenotypic expression of allergic disease 
depends on a complex interaction between genetic factors, 
environmental factors (food or inhalant allergen exposure) and 
risk/protective factors
• The concept of the hygiene hypothesis has been extensively 
investigated and has influenced our understanding of early-life 
events
• Some susceptible/predisposed individuals may benefit from 
reduction of allergen exposure
• Exposure to food or inhalant allergens cannot be totally avoided, 
and observational and interventional studies on avoidance/
reduction of exposure have not shown convincing results
• Multifaceted allergy avoidance during infancy with avoidance of 
both foods and airborne indoor allergens have shown a persisting 
reduction of asthma
The development and phenotypic 
expression of allergic disease de-
pends on the interaction between 
genetic and environmental factors 
such as exposure to allergens to-
gether with risk and/or protective 
factors (Table  1). Over the last 
decades an increase in the preva-
lence of allergic diseases has been 
reported worldwide. From pro-
spective birth cohort studies, pos-
sible protective and risk factors 
have been identified (Table 2, 3). 
A family history of allergic disease 
(asthma, allergic rhinoconjunctivi-
tis, atopic eczema or food allergy) 
in first degree relatives, is strongly 
associated with an increased risk 
for allergic disease. 
Considering that the increase in 
the prevalence of allergic diseas-
es cannot be ascribed solely to 
genetic factors, most studies on 
development of allergic diseases 
have focused on the influence of 
in environmental factors, e.g. ear-
ly feeding (breastfeeding vs. cow’s 
milk formula), diets/nutrients, 
exposure to allergens, tobacco 
smoking, pollution, farm vs. urban 
environment, and infectious load. 
Many hypotheses have been pro-
posed based on observed asso-
ciations between environmental 
factors and development of aller-
Arne Høst  
Hans Christian Andersen Children’s Hospital 
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gic diseases. Such associations can 
only be used for generation of hy-
potheses. 
Many hypotheses on causes of 
the increase in allergic diseases 
have been suggested, most often 
without convincing and consist-
ent results (Table 4). The concept 
of the hygiene hypothesis has been 
extensively investigated and has 
influenced our understanding of 
early-life events. According to 
this hypothesis, early exposure to 
common bacterial triggers such 
as endotoxins, LPS or helminths 
might have an allergy preventive 
effect. The hygiene hypothesis 
may in part explain the increase in 
the incidence of allergic diseases . 
However, multifactorial environ-
mental factors may play a role and 
interact (Table 3). 
A strong association between ex-
posure to allergens and IgE sensiti-
zation has been documented and 
also a strong association between 
sensitization and development of 
allergic disease, such as allergic 
asthma and rhinoconjunctivitis. 
Sensitization to foods appears 
first, followed by sensitisation to 
indoor allergens (e.g. house dust 
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mites, pets) and later by sensiti-
sation to outdoor allergens (e.g. 
pollen, mould). However, sensiti-
zation may be a transient normal 
phenomena followed by develop-
ment of tolerance. 
THE CONCEPT OF AVOIDANCE
For decades, primary prevention 
addressing prevention of sensiti-
zation and development of clini-
cal allergic disease has mostly fo-
cused on avoidance of exposure to 
allergens (e.g. foods, indoor aller-
gens). Over the last decade, a new 
concept of primary prevention has 
emerged. Earlier it was believed 
that breastfeeding and avoidance 
of cow’s milk proteins could pre-
vent development of cow’s milk 
protein allergy. However, human 
milk contains cow’s milk proteins, 
if the mother has an intake of cow’s 
milk. Other food proteins are also 
present in human milk. Thus, for-
eign proteins cannot be avoided 
by exclusive breastfeeding. The 
concept of avoidance of foods dur-
ing breastfeeding is wrong. Infants 
are exposed to small amounts of 
foreign proteins (reduced expo-
sure), which may rather lead to 
tolerance than to clinical allergic 
disease. Furthermore, breast milk 
contains many immune-modulat-
ing factors that may influence the 
development of allergy (Table 5).
TABLE 2
Predictors for sensitisation and persistent allergic disease 
Predictors for sensitization and allergic disease
• Atopic heredity
• Elevated cord blood IgE
• Early sensitization to foods and aeroallergens
• Persistent sensitization 
Predictors for persistent allergic airway disease into adolescence/adulthood
• Persistent sensitization
• High degree sensitization and polysensitization
• Early onset of persistent asthma
• Severe disease
• Reduced lung function
• Presence of another atopic disease
TABLE 3
Possible environmental factors influencing development of allergic diseases
Risk factors Protective factors
Allergen exposure Exclusive breastfeeding 4-6 months
Tobacco smoke?
Early exposure to endotoxins, LPS, 
helminths?
Lack of breastfeeding? Infections?
Early introduction of solid foods?
Diets/nutrients? 
Antioxidants, lipids, probiotics, vitamins
Mode of delivery (Caesarean section)
Infections?
Early treatment with antibiotics?
TABLE 4
Hypotheses on causes of increase 
in allergic diseases
• Changes in dietary factors
• Changes in  allergen exposure
• Modified infectious load – 
hygiene hypothesis
• Pollutants/irritants
• Obesity
• Life style factors
Perinatal risk and protective factors for allergic diseases
TABLE 1
Development of allergic disease
The development and phenotypic expression of allergic disease depends on a 
complex interaction between:
• Genetic factors
• Environmental factors
  food allergen exposure
  inhalant allergen exposure
• Risk/protective factors e.g.
  tobacco smoke
  microbials, endotoxins, LPS
  infections
  diet (nutrients/foods)
  other
Age, dose and duration of exposure are important
Synergistic effects
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Other routes of exposure occur via 
inhalation (proteins in house dust), 
or via the skin. Likewise, exposure 
to inhalant allergens cannot be 
totally avoided, and observation-
al and interventional studies on 
avoidance/reduction of indoor al-
lergen exposure (house dust mite, 
cat) have not shown convincing re-
sults. However, multifaceted aller-
gy avoidance during infancy with 
avoidance of both foods and air 
born indoor allergens have shown 
a persisting reduction of asthma. 
Importantly, the development of 
allergy to environmental allergens 
is a complex gene-environment 
interaction and some suscepti-
TABLE 5
Factors in human milk influencing development of allergy
Factors Inducing Protective
Antigens (e.g. food proteins) Sensitising allergens Tolerising allergens
Cytokines
IL-4 TGF-beta
IL-5 sCD 14
IL-13
Immunoglobulins s-IgA
PUFA
Arachidonic acid N3-PUFA
N-6 PUFA Other
TABLE 6
Evidence-based recommendations for primary prevention of food allergy
For all infants:
• No special diet during pregnancy or for the lactating mother
• Exclusively breastfeeding for 4-6 months
Further recommendations for infants with atopic predisposition:
• If supplement is needed during the first 4 months a documented hypoaller-
genic formula is recommended
Introduction of complementary foods after the age 4 months according to nor-
mal standard weaning practices and nutrition recommendations for all children 
irrespective of atopic heredity
TABLE 7
Evidence-based recommendations for prevention of allergy to inhalant al-
lergens
• Avoid exposure to tobacco smoke
• Avoid pets at home if parents or siblings are allergic to pets
Common sense:
• Restrict exposure to house dust mites and pets for children with atopic dis-
position
ble/predisposed individuals may 
benefit from reduction of allergen 
exposure. Further studies on the 
influence of both genetic and envi-
ronmental factors are warranted. 
The present recommendations for 
primary prevention of allergic dis-
eases are shown in Table 6 and 7.
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• The number of microorganisms living in and on our body surfaces 
outnumbers human cells by a factor of 10
• The microbiome is essential for a healthy immune response
• The gut microbiome plays an important role in protecting from 
the development of allergic airway disease in mice
• Exposure to a rich and diverse microbial environment such as 
seen on traditional farms protects from allergic diseases
All plants, animals and humans 
live in close association with mi-
crobial organisms. Historically, 
microbiologists have isolated and 
grown microorganisms to identi-
fy pathogens causing disease. The 
advent of DNA based sequencing 
methods has allowed amplifica-
tion of DNA from microorganisms 
and thereby identification of a 
large variety of microorganisms 
that have never been cultured 
before. The Human Microbiome 
Project has shown that the hu-
man body contains trillions of mi-
croorganisms, which outnumber 
human cells by 10 to 1 (Figure 1). 
Their genes encode products es-
sential for human survival. In the 
gastro-intestinal tract microbes 
break down many of the proteins, 
lipids and carbohydrates from our 
diet into nutrients so that we can 
absorb them. Moreover, microbes 
produce beneficial compounds 
such as vitamins. The microbiome 
also profoundly affects the host’s 
immune response. Mice raised 
under germ-free conditions have 
profound deficits in innate and 
adaptive immunity suggesting 
that the microbiome educates a 
child’s immune system.
Experimental studies in mice, fur-
thermore suggest that the micro-
Erika von Mutius  
Dr. von Hauner Children's Hospital 
Munich, Germany
THE ROLE OF MICROBIOME7
Ke y   m e ssag e s
biome has a role for the develop-
ment of allergic diseases.  Germ 
free mice develop more easily al-
lergic asthma than conventionally 
raised mice. Reconstitution of ne-
onates—but not adult—germ free 
mice with a conventional micro-
biota protected the animals from 
allergic disease. This protective 
effect may be mediated by activa-
tion of immune responses by mi-
crobial compounds. Alternatively 
or additionally metabolites secret-
ed by microbes such as short-
chain fatty acids may mediate 
these beneficial effects. Changes 
in the microbiome will occur with 
diet and antibiotics as long as they 
are ingested. But also microbial 
exposures in the environment will 
affect the microbiome and there-
by the risk of allergic diseases. 
Children being raised in environ-
ments rich in microbial exposures 
such as on traditional farms (Fig-
ure 2) have a much lower prev-
alence of asthma, hay fever and 
allergic sensitization as children 
grown up in urban settings. The di-
versity of the microbial exposure 
has been shown to account for 
the asthma-protective farm effect 
(Figure 3). In urban areas high ex-
posure to environmental microbes 
(e.g. by keeping dogs indoors) also 
relates to a lower prevalence of 
allergic disease. A recent mouse 
study has demonstrated the piv-
otal role of the gut microbiome in 
mediating this protective environ-
mental exposure. Some birth co-
hort studies also suggest that the 
composition of the gut microbiota 
may be a predictor for the onset of 
atopic eczema in young children, 
but these observations are not 
consistent and need further con-
firmation.  
The role of microbiome
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Figure 1 The diversity of the skin microbiome at different anatomical areas. (Reprinted by permission from Macmillan 
Publishers Ltd: Nat Rev Microbiol, Grice EA1, Segre JA, The skin microbiome, 9,244-253, copyright 2011.) 
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Figure 2 Protection from childhood asthma and allergies has been shown for young children growing up on traditional 
farms rich in microbial exposures in the environment.
Figure 3 The diversity of bacterial and fungal exposure in the environment protects from childhood asthma. (From New 
Engl J Med, Ege MJ, Mayer M, Normand AC, et al. Exposure to environmental microorganisms and childhood asthma,364,701-9, 
Copyright  2011 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.)
The role of microbiome
Section C
ALLERGY DIAGNOSIS
* Skin tests
* Nasal and bronchial provocation tests
* Food provocation tests 
* In vivo diagnosis of  NSAID hypersensitivity 
(Aspirin  provocation  tests)
* Drug provocation tests  
* The allergen challenge chamber 
* Allergen- specific IgE 
* Molecules and component-resolved diagnosis 
* Cellular allergy testing
* Biomarkers for allergy diagnosis and treatment
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• Performing skin tests needs a specific training
• Skin Prick Tests are an excellent tool to detect sensitizations to 
inhalant and food allergens
• Intradermal tests are of paramount importance in venom and 
drug hypersensitivity
Skin tests are an important diag-
nostic tool in the work up of many 
allergic diseases (Table 1). Skin 
tests are widely used for the diag-
nosis of inhalant allergies, but also 
allergies to foods, venom, occupa-
tional agents and drugs can be in-
vestigated by skin tests.
TYPES OF SKIN TESTS AND 
REQUIREMENTS
Skin prick tests (SPTs) and intra-
dermal tests are still the corner-
stone of the diagnosis of IgE-me-
diated (type I) allergy.  Especially 
SPTs are widely used (Figure 1). As 
they are usually easy to perform, 
cheap and allow a fast reading, 
they are an ideal tool for bedside 
diagnosis. Intradermal also named 
intracutaneous testing  (Figure 2) 
is more demanding, but allows by 
titration of various allergen con-
centrations a very accurate rating 
of the sensitization level.
Epicutaneous or patch tests are 
used in patients with suspected 
type IV allergies for contact der-
matitis or delayed type of drug 
hypersensitivity. Due to its po-
tentially scar-inducing effect skin 
testing by scratching is limited to 
some special aspects of drug or 
mostly occupational allergens. The 
atopy patch tests (APT) may help 
to find out causes of exacerbation 
in atopic dermatitis or Eosinophil-
ic Esophagitis,  but its value is still 
controversial. Performing skin 
tests needs a specific training, es-
pecially for intradermal and epicu-
taneous tests with nonstandard-
ized allergen material. 
Contraindications such as the use 
of some drugs, pregnancy or other 
conditions precluding some types 
of allergy testing should be evalu-
ated. Also the skin condition of the 
patient must allow testing in the 
skin. Patients have to abstain from 
medications such as antihistamin-
ics that could mask a positive type 
I reactions; on the other hand con-
ditions such as dermographism/
pressure urticaria able to provoke 
false positive skin reactions must 
be considered. Using controls 
such as histamine for positive and 
saline as negative controls are cru-
cial for SPT/intradermal testing.
SKIN TESTS FOR INHALANT 
ALLERGENS 
SPT are the classical diagnostic 
tool get prompt information about 
sensitizations against inhalant al-
lergens such as pollen, house dust 
mites, pets and, to a lesser extent 
moulds. As they are usually easy 
to perform, cheap and allow a fast 
reading, thus an ideal tool for bed-
side diagnosis. Recommendations 
for standard series of SPT solu-
tions are available for many geo-
graphic and climatic regions.
Skin prick tests can also be used 
in tropical areas and in countries 
with limited resources, where al-
lergy is booming. However, local 
allergens may not necessarily be 
identified or available and can 
therefore be missed for skin test-
ing.  For example, it is crucial to 
include allergens such as Blomia 
tropicalis in the skin test battery of 
tropical countries.
IN VIVO ALLERGY 
DIAGNOSIS - SKIN TESTS1
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In vivo allergy diagnosis - skin tests
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In vivo allergy diagnosis - skin tests
TABLE 1
Difference between basophils and mast cells
Skin  
Prick Test
Intradermal 
Tests
Epicutaneous 
 (Patch) Tests
Atopy 
Patch Test
Inhalant allergies
+++ 
Standard
Rarely needed, few 
available allergens
n.a.
Some forms of atopic 
dermatitis1
Food allergy
++  
With commercially 
available extracts and 
fresh food
n.a. n.a.
Eosinophilic 
esophagitis? Some 
forms of atopic 
dermatitis2
Venom allergy
+  
(reduced sensitivity) 
+++ 
(Titration)
n.a. n.a.
Drug hypersenstivity + to ++
+++ 
 (with all soluble drugs; 
Titration)
(++) 
In delayed drug 
hypersensitivity3 
n.a.
Contact allergens
(+) 
( in case of protein 
contact dermatitis)
n.a. +++
1 If Atopic Dermatitis seems to exacerbated by the presence of  inhalant allergens 
2 If Atopic Dermatitis seems to exacerbated by the presence of  food allergens
3 Especially if cutaneous manifestations of delayed type (eczema,maculo-papular rash) occur
a
b
Figure 1 Skin prick test with a) 
inhalant allergens and b) fresh food.
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SKIN TESTS FOR FOOD 
ALLERGY 
For food allergy mostly SPT is 
used,  done with commercially 
available food allergen extracts 
but also with fresh food (Prick-to 
Prick technique, Figure 1b).  Test-
ing with fresh food enables a fast 
detection of sensitization also to 
foods individually provided by the 
patient or only locally available. As 
skin testing does not discriminate 
between sensitization and clinical 
relevant food allergy, additional 
tools such as food allergen oral 
provocation tests, elimination 
diets and more recently compo-
nent-resolved in vitro diagnosis 
are indicated.  Intradermal testing 
with food allergens is not recom-
mended.
SKIN TESTS FOR 
HYMENOPTERA VENOM 
ALLERGY
Skin testing for hymenoptera 
venom allergy is a very reliable 
and useful diagnostic tool. While 
SPT with venoms has limited sen-
sitivity, intradermal testing with 
increasing concentrations allows 
the detection of the sensitization 
threshold, with high sensitivity 
and specificity. Concentrations 
starting at 0.00001 μg/ml with a 
ten-fold increase in doses at each 
step till 1.0 μg/ml are used.  Simul-
taneous testing with two hyme-
noptera venoms seems to be safe 
and allows fast bed-side diagnosis.
SKIN TESTS IN DRUG 
HYPERSENSITIVITY
Skin tests are a very useful but also 
delicate tool to investigate drug 
hypersensitivity. Especially for in-
tradermal testing of soluble drugs, 
the ideal concentrations need to 
be evaluated. In a recent position 
paper of the ENDA/EAACI Drug 
Allergy Interest Group drug con-
centration for skin testing aiming 
to achieve a specificity of at least 
95% have been postulated. Cur-
rently such drug concentration 
can be recommended for beta-
lactam antibiotics, perioperative 
drugs, heparins, platinum salts 
and contrast media. For many oth-
er drugs, there is still insufficient 
evidence to define an appropriate 
drug concentration. 
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Figure 2 Intradermal testing with 
venom (Honey bee) in different 
concentrations (titration).
In vivo allergy diagnosis - skin tests
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• Nasal and bronchial provocation tests are of additional value in 
the understanding and diagnosis of allergic rhinitis and asthma
• These tests need to be performed in a clinical setting by 
dedicated staff
• It is strongly recommended to follow a validated and standardized 
protocol
• In experienced hands, the safety risks of challenge tests are low
INTRODUCTION
Epidemiological studies have 
shown that inhaled allergens are 
an important cause of allergic rhi-
nitis (AR) and asthma. Allergen 
inhalation challenge mimics the 
natural situation and is useful for 
understanding the mechanisms 
of allergic airway inflammation 
and airway hyperresponsiveness 
(AHR). Moreover, provocation 
tests play an important role in the 
diagnosis of asthma, and to a less-
er extent also in AR. Via a bron-
chial provocation test (BPT), AHR 
can be measured by challenging 
the airways with a variety of phys-
ical and inhaled chemical stimuli 
resulting in airway constriction 
(Figure 1). The airway narrowing 
is measured by changes in FEV1 
after gradually increasing the dose 
of provoking agent. 
A nasal provocation test (NPT) is 
used in case of a typical history 
of AR and a negative allergy test 
(Figure 2). It is of importance to 
differentiate AR from non-allergic 
rhinitis since management may be 
different. A positive test result is 
defined by the presence of symp-
toms typical for AR plus objective 
parameters, such as decreased 
upper airway patency (measured 
with acoustic rhinometry or an-
IN VIVO ALLERGY DIAGNOSIS- 
NASAL AND BRONCHIAL 
PROVOCATION TESTS
2a
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In vivo allergy diagnosis - nasal and bronchial provocation tests
terior rhinomanometry) or nasal 
secretion of inflammatory media-
tors. Patients can have immediate 
or dual responses.
METHODS
Different methods for NPT and 
measurement of nasal respons-
es are used. Medication that may 
interfere with the results should 
be stopped prior to the test and 
contra-indications should be ruled 
out. If available, it is advised to fol-
low a validated and standardized 
protocol. 
Inhaled allergen challenge starts 
early in the morning in order to 
measure a late asthmatic response. 
Ideally, patients are observed for a 
longer period. It is strongly recom-
mended to perform BPT in a clini-
cal setting. In daily clinical practice 
for AHR diagnosis, the preferred 
agents are histamine, methacho-
line and mannitol. These agents 
give a bronchoconstrive response 
that is less prolonged and quickly 
reversible with bronchodilators 
and inhaled corticosteroids. Diag-
nosis of occupational asthma and 
rhinitis may require specific inha-
lation tests.
LIMITATIONS
Inhaled allergen provocation tests 
are safe in a dedicated setting with 
experienced staff. Several objec-
tive and validated parameters to 
measure response are available 
for BPT, but not for NPT. Allergen 
application may produce nonspe-
cific reactions. A limited number 
of standardized allergen extracts 
are commercially available. Aller-
gen challenge can result in a tran-
sient increase in symptoms and 
medication use. 
Gert Jan Braunstahl   
St. Franciscus Gasthuis 
Rotterdam, the Netherlands
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In vivo allergy diagnosis - nasal and bronchial provocation tests
TABLE 2
Contra-indications for NPT or BPT
• Advanced nasal polyposis (NPT)
• A recent history of nasal surgery (NPT) 
• Respiratory tract infection in the last 2 weeks. 
• Instable asthma (BPT)
• FEV1 < 70% of predicted (BPT)
• Pregnancy
• Recent vaccination (< 1 week)
• Use of systemic Beta-blockers 
Figure 1 Mechanism of action in bronchial provocation tests. (Reproduced with permission from O’Byrne PM, Gauvreau GM, 
Brannan JD. Provoked models of asthma: what have we learnt? Clin Exp Allergy 2009;39:181-92, with permission from Willey 
Blackwell.)
TABLE 1
Indications for NPT or BPT
• To confirm a diagnosis of occupational allergic 
rhinitis or asthma.
• Discrepancy between history and routine 
diagnostic procedures. 
• To confirm a diagnosis in a patient who has 
difficulty accepting the consequences of disease, 
such as avoiding pets or changing jobs.
• To study pathophysiological mechanisms and 
pharmacological efficacy of medication
Exercise/eucapnic voluntary hypnoea
Respiratory water loss
Mucosal dehydration
Increase in osmolarity 
of airway surface liquid
Allergen inhalation
Mucosal presentation of allergen
Allergen-IgE complex
Hypertonic aerosols 
e.g. hypertonic 
saline, mannitol
Adenosine 
monophosphate 
(AMP)
Methacholine 
or histamine
Epithelium
Submucosa
Presence of increased cellular inflamamation
e.g. mast cells (Fc epsilon R1, A2B receptors), eosinophils
Mediator release from cellular inflammation
Sensitive bronchial smooth muscle
Bronchial smooth muscle contraction and airway narrowing
Allergen challenge
+
+
Augmented 
during late airway 
response to 
allergen
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In vivo allergy diagnosis - nasal and bronchial provocation tests
SAFETY AND SIDE EFFECTS
NPT and BPT are safe procedures. 
Generalized reactions are rare 
after BPT, but asthma exacerba-
tions may occur. After allergen 
challenge the magnitude of the 
bronchoconstriction may be more 
difficult to control than with direct 
challenges, such as histamine or 
methacholine. Moreover, the in-
duced bronchoconstriction is usu-
ally prolonged due to the release 
of proinflammatory mediators. 
Therefore, it is necessary that 
during an inhaled allergen provo-
cation a doctor is present, the res-
cue medication is ready to use and 
a resuscitation set is available on 
the ward.
KEY REFERENCES
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4. Rondon C, Campo P, Togias A, Fok-
kens WJ, Durham SR, Powe DG, 
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cept, pathophysiology, and man-
agement. J Allergy Clin Immunol 
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Figure 2 Diagnostic approach to the patient with allergic rhinitis. (Reprinted from J Allergy Clin Immunol, 129/6, Rondon 
C, Campo P, Togias A, et al. Local allergic rhinitis: concept, pathophysiology, and management, 1460-1467, Copyright 2012, with 
permission from Elsevier.)
Clinical History suggestive of rhinitis symptoms
Skin Prick Test with aeroallergens
Positive Negative
Concordant with 
clinical history
Disconcordant with 
clinical history Serum specific-IgE
Allergological target organ evaluation:
NAPT and/or nasal specific IgE
Local Allergic Rhinitis Non - Allergic Rhinitis
Positive & concordant 
with clinical history
Positive & disconcordant 
with clinical history Negative
Positive Negative
Allergic Rhinitis
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since the presence of atopy in an individual might lead to false 
positive interpretation of IgE testing
• Patient safety is key to the design of a food challenge  
• Interpreting a food provocation test can be challenging, the 
experience of the staff is decisive
• Food challenges are essential procedures in the follow-up of 
food allergy
WHY DO WE DO FOOD 
CHALLENGES?
Diagnosis of food allergy can be 
obvious, for example in the case 
of a child reacting with urticar-
ia 10 minutes after having eaten 
peanuts. In this case caused by an 
IgE-mediated reaction, skin prick 
tests and in-vitro diagnosis, by 
measuring specific IgE in the se-
rum, are most often positive and 
clearly relate to the symptoms. 
Food challenge might be done in 
patients with vague symptoms 
possibly related to food allergy, 
with a significant proportion of 
patients having positive IgE tests 
not related to the symptoms but 
to an atopic predisposition (false 
positive tests indicating only sen-
sitization). In this context, a food 
challenge will be the gold standard 
for diagnosis (Figure 1).
HOW DO WE DO FOOD 
CHALLENGES?
Several variables have to be taken 
into account when organizing a 
food challenge. Most important-
ly, the food challenge must be 
designed in a safe way. The food 
challenge must be performed in a 
location, where emergency medi-
cation can be administered. When 
doing high risk challenges, it is im-
portant to have rapid access to in-
Philippe Eigenmann  
University Hospitals of Geneva 
Geneva, Switzerland
IN-VIVO ALLERGY DIAGNOSIS- 
FOOD PROVOCATION TESTS 2b
Ke y   m e ssag e s
In-vivo allergy diagnosis – food provocation tests
tensive care facilities. In all cases, 
the food challenge must be super-
vised by nurses trained to recog-
nize early signs of reactions. Also, 
the supervising physician must be 
trained in order to have sufficient 
experience in interpreting the 
various clinical signs possibly ob-
served during a food challenge. 
The food is provided to the patient 
in increasing doses. The starting 
dose, as well as the time interval 
between the doses, will be deter-
mined by the initial history of the 
patient and by the purpose of the 
challenge. A food challenge aiming 
to determine the threshold level 
of a reaction will start with a very 
low dose. 
The food can be administered 
openly, but also in a double-blind 
placebo controlled manner. Dur-
ing this procedure, the challenge is 
separated into two parts, the food 
being hidden in a vehicle in order 
for blind both the patient and the 
examiner (Figure 2).
LIMITATIONS OF A FOOD 
CHALLENGE 
A well designed food challenge 
will provide definite information 
about the presence or the absence 
of a food allergy. Nevertheless, 
one needs to be aware of some 
caveats. A food challenge is valid 
only for the type of preparation of 
the food. As an example, patients 
may react to raw egg, but not to 
cooked egg, and a patient with a 
negative challenge to cooked egg 
might afterwards react to a prepa-
ration with raw or not completely 
cooked egg. Similarly, a negative 
challenge to a specific fish does 
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Figure 1 Decision tree for food allergy including either an open food challenge, or a double-blind, placebo-controlled 
food challenge (DBPCFC). (Reproduced with permission from Niggemann B and Beyer K. Diagnosis of food allergy in children: 
toward a standardization of food challengeJ Pediatr Gastroenterol Nutr 2007, 45,  399-404.) 
not indicate that the patient can 
eat all types of fish.
A well designed food challenge 
is the definite diagnostic tool for 
food allergy. In addition, it is also 
a very useful tool in the follow-up 
of food allergic patients. A positive 
food challenge  provides valuable 
information to the patient on how 
the reaction could take place and 
how to treat it, thus increasing the 
patient’s quality of life. 
KEY REFERENCES
1. Bindslev-Jensen C, Ballmer-We-
ber BK, Bengtsson U, Blanco C, 
Ebner C, Hourihane J et al. Stand-
ardization of food challenges in 
patients with immediate reactions 
to foods – position paper from the 
European Academy of Allergology 
and Clinical Immunology. Allergy 
2004;59:690-697. 
2. Perry TT, Matsui EC, Conover-Walk-
er MK, Wood RA. Risk of oral food 
challenges. J Allergy Clin Immunol 
2004;114:1164-1168. 
3. Sampson HA, Gerth van Wijk R, 
Bindslev-Jensen C, Sicherer S, 
Teuber SS, Burks AW et al. Stand-
ardizing double-blind, place-
bo-controlled oral food challeng-
es: American Academy of Allergy, 
Asthma & Immunology–European 
Academy of Allergy and Clinical 
Immunology PRACTALL consen-
sus report. J Allergy Clin Immunol 
2012;130:1260-1274. 
4. Eigenmann PA, Caubet JC, Zamo-
ra SA. Continuing food-avoidance 
diets after negative food chal-
lenges. Pediatr Allergy Immunol 
2006;17:601-605. 
5. Niggemann B, Beyer K. Pitfalls 
in double-blind, placebo-con-
trolled oral food challenges. Allergy 
2007;62:729-732. 
Figure 2 Pastry containing a peanut butter or placebo cream prepared for a 
double-blind, placebo-controlled food challenge to peanuts.
In-vivo allergy diagnosis – food provocation tests
Immediate type clinical 
reaction < 1 year of age
Immediate type clinical 
reaction 1+ year of age
Late phase clinic reaction 
(AE & GI) at any age
Open food challenge DBPCFC
negative positive
Objective, immediate 
symptom
Subjective or  
late phase reaction
no diet diet
negative positive
no diet
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s • Aspirin (ASA) challenge tests are performed to confirm history 
of ASA hypersensitivity or to confirm/exclude cross-reactivity 
• Oral provocation test (OPT) with ASA is the gold standard, 
but may be substituted by inhaled or intranasal challenge with 
lysine-ASA in patients with respiratory type of reaction to non-
steroidal anti-inflammatory drugs (NSAIDs) 
• OPT can be also used for testing hypersensivity to other culprit 
NSAIDs or to assess tolerance to an alternative NSAIDs 
Oral provocation test (OPT) 
with aspirin (ASA) is the gold 
standard for the diagnosis of 
cross-reactive types of hypersen-
sitivity to NSAIDs, which include 
NSAIDs-exacerbated respiratory 
disease (NERD), NSAIDs-exacer-
bated cutaneous diseases (NECD) 
and NSAIDs-induced angioede-
ma/urticaria. In patients with 
single NSAIDs induced type of 
reactions, ASA is rarely a culprit 
drug, so OPT with the suspected 
NSAID may be performed. In pa-
tients with NERD, bronchial or 
nasal challenges with the soluble 
form of ASA (lysine-ASA) may be 
an alternative to OPT to confirm/
exclude NSAIDs hypersensitivity. 
ORAL PROVOCATION TEST 
Oral challenge with ASA is recom-
mended in patients with suspect-
ed respiratory  or cutaneous form 
of  reactions to NSAIDs. Appropri-
ate safety measures should be fol-
lowed and contraindications con-
sidered (Table 1). In patients with 
NERD, the two day protocol starts 
with placebo capsules adminis-
tered on the first day, every 1.5-2 
hours, with   FEV1 measured every 
30 minutes to establish baseline 
variability (Table 2). On the second 
day, the patient receives initially 
10-30 mg of aspirin and the dose is 
Marek L. Kowalski  
Medical University of Lodz 
Lodz, Poland
IN VIVO DIAGNOSIS OF  
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In vivo diagnosis of  NSAID hypersensitivity
doubled at 1.5 hours intervals, un-
til a positive reaction occurs, de-
fined by at least 20% fall in FEV1 
and /or extra-bronchial symptoms 
(nasal or ocular congestion, rhin-
orrhea, erythema of the skin, gas-
tro-intestinal symptoms). The test 
is negative if none of the above ap-
pears and the final ingested dose 
of 312 mg of ASA is well tolerated. 
A similar protocol, with extended 
intervals between ASA doses is 
indicated for the diagnosis of the 
cutaneous type of NSAIDs hyper-
sensitivity (Table 3).  
TESTING WITH OTHER NSAIDS 
OPT can be used for testing hyper-
sensitivity to other culprit NSAIDs 
or to assess tolerance to an alter-
native NSAIDs in patients with 
both cross-reactive and immu-
nologically-mediated reactions. 
Even if no immediate indications 
for treatment with NSAIDs exist, 
the potential patient’s need for an 
analgesic, antipyretic or anti-in-
flammatory treatment should be 
anticipated. Tests with alternative 
NSAIDs usually start with the oral 
administration of half of the ther-
apeutic dose followed by monitor-
ing in the doctor’s office up to two 
hours.
INHALATION PROVOCATION 
TEST  
In patients with NERD, inhalation 
or intranasal challenge with Lysine 
(L)-ASA (a soluble form of acetyl-
salicylic acid) can be used as an 
alternative to ASA-OPT (Figure 1)
The bronchial provocation test 
start with the inhalation of a dil-
uent, followed by increasing dos-
es of L-ASA administered using 
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In vivo diagnosis of  NSAID hypersensitivity
TABLE 1
Indications and contra indications to oral aspirin challenge in patients with 
NSAIDs hypersensitivity 
Indications
• Ambiguous or not clear history of response to aspirin/NSAIDs
• Confirmation/exclusion of cross-sensitivity  if aspirin is not a culprit NSAID
• Beginning of desensitization 
Contraindications 
• History of severe anaphylactic reactions induced by aspirin or other NSAIDs
• Not well controlled  underlying disease (asthma/urticaria) 
• Low  baseline FEV1 (below 70% of the predicted value )
• Severe delayed type reactions 
• Concomitant disorders potentially aggravated by the challenge    
TABLE 2
Protocol for the oral aspirin challenge in  a patient  with  suspected NSAIDs 
exacerbated respiratory diseases 
8:00 Placebo 10 mga 
9:30 Placebo 27 mg 
11:00 Placebo 44 mg 
12:30 Placebo 117 mg 
14:00 312 mg 
a Optional in patients with a  history of severe reaction to NSAIDs
TABLE 3
Protocol for oral aspirin challenge in  a patient  with  suspected NSAIDs 
exacerbated cutaneous disease
Time Day 1 Day 2 
8:00 Placebo 71 mg 
10:00 Placebo 117 mg 
12:00 Placebo 312 mg 
14:00 Placebo 500 mg 
a dosimeter at 30 minutes inter-
vals, allowing  to  complete the 
procedure in an outpatient set-
ting in less than 5 hours.  The test 
is considered positive, if at least 
20% drop in FEV1 is recorded at 
10, 20 or 30 minutes after inha-
lation. If the positive reaction is 
observed PD20 ASA is calculated 
from the dose-response curve. 
Inhalation challenge may induce 
extrabronchial symptoms and may 
also involve a late phase reaction. 
Both oral and inhaled tests have 
similar sensitivity and specificity 
but, as compared to the oral chal-
lenge, the inhalation test, is faster 
and safer to perform (the reaction 
is usually easily reversible with 
nebulized beta2 agonists). 
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Advantages Limitations 
Oral 
challenge
Gold standard  (reliable ) Risk of severe reaction
Useful in patients with extra 
bronchial symptoms 
Time-consuming
Bronchial 
challenge
Short  duration   (< 4  h) 
Only  in patients with 
bronchial/nasal symptoms
Reaction easily reversible
Requires special equipment 
(dosimeter)
Nasal 
challenge
Safe in patients with severe/ 
unstable asthma 
Only  in patients with 
bronchial/nasal symptoms
Not possible in patients with 
nasal obstruction 
The nasal provocation test with 
L-ASA  is particularly recommend-
ed in  asthmatic patients with  low 
pulmonary function not suitable 
for bronchial provocation. The 
challenge starts with instillation of 
saline followed by L-ASA solution 
increasing concentrations applied 
into each nostril every 30 minutes. 
All parameters (objective and 
subjective) are recorded every 10 
minutes.  Alternatively, ketorolac 
nasal spray solution can be used. 
For the assessment of the chal-
lenge, clinical symptoms are com-
bined with the objective measures 
of nasal airflow patency (acoustic 
rhinometry,  rhinomanometry or 
peak nasal inspiratory flow).
The reaction is considered posi-
tive, if clinical symptoms appear 
and/or a significant nasal obstruc-
tion is objectively documented (a 
25% decrease in total nasal flow or 
40% drop  of the inspiratory nasal 
flow, as compared to baseline). 
In experienced hands the sensi-
tivity of intranasal aspirin prov-
ocation may rise above 80%  and 
specificity approaches 95%,  thus 
reaching the performance of the 
bronchial challenge. 
The nasal challenge route is not 
recommended in patients with 
significant nasal obstruction, tur-
bulent nasal flow or with unspecif-
ic nasal responsiveness.
KEY REFERENCES 
1. Kowalski ML, Asero R, Bavbek S, 
Blanca M, Blanca-Lopez N, Bo-
chenek G et al. Classification and 
practical approach to the diagnosis 
and management of hypersensitiv-
ity to nonsteroidal anti-inflamma-
tory drugs. Allergy 2013;68:1219-
1232.
2. Nizankowska-Mogilnicka E, Bo-
chenek G, Mastalerz L, Swierczyńs-
ka M, Picado C, Scadding G et al. 
EAACI/GA2LEN guideline: aspirin 
provocation tests for diagnosis of 
aspirin hypersensitivity. Allergy 
2007;62 :1111-1118.
3. Melillo G, Balzano G, Bianco S, 
Dahlen B, Godard P, Kowalski ML, 
et al. Oral and inhalation provoca-
tion tests for the diagnosis of aspi-
rin-induced asthma.  Allergy 2001; 
56:899-911.
4. Lee RU, White AA, Ding D, Dursun 
AB, Woessner KM, Simon RA, et 
al. Use of intranasal ketorolac and 
modified oral aspirin challenge for 
desensitization of aspirin-exac-
erbated respiratory disease. Ann 
Allergy Asthma Immunol 2010;105: 
130-135.
Figure 1 Advantages and limitations of oral, bronchial and intranasal  route of aspirin challenge 
in patients with NSAIDs- exacerbated respiratory disease.
In vivo diagnosis of  NSAID hypersensitivity
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• For many drug hypersensitivity reactions, no sensitization can 
be demonstrated
• A drug provocation test is the controlled administration of a drug 
for diagnostic purposes 
• It is the golden standard to confirm or exclude drug 
hypersensitivity
• Specific protocols are available for several drugs
• A drug provocation test is often the only reliable way to establish 
a diagnosis and should be considered after risk-benefit analysis
BACKGROUND AND 
INDICATIONS
A drug hypersensitivity (DH) re-
action is particularly difficult to 
prove, as the history may be un-
reliable and for many drugs and 
reactions no sensitization can be 
demonstrated by skin tests or 
in-vitro tests. A drug provoca-
tion test (DPT) is performed: a) to 
exclude DH in a non-suggestive 
history (e.g. unspecific symptoms 
arising after intake of a penicillin), 
b) if a cross-reactivity in proven 
hypersensitivity has to be exclud-
ed (e.g. to other pain medications 
in acetylsalicylic acid hypersen-
sitivity), c) if a firm diagnosis in 
suggestive history of DH with neg-
ative, non-conclusive or non-avail-
able allergological tests shall be 
established (Table1). It is consid-
ered to be the gold standard for 
DH diagnosis, required when oth-
er allergy tests do not allow rele-
vant conclusions. 
PROCEDURE
A drug provocation test (DPT) is 
the controlled administration of 
a drug for diagnostic purposes, 
performed under close medical 
surveillance with emergency med-
ication available and always after 
an individual risk-benefit analysis. 
Requirements for a DPT include 
Knut Brockow   
Technische Universität München  
München, Germany
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In vivo allergy diagnosis - drug provocation test
the possibility to hospitalize pa-
tients, experience with emergen-
cy treatment, consideration of 
pharmacological effects of tested 
drugs, exclusion of contraindi-
cations, informed consent of the 
patient and sufficient wash-out 
interval from anti-allergic medi-
cation. It is a high risk procedure 
as it induces symptoms similar to 
the original ones, albeit normally 
milder because of initially low and 
fractionated doses and immediate 
treatment (Figure 1, Table 2). 
The oral provocation test is the 
preferred route for most DPTs, 
although subcutaneous (e.g. for 
local anaesthetics, heparins, in-
sulins), local or even intravenous 
provocations (e.g. for heparin) 
are possible. The time interval be-
tween dose escalations and the 
Figure 1 Mild generalized acute 
urticaria after oral drug provocation 
test with 500 mg acetylsalicylic acid 
(as in Aspirin®) in a patient with 
reported drug hypersensitivity to 
another potentially cross-reacting 
pain medication.
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duration of provocation have to be 
determined considering the origi-
nal reaction and suspected mech-
anism. 
General guidelines for perform-
ing DPT have been published and 
specific protocols are available for 
some drugs, such as betalactam 
drugs, nonsteroidal anti-inflam-
matory drugs or radiocontrast 
media. 
INTERPRETATION
In the majority of patients, DH can 
be excluded by DPT. In some pa-
tients, the reappearance of reac-
tions confirms the diagnosis. False 
positive and false negative results 
to DPTs are possible. In medicine, 
a DPT can never guarantee toler-
ance in 100% of patients, but helps 
to decide, if lifelong avoidance is 
justified. Studies evaluating the 
validity of the DPT show that the 
majority of patients (>95%) toler-
ated the drug in real life, if there 
were no reaction in the DPT and 
conclude that this test is beneficial 
for the patient.
KEY REFERENCES
1. Aberer W, Bircher A, Romano A, 
Blanca M, Campi P, Fernandez J et 
al. Drug provocation testing in the 
diagnosis of drug hypersensitivity 
reactions: general considerations. 
Allergy 2003;58:854-863.
2. Messaad D, Sahla H, Benahmed 
S, Godard P, Bousquet J, Demoly 
P. Drug provocation tests in pa-
tients with a history suggesting 
an immediate drug hypersensi-
tivity reaction. Ann Intern Med 
2004;140:1001-1006.
3. Joint Task Force on Practice Pa-
rameters; American Academy of 
Allergy, Asthma and Immunology; 
American College of Allergy, Asth-
ma and Immunology; Joint Council 
of Allergy, Asthma and Immunolo-
gy: Drug allergy: an updated prac-
tice parameter. Ann Allergy Asthma 
Immunol 2010;105:259-273.
TABLE 1
Indications for a drug provocation test 
• To exclude hypersensitivity in non-suggestive history of drug hypersensitivity 
• To exclude cross-reactivity of related drugs in proven hypersensitivity
• To establish a firm diagnosis in suggestive history of drug hypersensitivity with 
negative, non-conclusive or non-available allergological tests
• Validation of the history and other allergological tests (reference standard)
Modified from Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the 
diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58: 
854-863.
TABLE 2
Clinical reactions to drug provocation tests in 241 patients with confirmed drug 
hypersensitivity
Manifestation Number (Percentage)
Urticaria 160 (66.4%)
Maculopapular exanthema 22 (9.1%)
Bronchospasm 9 (7.9%)
Laryngeal edema 10 (4.1%)
Anaphylaxis without shock 17 (7%)
Anaphylatic shock 13 (5.4%)
In vivo allergy diagnosis - drug provocation test
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• A challenge in the allergen challenge chamber (ACC) affects 
several target organs of type I allergy
• A stable and reproducible allergen load in the ACC is the basis for 
consistent subjective symptom scores
• Challenge sessions with comparable meaningful results are 
possible all over the year 
• ACC enables to obtain objective parameters supporting 
subjective symptom scores
• ACC can monitor specific immunotherapy and pharmacotherapy
• ACC can reduce the cost of drug development
In contrast to several other prov-
ocation tests, allergen challenge 
chamber (ACC) tests are not fo-
cused on single organs, but on 
several targets of type I allergic 
reactions like eyes, upper and 
lower respiratory tract and even 
skin. In contrast to other allergy 
tests, ACCs are usually not ap-
plied for individual diagnosis, but 
for assessing allergic treatments, 
studies in occupational allergy and 
basic research.
At present, there are twelve  ACCs 
active in Europe, USA, Canada and 
Japan (Figure 1). There is a broad 
conformity between the systems, 
although individual differences 
are to be mentioned. All ACCs are 
validated for pollen challenges like 
grass/ birch/ragweed or Japanese 
cedar pollen; some are also vali-
dated for house dust mite or even 
for cat (Figure 2).
The main common feature of all 
ACCs is a pre-defined and stable 
allergen concentration in the air, 
which has to be high enough to 
induce symptoms in sensitized 
subjects.  In addition, the allergen 
concentration climatic conditions 
like temperature, humidity and 
CO2 concentration are kept sta-
ble over several hours. All param-
eters are constantly controlled to 
Friedrich Horak  
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The allergen challenge chamber
ensure high reproducibility of the 
ACC model. During a challenge 
session patients record their sub-
jective symptoms several times an 
hour with good compliance. There 
is usually no application of rescue 
medication, which could possibly 
complicate the interpretation of 
the symptom score. Usually nasal, 
ocular and/or bronchial symptoms 
are scored using a 4-point scale (0 
to 3).
A challenge session lasts at least 
two hours, because by then a pla-
teau is normally reached in all of 
the patients’ symptoms, which will 
then not vary, if the allergen load is 
kept stable. This plateau-reaction 
is usually monitored for two to six 
hours (Figure 3).
In contrast to field or park studies, 
it is possible to additionally monitor 
and report objective assessments 
during the challenge sessions. These 
objective parameters offer the 
opportunity to check the proper-
ness and accuracy of the subjective 
scoring (Table 1). Furthermore, it is 
possible to take blood samples at 
several time points of the challenge 
session to follow the ongoing aller-
gic reaction.
The ACC model is approved by the 
FDA and EMA, at least for phase 
II trials and further supporting 
phase III trials. EMA suggests ACC 
trials for conducting dose finding 
trials of immunotherapeutic prod-
ucts. Potential fields of application 
of ACC trials, however, can be 
more extensive (Table 2).
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ACC can monitor specific immu-
notherapy and reduce the cost of 
drug development substantially, 
not only by proof of concept stud-
ies. Requiring significantly less 
time than field studies and small-
er numbers of individuals per trial 
are the essential arguments for 
application of ACCs. Besides sev-
eral advantages some disadvan-
tages are to be mentioned (Table 
3). The standardization of several 
ACCs worldwide and the “be-
tween-unit” reproducibility are 
still unmet targets.
KEY REFERENCES
1. Day JH, Horak F, Briscoe MP, Ca-
nonica GW, Fineman SM et al. The 
role of allergen challenge chambers 
in the evaluation of anti-allergic 
TABLE 1
Objective assessments performed 
in an ACC
Rhinomanometry
Spirometry
Peak Expiratory Flow (PEF)
Nasal secretion weight
Nasal scraping
Nasal lavage
Nasal Peak Inspiratory Flow (NPIF)
Slit lamp investigation
Conjunctival imaging
Digital Endoscopy
Acoustic rhinometry
Blood samples (drug level, 
mediators,…)
Figure 1 Distribution of Allergen 
Challenge Chambers in the World.
Figure 2 The Vienna Challenge Chamber (VCC)
The allergen challenge chamber
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TABLE 2
Documented clinical trials in an 
ACC
Proof of concept
Dose finding
Onset of action
Magnitude and duration of action
Additive treatments
Pharmacodynamics
Pharmacokinetics
Competitive trials
TABLE 3
Possible environmental factors influencing development of allergic diseases
Advantages Disadvantages and unmet needs
Exposure to a defined, controlled 
level of allergen
Potential effects of claustrophobia 
or the influence of other subjects on 
subjective symptom scores 
Out-of-season use for seasonal 
inhalant allergens and the ability 
to save up to 12 months in the 
development programme
Short exposure times (no more than 
several hours)
Rescue medication use can be 
prohibited or suspended during the 
challenge
A potentially abrupt challenge 
Ability to collect biological samples 
from participants
Lack of seasonal priming in out-of-
season challenges 
Investigation of dose-ranging and 
onset of action
Low number of operational ACCs 
worldwide
Overall cost and ethical benefits due 
to use of lower number of subjects 
than in natural-exposure trials
Lack of standardization between the 
different ACCs in the World
medication: an international con-
sensus paper. Clin Exp Allergy Re-
views 2006;6:31-59.
2. Ellis AK, North ML, Walker T, Stea-
cy LM. Environmental exposure 
unit: a sensitive, specific, and re-
producible methodology for aller-
gen challenge. Ann Allergy Asthma 
Immunol 2013;111:323-328.
3. Hohlfeld JM1, Holland-Letz T, Lar-
big M, Lavae-Mokhtari M, Wieren-
ga E, Kapsenberg M et al. Diag-
nostic value of outcome measures 
following allergen exposure in an 
environmental challenge chamber 
compared with natural conditions. 
Clin Exp Allergy 2010;40:998-1006.
4. Devillier P, Le Gall M, Horak F. The 
allergen challenge chamber: a valu-
able tool for optimizing the clinical 
development of pollen immuno-
therapy. Allergy 2011;66:163-169.
5. Yuki A, Terada T, Ichihara T, Fujii 
K, Hyo S, Kawata R, et al. Evaluat-
ing the effects of testing period on 
pollinosis symptoms using an aller-
gen challenge chamber. Allergol Int 
2011;60:533-539.
6. Bernstein JA. Correlation between 
a pollen challenge chamber and a 
natural allergen exposure study 
design for elicting ocular and nasal 
symptoms: early evidence support-
ing a paradigm shift in drug investi-
gation? J Allergy Clin Immunol 2012; 
130:128-129.
Figure 3 Total Nasal Symptom Score 
(TNSS) of > 500 subjects with placebo 
treatment.
The allergen challenge chamber
166
Global atlas oF allerGy
se
c
t
io
n
 c
 - 
A
lle
rg
y 
d
ia
gn
o
si
s • Elevated serum levels of allergen-specific IgE demonstrate 
the atopic status of a patient and are indicative for an eventual 
clinically significant allergy 
• Determination of allergen-specific IgE in serum allows rapid 
screening of the sensitization spectrum of a patient without risks 
for adverse reactions 
• Multiplex specific IgE measurements to pure natural 
or recombinant allergens allow a component-resolved 
diagnostics, which can be useful to design a patient-tailored 
immunotherapeutic intervention
• For allergy diagnosis elevated allergen-specific serum IgE levels 
need to be interpreted in the light of clinical history. In some 
cases, in vivo provocation tests performed with the suspected 
allergen are needed to confirm the diagnosis 
The breakthrough allowing the 
development of highly specific and 
sensitive in vitro tests for allergic 
diseases was the discovery of the 
‘‘reaginic antibody’’ termed immu-
noglobulin E (IgE) more than 40 
years ago. The prototype for the 
in vitro detection of serum IgE (the 
Reto Crameri  
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In vitro allergy diagnosis – allergen-specific IgE
radioallergosorbent test, RAST) 
first described in 1967 used a pa-
per disc as a solid phase to cova-
lently immobilize the allergen fol-
lowed by the addition of patient’s 
serum. After different washing 
procedures to remove unbound 
serum proteins and antibodies, 
bounded IgE was detected with 
125I-labelled polyclonal anti-hu-
man IgE (Figure 1). Modern assays 
for the detection of allergen-spe-
cific IgE have undergone impres-
sive improvements including the 
calibration against the WHO 
Standard 72/502, allowing quan-
titative determinations, and the 
implementation of fully automat-
ed devices (Figure 2). To date the 
most commonly used system to 
determine allergen-specific IgE is 
the ImmunoCAP system (Thermo 
Fisher Scientific, Uppsala) con-
sidered as the “gold standard” for 
the in vitro diagnosis of allergic 
conditions. More recently, novel 
diagnostic tests based on allergen 
microarrays have been introduced 
both in research and clinical prac-
tice. Multiplex-based in vitro tools 
for allergy diagnosis allow a com-
ponent resolved diagnostics of the 
atopy status of a patient in a cost 
effective way. 
Figure 1 Typical immunoassay for 
the detection of allergen-specific 
IgE in three steps: 1) the allergen is 
adsorbed and immobilized to a solid 
phase, 2) patient’s serum is added 
followed by incubation during 30-60 
min and several washing steps and 3) 
allergen-bound IgE is detected by an 
enzymatically labelled anti-human IgE 
monoclonal antibody (      ). 
1) Allergen
2) Serum
3) Labelled anti-human IgE
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Despite the relevant technological 
improvement, several problems 
related to the in vitro diagnosis of 
allergy remain unsolved (Figure 
3).  Allergen-specific IgE in serum 
is a marker for sensitization and a 
Figure 2 Most commonly used techniques for the detection of allergen-
specific IgE used in research and clinics. All techniques are based on the 
immunoassay principle described in Figure 1. 
Allergen- 
Specific 
IgE
Basophil 
Activation 
tests 
Allergen 
Challenge 
tests 
Allergic 
Disease 
Chronic
Allergic 
Disease 
Sensitization 
Cell activation / mediator release 
In vivo cell activation / mediator release 
Inflammation / hypersensitivity 
Tissue remodelling 
Figure 3 Steps involved in the development of allergic diseases. A switch 
to the production of allergen-specific IgE detectable in serum leads to the 
sensitization of a patient, reflecting its atopic status. However, not all sensitized 
individuals suffer from allergic symptoms highlighting the limitation of in 
vitro allergy diagnoses. Allergen challenge tests are needed to confirm the 
clinical relevance of an allergy suspected from the clinical history and from the 
presence of allergen-specific IgE in serum. (Reproduced with permission from 
Bousquet J, Anto JM, Bachert C,et al. Factors responsible for differences between 
asymptomatic subjects and patients presenting and IgE sensitization to allergens: a 
GA2LEN project. Allergy 2006:61;671-680, with permission from Willey Blackwell.)  
prerequisite for the development 
of an IgE-mediated allergy, but is 
not sufficient for the induction 
of symptoms. In fact, more than 
20% of the individuals with aller-
gen-specific serum IgE are asymp-
tomatic. We should be aware that 
allergen-specific serum IgE is bi-
ologically irrelevant as long as it 
doesn’t bind to the high affinity 
receptor for IgE on effector cells. 
Therefore, the presence or the 
absence of allergen-specific IgE in 
serum is not sufficient to confirm 
or exclude an allergy in all cases. 
At the current state of the art, it is 
worthwhile to maintain a healthy 
scepticism about allergy diagnos-
tic test results solely based on the 
determination of allergen-specif-
ic serum IgE levels and to let the 
clinical history, corroborated by 
adequate provocation tests, which 
drive the diagnosis before consid-
ering immunotherapeutic inter-
ventions. 
KEY REFERENCES
1. Ishizaka K, Ishizaka T. Identification 
of gamma-E antibodies as a carri-
er of reaginic activity. J Immunol 
1967;99:1187–1198.
2. Wide L, Bennich H, Johansson SG. 
Diagnosis of allergy by an in-vitro 
test for allergen antibodies. Lancet 
1967;2:1105-1107. 
3. Shreffler WG. Microarrayed re-
combinant allergens for diagnos-
tic testing. J Allergy Clin Immunol 
2011;127:843-849.
4. Bousquet J, Anto J, Bachert C, 
Bousquet PJ, Colombo P, Crameri R 
et al. Factors responsible for differ-
ences between asymptomatic sub-
jects and patients presenting and 
IgE sensitization to allergens: a GA-
2LEN project. Allergy 2006:61;671-
680. 
5. Crameri R. The crux with a reliable 
in vitro and in vivo diagnosis of al-
lergy. Allergy 2013:68;393-394. 
In vitro allergy diagnosis – allergen-specific IgE
ELISA-Plates Research
Western blots Research
Strips Commercial
ImmunoCAPs Commercial
Microarrays Commercial
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of paradigm in diagnosing IgE-mediated allergies
• Component-resolved analysis of the specific IgE response provides 
a more individualized and stratified diagnosis of allergic patients
• Component-resolved diagnosis (CRD) of the specific IgE response 
improves the  sensitivity, specificity and clinical performance of 
the laboratory assay 
• CRD has the potential to better select patients for 
immunotherapy, to predict the risk for severe allergic reactions 
and to monitor patients for immunotherapy outcome
The history of in vitro (laboratory) 
tests for allergy diagnosis started 
in the early seventies, soon after 
the discovery of IgE in 1967. The 
first generation assays, starting 
from the very first RAST, allowed 
researchers and allergists to im-
prove the diagnosis of IgE-medi-
ated diseases. The first generation 
IgE assays were mainly based on 
allergenic extracts – a mixture 
of allergenic and non-allergenic 
compounds derived from natural 
sources (e.g. a pollen extract). 
A great step forward to a broader 
use of in vitro diagnosis in allergy 
was achieved in the early nine-
ties, when the more reliable sec-
ond generation assays appeared 
in laboratories worldwide and in 
parallel a new kind of test reagent 
started to be available. In fact, 
during the nineties an increasing 
number of allergenic molecules 
have been identified, character-
ized and, most important, progres-
sively translated into the daily use 
in diagnosis (Figure 1A). Most of 
the available allergenic molecules 
have been obtained by using the 
recombinant DNA technology, 
allowing cloning and production 
of recombinant allergens in a re-
producible large scale. Within the 
last decades, allergenic molecules 
IN VITRO ALLERGY DIAGNOSIS – 
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have been increasingly used in re-
search and clinical studies leading 
to a cumulative number of scientif-
ic publications (Figure 1B). 
This knowledge is now displayed 
in several free accessible inter-
net-based resources documenting 
the magnitude of the worldwide 
allergy health problem (Table 1). 
The most recent keystone im-
provement in this area has been 
the application of microtechnolo-
gy to in vitro diagnosis of IgE-me-
diated diseases. In the last decade, 
a new tool has become available 
to allergists allowing them the 
parallel diagnosis on hundreds of 
allergenic molecules from a huge 
collection of allergenic sources in 
a single test run (Figure 2). This 
multiplex microarray test is now 
available worldwide and allows 
allergic patients to be tested with 
the same panel of allergens re-
gardless of age, gender and kind of 
allergen and route of exposure. 
Within the last decade, multi-
ple studies from many countries 
around the world independently 
reported an added diagnostic val-
ue by using molecular components 
for in vitro allergy diagnosis in the 
singleplex test systems – the more 
traditional approach in allergy 
laboratory testing. This progress 
became mainly evident in some of 
the most severe allergic diseases 
such as anaphylaxis due to food 
intake or insect stings, which can 
result in fatal outcome. Through 
the advent of molecular technolo-
gies, some of the weaknesses and 
Markus Ollert  
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Figure 1 A - Cumulative number of identified allergenic molecules during the last three decades. (source: www.
allergome.org); B - Number of scientific papers on identification, characterization and clinical use of allergenic molecules 
per year published in the last three decades. 
Figure 2 The new microtechnology-based tool used to detect specific IgE.  
Allergenic molecules, represented by proteins available as purified natural 
compounds or recombinants, are immobilized as microspots (200 μm in 
diameter) on a solid phase area of 7 x 10 mm and are grouped by sources and 
tissues and also on the basis of their biochemical structure and their IgE epitope 
sharing. It is thus possible to visualize the IgE cross-reactivity, now better-
defined as IgE co-recognition, as a cluster of fluorescent spots. The extension 
of cluster IgE recognition can help clinical decision on whether an allergenic 
source must be avoided or not.
shortcomings of the classical diag-
nostic algorithm, which was solely 
based on allergenic extracts from 
nature, could be solved in terms 
of assay sensitivity, specificity and 
prediction of clinical severity and 
risk. Nowadays, several prominent 
examples exist, where the meas-
urement of sIgE to molecular aller-
gen components is a recommend-
ed state-of-the-art procedure 
within the algorithm for clinical 
decision-making (Table 2). 
From a global perspective – de-
spite the immense progress that 
has been achieved in the field of 
molecular allergy in vitro testing 
within the last two decades – there 
is a clinical and research need for 
a better reflection of allergenic 
molecules based on regional dif-
ferences in the world. Not all aller-
gens are global, some of them are 
regional, but still can cause severe 
allergic disease. This new era of 
allergy diagnosis, which calls for 
a global definition of allergenic 
source and molecules, has already 
been entered. The analysis of such 
wealth of data is now possible by 
using advanced information and 
communication technologies, 
which will ultimately result in bet-
ter care for allergic patients.
170
Global atlas oF allerGy
se
c
t
io
n
 c
 - 
A
lle
rg
y 
d
ia
gn
o
si
s
TABLE 2
Molecular components or allergens with a demonstrated utility for clinical decision making in various allergic 
conditions
Allergic Disease
Molecular 
Component / 
Allergen
Diagnostic Problem Solved
Countries of Major 
Studies 
Insect venom 
anaphylaxis
Api m 1, Ves v 1, Ves 
v 5, Pol d 5
Better differentiation of honey bee and vespid 
venom double-sensitized patients
GER, SUI, AUT, SLO, 
USA, ITA, POL, ESP
Insect venom 
anaphylaxis
Ves v 5
Increased sIgE assay sensitivity through spiking of 
vespid venom with rVes v 5
GER, SUI, AUT
F/WDEIA Tri a 19 Marker allergen for food-/wheat-dependent 
exercise-induced anaphylaxis (F/WDEIA)
JAP, FIN, DAN, GER, 
SUI
Peanut allergy Ara h 2, Ara h 6 Predictive marker allergens for severe reactions to 
ingested peanut
USA, GBR, GER, 
AUS
Allergy to red meat α-Gal Marker allergen for delayed anaphylactic reactions 
to red meat and offal
USA, SWE, GER, 
AUT
Pollen Allergy; Insect 
venom anaphylaxis
CCD
Marker for broad IgE-based cross-reactivity without 
clinical relevance
ITA, NED, GER, AUT
Insect venom 
anaphylaxis
Api m 10, Api m 3
Prediction of patients at risk for therapeutic failures 
in honey bee venom immunotherapy
GER, SUI
Abbreviations and explanations:
Tri a 19, wheat allergen ω-5 gliadin; α-Gal, mammalian carbohydrate determinant (galactose-α-1,3-galactose); CCD, carbohy-
drate cross-reactive determinants (β-1,2-xylose and α-1,3-fucose); Api m 1, 3, 10, honey bee venom allergens Phospholipase A2, 
Acid Phosphatase, Icarapin; Ves v  1, 5, vespid venom allergens Phospholipase A1, Antigen 5; Pol d 5, Polistes venom allergen 
Antigen 5; Ara h 2, 6, major peanut allergens storage protein allergens.
TABLE 1
Comprehensive allergen databases providing free access.
Database URL Target/Function
WHO/IUIS Allergen 
Nomenclature Sub-
Committee
http://www.allergen.org/
Responsible for maintaining and developing a unique, 
unambiguous and systematic nomenclature for allergenic 
proteins
ALLERGOME http://www.allergome.org/
A web site designed to supply information on allergenic 
molecules (allergens) for clinicians and researchers
AllergenOnline
http://www.allergenonline.
org/
Provides access to a peer reviewed allergen list and sequence 
searchable database
AllFam
http://www.meduniwien.
ac.at/allergens/allfam/
The AllFam database is a resource for classifying allergens into 
protein families (based on the Allergome website)
Abbreviations and explanations:
WHO, World Health Organization; IUIS, International Union of Immunological Societies.
KEY REFERENCES
1. Mari A. When does a protein be-
come an allergen? Searching for a 
dynamic definition based on most 
advanced technology tools. Clin Exp 
Allergy 2008;38:1089-1094.
2. Scala E, Alessandri C, Bernardi 
ML, Ferrara R, Palazzo P, Pomponi 
D et al. Cross-sectional survey 
on immunoglobulin E reactivity 
in 23 077 subjects using an aller-
genic molecule-based microarray 
detection system. Clin Exp Allergy 
2010;40:911-921.
3. Koid AE, Chapman MD, Hamilton 
RG, Van Ree R, Versteeg SA, Dre-
skin SC et al. Ara h 6 complements 
Ara h 2 as an important marker 
for IgE reactivity to peanut. J Ag-
ric Food Chem 2013 Dec 11. [Epub 
ahead of print].
4. Grunwald T, Bockisch B, Spillner E, 
Ring J, Bredehorst R, Ollert MW. 
Molecular cloning and expres-
sion in insect cells of honey bee 
venom allergen acid phosphatase 
(Api m 3). J Allergy Clin Immunol 
2007;117:848-854.
In vitro allergy diagnosis – molecules and component-resolved diagnosis
171
Global atlas oF allerGy
se
c
t
io
n
 c
 - A
llergy d
iagn
o
sis 
• Cellular allergy tests expand the tools of the allergist to diagnose 
and monitor allergic disease
• The basophil activation test (BAT) documents type I sensitisation 
to an allergen, as fraction of blood basophils activated by soluble 
allergen
• Measuring basophil sensitivity as activation at graded dilutions of 
allergen expands the options since sensitivity to allergen is a more 
reproducible metric of allergic disease than provocation testing. 
It can be used to identify sufficiently sensitised individuals and to 
monitor natural and therapeutic resolution of allergy
• Identification of culprit drugs in T cell mediated Type IV drug 
allergy by Elispot or flow cytometry is only available at very few 
laboratories
Cellular allergy testing is essen-
tially induction of the allergic 
response in a test tube. As any in 
vitro test, it has the advantage of 
quantifying the allergic response 
without any risk to the patient. 
The most common cellular test 
applied is basophil activation by 
allergen (BAT) (Figure 1). This is 
used when the patient history 
and specific IgE or skin tests are 
discordant, when there is no reli-
able specific IgE or skin test, or if 
the patient history indicates that 
skin tests may elicit a systemic re-
sponse. Determination of basophil 
sensitivity with serial dilutions 
of allergen can be used to meas-
ure the point of inflection or half 
maximal allergen concentration as 
measure of allergic response. This 
is a more reproducible measure of 
allergic disease than provocation 
testing. Basophil sensitivity can 
be used to identify food allergens, 
the primary sensitizer amongst 
cross-reacting allergens or aller-
gen preparations and to monitor 
progress of allergen immunother-
apy and anti-IgE therapy (Figure 
2). 
Basophil activation is measured 
as either histamine release or as 
upregulation of granule proteins 
to the cell surface in response 
Hans Jürgen Hoffmann  
Aarhus University Hospital 
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to allergen exposure. The most 
common antigen to be measured 
on the surface of blood basophils, 
which are identified as CD193 or 
CD203c positive cells in whole 
blood is the tetraspannin, CD63. 
CD63 resides in the same vesicles 
as histamine in blood basophils 
and in tissue mast cells. 
For optimal performance, intro-
duction of basophil activation 
including setting up the flow cy-
tometer should be done in the 
context of the existing network of 
units offering this service. There is 
a strong movement toward stand-
ardisation of measurement of ba-
sophil activation by flow cytome-
try, embodied amongst others by 
the EAACI-EuroBAT meetings and 
an EAACI Task Force on this top-
ic.  Contribution to and complying 
with standardisation will enhance 
the quality of this recent diagnos-
tic tool for allergy diagnosis.
Type IV reactions to drugs can be 
severe and it is important to iden-
tify the eliciting allergen in these 
patients. This is done with the 
lymphocyte transformation test, 
but increasingly also by Elispot 
and with flow cytometric tech-
niques. These analyses remain in 
the hands of specialised units that 
deal with these severely afflicted 
patients.
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J, Roos D. Monitoring human ba-
sophil activation via CD63 mono-
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Immunol 1991;88:328–338. 
2. Hausmann OV, Gentinetta T, Bridts 
CH, Ebo DG. The basophil activa-
tion test in immediate-type drug 
allergy. Immunol Allergy Clin North 
Am 2009;29:555–566. 
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peanut challenge identifies an 
allergy but the peanut allergen 
threshold sensitivity is not repro-
ducible. PloS One 2013;8:e53465. 
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Cultured Human Mast Cells Are 
Heterogeneous for Expression 
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tor FcεRI. Int Arch Allergy Immunol 
2012;157:246–250. 
5. Porebski G, Gschwend-Zawodniak 
A, Pichler WJ. In vitro diagnosis of T 
cell-mediated drug allergy. Clin Exp 
Allergy 2011;41:461–470. 
Figure 1 Basophil activation in clinical diagnosis of allergy to celery. Patient (left) with negative (green) and positive 
(blue) controls, and allergen response in red is reactive. A tolerant control person is shown on the right (unpublished). 
Figure 2 Anti-IgE treatment monitored with basophil sensitivity to allergen. Before treatment the patient was 
extremely sensitive (red) and after two months of treatment both sensitivity and reactivity had decreased (green). Rubak 
and Hoffmann, unpublished.
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• Novel biomarkers, as well as appropriate biomarker combinations 
are important to improve allergy diagnosis and treatment
• Classifying allergic diseases into several endotypes and using 
appropriate biomarkers to evaluate the molecular target for 
endotype will increase drug effectiveness
• Fractional exhaled nitric oxide is considered a surrogate 
biomarker for eosinophilic airway inflammation and for steroid 
responsiveness in asthma patients
• Periostin has emerged as a surrogate biomarker of type 2 
inflammation and tissue remodeling in asthma
Biomarkers are used to diagnose 
diseases, estimate disease se-
verity, or investigate underlying 
inflammation types, thus predict-
ing the efficacy of therapeutics. 
For example, measuring a specific 
IgE or urinary leukotriene E4 is 
important for diagnosis of atopic 
status or aspirin-sensitive asthma, 
respectively. Discovering novel 
biomarkers, as well as finding ap-
propriate combinations with ex-
isting biomarkers, is an important 
goal in allergy research aiming to 
improve diagnosis and treatment.
“Companion diagnostics”, which 
can predict therapeutic efficacy, 
is now being widely recognized 
due the development of molecular 
targeted drugs against allergic dis-
eases, particularly asthma. These 
drugs, mostly biologics, are expen-
sive and are effective only for par-
ticular types of patients. It is now 
thought that asthma is not a single 
disease, but a “syndrome.” Thus, 
it is important to classify asthma 
into several endotypes, based on 
their pathogenesis, and evaluate 
for which endotype, using the ap-
propriate biomarkers each mo-
lecular targeted drug is effective 
using the appropriate biomarkers.
Although inhaled corticosteroids 
(ICS) provide beneficial effects for 
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most asthma patients, 5-10% of 
patients are resistant or hypo-re-
sponsive to ICS. Any biomarker in-
dicating the cause of the resistance 
to ICS would be useful. Moreover, 
biomarkers that can predict asth-
ma relapse upon steroid reduction 
would be also valuable. Eosino-
philc airway inflammation is at 
least one factor associated with 
steroid responsiveness. Fractional 
exhaled nitric oxide (FeNO) is con-
sidered a surrogate biomarker for 
eosinophilic airway inflammation 
and is regarded as a biomarker for 
steroid responsiveness (Figure 1). 
Although still controversial, the ac-
cumulated evidence has suggested 
that FeNO is useful for assessing 
control with ICS, predicting relapse 
upon ICS reduction, and estimating 
lung function.  
Periostin, a downstream molecule 
of IL-4 and/or IL-13, has emerged 
as a surrogate biomarker of type 
2 inflammation and tissue remod-
eling in bronchial asthma. It has 
been shown that serum perios-
tin can predict the efficacy of an-
ti-IL-13 antibody (lebrikizumab) 
and anti-IgE antibody (omalizum-
ab), thus proving a prototype bi-
omarker for the companion diag-
nostic of allergic diseases (Figure 
2). Moreover, high serum periostin 
is linked to hypo-responsiveness 
for ICS, particularly in late-onset 
eosinophilic asthma (Figure 3). In 
addition to periostin, sputum eo-
sinophils are useful for estimating 
the efficacy of anti-IL-5 antibody 
(mepolizumab). 
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Genetic biomarkers, such as the 
filaggrin gene for skin barrier dys-
function or the glucocorticoid-in-
duced transcript 1 gene for re-
sponsiveness to steroid therapy, 
represent another avenue to be 
explored in allergy research.
KEY REFERENCES
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ers. J Allergy Clin Immunol 2012; 
129:S9-23.
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FeNO <25 ppb 25-50 ppb 50< ppb
Symptoms (+)
Consider 
alternative 
diagnosis
Uncontrolled Uncontrolled
Symptoms (-)
Well controlled
Consider taper 
or withdrawal
Well controlled
Risk of relapse 
upon ICS 
reduction
Serum periostin High Low
Anti-IL-13 antibody
(lebrikizumab)
Responsive No responsive
Anti-IgE antibody
(omalizumab)
Responsive No responsive
Asthma patients
Other agents
Th2 antagonists
ICS
Low
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Effective
Ineffective
Measurement of 
serum periostin levels
Figure 1 A treatment guideline 
for adult asthma patients based on 
existing symptoms and FeNO levels 
(Modified from Ref. 4)
Figure 2 Serum periostin as a biomarker to select Th2 antagonists for asthma patients Upper panel: Responsiveness 
in asthma patients to Th2 antagonists depending on serum periostin is depicted. Patients showing high serum periostin 
are responsive to anti-IL-13 antibody (lebrikizumab) and anti-IgE antibody (omalizumab), whereas those showing low 
serum periostin are unresponsive to these agents. (Summarized from Corren J, Lemanske RF, Hanania NA, Korenblat PE, 
Parsey MV, Arron JR, Harris JM. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011 365; 12, 1088-1098, 
Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy D F. Exploring the effects of omalizumab in allergic asthma: 
an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013 187; 804-811) Lower panel: An algorithm 
of treatment of asthma patients is shown. The first choice for asthma patients is ICS. If the patients are resistant to ICS, 
measurement of serum periostin is recommended. If serum periostin is high, Th2 antagonists are recommended; if low, 
other agents are recommended.
Biomarkers for allergy diagnosis and treatment
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Figure 3 Serum periostin as a biomarker to predict responsiveness to ICS in asthma patients. Upper left panel: Serum 
periostin levels in rapid and non-rapid  FEV1 decliners are depicted (8). Upper right panel: Clustering of asthma patients 
based on peripheral neutrophils and eosinophils is depicted. Lower left panel: Characteristics of each subtype are shown. 
Lower right panel: Correlation between serum periostin and responsiveness to ICS in cluster 3 is depicted. (Reprinted from 
J Allergy Clin Immunol, 133/5, Nagasaki T, Matsumoto H, Kanemitsu Y et al. Integrating longitudinal information on pulmonary 
function and inflammation using asthma phenotypes, 1474-1477, Copyright 2014, with permission from Elsevier.) 
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Section D
MAJOR ALLERGIC DISEASES 
* Allergic rhinitis
* Chronic rhinosinusitis and nasal polyposis
* Ocular allergy 
* Pediatric Asthma
* Adult asthma
* Anaphylaxis
* Drug allergy
* Food allergy
* Atopic dermatitis
* Urticaria
* EAACI - GA2LEN - EDF - WAO Guideline on 
Urticaria
* Angioedema
* Allergic contact dermatitis
* Latex allergy
* Insect sting allergy
* Occupational allergy
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nasal mucosa
• Allergen-specific IgE and eosinophilic inflammation are key 
features of allergic rhinitis
• The allergic reaction extends beyond the nasal cavity, with 
conjunctivitis and asthma often being associated with allergic 
rhinitis 
• Treatment of allergic rhinitis aims at dampening the allergic 
immune response or inducing tolerance
Allergic rhinitis (AR) represents a 
global health care problem affect-
ing 10 to 20% of the total popu-
lation, making AR the most prev-
alent chronic non-communicable 
disease. Therefore, the economic 
impact of AR with significant di-
rect and indirect costs should not 
be underestimated. 
The diagnosis of AR is based on 
the history of the patient with 
minimally 2 nasal symptoms, with 
consistent findings at anterior rhi-
noscopy and positive skin prick 
test results or blood analysis for 
allergen-specific IgE. In AR, CD4+ T 
lymphocytes play a key role in the 
initiation and orchestration of the 
allergic immune response through 
the secretion of cytokines like IL-
4, IL-5, IL-10 and IL-13 (Figure 1). 
IL-4 is a cardinal cytokine in driv-
ing the sensitization to allergens 
by inducing the IgE class switch in 
B lymphocytes. The cross-linking 
of allergens with allergen-specif-
ic IgE on the surface of mast cells 
leads to a rapid release of pre-
formed mediators like histamine 
causing the symptoms of the early 
nasal response, i.e. sneezing, rhi-
norrhoea and nasal itching. Both 
histamine and tumor necrosis fac-
tor alpha (TNF-α), as well as newly 
generated lipid mediators like leu-
kotriene C4 and prostaglandin D2, 
contribute to the influx of inflam-
matory cells like eosinophils, CD4+ 
cells and basophils. The influx of 
these cells characterizes the late 
allergic response with mainly 
nasal obstruction as presenting 
symptom. Both allergen-specific 
IgE as well as eosinophilic nasal 
inflammation are features of AR 
and distinguish AR from other 
forms of rhinitis like infectious 
rhinitis, hormonal rhinitis, rhinitis 
medicamentosa, rhinitis in the el-
derly and non-allergic occupation-
al rhinitis. Recently, re gulatory T 
lymphocytes have been shown to 
be critical in the maintenance of 
immune responses. Naturally oc-
curring CD4+CD25+ regulatory T 
cells and/or IL-10 producing Tr-1 
cells suppress Th2 lymphocyte 
responses to allergens in health, 
whereas this inhibition is atten-
uated in allergic conditions. Suc-
cessful immunotherapy for Th2 
mediated allergic conditions is as-
sociated with the induction of IL-
10 and TGF-β producing Tr-1 cells. 
Other forms of medical treatment 
aim at suppressing the allergic in-
flammatory cascade. The major-
ity of AR is well controlled with 
guideline-based treatment. Sever-
al considerations need to be made 
in case of lack of control (Figure 2).
The allergic immune response in-
volves a nasal as well as systemic 
immune response. The systemic 
nature of the allergic immune re-
sponse with increased levels of 
IgE, IL-5 and blood eosinophilia 
has been recognized for several 
decades. In addition to nasal symp-
Peter W. Hellings   
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Allergic rhinitis
apeutic approach of rhinosinusi-
tis, tubal dysfunction and middle 
ear problems, laryngopharyngeal 
disorders and dysphonia. In view 
of the consideration of AR and al-
lergic asthma (AA) being part of 
the airway allergy syndrome, we 
have nowadays good insight into 
the epidemiologic association be-
tween these two co-morbidities, 
diagnostic requirements for con-
sidering the problem of upper or 
lower airways as one entity, and 
therapeutic implications for opti-
mal treatment of AR and AA. The 
immunologic mechanisms of the 
naso-bronchial interaction in-
volve the systemic blood circula-
tion as well as the naso-bronchial 
neural network.
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Figure 1 Mechanisms of immediate and late phase reaction in allergic rhinitis. 
(Reprinted from The Lancet, 378, Greiner AN, Hellings PW, Rotiroti G, Scadding GK, 
Allergic rhinitis, 752-756, Copyright 2011, with permission from Elsevier.)
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Figure 2 Considerations to be made in case of uncontrolled AR. (Reproduced 
with permission from Hellings PW, Fokkens WJ, Akdis C et al. Uncontrolled allergic 
rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013;68:1-7, 
with permission from Willey Blackwell.)
toms, inhalation of airborne aller-
gens may give rise to conjunctival 
symptoms like itchy eyes, tearing, 
congestion of the conjunctival 
vessels, chemosis and periorbital 
oedema. AR may be a predisposing 
factor to develop disease in adja-
cent structures like the paranasal 
sinus cavities, middle ear, naso-
pharynx and larynx. From clinical 
studies, it is obvious that any ne-
glect of an adequate diagnosis of 
sensitization to inhalant allergens 
may result in a suboptimal ther-
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s • Chronic rhinosinusitis (CRS) affects approximately 5–15% of the 
general population both in Europe and USA, with an increased 
incidence in smokers
• In the USA, the prevalence of NP was found to be 4.2% with a 
higher prevalence (6.7%) in the asthmatic patients
• Missed working days due to sinusitis reach 12.5 million, while 
reported restricted activity days were up to 58.7 million days in 
Europe
• National healthcare costs for CRS reach an estimated 8.6 billion 
dollar per year in the US
CHRONIC RHINOSINUSITIS 
AND NASAL POLYPOSIS
Chronic rhinosinusitis (CRS) is 
one of the most common chronic 
medical conditions, with a signif-
icant impact on patient quality of 
life. CRS is broadly classified into 
two groups: CRS with nasal poly-
posis (CRSwNP) and CRS without 
NP (CRSsNP). CRS is defined as 
inflammation of the nose and the 
paranasal sinuses for ≥12 weeks, 
without complete resolution of 
symptoms. In CRSwNP, nasal pol-
yps accompany the CRS inflam-
mation. Polyps can be divided in 
eosinophilic and non-eosinophilic 
(NE). NE polyps demonstrate glan-
dular hypertrophy and dense col-
lagen deposition.
Recent data have demonstrated 
that CRS affects approximately 
5–15% of the general population 
both in Europe and the USA. The 
prevalence of doctor-diagnosed 
CRS was 2-4%. 
NPs were more frequent in men 
(2.2 to 1), in the elderly (5% at 60 
years of age and older) and in asth-
matics. In the USA, the prevalence 
of NP was found to be 4.2% with 
a higher prevalence (6.7%) in the 
asthmatic patients. The preva-
lence of CRS has been reported to 
be higher in smokers.
CHRONIC RHINOSINUSITIS 
AND NASAL POLYPOSIS2
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Chronic rhinosinusitis and nasal polyposis
Mechanisms involved in CRS w/
wo NP involve both Th2-type and 
Th1/Th17 type inflammation, B 
cell activation and local produc-
tion of high IgE levels, superanti-
gens and biofilm formation (Table 
2 and Figure 1). Several disease 
endotypes were proposed (Figure 
2).
ECONOMIC COSTS OF 
CRSWNP 
CRSwNP has a high impact on 
quality of life. Indirect costs are 
related to episodes of illness,
linked to missed workdays, dis-
ability claims, and absenteeism. 
Indirect costs account for 40% of 
the total costs of rhinosinusitis. 
Missed worked days due to sinusi-
tis was 12.5 million and restricted 
activity days was 58.7 million days.
National health care costs in the 
US remain very high for CRS, at 
an estimated 8.6 billion dollar per 
year. In US the total cost of treat-
ing a patient with CRS was $2609 
per year; in Europe the direct 
costs of a patient treated in a uni-
versity hospital for severe chronic 
rhinosinusitis was $1861/year. 
Endoscopic sinus surgery is ex-
pensive, but causes a drop in costs 
for the 2 post-operative years. The 
ESS-procedure and the 45-day 
post procedure period count for 
$7,726 ($7,554 – $7,898).
Recommendations for CRSwNP 
treatment are shown in Figure 3.
Cemal Cingi   
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Chronic rhinosinusitis and nasal polyposis
TABLE 1
Diseases associated with CRSwNP 
Ciliary impairment
NPs are present in about 40% of patients with 
cystic fibrosis
Allergy
The prevalence with NP has been reported as 
varying from 10% to 64%.
Asthma Reported by 26% of patients with CRSwNP
Aspirin sensitivity 36-96% patients have CRSwNP
Biofilms and S aureus Correlated with severe forms of NPs
TABLE 2
Mechanisms involved in chronic rhinosinusitis
Eosinophil levels and Th2 cytokine skewing are most closely associated with 
Western CRSwNP
Asian polyps are less eosinophilic than Western CRSwNP, exhibiting a 
Th1/17 cytokine skewing
CRSwNP exhibits oedema, low TGF-β levels and low T regulatory cells 
activity.
Increase in T lymphocytes numbers and activated T-lymphocytes, CD4+/
CD8+ T cells, and eosinophils 
Elevations of tissue B cells, plasma cells and immunoglobulins (high local IgE 
levels) are associated with CRSwNP
Approximately 50% of CRSwNP patients demonstrate B and T cells responses 
in the tissue consistent with prior local staphylococcal superantigen 
exposure
Biofilms and/or intracellular residence of bacteria may increase resistance 
to standard therapy 
Allergic fungal rhinosinusitis is associated in 14% of CRSwNP
Levels of Vitamin D3, an immunoregulatory molecule were low in CRSwNP 
suggesting a potential role for replacement therapy
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Chronic rhinosinusitis and nasal polyposis
Figure 1 Mechanisms behind chronic rhinosinusitis. (Reprinted from J Allergy Clin Immunol, 131/6, Nagasaki T, Akdis CA, 
Bachert C, Cingi C et al. Endotypes and phenotypes of chronic rhinosinusitis, 1479-1490, Copyright 2013, with permission from 
Elsevier.)
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Figure 2 Proposed disease 
phenotypes and endotypes in CRS. 
(Reprinted from J Allergy Clin Immunol, 
131/6, Nagasaki T, Akdis CA, Bachert C, 
Cingi C et al. Endotypes and phenotypes 
of chronic rhinosinusitis, 1479-1490, 
Copyright 2013, with permission from 
Elsevier.)
Figure 3 Treatment evidence and recommendations for CRSwNP. (Adapted from Fokkens WJ, Lund VJ, Mullol J, et al. 
European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2011; 1-298.) 
Chronic rhinosinusitis and nasal polyposis
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s • Allergic conjunctivitis (AC) is the commonest of all allergic disorders 
affecting approximately 25% of the population; it most commonly 
occurs with allergic rhinitis; seasonal and perennial AC, while not 
life-threatening, have a significant impact on quality of life
• Dry eye and AC frequently co exist and both require optimal 
management
• AC benefits from use of intranasal corticosteroids as well as 
specific topical ocular therapy
• The complex disorders, atopic keratoconjunctivitis and vernal kera-
toconjunctivitis are sight threatening, may require use of topical cor-
ticosteroids and require co- management with an ophthalmologist
• Potent, well-tolerated topical mast cell stabilisers have greatly 
improved management of ocular allergy; there is no role for 
topical corticosteroids in AC; newer immunosuppressive agents 
may be beneficial in sight- threatening forms of AC
Allergic conjunctivitis (AC) refers 
to a broad group of disorders in-
volving inflammation of the con-
junctiva and presents in a number 
of forms. It is the most common oc-
ular allergic disorder affecting ap-
proximately 25% of the population 
and is responsible for presentation 
to a number of doctors including 
general practitioners, allergists 
and ophthalmologists. The charac-
teristic s of AC include ocular itch, 
tearing, redness, chemosis and lid 
oedema (Figure 1). Itch is consid-
ered a hallmark symptom but may 
also be experienced in those with 
dry eye. Signs are usually more 
dramatic and obvious in those with 
SAC compared to those with PAC.
Seasonal and perennial AC (SAC 
and PAC) are the most common 
forms and most frequently occur 
with nasal allergy. They are caused 
by a classic type 1 hypersensitivity 
reaction to common aeroallergens. 
SAC, accounting for approximately 
80% of all ocular allergy cases, usu-
ally has a more dramatic appear-
ance and is more problematic than 
PAC. Triggers are those for season-
al allergic rhinitis, typically, pollen 
from trees, grasses and weeds. PAC 
is similar to SAC, but is experienced 
year round. It is triggered by chron-
ic exposure to aeroallergens such 
Constance H. Katelaris  
University of Western Sydney and Campbelltown Hospital 
Sydney, Australia
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Ocular allergy
as house dust mite, animal dander 
and mould. In general, SAC and 
PAC are self limiting, depending on 
allergen exposure.  
Other forms of ocular allergy, 
namely vernal keratoconjunctivi-
tis (VKC) and atopic keratocon-
junctivitis (AKC) are potentially 
sight-threatening disorders. They 
have a much more complex im-
munopathophysiology. VKC is un-
common, occurring in children and 
teenagers with a male predom-
inance of 2:1. There is seasonal 
variation in severity although the 
condition is not directly caused by 
aeroallergen exposure and is more 
severe and prevalent in hot, dry 
climates. It usually runs a course 
spanning 2-10 years and is always 
eventually outgrown. Intense 
itch, marked photophobia and a 
ropey discharge are characteristic 
symptoms while physical exami-
nation most often reveals upper 
lid swelling with cobblestoning of 
the superior palpebral conjuncti-
va, when the lid is everted. Other 
signs include Trantas dots (com-
posed of eosinophils and cellular 
debris; seen around the limbus), 
and in severe cases, corneal in-
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b
Figure 1 a - tearing, redness, chemosis and lid oedema in allergic 
conjunctivitis; b - cobblestoning of the superior palpebral conjunctiva in atopic 
and vernal keratoconjunctivitis.
volvement may occur, ranging 
from punctuate keratitis to shield 
ulcer formation which can be sight 
threatening. AKC is the chronic, 
bilateral, severe conjunctivitis as-
sociated with atopic dermatitis. 
It develops in approximately 25% 
of the adult atopic dermatitis pop-
ulation with skin signs preceding 
ocular inflammation and eyelid ec-
zema a common accompaniment. 
Symptoms may be debilitating; 
subconjunctival scarring and dis-
tortion of lid margins may occur; 
chronic conjunctival inflammation 
and tear film disturbance may lead 
to ulceration, scarring and vision 
loss. Of all AKC patients, about 5% 
develop cataract and are at risk of 
other complications such as kera-
toconus, retinal detachment and 
herpetic ocular infection.
Giant papillary cell conjunctivitis is 
a condition not seen as frequently 
these days. It is caused by chron-
ic exposure to a foreign body and 
was most commonly seen with 
long term contact lens use but with 
modern daily lenses, this is much 
less frequently seen. It may be seen 
in those with ocular prostheses and 
ocular sutures. Dry eye syndrome 
results from decreased tear pro-
duction or disruption to the tear 
film stability. It can be confused 
with allergy and can commonly 
co-exist with AC. It is worsened by 
the use of oral antihistamines. Reg-
ular use of lubricants is a useful ad-
ditional therapeutic option in these 
patients as they assist in removal 
of allergen and relieve symptoms 
simultaneously.
Management strategies for all 
forms of AC begin with allergen 
identification, removal or mini-
misation, then trials of non phar-
macological therapy such as eye 
irrigation and lubrication and 
pharmacological therapy. Treat-
ing the nasal component of aller-
gic rhinoconjunctivitis can bring 
significant relief from the ocular 
symptoms but several specific oc-
ular allergy treatments are also 
available. In general, topical anti-
histamine preparations are much 
more effective than oral antihis-
tamines which can exacerbate 
the dry eye component if taken 
regularly. A number of mast cell 
stabilising agents are available for 
those who experience frequent 
and distressing symptoms; these 
Ocular allergy
must be commenced 1-2 weeks 
before the anticipated onset of 
the allergy season to give maxi-
mum relief. They are often used 
in combination with symptomat-
ic topical antihistamine therapy. 
Medications with multiple actions 
(mast cell stabilising and antihis-
tamines) have become mainstay 
treatment for patients with more 
troublesome symptoms.
Topical corticosteroids are an im-
portant component of manage-
ment of VKC and AKC, but their 
use must be monitored carefully 
by an ophthalmologist. Topical cy-
closporin (Restasis) may be useful 
in those with a T cell driven chron-
ic inflammation such as VKC and 
AKC, where it can be steroid spar-
ing.
Ocular allergy is most common-
ly managed by the general prac-
titioner, but a patient, who is 
non-responsive to standard ther-
apy, or who has one of the com-
plex, potentially sight-threatening 
disorders, or who requires topical 
corticosteroids needs to be re-
ferred for specialist management.
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s • Over the last 20 years, more emphasis has been placed on 
recognizing the burden of asthma in children, and steps have 
been taken to recognize the disease and to intervene earlier
• Standardized outcome measures for treatment effects are not 
clear, especially in young children
• The younger the child, the more limited the information available 
on efficacy and safety of medication. As children get older, 
the principles of treatment closely reflect those used in older 
children and adults
• Current research in pediatric asthma is directed at methods to 
eliminate asthma exacerbations and to alter the natural history 
of asthma
WHAT IS ASTHMA?
In the current update of the Glob-
al Initiative for Asthma, asthma is 
described as a heterogeneous dis-
ease, usually characterized by air-
way inflammation, and defined by 
the presence of respiratory symp-
toms such as wheeze, shortness of 
breath, chest tightness and cough 
that vary over time and in intensity, 
together with variable expiratory 
airflow limitation. It is a chronic 
respiratory disease that can affect 
1 to 18% of the population with 
considerable variability among 
countries (Figure 1). The variation 
of symptoms over time is triggered 
by factors such as exercise, aller-
gen exposure, weather, or viral 
respiratory infections. Symptoms 
and airflow limitation may resolve 
spontaneously or in response to 
medication, and may sometimes 
be absent for weeks or months at 
a time. Patients can experience ep-
isodic flare-ups (exacerbations) of 
asthma that may be life-threaten-
ing and carry a significant burden 
to patients and the community.
While there are no confirmatory 
diagnostic tests, asthma can pres-
ent in early childhood as respira-
tory tract illnesses. With increas-
ing frequency of these illnesses, 
respiratory distress appearing 
Stanley J. Szefler  
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between illnesses, and the devel-
opment of allergy, the diagnosis 
becomes apparent. Symptoms 
are temporarily relieved with 
short-acting bronchodilator ther-
apy. An increase in symptoms of-
ten triggers the initiation of long-
term controller therapy, especially 
inhaled corticosteroids.
Over the last 20 years, more em-
phasis has been placed on rec-
ognizing the burden of asthma, 
especially in children, and steps 
have been taken to recognize the 
disease and to intervene earlier. 
However, standardized outcome 
measures for treatment effects 
are not clear, especially in young 
children. The current state of asth-
ma management is summarized in 
the Global Initiative for Asthma 
Strategy Report. 
WHERE DO WE GO FROM 
HERE?
Clinicians are not satisfied with 
the available tools to diagnose 
and monitor asthma. Our current 
treatment has evolved over time 
to emphasize long-term control-
ler therapy to prevent symptoms 
(Figure 2). However, the young-
er the child, the more limited the 
information available on efficacy 
and safety of medication. As chil-
dren get older, the principles of 
treatment closely reflect those 
used in older children and adults.
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Figure 1 Data are "provide" 
by Dr. Richard Beasley and 
based on ISAAC Phase III (Lai 
CKW et al. Thorax 2009; 64: 
476-83). Where no data are 
available from ISAAC Phase 
III, prevalence figures have 
been taken from the Global 
Burden of Asthma Report 
(Masoli M et al. Allergy 2004; 
59: 469-78). The prevalence 
of current asthma in the 13-
14 year age group is estimated 
at 50% of the prevalence of 
self-reporting wheezing in the 
previous 12 months. (From 
the Global Strategy for Asthma 
Management and Prevention 
(Online Appendix), revised 
2014, © Global Initiative 
for Asthma (GINA) all rights 
reserved. Available from http://
www.ginasthma.org.)
Figure 2 Advances in asthma treatment based on an effort to improve asthma 
outcomes.
early, intervene more effectively, 
and further reduce asthma mor-
bidity and mortality.
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Research Focus
Current research in pediatric 
asthma is directed at methods to 
eliminate asthma exacerbations 
and to alter the natural history of 
asthma. Efforts are being made to 
understand the factors contribut-
ing to asthma exacerbations and 
progression of the disease. The fu-
ture is bright for advancing asth-
ma care to recognize the disease 
≥ 10.0
5.0 – 9.9
0 – 4.9
No standardised 
data available
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s • Asthma involves the entire respiratory tract from the upper 
airways to the peripheral small airways
• Steroid refractory airway inflammation and remodeling is a 
common phenomenon in adult asthma 
• Insufficient asthma control by standard inhaled corticosteroid 
therapy is either due to uncontrolled small airway inflammation 
or uncontrolled co-morbidity
• Future sthma therapy should address the systemic component 
of the disease and the aim should be to, not only control, but to 
modify the course of the disease
INTRODUCTION 
Asthma is a global problem affect-
ing around 300 miljon individuals 
around the world and as it mostly 
involves people in working ages, 
the socioeconomic burden is high. 
The common view of asthma have 
changed considerably during the 
last 50 years. From initially being 
regarded as primarily a bronchos-
pastic disorder, the inflammatory 
part of the disease and lately the 
systemic inflammatory part has 
been increasingly recognized. The 
new view of asthma as a primarily 
a systemic inflammatory disor-
der, will call for new management 
and treatment strategies, closely 
linked to Allergology and Clinical 
Immunology.  
FROM RELEASE OF BRONCHO-
SPASM TO CONTROLLING 
AIRWAY INFLAMMATION
During the last decade there has 
been several paradigm shifts in 
the understanding of the disease 
mechanisms in adult asthma. In 
the 60th -70th much focus was on 
the smooth muscle component 
and the systemic and inhaled 
bronchodilators were used both 
as maintenance therapy and dur-
ing acute attacks. From late 70th 
a paradigm shift occurred from 
bronchodilation to anti-inflam-
Leif Bjermer  
Lund University 
Lund, Sweden
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matory treatment mainly with 
inhaled corticosteroids. Asthma 
was regarded as a central airway, 
eosinophilic disorder and it was 
believed that proper anti-inflam-
matory treatment with inhaled 
corticosteroids (ICS) can achieve 
asthma control, and in some cases, 
even could cure the disease. How-
ever, it soon became clear that ICS 
treatment only controlled parts 
of the disease with a rapid relapse 
as soon as the ICS treatment was 
stopped. Even though corticos-
teroids cover a wide range of the 
asthmatic inflammation, there are 
other steroid refractory mecha-
nisms that in the long run induces 
tissue changes, i.e. airway remod-
elling, resulting in persistent air-
way hyper responsiveness and an 
accelerated lung function decline. 
Chronic asthmatic inflammation 
and tissue remodeling, thus repre-
sents one of the major future chal-
lenges in asthma management. 
THE IMPORTANCE OF SMALL 
AIRWAYS IN ASTHMA
It is a well-recognized fact that a 
large fraction of patients treated 
with ICS do not achieve accept-
able clinical control, even when 
bad adherence is corrected for. 
One probable explanation is that 
ICS do not cover all aspects of the 
asthmatic inflammation (different 
inflammatory endotypes). It has 
also been shown that these pa-
tients have an increased, partially 
steroid resistant inflammation in 
the peripheral airways. The pe-
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ripheral small airways, usually 
referred to as the “silent zone”, 
provides less than 10 % of airway 
resistance but more than 90 % of 
the total volume. This may explain 
lung function measured as PEF or 
FEV relates poorly to important 
asthma outcomes, such as symp-
toms, exacerbations and quality 
of life. In the clinical context, small 
airways are not that silent. Impor-
tant features of the disease such 
as nocturnal or exercise induced 
symptoms, risk for asthma exac-
erbations are all related to uncon-
trolled inflammation in the small 
airways. 
FROM A LUNG DISEASE TO A 
SYSTEMIC INFLAMMATORY 
DISORDER
The traditional view of asthma has 
been organ centered, focusing on 
asthma as a pure lung disorder. 
However, in the real life setting, 
most of the patients with asthma 
have one or more co-morbidities 
interfering with the disease. More 
than 80% of patients with asthma 
have concomitant rhinitis or rhi-
nosinusitis and this link becomes 
stronger by disease severity. Thus, 
with more severe uncontrolled 
disease, concomitant rhinitis/rhi-
nosinusitis is almost always pres-
ent. Unfortunately, this obvious 
fact has been ignored by the phar-
maceutical companies developing 
asthma drugs, excluding the most 
common asthma phenotype, i.e. 
the asthma-rhinitis patient from 
clinical asthma trials. 
Not only the upper airways have 
a great impact on the asthma con-
trol. It is well known that food 
allergen sensitization increases 
the risk for asthma development 
later on in life. Recent data also 
suggests a close link between skin 
barrier dysfunction, dermatitis 
and inflammation in the airways. 
Thus, not only the lungs, but also 
a reduced skin barrier may be an 
important entrance for allergic 
sensitization also to airborne al-
lergens. 
A third important link with sys-
temic inflammation and asthma is 
the neuroimmunologic network 
(Figure 1). Anxiety and depres-
sion are more prevalent among 
patients with asthma and allergy. 
Moreover, the neuroendocrine re-
sponse to biological stress affects 
several somatic functions includ-
ing the airways and this will prob-
ably be a very important research 
area in the near future. 
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Figure 1 The new view of asthma as a systemic inflammatory disorder with 
a close link between the upper and the lower airways. The majority of patients 
with asthma have concomitant rhinosinusitis. Many patients with rhinitis/
rhinosinusitis have airway hyperresponsiveness, while development of clinical 
asthma is associated with an extended involvement of the peripheral “small 
airways”. The respiratory system is also under the influence by co-morbid 
conditions related to the gastrointestinal tract (food sensitization, bowel 
inflammation), the Skin (eczema, barrier dysfunction) as well as the nervous 
system (neuroimmunologic network, cognitive dysfunction).
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• Anaphylaxis is diagnosed based on validated clinical criteria. 
It is commonly IgE-mediated, but can also occur through IgE-
independent immune mechanisms or direct mast cell stimulation. 
• Vulnerable patients with anaphylaxis include infants, 
adolescents, pregnant women, the elderly, patients with asthma, 
cardiovascular disease, mast cell activation disorders, and those 
concurrently taking certain medications. Amplifying co-factors 
include exercise, infection, and emotional stress.
• Initial treatment focuses on prompt epinephrine (adrenaline) 
intramuscular injection in the mid-outer thigh, calling for help, 
positioning the patient supine, providing supplemental oxygen 
and intravenous fluids, and vigilant monitoring. 
• Post-discharge management includes preparing the patient to 
treat recurrences in the community, and preventing recurrences 
by confirming the anaphylaxis trigger(s), and initiating allergen 
avoidance and immune modulation.
Anaphylaxis is a serious allergic 
or hypersensitivity reaction that 
can cause death. It is rapid in on-
set (minutes to a few hours) and 
typically involves multiple body 
systems. The lifetime prevalence 
of anaphylaxis from all triggers is 
at least 1%.  Patient factors and 
co-factors that affect anaphylaxis 
are similar worldwide (Figure 1). 
The importance of different ana-
phylaxis triggers varies with age 
and geography. Anaphylaxis com-
monly occurs through an IgE-de-
pendent immunologic mechanism 
triggered by foods, stinging insect 
venoms, medications or latex. 
It can also be induced by other 
immunologic mechanisms or by 
direct mast cell stimulation. In id-
iopathic anaphylaxis, the possibil-
ity of a novel trigger or a mast cell 
activation disorder should be con-
sidered (Figure 2). 
Clinical criteria for the diagnosis 
of anaphylaxis have been validat-
ed for use in medical settings and 
epidemiologic studies and have 
high sensitivity, good specifici-
ty, and a high negative predictive 
value. Skin and mucous mem-
brane symptoms and signs such 
as itching, flushing, hives, and an-
gioedema are present in 80-90% 
of episodes. Respiratory, gastroin-
F. Estelle R. Simons  
University of Manitoba 
Manitoba, Canada
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testinal, and cardiovascular symp-
toms are also common; however, 
shock is not necessarily present, 
even in severe or fatal anaphylaxis 
(Figure 3). 
Initial management involves hav-
ing a protocol, assessing the pa-
tient, then promptly and simulta-
neously calling for help, injecting 
epinephrine (adrenaline) intra-
muscularly in the mid-outer thigh 
and positioning the patient supine 
or in a position of comfort. Sup-
plemental oxygen, intravenous 
fluid resuscitation and cardiopul-
monary resuscitation should be 
provided. Heart rate and function, 
blood pressure, and oxygenation 
should be monitored, if possible, 
H
1
-antihistamines, H
2
-antihista-
mines, glucocorticoids, and beta-2 
adrenergic agonists should not be 
administered before epinephrine 
treatment, or as monotherapy 
(Figure 4). Patients with anaphy-
laxis refractory to epinephrine, 
supplemental oxygen, and intra-
venous fluid resuscitation need in-
tensive care treatment with venti-
latory and inotropic support. 
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Figure 1 Age-related factors, concomitant diseases, concurrent medications, and amplifying co-factors in anaphylaxis. 
Multiple factors and cofactors likely contribute to some anaphylactic episodes. (Reprinted from J Allergy Clin Immunol, 
127/3, Simons FER, Ardusso LRF, Bilo MB, et al. World Allergy Organization anaphylaxis guidelines: summary, 587-593.e1-e22, 
Copyright 2011, with permission from Elsevier.)
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Figure 2 Anaphylaxis mechanisms and triggers. Anaphylaxis is commonly triggered by an allergen through an IgE-
dependent mechanism; however, it can also be triggered through other immunologic mechanisms or direct mast cell 
stimulation. (Reprinted from J Allergy Clin Immunol, 127/3, Simons FER, Ardusso LRF, Bilo MB, et al. World Allergy Organization 
anaphylaxis guidelines: summary, 587-593 .e1-e22, Copyright 2011, with permission from Elsevier.)
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Figure 3 Clinical criteria for the diagnosis of anaphylaxis. These criteria were developed as an instrument to aid in 
recognition of anaphylaxis in patients with a sudden onset of characteristic symptoms and signs. They have been validated 
for use in clinical and epidemiologic studies. (Reprinted from J Allergy Clin Immunol, 127/3, Simons FER, Ardusso LRF, Bilo MB, et 
al. World Allergy Organization anaphylaxis guidelines: summary, 587-593 .e1-e22, Copyright 2011, with permission from Elsevier.)
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Figure 4 Initial management of anaphylaxis. Preparedness is critically important. Treatment should be initiated as 
soon as anaphylaxis is recognized, as death can occur within minutes. Before initiating rescue breaths, cardiopulmonary 
resuscitation should begin with chest compressions (rate 100-120/minute and depth of 5-6 cm in adults; rate of ≥ 100 
compressions/minute and depth of 5 cm in children [4 cm in infants]). (Reprinted from J Allergy Clin Immunol, 127/3, Simons 
FER, Ardusso LRF, Bilo MB, et al. World Allergy Organization anaphylaxis guidelines: summary, 587-593 .e1-e22, Copyright 2011, 
with permission from Elsevier Reprinted from J Allergy Clin Immunol, 117/2, Sampson HA, Munoz-Furlong A, Campbell RL, et al. 
Second symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and 
Infectious Disease/Food Allergy and Anaphylaxis Network Symposium, 391-397 Copyright 2006, with permission from Elsevier.)
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After treatment of an anaphylactic 
episode, a patient should be pre-
pared to self-manage recurrences 
in the community by consistently 
carrying one or more epinephrine 
auto-injectors and injecting epi-
nephrine promptly, when anaphy-
laxis occurs; also by developing 
and using a personalized emer-
gency action plan, and wearing 
medical identification (Figure 5).
For prevention of recurrences, a 
patient who has been treated for 
anaphylaxis should be evaluated 
by an allergy/immunology special-
ist who will confirm the trigger(s) 
by using skin tests, measurement 
of allergen-specific IgE levels, and 
other investigations as indicated. 
Skin tests are performed at least 
3-4 weeks after the anaphylactic 
episode and if negative in a patient 
with a strong history of anaphylax-
is, they should be repeated weeks 
or months later. Information about 
avoidance of relevant triggers 
should be provided. If applicable, 
immune modulation using allergen 
specific immunotherapy or drug 
desensitization protocols should 
be initiated. Co-morbidities such 
as asthma or cardiovascular disor-
ders should be optimally managed 
(Figure 5). 
Anaphylaxis research is no longer 
hindered by the perception that 
the disease is rare, by absence of 
an acceptable definition, or by 
lack of validated diagnostic clin-
ical criteria. A global agenda for 
anaphylaxis research has been de-
veloped to improve understand-
ing of epidemiology, patient risk 
factors, mechanisms and triggers, 
and optimal methods of diagnosis, 
management, and prevention. 
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Figure 5 Post-discharge management. Panel 1: post-discharge management 
after treatment of anaphylaxis in a healthcare setting. Panel 2: anaphylaxis 
triggers suggested by the history are confirmed by skin tests and measurement 
of allergen-specific IgE levels. Panel 3: long-term management involves 
avoidance of confirmed trigger(s) and relevant immune modulation. (Reprinted 
from J Allergy Clin Immunol, 127/3, Simons FER, Ardusso LRF, Bilo MB, et al. World 
Allergy Organization anaphylaxis guidelines: summary, 587-593 .e1-e22, Copyright 
2011, with permission from Elsevier.). Figures 1-5 prepared by J. Schaffer.
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• Drug hypersensitivity reactions (DHRs) comprise 15 % of all 
adverse drug reactions and affect more than 7 % of the general 
population 
• The term "drug allergy" is reserved to immunologically-mediated 
DHRs with direct or indirect evidence of drug-specific antibodies 
or T-cells 
• Clinical presentations are classified as immediate and non-
immediate reactions; the first category is mostly IgE-mediated, 
whereas the latter is specific T cell-mediated
• Both under-diagnosis (due to under-reporting) and over-
diagnosis (due to an over-use of the term “allergy”) are common. 
• The diagnostic work-up of DHRs is a step-wise approach, starting 
with an as exhaustive as possible clinical history, followed, when 
validated, by in vivo (skin and provocation) tests and in some rare 
cases by in vitro biological tests
Adverse drug reactions (ADRs) 
resembling clinically to allergy are 
called drug hypersensitivity reac-
tions (DHRs). They comprise 15% 
of all ADRs and affect more than 
7 % of the general population. The 
term "drug allergy" is reserved to 
immunologically-mediated DHRs, 
after showing direct or indirect 
evidence of either drug-specific 
antibodies or T-cells. These reac-
tions are mostly unpredictable. 
They can be life threatening, may 
require or prolong hospitalization 
and necessitate changes in sub-
sequent therapy. They are of sig-
nificant concern for clinicians and 
patients.
Even though urticaria and macu-
lopapular eruptions are the most 
frequent manifestations, there 
are many other clinical presenta-
tions artificially classified into two 
types (Figure 1), according to the 
delay of onset of the reaction after 
the last administration of the drug: 
1) Immediate reactions, occurring 
less than 1 hour after the last drug 
intake, usually in the form of isolat-
ed urticaria, angioedema, rhinitis, 
conjunctivitis, broncho spasm, gas-
tro-intestinal symptoms (nausea, 
vomiting, diarrhea), or anaphylax-
is with or without cardiovascular 
collapse (anaphylactic shock) and 
Pascal Demoly  
University Hospital of Montpellier  
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2) Non-immediate reactions, with 
variable cutaneous symptoms oc-
curring after more than 1 hour and 
up to several days after the last 
drug intake, such as late-occurring 
urticaria, maculopapular erup-
tions, fixed drug eruptions, vascu-
litis, blistering diseases (such as 
toxic epidermal necrolysis (TEN), 
Stevens-Johnson syndrome (SJS) 
and generalized bullous fixed drug 
eruptions), drug reaction with eo-
sinophilia and systemic symptoms 
(DRESS), acute generalized exan-
thematous pustulosis (AGEP) and 
symmetrical drug-related inter-
triginous and flexural exanthemas. 
Internal organs can be affected 
either alone or with cutaneous 
symptoms and include hepatitis, 
renal failure, pneumonitis, ane-
mia, neutropenia, and thrombo-
cytopenia. The first category is 
mostly mediated through specific 
IgE, whereas the latter is specific T 
cell-mediated.
Both under-diagnosis (due to un-
der-reporting) and over-diagnosis 
(due to an over-use of the term 
“allergy”) are common. The diag-
nostic work-up of DHRs is a step-
wise approach, starting with an 
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as exhaustive as possible clinical 
history, followed, when validated 
for some drug classes, by in vivo 
(skin and provocation) tests and in 
some rare cases by in vitro biologi-
cal tests. 
Several guidelines and consensus 
documents on general or speci-
fic drug class-induced DHRs are 
available to support the diagno-
sis. The recent International Con-
sensus (ICON) on Drug Allergy 
synthesizes multiple guidelines 
into one generally approved and 
accepted consensus document. It 
provides guidance for firm diag-
nosis and solutions to find alter-
natives when the responsibility of 
the drug is confirmed (Figure 2). 
Only a thorough diagnostic work-
up will allow a better classification 
of the reactions and provides pa-
tients with more reliable infor-
mation and recommendations for 
future treatments. A lot still needs 
to be done to understand better 
DHRs and diagnose severe cuta-
neous reactions for which drug 
provocation tests are contraindi-
cated and in the field of biological 
diagnosis.
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Results
Results
Figure 1 Chronology of 
DHRs. (Reproduced with 
permission from Demoly P, 
Adkinson NF, Brockow K, et 
al. International Consensus 
on drug allergy. Allergy 
2014;69:420-37, with 
permission from Willey 
Blackwell.)
Figure 2 Flow chart when assessing DHRs. *Currently available 
biological tests to diagnose drug allergy lack sensitivity.**In the absence of 
contraindications. ***If no alternative is available (e.g., NMBA, chemothera-
peutic  drugs), readministration of the drug is allowed under close surveillance, 
considering premedication and/or desensitization. (Reproduced with permission 
from Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug 
allergy. Allergy 2014;69:420-37, with permission from Willey Blackwell.)
Drug allergy
199
Global atlas oF allerGy
se
c
t
io
n
 D
 - M
ajo
r A
llergic D
iseases 
• Food allergy can result in considerable morbidity, impairment of 
quality of life & costs 
• Life-threatening anaphylaxis can complicate the course of food 
allergy 
• The point prevalence of self-reported food allergy is 
approximately six times higher than challenge proven food 
allergy
• Presence of allergen-specific IgE indicates sensitization, 
whereas a clinical allergic reaction can be proven only by oral 
food challenges
• Management includes avoidance of the offending food, 
insurance of a sufficient diet and education e.g. as regards 
behavioral approaches to avoid allergens and management of 
acute reactions
Allergies to foods associate con-
siderable morbidity, impaired 
quality of life and costs – and 
can in some instances result in 
life-threatening anaphylaxis. 
Therefore, it is important to im-
prove awareness and access for 
all to a proper diagnosis and treat-
ment to ensure a safe and good 
life. Adverse reactions to foods 
encompasses many different reac-
tions with different mechanisms 
including toxic, enzymatic and 
hypersensitivity reactions “Food 
allergy” refers to the subgroup of 
food hypersensitivity reactions in 
which immunologic mechanisms 
have been demonstrated, whether 
IgE and/or non-IgE-mediated (Fig-
ure 1).
The clinical presentation of food 
allergy involves a large spectrum 
of symptoms (Table 1), triggered 
by ingestion of food, sometimes in 
very small amounts or even by in-
halation and skin contact.
Although these symptoms are re-
ported frequent in the population, 
if investigated appropriately often 
they are not caused by food allergy. 
In a recent systematic review, the 
point prevalence of self-reported 
food allergy was approximately six 
times higher than challenge-prov-
en food allergy. The prevalence of 
FOOD ALLERGY8
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food allergy was generally higher 
in children compared to adults. 
While the prevalence of primary 
food allergy appeared to be sta-
ble over time, the prevalence of 
secondary food allergy caused by 
cross-reactions of food allergens 
with inhalant allergens appears to 
be increasing.
A proper diagnosis is necessary 
for a sufficient and safe treatment. 
A careful diet history is fundamen-
tal, since it can establish the likeli-
hood of the diagnosis and identify 
the potential food triggers (Table 
2). Positivity of skin prick tests and 
specific IgE to food allergens, can 
determine sensitization only, and a 
relevant elimination diet followed 
by an oral food challenge test is 
necessary to confirm the diagno-
sis food allergy (Figure 2). Recent-
ly, in vitro measurement of IgE to 
specific components of some food 
allergens (compenent resolved 
diagnosis) has shown promising 
results, but further studies are 
necessary to validate its value and 
clinical relevance.
Due to the good prognosis of 
many food allergies with spon-
taneous resolution, especially in 
children, re-challenges should be 
performed regularly to detect de-
Susanne Halken  
Odense University Hospital 
Odense, Denmark
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Padua, Italy 
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TABLE 1
Clinical features of food protein allergy
Reactions Mechanism
Cutaneous reactions
Urticaria, acute or chronic (rare)
Angioedema
Contact rash
Atopic dermatitis
IgE and/ or non-IgE mediated
Gastrointestinal reactions
Oral allergy syndrome 
Nausea/vomiting
Abdominal pain
Diarrhea, constipation
IgE and / or  
non-IgE mediated
Respiratory reactions
Allergic eosinophilic gastritis, enteritis & colitis
Protein-losing enteropathy
Non-IgE mediated
Rhinoconjunctivitis
Asthma
Laryngeal edema
IgE and / or 
non-IgE mediated
Other reactions
Anaphylaxis
IgE and / or 
non-IgE mediated
Food dependent exercise induced anaphylaxis
IgE and / or 
non-IgE mediated
Food hypersensitivity (FH)
Immune-mediated
Food allergy (FA)
Non-immune mediated FH
IgE-mediated FA Non-IgE-mediated FA
Figure 1 Food allergy - classification.
Food allergy
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TABLE 2
When to suspect food allergy
Symptoms suggestive of food allergy
• Persistent symptoms,
• Symptoms related to food intake
• Two or more different symptoms
Especially in children with allergic predisposition
TABLE 3
Recommendations for primary prevention of food allergy
Recommendations for all infants:
• No special diet during pregnancy or for the lactating mother
• Exclusively breastfeeding for 4 – 6 months
Further recommendations for infants with atopic predisposition:
• If supplement is needed during the first 4 months a documented hypoallergenic formula is recom-
mended
Introduction of complementary foods after the age of 4 months according to normal standard weaning 
practices and nutrition recommendations, for all children irrespective of atopic heredity 
Reproduced with permission from Muraro A, Halken S, Arshad SH, et al. EAACI Food Allergy and Anaphylaxis 
Guidelines. Primary prevention of food allergy. Allergy 2014;69:590-601, with permission from Willey Blackwell.
velopment of tolerance.Studies on 
possible prevention of develop-
ment of food allergy have shown 
that simple dietary measurements 
in infancy can reduce the risk for 
food allergy (Figure 2, Table 3).
So far, the only safe treatment is 
identification and avoidance of 
the offending food. Education of 
the patient, families, health care 
professionals and others in the 
network around the patient on 
how to avoid ingesting the food 
and how to recognize and manage 
allergic reactions is important. In 
addition, especially in young chil-
dren a nutritional balanced diet 
should be ensured to compensate 
the exclusion of the culprit food. 
Several new strategies such as 
oral immunotherapy are currently 
being investigated, and may prove 
to be useful in the future.
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Figure 2 Reaction to a diagnostic 
oral challenge with hen’s egg.
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• Atopic dermatitis (AD) shows an increase in the worldwide 
prevalence
• AD is the most common chronic inflammatory skin disease and 
displays a complex clinical phenotype
• AD has a substantial impact on quality of life and socio-economic 
burden and represents an important public health
• AD often represents the first step of the atopic march and may 
thus offer an opportunity for disease modifying strategies
Atopic dermatitis (AD) is the most 
common chronic inflammatory 
skin disease and may represent 
the very initial phase of the so-
called atopic march (Figure 1). The 
incidence of AD has increased by 
two- to three-fold during the past 
three decades in industrialized 
countries. AD affects up to 20 % of 
the children and 2 to 10 % of adults 
and has a deep impact on the qual-
ity of life of patients and parents. 
The increasing prevalence may be 
linked to the Western lifestyle. AD 
generates a substantial econom-
ic burden. The average costs for 
an AD patients in Germany have 
been estimated to a total of about 
4400€ (1450 € reimbursed direct 
costs, 1130€ costs not reimbursed 
costs and 1850 indirect costs). 
Due to its complex pathophysiol-
ogy, the natural history of AD is 
highly variable and may be deter-
mined by a number of (epi)genetic 
as well as environmental factors 
including the recently identified 
microbiome (Figure 2). About 30 
% of the children, who have start-
ed the disease in the first weeks 
or months of life (early onset) will 
suffer from allergic rhinitis and/or 
asthma: the so-called the atopic 
march. Another half of the affect-
ed children will experience a re-
Thomas Bieber  
Friedrich-Wilhelms University of Bonn 
Bonn, Germany
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mission before puberty (Figure 3). 
Social interactions, psychological 
adjustments, work success, sexu-
al relationships, and quality of life 
often are dependent on the course 
of disease. Thus, the therapeu-
tic goal should be the long-term 
control of the disease, i.e. the re-
duction of the flares and bacterial 
and viral complications. Disease 
modifying strategies should be 
developed to establish an optimal 
prevention and management dur-
ing a window of opportunity in in-
dividuals at risk to experience an 
atopic march. These approaches 
will greatly benefit from the iden-
tification and validation of predic-
tive biomarkers in the context of a 
stratified medicine in AD.   
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Figure 1 Atopic dermatitis is considered as the first manifestation of the atopic march. Individuals at high risk to develop 
allergic rhinitis and asthma could be identified at an early stage and subjected to tailored prevention and disease-
modifying strategies. (Reproduced from Br Med J, Barnetson RS, Rogers M. Childhood atopic eczema, 324, 1376-9, Copyright 
2002 with permission from BMJ Publishing Group Ltd.)
Figure 2 Atopic dermatitis is a paradigmatic chronic inflammatory skin disease where gene-gene and gene-environment 
interactions are involved. More recently, the role of epigenetic regulation and of the microbiome have been highlighted 
with the aim to focus of new prevention strategies. This figure depicts the archetypical natural history of an AD with an 
early onset, followed by the classic atopic march, leading to allergic rhinitis and asthma. (Adapted from Bieber T. Atopic 
dermatitis. N Engl J Med 2008;358:1483-1494.)
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Figure 3 Heterogeneity of the natural history of AD. Prevention and therapeutic strategies must be adapted to the 
individual situations. Reliable predictive biomarkers represent an unmet need in the stratification of AD patient-tailored 
intervention. (Reproduced with permission from Garmhausen D, Hagemann T, Bieber T,et al. Characterization of different courses 
of atopic dermatitis in adolescent and adult patients. Allergy 2013;68:498-506, with permission from Willey Blackwell.)
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of life
• Urticaria should be divided into acute and chronic, spontaneous 
or inducible, with emphasis on possible eliciting factors
• The key cell involved is the mast cell, which can be activated by a 
vast variety of stimuli and the major mediator is histamine
• Urticaria can be treated efficiently without significant side 
effects in the vast majority of patients, children or adults
• Non-sedating antihistamines, sometimes in doses up to four 
times the recommended dose, are the mainstay of treatment
Urticaria is a common, heteroge-
neous group of disorders with a 
large variety of underlying caus-
es. It is characterized by the ap-
pearance of fleeting wheals, each 
lasting 1–24 hours and/or an-
gioedema lasting up to 72 hours. 
The key cell involved is the mast 
cell, which can be activated by a 
vast variety of stimuli. Activation 
of superficially situated mast cells 
in the skin gives rise to urticaria, 
whereas mast cells in dermis are 
involved in angioedema. Often 
both manifestations are present 
in the same patient. Histamine is 
the key mediator in urticaria and 
most cases of angioedema, where-
as bradykinin is responsible for 
some types of angioedema (he-
reditary angioedema and Angio-
tensin- Converting-Enzyme (ACE) 
induced angioedema).
It is estimated that up to 25% of 
adults will experience at least one 
episode of acute urticaria some-
time in their lifetime, while only 
around 3% will develop chronic 
spontaneous urticaria (point prev-
alence 0.6%). In children, urticaria 
appears to be less common (3-5 %) 
with chronic urticaria being much 
less prevalent. Very little is known 
on the natural history of the dis-
ease, but the duration is most of-
Carsten Bindslev-Jensen  
Odense University Hospital 
Odense, Denmark
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ten less than 5-10 years. Quality 
of Life in the patient is often se-
verely affected.
International guidelines divide ur-
ticaria in acute and chronic (with 
an arbitrary limit set at 6 weeks 
of duration) and in spontaneous 
forms (without a known underly-
ing cause except autoantibodies 
directed against the receptor for 
IgE) and inducible forms (Tables 1 
and 3).
The diagnosis is easily made in 
typical cases, but a thorough med-
ical history is critical both for cor-
rect classification and for avoid-
ance of extensive investigations 
for underlying disease. Normally, a 
test for autoimmune urticaria with 
autologous serum or via in vitro 
tests together with investigations 
for a chronic infection is sufficient. 
Urticaria can, however also be a 
feature of more severe diseases 
and should not be overlooked. The 
severity of the disease is assessed 
according to the score system pre-
sented in Table 2. Since disease, 
severity is often fluctuating during 
the day, a 24-hour score is advised, 
Table 2.
In the inducible forms, the treat-
ment of choice (but not always 
possible) is avoidance. Pharma-
cological treatment can in the 
majority of the cases be confined 
to non-sedating antistamines in 
doses up to four times the recom-
mended dose (Figure 1). Treat-
ment should be on an every day 
basis in more severe cases and 
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TABLE 1
Urticaria classification
Type Subtype Definition Comments
Spontaneous 
urticaria
Acute spontaneous urticaria Spontaneous wheals for < 6 weeks Can be associated with 
concomitant diseases such as 
chronic infections or thyroid 
diseases, but causality is only 
rarely established
Chronic spontaneous urticaria Spontaneous wheals for > 6 weeks
The single wheal disappears within 
24 hours. Longer standing wheals are 
a feature of urticaria vasculitis
Inducible 
urticaria
Acute, but may be recurrent 
even on an everyday basis
Wheals induced by a defined, 
external or internal stimulus
See Table 3
TABLE 2
Severity Scoring
Score Wheals Pruritus
0 None None
1
Mild 
(< 20 wheals in 24 hours)
Present (but not annoying nor troublesome)
2
Moderate 
(20-50 wheals in 24 hours)
Moderate (troublesome but does not interfere with normal 
daily activity or sleep)
3
Severe 
(>50 wheals in 24 h or large 
confluent areas of wheals)
Intense (severe pruritus, which is sufficiently troublesome 
to interfere with normal daily activity or sleep)
Sum of score 0-6; Reproduced with permission from ZuberbierT,Asero R, Bindslev-Jensen C,et al.EAACI/GA(2)
LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria, Allergy 2009;64:1417-26, with 
permission from Willey Blackwell.
Non sedating H1-antihistamine (nsAH)
Increased dosage up to fourfold
Add on: leukotriene receptor antagonist or change nsAH
Exacerbation: Systemic corticosteroid (for 3-7 days)
Add Ciclosporin A, H2-antihistamine, Dapsone, Omalizumab
Exacerbation: Systemic corticosteroid (for 3-7 days)
If symptoms persist 
after 2 weeks
If symptoms persist 
after 1-4 weeks
Figure 1 Treatment algorithm for 
chronic urticaria. (Reproduced with 
permission from ZuberbierT,Asero R, 
Bindslev-Jensen C,et al.EAACI/GA(2)
LEN/EDF/WAO guideline: management 
of urticaria, Allergy 2009;64:1427-43, 
with permission from Willey Blackwell.)
Urticaria
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only as needed in milder forms.
Omalizumab, originally registered 
as a drug for treatment of asthma 
has recently been approved for ur-
ticaria also and has demonstrated 
very promising efficacy in recalci-
trant cases of urticaria.
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TABLE 3
Inducible urticaria (acute forms)
Stimulus Comments
Physical urticaria
Cold contact
Heat contact
Vibration
UV light
Pressure
Typically wheals are elicited immediately except in de-
layed pressure urticaria, where symptoms are elicited 
hours after stimulus.
Allergic urticaria
Food (peanut, nuts, milk, egg)
Drugs (penicillin, aspirin)
Insect venom (wasp, honey bee)
Often elicited in combination with other allergic symp-
toms and signs such as asthma, rhinitis, gastro-intesti-
nal symptoms or anaphylaxis.
Skin contact with allergen Including skin testing with allergen. Also elicited by 
urticariogenic substances
Food and physical exercise Food-dependent, exercise-induced anaphylaxis: only 
elicited by a combination of food intake (wheat) and 
physical exercise
Infection Acute infection (most often virus)
Commonly seen in children with acute infection, much 
less frequent in adults
Other types
Water
Rise in body core temperature
Exercise (without food intake)
Aquagenic urticaria
Cholinergic urticaria (pin point wheals)
Exercise induced urticaria (or anaphylaxis)
Urticaria
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• The 2013 revisions and update of the EAACI/GA2LEN/EDF/
WAO guidelines is based on the GRADE methodology
• The impact on quality of life should be measured. Urticaria can 
be highly debilitating: reduction of productivity reaches 25-30% 
in moderate to severe cases and there is a major impact on sleep.
• Urticaria treatment is based on a step up algorithm with first line 
non-sedating antihistamines
• The aim of treatment is the complete absence of symptoms
• Areas of further research in urticaria are underlined
The EAACI/GA2LEN/EDF/WAO 
guidelines on urticaria were 
launched in 2009. Following a 
consensus conference held in 
2012 in Berlin, a joint initiative of 
the European Academy of Allergy 
and Clinical Immunology (EAA-
CI) Dermatology Section, Global 
Allergy and Asthma European 
Network (GA2LEN), the European 
Dermatology Forum (EDF), and 
the World Allergy Organization 
(WAO) performed a systematic 
literature review using the ‘Grad-
ing of Recommendations Assess-
ment, Development and Evalua-
tion’ (GRADE) methodology. The 
2013 revised EAACI/GA2LEN/
EDF/WAO guidelines are the re-
sult of the above. The strength of 
a recommendation and the quality 
of supporting evidence were as-
sessed independently by two as-
sessors for each recommendation. 
They took into consideration as 
negative/risk: side-effects (grad-
ed on severity) and costs; and as 
benefits: reduction in urticaria 
symptoms and improvement in 
quality of life (QoL). The GRADE 
system permits strong recommen-
dations supported by low- quality 
evidence from downgraded RCTs 
or observational studies. On the 
other hand, weak recommenda-
tions may be based on high-quali-
EAACI - GA2LEN - EDF - WAO 
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ty evidence if other factors are im-
portant, for example the price of a 
treatment option.
All aspects of the disease were 
critically evaluated using the 
GRADE methodology: definition, 
clinical aspects, diagnostic work-
up, assessment of disease activi-
ty and impact, and management. 
Ideally, the diagnostic work up in 
chronic urticaria (CU) (Figure 1) 
reveals a cause that can be treat-
ed, but frequently this is not possi-
ble. Especially the inducible forms 
of CU are mainly idiopathic. It is 
strongly advised to search for un-
derlying causes in chronic spon-
taneous urticaria only in patients 
with longstanding and/or severe 
disease and to perform extended 
diagnostic testing based on the 
patient history.
Aiming for complete symptom con-
trol in urticaria as safely as possible 
is recommended. Treatment with 
non sedating H1-antihistamines 
is the first line option (safety data 
are available for their use for sev-
eral years continuously). Continu-
ous use is superior to on demand 
use, as antihistamines block the 
development of new wheals and 
angioedema, but do not help to 
decrease the time to resolution of 
already existing ones.
It is recommended not to use old-
er first generation antihistamines, 
because they have pronounced 
adverse events. For example, they 
can interfere with rapid eye move-
ment (REM) sleep and impact on 
learning and performance. As 
shown by a recent head to head tri-
al, there are no benefits from non 
Torsten Zuberbier Marcus Maurer
Charité Medical University 
Berlin, Germany
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EAACI - GA2LEN - EDF - WAO guideline on urticaria
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Figure 1 Diagnostic algorithm for patients presenting with wheals, angioedema, or both. AAE: Acquired angioedema 
due to C1-inhibitor deficiency; ACE-Inh: angiotensin converting enzyme inhibitor; AE: angioedema; AH: Antihistamine; 
AID: Auto-inflammatory disease; HAE: Hereditary angioedema; IL-1: Interleukin-1. 1 Other (new) drugs may also induce 
bradykinin-mediated angioedema. 2 Patients should be asked for a detailed family history and age of disease onset. 3 Test 
for elevated inflammation markers (C-reactive protein, erythrocyte sedimentation rate), test for paraproteinemia in 
adults, look for signs of neutrophil-rich infiltrates in skin biopsy; perform gene mutation analysis of hereditary periodic 
fever syndromes (e.g. Cryopyrin-associated periodic syndrome), if strongly suspected. 4 Patients should be asked: “How 
long do your wheals last?”. 5 Test for Complement C4, C1-INH levels and function; in addition test for C1q and C1-INH 
antibodies, if AAE is suspected; do gene mutation analysis, if former tests are unremarkable but patient’s history suggests 
hereditary angioedema. 6 Wait for up to 6 months for remission; additional diagnostics to test for C1-inhibitor deficiency 
should only be performed, if the family history suggests hereditary angioedema. 7 Does the biopsy of lesional skin show 
damage of the small vessels in the papillary and reticular dermis and/or fibrinoid deposits in perivascular and intersti-
tial locations suggestive of UV (urticarial vasculitis)? 8 Patients should be asked: “Can you make your wheals come?”. 9 In 
patients with a history suggestive of inducible urticaria standardized provocation testing according to international con-
sensus recommendations should be performed. 10 Acquired AIDs (autoinflammatory syndromes) include Schnitzler´s syn-
drome as well as systemic-onset juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD); hereditary AIDs 
include Cryopyrin associated periodic syndromes (CAPS) such as familial cold auto-inflammatory syndromes (FCAS), 
Muckle-Wells syndrome (MWS) and neonatal onset multisystem inflammatory disease (NOMID), more rarely hyper-IgD 
syndrome (HIDS) and tumor necrosis factor receptor alpha-associated periodic syndrome (TRAPS). 11 In some rare cases 
recurrent angioedema is neither mast cell mediator-mediated nor bradykinin-mediated, and the underlying pathomech-
anisms remain unknown. These rare cases are referred to as "idiopathic angioedema" by some authors. (Reproduced with 
permission from Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO Guideline for the definition, classification, 
diagnosis and management of Urticaria, The 2013 revision and update. 2014 Apr 30. doi: 10.1111/all.12313. [Epub ahead of 
print], with permission from Willey Blackwell.)
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sedating antihistamines regarding 
efficacy including improvement of 
quality of sleep. 
The second line treatment option 
in CU is updosing of non-sedating 
second generation antihistamines. 
This has been verified in studies us-
ing up to fourfold higher than rec-
ommended doses of bilastine, ceti-
rizine, desloratadine, fexofenadine, 
levocetirizine, and rupatadine.
The recommended third line 
treatment is to use omalizumab, 
cyclosporin A or montelukast as 
an add-on therapy to fourfold an-
tihistamine treatment. Of these 
options, omalizumab is the only 
treatment licensed for chronic 
spontaneous urticaria, whereas 
cyclosporin A, where the level of 
evidence is also good, as well as 
montelukast, remain off-label. 
This is also the case for numer-
ous other therapies that are not 
well-proven to be efficacious.
Patient-related outcomes are im-
portant to be looked at in the man-
agement for urticaria. The availa-
ble data indicate that urticaria has 
a detrimental effect on both ob-
jective functioning and subjective 
wellbeing. In one study, health sta-
tus scores in patients with chronic 
spontaneous urticaria (CSU) were 
comparable to those reported 
by patients with coronary artery 
disease. The extent and nature of 
disability shows a large variation 
within different urticarial subsets. 
A QoL Questionnaire (CU-Q2oL), 
specifically developed for CSU, 
was validated, including for phys-
ical, emotional, social, and practi-
cal aspects characteristic of this 
condition. Another questionnaire 
(AE-QoL) covers patients with 
angioedema. There is a strong rec-
ommendation for both this ques-
tionnaires. 
The panel and participants identi-
fied several areas in which further 
research in urticaria is needed (ta-
ble 1). 
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tions. Allergy 2009;64:1715-1721.
2. Zuberbier T, Aberer W, Asero 
R, Bindslev-Jensen C, Brzoza Z, 
Canonica GW et al. The EAACI/
GA²LEN/EDF/WAO Guideline for 
the definition, classification, diag-
nosis and management of Urticar-
ia. The 2013 revision and update. 
Allergy 2014 Apr 30. doi: 10.1111/
all.12313. [Epub ahead of print]
TABLE 1
Areas of further research in urticaria
• Global epidemiology, in adults and children
• The socio-economic consequences
• Identification of mast cell/basophil activating factors
• Identification of new histological markers
• Identification of serum biomarkers of urticarial activity/mast cell activation
• Determination of minimal important differences for instruments that assess disease activity or impact relevant re-
sponse (e.g., UAS, CU-Q2oL)
• Clarification of the role of coagulation/coagulation factors in CSU
• Development of commercially available in vitro tests for detecting serum auto-antibodies for anti-IgE or anti-FcξRI
• Clarification of associated psychiatric/psychosomatic diseases and their impact
• Pathomechanisms in antihistamine-resistant urticaria/angioedema
• Double-blind control trials comparing different modern second- generation anti-H1s in higher doses in CSU and dif-
ferent subtypes of urticaria
• Regular v. on demand use of anti-H1 antihistamines on the duration of urticaria/severity of urticaria
• Multicenter studies on the possible effect of anticoagulants (oral and heparin derivatives) on CSU
• Controlled multicenter trials on the possible effect of add-on of anti-H2, montelukast, sulfone, methotrexate, aza-
thioprine
(Reproduced with permission from Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO Guideline for the defini-
tion, classification, diagnosis and management of Urticaria, The 2013 revision and update. 2014 Apr 30. doi: 10.1111/all.12313. 
[Epub ahead of print], with permission from Willey Blackwell.)
EAACI - GA2LEN - EDF - WAO guideline on urticaria
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s • Angioedema can be hereditary or acquired and is characterized 
by recurrent, acute episodes of cutaneous or mucosal swelling, 
more frequently of the face and neck
• Angioedema is one of the most frequent clinical manifestations 
of allergy and is often associated with drug, food or hymenoptera 
venom hypersensitivity
• Vasoactive mediators including histamine, bradykinin, 
leukotrienes, prostaglandins and platelet activating factor (PAF), 
are involved in the pathogenesis of angioedema
• Most attacks of angioedema are limited to the skin, but in some 
cases severe abdominal symptoms or life-threatening laryngeal 
angioedema may occur
• Different forms of angioedema respond to specific therapies 
and, therefore, precise diagnosis of the type of angioedema 
is mandatory for implementing an effective prevention and 
treatment
Angioedema is defined as local-
ized and self-limiting swelling of 
the subcutaneous and submucosal 
tissue, due to a transient increase 
in vascular permeability caused 
by the release of vasoactive medi-
ators (Figure 1). It frequently oc-
curs simultaneously with urticaria 
(the so called urticaria-angioede-
ma syndrome) with the concom-
itant appearance of wheals and 
angioedema. Urticaria and an-
gioedema share the same patho-
physiological events including an 
acute vasodilation of small vessels 
and an increase in vascular per-
meability leading to extravasation 
of plasma and macromolecules in 
the superficial dermis (urticaria) 
or deep dermis and subcutaneous 
tissue (angioedema). 
Massimo Triggiani  
University of Salerno 
Salerno, Italy
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Angioedema is becoming a very 
frequent clinical emergency and 
it is the second cause of hospital-
ization after asthma as an allergic 
disorder. The current classifica-
tion of angioedema identifies both 
hereditary and acquired forms of 
the disease. Hereditary angioede-
ma (HAE) is due to deficiency of 
C1 inhibitor (C1INH) a plasma 
protein that controls activation of 
the kinin system, the complement 
pathway and coagulation (Figure 
2). Deficiency of C1INH leads to 
uncontrolled generation of brad-
ykinin, a potent vasoactive medi-
ator that is responsible for HAE 
attacks. Rare forms of HAE with 
normal C1INH have been associ-
ated with activating mutations of 
Factor XII, the trigger of the brad-
ykinin cascade. Acquired forms 
of angioedema include those as-
sociated with allergic reactions, 
mostly induced by drugs, food or 
hymenoptera stings. These forms 
of allergic angioedema are due 
to vasoactive mediators such as 
histamine, prostaglandins, leu-
kotrienes and platelet activating 
Figure 1 A typical angiodema of 
the lips in a child with hereditary 
angioedema.
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Plasmin Fibrinolytic system
Kallikrein
Prekallikrein
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system
Bradykinin B2-R
C42
Bradykinin
ANGIOEDEMA
Figure 2 Mechanisms of angioedema due to C1 inhibitor (C1-INH) deficiency. Arrows indicate the biochemical steps 
controlled by C1-INH in the complement cascade, the kinin pathway and the fibrinolytic system. The generation of 
activated Factor XII (Factor XIIa), induced by local trauma, results in the conversion of prekallicrein into the active 
enzymatic form of kallicrein. This enzyme acts on high molecular weight kininogen (HMK) and generates bradykinin, 
a small peptide that induces angioedema by interacting with specific B2 receptors (bradykinin B2-R) expressed on 
endothelial cells and smooth muscle cells of small vessels.
factor (PAF) released by activat-
ed mast cells. Two other variants 
of acquired angioedema are me-
diated by bradykinin and include 
those due to an acquired deficien-
cy of C1INH, frequently associ-
ated with hematologic tumors, 
and angioedema induced by ACE 
inhibitors. ACE is a key enzyme 
responsible for bradykinin inacti-
vation and its blockade by ACE in-
hibitors, a commonly used class of 
antihypertensive agents, may trig-
ger acute attacks of angioedema 
in genetically predisposed individ-
uals. In many patients, however, 
the cause of angioedema remains 
unknown and they are defined as 
having “idiopathic” angioedema. 
Idiopathic angioedema can be ei-
ther histaminergic or non-hista-
minergic depending on whether 
antihistamines prevent it.
Regardless of its cause and wheth-
er hereditary or acquired, an-
gioedema is clinically character-
ized by recurrent swelling of the 
face (mostly eyelids and lips), neck, 
upper or lower extremities and ex-
ternal genitals. Mucosal angioede-
ma is most frequently localized to 
the mouth (tongue and uvula), the 
gastrointestinal tract, with severe 
abdominal pain resembling an 
acute abdomen syndrome, or to 
upper respiratory tract. Laryngeal 
angioedema is the most severe lo-
cation and may lead to death if not 
treated rapidly and appropriately. 
Even though allergic angioedema 
and angioedema due to C1INH 
deficiency have similar clinical 
features, their treatment is re-
markably different. Attacks of 
allergic angioedema usually re-
spond to antihistamines, gluco-
corticoids and epinephrine (if part 
of anaphylaxis), whereas those 
due to C1INH deficiency require 
treatment with C1 inhibitor (re-
placement therapy), ecallantide 
(a kallicrein inhibitor) or icatibant, 
a bradikinin B2 receptor antago-
nist. Table 1 summarizes the main 
clinical clues and the diagnostic 
tests to differentiate between the 
two main forms of angioedema. A 
rapid recognition of the type of an-
gioedema and a precise diagnosis 
is mandatory to initiate an appro-
priate treatment and to prevent 
life-threatening attacks of laryn-
geal angioedema. 
Angioedema
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TABLE 1
Main clinical features, diagnostic tests and treatments of allergic angioedema 
and angioedema due to deficiency of C1 INH
Allergic
(e.g. Anaphylaxis)
C1 Inhibitor Deficiency
(e.g. HAE)
Urticaria + -
Course Rapid (min) Slow (hours)
Duration 12 - 24 h 48 - 72 h
Laryngeal Edema +/- +
Bronchospasm Frequent Absent
Abdominal Pain Rare Frequent
Hypotension + -
Diagnostic Test Tryptase 
C1 Inhibitor (functional)
C4
Treatment
Epinephrine
Antihistamines
Steroids
C1 inhibitor
Icatibant
Ecallantide
KEY REFERENCES
1. Zuraw BL, Christiansen SC. 
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ma. Ann Allergy Asthma Immunol 
2012;109:395-402.
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Craig T, Li HH, Longhurst H et al.; 
HAWK (Hereditary Angioedema 
International Working Group). Ev-
idence-based recommendations 
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group. Allergy 2012;67:147-157.
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• Allergic contact dermatitis is a T-cell mediated, delayed-type 
hypersensitivity reaction in the skin, with skin-infiltrating, CD3+ 
CD4+ T helper cells
• The clinical features depend on the type of responsible allergens: 
usually, dermatitis occurs at the site of allergen application, but 
spreading of the dermatitis is possible
• A good history and patch testing are the mainstays for diagnosis 
• The management consists of the elimination or the reduction of 
contact allergens and the use of a topical steroid or of a topical 
calcineurin inhibitor
• Up to 70% of patients sensitized to wide-spread allergens will 
have some degree of chronic dermatitis 
Allergic contact dermatitis (ACD) 
is a typical manifestion a T-cell 
mediated, delayed-type hyper-
sensitivity reaction in the skin. 
Most allergens in allergic contact 
dermatitis are so-called haptens 
of low molecular weight and need 
to link with proteins (carriers) in 
the skin, before they become an-
tigenic. ACD is not related to ato-
py, however, patients with atopic 
dermatitis develop epicutaneous 
sensitizations more frequently as 
compared to non-atopic individ-
uals, probably due to the related 
barrier defect of the skin.
CD3+ CD4+ T helper are the ma-
jor skin-infiltrating cells. The role 
of skin-infiltrating CD8+ T cells is 
not clear yet, but a subpopulation 
of these cells may function as sup-
pressor cells, which dampen down 
the reaction. Spontaneous reso-
lution occurs after the antigen is 
removed and the T-cell mediators 
disappear. A number of cells (e.g. 
naïve or induced Tregs) and mol-
ecules (e.g. IL-10, prostaglandin E) 
are involved in the downregula-
tion of the inflammatory response. 
The clinical features of ACD de-
pend on the type of responsible al-
lergens. Usually, dermatitis occurs 
at the site of allergen application, 
but spreading of the dermatitis is 
Thomas Werfel  
Hannover Medical School 
Hannover, Germany
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Allergic contact dermatitis
possible (Figure 1a and b). Contact 
dermatitis caused by an airborne 
material may be difficult to iden-
tify, but this can occur (e.g. with 
plants or volatile preservatives in 
wall colors). If a contact allergen 
is ingested or inhaled it can rare-
ly lead to hematogenous allergic 
contact dermatitis. 
Worldwide, nickel sulfate is the 
leading cause of ACD. Women 
present more commonly than men 
with ACD, and there is an increase 
in incidence with advancing age. 
A good history and patch testing 
(Figure 2) are the mainstays in 
the diagnosis of allergic contact 
dermatitis. In taking the patient’s 
history, it is important to consider 
occupational, household, and rec-
reational exposure to possible al-
lergens. Once there is a suspicion 
of ACD, patch testing is indicated. 
The European baseline series from 
the European Society of Contact 
Dermatitis is a recommendation 
of a minimum set of allergens to 
which European patients should 
be tested (http://www.escd.org/
aims/standard_series/). These can 
be adapted to regional occurenc-
es of contact allergens and can be 
monitored to estimate incidence 
of contact sensitzations to indi-
viduals allergens. According to the 
history, a more extensive allergen 
set shall be applied, if ACD is sus-
pected. 
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The management of all types of 
suspected ACD consists of the 
elimination or the reduction of 
contact allergens and the use of 
a topical steroid or – particularly 
in sensitive areas (face, intertrig-
inous sites) – a topical calcineurin 
inhibitor to return the skin to a 
normal state. Allergen avoidance 
can be simple or virtually impossi-
ble at other times. Unfortunately, 
up to 70% of patients sensitized 
to wide-spread allergens will still 
have some degree of dermatitis 
after some years. 
Physicians who perform patch 
testing must be able to commu-
nicate to the patient materials, 
which may contain offending aller-
gens. The identification of a causa-
tive occupational contact allergen, 
which may be avoided thereaf-
ter can help to keep a patient at 
a workplace. It is recommended 
that the patient gets an ‘allergy 
passport’ with information about 
identified allergens. 
KEY REFERENCES 
1. Mortz CG, Andersen KE. New as-
pects in allergic contact dermati-
tis. Curr Opin Allergy Clin Immunol 
2008;8:428-432. 
2. Schnuch A, Geier J, Lessmann H, 
Arnold R, Uter W. Surveillance of 
contactallergies: methods and re-
sults of the Information Network 
of Departments of Dermatology 
(IVDK). Allergy 2012;67:847-857. 
3. Spiewak R. Contact dermatitis in 
atopic individuals. Curr Opin Allergy 
Clin Immunol 2012;12:491-497. 
4. Thyssen JP, McFadden JP, Kimber 
I. The multiple factors affecting the 
association between atopic derma-
titis and contact sensitization. Aller-
gy 2014;69:28-36.
Figure 1 a - Nickel allergy induced by a nickel containing jeans button; b - 
Chronic hyperkeratic allergic contact dermatitis to chromium. Irritant contact 
dermatitis is an important differential diagnosis.
Figure 2 Patch testing and a positive patch test reaction.
Allergic contact dermatitis
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• Allergy to natural rubber latex protein can result in a spectrum 
of presentations from localised erythema and burning to contact 
urticaria and anaphylaxis
• Individuals at risk of developing latex allergy are atopics, 
healthcare and rubber industry workers and patients with spina 
bifida 
• Allergic reactivity depends on the IgE sensitization profile to 
latex proteins in rubber
• The latex allergy epidemic starting in 1980’s has been controlled 
by measures to identify and avoid products containing latex in 
at risk settings and removal of powdered latex gloves from the 
workplace
Latex allergy emerged as a ma-
jor public health problem in the 
1980’s from the widespread use 
of latex gloves in the healthcare 
setting to protect against the 
transmission of viral infections, 
including hepatitis and human im-
munodeficiency virus, on a back-
ground of a rising prevalence of 
atopic disease. The presentation 
of IgE-mediated Type I latex aller-
gy ranges from mild itching and 
erythema at the site of skin or mu-
cosal contact, localised urticaria 
(Figure 1) to anaphylaxis. This di-
verse spectrum of reactions has 
been referred to as the contact 
urticaria syndrome. 
Individuals at risk of immediate 
hypersensitivity reactions to la-
tex include health care workers, 
dentists, patients with spina bifi-
da requiring long term catheter-
isation, those with atopy or hand 
dermatitis and workers in the rub-
ber industry. Wearing powdered 
gloves appears to increase the risk 
of allergic sensitisation substan-
tially and these have been banned 
in most healthcare settings in fa-
vour of non-powdered gloves and 
non-rubber alternatives, including 
vinyl and nitrile. Coupled with the 
adoption of stringent corporate 
measures to identify and avoid 
Clive E. Grattan  
Norfolk and Norwich University Hospital  
Norwich, UK
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Figure 1 Contact urticaria due to a household rubber glove.
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latex exposures in risk settings 
(Table 1) and the reduction of 
leachable latex protein in person-
al products has reduced the ‘latex 
epidemic’ to manageable propor-
tions in most settings, although it 
is likely to remain a potential prob-
lem for many more years, because 
sensitisation is probably lifelong. 
Developing allergic contact der-
matitis to chemicals used in the 
manufacture of rubber products 
(type IV hypersensitivity), includ-
ing rubber accelerators, and the 
risk of irritant contact dermatitis 
through prolonged glove wearing 
remains a problem in some occu-
pations, including dentistry, hair-
dressing, mechanics and manufac-
turing industry. 
Natural rubber latex is harvest-
ed from the rubber tree, Hevea 
braziliensis, which is indigenous 
to the Amazon region, but mainly 
cultivated in Malaysia and Thai-
land. Latex forms the cytoplasm of 
specialized cells called lacticifers 
that function to seal damaged 
sites. It contains water, rubber 
(cis-1,4-polyisoprene), protein, 
resins, sugars, ash and sterol gly-
cosides. 
In adult latex allergic patients, pro-
hevein (Hev b 6.01), hevein (Hev 
b 6.02), rubber elongation factor 
(Hev b 1) and Hev b 5 are impor-
tant allergens. In children with spi-
na bifida or those with a history of 
multiple operations, Hev b 1 and 
rubber elongation factor homo-
logue (Hev b 3) are important. Hev 
b 8, on the other hand is a profilin 
with high cross-reactivity to many 
species of tree (including silver 
birch), grass, vegetable and some 
fruits (the latex-fruit syndrome). 
IgE against Hev b 8 was the com-
monest mono-sensitisation on 
microarray in a series of 41 pa-
tients with elevated specific latex 
IgE, but only one of them showed 
symptoms, illustrating that clinical 
latex allergy depends on the sen-
sitization profile to the different 
latex proteins in rubber. 
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2013;3:11.
3. Larese Filon F, Bochdanovits L, 
Capuzzo C, Cerchi R, Rui F. Ten 
years incidence of natural rubber 
latex sensitization and symptoms 
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care workers using non-powdered 
latex gloves 2000-2009. Int Arch 
Occup Environ Health 2013 May 23. 
[Epub ahead of print]
4. Merget R, van Kampen V, Sucker 
K, Heinze E, Taeger D, Goldscheid 
N et al. The German experience 
10 years after the latex allergy ep-
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with latex allergy. Int Arch Occup En-
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TABLE 1
Risk minimization measures for latex allergy in operating theatres
• Identify patients at risk by pre-operative assessment (history, measurement of 
specific IgE and skin prick testing)
• Clear identification of at risk patients in theatres (ID bracelet and chart alerts)
• Careful pre-operative assessment by the anaesthetist
• First on the morning list for operations
• Avoidance of all latex products, including gloves, catheters, anaesthetic equip-
ment, giving sets with natural rubber latex ports, vials and syringes with rub-
ber stoppers
• Resuscitation facilities immediately available.
Latex allergy
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• Hymenoptera stings may cause systemic reactions of varying 
severity up to fatal anaphylaxis
• Several new factors influencing the severity of hymenoptera 
sting reactions in untreated patients have been identified
• Component resolved diagnosis might greatly enhance the 
accuracy of the diagnosis, allowing physicians to optimize patient 
selection for immunotherapy
• Subcutaneous venom immunotherapy is the only effective 
treatment for hymenoptera venom allergic patients and also 
improves health-related quality of life
• The general population and healthcare workers need to be 
made more aware of the disease and the availability of venom 
immunotherapy
Hymenoptera stings are respon-
sible for significant morbidity 
and deterioration in health-relat-
ed quality of life (HRQL) due to 
the allergic reactions they cause, 
ranging from large local reactions 
(LLRs) to the most severe system-
ic reactions (SR), which can cul-
minate in fatal anaphylaxis. The 
offending hymenoptera belong 
to the suborder Aculeate, which 
are made up of the Apoidea (Apis 
mellifera and Bombus species) and 
Vespidae (Vespinae and Polistinae 
subfamilies) (Figure 1). In the USA, 
stinging hymenoptera also include 
the fire ant (Solenopsis invicta), and 
in Australia, the jack jumper ant 
(Myrmecia pilosula). Worldwide 
epidemiological studies report a 
prevalence of SRs between 0.3 
% and 8.9 %, with anaphylaxis re-
ported in 0.3–42.8% of cases. The 
prevalence of SRs in paediatric 
subjects seems to be lower. 
To date, there is no existing pa-
rameter that enables clinicians to 
predict, who will have a future re-
action and whether it will be a LLR 
or generalized anaphylaxis. Sev-
eral concomitant factors, which 
include the environment, genetics 
and individual elements, may ac-
count for the occurrence and the 
M. Beatrice Bilò  
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severity of a SR (Table 1).
The skin tests (usually intrader-
mal) continue to play a fundamen-
tal role in the diagnosis of venom 
allergy. Component resolved di-
agnosis might greatly enhance the 
accuracy of the diagnosis, allowing 
physicians to optimize patient se-
lection for immunotherapy, espe-
cially in ‘double-positive’ patients. 
However, some relevant venom 
allergens are not commercially 
available in the recombinant form. 
Additional tests (like basophil ac-
tivation test) are restricted to lab-
oratories with expert technicians 
for the moment.
Patients with a history of a sys-
temic reaction are strongly ad-
vised to carry emergency kits con-
taining self-injectable epinephrine 
and to refer to an allergy specialist 
for evaluation and consideration 
of venom immunotherapy (VIT).
Subcutaneous VIT is a highly effec-
tive treatment, which is designed 
to reduce the risk of a subsequent 
SR, prevent morbidity and also 
improve HRQL. While there is a 
strong consensus that VIT is indi-
cated for severe SRs, there is less 
agreement on whether adults, and 
especially children, with systemic 
cutaneous reactions are suitable 
candidates, as the prognosis in 
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TABLE 1
Factors influencing the severity of Hymenoptera stings 
• History of prior severe sting reaction (with respiratory or cardiovascular 
symptoms)
• Insect type (honeybee, European hornet)
• Older age
• Mast cell diseases, elevated baseline serum tryptase concentration 
• Pre-existing disease (cardiovascular and respiratory diseases)
• Treatment with beta blockers, angiotensin-converting enzyme inhibitors
TABLE 2
Risk factors for side effects during VIT 
• Honeybee venom 
• Build-up phase 
• Fast increase schedule 
• Mastocytosis, elevated baseline serum tryptase concentration (build-up 
phase) 
• Cardiovascular diseases
• Treatment with beta-blockers*, ACE-inhibitors*
* Not confirmed by all studies
Vespula 
germanica
Apis 
mellifera
Polistes 
dominulus
Vespa 
crabro
dermal reactors is usually consid-
ered to be good. A better knowl-
edge of risk factors for VIT side ef-
fects may reduce their occurrence 
(Table 2).
A number of new strategies for 
VIT, mostly based on recombinant 
technologies are evaluated, as 
well as alternative routes for the 
administration of VIT, the majority 
of which have not yet been used in 
humans.
Figure 1 Pictures of Hymenoptera.
Insect sting allergy
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• Occupational allergy is the result of an interaction between 
multiple genetic, environmental and behavioral influences
• Diagnosing occupational allergy is a complex undertaking, 
the primary goal of which is to demonstrate a causal relation 
between exposure to a specific agent encountered at work, 
allergic responses and symptoms
• A reliable diagnosis is of utmost importance for the management 
of patients with occupational allergy, since the treatment is 
essentially based on the avoidance of the allergen source 
• The clinical history is a key element of the investigation of 
occupational allergic disorders. Immunologic tests should be 
performed to identify sensitization to specific occupational 
allergens 
• Environmental control is crucial for prevention, and every effort 
should be made to keep the workplace without an exposure 
hazard
Occupational allergy refers to 
those disorders or conditions that 
are caused by exposure to sub-
stances in the work environment 
and in whose pathogenesis aller-
gic factors are determinant. The 
allergic diseases that may be con-
tracted as a consequence of expo-
sure to sensitizing agents in the 
workplace are rhinitis, conjuncti-
vitis, asthma, eosinophilic bron-
chitis, hypersensitivity pneumo-
nitis, allergic contact dermatitis, 
immunologic contact urticaria and 
occupational anaphylaxis. When 
these disorders are not caused by 
occupational exposures, but are 
aggravated in the workplace the 
term work-exacerbated is used. 
Workplace agents are complex 
mixtures of specific and non-spe-
cific components (Figure 1). Sen-
sitization precedes the develop-
ment of allergic symptoms, which 
may follow the pattern of an “oc-
cupational allergic march” (Figure 
2). 
Occupational rhinitis is an in-
flammatory disease of the nose, 
characterized by intermittent or 
persistent nasal symptoms, and/
or variable nasal airflow limita-
tion and/or hypersecretion due to 
causes and conditions attributable 
to a particular work environment 
Santiago Quirce  
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Occupational allergy
and not to stimuli encountered 
outside the workplace.
Occupational asthma (OA) re-
fers to de novo asthma or the re-
currence of previously quiescent 
asthma induced by either sensiti-
zation to a specific substance (eg, 
an inhaled protein or a chemical at 
work), which is termed allergic or 
sensitizer-induced OA, or by expo-
sure to an inhaled irritant at work, 
which is termed irritant-induced 
OA (Figure 3). Approximately 372 
different causes of allergic OA 
have been identified. These agents 
are categorized into high-molec-
ular-weight (HMW) compounds, 
which are proteins acting through 
an IgE-mediated mechanism, and 
low-molecular-weight (LMW) 
compounds, which are chemical 
sensitizers that, with few excep-
tions, are not associated with an 
IgE-dependent mechanism. 
Hypersensitivity pneumonitis 
(HP) is an allergic lung disease that 
occurs as the result of an immu-
nologic inflammatory reaction to 
the inhalation of any of a variety of 
organic dusts or LMW chemicals 
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with or without systemic manifes-
tations. The disease is a diffuse, 
predominantly mononuclear in-
flammation of the lung parenchy-
ma, particularly the terminal bron-
chioles, interstitium, and alveoli. 
There is a wide variety of agents 
that can cause the disease, most 
of which are present in the work-
place. Pathogenic mechanisms of 
OA and HP are summarized in Fig-
ure 4. 
Occupational allergic contact 
dermatitis is one of the most com-
mon occupational diseases. Mak-
ing a timely and accurate diagno-
sis is important to improving the 
outcome. Taking a work history 
and patch testing are essential el-
ements in the diagnostic process.
The appropriate treatment of 
occupational allergic disorders 
remains early removal from expo-
sure to the causative agent, in ad-
dition to providing conventional 
allergy treatment.
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Figure 1 Source of exposure (complex organic dusts or chemicals) contains 
specific and non-specific components, relevant antigens or haptens and possible 
adjuvants (cofactors), as well as the true disease-eliciting molecules.
Onset 
of exposure
Allergic sensitization
•  IgE-mediated
•  Non-IgE-mediated
[Contact dermatosis]
Occupational rhinitis/
conjunctivitis
Occupational asthma
Figure 2 The theoretical model of the natural history of allergic occupational 
asthma considers that exposed workers first develop immunological reactivity 
and subsequent to this, symptoms related to a specific organ (skin, naso-
conjunctival, respiratory). Cutaneous manifestations may be present or not. 
This sequence can be termed the ‘occupational allergic march’. 
Occupational allergy
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Figure 3 Classification of work-related asthma and work-related rhinitis. (Reproduced with permission from Moscato G, 
Vandenplas O, Gerth Van Wijk R,et al. Occupational rhinitis. Allergy 2008;63:969-980, with permission from Willey Blackwell.)
Figure 4 Inhaled allergens can give rise to either asthma or hypersensitivity pneumonitis (HP). Asthma is considered 
to be a Th2 disease, whereas the pathogenesis of HP is much more complex, with significant participation of delayed 
hypersensitivity, Th1 cytokines and CD8+ cells. 
Allergen
TH2 cells 
eosinophils 
mast cells
IgE
IL-4/5/13
Asthma
TH1 cells 
macrophages 
CD8+ cells
MIP-1α TNF-α
IL-2/8/12/IFNγ
HP
Occupational allergy

Section E
OTHER HYPERSENSITIVITY DISEASES
* Eosinophilic esophagitis
* Food protein-induced enterocolitis syndrome 
* Reactions to food and drug additives
* Adverse reactions to vaccines for infectious 
diseases
* Allergic bronchopulmonary aspergillosis 
* Hypersensivity pneumonitis
* Mastocytosis
* Hypersensitivity vasculitis
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s • Dysphagia for solids is a red flag sign requiring a gastro-
eosophageal endoscopy
• Eosinophilc esophagitis (EoE) is a clinicopathological entity 
diagnostically based on symptoms and eosinophil-predominant 
inflammation of the esophageal mucosa
• Patients with active EoE have to be treated in order to prevent 
food impactions and esophageal remodeling
• Drugs (topically steroids), diet and dilation are the currently 
available treatment modalities
HISTORY
The esophagus is a simple tubular 
organ, responsible for the trans-
port of food from the oral cavity to 
the stomach. Originally no striking 
absorptive or immunologic func-
tions were attributed to this organ. 
In the mid-1990s, two case series 
described patients suffering from 
dysphagia accompanied by a prom-
inent eosinophilic infiltration of the 
esophagus. Eosinophilic esophagi-
tis (EoE) was recognized as its own 
entity in the medical literature.
MOLECULAR AND CLINICAL 
CHARACTERISTICS
EoE represents a Th2-type inflam-
matory disease with IL-5, IL-13 
and eotaxin as key mediators and 
eosinophils, T cells and basophils 
as critical cells involved. Remode-
ling of the esophagus is a hallmark 
of EoE, leading to esophageal 
dysfunction and bolus impaction. 
Familial occurrence, an inflamma-
tion-dependent genetic signature 
together with a genetic abnormal-
ity in the eotaxin 3 genes under-
score the influence of genetics in 
this disease. 
EoE may affect individuals at any 
age, though the clinical presenta-
tion is highly age-dependent. 
Whereas children show a wide 
spectrum of symptoms, including 
chest pain, feeding problems and 
failure to thrive, adults present 
with a rather narrow spectrum, 
specifically, dysphagia for solids 
up to food impaction. 
There is a significant allergic bias 
in the EoE population, with more 
than 70% of patients having con-
current allergic rhinitis, asthma, 
eczema and/or a history of atopy. 
Of note, in children, EoE seems to 
be primarily a food antigen driven 
disease, whereas in adults, main-
ly aeroallergen sensitization has 
been observed. 
ENDOSCOPICAL AND 
HISTOLOGICAL FEATURES
Endoscopy reveals some typical 
signs, such as edema with loss of 
vascular pattern, longitudinal fur-
rows and white exudates in the 
acute inflammatory stage (Figure 
1), and strictures and rings, lead-
ing to a rigid and narrow esopha-
gus in the fibrotic stage (Figure 2).
Histopathologic key feature of 
EoE is a characteristic prominent 
eosinophil infiltration (Figure 3), 
refractory to treatment with pro-
ton-pomp inhibitors.
TREATMENT
Treatment modalities for EoE in-
clude the 3D’s: Drugs, mainly top-
ical corticosteroids and biologic 
agents, Diet, and Dilation. Due 
to their convincing efficacy with 
response rates of approximately 
70% swallowed topical corticos-
teroids are considered as first line 
drugs, whereas biologicals or im-
munosuppressant’s are used only 
for refractory disease. 
Alex Straumann  
University Hospital Basel 
Basel, Switzerland
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Eosinophilic esophagitis
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Among dietary approaches, ele-
mental diet avoiding any proteins 
is the most powerful modality, 
but requires usually a nasogastric 
feeding tube. Dilation is efficient 
in relieving symptoms, but does 
not influence the underlying in-
flammation and is therefore main-
ly used as second line modality in 
patients having strictures refrac-
tory to medical or dietary treat-
ment.
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Figure 1 Endoscopic picture from a patient with active EoE, 
showing a typical combination of several inflammatory signs, in 
particular white exudates, longitudinal furrows and edema. 
Figure 2 Endoscopic picture from a patient with longstanding 
EoE, showing a minimal inflamed mucosa but distinct fibrotic rings. 
Figure 3 Esophageal mucosa from a patient with active EoE 
showing a marked infiltration of the epithelium with eosinophils. 
(HE staining, original magnification 400x.) 
Eosinophilic esophagitis
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as a non-IgE-mediated food allergy
• FPIES-diagnosis is frequently delayed due to absence of allergic 
cutaneous and respiratory symptoms and lack of biomarkers
• Supervised oral food challenge is necessary for monitoring FPIES 
resolution
• FPIES is usually outgrown by age 3-5 years; IgE-sensitization 
may develop in a subset of subjects and seems to be associated 
with a more protracted course
Food protein-induced enter-
ocolitis syndrome (FPIES) is a 
non-IgE-mediated food aller-
gy with typical onset in infancy. 
FPIES is characterized by repeti-
tive vomiting that begins approx-
imately 2 hours following food 
ingestion, and often progresses to 
lethargy, diarrhea and additional 
signs and symptoms suggesting 
a systemic reaction distinct from 
IgE-mediated anaphylaxis (e.g., 
lacking urticaria or obstructive 
respiratory symptoms). In severe 
cases (about 15%) hypothermia, 
methemoglobinemia, acidemia, 
and or hypotension/shock may 
develop. Laboratory findings typ-
ically reveal elevated white blood 
cells with neutrophilia, and may 
include thrombocytosis. In young 
infants, the presentation often 
mimics sepsis. 
Manifestations of FPIES vary de-
pending on the exposure to the 
offending food and may be acute 
of not of chronic (Table 1). The ap-
pearance of acute symptoms fol-
lowing a period of food avoidance 
is the feature that distinguishes 
FPIES from other gastrointestinal 
food allergy disorders, such as en-
teropathy, eosinophilic gastroen-
teritis, or celiac disease. 
In the majority of children (>60%) 
Anna Nowak-Węgrzyn  
Icahn School of Medicine at Mount Sinai 
New York, USA 
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Food protein-induced enterocolitis syndrome 
FPIES is caused by a single food. 
The most common single food al-
lergens in FPIES are cow’s milk 
(CM), soy and rice. Solid foods 
including cereal proteins such as 
rice and oat, egg, fish, vegetables, 
and poultry have been reported 
in children, whereas shellfish and 
mollusks have been reported in 
adults. 
The prevalence of FPIES is un-
known. The only population-based 
birth cohort study in Israel report-
ed CM-FPIES in 0.34% of 13,019 
infants, compared to 0.5% of 
IgE-mediated CM-allergy diag-
nosed in the first year of life. 
The pathophysiology of FPIES re-
mains poorly defined. Ingestion 
of food allergens may cause local 
inflammation leading to increased 
intestinal permeability and flu-
id shift. Antigen-specific T cells 
and imbalance between TGF-β 
and IFN-γ that affects intestinal 
barrier permeability may play a 
role. Systemic food-specific IgE 
antibodies are typically absent in 
FPIES. 
Diagnosis of FPIES relies on recog-
nition of a constellation of symp-
toms and an oral food challenge 
(OFC) (Table 1 and 2). In infants 
with classic symptoms, recurrent 
reactions, especially associated 
with hypotension, and who are 
well when the food is eliminated, 
OFC may not be necessary for an 
initial diagnosis. OFCs are neces-
sary for evaluating for FPIES reso-
lution. Management relies on food 
elimination, treatment of acute re-
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TABLE 1
Characteristics of acute and chronic FPIES
Acute FPIES (Food ingested intermittently)
Chronic FPIES* (Food ingested on a regular 
basis, e.g. CM or soy infant formula)
Clinical 
features
Always: Vomiting: onset usually in 2 hours [30 min-4 
hours], repetitive (up to 10-20 times), may be severe and 
projectile; Almost always: pallor, lethargy; Other varia-
ble features: dehydration, diarrhea (onset usually within 
12 h), bloody diarrhea, abdominal distention, hypoten-
sion, hypothermia
Intermittent vomiting, diarrhea, lethargy, 
weight loss, failure to thrive, weight gain <10 
g/day, bloody diarrhea, abdominal distention, 
Dehydration
Symptoms usually resolve within 6-12 hours Symptoms usually resolve within several days
Laboratory 
features
Elevated white blood count (WBC) with left shift, throm-
bocytosis, methemoglobulinemia, acidosis
Elevated WBC with left shift and eosinophilia, 
anemia, hypoalbuminemia, low total protein, 
acidosis, methemoglobulinemia
Stool: Blood, mucous, sheets of leukocytes and eosino-
phils, and increased carbohydrate content
Stool: Occult blood, polymorphonuclear neu-
trophils, eosinophils, Charcot-Leyden crystals 
and reducing substances
Intramural gas may be seen on abdominal x-rays
Air-fluid levels, non-specific narrowing and 
thumb-printing of the rectum and sigmoid, and 
thickening of the plicae circulares in the duo-
denum and jejunum with excess luminal fluid
Endoscopy: friable mucosa with rectal ulceration and 
bleeding 
Endoscopy: friable mucosa with rectal ulcera-
tion and bleeding 
Food triggers Any food; most common CM, soy**, and rice CM and soy
Age of onset
Any; most cases start under 1 year but fish and shellfish 
FPIES may start at any age
Within 1st year of life
Diagnosis
Based on typical clinical manifestations; oral food challenge 
(OFC) may be not necessary in infants with repeated reac-
tions, especially with hypotension, who are well when food 
is eliminated from the diet. Skin prick tests and serum spe-
cific IgE antibodies to offending food(s) usually negative
Suspected on the basis of clinical manifesta-
tions, confirmed by a supervised OFC follow-
ing a period of dietary food elimination. Skin 
prick tests and serum specific IgE antibodies to 
offending food(s) usually negative
Differential 
diagnosis
Sepsis; Gastrointestinal infections; Anaphylaxis; Ileus, in-
tussusception; Necrotizing enterocolitis (NEC); 
Eosinophilic gastro-enteropathies, Food protein-in-
duced enteropathy, Allergic proctocolitis; Celiac 
disease; Inborn errors of metabolism; Congenital 
methemoglobinemia; Cardiovascular or neurologic 
disorders; Gastroesophageal reflux disease
Management
Strict food elimination, may require nutritional consul-
tation; breast-feeding is usually well tolerated; Fluid re-
suscitation; Single dose of methylprednisolone for more 
severe reactions; Ondansetron may be considered for 
severe emesis; Bicarbonate for acidosis; Methylene blue 
for methemoglobulinemia; Food reintroduction can be 
attempted within several months following the most re-
cent reaction; in one approach, OFC is delayed for 12-18 
months following a reaction***
Strict food elimination, may require nutrition-
al consultation; breast-feeding is usually well 
tolerated
Fluid resuscitation
Bicarbonate for acidosis 
Methylene blue for methemoglobulinemia
Temporary bowel rest with intravenous feed-
ing
Age of 
resolution
Variable, population-dependent; CM-FPIES resolution by age 3 years ranges from 30% in referral popula-
tion to 100% in unselected populations
* Chronic FPIES has become uncommon, presumably due to the wide availability of the hypoallergenic infant formulas that are 
being used empirically.
** In the US the reactivity to both CM and soy, as demonstrated in single center retrospective case series, has been noted to range 
between 30-50%. However, outside the US, a far smaller percentage of children suffer concomitant FPIES to CM and soy.
***This is an empiric approach; controlled studies are necessary to develop evidence-based guidelines for FPIES management.
Food protein-induced enterocolitis syndrome 
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TABLE 2
Characteristics of acute and chronic FPIES
Basic requirements
Physician supervision
Secure peripheral intravenous access in patients with history of severe FPIES re-
actions or those with anticipated difficult access, e.g., infants
Immediate availability of fluid resuscitation
Baseline laboratory tests Peripheral neutrophil count [complete blood count with differential]
Challenge administration
Food amount is calculated as 0.06 - 0.6 g/kg body weight in three equal doses, 
generally not to exceed total 3 g protein or 10 g of total food (100 ml of liquid) for 
an initial feeding*
Food is divided in 3 equal portions and fed over 30 minutes if food-specific IgE is 
negative; modification of the challenge and more incremental dosing is used for 
patients with positive food-specific IgE
Treatment of the reaction
Fluid resuscitation: 20 ml/kg IV boluses of normal saline
Steroids: methylprednisolone 1 mg/kg IV, max 60 to 80 mg
The role of intravenous ondansetron in the management of acute FPIES reactions 
is being currently evaluated
Epinephrine and antihistamines are not effective in FPIES
Post-challenge laboratory tests
Peripheral neutrophil count [completed blood count with differential]: at 6 hours 
if the patient reacted or at discharge if the patients tolerated the challenge
If stool sample available: test for occult blood and stool smear for leukocytes
Post-challenge observation
About 6 hours after the resolution of symptoms or 4 hours after feeding in case 
of no symptoms
Criteria for challenge positivity**
1. Emesis (onset 0.5-4 hours, usually 2 hours)
2. Diarrhea (onset 2-10 hours, mean 5 hours) 
3. Elevated neutrophil count (>3500 cells/mL, peaks at 6 hours)
4. Fecal leukocytes
5. Fecal eosinophils
*If no reaction in 2-3 hours, administer an age appropriate serving of the food followed by several hours of observation; 
** Challenge is considered positive if 3 of 5 criteria are met and equivocal if 2 of 5 criteria are met. 
actions and periodic OFC, as out-
lined in Figure 1.
Resolution of FPIES varies wide-
ly among reports from different 
countries. The Israeli birth cohort 
showed 90% resolution of CM-
FPIES by age 3 years, whereas 
experience from allergy referral 
populations in the U.S. showed 
60% resolution by age 3 years. 
Sicherer et al.observed that chil-
dren with detectable food-specific 
IgE tend to have a more protracted 
course and are at risk of develop-
ing IgE-mediated immediate-type 
symptoms. Therefore, including 
SPT and/or measurement of se-
rum food-specific IgE levels in the 
initial as well as follow-up eval-
uations is prudent to determine 
timing and the type of oral food 
challenges. 
 Further research should focus on 
the pathophysiology and natural 
history of FPIES, as well as the 
unique diagnostic tools for initial 
diagnosis and monitoring of toler-
ance development.
Food protein-induced enterocolitis syndrome 
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Food protein-induced enterocolitis syndrome 
Figure 1 Empiric approach to FPIES management. (*The timing of the follow up food challenges is arbitrary; food 
challenge may be performed earlier or deferred for a longer time, depending on individual circumstances. ** A subset 
of patients may develop IgE-sensitization and progress to immediate symptoms, requiring modification of the oral food 
challenge procedure)
Confirmed FPIES
Strict avoidance of the offending food for about 12-18 months
Gradual introduction of new foods
Interim accidental reactions
Continue avoidance
Re-evaluate n in 12-18 months*
Perform skin prick test and / or blood level of 
food-specific IgE antibody**
Perform an oral food challenge 
under physician supervision with 
intravenous line in place
Obtain baseline CBC with differential
Administer 3 equal doses of food 
over 30 minutes
Consider delaying OFC or FPIES 
oral food challenge under physician 
supervision with intravenous line 
in place; obtain baseline CBC with 
differential; administer incremental 
doses of food every 10-15 minutes 
due to the risk of an acute allergic 
reaction
No symptoms after 4-6 hours
FPIES resolved
Add food to the diet at home
Symptoms [emesis] and 
elevated neutrophil count
Continue strict food avoidance’ 
re-evaluate on 12-18 months*
Yes No
Negative
Negative Positive
Positive
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proven by double-blind placebo-controlled food challenge
• The frequency of non-IgE dependent food or drug 
hypersensitivity reactions in the general population is 1-2%
• Food and drug additives (e.g. colorants, preservatives) can 
trigger immediate hypersensitivity reactions
• Clinical manifestations include primarily urticaria, asthma and 
eczema
•  A possible association between the high intake of food additives 
and hyperreactivity is highly controversial
Food or drug intolerance describes 
any reaction to food or drugs 
ranging from food toxicities to re-
producible symptoms consistent 
with an IgE-mediated reaction to 
non-reproducible symptoms such 
as diarrhoea or headache. 
Reported triggers include natu-
rally derived and artificial food or 
drug additives including colour-
ings, flavourings and preservatives, 
but also other ingredients such as 
lactose and artificial sweeteners. 
Patient-reported rates of food 
intolerance range from 7 to over 
20%. The reported rate is 6 to 10 
times greater than the prevalence 
determined through double-blind 
placebo-controlled food challenge 
(DBPCFC). Approximately 1 to 2% 
of the population may have non-al-
lergic food hypersensitivity. Drug 
intolerance due to additives has 
been rarely reported in the liter-
ature, but there are no controlled 
prospective studies on its preva-
lence.
Immune reactions are usually me-
diated through non-IgE mediated 
mast cell degranulation (Figure 1). 
Non-immune reactions might be 
derived due to:
1. Pharmacological effects: Food 
rich in vasoactive amines (e.g. 
histamine) can induce symp-
Margitta Worm  
Charité-Universitätsmedizin  
Berlin, Germany
REACTIONS TO FOOD AND 
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Reactions to food and drug additives
toms, either by direct action or 
by causing the release of hista-
mine in vivo.
2. Enzyme deficiencies: Exces-
sive consumption of fruit juices 
(fructose) or sugar-free foods 
(sorbitol) can promote anos-
motic diarrhoea which may mis-
takenly be diagnosed as food 
intolerance.
Food or drug additives are used 
to resolve or improve the texture 
and taste of the related products. 
Tartrazine, the most studied ad-
ditive is an artificial food colorant 
reported to provoke urticaria, ec-
zema, vasculitis, asthma and even 
anaphylaxis. Sulfite is also used 
to preserve food and drugs. It 
can cause bronchoconstriction in 
children and in adults with asth-
ma. Benzoic acid is a preservative 
in drinks and pickled foods and is 
also frequently found in liquid for-
mulations of common medicines 
including non-steroidal antiin-
flammatory drugs. Benzoate can 
trigger urticaria, atopic eczema 
or rhinitis. Monosodium gluta-
mate is obtained synthetically and 
is used as a flavour enhancer in 
many foods. It has been reported 
in a set of symptoms known as the 
“Chinese restaurant syndrome”, 
which includes flushing, headache 
and palpitations. Salicylates in-
volvement is controversial and de-
pends on their acetylation status. 
Acetylated salicylates can trigger 
asthma, but also other symptoms 
of an allergic reaction.
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Such provocation tests are also 
applicable if a drug additive hyper-
sensitivity reaction is suspected. 
In the absence of a positive DBPC 
challenge the elimination diet 
should be stopped. 
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Figure 1 Possible mechanisms of additive triggered mast cell activation.
TABLE 1
Examples of food or drug additives triggering non-IgE hypersensivity reac-
tions
Colourings
Colourings may trigger symptoms in chronic urticaria and 
atopic dermatitis.
Tartrazine may trigger bronchospasm in a limited number of 
individuals with asthma.
Preservatives
Benzoates & acetylated salicylates (aspirin) may be a trigger 
in chronic urticaria and atopic dermatitis.
Sulfites can trigger asthma, probably through release of 
sulphur dioxide.
Artificial 
Sweeteners
The few case reports of urticaria to aspartame were not 
replicated by most studies using DBPC challenges.
Flavouring/
enhancers
The hypothesis that monosodium glutamate causes 'chinese 
restaurant syndrome' was not replicated with DBPC 
challenges.
Antioxidants
The few case reports of urticaria to BHA/BHT were not 
replicated with DBPC challenges.
A summary of evidence for food 
additives and colourings as a cause 
of non-allergic food hypersensitiv-
ities is depicted in table 1.
An association between the high 
intake of food additives and hyper-
activity is highly controversial. The 
Southampton Study published in 
2007 reported a small, but statisti-
cally significant increase in hyper-
activity levels with additives com-
pared to placebo, but the effect 
was not consisted across both age 
groups and the overall effect did 
not reach statistical significance. 
In summary, there is not enough 
consistent data to confirm a role 
of food colourings in hyperactive 
behaviours.
The standard diagnostic proce-
dure in patients with suspected 
non-IgE-mediated food hypersen-
sitivity to additives is an elimina-
tion diet over 4 weeks followed by 
DBPC challenges using the addi-
tives in standard concentrations. 
mast 
cell
drugs
food additives
(e.g. benzoate, 
dyes
mediator 
release
asthma
urticaria
atopic 
eczema
direct activation?
secondary messenger?
G-proteins?
Fcε-RI?
Reactions to food and drug additives
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reported and correct diagnosis and management of potential 
severe reactions is essential to avoid a decreased vaccination 
rate
• Local reactions have not been associated with a higher rate of 
systemic reactions and an allergic workup is usually not required
• The most common systemic reactions include maculopapular 
or delayed urticarial skin rashes. These reactions do not 
contraindicate further vaccine administration
• Systematic approaches have been proposed to optimally manage 
patients with a suspicion of vaccine hypersensitivity
Adverse events after vaccine ad-
ministration are commonly re-
ported, constituting a major prob-
lem in clinical practice. A correct 
management of these reactions 
is of major importance, as they 
are clearly associated with a de-
creased vaccination rate in the 
general population. 
LOCAL REACTIONS TO 
VACCINES
Local reactions are the most fre-
quent adverse event after vaccine 
administration and patients expe-
riencing this type of reactions are 
often falsely labeled as allergic. 
However, local reactions have not 
been associated with a higher rate 
of systemic reactions and an aller-
gic workup is usually not required.
In patients developing large lo-
cal reactions (suspicion of Arthus 
reaction) measurement of serum 
vaccine-specific antibodies can 
be useful for the decision to with-
hold additional dose. In patients 
developing eczema or persis-
tent nodules, patch tests can be 
performed to diagnose delayed 
hypersensitivity to vaccine pre-
servative or adjuvant. However, a 
positive patch test should not be 
considered as a contraindication 
for booster injection.
ADVERSE REACTIONS TO 
VACCINES FOR INFECTIOUS 
DISEASES
4
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Adverse reactions to vaccines for infectious diseases
SYSTEMIC REACTIONS TO 
VACCINES
The most common systemic re-
actions include maculopapular 
or delayed urticarial skin rashes. 
These reactions do not contrain-
dicate further vaccine administra-
tion, as they are believed to result 
from a non-specific activation of 
the immune system. 
Real IgE-mediated allergies to vac-
cine are extremely rare, but their 
identification is important due to 
the potential life-threatening risk. 
Systematic approaches have been 
proposed to optimally manage pa-
tients with a suspicion of vaccine 
hypersensitivity (Figure 1).
• In patients with a history of al-
lergy to one of the vaccine con-
stituents (i.e. egg, gelatin, yeast, 
formaldehyde, antibiotics and 
latex), who have not received 
the vaccine before, a complete 
allergic work-up is recommend-
ed (i.e. skin tests, specific IgE 
measurement and/or a provo-
cation test) to confirm an aller-
gy. If this is the case, skin test 
with the vaccine itself should 
be performed. If positive, the 
vaccine can still be adminis-
tered using adapted protocols. 
Regarding administration of in-
fluenza vaccine in patients with 
severe egg allergy, it has been 
shown that the vaccine can be 
Jean-Christoph Caubet   
University Hospitals of Geneva  
Geneva, Switzerland
Ingrid Terreehorst  
Academic Medical Center 
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administered safely with some 
precautions. Skin test to the in-
fluenza vaccine before vaccina-
tion is no longer recommended. 
• In patients with a history of sys-
temic reactions to vaccine, the 
allergic workup should include 
testing of the vaccine itself as 
well as its components. In case 
of a positive test to one of the 
components, one can consider 
a vaccine not containing that 
component, if available. If the 
patient is positive to the vac-
cine, a risk-benefit assessment 
should be performed; the physi-
cian should determine whether 
subsequent doses of the sus-
pected vaccine are necessary. 
Measurement of vaccines an-
tibodies to determine whether 
they are at protective levels 
helps determining whether 
booster injection can be with-
held. 
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Figure 1 Management of patients with suspected hypersensitivity to a vaccine and of patients with known allergy to 
a vaccine component. (Reproduced with permission from Caubet JC, Rudzeviciene O, Gomes E, et al. Managing a child with 
a possible allergy to vaccine, Pediatric Allergy Immunology 2013;Oct 16. doi: 10.1111/pai.12132. [Epub ahead of print] with 
permission from Willey Blackwell.)
Clinical history
Positive history of reactions after 
vaccine administration
Positive history of immediate allergy to 
gelatin, latex, yeast or egg
Nonimmediate 
reaction
Immediate 
reaction
• In most cases, no 
allergological work-up
• After contact dermatitis or 
nodules consider patch test
In almost all cases, the vaccine 
can be given according to 
general recommendations
Skin testing 
(prick test and/or intradermal test)
Vaccine and/or its components should be tested
Positive Negative
If additional doses required, the 
vaccine can be given in graded 
doses
If additional doses required, the 
vaccine can be given according 
to general recommendations
Adverse reactions to vaccines for infectious diseases
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s • Allergic bronchopulmonary mycoses are rare pulmonary type 
I and III hypersensitivity reactions, most commonly directed 
against Aspergillus fumigatus, but many other fungi can serve as 
antigen source
• ABPA occurs on the background of either allergic asthma or 
cystic fibrosis 
• Symptoms include wheezing, cough, malaise, fever, chest pain 
and the production of copious amounts of purulent sputum 
containing fungal hyphae 
• Radiological features of ABPA are central bronchiectasis and 
fleeting pulmonary infiltrates. Considerable airflow obstruction, 
often combined with loss of lung volume is also present
• The diagnosis of ABPA is difficult and requires a multidisciplinary 
approach. Major and minor criteria are described 
• Treatment aims to prevent exacerbations to avoid progressive 
and eventually fatal loss of lung tissue. Glucocorticosteroids and 
antimycotics are the mainstay of treatment. Allergen avoidance 
is crucial to prevent progression
Allergic bronchopulmonary my-
coses are rare pulmonary hyper-
sensitivity reaction , most com-
monly directed against Aspergillus 
fumigatus (Allergic Bronchopul-
monary Aspergillosis - ABPA). 
Many other fungi can also serve as 
antigen source, hence the term al-
lergic bronchopulmonary mycosis. 
ABPA occurs on the background 
of either allergic asthma or cystic 
fibrosis. The disease occurs main-
ly sporadic, but familial clustering 
has been reported. The pathogen-
esis of ABPA involves complex lo-
cal as well as systemic hypersensi-
tivity reactions to fungal antigens 
from fungal mycelia, which grow 
in the bronchial lumen, where 
they cause local inflammation and 
subsequent tissue destruction re-
sulting in central bronchiectasis. 
In addition to a marked cellular 
inflammation with eosinophils 
and neutrophils there is a humor-
al component involving polyclon-
al IgE-, IgG- and IgA production. 
Consequently, the complex immu-
nopathogenesis of ABPA appears 
to involve type I as well as type III 
immune reactions. Comorbidities 
such as allergic rhinitis are fre-
quent. 
Symptoms include wheezing, 
cough, malaise, fever, chest pain 
J. Christian virchow  
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Allergic bronchopulmonary aspergillosis
and the production of copious 
amounts of purulent sputum, 
which often contains fungal hy-
phae. Radiological features of 
ABPA are central bronchiecta-
sis and fleeting pulmonary infil-
trates, which do not respond to 
antibiotic therapy but to systemic 
corticosteroids instead. Most pa-
tients have a considerable airflow 
obstruction, often combined with 
loss of lung volume due to pulmo-
nary destruction by infiltrates and 
bronchiectasis and require high 
dose bronchodilator therapy in 
addition to anti-inflammatory glu-
cocorticosteroids.
The diagnosis of ABPA (Table 1) is 
difficult and there is a considera-
ble lag time between first occur-
rence of symptoms and diagnosis, 
often lasting many years. Recom-
binant Aspergillus antigens such 
as rASP f4 and rASP f6 have been 
implicated to be rather specifical-
ly elevated in ABPA. IgE levels in 
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TABLE 1
Diagnostic criteria for the diagnosis of ABPA
Major 
criteria
• asthma or cystic fibrosis
• central bronchiectasis (HRCT)
• positive skin tests to fungal allergens, most frequently to A. fumigatus
• elevated IgE levels (>400kU/L)
• elevated specific IgE- or IgG-concentrations against Aspergillus-
specific antigens
Minor 
criteria
• radiologic inflitrates
• precipitating antibodies against A. fumigatus (or other fungi)
• peripheral blood eosinophilia of 1000/ml
• tenacious, brown-coloured sputum plugs
• positive A. fumigatus cultures from sputum
• late reaction to A. fumigatus skin prick tests
TABLE 2
Stages for ABPA
Criteria
Stages
Seropositive 
ABPA
Stage I 
(acute)
Stage II  
(Remission)
Stage III  
(Exacerbation)
Stage IV 
(Asthma)
Stage V 
(Fibrosis)
Asthma + + + + + +
Radiologic infiltrates/ 
radiologic changes
+/- (+) +/- + +/- +
Cutaneous reaction to 
A. fumigatus 
++ + + + + +
Elevated IgE levels ++ +++ +/- +++ +/- +/-
Precipitating 
antibodies to A. 
fumigatus
+ + +/- + +/- +/-
Peripheral blood 
esinophilia
+/- + - + +/- -
Central/proximal 
bronchiectasis
- + + + + +
Elevated A. fumigatus-
specific IGe and IgG + + +/- + +/- +/-
Allergic bronchopulmonary aspergillosis
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ABPA can serve as markers for im-
pending exacerbations. ABPA has 
been classified in different stages 
(table 2)
Treatment of ABPA requires con-
siderable experience and a spe-
cialist environment. Treatment 
aims are to prevent exacerbations 
by reducing endo-bronchial in-
flammation to avoid progressive 
and eventually fatal loss of lung 
tissue. Glucocorticosteroids and 
antimycotics, both with a consid-
erable potential for side-effects, 
are the central pillars of treat-
ment. There are occasional case 
reports of successful treatment 
of ABPA with Omalizumab. Many 
patients in stage IV require main-
tenance treatment with systemic 
corticosteroids.
Allergen avoidance at home or 
workplace are crucial to prevent 
progression. Treatment in high al-
titude such as Davos, Switzerland 
improves symptoms and reduces 
inflammation, most likely due to 
the low antigen content in these 
special environments.
Prognosis is highly dependent on 
an early diagnosis and appropriate 
treatment. Therefore, pneumo-
logic experience and a compre-
hensive clinical, immunologic and 
radiologic workup are necessary 
to identify patients with this debil-
itating disease. Treatment should 
be directed at the early identifica-
tion of exacerbations to avoid the 
development of fatal pulmonary 
destruction.
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Figure 1 Immunopathogenesis of ABPA. (Modified from Virchow J.C. Allergische bronchopulmonae Aspergillose. In: Heppt W, 
Bachert C, eds. Praktische Allergologie, Thieme, Stuttgart 2nd ed, 2011; pages 57-64.)
Allergic bronchopulmonary aspergillosis
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• Hypersensitivity pneumonitis (HP) is an interstitial lung disease 
due to a combined type III and IV reaction with a granulomatous 
inflammation, caused by T lymphocytes in a Th1/Th17 milieu, 
chaperoned by a deficient suppressor function of T regulatory 
cells. Skewing toward a Th2 phenotype is reported for chronic 
HP
• Phenotypic expression and severity depends on environmental 
and/or host genetic and immune co-factors 
• The wide spectrum of causative antigens is continuously updated 
with new sources of airborne organic particles and drug-induced 
HP
• The diagnosis requires a detailed history, measurement of 
environmental exposure, pulmonary function tests, imaging, 
detection of serum specific antibodies, broncho-alveolar lavage, 
antigen-induced lymphocyte proliferation, environmental or 
laboratory-controlled inhalation challenge and lung biopsy
• Complete antigen avoidance is the best therapeutic measure, 
although very difficult to achieve in some cases. Systemic 
steroids are of value for subacute and chronic forms of HP, but do 
not influence long-term outcome. Manipulation of the immune 
response holds future promise
Hypersensitivity pneumonitis 
(HP) is an interstitial lung disease 
due to a combined type III and IV 
reaction with a granulomatous 
inflammation. The current view 
is that HP is caused by cytotoxic 
delayed hypersensitivity lympho-
cytes, in a Th1/Th17 milieu (Figure 
1). Both TLRs 2 and 9 contribute to 
the Th17 response and neutrophil 
recruitment. Additional mediators 
and pattern recognition receptors 
are involved in granuloma for-
mation. Loss of T-regulatory cells 
(Tregs) control over the immune 
response is essential for the im-
paired immune tolerance in HP. 
The mechanisms of progression 
to a chronic form remain unclear. 
For chronic HP a skewing toward 
a Th2 phenotype facilitated by 
group 2 innate lymphoid cells was 
described.
Although many individuals are ex-
posed to environmental antigens 
known to induce HP only 5-15% 
develop the disease. The pheno-
typic expression of the disease 
depends on environmental co-fac-
tors, such as viruses and/or host 
genetic and immune co-factors, 
which also promote considerable 
variability in disease severity and 
response to treatment. 
HP can occur in an occupational 
Ioana Agache  
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Hypersensivity pneumonitis
setting or after home exposure, 
following inhalation of organic 
antigens (mammalian and avian 
proteins, fungi, bacteria), low-mo-
lecular-weight chemicals or My-
cobacterium avium-intracellulare 
complex organisms. As a non-in-
halant variant HP can appear as 
a manifestation of drug-induced 
lung disease. Most recent re-
ported drugs inducing HP are im-
mune modulators used to treat 
neoplastic and connective tissue 
diseases or transplant recipients. 
New sources of airborne organ-
ic particles are continually being 
recognized, such as the throm-
bone player, Chacinero's lung, 
HP associated with catechin-rich 
green tea extracts, use of ultra-
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sonic misting fountains at home, 
Shiitake mushroom spores, mos-
quito-coil smoke, medium-density 
fiberboard or cash handling.
There is no single diagnostic single 
procedure or biomarker to confirm 
the diagnosis of HP. The diagnosis 
requires a detailed and careful 
history that would include social, 
environmental, and occupational 
status, measurement of environ-
mental exposure, pulmonary func-
tion tests, imaging, detection of 
serum specific antibodies, exami-
nation of broncho-alveolar lavage 
fluid (BALF), antigen-induced lym-
phocyte proliferation, environ-
mental or laboratory-controlled 
inhalation challenge with the sus-
pected antigen and lung biopsy. A 
sentinel case should prompt to the 
identification of exposed subjects, 
who might develop the disease. 
Improvement of symptoms away 
from exposure and/or a rapid re-
sponse to oral steroids should 
heighten the awareness of HP. 
For monitoring HP activity meas-
urement of alveolar NO following 
re-exposure and of biomarkers 
reflecting the lung injury/regen-
eration cycle such as serum serum 
Krebs von den Lungen-6 mucin 
(KL-6) and surfactant protein D 
are proposed. 
Complete antigen avoidance is the 
essential step in the management 
of HP. The majority of cases im-
proves or heals, but some evolve 
to a chronic form probably due 
to persistence of exposure at an 
undetectable level in association 
with genetic and immunologic 
factors. Systemic corticosteroids 
are recommended for subacute 
and chronic forms of HP, although 
they do not influence long-term 
outcome. For progressive chronic 
HP immunosuppressants may be 
necessary (Figure 2).
Modulation of the immune re-
sponse holds future promise for 
treatment. In a HP experimental 
model CTLA-4Ig promoted a sig-
Figure 1 Pathogenenic mechanisms in hypersensivity pneumonitis. (From Agache I, Rogozea L. Management of 
hypersensivity pneumonitis. Clin Transl Allergy. 2013;3:5; Reprinted with permission under the Creative Common Attribution 
License or equivalent.)
Hypersensivity pneumonitis
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Host genetic and immune co-factors 
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of epithelial cells, defective Tregs) 
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acute disease subacute diseaseasymptomatic chronic disease
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complement activation
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lymphocitic 
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Figure 2 Management of hypersensivity pneumonitis. (From Agache I, Rogozea L. Management of hypersensivity 
pneumonitis. Clin Transl Allergy. 2013;3:5; Reprinted with permission under the Creative Common Attribution License or 
equivalent.)
nificant decrease in the extent of 
lung damage and in the number 
of BALF inflammatory cells, with 
diminished CD4/CD8 T cell ratio 
and a significant increase in the 
lung γδT, NKT cells and Tregs. Oth-
er potential targets for immune 
modulation are T-bet, dendritic 
cells and adjuvant factors, Tregs 
and activated cytotoxic T cells (fig-
ure 2).
The GAP model, a clinical predic-
tion model based on sex, age, and 
lung physiology, predicts mortality 
in chronic HP. Pulmonary hyper-
tension is not rare in chronic HP 
and significantly impacts survival. 
The reported prevalence of lung 
cancer in chronic HP (10.6%) is 
similar to idiopathic pulmonary 
fibrosis.
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Hypersensivity pneumonitis
early diagnosis
high index of suspicion
sentinel cases
careful history 
social, environmental, and occupational status
diagnostic tests:
• HRCT
• serum specific antibodies
• BALF examination
• antigen-induced lymphocyte proliferation
• environmental or laboratory-controlled inhalation challenge
• lung biopsies
removal of exposure
measurement of 
environmental 
exposure
??systemic corticosteroids 
in severe subacute 
and chronic forms
immune modulation
CTLA4-Ig
anti IL-17
galectin-9
repertaxin and other
antifibrotic agents
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diagnosis should follow strict diagnostic criteria 
• Episodes of mast cell mediator release may occur, which include 
flushing and even anaphylaxis 
• Cutaneous mastocytosis in children may resolve with time. In 
adults, cutaneous disease usually persists and is accompanied by 
systemic disease
• The treatment of mastocytosis is largely symptomatic. 
Aggressive forms of disease are treated with cytoreductive 
agents including tyrosine kinase inhibitors and performed in a 
collaborative effort with a hematologist
• The care of a patient with mastocytosis must include counseling 
on the consequences of the disease and careful follow-up
Mastocytosis is a clonal disorder 
of the hematopoietic system in 
which there is a pathological ac-
cumulation of mast cells in tissues. 
In some cases, mastocytosis pre-
sents with episodes of mediator 
release, which are associated with 
flushing or anaphylaxis. It can af-
fect all age groups. The prevalence 
is not known. Recent studies have 
reinforced the role of activating 
mutations in KIT. 
DIAGNOSIS AND 
CLASSIFICATION
The diagnosis of systemic masto-
cytosis (SM) is established on the 
basis of a bone marrow biopsy and 
smear, flow cytometry, mutational 
analysis of KIT, and serum tryptase 
(Table1). The classification of vari-
ants of mastocytosis is shown in 
Table 2. 
The most frequent form of masto-
cytosis is indolent systemic mas-
tocytosis (ISM), which tends to fol-
low a benign course. In contrast, 
aggressive forms of mastocytosis, 
including SM with an associated 
hematologic non-mast-cell-lin-
eage disease (SM-AHNMD), ag-
gressive systemic mastocytosis 
(ASM), and mast cell leukemia 
(MCL), may lead to disability or 
even death. 
Dean D. Metcalfe  
National Institute of Allergy and Infectious Diseases 
Bethesda, USA
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CLINICAL FEATURES OF 
DISEASE
Two-thirds of all cases of masto-
cytosis present in childhood, with 
a second peak of onset in the late 
third to early fourth decade. The 
disease occurs in both males and 
females with roughly equal fre-
quency. Cases of mast cell dis-
ease diagnosed in childhood often 
resolve by adulthood, whereas 
adult-onset mastocytosis usually 
persists. Although there are cases 
of familial cutaneous mastocyto-
sis, most patients report no fami-
ly history. IgE-mediated allergy is 
not increased. 
Clinical symptoms follow patterns 
of organ system involvement, 
which includes the skin (Figure 
1), gastrointestinal tract, lymph 
nodes, liver, spleen, and bone 
marrow. Episodes of flushing and 
life-threatening episodic hypoten-
sion may occur and are sometimes 
related to alcohol ingestion, insect 
stings, infection, certain medica-
tions, and radio -contrast mate-
rials. In patients with aggressive 
disease, fatigue and musculoskel-
etal pain are frequent and may be 
accompanied by weight loss, fever 
and sweats. Chronic symptoms in-
clude headache, decreased atten-
tion span, irritability and depres-
sion. Abdominal pain is common, 
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TABLE 1
WHO Diagnostic Criteria for Cutaneous and Systemic Mastocytosis
Cutaneous 
Mastocytosis (CM)
Typical clinical findings of urticaria pigmentosa(UP)/maculopapular cutaneous mastocytosis 
(MPCM) diffuse cutaneous mastocytosis (DCM) or solitary mastocytoma, and typical 
infiltrates of mast cells in a multi-focal or diffuse pattern on skin biopsy.
Systemic Mastocytosis 
(SM)
The diagnosis of SM is made if one major and one minor criterion are present, or, if three 
minor criteria are met.
Major Criterion
Multifocal, dense infiltrates of mast cells (15 or more in aggregates) detected in sections 
of bone marrow and/or another extracutaneous organ, and confirmed by tryptase 
immunohistochemistry or other special stains.
Minor Criteria
• In biopsy sections of bone marrow or other extracutaneous organs, more than 25% of the 
mast cells in the infiltrate are spindle-shaped or have atypical morphology, or, of all mast 
cells in bone marrow aspirates smears, more than 25% are immature or atypical mast cells.
• Detection of an activating point mutation at codon 816 of KIT in bone marrow, blood or 
another extracutaneous organ.
• Mast cells in bone marrow, blood or another extracutaneous organ express CD117 with 
CD2 and/or CD25.
• Serum total tryptase persistently greater than 20 ng/ml in the absence of an associated 
clonal myeloid disorder.
TABLE 2
WHO systemic mastocytosis variants
Cutaneous mastocytosis (CM)
Urticaria pigmentosa (UP)=maculopapular CM (MPCM)
Diffuse CM (DCM)
Mastocytoma of skin
Indolent systemic mastocytosis 
(ISM)
Smoldering SM
Isolated bone marrow mastocytosis
Systemic mastocytosis with an 
associated clonal haematologi-
cal non-mast-cell-lineage disease 
(SM-AHNMD)
SM-AML
SM- MDS
SM-MPD
SM-CMML
SM-NHL
Aggressive systemic mastocytosis 
(ASM)
Mast cell leukaemia (MCL) Aleukaemic MCL
Mast cell sarcoma
Extracutaneous mastocytoma
Abbreviations: SM, systemic mastocytosis; AML, acute myeloid leukaemia; MDS, myelodysplastic disease; 
MPD, myeloproliferative disease; CMML, chronic myelomonocytic leukaemia; NHL, non-Hodgkin lymphoma.
Mastocytosis
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followed by diarrhea, nausea, 
and vomiting. Mild hepatomeg-
aly is often seen in patients with 
long-standing SM, and may be 
accompanied by mildly elevated 
levels of liver enzymes. Aggressive 
forms of mastocytosis are associ-
ated with liver fibrosis, cirrhosis, 
ascites, and portal hypertension. 
Splenomegaly is observed in sys-
temic disease. Bone pathology 
ranges from osteoporosis to oste-
osclerosis.
Cytopenias including anemia, 
thrombocytopenia, and neutro-
penia are common in aggressive 
forms of SM. Neutrophilia, mono-
cytosis, and eosinophilia are also 
observed. Central and peripheral 
lymphadenopathy may occur. 
MANAGEMENT 
In adults, ISM tends to remain 
relatively stable or evolve slow-
ly. Transformation from ISM into 
more aggressive forms of disease 
is unusual. Aggressive forms of 
disease, such as SM-AHNMD, of-
ten progress and may require in-
terventional therapy directed at 
decreasing the mast cell burden 
and treating the associated hema-
tologic disease.
Treatment of those with mas-
tocytosis begins with symptom 
management with anti-mediator 
therapy. In most patients, symp-
toms are controlled using such 
drugs. If not controlled use of glu-
cocorticoids may be considered. 
For those with skin disease, man-
agement includes good skin care, 
with preservation of moisture 
within the skin. Mastocytosis can 
be associated with spontaneous 
hypotension associated with an 
episode of mediator release (ana-
phylactic shock), which is managed 
in the same way as anaphylaxis in 
allergic patients without masto-
cytosis. Cytoreductive therapies 
including KIT-targeting tyrosine 
kinase inhibitors are reserved for 
the treatment of those with ASM, 
MCL, and SM-AHNMD. Referral 
to a center with expertise in man-
aging rare forms of disease may be 
desirable.
KEY REFERENCES
1. Horny HP, Metcalfe DD, Bennett 
JM et al, eds. WHO classification 
of tumours of haematopoietic and 
lymphoid tissues. London: IARC; 
2008:54-63.
2. Brockow K, Jofer C, Behrendt H, 
Ring J. Anaphylaxis in patients with 
mastocytosis: a study on history, 
clinical features and risk factors in 
120 patients. Allergy 2008;63:226-
232.
3. Nagata H, Worobec AS, Oh CK, 
Chowdhury BA, Tannenbaum S, 
Suzuki Y et al. Identification of a 
point mutation in the catalytic do-
main of the protooncogene c-kit in 
peripheral blood mononuclear cells 
of patients who have mastocytosis 
with an associated hematological 
disorder. Proc Natl Acad Sci 1995; 
92:10560-10564.
4. Lim KH, Tefferi A, Lasho TL, Finke 
C, Patnaik M, Butterfield JH, et al. 
Systemic mastocytosis in 342 con-
secutive adults: survival studies 
and prognostic factors. Blood 2009; 
113:5727-5736.
5. Metcalfe DD. Mast cells and masto-
cytosis. Blood 2008;112:946-956.
Figure 1 Typical lesions of urticaria pigmentosa (UP) appear on the chest and arms of an adult patient with ISM.
Mastocytosis
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• Patients with hypersensitivity vasculitis are usually adults, who 
develop palpable purpura and a maculopapular rash after an 
infection or the use of medication
• The biopsy of a skin lesion shows leukocytoclastic vasculitis and 
perivascular immune complexes that lack IgA
• Discontinuation of the eliciting drug or resolution of the 
underlying infection results in the resolution of skin signs and 
symptoms
INTRODUCTION, 
NOMENCLATURE AND 
CLASSIFICATION
Hypersensitivity vasculitis (HV) is 
one of the most common types of 
vasculitis seen by allergologists. 
Vasculitis is defined by blood ves-
sel damage and the presence of 
inflammatory leukocytes in vessel 
walls. Vasculitides are categorized 
by the size of the blood vessels af-
fected, i.e. small, medium and large 
vessel vasculitis. HV is a small ves-
sel vasculitis. 
CLINICAL PICTURE, DIAGNOSIS, 
AND TREATMENT
HV is typically caused by drugs 
(most commonly antibiotics such 
HYPERSENSITIVITY 
VASCULITIS8
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Hypersensitivity vasculitis
as penicillins, cephalosporins, 
sulfonamides, diuretics, NSAIDs, 
allopurinol, biologicals) or infec-
tions, viral (e.g. hepatitis B or C 
virus, parvovirus 19) or bacterial 
(e.g. streptococcal). 
HV signs and symptoms (palpable 
purpura and maculo-papular rash, 
figure 1) usually begin 7 to 10 days 
after the use of eliciting drugs or 
responsible infections. This peri-
od may be shorter with repeated 
antigen exposure. Acute HV usu-
ally resolves when the antigen is 
cleared, which is not always possi-
ble. Especially chronic hepatitis B 
or C virus infections can be asso-
ciated with a more chronic course. 
HV is diagnosed based on the typ-
ical clinical findings, the history 
(drug or infection) and a skin biop-
sy, showing leukocytoclastic vas-
culitis and perivascular immune 
complexes that lack IgA. Patients 
should be tested for serum com-
plement levels, markers of inflam-
mation (ESR/CRP), and cryoglobu-
lins. HV is defined by the American 
College of Rheumatology criteria 
(Table 1). These criteria, how-
ever, do not reliably distinguish 
HV from IgA vasculitis (formerly 
called Henoch-Schönlein purpu-
ra). IgA vasculitis and HV are both 
immune complex-mediated, but 
IgA vasculitis shows internal or-
gan involvement, whereas HV is, 
in almost all cases, limited to the 
skin.
The treatment of HV is the discon-
tinuation of the provoking drug or 
antigen, which usually leads to the 
resolution of the signs and symp-
toms within a few days to weeks, 
Marcus Maurer Torsten Zuberbier
Charité – Universitätsmedizin  
Berlin, Germany
TABLE 1
American College of Rheumatol-
ogy diagnostic criteria for hyper-
sensitivity vasculitis
1. age >16 years, 
2. use of a possible offending 
drug in temporal relation to the 
symptoms, 
3. palpable purpura (figure 1), 
4. maculopapular rash, 
5. biopsy of a skin lesion showing 
neutrophils around an arteriole 
or venule. 
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Hypersensitivity vasculitis
but some cases remain idiopathic 
and become chronic. In severe or 
persistent cases antihistamines, 
colchicine, or dapsone may be 
helpful. Immunosuppressive drugs 
(e.g. glucocorticoids) should be re-
served for patients with progres-
sive disease, after infections have 
been ruled out as the underlying 
cause.
KEY REFERENCES
1. Calabrese LH, Michel BA, Bloch 
DA, Arend WP, Edworthy SM, Fau-
ci AS et al. The American College 
of Rheumatology 1990 criteria 
for the classification of hypersen-
sitivity vasculitis. Arthritis Rheum 
1990;33:1108.
2. Sunderkötter C. Hautmanifesta-
tionen der verschiedenen Vasku-
litiden. Z Rheumatol 2013;72:436-
444.
3. Carlson JA. The histological assess-
ment of cutaneous vasculitis. Histo-
pathology 2010;56:3-23.
4. Chen KR, Carlson JA. Clinical ap-
proach to cutaneous vasculitis. Am 
J Clin Dermatol 2008;9:71-92.
Figure 1 Palpable purpura and maculopapular rash in hypersensivity vasculitis.
Section F
SPECIAL CONSIDERATIONS
* Primary immunodeficiency diseases
* Allergic disease in the elderly
* Allergic diseases in pregnancy 
* Allergic diseases and sports
* Allergic diseases in adolescents 
* Adherence to the management plan 
* Allergic diseases and quality of life
* Allergic diseases in animals
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underestimated
• Newborn screening for severe combined immunodeficiency (an 
immune deficiency that is uniformly fatal if not diagnosed and 
treated) has led to early diagnosis and treatment of these infants
• Hematopoietic stem cell transplantation has been a major ad-
vance in the cure for many primary immune deficiency disorders
• Immunoglobulin replacement therapy has led to improved 
outcomes in patients with antibody deficiency disorders
• More research is needed to reduce and identify comorbid 
conditions in patients with primary immune deficiency to 
improve outcomes and life expectancy
Primary immune deficiencies 
(PID) are a group of inherited 
disorders of the immune system 
that increase the susceptibility of 
the individual to severe and often 
difficult to treat infections, auto-
immunity and in some patients 
malignancy. Over 200 genetic ab-
normalities that lead to a variety 
of PID have been identified. Ap-
proximately 250,000 people in the 
United States are diagnosed with 
PID, but according to estimates of 
the National Institutes of Health 
over 250,000 people are under 
diagnosed. In order to estimate 
the prevalence of PID in Europe as 
well as to establish and evaluate 
harmonized guidelines for the di-
agnosis and treatment of PID, the 
European Society for Immunode-
ficiencies (ESID) has developed an 
internet-based database for clini-
cal and research data on patients 
with PID (Table 1).
About 55% of the PID are humoral 
or B-cell abnormalities, 25% are 
T-cell or combined T and B-cell im-
mune deficiencies, 25% are phago-
cytic disorders, 25% are immune 
dysregulation syndromes, and 
<10% are complement deficien-
cies (Figure 1). 
The most severe type of PID is 
lack of immune system at birth, 
e.g. absent T and B-cells (Severe 
combined immunodeficiency or 
SCID). SCID infants often die in 
the first year of life. Intervention 
with a bone marrow hematopoie-
tic stem cell transplant is curative. 
Recent data shows that the prog-
nosis of these infants is better if 
the diagnosis is made before 3 
months of age for stem cell trans-
plantation. Towards this goal in the 
United States newborn screening 
using quantification of T-cell re-
ceptor excision circles (TRECs) has 
been initiated in 15 states. This 
initiative has resulted in the early 
diagnosis and treatment of SCID 
infants, and has changed the inci-
dence from 1:100,000 from older 
epidemiologic studies to a more 
recent estimate of <1:50,000 live 
births. Another approach to the 
treatment of SCID patients has 
been gene therapy. 
27% of PID are diagnosed before 
age 6, but 51% are diagnosed after 
age 30. This latter group is mainly 
patients with B-cell immune defi-
ciency, the most common of which 
is the Common Variable Immu-
nodeficiency (CVID). The delay in 
diagnosis of these adult patients 
is 9-12 years and contributes to 
chronic lung disease and other 
comorbid conditions (Figure 2). 
Likewise, it is important to iden-
tify CVID patients early in order 
to start them on replacement im-
Mark Ballow  
University of South Florida  
St Petersburg, USA
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Primary immunodeficiency diseases
TABLE 1
Primary immunodeficiency prevalence based on reported cases in the European Society for 
Immunodefiencies (ESID) database*
Country
Alive PID patients 
documented
Population (millions 
inhabitants)
Documented PID patients 
per 100 000 inhabitants
France 2399 64 • 47 3 • 72
Ireland 76 4 • 24 1 • 79
Turkey 1083 70 • 59 1 • 53
United Kingdom 878 60 • 59 1 • 45
Estonia 15 1 • 34 1 • 12
Italy 655 59 • 13 1 • 11
Belgium 98 10 • 53 0 • 93
Poland 352 38 • 12 0 • 92
Czech Republic 88 10 • 31 0 • 85
Greece 89 11 • 17 0 • 8
Germany 552 82 • 24 0 • 67
Serbia 47 7 • 27 0 • 65
Switzerland 38 7 • 59 0 • 5
Slovakia 22 5 • 43 0 • 41
Sweden 32 9 • 18 0 • 35
Slovenia 6 2 • 02 0 • 3
Portugal 27 10 • 95 0 • 25
Total populations source: Wikipedia.
* Only countries with a prevalence >0.2 are displayed. Reproduced from Gathmann B, Grimbacher B, Beauté J, et 
al; The European internet-based patient and research database for primary immunodeficiencies results 2006-
2008. Clin Exp Immunol. 2009;157(suppl 1):3-11 with permission from John Willey and Sons, Inc.
Figure 1 Distribution of Primary Immune Deficiency Diseases in the ESID registry database. (Reproduced from Gathmann 
B, Grimbacher B, Beauté J, et al; The European internet-based patient and research database for primary immunodeficiencies 
results 2006-2008. Clin Exp Immunol. 2009;157(suppl 1):3-11 with permission from John Willey and Sons, Inc. Updated 2013 
- 119 centers and 18,720 total patients. http://esid.org/Working-Parties/Registry/ESID-Database-Statistics accessed Jan 19, 
2014.)
B-cell immune def
T-cell immune def
Other well defined PIDD
Phagocytic disorders
Complement def
Autoimmune/dysregulation
Innate PIDD
Unclassified PIDD
Autoinflammatory
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Figure 2 Survival of patients with CVIDs, by years since diagnosis and by clinical phenotype. Yellow line represents 
those patients without complications; Turquoise line represents those patients with at least one disease related 
complication. Kaplan–Meier plot of survival. (Republished with permission of Blood, from Common variable immunodeficiency 
disorders: division into distinct clinical phenotypes, Chapel H, Lucas M, Lee M, et al,112,2,2008; permission conveyed through 
Copyright Clearance Center, Inc.)
munoglobulin (Ig) therapy. Dosage 
requirements for optimal manage-
ment of CVID patients have been 
recently discussed in several pub-
lications. The consensus by clinical 
immunologist is that the optimal 
dose of Ig therapy is the dose, 
which minimizes infection and 
improves patient outcome. Two 
routes for replacement Ig therapy 
are recommended either intrave-
nous or subcutaneous. The latter 
has been utilized in Europe for 
several decades with advantages 
over the IV route of less system-
ic side effects, improved steady 
state serum IgG levels, home-
based self-administration and bet-
ter quality of life.
KEY REFERENCES
1. Buckley RH. The long quest for ne-
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Transplantation of hematopoietic 
stem cells and long-term survival 
for primary immunodeficiencies in 
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we do better? J Allergy Clin Immunol 
2010;126:602–610.
3. Buckley RH. Transplantation of he-
matopoietic stem cells in human se-
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longterm outcomes. Immunol Res 
2011;49:25-43.
4. Al-Herz W, Bousfiha A, Casanova 
JL, Chapel H, Conley ME, Cun-
ningham-Rundles C et al. Primary 
immunodeficiency diseases: an up-
date on the classification from the 
international union of immunolog-
ical societies expert committee for 
primary immunodeficiency. Front 
Immunol 2011;2:54.
5. Chapel H, Cunningham-Rundles C. 
Update in understanding common 
variable immunodeficiency disor-
ders (CVIDs) and the management 
of patients with these conditions. 
Br J Haematol 2009;145:709-727.
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• Asthma and allergic rhinitis are not uncommon in the elderly.
• Asthma in the elderly is heterogeneous in origin and often 
associated with loss of lung function
• Co-morbid conditions can affect treatment. Smoking adversely 
affects outcomes
• Additional research into pathophysiology and phenotypes is 
needed to improve treatment approaches
EPIDEMIOLOGY
The prevalence of allergic respira-
tory disease (allergic rhinitis and 
asthma) in the elderly is difficult 
to estimate due to differences in 
cut-off ages (≥55, ≥65, ≥75 e.g.). 
Nonetheless, in vitro assays for 
specific IgE in adults age ≥55 years 
in the U.S. showed that ~65% were 
sensitized to at least one allergen. 
However, a Swiss study found 
that only 26% of men and 18% of 
woman aged >60 years were sen-
sitized. Skin prick testing of elder-
ly Koreans found a similar lower 
rate of allergic sensitization (17-
18%). Chronic rhinitis was also 
fairly common in the elderly Ko-
rean population (25%), but allergic 
sensitization did not show a signif-
icant association. The Swiss study 
found the prevalence of self-re-
ported allergic rhinitis to be 13% 
for men and 15% for women ages 
>60 years. The lifetime prevalence 
of allergic rhinitis in adults (18-79) 
in Germany was similarly estimat-
ed to be 15%.
Of more concern is asthma in the 
elderly, which is difficult to esti-
mate, because of confusion with 
COPD, the overlap of asthma with 
COPD, and confounding condi-
tions like congestive heart failure. 
Reported incidence of newly diag-
Robert K. Bush  
University of Wisconsin-Madison 
Wisconsin, USA
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Allergic disease in the elderly
nosed asthma in a U.S. population 
was 103/100,000 at age 65-74 
years, 81/100,000 ages 75-84 
years, and 58/100,000 age >85 
years. Allergic sensitization does 
not appear to be a major factor in 
the development of asthma in the 
elderly. 
The prevalence of asthma in the 
elderly is variable in different 
populations (Table 1), but appears 
to be rising over the past decade. 
Only 2% of Chinese citizens ages 
>50 self-reported having asthma. 
However, physician diagnosed 
asthma was higher in Hong Kong 
Chinese aged ≥70 years (4-5%). 
Doctor diagnosed asthma in Swiss 
citizens aged >60 years was 6.6% 
in men and 7.6% in women. Cur-
rent asthma in U.S. citizens ≥65 
years were similar at 6.3% (Table 
1). Asthma death rate increases 
with age (Figure 1).
PROGNOSIS
Some 8-15% of older adults in the 
U.S. are annually admitted to the 
hospital. Often elderly adults lack 
a perception of dyspnea and hos-
pitalized patients used peak-flow 
meters less often than younger 
patients and had less self-manage-
ment knowledge. Women 50-60 
years old being non-white and less 
educated appear to be at risk for 
hospitalization. Fortunately, when 
controlled for age, asthma is not 
associated with all-cause mortali-
ty. However, patients with asthma 
associated with COPD have wors-
ened survival. 
FUTURE RESEARCH
Asthma in the elderly presents di-
agnostic challenges defining the 
pathophysiologic mechanism, and 
further characterization of pheno-
type can lead to better treatments. 
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Smoking avoidance and cessation 
can clearly reduce the burden of 
asthma in the elderly. 
KEY REFERENCES
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gic sensitization among asthmatic 
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2006. Ann Allergy Asthma Immunol 
2013;110:247-252.
2. Wüthrich B, Schmid-Grendelmeier 
P, Schindler C, Imboden M, Birch-
er A, Zemp E et al. Prevalence of 
atopy and respiratory allergic dis-
eases in the elderly SAPALDIA 
population. Int Arch Allergy Immunol 
2013;162:143-148.
3. Reed CE. Asthma in the elderly: di-
agnosis and management. J Allergy 
Clin Immunol 2010;126:681-687.
4. Hannia NA, King MJ, Braman SS, 
Saltoun C, Wise RA, Enright P et 
al. Asthma in the elderly workshop 
participants. Asthma in the elder-
ly: current understanding and fu-
ture research needs – a report of 
a National Institute on Aging (NIA) 
workshop. J Allergy Clin Immunol 
2011;128:54-24. 
TABLE 1
Reported Prevalence of Asthma in OIder Populations
Prevalence Population Age (years)
2% Chinese, self-reported >50
3.9% Chinese, symptoms >50
4-5% Hong Kong, physician-diagnosed ≥70
6.6% males 
7.6% females Swiss, physician-diagnosed >60
6.3% U.S., NHANES study ≥65
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Figure 1 Asthma Death Rates by Race and Age, United States 2007-2009. (From Centers for Disease Control and 
Prevention, Morbidity and Mortality Weekly Report, 2012;61:315.) 
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• Pregnant asthmatics have a higher risk of adverse perinatal 
outcomes
• Unlike rhinitis of pregnancy, which presents with predominant 
nasal congestion symptoms, patients with allergic rhinitis often 
report prominent sneezing, nasal pruritus, and watery rhinor-
rhea, and some have concomitant ocular itching and irritation
• Treatment for urticaria during pregnancy may be necessary, if it 
is affecting quality of life
• Atopic dermatitis is the most common skin disorder observed 
during pregnancy
• Anaphylaxis is a rare event during pregnancy, but may be 
associated with severe maternal and neonatal complications
ASTHMA
A meta-analysis, derived from 
a substantial body of literature 
spanning several decades and 
including very large numbers of 
pregnant women, (over 1,000,000 
for low birth weight and over 
250,000 for preterm labor), indi-
cates that pregnant women with 
asthma are at a significantly in-
creased risk of a range of adverse 
maternal and fetal outcomes (Ta-
ble 1). Suboptimal control of asth-
ma or more severe asthma during 
pregnancy is associated with in-
creased maternal or fetal risk. 
Once the diagnosis of asthma is 
confirmed a decision regarding 
the need for controller medica-
tion versus rescue medication 
ALLERGIC DISEASES IN 
PREGNANCY 3
Ke y  m e ssag e s
Allergic diseases in pregnancy
can be made (Table 2). Inhaled 
corticosteroids are the mainstay 
of controller therapy during preg-
nancy, but addition of long-acting 
beta agonists is appropriate, if re-
quired to achieve control. Adher-
ence to therapy can change during 
pregnancy with a corresponding 
change in asthma control. Most 
commonly observed is decreased 
adherence as a result of a mother’s 
concerns about the safety of medi-
cations for the fetus.
ALLERGIC RHINITIS
Allergic rhinitis (AR) is usually pre-
existing, although it may develop 
or be recognized for the first time 
during pregnancy. Patients with AR 
often report prominent sneezing, 
nasal pruritus, and watery rhinor-
rhea, and some have concomitant 
ocular itching and irritation. Com-
mon triggers include dust mites, 
animal danders, molds, and pol-
lens. The mainstays of therapy are 
avoidance of triggers, oral antihis-
tamines and intranasal glucocorti-
coids. No important differences in 
efficacy or safety appear to exist 
between the various intranasal 
glucocorticoid preparations. Preg-
nant women who require antihis-
tamines for AR should generally be 
treated with a second generation 
agent such as loratadine (10 mg 
once daily) or cetirizine (10 mg dai-
ly), since these drugs have reassur-
Jennifer A. namazy  
Scripps Clinic 
San Diego, USA
Michael Schatz  
Kaiser Permanente Medical Center 
San Diego, USA
TABLE 1
Adverse fetal outcomes reported 
to be increased in infants of 
asthmatic women 
Low birth weight
Preterm birth
Small for gestational age
Congenital anomalies
Stillbirth
Low APGAR scores at birth
254
Global atlas oF allerGy
se
c
t
io
n
 F
 - 
Sp
ec
ia
l c
o
n
si
d
er
at
io
n
s
ing animal and human data, are less 
sedating, and have fewer anticho-
linergic side effects compared with 
first generation (Table 3). 
ATOPIC DERMATITIS
Atopic dermatitis (AD), or eczema 
is one of the most frequently ob-
served skin diseases in pregnant 
patients. Most pregnant patients 
with AD present with lesions on 
the flexural aspects of the extremi-
ties, although truncal involvement 
is not uncommon. AD can change 
in severity during pregnancy, but 
has not been associated with an 
increased risk of perinatal com-
plications such as congenital mal-
formations. Similar to treatment 
of AR, the treatment for AD relies 
on avoidance of triggers and the 
judicial use of medications such 
as antihistamines for pruritus and 
topical corticosteroids (Table 4). 
URTICARIA/ANGIOEDEMA
While there is no specific pregnan-
cy-related urticaria, idiopathic urti-
caria may occur during pregnancy 
as well as urticaria due to any of the 
causes known to affect non-preg-
nant women.There have been no 
associations between presence 
of urticaria and adverse fetal out-
comes. As in non-pregnant pa-
tients with urticaria, the treatment 
of choice is oral antihistamines, 
especially loratadine or cetirizine 
as noted above. Although not stud-
ied specifically in pregnancy for 
this purpose, leukotriene receptor 
antagonists such as montelukast 
(FDA Category B) may also be con-
sidered for recalcitrant urticaria, 
and may be continued, if started 
prior to pregnancy.
ANAPHYLAxIS
Anaphylaxis during pregnancy is 
considered a rare condition with 
an estimated prevalence of 2.7 
cases/100,000 deliveries. Antibi-
otics are the most common trigger. 
If maternal oxygenation is com-
promised there may be associat-
ed fetal hypoxemia. Epinephrine 
remains the treatment of choice in 
pregnant patients. Anaphylactoid 
Syndrome of Pregnancy (ASP) is 
a rare complication of delivery in 
mother and/or infant during the 
process of birth. The maternal 
mortality rate worldwide for this 
complication is between 10 and 
16%, while the fetal mortality rate 
is upwards of 30%. While the ma-
jority of infants will survive, the 
majority will also incur some form 
of neurologic defect. The patho-
physiology is thought to be related 
to amniotic fluid or fetal cells en-
tering maternal circulation. Mast 
cell degranulation appears to be a 
TABLE 2
Safety of commonly used medications for the treatment of asthma during pregnancy
Drug FDA Perinatal Outcome
Inhaled Bronchodilators
Short-acting Bronchodilators Albuterol(C)
Reassuring human data; some associations with specific 
malformations but may be chance or confounded by severity
Long-acting bronchodilators
Formoterol(C)
Salmeterol(C)
Small amount of human data has been reassuring
Theophylline
No increase in congenital malformations; toxicity may be an 
issue
Systemic Corticosteroids
Associated with oral clefts, low birth weight, preterm birth, 
preeclampsia and intrauterine growth retardation. Some of 
these effects may be confounded by severity.
Inhaled Corticosteroids
Budesonide –B
Beclomethasone-C
Fluticasone_C
Mometasone –C
Triamcinolone -C
Substantial reassuring data. Risk of increased malformations 
with high dose, but may be confounded by severity. Most 
data for budesonide.
Leukotriene Receptor 
Antagonist
Montelukast –B
Zafirlukast -B Moderate amount of reassuring data
5-LO Inhibitor Zileuton -C Animal studies not reassuring; no human data
Anti-IgE Xolair-B
Increased risk of low birth weight and preterm birth, but 
may be confounded by severity
Adapted from Schatz M, Zeiger RS, Falkoff R, Chambers C, Macy E, Mellon MH. Asthma and allergic diseases during pregnancy. In: 
Middleton’ s Allergy: Principles and Practice, 8th ed, Adkinson, NF, Bochner BS, Burks AW et al (Eds), Mosby, St. Louis, MO 2014, 
pp. 951-69
Allergic diseases in pregnancy
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TABLE 3
Safety of commonly used medications for the treatment of rhinitis during pregnancy
Drug Class Drug/FDA Class Adverse perinatal Outcome
Oral 
Antihistamines
Azelastine -C
No human data, animal studies show increase in teratogenicity, 
skeletal abnormalities and fetal death in high doses
Cetirizine -B No increase in congenital malformation
Chlorpheniramine No increase in congenital malformation
Dexchlorpheniramine -B No increase in congenital malformation
Fexofenadine -C
This active metabolite of terfenedine has been associated with dose 
related weight gain animal studies.
Diphenhydramine No increase in congenital malformation ;withdrawal syndrome a risk
Hydroxyzine No increase in congenital malformations; withdrawal syndrome a risk
Loratadine -B
No increase in congenital malformations, low birth weight, or small for 
gestational age
Decongestants
Oxymetazoline
No increase in congenital malformations; possible utero-placental 
insufficiency with higher doses
Phenylephrine Associated with club foot, eye/ear malformations
Phenylpropanolamine
Increase in total and specific congenital malformations in one study, 
association with gastroschisis and VSD in case-control studies
Pseudoephedrine
Association with gastroschisis, hemifacial microsmia and small 
intestinal atresia in some case-control studies
Intranasal 
Antihistamines
Azelastine No controlled studies;
Olapatadine No controlled data; animal studies reassuring
Intranasal 
Corticosteroids
Budesonide –B
Fluticasone -C
Triamcinolone-C
Mometasone-C
Substantial reassuring data for inhaled corticosteroids. Risk of 
increased malformations with high dose, but may be confounded by 
severity. Most data for budesonide.
Adapted from Schatz M, Zeiger RS, Falkoff R, Chambers C, Macy E, Mellon MH. Asthma and allergic diseases during pregnancy. 
In: Middleton’ s Allergy: Principles and Practice,8 th. Adkinson, NF, Yunginger, JW, Busse, WW et al (Eds), Mosby, St. Louis, MO (in 
press)
TABLE 4
Treatment options for atopic der-
matitis in pregnancy 
Safe
Emollients, mild to 
moderate strength 
topical corticosteroids, 
oral antihistamines, 
ultraviolet B light
Relatively 
safe 
(caution)
Oral corticosteroids, 
cyclosporine, 
azathioprine, topical 
calcineurin inhibitors
Avoid
Methotrexate, 
mycophenolate 
mofetil, psoralens 
plus ultraviolet A light 
(PUVA)
prominent part of this syndrome. 
Symptoms typically include vas-
cular collapse and disseminated 
intravascular coagulation. Treat-
ment relies on controlling hemor-
rhage as well as vascular instabil-
ity.
KEY REFERENCES
1. Namazy J, Murphy V, Powell H, 
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2013;41:1082-1090. 
2. Kallen B. Use of antihistamine 
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ery outcome. J Matern Fetal Neona-
tal Med 2002;11:146–152.
3. Babalola O,Strober BE. Treatment 
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Dermatol Ther 2013;26:293-301.
4. Weatherhead S,Robson SC, Reyn-
olds NJ. Eczema in pregnancy. BMJ 
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Allergic diseases in pregnancy
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s • Physical activity is highly recommended to maintain health 
status and prevent chronic inflammatory conditions, including 
allergic diseases
• Exercise, however, may trigger bronchial, nasal, ocular, skin and even 
systemic symptoms, particularly in subjects with allergic diseases
• Accordingly, allergic diagnosis should be part of the routine medical 
examination in both competitive and non-competitive exercisers
• Early diagnosis of exercise-related symptoms and their adequate 
management may allow allergic subjects not only to practice 
sports safely, even at competitive level, but also to make physical 
exercise as a pillar of their therapeutic strategy
• Diagnosis and treatment of allergic diseases in elite athletes 
require special considerations in order to ensure the best 
performances, while respecting current anti-doping regulations 
Physical exercise, although recom-
mended for the general population 
and for allergic subjects, may repre-
sent a trigger of bronchial obstruc-
tion (in subjects with or without 
co-existing clinical asthma), rhi-
no-conjunctivitis symptoms, skin 
manifestations and even severe an-
aphylaxis. Atopy has been shown 
to represent a risk factor for these 
conditions in both competitive and 
non-competitive exercisers.
ExERCISE-INDUCED 
BRONCHOCONSTRICTION
Exercise-Induced Bronchocon-
striction (EIB) represents a sign 
of poor asthma control. However, 
EIB may also occur in subjects with 
no evidence of clinical asthma, 
particularly in children, athletes, 
patients with atopy or rhinitis and 
following respiratory infections. 
The type, duration and intensity of 
physical exercise and environmen-
tal conditions are critical factors 
for the occurrence of EIB.
EIB recognizes a peculiar 
patho-physiological pathway. The 
hyperventilation, particularly of 
cold and dry air, causes water loss 
and increased osmolarity of the 
airways which results in epitheli-
al damage and release of several 
inflammatory agents. Additional 
mechanisms have been suggested.
ALLERGIC DISEASES AND 
SPORTS4
Ke y  m e ssag e s
Allergic diseases and sports
Self-reported symptoms after 
exercise are not sufficient for a 
diagnosis of EIB, which has to be 
documented through pulmonary 
function tests before and after 
a standardized bronchial provo-
cation. Exercise challenge or its 
surrogate indirect tests (Eucap-
nyc Voluntary Hyperpnea and 
Hypertonic Saline or Mannitol) 
are recommended. Direct bron-
chial provocation with histamine 
or methacholine is less accurate to 
document EIB, particularly in sub-
jects without underlying asthma. 
EIB is usually efficiently reversed 
by beta-2 adrenergic agent inhala-
tion. The best preventive strategy 
for EIB in asthmatics is represent-
ed by achieving complete asth-
ma control, according to GINA 
guidelines. Prevention of EIB in 
subjects without clinical asthma 
includes both pharmacologic and 
non-pharmacologic measures. 
RHINITIS AND 
CONJUNCTIVITIS
Allergic rhino-conjunctivitis is a very 
frequent condition in exercisers. 
The type of sport influences mech-
anisms and symptoms (swimmer, 
winter, runner, boxer nose). Expo-
sure to specific sensitizing allergens 
Matteo Bonini  
“Sapienza” University of Rome 
Rome, Italy
Sergio Bonini  
Second University of Naples 
Naples, Italy
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Figure 1 The swimmer nose: incidence, symptoms and inflammatory 
phenotype.
during in-door or out-door exercis-
ing may trigger or exacerbate nasal 
and ocular symptoms and affect 
performance. Rhinitis and conjunc-
tivitis may also occur in non-allergic 
subjects: non-allergic rhinitis with 
neutrophilia has been reported in 
swimmers (Figure 1), possibly in 
relation to chlorine exposure, while 
cold air exposure may cause vas-
omotor rhinitis in winter athletes. 
Diagnosis and treatment do not 
differ from those recommended by 
ARIA guidelines in the general pop-
ulation. Particular attention should 
be placed on the potential negative 
effects on vigilance and reaction 
times of anti-histamines, particular-
ly of those of the first-generation.
ALLERGIC SKIN DISEASES
Urticaria and angioedema may oc-
cur not only in relation to physical 
activity, but also to other factors 
connected to the specific sport 
practiced (pressure by sport in-
struments; exposure to water, 
cold, sun, etc.). Sports instruments 
and vests (often made by rubber) 
may cause allergic contact derma-
titis and eczema in exposed sensi-
tized individuals.
ExERCISE-INDUCED 
ANAPHYLAxIS
Exercise-Induced anaphylaxis 
(EIAn) is a rare, but unpredictable 
and severe, syndrome in which 
anaphylaxis occurs in conjunc-
tion with exercise. EIAn is often 
associated with food allergy and 
may only occur as a combination 
of exercise and ingestion of the 
sensitizing food (FDEIAn). There-
fore, an accurate diagnosis of food 
allergy (including molecular diag-
nostics) has to be made in subjects 
with EIAn, and the sensiting food 
should be eliminated from the diet 
(possibly also avoiding any food in-
gestion in the three hours before 
exercising).
ALLERGIC DISEASES IN ELITE 
ATHLETES
Several studies indicate that sen-
sitization and allergic diseases 
occur in elite athletes with a high-
er prevalence than in the general 
population (Figure 2). Suggested 
mechanism is the combined effect 
of a strenuous, chronic training 
and environmental exposure (al-
lergens, pollutants, cold air, etc.) 
on both the immune system (with 
a switch to a Th2 cytokine profile, 
this also explaining the higher in-
cidence of infections, particular-
ly of the upper respiratory tract) 
and target organs. Diagnosis and 
treatment of allergic diseases in 
elite athletes require special con-
siderations in order to ensure the 
best performances, while respect-
ing current anti-doping regula-
tions (Table 1).
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Figure 2 Prevalence of sensitization and allergic diseases in 378 Italian Olympic athletes (Bonini M. et al, 2014 
submitted).
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TABLE 1
WADA rules for anti-allergic drugs
Treatment WADA Rules Notes
Antihistamines Permitted
Second generation molecules should be preferred to 
avoid side effects
Leukotriene modifiers Permitted
Inhaled steroids Permitted
Immunotherapy Permitted
SCIT should not be performed before of after physical 
exercise
β2 agonists
Inhaled Salbutamol (max 
1600 mcg/24h)
The presence in urine of salbutamol > 1000 ng/mL 
or formoterol  > 40 ng/mL is presumed not be an 
intended therapeutic use of the substance and will be 
cnsidered as an Adverse Analytical Finding
Formoterol (max 54 
mcg/24H) and Salmeterol
All others prohibited in and 
out competition
Systemic steroids Prohibited in competition
Ephedrine, 
methylephedrine
Prohibited in competition
A concentration in urine greater than 10 µg/mL 
represent an Adverse Analytical Finding
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• Many adolescents are affected by allergic diseases, and allergies 
have a major impact on their daily life
• The developmental milestones of adolescence can be challenging 
for patients, their parents and their clinicians
• Adolescent patients need to be approached in a way that 
promotes their development as active patients, who are 
empowered to take ownership of their allergies
IMPACT OF ALLERGY IN 
ADOLESCENCE 
Many adolescents are affected by 
allergies. More than a third have 
symptoms of rhinoconjuctivi-
tis, about 1 in 7 have asthma and 
around 1 in 50 have food allergy. 
This group experiences more mor-
bidity and mortality than would be 
expected, they are overrepresent-
ed in fatal series of food allergy 
and asthma death registry data. 
Therefore adolescents deserve 
special attention in any allergy 
clinic.
ADOLESCENTS AS PATIENTS 
Adolescence is a challenging time 
for any individual, even if they 
do not have a chronic medical 
condition. While coping with the 
Graham Roberts  
University of Southampton 
Southampton, UK
ALLERGIC DISEASES IN 
ADOLESCENTS 5
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Allergic diseases in adolescents
physical changes associated with 
puberty, they have to start taking 
responsibility for themselves and 
others, gain independence, devel-
op relationships outside their im-
mediate families and renegotiate 
the rules at home (Figure 1). 
All this may perhaps explain why 
adolescents are often poorly en-
gaged with their healthcare pro-
vider. For example, despite follow 
up in an allergy clinic, adolescent 
patients often fail to avoid their 
triggering food allergens and car-
ry their adrenaline autoinjector. 
There are similar issues with asth-
ma. Looking at an allergy clinic 
from the adolescents’ perspective, 
they may see consultations as be-
ing dominated by their parents, 
perhaps do not feel that clinic is 
relevant for them and may have 
issues around their confidentiality.
HOW CAN WE IMPROVE 
THE MANAGEMENT OF 
ADOLESCENT PATIENTS? 
During adolescence, children must 
develop into independent adults 
with responsibilities for maintain-
ing health status moving from par-
ents to patient. Parents find this 
challenging, and adolescent may 
have limited opportunities to take 
on responsibility for their health. 
The management of adolescent 
patients, therefore needs to pro-
mote this transition. 
There are a number of generic ap-
proaches that may help to engage 
adolescent patients: 
• Ensure that adolescent patients 
are active participants in clin-
ic using appropriate language, 
being empathic, respectful, and 
non-judgmental. 
• Taking a patient rather than a 
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diseased centred approach may 
help adolescents realise the val-
ue of a clinic appointment. 
• Slowly transition from parents. 
Seeing adolescent patients on 
their own for the initial part of 
the consultation may help to 
empower them to take owner-
ship of their allergies.
For individual allergic diseases 
there are additional specific ap-
proaches that may be helpful. For 
asthma, for example, the focus 
should be on what activities asth-
ma stops them doing and dealing 
with these by prescribing thera-
pies that fit into their daily sched-
ule. For food allergy, for example, 
education around the recognition 
and management of allergic re-
actions should be directed at the 
adolescent patient using scenario 
based role playing and adrenaline 
autoinjector simulators. 
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Older adolescent
• Large and 
postpubertal
• Independent
• Emotionally 
mature
• Complex abstract 
thinking
• Socialise with peers 
of opposite gender
Challenges for teenagers: 
• Gaining independence 
• Taking risks 
• Taking responsibility for 
self and others
• Getting a job
• Developing relationships
Challenges for clinicians: 
• Compliance
• Identity
• Consent
• Confidentiality
• Teenager-parent relation-
ships
Figure 1 Adolescent development: challenges for patients and clinicians.
Younger adolescent
• Small and 
prepubertal
• Dependent on 
parents
• Emotionally 
immature
• Concrete in their 
thought process
• Socialise with peers 
of same gender
Allergic diseases in adolescents
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• Adherence is the extent to which a patient’s behavior reflects 
the “agreed upon” the management plan as outlined by their 
healthcare provider
• Barriers to adherence are numerous and include disease and 
patient specific concerns, as well as, provider practice pattern, 
health system constraints, and the larger societal context
• Strategies to improve adherence include written action plans, 
simplification of treatment regimens, and novel technologies 
such as social media or text messaging (SMS)
• Shared decision making between patients and provider is crucial 
in constructing an effective treatment plan and improving 
adherence
The global burden of non-adher-
ence in allergic diseases is substan-
tial. Developing an optimal man-
agement plan in allergic diseases 
depends equally on appropriate 
medication recommendations as 
well as the patient’s ability and 
desire to adhere to the proposed 
treatment. Adherence is the ex-
tent to which a patient’s behavior 
resembles the “agreed upon” man-
agement plan as outlined by their 
healthcare provider. The qualifica-
tion of ‘agreed upon’ emphasizes 
the importance of shared decision 
making between patient and their 
providers. Adherence contrasts 
the term compliance, which con-
ceptualizes the patient’s role as 
limited to following recommenda-
tions, without explicit considera-
tion of patient’s preferences and 
goals. In allergic disease, adher-
ence issues have been most fully 
explored in asthma care, primarily 
due to the increased availability 
of traceable outcome measures, 
such as exacerbation rates, sys-
temic corticosteroids use, emer-
gency department visits, and hos-
pitalizations. 
Patient’s adherence to the “agreed 
upon” management plan can be 
difficult to assess and sometimes 
not evident until poor outcomes 
ADHERENCE TO THE 
MANAGEMENT PLAN 6
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Adherence to the management plan
are suffered. Barriers to adher-
ence are numerous and include 
chronicity of disease, increasing-
ly complex medication regimens, 
high medication cost, and lack 
of perceived treatment benefit 
(Figure 1). Assessing the level of 
adherence is crucial and can be 
accomplished by direct patient 
interviewing, pharmacy fill rate, 
medication monitoring methods 
(pill counting, inhaler dose coun-
ters, etc) or through biochemi-
cal assays. Exhaled nitric oxide is 
emerging as a potentially power-
ful bioassay for measuring inhaled 
corticosteroid adherence in pa-
tients with asthma. 
Improve adherence is critically 
important in the management of 
allergic diseases. Written Action 
Plans (WAPs) may be a useful 
tool for the practicing allergist to 
enhance patient understanding 
of the management plan (Figure 
2). In the acute care setting, WAP 
have been shown to significant-
ly increase patient adherence to 
inhaled corticosteroids, improve 
asthma control, and medical fol-
low up. WAPs are available for a 
number of allergic diseases includ-
ing anaphylaxis and allergic rhini-
tis. Simplifying the management 
plan can also improve patient ad-
herence (Figure 3). 
The widespread availability and 
acceptability of technologic inter-
Andrew nickels James T. Li 
Mayo Clinic  
Rochester, USA
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ventions, such as text messaging 
or social media, may be useful tool 
in improving adherence rates and 
evidence on this topic is emerging. 
Of all the potential interventions 
aimed at improving patient adher-
ence, striving to strengthen the 
provider-patient relationship and 
focusing on management plans 
that takes the patient’s preference 
into account may lead to optimal 
treatment outcomes in allergic 
diseases.
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Figure 3 This patient found herself 
overwhelmed by a complex treatment 
plan for her allergic diseases. 
Simplification of treatment regimens, 
as well as, understanding patient’s 
treatment preferences and goals lead 
to improved adherence. 
Figure 1 Barriers to adherence are numerous and are influenced by a multitude of levels. Societal concerns and the 
health system culture set the stage for the patient-provider interaction. On an individual level, a clinician’s practice 
pattern and the patient’s individual preferences and goals affect the milieu in which the treatment plan is made. 
The particulars of the disease and the available medications make up the specific variable of this complex equation. 
(Reproduced from Middleton's Allergy: Principles and Practice, 8ed, Apter A, Bender B, Rand C, Ed. Adkinson et al, Adherence, 
1473, copyright 2013 with permission from Elsevier.)
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Figure 2 Written Action Plans, such as this Asthma Action Plan, may be a useful tool for the practicing allergist to 
enhance patient understanding of the management plan. Written Action Plans are available for a variety of allergic 
disease including anaphylaxis, food allergy, asthma, and eczema. Reproduced from the Minnesota (USA) Department 
of Health with permission. Accessed January 27, 2014. URL: http://www.health.state.mn.us/divs/hpcd/cdee/asthma/
ActionPlan.html
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s • Health-related quality of life (HRQL) is one of the most important 
outcomes in studies on allergic diseases
• HRQL may be accurately measured using instruments developed 
for this purpose 
• HRQL is unjustifiably underutilized in clinical studies
• Use of HRQL in clinical practice requires further research 
Allergic diseases are rarely fatal. 
Even the most extreme and severe 
form of allergy, anaphylaxis, has a 
low mortality rate. Allergic diseas-
es rarely lead to traditional forms 
of infirmity, and societal aware-
ness and concern regarding aller-
gic diseases has thus been limited. 
However, research carried out 
over the last decades has shown 
that allergic diseases significant-
ly impact quality of life (QoL) of 
patients, and this knowledge has 
dispelled many notions of allergy 
as being a “trivial” disease. Despite 
this, misunderstandings about the 
correct development and use of 
instruments measuring QoL may 
give the impression that these 
outcomes are “soft” and subjec-
tive. In fact, proper application of 
good instruments generates out-
comes that are neither. 
HEALTH-RELATED QUALITY 
OF LIFE: WHAT MATTERS TO 
PATIENTS?
Health-related quality of life 
(HRQL) is that part of overall 
QoL, which is affected by health 
and disease (Figure 1). The most 
important aspect of question-
naires measuring HRQL is that 
they are properly validated, as 
it is this process, which ensures 
that non-disease-related QoL is-
Anthony E.J. Dubois  
University of Groningen 
Groningen, The Netherlands
ALLERGIC DISEASES AND 
QUALITY OF LIFE7
Ke y  m e ssag e s
Allergic diseases and quality of life
sues are excluded and that only 
HRQL is measured. Many in-
struments have also ascertained 
the minimal clinically important 
difference (MCID), which repre-
sents the smallest change or dif-
ference in HRQL scores, which is 
clinically meaningful to patients. 
Thus, HRQL 
i n s t r u m e n t s 
can accurately 
measure as-
pects of disease 
important to 
patients. In ad-
dition, they can 
show if chang-
es, for example 
brought about 
by treatment 
are relevant 
from the pa-
tient’s point of 
view. 
MEASURING HEALTH-RELATED 
QUALITY OF LIFE IN ALLERGIC 
DISEASES 
Over the past 25 years, instru-
ments for measurement of HRQL 
have been developed for rhinitis, 
asthma and atopic dermatitis, al-
lergic diseases which tend to be 
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chronic and where the impact on 
HRQL is of paramount importance 
in the assessment of management. 
More recently, instruments have 
been developed for measuring 
HRQL in patients at risk for ana-
phylaxis, both from vespula ven-
oms and foods, where the expecta-
tion of outcome of future episodes 
and consequent avoidance behav-
ior, rather than chronic symptoms, 
drives HRQL. The choice of the 
correct tool to measure HRQL is 
essential (Figure 2).
Despite the eminent suitability 
of these measurements for re-
search purposes, HRQL is usually 
a secondary rather than a primary 
outcome in most studies. Ironical-
ly, symptom-medication scores, 
which are frequently used instead, 
are difficult to interpret, because 
it is usually unknown what chang-
es are big enough to be important 
to patients. Application of HRQL 
measures in clinical practice is lim-
ited by the lack of studies formally 
assessing the contribution of this 
information to management. 
KEY REFERENCES 
1. Dietz de Loos DA, Segboer CL, 
Gervorgyan A, Fokkens WJ. Dis-
ease-specific quality-of-life ques-
tionnaires in rhinitis and rhinosi-
nusitis: Review and evaluation. Curr 
Allergy Asthma Rep 2013;13:162-
170.
2. Wilson SL, Rand CS, Cubana MD, 
Foggs MB, Halterman JS, Olson 
L et al. Asthma outcomes: Qual-
ity of life. J Allergy Clin Immunol 
2012;129:S88-123.
3. Rehal B, Armstrong A. Health out-
come measures in atopic dermati-
tis: A systematic review of trends in 
disease severity and quality-of-life 
instruments 1985-2010. PLoS ONE 
2011;6:e17520.
4. Oude Elberink JN, Dubois AE. 
Quality of life in insect venom aller-
gic patients. Curr Opin Allergy Clin 
Immunol 2003;3:287-293.
5. van der Velde JL, Dubois AE, Flok-
stra-de Blok BM. Food allergy 
and quality of life: what have we 
learned? Curr Allergy Asthma Rep 
2013;13:651-661.
FAQLQ-AF
FAQL-PB
Adult Child (0-18) Caregiver
Systemic 
food allergy OAS No validated tool 
Consider generic or 
disease-specific validated 
HRQL questionnaire with 
an independent measure 
of disease severity
(not all tools validated for 
individual use)
IgE Mediated Non-IgE Mediated
Research 
(Group Setting)
Clinical
(Individual Setting)
< 8 years
FAQLQ-PF
>8 years
FAQLQ-PF
FAQLQ-CF
0-12 years 13-18 years
FAQLQ-TF
FAQL-teen
You and Your Allergy
HRQLQ
Figure 1 Choosing an appropriate Food Allergy 
HRQLQ. (Reproduced with permission from Muraro A, 
Dubois AE, Dunngalvin A, et al. EAACI Food Allergy and 
Anaphylaxis Guidelines. Food allergy health-related quality 
of life measures. Allergy. 2014 May 2. doi: 10.1111/
all.12405. [Epub ahead of print], with permission from 
Willey Blackwell.)
Allergic diseases and quality of life
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s • Hypersensitivity disorders, particularly allergy is frequent in 
animals and affect all commonly treated species
• The main target organs are the skin and the intestinal tract even 
though a counterpart of asthma is recognized in cats and horses
• Atopic dermatitis, the most frequent allergy in dogs and cats, 
affect up to 50% of individuals in some predisposed breeds
• Treatment of allergic disorders in animals is mainly based 
on allergen avoidance, use of immunomodulatory drugs and 
allergen-specific immunotherapy
Hypersensitivity disorders repre-
sent a major burden for compan-
ion and large animals, especially 
dogs, cats and horses. The other 
species are probably also affected 
even though data are only sparse. 
Major allergens include insect 
(flea, flies), environmental (house 
dust and storage mites, pollens, 
molds, epithelia) and food aller-
gens. From a clinical point of view, 
the skin and the gastrointestinal 
tract are by far the most frequent-
ly affected, even though horses 
and cats may present with clinical 
signs of allergic asthma.
Insect allergies were the first well 
characterized allergy disorders in 
animals and are considered to be 
type I and type IV hypersensitivity 
reactions. In dogs and cats, fleas 
are frequently involved and flea 
hypersensitivity dermatitis was 
long considered the first cause of 
skin disorders in both dogs and 
cats. In horses numerous flies have 
been suspected to induce similar 
disorders. Affected animals pres-
ent with intense itch usually lo-
calized on the dorsal aspect of the 
body. In contrast, bee and wasp 
allergies are comparatively rare 
in domestic animals and are usu-
ally associated with urticaria, an-
gioedema and/or anaphylaxis.
Claude Favrot  
University of Zurich  
Zurich, Switzerland
ALLERGIC DISEASES IN 
ANIMALS8
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Environmental allergies mostly 
target the skin in animals. Atopic 
dermatitis is the most frequent dis-
eases in dogs and in some breeds 
(French Bulldog, Shar pei, West-
Highland-White Terrier more than 
50% of individuals are affected. 
Affected animals present with itch 
and erythema usually localized to 
the head, feet and ventral parts of 
the body (Figure 1). Canine atopic 
dermatitis is considered the coun-
terpart of human disease and most 
of the findings observed in humans 
are applicable to the dog. In fact, 
canine atopic dermatitis is a Th2 
driven disorder in the acute phase 
of the disease and is mainly Th1 in 
the more chronic one. The most 
frequently involved allergens are 
house dust mites even though sim-
ilar symptoms have been observed 
with pollen and food allergies. AD 
is less well characterized in cats, 
horses and other domestic ani-
mals but the disease is recognized 
in all of these species.
Mites and pollen allergens are 
also involved in the pathogene-
sis of equine and feline asthma. 
Equine heaves is a spontaneous 
occurring asthma-like condition 
affecting 10–20% of adult horses 
in the northern hemisphere and 
other temperate climates. Similar-
ly to asthma, heaves is a chronic 
disorder of the airways, which is 
characterized by variable and re-
curring airflow obstruction, bron-
chial hyperresponsiveness and 
airway inflammation. During dis-
ease exacerbation, horses present 
increased respiratory efforts at 
rest, coughing and exercise intol-
Allergic diseases in animals
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Figure 1 Atopic dermatitis in a dog.
erance. Clinical signs are triggered 
or exacerbated by inhalation of 
dust particles present in the sta-
bles, especially those associated 
with hay feeding. Neutrophils and 
macrophages are present in large 
numbers in the airways of horses 
with heaves and may contribute to 
the disease through the release of 
several inflammatory mediators. 
Experimental models of feline 
asthma have been developed with 
cats sensitized to various allergens 
including mites and pollens. Sim-
ilarities of horse heaves with the 
human asthma are currently being 
used to evaluate airway remod-
elling and its reversibility in ways 
that are not possible in humans 
for ethical reasons.  Research per-
spectives that can be relevant to 
asthma include the role of neutro-
phils in airway inflammation and 
their response to corticosteroids, 
systemic response to pulmonary 
inflammation, and maintaining 
athletic capacities with early in-
tervention.
Treatment of allergic disorders 
in animals is mainly based on al-
lergen avoidance (insects: use of 
antiparasitic treatment avoidance 
or organic dust for heaves), use of 
allergen-specific immunomodula-
tory (AIT) drugs such as glucocor-
ticoids or cyclosporine and desen-
sitization. AIT is mainly used for 
the treatment of atopic dermatitis 
in dogs and cats and is success-
ful in about 60-70% of the cases. 
Bronchodilators and corticoster-
oids are administered systemi-
cally or by inhalation in heaves to 
provide rapid relief of airway ob-
struction, or when control of the 
environment is partial or absent.
KEY REFERENCES
1. Scott DW. Chapter 8. Skin immune 
system and allergic skin diseases. 
Small Animal Dermatology. D. W. 
Scott. Philadelphia, Saunders Co. 
(2013).
2. Marsella R, Sousa CA, Gonzales AJ, 
Fadok VA. Current understanding 
of the pathophysiologic mecha-
nisms of canine atopic dermatitis. 
J Am Vet Med Assoc 2012; 241:194-
207.
3. Griffin CE, Hillier A. The ACVD task 
force on canine atopic dermatitis 
(XXIV): allergen-specific immuno-
therapy. Vet Immunol Immunopathol 
2001 ;81: 363-384.
4. Leclere M, Lavoie-Lamoureux A, 
Lavoie JP. Heaves, an asthma-like 
disease of horses. Respirology. 
2011;16:1027-1046.
Allergic diseases in animals
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MANAGEMENT OF ALLERGIC DISEASES 
* Overview: avoidance, treatment, induction of 
tolerance
* Avoidance measures in the management of allergic 
diseases – focus on environment
* Avoidance measures - focus on diet
* Perinatal risk factors and strategies for allergy 
prevention
* Pharmacological treatment of allergic disease 
* Anti IgE treatment for allergic disease
* Biological agents for the treatment of allergic 
disorders
* Biosimilars and allergy treatment 
* Targeting basophils and mast cells for novel 
treatment approaches
* Tolerance induction: principle and modalities
* Allergen immunotherapy- overview
* Mechanisms of allergen immunotherapy
* Subcutaneous allergen immunotherapy
* Sublingual allergen immunotherapy
* Oral allergen Immunotherapy for foods
* Recombinant allergens for allergen immunotherapy
* Peptide immunotherapy for allergic disease
* New routes for allergen immunotherapy
* Measuring clinical outcomes in allergen 
immunotherapy
* Implementing a healthy life style 
* Psychological support in the management of allergic 
patients
* Pharmacogenetics and pharmacogenomics of 
allergic diseases
* Pharmacoeconomics of allergic diseases
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factors: (a) how easy it is to avoid the trigger, (b) whether there 
are multiple triggers and (c) how easy it is to induce tolerance
• Drug treatment for allergies focuses on blockade of key mediators 
of inflammation and more broadly on anti-inflammatory agents, 
which block the activation of key cytokines which augment and 
sustain airways inflammation
• More targeted therapies are useful in selected patients
• Allergen-specific immunotherapy induces tolerance by deviating 
the immune response away from the allergic pattern
Allergy is a trigger for a variety of 
conditions. Allergy testing is di-
rected towards establishing which 
triggers, if any, are responsible 
for the particular problems a pa-
tient experiences. Once an aller-
gic trigger has been identified, the 
management plan will depend on 
three main factors: (a) how easy it 
is to avoid the trigger, (b) whether 
there are multiple triggers and (c) 
how easy it is to induce tolerance 
(Figure 1).
The possibility of avoidance de-
pends on the source for airborne 
allergens. Pollens and mould 
spores may be ubiquitous and so 
avoidance measures are impossi-
ble. In contrast, occupational aller-
gens may be contained by altera-
tions to manufacturing processes 
or air supply system. Animal dan-
ders may be avoidable in ones own 
home, but may be a problem, if the 
patient has to visit other homes in 
the course of their work. Exposure 
to house dust mite allergens can be 
contained by exclusion covers, but 
has not always proved as effective 
as one might hope. In part, this may 
reflect the existence of multiple 
triggers, but it is also possible that 
the mechanisms, which lead to the 
induction of perennial allergic asth-
ma and rhinitis are not the same as 
those which lead to its perpetua-
tion. Extreme forms of dust mite 
avoidance, through living at high al-
titude, appear more effective than 
the measures that can be achieved 
as sea level (Table 1).
Drug treatment for allergies focus-
es on blockade of key mediators 
of inflammation (e.g. antihista-
mines and anti-leukotrienes) and 
more broadly on anti-inflammato-
ry agents, principally glucocorti-
coroids, which block the activation 
of key cytokines which augment 
and sustain airways inflammation. 
For full-blown anaphylaxis, self-ad-
ministered adrenaline injection 
can be life-saving. More targeted 
therapies include monoclonal anti-
bodies against IgE and against var-
ious pro-allergic cytokines (e.g. an-
ti-IL-5). Although expensive, these 
therapies are useful in the manage-
ment of selected patients.
Tolerance implies that the individ-
ual either ceases to react or has a 
reduced reaction on exposure to 
allergens, which previously caused 
symptoms. Specific immunother-
apy can do this by deviating the 
immune response away from the 
allergic pattern. The results are 
more impressive for anaphylaxis 
to insect venom than for airborne 
allergies, but there is no doubt 
some patients do extremely well. 
Recent reports of inducing toler-
ance in peanut allergy suggest that 
there is scope for further develop-
ment of tolerance induction as a 
means of controlling food-related 
anaphylaxis. 
Anthony J. Frew  
Royal Sussex County Hospital  
Brighton, UK
OVERVIEW: AVOIDANCE, 
TREATMENT, INDUCTION OF 
TOLERANCE
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Overview: avoidance, treatment, induction of tolerance
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Overview: avoidance, treatment, induction of tolerance
TABLE 1
Studies investigating allergen avoidance in infancy
CCAPPS PREVASC SPACE
Country Canada Netherlands Europe
Study 
population
High Risk High Risk High Risk 
Design
Prospective randomised controlled 
trial to determine the effectiveness 
of a multifaceted intervention pro-
gramme in the primary prevention 
of asthma in high risk infants in two 
Canadian centres.
A multi-faceted 
intervention study 
to reduce environ-
mental exposure to 
inhalant and food al-
lergens and cigarette 
smoke in genetically 
susceptible children. 
A prospective randomised controlled 
trial of multifaceted design.
Interven-
tion
Allergen impermeable covers
Weekly bed sheet laundering
Acaricide washes
Removal of pets
Smoking cessation advice 
Breast feeding encouraged for entire 
first year 
Delay introduction of solids until 
6 months Cow’s milk, peanuts and 
seafood discouraged in infancy. 
Avoid day care until after the first 
year
Pets to be kept 
outside. 
Allergen impermea-
ble covers
Exclusive breast 
feeding to 6months
Smoking cessation 
advice
Avoid solid food and 
cow’s milk until 6 
months.
Exclusive breast feeding for as long as 
possible 
Delay solids until 6 months. 
Cow’s milk, egg and fish avoided until 
12 months. 
Peanut/tree nut avoided until 3 years. 
Allergen impermeable bed covers
Remove carpet from the infant’s room 
Hot wash soft furnishings weekly 
Ventilate infant’s room at least once a 
day and vacuum weekly
Pets and smoking discouraged.
Numbers 545 476 696
Age last 
assessed
7 years 6 years 2 years
Clinical 
outcome
The proportion of children with 
probable asthma (as defined by 
wheeze in the last 12 months plus 
bronchial hyper-responsiveness) 
was lower in the intervention group 
when adjusted values were used 
25% vs. 12.9% (p= 0.002)(39).  
Bronchial hyper-responsiveness was 
not statistically different between 
the two groups. 
No significant 
influence on the 
diagnosis of asthma 
diagnosis at the age 
of 6 years. 
There was also no 
effect on the lung 
function tests. 
No significant difference between the 
two groups in the diagnosis of asthma/
wheezy bronchitis (18.1%in the active 
vs. 17.8% in the control group) (54). 
The number of children sensitised to 
HDM allergen was lower in the active 
group, but this was probably not signifi-
cant (1.86% vs. 5%). 
Additional 
informa-
tion
More of the intervention group had 
been to hospital emergency depart-
ments with wheeze in the preceding 
12 months.
The level of house dust mite allergen 
found in the homes of each group 
was significantly different however 
there was no significant difference in 
the SPTs between the two groups.
HDM exposure is 
low in the Nether-
lands making im-
provements difficult.
The number of 
weeks children were 
breast fed didn’t 
significantly differ 
between the groups. 
It was postulated that HDM induced 
asthma usually presents later in 
childhood and an effect may be seen at 
a later date, however a follow up was 
published at 24months which did not 
show any evidence of an improvement 
in symptomatic allergy  and no further 
follow up studies have been published.
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Easy 
to avoid 
allergen?
Well 
Controlled
No: 
try anti-allergic drugs
Well 
Controlled
Yes: try 
avoidance measures
Yes: 
No need for 
immunomodulation
No: consider 
specific immunotherapy  
(if vaccine available)
Figure 1 Step-wise management of allergic diseases.
Overview: avoidance, treatment, induction of tolerance
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• Several allergic manifestations of the upper and lower airways as 
well as the skin may exacerbate upon environmental exposure to 
outdoor or indoor allergens
• Causal relationship between environmental allergens and allergic 
symptoms is suggested by targeted avoidance and reexposure
• Exposure related allergies can be reproduced artificially in the 
lab or exposure chambers
• Complete avoidance of outdoor allergens in most cases is 
unrealistic. Avoidance of indoor allergens should always be tried 
as a first treatment of choice, however, results are variable and 
complete avoidance is not easy to achieve
Sensitization to environmental al-
lergens may occur throughout life, 
however, the first two decades of 
life show the highest incidence 
of IgE-antibody-development to 
outdoor (pollen and moulds) or 
indoor (dust mite, cockroaches, 
pets, moulds) allergens.
Sensitization usually precedes the 
manifestation of clinical symp-
toms by months or years. It has 
be shown to be determined by 
genetic susceptibility, following 
a dose dependent risk. Children 
growing up in a domestic environ-
ment with high levels of indoor 
allergens from pets or mites who 
develop sensitization during the 
first years of life, have been shown 
to have a significantly increased 
risk for lung function impairment 
during school age and for chron-
ic persistence of allergic asthma. 
Therefore allergen avoidance or 
at least reduction of allergen ex-
posure to the lowest possible level 
has always been a key element of 
the allergic patient care.
OUTDOOR ALLERGENS
Given the fact that pollen with the 
greatest allergological relevance 
may be carried by wind for long 
distances, it is obvious, that com-
plete outdoor allergen avoidance 
is not realistic in most cases. Text-
Ulrich Wahn  
Charité Medical University 
Berlin, Germany
AVOIDANCE MEASURES IN THE 
MANAGEMENT OF ALLERGIC 
DISEASES – FOCUS ON ENVIRONMENT
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Avoidance measures in the management of allergic diseases – focus on environment
books are usually recommending 
to stay indoors, close the windows 
or wash the hair, once it is con-
taminated by allergenic pollen, 
however, these recommendations 
are rather pragmatic and not re-
ally based on scientific evidence. 
Another pragmatic approach is to 
travel to privileged sites with low 
aeroallergen exposure during the 
main pollen season (seaside, high 
altitude resorts).
INDOOR ALLERGENS
The key indoor allergens with 
global relevance are produced by 
different species of house dust 
mite (HDM). Growth and repro-
duction of mites is facilitated by 
modern house insulation, higher 
temperatures and particularly 
high indoor humidity. Wall to wall 
carpets may also contribute to 
higher HDM allergen level. Hu-
man exposure is particularly high 
during the night, since dust mites 
are found in mattresses at the 
highest concentrations (figure 1). 
While frequent vacuum cleaning 
and acaricides have been shown 
to be of insufficient, specific mat-
tress encasing (Figure 2) which al-
lows the exchange of humidity but 
not the transfer of allergens have 
been demonstrated to be useful 
barriers between the human body 
and dust mites in the mattress 
(Figure 3). In monosensitised asth-
matic children these encasings 
are not only able to reduce aller-
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Figure 1 Allergen exposure at night time and the intervention of the laminar airflow.
Figure 2 Bed encasing for HDM avoidance.
Avoidance measures in the management of allergic diseases – focus on environment
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gen exposure but to reduce bron-
cho-hyperresponsiveness. More 
recently laminar airflow systems 
in connection with allergen filters 
have been shown to be useful for 
HDM allergic patients during the 
night, particularly in severe, un-
controlled asthma (figure 1).
The elimination of moulds and 
their allergens obviously relates 
to indoor humidity. Strategies 
for elimination are currently not 
based on scientific evidence.
Avoidance of pet allergens has to 
do with avoidance of pets in the 
domestic environment. While ex-
posure to allergens from cats may 
be relevant in kindergardens and 
schools, most children spend the 
majority of time indoors at home, 
so that elimination of domestic 
pets is still a reasonable recom-
mendation for affected families. 
Realistically we have to assume 
that still relevant airborne con-
centrations from cats and other 
animals will remain in the domes-
tic environments even months af-
ter elimination.
KEY REFERENCES
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U. Reducing domestic exposure to 
dust mite allergens reduces bron-
chial hyperreactivity in sensitive 
children with asthma. J Allergy Clin 
Immunol1992:90:135-138.
2. Lau S1 Illi S, Sommerfeld C, Nigge-
mann B, Bergmann R, von Mutius E 
et al. Early exposure to house-dust 
mite and cat allergens and devel-
opment of childhood asthma: a co-
hort study. Lancet 2000;356:1392-
1397.
3. Boyle RJ, Pedroletti C, Wickman M, 
Bjermer L, Valovirta E, Dahl R et al. 
Nocturnal temperature controlled 
laminar airflow for treating atopic 
asthma: a randomised controlled 
trial. Thorax 2012;67:215-221.
4. Devillier P1 Le Gall M, Horak F. The 
allergen challenge chamber, a valu-
able tool for optimizing the clinical 
development of pollen immuno-
therapy. Allergy 2011;66:163-169.
5. Platts-Mills TA. Allergen avoid-
ance. J Allergy Clin Immunol 
2004;113:388-391.
TABLE 1
Strategies for elimination of in-
door allergens
• Avoid furred pets (cats, dogs, 
guinea pigs, rats etc.)
• Reduce indoor humidity
• Improve ventilation
• Implement encasings for mat-
tress and duvets/pillows
• Most acaricides (benzylbenzo-
ate) are ineffective !
• Avoid wall-to-wall carpets
• Consider laminar airflow system
Figure 3 Comparison between bed encasing and acaricides. 
Avoidance measures in the management of allergic diseases – focus on environment
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failed to prevent the development of allergic disease
• Food allergen consumption is necessary to establish the immune 
response leading to oral tolerance
• The only current recommendations to prevent allergic disease 
are exclusive breast-feeding at least 4 to 6 months and if 
breastfeeding is insufficient or not possible, hypoallergenic 
formula for high risk infants
• There is evidence consistent with the hypothesis that 
sensitisation to foods may occur via the cutaneous route
• Oral tolerance induction or improving skin barrier function 
may prevent the development of food allergy and other allergic 
diseases 
Food allergy and other allergic 
diseases have become more prev-
alent in the past years. There is 
no clear evidence as to why this 
has occurred. Infantile eczema 
and food allergy are usually the 
first steps in the allergic march, 
followed later on by respiratory 
allergies, including asthma and 
allergic rhinitis. For many years, 
food allergen avoidance in preg-
nancy, lactation and infancy was 
recommended to prevent the de-
velopment of food allergy, and 
possibly other allergic diseases, 
with the view that allergic sensiti-
sation happens in the gastrointes-
tinal tract and would not happen 
in the absence of gastrointestinal 
exposure. However, public health 
guidelines supporting allergen 
avoidance have failed to prevent 
the development of food allergies 
(Figure 1). This may be because 
allergen is required for the estab-
lishment of oral tolerance and/
or because sensitisation does not 
occur via the gastrointestinal tract 
but via other routes. 
The immune response leading to 
oral tolerance develops in the gut 
and requires the presence of food 
allergens. Other facilitating fac-
tors such as diverse gastrointesti-
nal microbiome, and immunomod-
AVOIDANCE MEASURES - 
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ulatory factors in saliva and breast 
milk may also be necessary for the 
acquisition of tolerance. There 
is some observational evidence 
that initial sensitisation to food 
allergens occurs via the cutaneous 
route. For instance, early-onset 
severe eczema is associated with 
food allergy and topical exposure 
to peanut oil and high exposure to 
environmental peanut are associ-
ated with peanut allergy.
Currently, there are no clear 
guidelines other than recom-
mending exclusive breast-feeding 
for the first 4-6 months of life and 
if breastfeeding is insufficient or 
not possible, hypoallergenic for-
mula for high risk infants. Recent 
studies suggest that increased 
diversity of food within the first 
year of life might have a protec-
tive effect on asthma, food allergy, 
and food sensitization. Further-
more, early consumption of pea-
nuts in infancy is associated with 
a low prevalence of peanut allergy. 
Randomised controlled studies 
looking at the impact of early in-
troduction of allergenic foods on 
the prevalence of food allergy and 
other allergic diseases are under-
way. 
If a food is consumed in a certain 
society and location, this results 
in both environmental and oral 
Alexandra F. Santos Gideon Lack
King's College London 
London, UK
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exposure (Figure 2). If in fact sen-
sitisation occurs via the cutaneous 
route and oral tolerance occurs via 
the oral route, novel ways to pre-
vent food allergy might include: 
oral tolerance induction both in 
high and low risk infants through 
early introduction of food, or im-
provement of the skin barrier. 
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Figure 1 a - Change in commencing solids between 1975 and 1986; b - Change in the prevalence of allergic conditions in 
children in South Wales between 1973 and 1988.
Figure 2 Dual-allergen exposure 
hypothesis for the pathogenesis of 
food allergy. Allergic sensitisation 
results from cutaneous exposure and 
tolerance occurs as a result of oral 
exposure to food. (Reprinted from J 
Allergy Clin Immunol, 121/6, Lack G. 
Epidemiologic risks for food allergy, 
1331-1336, Copyright 2008, with 
permission from Elsevier.) 
a b
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discouraged at every age, particularly in pregnancy and childhood
• Breastfeeding is recommended for at least 6 months for many 
reasons, although the specific evidence for allergy prevention is 
not strong
• There is little evidence that avoiding allergenic foods or delaying 
the introduction of complementary solid foods reduces the risk 
of allergy 
• Most importantly, there is ongoing research to explore the role 
of probiotic and prebiotic supplements to restore declining 
microbial diversity, and other immunomodulatory dietary 
nutrients such as polyunsaturated fatty acids, antioxidants, 
folate and vitamin D in allergy prevention – which may all reduce 
the risk of many other inflammatory non-communicable diseases
Modern environmental changes 
have had many adverse effects on 
human health, increasing the risk 
of many inflammatory non-com-
municable diseases (NCDs). Most 
of these chronic diseases of ‘mod-
ern life’ (including asthma, aller-
gies, heart disease, diabetes and 
obesity) are associated with sim-
ilar modern environmental risk 
factors. Allergy is the earliest on-
set NCD, often beginning in the 
first months of infancy and a clear 
indication that the developing im-
Susan L. Prescott  
University of Western Australia  
Perth, Australia
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mune system is particularly vul-
nerable to environmental change. 
In this regard, we can consider 
allergy as ‘the canary in the coal 
mine’- a useful early barometer of 
environmental impact on human 
health (Figure 1). These environ-
ment-driven changes begin in 
pregnancy, with emergent differ-
ences in immune function detect-
able at birth for newborns, who go 
on to develop allergies (Figure 2). 
Maternal diet, microbial expo-
sures and toxic exposures in preg-
nancy are implicated in allergy and 
in many other NCDs, increasing 
the predisposition, sometimes 
many years later. These same risk 
factors have ongoing role in early 
childhood, influencing the balance 
of gut bacteria, and developing 
immune and metabolic responses, 
and the predisposition to both al-
lergy and other NCDs (Figure 3). 
The keys to prevent disease must, 
therefore lie in very early life be-
fore the onset of disease, and be-
fore allergic immune responses 
have become consolidated. Over 
the past decades, there has been 
a shift away from allergen avoid-
ance strategies and towards more 
immunomodulatory approaches. 
This is because allergen exposure 
‘Canary'in'the'coal'mine’'
Figure 1 A ‘canary in the coal mine’: 
Beginning in infancy allergy is the 
earliest onset NCD, and a sensitive 
early measure of the effects of the 
modern environment on immune 
health. (Reproduced with permission 
from Prescott SL. Disease Prevention in 
the Age of Convergence - the Need for a 
Wider, Long Ranging and Collaborative 
Vision. Allergol Int 2014; 63:11-20.) 
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Figure 2 Maternal environmental exposures in pregnancy may influence many aspects of development through changes 
in fetal gene expression. Coupled with ongoing environmental exposures in the first months of life, this will influence 
the risk of early and late onset NCDs. ( Reproduced with permission from Martino D, Prescott SL. Silent mysteries: epigenetic 
paradigms could hold the key to conquering the epidemic of allergy and immune disease. Allergy 2010; 65:7-15, with permission 
from Willey Blackwell.)
is unlikely to be driving the allergy 
epidemic, and there is little evi-
dence that allergen avoidance in 
pregnancy, lactation or the infant 
diet plays any role in prevention 
of allergic disease. The optimal 
timing for introduction of aller-
genic foods for allergy prevention 
is still the subject of research 
trials. Based on the currently 
available evidence, most experts 
recommend introducing comple-
mentary solid foods from around 
4-6 months, including potentially 
‘allergenic’ foods. Breastfeeding 
is strongly encouraged, and there 
have been some suggestions that 
breastfeeding during the period 
that foods are first introduced 
may help prevent the develop-
ment of allergy, although this is 
not proven.
A more promising and logical strat-
egy to prevent disease is to target 
the background environmental 
risk factors (Figure 3) that appear 
to be driving the rising risk of aller-
gy and other inflammatory diseas-
es – beginning in early life (Figure 
4). At present, there are a number 
of trials underway to explore the 
role of immunomodulatory fac-
tors such as prebiotics (soluble di-
etary fibre) and probiotics, which 
may restore more favorable gut 
colonisation for the optimal meta-
bolic and immune maturation. Pol-
yunsaturated fatty acids and oth-
er nutrients, such as antioxidants 
and vitamin D may also play a role 
in counteracting the rising pro-
pensity for allergy and inflamma-
tion. These strategies are likely to 
have benefits for not just allergies 
but all NCDs. Common risk factors 
will mean common solutions in 
overcoming the modern pandem-
ic of NCDs, highlighting the need 
for cross-sector, interdisciplinary 
approaches. 
Perinatal risk factors and strategies for allergy prevention
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Figure 3 Many of the modern environmental risk factors implicated in the rise in allergy and other NCDs have effects 
on both metabolic and immune development. These are all the logical targets for preventing disease. (Reproduced with 
permission from Prescott SL. Disease Prevention in the Age of Convergence - the Need for a Wider, Long Ranging and Collaborative 
Vision. Allergol Int 2014; 63:11-20.)
Figure 4 Early environmental exposures have lasting effects on may aspects of growth and development, and the most 
effective strategies for preventing disease must begin in early life. (Reproduced with permission from Prescott SL. Disease 
Prevention in the Age of Convergence - the Need for a Wider, Long Ranging and Collaborative Vision. Allergol Int 2014; 63:11-20.)
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• A variety of medications are utilized for symptomatic therapy of 
allergic diseases, usually in step management strategies
• Different from allergen immunotherapy, pharmacologic therapy 
usually does not modify the long-term outcome of allergy
• Treatment should be tailored to the primary symptom and to the 
severity of symptoms
• The optimal utilization of pharmacologic therapies varies among 
regions and countries. This variance may reflect the reliance on sub-
jectivity in the clinical assessment, the variability of disease pheno-
types and varying preference of therapies in different populations
• The availability of multiple options is desirable to tailor therapy 
to the individual
Allergic diseases affect over 30% of 
the population with variable sever-
ity based upon allergen exposure 
and the degree of hypersensitivity. 
A variety of medications are uti-
lized for symptomatic therapy. In 
general, the treatment should be 
tailored to the primary symptom 
or symptoms and to the severity 
of symptoms. Usually specific me-
diator inhibitors, such as antihis-
tamines provide more rapid relief, 
but are less effective for chronic 
symptoms, such as congestion. The 
variability of allergic diseases, their 
phenotypes and multiple treat-
ment options have resulted in sev-
eral step management strategies 
(Table 1, Figures 1 and 2). Combi-
nation therapies are often utilized 
though efficacy data are sparse. 
As contrasted with allergen immu-
notherapy, pharmacologic therapy 
usually does not modify the long-
term outcome of allergy, although 
there are some exceptions.
ANTIHISTAMINES
Oral: Second-generation antihis-
tamines are more selective for the 
primary histamine receptor than 
first-generation antihistamines, and 
fexofenadine has a very low central 
nervous system concentration. The 
result is a much lower risk of side ef-
fects for second-generation antihis-
Dennis K. Ledford  
University of South Florida 
Tampa, USA
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tamines, with a preference for these 
due to safety but not enhanced effi-
cacy. Compared to first-generation 
anti-histamines, second-generation 
antihistamines have less anti-cho-
linergic effects and less effect on 
glandular secretions. 
Topical: Intranasal or ocular an-
tihistamines are probably more 
effective for nasal or ocular symp-
toms than oral antihistamines. The 
advantages include a more rapid 
onset of symptom relief and some 
benefit for congestion and possi-
bly for inflammation. Allergic con-
junctivitis will also improve with 
nasal antihistamine treatment, 
but a variety of topical, ocular an-
tihistamines are more effective. 
Non-allergic rhinitis does not re-
spond to oral antihistamines, but 
likely improves with nasal antihis-
tamine therapy, primarily because 
of the benefit on congestion. Cur-
rently, available intranasal anti-
histamines result in mild sedation 
due to systemic absorption. Ef-
ficacy of nasal antihistamines is 
less than nasal corticosteroids, al-
though some studies show the two 
therapies to be equivalent. 
CORTICOSTEROIDS
Topical: Intranasal corticosteroids 
are the single most effective ther-
apy for intermittent and persis-
tent allergic rhinitis. The delayed 
onset of action makes the thera-
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py less appealing for intermittent 
use as would be typically utilized 
for intermittent rhinitis. Intranasal 
corticosteroids are superior to the 
combination of oral antihistamine 
and leukotriene antagonist. Nasal 
corticosteroids are effective with 
as needed use, but efficacy is great-
er with regular nasal application. 
Local side-effects are minimal and 
include nasal dryness and irritation 
and nasal bleeding. Rare reports of 
nasal septal perforation are in the 
literature, but this is very unlikely. 
There is systemic absorption of na-
sal corticosteroid as demonstrat-
ed with careful studies of growth 
in children. The magnitude of the 
systemic effects is small due to the 
low dose, but concerns of growth, 
glaucoma, cataracts and even bone 
loss are real, albeit limited in occur-
rence. Ocular topical corticoster-
oids are also very effective, but the 
side-effect concerns are significant 
with the potential to exacerbate 
viral infection of the eye, particu-
larly herpetic keratitis, to increase 
intraocular pressure and to en-
hance the development of cata-
racts. Inhaled corticosteroids are 
the mainstay of asthma controller 
treatment and are recommended 
as first-line treatment (Figure 2). 
As with rhinitis their intermittent 
use is less proven. Local side ef-
fects include oral candidiasis and 
pharyngo-laryngeal irritation. As 
with the nasal steroids there is sys-
temic absorption with the risk of 
side effects such as growth retar-
dation, bone loss or osteoporosis, 
increased fragility of the skin and 
suppression of the adrenal gland. 
Topical application of corticoster-
oids on the skin is recommended 
as second-line treatment of atopic 
eczema or atopic contact dermati-
tis. The lowest strength controlling 
the symptoms should be used. The 
potential for skin atrophy exists 
whenever topical corticosteroids 
are used, even with low potency 
preparations. Skin atrophy, along 
with other undesirable side effects 
such as telangiectasia and striae, 
can very rarely appear within 2 to 
3 days of starting daily application, 
the greatest potential occurring 
when the application is occluded, 
when highly potent corticosteroids 
are applied or when the prepara-
tion is applied to fragile skin. Risk 
depends on the strength of the 
corticosteroid, the length of appli-
cation, the site treated, and the na-
ture of the skin problem. 
Systemic: Oral or parenteral cor-
ticosteroids are very effective 
for all of the symptoms of allergic 
diseases. Treatment with topical 
corticosteroids is preferable while 
systemic therapy is reserved for 
severe uncontrolled symptoms. 
Systemic corticosteroids have se-
rious potential side-effects, which 
include sleep disturbance, mood 
change, appetite increase, glucose 
intolerance, aseptic bone necrosis, 
accelerated bone loss, increase in 
central body fat, and decrease in 
muscle strength. Due to the serious 
side-effect profile, systemic corti-
costeroids ideally should be limited 
to a brief period of time.
CROMONES
Sodium cromolyn is available for 
topical treatment of allergic rhini-
tis, asthma and conjunctivitis and 
limited benefit for food allergy 
and gastrointestinal mastocyto-
sis. Since the action of the medi-
cation is to inhibit calcium fluxes 
in mast cells and basophils, the 
benefits generally are prevention 
of symptoms rather than relief of 
current or active symptoms. Thus, 
the optimal treatment is regular 
application during times of active 
symptoms or utilization prior to 
contact with known or suspected 
allergen. Cromones have an excel-
lent safety profile with no known, 
significant side effects. The neces-
sity for dosing multiple times a day 
markedly diminishes the effective-
ness of these agents, and they are 
generally not cost effective and 
only modestly effective.
LEUKOTRIENE INHIBITORS 
Oral leukotriene inhibitors im-
prove the symptoms of allergic 
rhinitis and asthma. The combina-
tion of leukotriene inhibitors and 
TABLE 1
Combination Therapy *
Combination Therapeutic considerations
Oral antihistamine + 
decongestant
More effective for nasal congestion than 
antihistamine alone
Oral antihistamine + 
leukotriene antagonist
May be more effective than either agent alone but 
less effective than nasal corticosteroid
Oral + topical 
antihistamine
No evidence of additive benefit, topical 
antihistamine may help congestion
Oral antihistamine + 
topical corticosteroid
No evidence of benefit of antihistamine added 
to topical corticosteroid, may relieve more 
effectively itching
INCS* + anticholinergic Improves rhinorrhea more than either agent alone
Intranasal 
antihistamine + 
corticosteroid
Combination product more effective than either 
agent alone, inadequate data if both administered 
independently
INCS** + oral 
leukotriene antagonist
Inadequate data
* (Adapted from Wallace DV, Dykewicz MS et al, J Allergy Clin Immunol 2008); 
**INCS: intranasal corticosteroid
Pharmacological treatment of allergic disease
283
Global atlas oF allerGy
se
c
t
io
n
 G
 - M
an
agem
en
t o
f allergic d
iseases
oral antihistamines is not clearly 
superior to either agent alone. 
Leukotriene inhibitors are less 
effective for itching and sneezing 
than antihistamines, but are likely 
more effective for congestion and 
cough. Improvement of asthma, 
frequently associated with aller-
gic rhinitis, is an advantage of oral 
montelukast therapy of rhinitis.
TOPICAL ANTICHOLINERGICS 
Intranasal ipratroprium bromide 
relieves rhinorrhea but has no ef-
fect on other symptoms. The com-
bination of nasal anticholinergic 
therapy and oral antihistamine is 
more effective than either agent 
alone. Recently inhaled long act-
ing anticholinergics (tiotropium) 
were evaluated as add-on control-
ler treatment for moderate/severe 
asthma and provided a similar effi-
cacy profile to long-acting beta2 
simpatomimetics (LABAs). There 
is no significant systemic side ef-
fects proven, although there have 
been questions raised about in-
haled anticholinergic therapy in-
creasing cardiovascular and cere-
brovascular disease. This concern 
has not been confirmed in large 
studies of inhaled anticholinergic 
therapy for chronic obstructive 
lung disease but has been suggest-
ed by retrospective data. 
TOPICAL BETA 2 
SIMPATOMIMETICS
Inhaled short-acting beta2-sim-
patomimetics are used as reliever 
medication for asthma, while LA-
BAs are recommended as add-on 
controller treatment when asthma 
is not controlled by inhaled corti-
costeroids alone. LABAs alone are 
contraindicated as single-agent 
controller for asthma due to the 
risk of increasing all cause mortal-
ity and asthma related severe ad-
verse events. 
ALTERNATIVE AND OPTIMIZED 
THERAPIES
Numerous pharmacologic agents 
Step 1
Preferred 
Intranasal or 
Oral AH PRN
Preferred 
INCS or 
Regular 
Intranasal AH 
Alternatives 
Oral AH or 
LTA or Oral 
AH + DC
Preferred 
Daily INCS
Alternatives 
Oral AH + LTA 
or Oral AH + 
LTA + DC
Consider 
allergen 
immunotherapy
Preferred 
Daily INCS + 
Intranasal AH
Alternatives 
Intranasal AH + 
Oral AH + LTA 
or DC
Strongly 
consider 
allergen 
immunotherapy
Preferred 
Daily INCS + 
Intranasal AH + 
Oral AH + LTA 
or DC
Alternatives 
Consider use 
of topical 
decongestants 
for short period 
of time with 
INCS. 5-7 
days of oral 
CS followed 
by topical 
treatment with 
INCS and AH. 
Ipratroprium 
bromide 
is added 
if anterior 
rhinorrhea is 
a problem. 
Omalizumab 
if coexisting 
asthma
Step 5
Step 2
Step 3
Step 4
Step Down if 
Possible 
Minimize 
cost andside 
effects
Assess 
Control 
Symptom 
severity, QOL
Step Up If 
Needed
First reconsider 
diagnosis, 
assess 
adherence, 
evaluate 
comorbidities
Mild* or intermittent# rhinitis Severe persistent rhinitis
Figure 1 Treatment Steps in Allergic Rhinitis (adapted from Meltzer Allergy Asthma Proceedings 2013); # Intermittent 
is defined by ARIA as symptoms for 4 days or less a week or less than 4 consecutive weeks; * Mild indicates the absence of 
sleep disturbance, impairment of daily activities, impairment of school or work productivity. Symptoms are noted but not 
troublesome. AH: Antihistamines, PRN: As needed, LTA: Leukotriene antagonists, INCS: Intranasal topical corticosteroid, 
DC: Decongestant, CS: Corticosteroid, QOL: Quality of life.
Pharmacological treatment of allergic disease
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have been tried topically and sys-
temically for allergic diseases with 
variable results. Most of these 
target specific inflammatory me-
diators or pathways. The optimal 
utilization of pharmacologic ther-
apies is outlined in various guide-
lines. These vary among regions 
and countries, and the assessment 
of the data in support of specific 
therapies is interpreted differ-
ently. This variance may reflect 
the reliance on subjectivity in the 
clinical assessment, the variability 
of disease phenotypes and specific 
allergens causing disease in differ-
ent parts of the world, and varying 
preference of therapies in differ-
ent populations. The availability of 
multiple, pharmacologic options is 
desirable to tailor therapy to the 
individual.
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Figure 2 Treatment steps on asthma. Asthma medications are divided in relievers and controllers. The reliever 
medications must be prescribed in each step. The main controller medications are inhaled corticosteroids; long acting 
bronchodilators (β2 agonists) can be added when asthma is not adequately controlled with corticosteroids. When 
patients are not controlled with optimal doses of inhaled corticosteroids in combination with long acting β2 agonists, 
other adjunctive secondary controller medications might be considered. (Reproduced from the Global Strategy for Asthma 
Management and Prevention, 2012 with permission of Global Initiative for Asthma (GINA)).
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Management Approach Based On ControlFor Children Older Than 5 Years, Adolescents and Adults
Controlleroptions***
* ICS = inhaled glucocorticosteroids**= Receptor antagonist or synthesis inhibitors *** = Pr ferred controller options are shown in shaded boxes
Treatment Steps
As needed rapid-acti g β2-agonistAs needed rapid-acting β2-agonistLow-dose ICS plus
long-acting β2-agon stSelect one
Leukotrienemodifier**
Select one
Medium-orhigh-dose ICSMedium-or high-doseICS plus long-actingβ2-agonist
Low-dose ICS plusleukotriene modifierLow-dose ICS plussustained releasetheophylline
To Step 3 treatment,selt on or or To Stp 4 treatment,ad ithrAsthma educationEnvironmental control
Low-dose i haledICS* Oral glucocorticosteroid(lowest dose)Anti-IgEtreatmentLeukotrienemodifi r
Su tained releaseth ophylline
ControlledMaintain and find lowest controlling stepPartly controlledConsider stepping up to gain controlUncontrolledStep up until controlled
ExacerbationTreat as exacerbation
Treatment ActionLevel of Con rolReduce
Reduc Increase
I nc re ase
2Step1Step 3Step 4Step 5Step
Management Approach Based On Control
For Children Older Than 5 Years, Adolescents and Adults
Controller
options***
* ICS = inhaled glucocorticosteroids
**= Receptor antagonist or synthesis inhibitors 
Treatment Steps
As needed rapid-
acting β2-agonist As needed rapid-acting β2-agonist
Low-dose ICS plus
long-acting β2-agonist
Select one
Leukotriene
modifier**
Select one
Medium-or
high-dose ICS
Medium-or high-dose
ICS plus long-acting
β2-agonist
Low-dose ICS plus
leukotriene modifier
Low-dose ICS plus
sustained release
theophylline
To Step 3 treatment,
select one or more
To Step 4 treatment,
add either
Asthma education.  Environmental control.
(If step-up treatment is being considered for poor symptom control, first check inhaler technique, check adherence, and confirm symptoms are due to asthma.)
Low-dose inhaled
ICS*
Oral glucocorticosteroid
(lowest dose)
Anti-IgE
treatment
Leukotriene
modifier
Sustained release
theophylline
Controlled Maintain and find lowest controlling step
Partly controlled Consider stepping up to gain control
Uncontrolled Step up until controlled
Exacerbation Treat as exacerbation
Treatment ActionLevel of Control
R
ed
uc
e
Reduce Increase
In
cr
ea
se
2Step1Step 3Step 4Step 5Step
*** = Recommended treatment (shaded boxes) based on group mean data.  Individual patient needs, preferences, and circumstances (including costs) should be considered.
Figure 4.3-2.
For management of asthma in children 5 years and younger, refer to the Global Strategy for the Diagnosis and Management 
of Asthma in Children 5 Years and Younger, available at http://www.ginasthma.org.
Alternative reliever treatments include inhaled anticholinergics, short-acting oral β2-agonists, some long-acting β2-agonists, and short-acting theophylline.
Regular dosing with short and long-acting β2-agonists is not advised unless accompanied by regular use of an inhaled glucocorticorsteriod.
285
Global atlas oF allerGy
se
c
t
io
n
 G
 - M
an
agem
en
t o
f allergic d
iseases
• IgE-mediated allergic reactions can be prevented by selected 
antibodies against IgE that specifically bind and neutralize IgE in 
circulation
• Anti-IgE antibodies prevent IgE from interacting with high and 
low affinity IgE receptors on mast cells, basophils, B cells and cer-
tain antigen-presenting cells
• Therapeutic anti-IgE antibodies do not recognize Fc receptor 
(R)-bound IgE and thus are non-anaphylactogenic
• Omalizumab is registered for the treatment of moderate-severe 
allergic asthma, where it significantly reduces exacerbations and 
corticosteroid use and enhances quality of life
• Omalizumab has recently been approved for patients with 
chronic idiopathic urticaria/chronic spontaneous urticaria, who 
remain symptomatic despite H1 antihistamine treatment
• Omalizumab induces down-regulation of FcεRI on mast cells 
and basophils, inhibits IgE-mediated allergen-presentation by 
FcεRI-bearing antigen-presenting cells, and reduces IgE produc-
tion after longer-term treatment
• Other applications of anti-IgE antibodies may include atopic der-
matitis, food allergy, as an adjunct to allergen immunotherapy 
and allergic rhinitis
Immunoglobulin E (IgE) plays an 
important role in the pathophys-
iology of allergies and allergic 
asthma and IgE-mediated aller-
gic reactions can be prevented by 
selected antibodies against IgE 
that specifically bind and neutral-
ize IgE in circulation. Due to their 
epitope-specificity, selected an-
ti-IgE antibodies prevent IgE from 
interacting with high affinity IgE 
receptors (FcεRI) on mast cells, 
basophils, and dendritic cells as 
well as with low-affinity IgE re-
ceptors (FcεRII/CD23) on B cells 
and certain antigen-presenting 
cells. Such therapeutic anti-IgE 
antibodies (e.g. Omalizumab) are 
directed against the region on 
IgE that is recognized by the two 
IgE receptors and therefore effi-
ciently block IgE binding to these 
receptors, but do not recognize 
receptor bound IgE and thus are 
non-anaphylactogenic (Figure 1) . 
Omalizumab is a humanized IgG1 
monoclonal anti-IgE antibody that 
was approved by the US Food and 
Drug Administration (FDA) in 2003 
for adults and adolescents with 
moderate-to-severe persistent al-
lergic asthma, whose symptoms 
are inadequately controlled with 
inhaled corticosteroids. In the Eu-
ropean Union, omalizumab is ap-
ANTI IgE TREATMENT FOR 
ALLERGIC DISEASE4
Ke y  m e ssag e s
Anti IgE treatment for allergic disease
proved for the treatment of patients 
with severe persistent allergic asth-
ma. Free IgE levels in serum of asth-
ma patients decline rapidly after 
start of omalizumab therapy and 
because IgE bound to omalizumab 
cannot interact with IgE receptors, 
omalizumab is able to prevent the 
IgE-induced release of inflamma-
tory mediators from mast cells and 
basophils without inducing degran-
ulation. Subsequently, the allergic 
inflammation involving T cell and 
eosinophils and their inflammatory 
mediators is attenuated and bene-
ficial effects on airway remodeling, 
(e.g. reduction of airway wall thick-
ening), can be observed. Omalizum-
ab also induces down-regulation of 
FcεRI on mast cells and basophils 
Christoph Heusser veit Erpenbeck
Novartis Institutes for Biomedical Research 
Basel, Switzerland
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and enhanced quality of life (Table 
1). In addition, omalizumab has re-
cently been approved for patients 
with chronic idiopathic urticaria/
chronic spontaneous urticaria 
who remain symptomatic despite 
H1 antihistamine treatment, 
where it showed a fast response 
and a high response rate. Further-
more, omalizumab has been eval-
uated in a number of allergic dis-
eases with reports of benefits e.g. 
in atopic dermatitis, seasonal and 
perennial allergic rhinitis, food al-
lergies, and as an adjuct therapy 
for allergen immunotherapy . 
Novel anti-IgE monoclonal anti-
bodies with improved pharmaco-
dynamic and immunomodulatory 
properties are under develop-
ment.
KEY REFERENCES
1. Heusser C, Jardieu P. Therapeutic 
potential of anti-IgE antibodies. Curr 
Opin Immunol 1997;9:805-813.
2. Global Initiative for Asthma 
(GINA). Global Strategy for Asthma 
Management and Prevention (up-
dated December 2012)
3. Humbert M, Busse W, Hanania NA, 
Lowe PJ, Canvin J, Erpenbeck VJ et 
al. Omalizumab in Asthma: An Up-
date on Recent Developments. J 
Allergy Clin Immunol Pract 2014, in 
press.  
4. Chang TW, The pharmacological 
basis fo anti-IgE therapy. Nature Bi-
otechnol 2000;18:157-162.
5. Humbert M, Beasley R, Ayres J, 
Slavin R, Hebert J, Bousquet J et 
al. Benefits of omalizumab as add-
on therapy in patients with severe 
persistent asthma who are inad-
equately controlled despite best 
available therapy (GINA 2002 step 
4 treatment): INNOVATE. Allergy 
2005;60:309-316.
6. Babu KS, Polosa R, Morjaria JB, An-
ti-IgE – emerging opportunities for 
Omalizumab. Expert Opin Biol Ther 
2013;13:765-777.
TABLE 1
Effects of anti-IgE treatment (omalizumab) in patients with severe allergic 
asthma on clinical endpoints in a representative clinical study 
Omalizumab 
N=209
Placebo 
N=210
Severe asthma exacerbations
Rate per 28-week period 0.24 0.48
% reduction, p-value for rate ratio 50.1%, p = 0.002
Emergency visits
Rate per 28-week period 0.24 0.43
% reduction, p-value for rate ratio 43.9%, p = 0.038
Physician`s overall assessment of treatment effectiveness
% excellent/good responders 60.5% 42.8%
p-value <0.001
Asthma Quality of Life
% of patients ≥0.5 improvement 60.8% 47.8%
p-value 0.008
Lung function (FEV1) 
Improvement after 28 week treatment 190 ml 96 ml
p-value 0.043
Inhibition of 
IgE production
by B cells
Neutralization of
circulating IgE
Inhibition of 
mediator
release
T-cell
IgM
Clinical
effects
Anti-IgE
(omalizumab)
Antigen
presenting 
cell
B-cell
Mast
cell
IgE
Antigen/Allergen
IgG
B-cell
IgE
B-cell
Figure 1 Mechanism of action of anti-IgE therapy. 
(which is controlled by free IgE), in-
hibits IgE mediated allergen pres-
entation by FcεRI bearing antigen 
presenting cells, and after longer-
term treatment reduces IgE pro-
duction (by interacting with surface 
IgE-positive B cells). 
Omalizumab is administered as a 
subcutaneous injection every two 
or four weeks with a dose adjusted 
to body weight and serum IgE lev-
els in order to guarantee sufficient 
neutralization of IgE and it is over-
all well tolerated. 
The clinical efficacy of omali-
zumab in patients with moder-
ate-to-severe and severe allergic 
asthma has been well documented 
in several large-scale clinical trials 
resulting in over 60% responders 
with reduction in exacerbations, 
reduction in corticosteroid use, 
Anti IgE treatment for allergic disease
287
Global atlas oF allerGy
se
c
t
io
n
 G
 - M
an
agem
en
t o
f allergic d
iseases
• Biological agents (biologicals or biologics) target a selected 
disease-inducing molecule
• In allergic disorders, several biologicals are being assessed in 
clinical trials, including biologicals inhibiting interleukin (IL)-4, IL-
5, IL-9, IL-13, and immunoglobulin E
• Most of these biologicals are still being tested in clinical 
trials, involving patients with allergic asthma, allergic rhinitis, 
food allergy, urticaria, atopic eczema, and diseases with high 
eosinophil counts
• It is to be expected that biologicals will replace or reduce the 
use of the currently prescribed unspecific pharmacotherapy of 
allergic inflammation
• Research on better understanding disease endotypes, 
identification of novel biomarkers and discovery of novel 
biologicals are developing in parallel
 In recent years, scientists have ex-
ploited the immune system to pro-
duce antibodies from single B cell 
clones, heralding the era of mon-
oclonal antibodies (Figures 1 and 
2). Biological agents (biologicals or 
biologics) have revolutionized the 
treatment of many rheumatic and 
immunological disorders and are 
currently being assessed for aller-
gic disorders. 
Better understanding the endo-
types and phenotypes of allergic 
disease may lead to specifically 
targeting the responsible molec-
ular mechanism by a biological 
(Figure 3). Unlike traditional ther-
apies of allergy, biologicals target 
a single molecule. Thus, the use of 
an anti-allergic biological ideally 
leads to the inhibition of a spe-
cific molecule involved in allergic 
inflammation, without weaken-
ing immunity against viruses and 
bacteria. The design and use of 
biologicals requires a profound 
understanding of the mechanisms 
underlying allergy.
Allergy is thought to arise as an 
aberrant immune response to 
one or more innocuous environ-
mental allergens, such as pollen, 
food, house dust mites, insects or 
animal products. Such encounter 
with an allergen results in the ac-
BIOLOGICAL AGENTS 
FOR THE TREATMENT OF 
ALLERGIC DISORDERS
5
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Biological agents for the treatment of allergic disorders
tivation of immune cells, such as 
type-2 T helper lymphocytes (TH2 
cells) that become stimulated and 
produce cytokines, including in-
terleukin-4 (IL-4), IL-5, IL-9, and 
IL-13 (Figure 3). Concomitantly, B 
lymphocytes are activated by the 
allergen and under the influence 
of TH2 cell-derived cytokines 
produce immunoglobulin E (IgE). 
Moreover, TH2 cell-derived cy-
tokines activate other immune 
cells, including eosinophils, mast 
cells, and basophils, which all pro-
mote allergy. Biologicals target for 
example IL-4, IL-5, IL-13 or IgE. 
Some of the biologicals targeting 
IL-4 appeared to show some ben-
efit in subgroups of patients with 
allergic asthma, while not causing 
any of the unwanted effects of 
conventional asthma treatments. 
Currently, IL-4 and IL-13-target-
ing biologicals are under devel-
opment and need further clinical 
trials with larger patient collec-
tives and longer study durations. 
Similarly, biologicals targeting 
IL-5 appeared to be beneficial in 
a subgroup of asthma patients 
characterized by the presence of 
high counts of eosinophils. Such 
Onur Boyman  
University Hospital Zurich 
Zurich, Switzerland
François Spertini  
Centre Hospitalier Universitaire 
Vaudois, Lausanne, Switzerland
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Figure 1 Several technologies 
are applied to produce monoclonal 
antibodies. (Reprinted from J Allergy 
Clin Immunol, 130/Ballow M, Akdis 
CA, Casale TB, Wardlaw AJ, Wenzel 
SE, Ballas Z, et al. Immune response 
modifiers in the treatment of asthma: A 
PRACTALL document of the American 
Academy of Allergy, Asthma & 
Immunology and the European Academy 
of Allergy and Clinical Immunology, 311-
24. Copyright 2012, with permission 
from Elsevier.)
Figure 2 Modifications of the Ig molecule in order to engance its pharmacological and clinical potency. (Reprinted from J 
Allergy Clin Immunol, 130/Ballow M, Akdis CA, Casale TB, Wardlaw AJ, Wenzel SE, Ballas Z, et al. Immune response modifiers in 
the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European 
Academy of Allergy and Clinical Immunology, 311-24. Copyright 2012, with permission from Elsevier.)
Biological agents for the treatment of allergic disorders
Engineering the variable domain 
to lower the isoelectric point to 
decrease elimination of IgG
Fab (monovalent format with short serum half life) or Fab-PEG 
(monovalent format with increased serum half life) fragments
Modulate antigen 
specificity and binding 
affinity (affinity 
maturation) of the 
variable domain
Immunoconjugates and toxins:
•Radioactive nuclides
•Chemotherapeutics
•Toxins, cytokines and enzymes
Fc-fusion proteins and peptides:
•Peptibody
•Mimetibody
•Single-chain Fv-Fc
•Small modular immunopharmaceuticals
•One-armed antagonist antibody
•IgG4-derived unibody
Modulate binding to Fc receptors:
• Increased complement activation (increased complement component C1q binding by isotypechimerism)
• Enhanced ADCC (low levels of fucose and/or mutations that lead to increased FCgRIIIA or decreased 
FCgRIIIB binding)
• Enhanced anti-inflammatory properties (addition of sialylatedglycans)
• Increased serum half life (increased binding to FcRn)
CDR
Disulphide
bond
Hinge
Humanization or de-immunization 
to decrease immunogenicity
CH2
CH3 Fc
re
gi
on
Mouse 
hybridoma
Human
hybridomas
•Genetic engineering
•V gene cloning
•CDR grafting
•Eukaryotic expression
Mouse Chimeric Humanized Human
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considerations also apply to an 
IL-13-targeting biological, since 
asthma patients with high serum 
periostin levels responded best to 
this drug.
Moreover, IL-4-targeting biolog-
icals are being tested in patients 
with allergic eczema, while bio-
logicals blocking IL-5 are being 
assessed in allergic disorders 
characterized by increased counts 
of eosinophils, such as eosinophil-
ic esophagitis and allergic nasal 
polyposis. Also, certain subtypes 
of urticaria might be amenable to 
biologicals inhibiting IL-1.
While the use of biologicals in al-
lergic disorders is - for most of the 
biologicals - still in its infancy, bio-
logicals have already changed the 
therapy of many rheumatic and 
immunological diseases. It is to be 
expected that the treatment of al-
lergic disorders will shift from the 
use of unspecific drugs to biologi-
cals.
KEY REFERENCES 
1. Akdis CA. Therapies for allergic in-
flammation: refining strategies to 
induce tolerance. Nat Med 2012;18: 
736-749.
2. Wenzel SE. Asthma phenotypes: 
the evolution from clinical to 
molecular approaches. Nat Med 
2012;18:716-25.
3. Papadopoulos NG, Agache I, 
Bavbek S, Bilo BM, Braido F, Car-
dona V et al. Research needs in al-
lergy: an EAACI position paper, in 
collaboration with EFA. Clin Transl 
Allergy 2012;2:21.
4. Ballow M, Akdis CA, Casale TB, 
Wardlaw AJ, Wenzel SE, Ballas 
Z et al. Immune response modifi-
ers in the treatment of asthma: A 
PRACTALL document of the Amer-
ican Academy of Allergy, Asthma 
& Immunology and the European 
Academy of Allergy and Clinical 
Immunology. J Allergy Clin Immunol 
2012;130:311-324.
Figure 3 T
H
2 immune processes in the airways of asthmatic patients. The pathway begins with the development of 
T
H
2 cells and their production of the cytokines IL-4, IL-5 and IL-13. These cytokines stimulate allergic and eosinophilic 
inflammation as well as epithelial and smooth-muscle changes that contribute to asthma pathobiology. APC, antigen-
presenting cell; CRTH2, chemoattractant receptor-homologous molecule expressed on T
H
2 cells; iNOS, induced nitric 
oxide synthase; PGD2, prostaglandin D2; TSLP, thymic stromal lymphoprotein. (Reprinted by permission from Macmillan 
Publishers Ltd: Nat Med, Wenzel SE, Asthma phenotypes: the evolution from clinical to molecular approaches, 18,716-25, 
copyright 2012.)
Biological agents for the treatment of allergic disorders
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s • A large number of blockbuster biotherapeutic molecules for 
allergic diseases and asthma are going off patent in the next few 
years
• There is a need to adjust medication costs to low-income markets
• Allergy and asthma treatment will dramatically change in the 
next decade. A great part of patients will use pharma treatments 
(generics or branded drugs) whereas a minority will need biologic 
treatmens (branded or biosimilars)
• Biosimilars are approved through an abbreviated route, which 
relies on limited safety and efficacy data. The cost is ten time less 
and the process to reach the market is shortened by 50%
• Biosimilars offer a good opportunity to reduce costs for biologic 
treatments
Globally, a large number of block-
buster biotherapeutic molecules 
will go off patent in the next few 
years. This will change the scenar-
io of allergy/clinical immunology 
and asthma treatments. There is 
a growth of generic drugs for the 
mass target therapy, accounting 
for the majority of patients (at 
least two/thirds as far as asthma 
is concerned) . Generic drugs have 
and will be developed to reduce 
the cost of asthma treatment, al-
though this will be complicated by 
potential change of the used de-
vice/inhaler (Figure 1).
On the other hand, a smaller pro-
portion of patients will require 
personalized (or in most cases 
phenotype driven) therapy. The 
real need for a cost/effective ap-
proach of this last treatment is the 
paucity of predictive biomarkers 
of response (if any exist up to now). 
These last patients are candidate 
to biologic treaments, mainly with 
monoclonal antibodies, however 
with a high cost. So, as for the “old” 
blockbusters, there is a need now-
adays to reduce expenses/costs 
for biologic treatments, mainly 
in chronic diseases (as already in 
many immunological diseases). A 
new opportunity in this sense is 
provided by the biosimilars.
G. Walter Canonica   
University of Genova 
Genova, Italy
BIOSIMILARS AND ALLERGY 
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Biosimilars and allergy treatment
THE DEFINITION OF 
BIOSIMILAR
Similar Biological Medicinal Product 
(EMA)
Follow-on Protein Product (FDA)
Subsequent Entry Biologic (Health 
Canada)
Follow-on Biologic (Japan)
In the European Community (EC), 
a copy which is claimed to be ‘sim-
ilar’ to a reference medicinal prod-
uct, which has been granted a mar-
keting authorization (MA) within 
the EC is defined ‘similar biological 
medicinal product’ or ‘biosimilar’. 
European Medicine Agency (EMA) 
approved the first biosimilar prod-
uct in 2006. The first “Guidelines 
on Biosimilars” have been re-
leased by EMA, and thus EC and 
EMA are leaders in the concept of 
biosimilars in the world.
DEVELOPMENT AND 
PRODUCTION OF BIOSIMILARS
Unlike generics, biosimilars are 
similar, but not identical to their 
reference products, because their 
chimical characteristics are direct-
ly related to the manufacturing 
process, which cannot be precise-
ly duplicated. Thus, biosimilars re-
quire an approach to grant the MA, 
different from both originators 
291
Global atlas oF allerGy
se
c
t
io
n
 G
 - M
an
agem
en
t o
f allergic d
iseases
and generics. Nonetheless, these 
products are approved through 
an abbreviated route, which relies 
on limited safety and efficacy data 
(Figure 2). The cost to reach MA 
for biosimilars is ten time less then 
the cost for the reference biologic 
compound. In addition, the pro-
cess to reach the market has been 
shortened to half of the required 
time. For emerging economies, it 
is imperative to be able to provide 
safe and cost effective drugs for 
their huge, non-insured and poor 
population. The use of biosimi-
lars will offer more opportunities 
to treat our patients at a reduced 
cost, making these expensive ther-
apies more accessible.
KEY REFERENCES
1. Braido F, Holgate SR, Canonica 
GW. From Blockbuster to Biosim-
ilars: an opportunity for patients, 
medical specialists and health care 
providers. Pulm Pharmacol Ther 
2012;25:483-486.
2. Lessons from Lipitor and the bro-
ken blockbuster model. Lancet 
2011;378:1976.
3. Hamburg MA, Collins FS. The path 
to personilized medicine. N Engl J 
Med 2010;363:301-304.
Figure 1 The future scenario of allergy and asthma treatment will dramatically change in the next decade. A great part 
of patients will use pharma treatments( generics or branded drugs) whereas a minority will need biologic treatmens 
(branded or biosimilars). 
Figure 2 The development of a biosimilars is much less expensive (1 log less) then the reference biologic product. This 
allows to commercialize the biosimilars with reduced costs.
Biosimilars and allergy treatment
GENERICS
BLOCKBUSTERS
BIOLOGICS
BIOSIMILARS
PERSONALIZED or PHENOTYPE TARGET THERAPY
2014 2025
Target
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Target
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Lead
identification
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optimization Preclinical Clinical
0.5 - 1 yr 0.5 - 1 yr 0.5 - 1 yr 2 - 3 yrs 1 - 2 yrs 4 - 6 yrs
No of patients inrolled in clinical 
trials: 500 pts.
Development cost: 100 - 150 million USD
Success probability: 50%
Time to market: 7 - 8 years
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s • Basophils and mast cells are important target cells for treatment 
of allergic diseases
• Activation of basophils and mast cells by allergens can be 
diminished by interfering in IgE binding to the high affinity Fc 
receptor for IgE
• During allergy immunotherapy basophil and mast cells activity is 
diminished due to direct and indirect effects
• Stimulus secretion coupling in basophils and mast cells can 
be altered by activation of inhibitory receptors and selective 
inhibitors of activation pathways
The important role of basophils 
and mast cells in allergy has 
prompted intensive research in 
ways to inhibit their activation 
(Figures 1, 2). Four different ap-
proaches listed below are being 
pursued (Figure 3): 
• Limiting the interaction be-
tween IgE and its high affinity 
Fc receptor (FcεRI) 
• Activation of inhibitory recep-
tors 
• Specific inhibitors of cellular ac-
tivation
• Reducing the function of baso-
phils and mast cells during aller-
gen immunotherapy
LIMITING THE INTERACTION 
BETWEEN IGE AND ITS HIGH 
AFFINITY FC RECEPTOR (FCεRI) 
Multiple approaches have been 
initiated to limit the interaction 
of allergens with IgE and IgE with 
FcεRI on mast cells and baso-
phils to diminish their activation 
in allergy. Small oligonucleotide 
aptamers, phage display-selected 
peptides, anti-IgE antibodies, an-
ti-FcεRI antibodies and designed 
ankyrin repeat proteins (DARPins) 
have been developed to block IgE 
receptor binding. 
Of these only the humanized an-
Edward F. Knol  
University Medical Center Utrecht  
Utrecht, The Netherlands
TARGETING BASOPHILS AND 
MAST CELLS FOR NOVEL 
TREATMENT APPROACHES
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Targeting basophils and mast cells for novel treatment approaches
ti-IgE antibody omalizumab is 
available for treatment. The ef-
fect of omalizaumab is limited, 
because it only depletes free IgE 
and cannot remove IgE from the 
basophil and mast cell membrane. 
It was shown that in skin mast cell 
response to allergen is hardly af-
fected within 2 months, whereas 
basophils responses are dimin-
ished within a week, probably due 
to the short half-life of basophils. 
Interesting novel developments 
are DARPins, which can actively 
promote the dissociation of IgE 
from FcεRI on basophils and mast 
cells within hours and in this way 
make these cells quickly insensi-
tive for allergens. 
ACTIVATION OF INHIBITORY 
RECEPTORS 
A large number of immune in-
hibitory receptors have been de-
scribed in immunology, including 
on basophils and mast cells. These 
receptors have the potential to 
down-regulate FcεRI-induced 
mast cell and basophil activation. 
Many of these receptors signal 
through the so-called immunore-
ceptor tyrosine-based inhibition 
motifs (ITIM) which selectively 
block the FcεRI-induced immuno-
receptor tyrosine-based activa-
tion motifs (ITAM). One of these 
ITIM coupled receptors is FcγRIIB 
(CD32b), that has already been 
used as a target for potential treat-
ments with fusion proteins. These 
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studies showed that fusion pro-
teins that co-aggregate FcγRIIB 
with FcεRI could be effective as 
novel drug candidates to prevent 
and treat allergic diseases. How-
ever, a clinical trial with an aller-
gen-CD32b conjugate has been 
stopped due to unknown reason. 
Other inhibitory receptors func-
tionally described on basophils 
and mast cells are CD200R, 
CD300a, Leukocyte immunoglob-
ulin-like receptor (LIR) family, 
CD84, SIRP-a, Siglecs, MAFA (not 
expressed on human basophils), 
Allergin-1 and LAIR-1/CD305. 
These families of inhibitory recep-
tors include potent novel treat-
ment modalities, but since these 
are not specific for basophils and 
mast cells it is a prerequisite to as-
sociate specific mast cell/basophil 
targeting strategies.
EFFECT OF SPECIFIC 
INHIBITORS ON CELLULAR 
ACTIVATION
Several compounds that are al-
ready in clinic do inhibit mast cell 
and basophil activation. A group 
of these drugs increase cellular 
cyclic AMP level via inhibiting 
phosphodiesterases, such as the-
ophylline and 3-isobutyl-1-me-
thyl-xanthine, siguazodan and 
rolipram. 
Although many NSAID potentially 
increase basophil and mast cell ac-
tivation, nimesulide is a chemically 
unrelated NSAID that inhibits both 
cell types. Glucocorticosteroids, 
known for their anti-inflammatory 
activities, also inhibit basophil, but 
not mast cell, activation. Calcineu-
rin inhibitors, such as cyclosporine 
A and FK-506 also inhibit basophil 
and mast cell activation, including 
inhibiting the synthesis of IL-4 and 
preformed mediators newly synthesized mediators cytokines/
chemokines
ALLERGEN / α−IgE
-histamine
-MBP
-CLC protein 
-interleukin-4
-interleukin-5
-interleukin-8
-interleukin-13
-RANTES
-leukotriene C4
-platelet-activating factor
fMLP
C5a
Chemokines
IL-33
Substance P
IgD – α-IgD
Compound 48/80
anti-microbial 
- β–defensin-3
- LL-37
?
Drugs?
Figure 1 Basophils and mast cells activation by different type of stimuli. The most prominent activation is via allergen 
interactions with IgE causing crosslinking of FcεRI. Also other ligands can stimulate the cells via binding to specific 
receptors. For other triggers activators receptors are not completely clear. Activation of basophils and mast cells results 
in release of several types of mediators and cytokines/chemokines that are important in allergic diseases.
Figure 2 Degranulated human 
basophil. Electron microscopic 
photograph of an activated human 
basophil. Magnification 19,600 times.
Targeting basophils and mast cells for novel treatment approaches
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Il-13 in basophils.
There is much interest in implica-
tion of specific signal-transduction 
cascade inhibitors that will block 
the signalling after activation of 
the FcεRI by allergens. In vitro ex-
periments have described potent 
inhibition by inhibiting PI3-kinase, 
protein kinase C or tyrosine kinas-
es such as Lyn, Syk and Zap-70. 
Very potent and specific inhibitors 
for this pathway have been de-
scribed, but since these signalling 
molecules are not specific for ba-
sophils and mast cells signalling, 
application in clinical studies is a 
challenge. 
REDUCING BASOPHILS AND 
MAST CELLS FUNCTION 
FOLLOWING ALLERGEN 
IMMUNOTHERAPY
The only curative treatment in 
allergy is allergen immunother-
apy (AIT). Several immunologi-
cal mechanisms are supposed to 
explain this effect; changes on T 
helper cells and induction of regu-
latory T cells, the release of IL-10 
and the synthesis of allergen-spe-
cific IgG and IgG4. 
Although some studies have indi-
cated that IL-10 can inhibit mast 
cells this is probably not its most 
likely effect with IgGs physical-
ly blocking allergen to reach IgE 
on basophils and mast cells more 
likely to support the effect. In ad-
dition, the IgG loaded allergens 
might still reach IgE on mast cells, 
but via simultaneous interaction 
with the FcγRIIb the activation will 
be diminished. 
Analysis of basophils during AIT 
have shown release of inhibitory 
factors in the plasma. Basophils 
responses to FcεRI signalling were 
diminished following oral AIT for 
peanut allergy, which seemes like 
an anergic type of response. 
Further research in AIT is focused 
on the development of allergen 
preparations that do not activate 
basophils or mast cells, while leav-
ing T cell activation intact. 
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Figure 3 Allergen-induced 
activation of basophils and mast cells 
can be inhibited via different ways. 
The signal triggered by crosslinking 
of IgE by the allergen can be inhibited 
by reducing IgE bound to the FcεRI, 
but also by blocking its downstream 
signalling by specific inhibitors. 
The inhibitors are depicted in red, 
whereas the positive signals are in 
green. Allergen-specific IgG induced 
after AIT can bind to the FcγRIIb 
blocking receptor. Calcineurin 
inhibitors, such as cyclosporine, 
block the calcium signalling, whereas 
increased cAMP, after inhibiting 
phosphodiesterases reduces 
activation. 
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• Immune tolerance is the lack of immune responsiveness to self-
antigens, and harmless environmental antigens such as allergens
• There are two major pathways of immune tolerance, central and 
peripheral tolerance, which prevent immunity to self-antigens 
during lymphocyte development, and environmental antigens, 
respectively 
• Regulatory T cells play a central role in peripheral tolerance, 
inhibiting effector pathways that drive allergic reactions, 
including allergen-specific Th2 and IgE responses, as well as cells 
that mediate allergic reactions such as mast cells and eosinophils
• Therapies such as allergen immunotherapy enhance regulatory 
T cell function to restore immune tolerance
• Regulatory B cells and immune regulatory subsets of other cells 
may play roles in immune tolerance to allergens
Immune tolerance is the unre-
sponsiveness of the immune 
system to substances, cells and 
tissues that elicit an immune re-
sponse (antigens). It prevents in-
appropriate immune responses 
to “self-antigens“ present in the 
body’s own tissues, which cause 
autoimmune disease, and reactiv-
ity to harmless environmental an-
tigens. Lack of immune tolerance 
to allergens (e.g. grass pollen, cat 
dander and house dust mites) can 
lead to allergic disease. 
Two major pathways of immune 
tolerance exist. During central 
tolerance immune cells (T and B 
lymphocytes) learn to discrimi-
nate self from non-self during de-
velopment in the thymus and bone 
marrow respectively. Lympho-
cytes that recognise self-antigens 
are either eliminated (deleted) or 
rendered harmless (e.g. B cell re-
ceptor editing). 
Peripheral tolerance develops 
after T and B lymphocytes ma-
ture and enter the periphery, and 
results in the lack of reactivity to 
environmental antigens. One im-
portant mechanism is through the 
induction of hyporesponsiveness 
(anergy) in T lymphocytes that en-
counter antigen in the presence of 
inhibitory signals or the absence 
Catherine M. Hawrylowicz  
King’s College London 
London, United Kingdom
TOLERANCE INDUCTION: 
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Tolerance induction: principle and modalities
of co-stimulatory signals that ac-
company inflammation. This leads 
to peripherally induced regulato-
ry T (Treg) cells, which suppress 
inappropriate immune responses 
through cell contact-dependent 
and -independent mechanisms 
(Figure 1). Treg cells are essential 
to inhibit immune pathways and 
cells that cause allergic disease, 
including Th2-mediated inflam-
mation, allergen-specific IgE, mast 
cells, and eosinophils (Figure 2). 
A major Treg cell subset important 
in allergy expresses the transcrip-
tion factor Foxp3. Young boys with 
a rare, X-linked, genetic mutation 
leading to the loss of Foxp3+ Treg 
(IPEX syndrome), suffer from mul-
tisystem autoimmunity, and symp-
toms of severe atopy including 
eczema, food allergy, and eosino-
philic inflammation, highlighting 
the role of this subset in prevent-
ing allergic disease. 
A second important T reg popu-
lation expresses the anti-inflam-
matory mediator interleukin 10 
(IL-10). Blood cells from non-al-
lergic individuals stimulated with 
allergen in the laboratory make 
significantly more IL-10 than cells 
from allergic patients. Individuals 
with severe allergic and asthmatic 
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disease show reduced IL-10 syn-
thesis.
Because peripheral tolerance 
develops as a result of exposure 
to environmental antigens it is 
amenable to therapeutic manipu-
lation. The best example is aller-
gen immunotherapy (AIT), which 
involves administering increasing 
doses of allergen to the patient in 
order to induce allergen-specific 
long-term immune tolerance. AIT 
increases Treg particularly those 
that synthesize IL-10. Considera-
ble research efforts are ongoing, 
including initiatives to identify 
adjuvants that can be used in con-
junction with AIT, to improve its 
safety and efficacy. 
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Mechanisms of inhibition by regulatory T cells
Treg
Treg
Treg
Treg
i. Inhibitory cytokines
IL-10, IL-35, TGFβ
DC Teff
ii. Cytolysis
Granzymes
iii. Metabolic disruption
Competition for growth factors
Cell death due to apoptosis
Cell death due to cytokine deprivation
Suppression by cAMP, adenosine
iv. Dendritic cell
Inhibition of maturation & 
activation
DC
Teff
Teff
Teff
Mechanisms of peripheral tolerance in 
allergy: Regulatory T cell actions
TregDC
Th2
Basophil Eosinophil Mast cell
Inhibition pro-inflammatory cytokines
Inhibition Teffector cell activation
Induction IL-10
Induction Treg (Foxp3+, IL-10+)
Inhibition Th2, and 
other allergen-
specific T effector
cells
B 
cell
Induction of IgG4
Suppression of IgE
Figure 1 Regulatory T cells (Treg) inhibit immune responses by (i) release of 
inhibitory cytokines that suppress dendritic cell (DC) and effector T cell (Teff) 
functions, (ii) the synthesis of granzymes that cause apoptotic cell death, (iii) 
metabolic disruption by competition for essential growth factors such as IL-2, 
through constitutive expression of the high affinity IL-2 receptor (CD25), result-
ing in cell death; cyclic AMP (cAMP)-mediated inhibition, and CD39/CD73-gen-
erated, adenosine–mediated immunosuppression; (iv) interaction with DC to 
promote a tolerogenic phenotype, inhibit pro-inflammatory cytokine release, 
enhance IL-10 and inhibit Teff activation.
Figure 2 Treg act at multiple levels of the allergic cascade to prevent and control disease: induction of tolerogenic 
DC, which prevent allergen-specific Teff activation, and promote Foxp3+ and IL-10+ Treg; inhibition of Teff migration to 
tissues and suppression of Teff activation, including Th2 cytokine secretion; decreased IgE and enhanced IgG4 production 
by B lymphocyes; suppression of mast cell, basophil and eosinophil activation and degranulation. Treg are induced by AIT 
to mediate many of these actions, however other therapies may also promote immune tolerance.
Tolerance induction: principle and modalities
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• Allergen immunotherapy (AIT) induces allergen-specific immune 
tolerance
• In contrast to pharmacotherapy, the effects of AIT persist 
after discontinuation and include prevention of new allergen 
sensitivities or progression to asthma
• AIT significantly improves in symptoms, medication use, and 
quality of life and is cost-effective compared to pharmacotherapy 
alone
• The two most commonly prescribed AIT routes are subcutaneous 
(SCIT) and sublingual (SLIT), with comparable efficacy; SLIT has a 
superior safety profile
• Adherence is equally poor with both routes and comparable with 
the low adherence seen with long-term pharmacotherapy
Allergen immunotherapy (AIT) is 
unique in that it treats both the 
symptoms of the allergic disease 
and its underlying cause by induc-
ing allergen-specific immune toler-
ance. Numerous randomized-con-
trolled trials have demonstrated 
significant improvement in symp-
toms, medication use, and quali-
ty of life with AIT in both asthma 
and allergic rhinitis patients. In 
contrast to pharmacotherapy, the 
treatment effects of AIT persist 
after discontinuation and include 
prevention of new allergen sensi-
tivities or progression to asthma. 
AIT has also been associated with 
significant long-term and during 
treatment cost-savings compared 
with pharmacotherapy alone. 
Globally, the two most commonly 
prescribed AIT routes are subcuta-
neous (SCIT) and sublingual (SLIT). 
The efficacy of these 2 routes ap-
pears comparable, with most dou-
ble-blind, placebo controlled trials 
demonstrating an approximate 
30% greater improvement in com-
bined symptom-medication score 
compared with placebo (Table 1). 
Greater magnitudes of improve-
ments have been seen in more 
symptomatic patient populations. 
Adverse reactions associated 
with SCIT include local reactions, 
Linda Cox  
Allergy and Asthma Center 
Fort Lauderdale, USA
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Allergen immunotherapy - overview
which are usually induration and 
erythema at the injection site 
and systemic reactions (SR). Sys-
temic reactions, which occur at 
a frequency of about 0.1 % of in-
jections, are generally mild (grade 
1 or 2), but could potentially be 
life-threatening or fatal.
Because of potential for serious 
systemic reactions, it is recom-
mended that SCIT be administered 
in a medically supervised setting 
with an appropriate wait-period 
after the injection. The safety pro-
file with SLIT is more favorable 
than SCIT, which allows for home 
administration. Local reactions, 
such as oromucosal pruritus, are 
very common with SLIT, affecting 
up to 75% of patients. Local reac-
tions usually occur during the be-
ginning of treatment and resolve 
within a few days or weeks with-
out any medical intervention such 
as dose adjustment, or premedica-
tion. 
Which route is prescribed depends 
on a number of factors, including 
but not limited to, allergenic ex-
tract availability, geographic loca-
tion of physician/patient, patient 
preference and ability to adhere 
with the particular regimen. With 
SCIT the treatment regimen re-
quires frequent - usually weekly 
- visits during the initial updosing 
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phase. This is followed by a main-
tenance phase, during which the 
injections are administered at 
monthly intervals. Many SLIT regi-
mens require no updosing and the 
need for an updosing phase has 
not been clearly established. The 
maintenance dosing frequency for 
SLIT is usually daily. Both routes 
require multi-year treatment 
(usually 3 to 5 years). 
Adherence is equally poor with 
both routes and comparable with 
the low adherence seen with long-
term pharmacotherapy. Interven-
tions such as more frequent clinic 
monitoring, telecommunication 
reminders and educational pro-
grams may improve adherence.
Efforts to improve AIT has result-
ed in some promising develop-
ments such as modified allergens, 
T-cell peptides, adjuvants and 
alternate routes (intralymphatic 
or epicutaneous) that may offer 
shorter, safer, more effective and 
more convenient AIT (Table 1).
TABLE 1
Comparison between different AIT regimens
Formulation Regimen Efficacy Safety Other
SCIT with 
unmodified 
extracts
Weekly updosing followed 
by 3 to 5 years monthly 
maintenance
~20-30% in CMS 
over placebo*
~0.1 % per injection SR
Premature 
discontinuation rates:** 
6-84%
SLIT 
Both no updosing and updos-
ing schedules, most use daily 
maintenance for 3 to 5 years
~20-30% in CMS 
over placebo*
Oromucosal reactions 
common, SR rate : 
0.056% per dose 
Premature 
discontinuation rates: 21 
to 93%
Intralymphatic
3 injections administered 
one month apart
Per nasal challenge 
more effective than 
placebo 
No systemic reaction, 
local site reactions 
common Efficacy comparable to 
3 years of SCIT in open 
study3 and 6 injections 
administered at “minimum 
14 days” apart
Per DBPC not 
more effective than 
placebo(5)
1/38 withdrew due to 
adverse effects
Epicutaneous
6 weekly patches worn for 
8 hours
30% improvement 
in VAS vs. placebo
11% discontinued 
treatment due to 
SR, local site eczema 
reactions common
T-cell peptide 
(cat) 
4 injections administered 
over 4 months 
Nasal challenge 
TRSS 66% greater 
than placebo
Safety events: no 
difference from 
placebo
Efficacy maintained for ~ 
2 years after treatment 
started
Modified SCIT 
(MATA MPL®) 
¥ Ragweed and 
Grass
4 injection administered 7 
days apart
Ragweed ECC: 
48% improvement 
in TSS vs. placebo
Most AE local reaction 
injection site, 5/95 
severe local reaction
Grass pollen 
season: 13.6% 
improvement in 
CMS vs placebo
Local reactions 
common, 1/514 severe 
SR in MATA MPL- 
erythema
Greater efficacy in sub-
group analysis: more se-
vere symptoms; 17%, >35 
years disease duration; 
31% 
Abbreviations: CMS: combined symptom –medication scores, VAS: visual analogue score, SR: systemic reaction, TRSS: total rhinitis 
symptoms score, TSS total symptoms scores (nasal plus non-nasal symptoms)
*Range of efficacy reported but generally between 20-30% greater than placebo with greater effect seen in more symptomatic 
patients
Premature discontinuation defined differently in various studies but generally defined as stopped without physician authorisation 
or < 2 or 3 years
¥ MATA MPL is a preparation containing pollen allergoid adsorbed onto tyrosine and with the adjuvant monophosphoryl lipid A 
(MPL).
Allergen immunotherapy - overview
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induced by AIT
• AIT mechanisms include changes in the profile of allergen-
specific memory T and B cell responses, the synthesis of specific 
antibody isotypes towards a non-inflammatory pattern, and 
decreased activation, tissue migration and degranulation of 
effector cells including mast cells, basophils and eosinophils 
• The shift in the balance from allergen specific Th2 toward Treg 
cells is central to development of allergen tolerance
• Novel biomarkers are needed to aid the selection of the best AIT 
responders
Allergen immunotherapy (AIT) 
utilizes multiple mechanisms, 
which elicit rapid desensitization 
and long-term allergen-specific 
immune tolerance as well as the 
suppression of allergic inflamma-
tion in the affected tissues. 
IMMUNE TOLERANCE TO 
ALLERGENS
Long-term clinical and immune 
tolerance to allergens can be in-
duced by AIT. Its mechanisms 
include changes in the profile of 
allergen-specific memory T and 
B cell responses, the synthesis of 
specific antibody isotypes towards 
a non-inflammatory pattern, and 
decreased activation, tissue mi-
gration and degranulation of ef-
fector cells including mast cells, 
basophils and eosinophils (Figure 
1). 
DESENSITIZATION OF 
EFFECTOR CELLS
Successful AIT is associated with 
the altered magnitude of media-
tor release from the effector cells 
below the “normal” threshold of 
systemic anaphylaxis. The shift 
in the balance between allergen 
specific Th2 and Treg cells is cen-
tral to either development of al-
lergen tolerance during AIT and 
the recovery from allergic disease 
Marek Jutel  
Wroclaw Medical University 
Wroclaw, Poland
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(Figure 1). In both healthy and 
allergic individuals three major 
types of allergen-specific subsets 
of T cells, the Th1, Th2 and Tr1 
cells, are to be found in different 
proportions. Studies with MHC-
class II tetramers showed a switch 
from dominating IL-4-producing 
T-cells to the FOXP3-positive and 
IL-10-producing antigen-specific 
CD4+ T-cells. T cell suppression 
can take place both in the second-
ary lymphoid organs and in the af-
fected tissues. 
Allergen-specific IgE and IgG 
responses. 
Allergen-specific B cells do not 
show tolerance or unresponsive-
ness to allergens but skew from 
IgE-producing to IgG4-producing 
cells. IL-10 regulates isotype for-
mation towards a non-inflamma-
tory phenotype – IgG4. IgG4 is 
also a blocking antibody that pre-
vents the activation and degranu-
lation of effector cells. The shift in 
isotype production cannot howev-
er, explain the therapeutic effect 
of SIT probably due to a very long 
life span of IgE-producing plasma 
cells in the bone marrrow. 
Suppression of allergic inflammation 
AIT efficiently modulates IgE-me-
diated activation and histamine 
release from mast cells and baso-
phils due to Treg cell-dependent 
mechanisms. IL-10 also downreg-
ulates eosinophil function and ac-
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tivity directly or by suppression 
of IL-5 production and reduces 
proinflammatory cytokine release 
from mast cells and. AIT results in 
decreased numbers of eosinophils 
and their mediators in the mucosal 
tissues .
FUTURE PERSPECTIVES
Novel early and late diagnostic bi-
omarkers should be validated to 
provide help in the selection of the 
best AIT responders as wells in the 
optimizing of their treatment. The 
advances in immunology and bio-
engineering provide improved ap-
proaches based on both the newer 
vaccines as well as combination 
of AIT and biological treatment. 
The better understanding of the 
AIT mechanisms will also help in 
elaboration of efficient prevention 
strategies and very early interven-
tion in pediatric subjects (Table 1). 
IL
-1
0
TG
F-
b
early induction of IgG4
late decrease in IgE
TReg
mast
cell
mucus 
production
Suppression of mucus 
production
Th2
mast cells and basophils show an early 
desensitization
Treg cells show direct and indirect  
suppressive effects 
on mast cells, basophils  and eosinophils
eosinophil
Suppression of Th2
and other  allergen-
specific effector T 
cells
Endothelial cells
Suppression of Th2 cell 
homing to tissues
basophil
Induction of
allergen-specific 
Treg cells
Figure 1 Mechanisms of long-term immune tolerance obtained by allergen-specific immunotherapy. After the first 
administration of the AIT vaccine, there is an early decrease in mast cell and basophil degranulation and a decreased 
tendency for systemic anaphylaxis due to early desensitization. Then, allergen-specific Treg cells are generated and there 
is suppression of allergen-specific Th2 cells and other effector cells. Due to immune tolerance in Th2 cells, they can no 
longer contribute to IgE production, endothelial cell activation and Th2 cell homing to tissues, mucus production by the 
epithelium, and tissue migration, priming and survival of mast cells, eosinophils and basophils. IL-10 and TGF-β directly 
and indirectly regulate B cells and effector cells. Other T cell subsets such as Th1, Th9, Th17 and Th22 are suppressed 
by Treg cells. Within the spectrum of changes in the immune system after SIT, there is a relatively early increase in the 
amount of IgG4 and a late decrease in IgE. A substantial decrease in the allergen-specific IgE/IgG4 ratio occurs after 
several months. A decrease in tissue mast cells and eosinophils and release of their mediators and decrease in late phase 
response is observed in the affected tissues. 
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TABLE 1
What is unknown in the mechanisms of allergen immunotherapy
• Molecular mechanisms of how Treg cells are generated in vivo
• Better adjuvants that specifically induce Treg cells 
• In vivo life span of Treg cells induced by AIT
• Potential deleterious roles of Treg cells, such as immune tolerance to tumor antigens 
and chronic infectious agents
• Role of resident tissue cells in immune tolerance
• Molecular mechanisms of spontaneous healing, remissions and exacerbations of 
allergic disease 
• Local tissue events during SLIT and epicutaneous AIT
• Early molecular markers and predictors to decide AIT start, stop and success
• Differences between the mechanisms of high and low dose AIT
• Mechanisms of long term maintenance of allergen tolerance
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• Subcutaneous allergen immunotherapy (SCIT) reduces the 
symptoms of allergic diseases and the need for medication, 
on top of the reduction of symptoms already obtained by 
pharmacotherapy
• SCIT is indicated for allergic rhinoconjunctivitis, allergic asthma 
and atopic dermatitis
• The beneficial effects of SCIT have been demonstrated with 
high-dose treatment
• After several months of SCIT the total costs of allergic respiratory 
disease management is lower than pharmacotherapy alone
With subcutaneous allergen im-
munotherapy (SCIT) allergen 
extract(s) are administered in a 
controlled, repetitive fashion, to 
finally create a state of tolerance, 
in which the patient no longer re-
acts to the allergen. During the 
build-up phase SCIT injections are 
administered once to twice week-
ly, with gradually incremental 
quantity of allergen (Figure 1). Af-
ter reaching the projected mainte-
nance dose the injection frequen-
cy is tapered to every 2-6 weeks, 
without further dose-escalation. 
It is crucial to reach a high level of 
allergen for SCIT to be effective 
(‘high dose’ SCIT). SCIT is aller-
gen-specific, resulting in tolerance 
to only those allergens adminis-
tered in the SCIT. A correct diag-
nosis of those allergens responsi-
ble for the patient’s symptoms is 
mandatory. Administration of too 
many allergens simultaneously is 
probably less effective. As such, 
the prescribing physician has to be 
thoroughly trained in allergy and 
SCIT to interpret skin prick tests 
or serologic testing correctly and 
select the right allergens for SCIT.
SCIT has been shown to be effec-
tive for several allergic diseases 
(Figure 2). High quality scientific 
evidence (Cochrane meta-analy-
Désirée Larenas Linnemann  
Hospital Médica Sur 
Mexico City, Mexico
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Subcutaneous allergen immunotherapy
sis) has shown that SCIT improves 
symptoms and reduces medica-
tion use in allergic rhinitis, allergic 
asthma, allergic conjunctivitis, at-
opic dermatitis and severe allergic 
reactions to hymenoptera venom. 
Its use in latex allergy is still inves-
tigational. Due to the risk of severe 
adverse reactions, SCIT should 
not be used for the treatment 
of food allergy, urticaria or ana-
phylaxis. When given at the right 
dose SCIT with extracts of grass, 
tree and weed pollen is effective, 
as well as with house dust mite, 
animal dander and hymenoptera 
venom. However, SCIT has till now 
only shown efficacy with a limited 
number of molds (e.g. Alternaria 
and Cladosporium). 
When applied in the correct way 
and by a specialized physician 
SCIT is generally safe. Local and 
systemic adverse reactions can 
occur (Figure 3). Due to safety rea-
sons injections are withheld in un-
stable patients and during acute 
illnesses. Patients with severe al-
lergic diseases –such as severe or 
uncontrolled asthma- are not can-
didate for SCIT, nor are patients 
who take systemic beta-blockers.
High dose SCIT reduces the symp-
toms of allergic diseases and the 
need for medication, on top of the 
reduction of symptoms already 
provided by pharmacotherapy. 
SCIT is the only disease modify-
ing treatment available today. The 
effects of SCIT last beyond the 
duration of the treatment (Figure 
4). In children with allergic rhinitis 
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a three year course of high-dose 
SCIT reduced the risk of devel-
oping allergic asthma even seven 
years after discontinuation of AIT 
(Figure 5). 
Although AIT is costly, after sever-
al months of SCIT the total costs 
for the management of allergic 
respiratory diseases are lower 
compared to pharmacotherapy 
alone.
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Figure 1 General dosing schedule for SCIT. On avarage the build-up phase 
lasts 3-6 months, during which the allergy shots are given 1-2 times/week; in 
the the maintenance phase injections are given every 2-6 weeks for at least 3 
years.
Allergic disease
Allergic asthma
Allergic rhinitis/
conjunctivitis
Hymenoptera venom allergy
Allergens
House dust mite
Animal dander
Mold: only Alternaria, Cladosporium
Latex: investigational
NOT for urticaria, anaphylaxis
Atopic dermatitis
Weed pollen
Grass pollen
Tree pollen
NOT: food
Hymenoptera
Figure 2 Indications for SCIT (diseases and allergens where SCIT proved 
efficacios).
Subcutaneous allergen immunotherapy
Figure 3 SCIT adverse reactions. 
SCIT can result in local adverse 
reactions with wheal and flare 
and pruritus at the injection site. 
Sometimes, mild systemic reactions 
can be documented and very rare 
severe systemic reactions occur. 
Consequently, SCIT should be applied 
under surveillance in an allergist 
office. 
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After 6 mo: 
less total 
cost of AR 
treatment
With 3 yrs SCIT: 
Long-lasting effect
In AR: less risk for asthma 
development
Less new 
allergen
sensitizations
Subcutaneous Allergen
Immunotherapy
Reduction in symptoms,
Less need for medication
Figure 4 Benefits of SCIT. 
The prolonged efficacy after 
discontinuation was demonstrated 
with a 3 years course of grass-
pollen SCIT: patients randomized 
to continue verum or placebo did 
just as well over the following three 
pollen seasons. (From New Engl J 
Med, Durham SR, Walker SM, Varga 
EM, et al. Long-term clinical efficacy of 
grass-pollen immunotherapy, 341,468-
75, Copyright  1999 Massachusetts 
Medical Society. Reprinted with 
permission from Massachusetts Medical 
Society.)
Figure 5 SCIT reduces the risk of developing 
asthma in children with allergic rhinitis. A three year 
SCIT course in children with allergic rhinitis showed 
a reduced risk for developing asthma 7 years after 
SCIT was stopped. (Reproduced with permission from 
Jacobsen L, Niggemann B, Dreborg S, et al. Specific 
immunotherapy has long-term preventive effect of 
seasonal and perennial asthma: 10-year follow-up on the 
PAT study. Allergy. 2007;62:943-8, with permission from 
Willey Blackwell.)
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alternative to subcutaneous allergen immunotherapy as a new 
therapeutic easy-to-take intervention with a better safety profile
• The clinical efficacy and the improved safety profile have been 
proven in large randomised clinical trials, both in the adult and 
the pediatric population
• Doses of 15 to 25 micrograms of the major allergy protein 
are recommended to obtain a statistically significant clinical 
improvement
• The long-lasting effect was proven in a randomised trial in 
patients with moderate-to-severe grass pollen-induced allergic 
rhinoconjunctivitis
In the 80’s, sublingual allergen 
immunotherapy (SLIT) was pro-
posed as an alternative to subcu-
taneous allergen immunotherapy. 
The main purpose was to provide 
the increasing allergic population 
a new therapeutic easy-to-take 
intervention with a better safety 
profile. Since then, the clinical effi-
cacy and safety of SLIT have been 
thoroughly evaluated mainly for 
aeroallergens for respiratory al-
lergy. New standardised products 
are currently commercially availa-
ble worldwide. SLIT can be admin-
istered as drops or fast-dissolving 
tablets.
Efficacy. Evaluating data from 
randomised double-blind placebo 
control trials, the clinical effica-
cy (assessed as the reduction of 
symptoms scores and the need 
of rescue medication) of SLIT for 
allergic rhinitis, allergic asthma, 
allergic conjunctivitis, house dust 
mite allergy and grass allergy, has 
been confirmed in various me-
ta-analyses (Table 1). Significant 
clinical and methodological heter-
ogeneity was shown amongst in-
cluded studies (Table 1). More re-
cently, well-powered studies using 
a large number of adult and paedi-
atric patients suffering from mod-
erate to severe allergic rhinocon-
Moisés A. Calderón  
Imperial College London  
London, UK
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Sublingual allergen immunotherapy
junctivitis due to grass pollen, with 
or without asthma, inadequately 
controlled by symptomatic med-
ications have been performed. 
These studies have confirmed the 
clinical efficacy of SLIT in reduc-
ing nasal and ocular symptoms 
and the use of relief symptomatic 
medication. Also, improvement 
in quality of life has been con-
sistently found using SLIT. No 
difference in clinical efficacy of 
single-allergen grass pollen SLIT 
was observed between mono- and 
poly-sensitised subjects. Doses of 
15 to 25 micrograms of the major 
allergy protein are recommended 
to obtain a statistically significant 
clinical improvement.
Safety. SLIT safety profile is very 
good. Drops and tablets are well 
tolerated by both children and 
adults. The most common adverse 
reactions due to SLIT are localised 
to the oral mucosa; 65-85% of the 
patients may complain of itching, 
lip/tongue swelling or ear pruritus. 
These are mild, self-limited symp-
toms which appear 10-15 min or 
a few hours after taking the SLIT 
preparation and last less than 14 
days. Systemic reactions are rare, 
but may appear, especially during 
the up-dosing phase. Systemic 
symptoms could be mild urticaria, 
angioedema and asthma. Only 11 
cases of anaphylaxis have been 
reported in over 2 billion doses of 
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T ABLE 1
Comparison between SLIT studies
Disease Author
Popula-
tion
Studies 
(n)
Participants Effect Size Heterogeneity
Active (n) Placebo (n) SMD (95% CI) I2
Symptom Scores
Rhinitis
Wilson D 
2003
Adults and 
children
21 484 475 -0.42 (-0.69, -0.15) 73%
Rhinitis
Penagos M 
2006 Children 10 245 239 -0.56 (-1.01, -0.10) 81%
Rhinitis
Radulovic S 
2011
Adults and 
children
49 2333 2256 -0.49 (-0.64, -0.34) 81%
Asthma
Calamita Z 
2006
Adults and 
children
9 150 153 -0.38 (-0.79, 0.03) 64%
Asthma
Penagos M 
2008
Children 9 232 209 -1.14 (-2.10, -0.18) 94%
Conjunctivitis
Calderon 
MA 2011
Adults and 
children
36 1725 1674 -0.41 (-0.53, -0.28) 59%
House Dust 
Mites
Compalati 
E 2009
Adults and 
children
8 194 188 -0.95 (-1.77, -0.14) 92%
Grass 
Allergens
Di Bona D 
2010
Adults and 
children
19 1518 1453 -0.32 (-0.44, -0.21) 56%
Medication Scores
Rhinitis
Wilson D 
2003
Adults and 
children
17 405 398 -0.43 (-0.63, -0.23) 44%
Rhinitis
Penagos M 
2006 Children 7 141 138 -0.76 (-1.46, -0.06) 86%
Rhinitis
Radulovic S 
2011
Adults and 
children
38 1737 1642 -0.32 (-0.43, -0.21) 50%
Asthma
Calamita Z 
2006
Adults and 
children
6 132 122 -0.91 (-1.94, 0.12) 92%
Asthma
Penagos M 
2008
Children 7 192 174 -1.63 (-2.83, -0.44) 95%
Conjunctivitis
Calderon 
MA 2011
Adults and 
children
13 560 478 -0.10 (-0.22, 0.03) 34%
House Dust 
Mites
Compalati 
E 2009
Adults and 
children
4 89 86 -1.88 (-3.65, -0.12) 95%
Grass 
Allergens
Di Bona D 
2010
Adults and 
children
17 1428 1358 -0.33 (-0.50, -0.16) 78%
Effect size (SMD): poor <-0.20; medium = -0.50; high >-0.80
Heterogeneity (I2)= 0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may 
represent substantial heterogeneity; 75% to 100%: considerable heterogeneity
Sublingual allergen immunotherapy
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SLIT administered worldwide. No 
fatalities due to SLIT have been 
registered.
The first SLIT dose should be tak-
en in the presence of a doctor 
(observation period of 30-60 min-
utes). In this way, patients are re-
assured about the safety of SLIT, 
their follow-up can be organised 
and compliance structured. SLIT 
drops or tablets are recommend-
ed to be taken at home for 3 years 
as continuous treatment during 
the year or as pre- and co-seasonal 
treatment. 
Long-term effect. The effect 
of disease modification of an 
SQ-standardised grass SLIT-tablet 
2 years after 3 years of treatment 
has been shown in a randomised 
trial in patients with moder-
ate-to-severe grass pollen-in-
duced allergic rhinoconjunctivitis. 
Outcomes such as rhinoconjunc-
tivitis symptom and medication 
scores, combined scores, quality 
of life, days with severe symptoms, 
immunologic end points, and safe-
ty parameters were all improved 
in the SLIT-tablet group compared 
with the placebo group.
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Sublingual allergen immunotherapy
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• There is currently no approved treatment available for food 
allergy and management consists of strict dietary avoidance of 
the allergen and access to readily available epinephrine
• Oral immunotherapy (OIT) for foods is an experimental and 
research modality 
• Preliminary data for OIT is encouraging and has shown that OIT 
can be effective for raising the amount of food needed to cause 
an allergic reaction
• OIT for foods is not ready for everyday use in clinical practice. 
Data are lacking regarding long-term safety and efficacy
• Further research and large, well designed, multicenter, 
randomized, double-blind, placebo-controlled clinical trials are 
needed before OIT can be used in clinical practice
Oral allergen immunotherapy (OIT) 
for foods is one of the most studied 
research options for the treatment 
of food allergy (FA) in young chil-
dren. At this time, management of 
FA consists of strict dietary avoid-
ance of the allergen and access to 
readily available epinephrine. De-
spite increased vigilance with food 
allergen avoidance, inadvertent 
exposure to the allergen is com-
mon and can result in potentially 
life-threatening reactions. There is 
a strong unmet need for the devel-
opment of disease modifying ther-
apies for the treatment of FA and 
to develop a cure for FA.
In the early 20th century, a report 
of a successful OIT regimen for the 
treatment of egg allergy was pub-
lished in the Lancet. Recently, sig-
nificant progress has been made 
in studying this strategy for the 
treatment of FA.
WHAT IS INVOLVED IN THE 
ADMINISTRATION OF OIT?
During OIT, doses of the food al-
lergen (which are in the form of a 
powder) are mixed in a food vehicle 
(such as pudding, ice-cream etc.) 
and are ingested by the individual 
in gradual incremental doses, start-
ing with extremely small amounts 
(Figure 1). This is in contrast to sub-
lingual immunotherapy in which 
ORAL ALLERGEN 
IMMUNOTHERAPY FOR 
FOODS
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Oral allergen Immunotherapy for foods
small drops of allergen extract are 
placed under the tongue, and are 
then swallowed or spit out.
While the exact protocol may vary, 
most OIT studies consist of an in-
itial dose escalation phase that is 
carried out in a closely supervised 
setting such as a research study 
center, followed by buildup and 
maintenance phases that are typ-
ically completed at home. Individ-
uals require close monitoring and 
must be evaluated at regular in-
tervals (Figure 2). 
The optimal duration for OIT for 
foods is unclear at this time. Stand-
ard immunotherapy for aeroaller-
Saira Z. Sheikh A. Wesley Burks
University of North Carolina at Chapel Hill 
Chapel Hill, USA
Figure 1 A maintenance dose of 
peanut OIT (consisting of peanut 
flour). This is mixed in a food vehicle 
(such as pudding, ice-cream etc.) 
before ingestion by the individual.
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Oral allergen Immunotherapy for foods
Figure 2 Oral Immunotherapy for Food Allergy. (Reproduced  with permission 
from Kulis M, Burks AW. Oral immunotherapy for food allergy: Clinical and preclinical 
studies. Advanced Drug Delivery Reviews 2013;65:774-781.)
gens and insect venoms is contin-
ued for a period of 3-5 years, so 
it may be reasonable to estimate 
that OIT for foods would require a 
similar time commitment. 
Adverse reactions to OIT are com-
mon and can range from mild aller-
gic symptoms to severe reactions 
that require treatment with epi-
nephrine (Table 1). 
OIT for foods is not ready for clin-
ical practice and remains an inves-
tigational approach at this time. 
Preliminary data is encouraging 
and has shown that OIT can be 
effective for peanut, milk and egg 
allergy and clinical improvements 
have been associated with favora-
ble immunologic changes (Table 
2). Many questions remain unan-
swered, such as tolerance versus 
desensitization mechanisms in-
volved in OIT (Table 3), and long 
term data is lacking regarding 
safety and efficacy. Large, well de-
signed, randomized, double-blind, 
placebo-controlled clinical trials 
are needed before OIT is ready for 
use in clinical practice.
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TABLE 1
Factors increasing the risk of an 
allergic reaction for individuals on 
OIT for food allergy
• Acute febrile illness or viral 
illness
• Menses
• Prolonged exertion/ after 
exercise
• Inadequately controlled asthma 
• If doses of OIT are taken on an 
empty stomach
TABLE 3
The differences in the concept of desensitization and tolerance in OIT stud-
ies for food allergy
Desensitization Tolerance
• Desensitization refers to a pro-
tective effect that requires daily, 
uninterrupted consumption of 
the food allergen or OIT in order 
to maintain protection or a de-
sensitized state
• Tolerance implies that a food al-
lergen could be ingested without 
symptoms of an allergic reaction, 
despite prolonged periods of 
avoidance and even when OIT is 
discontinued
• If the dosing of OIT or consump-
tion of the food allergen is inter-
rupted or discontinued, this pro-
tective effect can be lost. 
• Even if the dosing of OIT or con-
sumption of the food allergen is 
interrupted or discontinued, the 
protective effect should persist
• In research studies, desensitiza-
tion is measured by conducting 
a supervised oral food challenge 
while the individual is taking OIT
• The optimal way to measure toler-
ance is unknown. In research stud-
ies, this concept is tested by inter-
ruption of OIT dosing for at least 
4 weeks or longer followed by a 
supervised oral food challenge
TABLE 2
Immunologic changes seen during 
OIT for foods
↓ food allergen specific IgE anti-
bodies
↑ food-specific IgG4 antibodies (in-
ferring a possible protective effect)
↓ activation of mast cells shown 
by decreased size of food allergen 
specific skin prick tests
↓ basophil activation tests
↓ cytokines associated with an al-
lergic profile (Th2 cytokines)
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• Allergen-specific immunotherapy is the only allergen-specific 
and disease-modifying treatment for allergy
• Almost all clinically relevant allergen molecules are available in 
recombinant form and are used for diagnosis and immunotherapy
• Several clinical studies have demonstrated efficacy of 
recombinant allergen-based immunotherapy
• On the basis of recombinant allergens it will be possible to make 
allergy vaccines more safe, convenient and effective
Allergy is a major health problem 
for more than 25% of the popu-
lation. Allergic patients produce 
IgE antibodies against a variety of 
allergens, which upon inhalation, 
ingestions, skin contact and sys-
temic administration cause severe 
inflammatory reactions. Aller-
gen-specific immunotherapy (AIT) 
is the only allergen-specific and 
disease-modifying treatment with 
long-lasting effects . It is based 
on the administration of the dis-
ease-causing allergens in the form 
of vaccines. AIT with a grass pollen 
allergen extract was performed 
already in 1911 for the first time 
and since then is still based on 
crude allergen extracts. However, 
the use of such crude allergen ex-
tracts is a major bottle neck for the 
development of safe and effective 
allergy vaccines with convenient 
administration schedules because 
the composition of allergen ex-
tracts shows variations, cannot 
be controlled by the manufactur-
er and the administration of nat-
ural allergens can cause severe 
side effects. Accordingly, only too 
few patients can benefit from SIT 
and the compliance of SIT-treat-
ed patients is low. The majority 
of allergic patients is therefore 
RECOMBINANT 
ALLERGENS FOR ALLERGEN 
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Recombinant allergens for allergen immunotherapy
treated only with symptomatic an-
ti-inflammatory medications. 
MOLECULAR CHARAC-
TERIZATION OF ALLERGENS: 
RECOMBINANT ALLERGENS
The possibility of isolating the 
genes coding for allergens by mo-
lecular cloning has allowed to char-
acterize the structures of most of 
the clinically relevant allergens and 
to produce them as recombinant 
allergen molecules in unlimited 
amounts and in consistent quality 
(Figure 1). Furthermore, sever-
al technologies based on genetic 
engineering of the recombinant 
allergens have been developed to 
reduce the allergenic activity of al-
lergy vaccines and thus to increase 
the safety of AIT. In addition, ge-
netic engineering delivers recom-
binant allergen derivatives with 
increases immunogenicity thus 
inducing protective immunity with 
fewer administrations. 
The first immunotherapy trial 
based on recombinant allergens 
was indeed performed with genet-
ically modified recombinant aller-
gen derivatives of the major birch 
pollen allergen, Bet v 1 and since 
then several successful clinical tri-
als have been performed based on 
recombinant allergen molecules. 
Companion diagnostic tools based 
on micro-arrayed recombinant 
allergen molecules have been de-
veloped, which allow to determine 
the patients reactivity profile and 
thus to select the optimal allergy 
vaccines for treatment. Further-
more, the effects of vaccination 
can be assessed with the micro-ar-
rays by simple blood testing. 
Rudolf valenta verena niederberger
Medical University of Vienna 
Vienna, Austria
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ADVANTAGES OF 
RECOMBINANT ALLERGEN-
BASED ALLERGY VACCINES
Recombinant allergen-based vac-
cines offer many important advan-
tages and thus will revolutionize 
AIT. First, they contain defined 
amounts of the allergen compo-
nents, which can be manufactured 
in consistent quality with defined 
molecular and immunological 
characteristics. The composition 
of the vaccine can be tailored ac-
cording to patient’s sensitizations. 
Together with recombinant aller-
gen-based diagnostic tests as com-
panion diagnostics one can expect 
more and more personalized and 
stratified treatments becoming 
available which suit the individual 
allergic patients best. Importantly, 
the allergenic activity of the vac-
cines can be strongly reduced so 
that the risk of side effects can be 
minimized. This allows avoiding 
inconvenient up-dosing schedules 
and treatments based on numer-
ous injections or daily adminis-
trations. Instead it will be possible 
to treat patients with an optimal 
dose from the beginning with only 
few injections. 
Recombinant allergen-based vac-
cines have been developed and 
successfully evaluated for several 
respiratory allergen sources and 
recently also for severe forms of 
food allergy (http://www.aller-
gome.org:8080/fast/index.jsp). 
Scientific projects and trials are 
on their way to explore the po-
tential usefulness of recombinant 
allergen-based vaccines for the 
prophylaxis of allergy with a view 
towards the prevention of allergic 
sensitization . 
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Figure 1 From allergen genes to allergy vaccines. Based on the genes coding 
for allergens, recombinant allergen molecules and hypoallergenic derivatives 
can be made for allergen-specific immunotherapy. 
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• Pharmacotherapy for allergic diseases treats symptoms only, 
must be taken continuously to maintain symptom relief and does 
not modify the underlying disease process
• Allergen immunotherapy (subcutaneous and sublingual) for 
allergic rhinitis, using whole allergen preparations, is clinically 
efficacious and provides symptom relief that exceeds the 
duration of treatment
• Despite favourable efficacy, immunotherapy compliance is poor 
due to allergic side effects associated with the treatment and 
resulting protracted treatment course
• Peptide immunotherapy reduces IgE-mediated adverse events, 
thereby improving safety. A short course of 4 intradermal 
injections provided symptom relief for at least two years
Allergen immunotherapy (AIT) 
is clinically effective and, un-
like pharmacotherapy, is disease 
modifying. The duration of clini-
cal efficacy exceeds the period of 
treatment. AIT has been shown 
to prevent progression of allergic 
rhinitis towards asthma and to 
reduce the risk of developing new 
allergic sensitizations. However, 
AIT is associated with frequent 
adverse events (mainly local, but 
also potentially systemic) related 
to the fact that patients are ad-
ministered the allergen to which 
they are sensitized. Both subcu-
taneous and sublingual immuno-
therapy are associated with poor 
compliance. 
The allergenicity of whole allergen 
used in AIT is determined by the 
presence of B cell epitopes, which 
cross link allergen-specific IgE on 
effector cells, such as mast cells 
and basophils. 
The mechanisms of action of AIT 
are incompletely understood, but 
are known to involve modulation 
of both the T cell (e.g. induction 
of regulatory T cells) and B cell 
response (e.g. induction of aller-
gen-specific IgG). It remains un-
clear, which of these effects, or 
indeed other currently unknown 
mechanisms, are primarily respon-
Mark Larché  
McMaster University 
Hamilton, Canada
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sible for efficacy. 
Based on the hypothesis that aller-
gen-specific T cells coordinate al-
lergic inflammation and that B cell 
epitopes on whole allergens are 
primarily responsible for adverse 
events, a peptide immunotherapy 
approach has been developed us-
ing short linear peptide sequences 
constituting the dominant T cell 
epitopes of several major allergens 
(e.g. cat, house dust mite, grass).
In double-blind, placebo-con-
trolled, clinical trials conducted 
under controlled allergen expo-
sure conditions in environmental 
exposure chambers/units, sub-
jects were exposed to allergen, 
before and after treatment over a 
three month period (four or eight 
intradermal injections at 4 weeks 
intervals). Clinical efficacy was 
assessed as change from baseline 
in Total Rhinoconjunctivitis Symp-
tom Score (TRSS) at different time 
points after the initiation of treat-
ment. Clinical efficacy was demon-
strated with peptide immunother-
apies for cat allergy (Figures 1 and 
2), house dust mite allergy and 
grass pollen allergy. Treatment ef-
fects were greater in severe symp-
tomatic subjects. Adverse events 
profiles were similar to placebo in 
all cases. 
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Figure 1 TRSSs (means 6 SEMs) at each 30-minute time point (3 hours per day) in the chamber over 4 consecutive days: 
score at baseline (A), score at 18 to 22 weeks after the start of treatment (B), and score at challenge 50 to 54 weeks after 
the start of treatment (C). (Reprinted from J Allergy Clin Immunol, 131/1, Patel D,Couroux P, Hickey P, et al. Fel d 1-derived 
peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-
controlled study, 103-109, Copyright 2013, with permission from Elsevier.)
Peptide immunotherapy for allergic disease
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Thus, peptide immunotherapy 
may provide a solution to the 
poor compliance, high rates of 
adverse events and protracted 
course of treatment associated 
with traditional forms of allergen 
immunotherapy (subcutaneous 
or sublingual) performed with in-
tact allergens. The persistence 
of clinical efficacy for months 
to years after a short course of 
treatment suggests that the goal 
of safe, long-term disease modifi-
cation in a manner acceptable to 
both patients and clinicians can be 
achieved.
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Figure 2 Difference in TRSSs (means 6 SEMs) at each 30-minute time point (3 hours per day) in the chamber over 4 
consecutive days: score at baseline challenge minus score at PTC 50 to 54 weeks after start of treatment. (Reprinted 
from J Allergy Clin Immunol, 131/1, Patel D,Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a 
persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study, 103-109, Copyright 2013, 
with permission from Elsevier.)
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administrations and may cause allergic adverse events
• Intralymphatic allergen delivery (ILIT) is safe and strongly 
enhances efficacy
• Epicutaneous allergen delivery (EPIT) is convenient and 
ameliorates symptoms after six patch applications
• Both, ILIT and EPIT require further clinical development with re-
spect to dose, number and frequency of applications, and adjuvants
Allergen-specific immunotherapy 
(AIT) is the only treatment modal-
ity with long lasting effects that 
can stop progression of disease. 
However, due to the currently long 
treatment duration and potential 
adverse events, only a few percent 
of allergic patients chose to under-
go AIT and adherence is very low. 
In conventional subcutaneous AIT 
(SCIT) the allergen is injected sub-
cutaneously (Figure 1). Most of the 
injected dose remains at the site 
of injection and causes local reac-
tions via mast cells degranulation. 
Leakage of allergen to the vascu-
lature or inadvertent intravascular 
injection may also cause systemic 
allergic reactions. Only a small frac-
tion (<1%) of the injected allergen 
dose drains to the local lymph node 
where dendritic cells induce the T- 
and B-cell responses necessary for 
the immunotherapeutic effect.
One possibility to enhance AIT 
potency and to decrease adverse 
events is by delivering the allergen 
directly into lymph nodes, where 
the density of antigen-presenting 
dendritic cells and responding T- 
and B-cells is maximal, so called 
intralymphatic immunotherapy 
(ILIT). Another route, the epicu-
taneous allergen immunothera-
py (EPIT), relies on the epidermis 
NEW ROUTES 
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properties with a high density of 
antigen presenting Langerhans 
cells, but no mast cells and no vas-
culature, which should reduce lo-
cal and systemic side effects. 
ILIT: Direct intra lymph node injec-
tion delivers more allergen to den-
dritic cells, T- and B-cells. Simulta-
neously, local reactions should be 
reduced, as lymph nodes contain 
only few mast cells.
In fact, in the first randomized 
controlled trial, as little as three 
low dose injections of grass pollen 
extract into subcutaneous lymph 
nodes of the inguinal area proved 
readily feasible and painless. ILIT 
was found safer and showed ef-
ficacy similar to a three year per-
ennial SCIT regimen. These first 
findings have been reproduced by 
another group in a double-blind-
ed placebo controlled fashion. In 
another double-blinded place-
bo-controlled trial three low dose 
intralymphatic injections with a 
modified recombinant cat dander 
allergen (MAT-Fel d 1) were safe 
and induced a robust regulatory 
T cell responses correlating with 
IgG4 responses, as well as nasal 
tolerance to cat dander (Figure 2).
EPIT: Three double-blinded place-
bo controlled clinical trials were 
performed, where grass pollen 
extract was administered by ap-
plication of a patch to the skin of 
the upper arm (Figure 3). The area 
of the patch application was pre-
pared by adhesive tape stripping. 
All three trials found significant 
symptom amelioration over pla-
cebo. The total administered aller-
gen dose was correlated with the 
clinical response. The application 
Thomas M. Kündig Gabriela Senti
University Hospital Zurich  
Zurich, Switzerland
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Figure 2 Intralymphatic administration of a modified recombinant cat dander allergen (MAT-Fel d 1) induced a robust 
regulatory T cell responses correlating with IgG4 responses (left), as well as nasal tolerance to cat dander (right). 
(Reprinted from J Allergy Clin Immunol, 129/5, Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy 
induces tolerance after only 3 injections, 1290-1296, Copyright 2012, with permission from Elsevier.)
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Figure 3 Epicutaneous administration via adhesive allergen strips (upper 
panel). The total administered allergen dose was correlated with the clinical 
response (lower panel). (Reprinted from J Allergy Clin Immunol, 129/1, Senti G, von 
Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass 
pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escala-
tion study, 128-35, Copyright 2012, with permission from Elsevier.)
of 6 high dose patches for 8 hours, 
i.e. overnight, induced symptom 
amelioration of 70% vs. 25% in the 
placebo group. When preparing 
the skin by adhesive tape strip-
ping, patch application was safe. 
The most frequently reported ad-
verse event was itching and mild 
eczema under the patch.
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• An EAACI Task Force recently reported measures to standardise 
recording of efficacy of allergen immunotherapy trials. A 
simple combined symptom and medication score (CSMS) is 
recommended as primary endpoint
• The environmental exposure chamber is recognised as a potential 
alternative for phase 2b trials
• Provocation testing remains important for proof of concept 
studies and for dose-finding
• The recent availability of recommendations for standardised 
reporting of side effects is a further recent advance
• Rather than reliance on a single primary endpoint, the totality of 
evidence should be assessed in evaluating immunotherapy
Allergen immunotherapy (AIT) is 
indicated in patients with moder-
ate-severe IgE-mediated allergic 
rhinoconjunctivitis with/without 
mild asthma who fail to respond 
to anti-symptomatic drugs and/or 
experience unacceptable drug-re-
lated side-effects. Recent advanc-
es have included the availability of 
effective vaccines with an accept-
able tolerability and safety profile.
Several documents have informed 
the standardised performance 
and reporting of clinical trials of 
AIT. These include guidelines for 
reporting AIT-related systemic 
adverse events and the documen-
tation of local side effects during 
sublingual immunotherapy, there-
by providing the opportunity for 
harmonisation of reporting of al-
lergen vaccine-related side effects 
internationally. 
An unmet need has been the 
standardisation of clinical and 
surrogate endpoints for reporting 
the efficacy of AIT - the objective 
of a recent Task Force of the Eu-
ropean Academy of Allergy and 
Clinical Immunology. The docu-
mentation of symptoms during 
natural allergen exposure has 
been the gold standard with re-
cording of ‘rescue’ medication as 
a key secondary endpoint. A re-
MEASURING CLINICAL 
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cent World Allergy Organisation 
(WAO) position paper suggested 
that these two clinical outcomes 
are critically related and could be 
combined. The major recommen-
dation is the use of a combined 
rhinoconjunctivitis symptom and 
medication score (CSMS) as the 
key primary outcome in AIT trials. 
The symptom score is recorded on 
a scale of 0-3 for 6 symptoms, 4 
for rhinitis (itching, sneezing, run-
ny nose and nasal blockage) and 2 
for conjunctival symptoms (itchy/
red eyes and eye swelling). This 
provides a maximum total score 
of 0-18/6 ie range 0-3 maximum 
for symptoms. There is a caveat 
in that for mite-induced perennial 
symptoms the total nasal symp-
tom score ( ie 4 symptoms, total 
0-12/4, still giving 0-3 maximum) 
may be a reasonable alternative, 
as the consensus panel considered 
eye symptoms as less common/ 
bothersome in mite-induced dis-
ease. The rescue medication score 
is recorded on a comparable 0-3 
scale according to the ‘as needed’ 
daily intake of oral and/or topical 
antihistamine (score 1), intranasal 
steroid (score 2, with or without 
antihistamines) and oral predniso-
lone (maximal score 3, with/with-
out nasal steroid and/or antihis-
tamine). This approach provides 
a scale of 0-6 for the CSMS. The 
score is in line with the European 
Stephen R. Durham  
Imperial College London 
London, UK
Oliver Pfaar   
University Hospital 
Mannheim, Germany
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TABLE 1
World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Symptom(s)/sign(s) of 1 
organ system present*
Cutaneous
Generalized pruritus, 
urticaria, flushing, or 
sensation of heat or
warmth 
or
Angioedema (not 
laryngeal, tongue or 
uvular)
or
Upper respiratory
Rhinitis - (eg, sneezing, 
rhinorrhea, nasal 
pruritus and/ or nasal 
congestion)
or
Throat-clearing (itchy 
throat)
or
Cough perceived to 
originate in the upper 
airway, not the lung, 
larynx, or trachea
or
Conjunctival
Erythema, pruritus or 
tearing
Other
Nausea, metallic taste, 
or headache
Symptom(s)/sign(s) of 
more than 1 organ system 
present
or
Lower respiratory
Asthma: cough, 
wheezing, shortness 
of breath (eg, less than 
40% PEF or FEV1 drop, 
responding to an inhaled 
bronchodilator)
or
Gastrointestinal
Abdominal cramps, 
vomiting, or diarrhea
or
Other
Uterine cramps
Lower respiratory
Asthma (eg, 40% PEF or 
FEV1 drop
NOT responding to an 
inhaled bronchodilator)
or
Upper respiratory
Laryngeal, uvula, or 
tongue edema with or 
without stridor
Lower or upper 
respiratory
Respiratory failure with 
or without loss of con-
sciousness
or
Cardiovascular
Hypotension with or 
without loss of con-
sciousness
Death
Patients may also have a feeling of impending doom, especially in grades 2, 3, or 4.
Note: Children with anaphylaxis seldom convey a sense of impending doom and their behavior changes may be a sign of anaphy-
laxis; eg, becoming very quiet or irritable and cranky. Scoring includes a suffix that denotes if and when epinephrine is or is not 
administered in relationship to onset of symptom(s)/sign(s) of the SR:a, ::: 5 minutes; b, >5 minutes- to :::10 minutes; c: >10 to 
:::20 minutes; d:>20 minutes; z, epinephrine not administered.
The final grade of the reaction will not be determined until the event is over, regardless of the medication administered. The final 
report should include the first symptom(s)/sign(s) and the time of onset after the subcutaneous allergen immunotherapy injec-
tion*** and a suffix reflecting if and when epinephrine was or was not administered, eg, Grade 2a; rhinitis:10 minutes.
*Each grade is based on organ system involved and severity. Organ systems are defined as cutaneous, conjunctival, upper respira-
tory, lower respiratory, gastrointestinal, cardiovascular, and other. A reaction from a single organ system such as cutaneous, con-
junctival, or upper respiratory, but not asthma, gastrointestinal, or cardiovascular is classified as a grade 1. Symptom(s)/sign(s) 
from more than one organ system or asthma, gastrointestinal, or cardiovascular are classified as grades 2 or 3. Respiratory failure 
or hypotension with or without loss of consciousness define grade 4 and death grade 5. The grade is determined by the physi-
cian’s clinical judgment.tThis constellation of symptoms may rapidly progress to a more severe reaction. ***Symptoms occurring 
within the first minutes after the injection may be a sign of severe anaphylaxis. Mild symptoms may progress rapidly to severe 
anaphylaxis and death. §If signs or symptoms are not included in the table or the differentiation between a SR and vasovagal 
(vasodepressor) reaction, which may occur with any medical intervention, is difficult, please include comment, as appropriate.
(Reprinted from J Allergy Clin Immunol, 125/3, Cox L,Larenas-Linnemann D, Lockey RF, et al. Speaking the same language: The 
World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System, 569-574, Copyright 2010, with 
permission from Elsevier.)
Measuring clinical outcomes in allergen immunotherapy
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TABLE 2
Grading system for sublingual immunotherapy local adverse events 
Symptom/sign Grade 1: Mild Grade 2: Moderate Grade 3: Severe Unknown severity
Pruritus/swelling of 
mouth, tongue, or 
lip; throat irritation, 
nausea, abdominal 
pain, vomiting, 
diarrhea, heartburn, 
or uvular edema
d Not troublesome
AND
d No symptomatic 
treatment required
AND
d No discontinuation 
of SLIT because of 
local side effects
d Troublesome
OR
d Requires sympto-
matic treatment
AND
d No discontinuation 
of SLIT because of lo-
cal side effects
d Grade 2
AND
d SLIT discontinued 
because of local side 
effects
Treatment is discon-
tinued, but there is no 
subjective, objective, 
or both description of 
severity from the pa-
tient/physician
Each local AE can be early (<30 minutes) or delayed
Reprinted from J Allergy Clin Immunol, 132/1, Passalacqua G, Baena-Cagnani CE, Bousquet J,et al. Grading local side effects of 
sublingual immunotherapy for respiratory allergy: Speaking the same language, 93-98 Copyright 2013, with permission from 
Elsevier
Measuring clinical outcomes in allergen immunotherapy
Medicine Agency and WAO rec-
ommendations and has the advan-
tage of simplicity. None-the-less 
the CSMS will require testing and 
validation in comparison with al-
ternative methods in clinical trials. 
Allergen provocation testing is 
of the value for proof of concept 
studies and for allergen dose-find-
ing for subsequent phase 2b-phase 
3 trials. 
The use of a daily seasonal symp-
tom and medication score is crit-
ically dependent on the pollen 
count, with low counts resulting 
in a marked reduction in power to 
detect treatment differences. In 
this context the Environmental ex-
posure chamber was considered a 
potential alternative for phase 2b 
trials and as an adjunct to phase 3 
field studies, with the caveat that 
this method requires standardisa-
tion within and between centres 
before use in multi-centre studies. 
Finally it was considered that sole 
reliance on a single primary end-
point was undesirable and that the 
totality of clinical and surrogate 
endpoints should be taken into 
account when evaluating the effi-
cacy of AIT. 
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TABLE 3
Combined symptom and medication score (CSMS) 
a) Symptom score
Nasal symptoms (Score 0–3) 0 = no symptoms
1 = mild symptoms (sign/symptom clearly pres-
ent, but minimal awareness;
easily tolerated)
2 = moderate symptoms (definite awareness of 
sign/symptom that is bothersome but tolerable)
3 = severe symptoms (sign/symptom that is hard 
to tolerate; causes interference with activities of 
daily living and/or sleeping)
Itchy nose 0–3
Sneezing 0–3
Runny nose 0–3
Blocked nose 0–3
Conjunctival symptoms Itchy/red eyes 0–3
Watery eyes 0–3
(Total) daily symptom score (dSS)* 0–3 (max score is 3, i.e. 18 points/divided by 6 
symptoms)
b) Medication score
Oral and/or topical (eyes 
or nose) nonsedative H1 
antihistamines (H1A)
1
Intranasal corticosteroids 
(INS) with/without H1A
2
Oral corticosteroids with/
without INS, with/without 
H1A
3
(Total) daily medication score (dMS) 0–3 (max score is 3)
c) Combined symptom and medication score
CSMS dSS (0–3) + dMS (0–3) 0–6
*Max score 18/6 (i.e. 4 nasal symptoms, max score 12 and 2 conjunctival symptoms, max score 6) is optimal for studies of seasonal 
pollino- sis. This could possibly be modified for studies of perennial allergies (e.g. in mite-allergic patients), for example max score 
12/4 (i.e. 4 nasal symptoms with omission of eye symptoms). By assigning 0–3 for all individual symptoms and dividing by total 
number of symptoms, the symptom range 0–3 and maximum symptom score 3 would remain the same.
Reproduced with permission from Pfaar O, Demoly P, Gerth van Wijk R,et al.  Recommendations for the standardization of clinical 
outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: Allergy. 2014 Apr 25. doi: 10.1111/all.12383. 
[Epub ahead of print], with permission from Willey Blackwell.
Measuring clinical outcomes in allergen immunotherapy
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• Lifestyle factors are associated with the development of allergic 
diseases
• Studies are hampered by the difficulty to precisely define a 
given “lifestyle factor” for potential link to causality and by 
confounding factors
• Examples for lifestyle factors proposed to play important roles 
in the development or presentation of allergies include nutrition, 
physical exercise/obesity, psychological factors such as stress, 
and smoking
• Lifestyle factors may be operative already prenatally
• Lifestyle factors are potentially modifiable and represent prime 
targets for preventive interventions at the population level
• Further studies, especially interventional trials, should be given 
high priority
Lifestyle factors (figure 1) are 
discussed in the lay press as well 
as in scientific publications in the 
context of the development of 
many diseases, and allergies are 
no exception to this. While many 
associations have been report-
ed, the somewhat vague term of 
“lifestyle” makes it difficult to dis-
entangle the effects of different 
exposures summarized under this 
name, and adjustment for poten-
tial confounding factors is always 
a concern. Here, we highlight 
some recent advances regarding 
lifestyle factors such as nutrition, 
physical exercise/obesity, and psy-
cho-social factors, and give hints 
on possibly underlying mecha-
nisms. Additional lifestyle-factors 
that are not discussed here may 
also be of importance.
It has been proposed that lifestyle 
factors might influence inflam-
mation. Diet, physical exercise, 
behavioral changes might influ-
ence the “steady-state level” of 
inflammation. This may, together 
with genetic susceptibility, affect 
different systems, including the 
immune response and thereby 
predispose to allergies. A critical 
window of time might be early life, 
although later impact on allergies 
and asthma cannot be excluded.
IMPLEMENTING A 
HEALTHY LIFE STYLE 10
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Implementing a healthy life style
NUTRITION, PHYSICAL 
ExERCISE, OBESITY
Food as an essential pillar of life 
stands in the limelight of most, if 
not all, human societies, at least 
once starving is not a problem an-
ymore. It is held responsible for 
health and disease very often, by 
popular belief, as well as in some 
cases, by scientific evidence. In the 
context of allergies, food compo-
nents can act as triggers of allergic 
reactions. Additionally, the role 
of nutrition in the development 
of allergies has received much at-
tention. For a long time, avoiding 
potentially allergenic food during 
early infancy,e.g. by delaying solid 
food introduction, was the accept-
ed state of the art. More recent 
data, however, have challenged 
this approach; studies show that 
food diversity in the first year of 
life or the consumption of specif-
ic foods such as fish, goes along 
with decreased rates of allergic 
diseases. Accordingly, new recom-
mendations do not advice parents 
anymore to avoid specific food for 
their babies in the absence of clin-
ically manifest allergy, i.e. only for 
prevention. 
Closely associated with nutrition 
on one hand and physical exercise 
Caroline Roduit   
Zurich University Children’s Hospital 
Zurich, Switzerland
Roger Lauener  
Children’s Hospital of Eastern 
Switzerland, St. Gallen 
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Implementing a healthy life style
on the other hand is obesity. Obe-
sity was associated especially with 
asthma. New studies suggest that 
the role of obesity may already be 
operative prenatally. For example, 
maternal BMI during pregnancy 
was associated with the child’s 
increased risk for asthma, but the 
confounding effect of the child’s 
own overweight in mediating such 
effects cannot be excluded. The 
fact that parents impose physical 
restrictions on their asthmatic 
children to avoid asthma symp-
toms may result in a vicious circle 
further aggravating the children’s 
situation. Management approach-
es including dietary interventions 
for weight loss and routine exer-
cise are safe in asthmatic patients, 
and improve important asthma 
outcomes, including quality of 
life. Asthma care providers should 
learn to facilitate weight loss for 
their obese patients. Pharmaco-
logic or surgical interventions for 
weight loss in extremely obese 
asthma may be considered.
SMOKING
Many patients and parents of pa-
tients spare no effort to imple-
ment actions in order to alleviate 
their allergies, even in the com-
plete absence of any supporting 
evidence for their action. In re-
markable contrast to this activ-
ism, sometimes an obvious thing 
to change in their lifestyle that is 
neglected is smoking. It cannot be 
stressed enough that one of the 
most, if not the most important 
potentially modifiable risk factor 
at least for asthma and allergic 
diseasesis smoking. 
PSYCHOSOCIAL FACTORS
The psychosocial environment is 
of undisputed importance in the 
manifestation of allergic diseas-
es. It is interesting to note that in 
German the term “Neurodermitis” 
is often used for atopic dermatitis, 
implicating a neurological/psycho-
logical component of this disease. 
Indeed, stress and anxiety influ-
ences e.g. skin test results. New 
data suggesting an association 
between perceived neighborhood 
safety and asthma or between fe-
tal exposure to maternal stress-
ful events and the risk of asthma 
and atopic diseases in childhood 
are intriguing, even if one takes 
into account the methodological 
difficulties, such studies have to 
surmount for adjusting for rele-
vant confounders. Interventions 
might be suggested from studies 
showing the importance of psy-
chological stress factors, although 
one has to admit that this might be 
more easily achieved on an indi-
vidual rather than on a population 
level.
LIFESTYLE FACTORS MAY 
BE OPERATIVE ALREADY 
PRENATALLY
In addition to maternal smoking, 
obesity or stress during pregnancy 
other exposures may be relevant 
already prenatally. One example 
for this is the observation that ex-
posure of the mother to animals 
goes along with a reduced risk for 
atopic dermatitis during the first 
years of life.
SUMMARY
Many studies suggest an impor-
tant role for lifestyle factors. The 
next steps should aim at defining 
Figure 1 Lifestyle factors influence allergy risk.
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even more precisely protective 
and harmful exposures and at in-
vestigating potential underlying 
mechanisms. Targeted interven-
tional studies are needed, to real-
ize the potential of modifying life-
style factors for promoting health 
also with regard to allergies and 
asthma. Comprehensive interven-
tions targeting multiple lifestyle 
factors are also warranted.
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psychological burden for the patient and their families
• Adopting a bio-psychosocial approach when consulting with a 
patient with allergy ensures that the wider consequences of their 
allergies are addressed and not just their physical symptoms 
• Psychological interventions may be helpful in the management 
of patients with allergic diseases and their families, but there is 
currently limited evidence of their effectiveness
• Clinicians need to be alert to the possibility of psychological 
co-morbidities, which means being attentive to changes in 
their patient’s emotional wellbeing and be willing to work 
with relatives, schools or workplaces to generate a safe and 
supportive environment
There is increasing awareness 
and evidence of the psychologi-
cal and social impacts of allergy 
on patients and their families. 
Psychological factors may also be 
an aggravating factor for allergic 
conditions. Stress has been recog-
nised as a trigger for asthma and 
eczema, and conversely post-trau-
matic stress disorder may follow 
near fatal episodes of asthma or 
anaphylaxis. Under performance 
and lack of attentiveness may arise 
from the allergic symptoms them-
selves, from disease complica-
tions, or from allergy treatments. 
In children, underperformance in 
the classroom may have a critical 
impact on their educational at-
tainment and socialisation. Food 
allergic children may be bullied, 
teased or harassed, because of the 
need to avoid certain foods and to 
carry medication with them at all 
times. The same applies for the 
need to carry rescue inhalers for 
asthma.
Allergic diseases rarely impact 
solely on the affected individu-
al, but their effects ripple out to 
parents, dependents, friends and 
peers. Examples include eczema-
tous itching disturbing the sleep 
patterns of both parents and child, 
or the snoring and sneezing of a 
Helen Smith  
Brighton & Sussex Medical School 
Brighton, UK
PSYCHOLOGICAL SUPPORT 
IN THE MANAGEMENT OF 
ALLERGIC PATIENTS
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Psychological support in the management of allergic patients
rhinitic adult interrupting their 
partner’s rest. Food avoidance 
within a family appears to have 
exceptionally far reaching impact; 
it may distort everyone’s dietary 
intake, reduce family cohesion, 
inhibit family activities and make 
mealtimes particularly stressful. 
So clinicians need to be constantly 
aware of the possible psychologi-
cal effects of allergic illness and its 
management on both the patient 
and their family. Patients with an 
allergic disease require not just 
an in-depth assessment of their 
physical problems, appropriate 
medication and advice, but also 
consideration of and support for 
the psycho-social aspects of their 
condition (Figure 1). 
There are a range of interventions 
used in clinical practice to help re-
duce patients’ fears, concerns and 
stress and to improve their coping 
mechanisms. These include edu-
cational interventions and vari-
ous psychological interventions, 
such as behavioural therapies, 
cognitive therapies, relaxation 
techniques and counselling (Table 
1). Educational and psychological 
approaches may be combined in a 
single intervention requiring mul-
ti-disciplinary working of health 
care professionals, psychologists, 
social workers, teachers and sup-
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port groups. Many educational 
programs are based on “Social 
Learning Theory” and strive to 
improve self efficacy through 
improving knowledge, skills and 
confidence. A simple psycholog-
ical technique such as relaxation 
might work in an eczematous 
patient by reducing anxiety and 
stress which exacerbate their per-
ception of itch. In paediatrics, the 
interventions may be offered to 
the parents rather than to the al-
lergic child. For example cognitive 
behavioural therapy may help par-
ents of food allergic children de-
velop new ways to deal with their 
stress and low mood. If successful, 
the therapy improves their quality 
of life as well as that of their aller-
gic child. 
Whilst patients report individual 
benefit from psychological inter-
ventions and some clinicians have 
case series supporting their use, 
we lack rigorous evidence about 
which interventions impact best 
on psychological distress, quali-
ty of life and symptoms. Despite 
this paucity of evidence adoption 
of a bio-psychosocial approach 
when developing a management 
plan ensures that the wider conse-
quences of allergy are addressed.
TABLE 1
Overview of Psychological and Educational Interventions
Psychological Interventions
Behavioural 
interventions
The therapist uses behavioural therapy to modify the patient or carer’s behaviour. 
For eczema habit reversal behavioural therapy is used to break the patient’s habit of 
unconscious, repetitive scratching and also to develop less damaging behaviours when there is a 
real desire to scratch. 
Relaxation 
techniques
Can be used to reduce stress and anxiety. There are many such techniques (also known as 
arousal reduction techniques). 
Two widely used methods are:
• Progressive relaxation: teaches individual to tense different muscles groups in their body 
and then relax them. The individual becomes able to recognise areas of tension and to 
consciously release that tension.
• Visualisation (or guided imagery): teaches the individual to use images associated with 
relaxation and calmness to purposefully induce these feelings in their own body
Other relaxation techniques are hypnotherapy, autogenic training and biofeedback.
Psychological 
therapies
These are predominantly ‘talking therapies’ that enable people to develop improved insight into 
their problems and then change their thought processes, behaviour and coping style. 
Cognitive behavioural therapy uses a strong theoretical base to achieve these changes whereas in 
counselling a non-directive, non-judgemental approach is used to support the individual develop 
more effective ways to cope. 
Family therapy focuses on the family rather than the individual and facilitates discussion 
between family members of the challenges of coping with allergies, and together they develop 
improved strategies for change.
Educational interventions
• Need to address the skills and confidence, as well as their knowledge, if they are to be successful 
• Can use a variety of instructional strategies (booklets, role play, problem solving, computer assisted instruction etc) 
• Can be delivered to individuals, to families or groups
• Can be combined with psychological interventions for enhanced impact
Psychological support in the management of allergic patients
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Figure 1 Bio-psychosocial model of health and illness. Psychosocial factors, including beliefs, relationships and mood, 
impact on patients’ quality of life and ability to cope with their illness. Incorporating a holistic view in the consultation can 
ensure patient’s wellbeing is addressed in its entirety.
Psychological support in the management of allergic patients
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• The current state of the art in pharmacogenetics/genomics of 
allergy is not yet predictive on a large scale, but provides a model 
for future study
• Pharmacogenetic profiling has been done mostly for asthma 
treatment, but also in the analysis of the response to treatment 
of other allergic diseases including rhinosinusitis, food allergy 
and atopic dermatitis
• Most of the studies of asthma pharmacogenetics have identified 
variability of responses to three classes of medications: inhaled 
and systemic glucocorticoids, leukotriene modifiers and beta 
adrenergic receptor agents
• A number of the genetic variants seen in the Th2 responses have 
been associated with severity and responses to treatment in 
chronic rhinosinusitis and in atopic dermatitis
Pharmacogenetics and pharma-
cogenomics of allergic diseases 
refers to the relationship between 
genotype and/or genetic variants, 
and the response to treatment 
(Table 1). Pharmacogenetic profil-
ing in association studies has been 
done mostly for asthma, but also 
in some circumstances in the anal-
ysis of the response to treatment 
of other allergic diseases including 
rhinosinusitis, food allergy and 
ato pic dermatitis.  
Most of the studies of asthma 
pharmacogenetics have identi-
fied variability of responses to 
three classes of medications: in-
haled and systemic glucocorti-
coids, leukotriene modifiers and 
beta adrenergic receptor (β2 AR) 
agents involved in bronchodilata-
tion (Table 2).  The demonstration 
that genetic variations influence 
FEV1 response to  asthma treat-
ment clearly supports the value 
of the pharmacogenetic approach 
to differentiate responders from 
non-responders. At this particu-
lar point, in time, the application 
of this approach in a widespread 
screening manner that would have 
meaningful implications for the 
treatment of asthma is somewhat 
hopeful and part of the future.  The 
current state of the art in pharma-
Lanny J. Rosenwasser  
University of Missouri-Kansas City  
Kansas City, USA
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Pharmacogenetics and pharmacogenomics of allergic diseases
cogenetics/genomics of allergy is 
such that it is not yet predictive on 
a large scale, but provides a model 
for future study. 
There is no question that phar-
macogenetics of glucocorticoids 
pathways has identified gene-
tic variance that defines severity 
within the asthmatic populations 
together with differential re-
sponses to treatment with glu-
cocorticoids. Genetic studies in-
cluded in the asthma Childhood 
Management Program (CAMP) 
identified SNPs in the CRHRI 
gene associated with changes in 
FEV1 in response to inhaled glu-
cocorticosteroids (ICS). Similarly, 
the genetic variance in the TBX2I 
gene identifies differences in the 
response to ICS in Asian popu-
lation. Further studies identified 
variations in a number of genes in-
cluding ORDML3 and cytochrome 
genes (CYP3A4, 3A5, 3A7) that 
correlate with the response to 
ICS.  In addition, genetic variants 
within the low affinity IgE Fc re-
ceptor, CD23 or FcεR2, have also 
been associated with the variabil-
ity of response to ICS in the CAMP 
study. 
Pharmacogenetics of the β2 AR 
pathway has been of great inter-
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est, because of the possibility of 
bronchodilator responses corre-
lating with greater risk for asthma 
exacerbations and even mortality. 
A variety of studies have identified 
changes in Arginine and Glycine at 
position 16 of the β2 AR gene sep-
arating responders from non-re-
sponders to the bronchodilator ef-
fects of long acting beta2 agonists. 
On the contrary, the association 
of asthma severity and mortality 
with any of these genetic variants 
has proven illusive.  
Cysteinyl leukotriene receptor 
genes also have been associated 
with asthma responses to treat-
ment. In addition, variants in 
5-lipoxygenase genes predict re-
sponses to the 5-lipoxygenase in-
hibitor Zileuton.  
All of these responses in the var-
ious treatment pathways in asth-
ma are clearly influenced by ge-
netic variants that control drug 
treatments. Pharmacogenomics 
identifies multiple pathways of 
genes that might be activated in 
response to treatments. Several 
studies are undergoing, but the 
data is not available for publica-
tion as yet. 
A number of the genetic variants 
seen in the Th2 responses have 
been associated with severity and 
responses to treatment in chronic 
rhinosinusitis and in atopic der-
matitis (AD).  Th2 genetic variants 
have also been identified as being 
potential contributors to AD, as 
well as a variety of genes including 
filaggrin that are important for the 
integrity of the epithelial barrier. 
In addition, a variety of genetic 
variants have been identified in 
the histamine pathway and recep-
tor system that influence allergy.
FUTURE PHARMACOGENETICS 
APPROACHES
There is no doubt that selection 
responders to treatment based 
on genetic variants will eventually 
be an accepted clinical attribute. 
Given the successful example of 
TABLE 1
Definition for Pharmacogenetics/Pharmacogenomics
• Pharmacogenetics-Influence of genetic variants on treatment response in 
Allergy and Asthma
• Pharmacogenomics – Influence of genomic expression on treatment 
response in Allergy and Asthma
TABLE 2
Example of Allergy/Asthma Treatment Pathways in Pharmacogenetics
Treatment Pathway Genetic Variants
Beta-Adrenergic Agents Beta-Adrenergic Receptors 
Inhaled Corticosteroids Inflammatory and Metabolic
Leukotriene Pathway agents 5-Lipoxygenase and LT receptors
Antihistamines Histamine receptor variants
Histamine pathway
the analysis of genetic pathways 
in tumors directing treatment 
for cancers, we can assume  that 
within the next five to ten years 
the pharmacogenetic/genomic ap-
proach will began to be accepted 
as part of the overall assessment 
for asthma and allergic diseases.
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• Allergic diseases are amongst the most common and costly 
chronic conditions seen in westernized societies; both direct and 
indirect costs contribute substantially to disease burden
• Allergic rhinitis (AR) is the fifth costliest chronic disease in the 
U.S., with estimated direct costs exceeding $11 billion in 2005. 
The direct cost of AR in Europe are not known but was estimated 
at €1.0 to €1.5 billion in late 1990s
• Allergen immunotherapy (AIT) has a disease-modifying 
effect that can prevent the progression of AR to asthma, the 
development of new allergy sensitivities, and progression of 
disease severity
• These combined outcomes translate the clinical efficacy of AIT 
into a significant economic benefit. This economic benefit has 
been confirmed in a number of studies that have compared 
subcutaneous and /or sublingual AIT with standard drug 
treatment from several different perspectives e.g. societal, 
healthcare system or 3rd-party payer
Allergic respiratory diseases are 
amongst the most common and 
costly chronic conditions seen in 
westernized societies. Globally, 
allergic rhinitis (AR) is the most 
common allergic disease affecting 
approximately 500 million peo-
ple world-wide, including an esti-
mated 113 million in Europe and 
30-60 million in the United States 
(U.S.) The prevalence rate of phy-
sician-diagnosed asthma was 4.3% 
in a 2002-2003 Global Health 
Survey, but varied by as much as 
21-fold amongst the 70 countries 
surveyed. Both conditions can be 
associated with a number of symp-
toms and comorbid illnesses that 
can significantly contribute to the 
indirect costs of their treatment, 
e.g., cognitive dysfunction, day-
time fatigue, sinusitis, and sleep 
disorders. 
Allergic rhinitis is the fifth cost-
liest chronic disease in the U.S., 
with estimated direct costs ex-
ceeding $11 billion in 2005. The 
direct cost of AR in Europe are not 
known, but was estimated at €1.0 
to €1.5 billion in late 1990s.
The indirect costs associated with 
AR are considerable. In a survey 
of U.S. employees, the total annu-
al cost of lost productivity attrib-
utable to AR was about $600 per 
Linda Cox  
Allergy and Asthma Center  
Fort Lauderdale, USA
PHARMACOECONOMICS OF 
ALLERGIC DISEASES13
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Pharmacoeconomics of allergic diseases
employee (2002 value), which was 
significantly higher than the cost 
for any other condition assessed 
including diabetes and coronary 
heart disease. In Europe, the loss 
due to untreated AR-related pre-
senteeism has been estimated 
to be approximately €100 billion 
(2011 value) annually. 
While pharmacotherapy can be 
effective in controlling allergic 
symptoms, it does not address the 
underlying allergic cause. Efficacy 
requires ongoing treatment and 
the benefits are lost shortly after 
the medication is discontinued. In 
contrast, the efficacy of allergen 
immunotherapy (AIT) can persist 
long after discontinuation due to 
the induction of allergen-specific 
tolerance. In addition to reducing 
the need for long-term sympto-
matic drug treatment, AIT’s dis-
ease-modifying effect can prevent 
the progression of AR to asthma, 
the development of new allergy 
sensitivities, and progression of 
disease severity. 
332
Global atlas oF allerGy
se
c
t
io
n
 G
 - 
M
an
ag
em
en
t 
o
f a
lle
rg
ic
 d
is
ea
se
s
These combined outcomes trans-
late the clinical efficacy of AIT into 
a significant economic benefit. 
This economic benefit has been 
confirmed in a number of studies 
that have compared subcutaneous 
(SCIT) and /or sublingual immuno-
therapy (SLIT) with standard drug 
treatment (SDT) from several dif-
ferent perspectives e.g. societal, 
healthcare system, 3rd-party pay-
er or some combination of these 
perspectives (tables 1A & IB). The 
analysis design employed in these 
comparative studies varied and 
included ‘real-life’ retrospective 
claims reviews and theoretical 
economic modeling (e.g., cost-con-
sequence analysis). The outcomes 
assessed also ranged from ‘re-
al-life’ total healthcare costs to 
theoretical Quality-adjusted Life 
Year (QALY) gained or number 
of asthma cases prevented. In 
some studies, cost-effectiveness 
was based on the presumption of 
persistent efficacy for years after 
discontinuation or prevention of 
asthma. 
There was some variability across 
the studies in the AIT cost-effec-
tive or break-even time point. In a 
6-year prospective study compar-
ing a 3-year course of SCIT with 
SDT, the cost-savings became sig-
nificant in the 3rd treatment year. 
AIT cost-savings reached 80% in 
the 4th year and was maintained 
through the 3 post treatment 
years. In some studies, the cost-ef-
fective ‘time-point’ was reached 
several years after discontinua-
tion, which likely reflects the time 
required for the sustained ben-
efits of AIT to outweigh the AIT 
treatment costs. However, in gen-
eral, studies that collected costs 
via medical encounters or claims 
data demonstrated significant 
cost- savings during treatment. 
A 12-year retrospective claims 
analysis (‘real-life’ data), which in-
cluded ~7.5 million people, found 
an 18- month total healthcare cost 
savings of 30% in adults and 42% 
in children with newly diagnosed 
AR, who received AIT compared 
with a matched AR population 
that did not receive AIT. This study 
confirmed the findings of a simi-
larly designed pediatric study, that 
found progressive cost-savings 
that were significant 3 months af-
ter AIT initiation. These ‘real-life’ 
retrospective studies lend strong 
support for the cost-effectiveness 
of AIT.
TABLE 1A
STUDIES COMPARING SLIT WITH STANDARD DRUG TREATMENT (SDT)
STUDY COMPARATORS TYPE PERSPECTIVE RESULTS
Schadlich 
2000
Pollen or HDM SCIT for 3 
years plus SDT as needed; SDT
CEA
Society, healthcare 
system, 3rd-party 
payer
SCIT < SDT over ten years. Break-even 
point reached in the 7th year. 
Petersen 
2005
Grass or HDM SCIT for 3-5 
years plus SDT as needed; SDT
CEA Society
Direct cost: SCIT >SDT If indirect costs 
of sick days included in the economic 
evaluation, SCIT costs < SDT
Ariano 2006 Parietaria SCIT for 3 years 
plus SDT as needed; SDT
CCA
Healthcare 
system, society
SCIT < SDT; 80% cost reduction found 3 
years after stopping SCIT 
Keiding 2007 Grass SCIT for 3 years plus 
SDT as needed; SDT
CEA 
CUA
Healthcare 
system, society
SCIT cost-effectiveness per QALY; in the 
range of €10,000-25,000 per QALY from 
perspective of the healthcare system. 
Omnes 2007 HDM or pollen SCIT 3 -4 years 
plus SDT as needed: SDT
CEA Society
Cost-effective per incremental cost of 
asthma cases avoided (ICER)
Bruggenjurgen 
2008
SCIT for 3 years plus SDT as 
needed; SDT
CUA
3rd-party payer, 
society
Break-even point =10 years. After 15 
years -annual cost savings of €140 per 
SCIT-treated patient. 
Hankin 2008
Costs 6 months before and 6 
months after SCIT
CCA Healthcare system
Weighted mean 6-month savings/patient: 
$401
Hankin 2010
SCIT for 18 months plus SDT 
as needed; SDT as needed for 
18 months
CCA Healthcare system
SCIT 18-month total healthcare costs 33% 
reduction compared with SDT
Hankin 2013
SCIT plus SDT as needed for 
18 months; SDT as needed for 
18 months
CCA Healthcare system
SCIT 18-month total healthcare costs 
compared with SDT: Children: 42% 
reduction Adults: 30% reduction
Pharmacoeconomics of allergic diseases
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TABLE 1B
STUDIES COMPARING SLIT WITH STANDARD DRUG TREATMENT (SDT)
STUDY COMPARATORS TYPE PERSPECTIVE RESULTS
Berto 
2005
1 year of SDT before 
SLIT; SLIT for 3 years
CEA
Healthcare 
system, 
society
Cost-savings with SLIT per healthcare system and society: 
• Year before SLIT: mean annual healthcare costs/ annual 
total costs per patient were €506 and €2672, respectively 
• During SLIT: €224 (healthcare costs) and €629 (total cost) 
Berto 
2006
Pollen SLIT for 3 years 
plus SDT as needed; SDT
CCA
Healthcare 
system, 
society
SCIT compared to SDT:
• Greater 6-year mean savings from payer and societal 
perspective.
• More asthma cases avoided and patients improved 
Bachert, 
2007
Grass SLIT for 3 years 
plus SDT as needed; SDT
CUA Society
SLIT cost-effective cost per QALY; average 0.0287 QALYs per 
season compared with SDT
Beriot-
Mathiot, 
2007
Grass SLIT for 3 years 
continuous or seasonal; 
SDT
CUA Societal
Per ICER seasonal SLIT was cost-effective. Continuous 
SLIT was cost-effective if sustained effect for ≥2 years after 
treatment 
Canonica 
2007
Grass SLIT for 3 years 
plus SDT as needed; SDT
CUA Society
SLIT cost-effective per QALY: average 0.0167 QALYs per 
season compared with SDT
Berto 
2008
Grass SLIT for 1 year; 
SDT for 1 year
CCA
3rd-party 
payer
Mean annual direct costs for SLIT greater than SDT €311.4 
and €179.8, respectively.
Nasser 
2008
Grass SLIT for 3 years 
plus SDT as needed; SDT
CUA Society
SLIT “very cost-effective” per QALY gained. QALY gained at 
9 years = 0.197; equivalent to an extra “72 days of perfect 
health” for patients treated with SLIT when compared with 
those receiving placebo
Ariano 
2009
SLIT for 3 years plus 
SDT as needed; SDT
CCA
Healthcare 
system
Healthcare costs greater for SLIT plus SDT in year 1, same 
in years 2 and 3, and significantly lower in years 4 and 5, 
compared with SDT
Ruggeri 
2013
SLIT for 3 years plus 
SDT as needed; SDT
CEA
3rd-party 
payer, society
SLIT cost effective per ICER; benefit of 0.127 QALYs in 
patients with medium AAdSS and 0.143 QALYs in patients 
with high AAdSS. 
CCA=cost-consequence analysis; CEA=cost-effectiveness analysis; CUA=cost-utility analysis; ICER=incremental cost-effectiveness 
ratio; QALY=quality-adjusted life year; SCIT=subcutaneous allergy immunotherapy; SLIT=sublingual allergy immunotherapy; 
SDT=standard drug treatment, HDM= house dust mite, AAdSS=adjusted average symptom score
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Section H
TOWARDS A COMPREHENSIVE GLOBAL STRATEGY 
FOR THE MANAGEMENTOF ALLERGIC DISEASES
* Contribution of allergy to the burden of 
non-communicable diseases
* Allergic diseases on the political agenda
* Policies and strategies to facilitate access to diagnosis and 
treatment for allergic diseases
* Policies and strategies to reduce risk factors for allergic 
diseases
* The role of primary care in the management of allergic 
diseases
* The role of allied health in the management of allergic 
diseases
* The role of patient organisations in the management of 
allergic diseases
* EAACI PAtient Organisations committee
* The role of pharmacists in managing allergic diseases
* The role of schools in managing allergic diseases 
* Comprehensive allergy management plan. Towards a 
patient-centered attitude 
* Social mobilization for management of allergic diseases
* Best buys for allergy prevention and control
* Dealing with the implementation gap for allergy 
prevention and control
* Generating resources for allergy prevention and control
* Strengthening the speciality of Allergology and Clinical 
Immunology
* EAACI-UEMS Exam in Allergology/Clinical Immunology
* Managing allergic diseases in developing countries 
* The “One Health” concept and allergic diseases
* Allergy and active and healthy ageing
* Allergy in internet 
* iCAALL: International Collaboration in Asthma, Allergy 
and Immunology
* Vision and roadmap to fight with allergies
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s • Asthma, rhinoconjunctivitis and eczema are three prevalent 
non-communicable diseases caused by allergy
• The majority of cases of allergic diseases can be diagnosed and 
managed in primary care, if there are functioning health systems, 
including access to essential medicines
• The WHO global action plan for prevention and control of 
non-communicable diseases 2013-2020 provides many policy 
options to bridge the gaps in diagnosis and treatment of major 
non-communicable diseases, including asthma
• Reducing premature mortality from chronic respiratory diseases, 
including asthma, can contribute to the global target of reducing 
premature deaths due to major non-communicable diseases by 
25% by 2025
ASTHMA, RHINO-
CONJUNCTIVITIS AND ECZEMA
Asthma, rhinoconjunctivitis and 
eczema are three prevalent non- 
communicable diseases, which 
are caused by allergy. They can 
result in limitation of activity and 
function and lower quality of life, 
particularly when they coexist 
together in the same individual. 
The prevalence varies between 
and within countries. Globally, the 
prevalence for current asthma, 
rhinoconjunctivitis and eczema 
in the 13-14-year age group has 
been reported to be 14.1%, 14.6% 
and 7.3%, respectively. In the 6-7-
year age group the prevalence for 
current asthma, rhinoconjunctivi-
tis and eczema has been reported 
to be 11.7%, 8.5% and 7.9%, re-
spectively. 
The data on the relationship be-
tween socioeconomic status and 
prevalence of these conditions 
have shown mixed results. Genet-
ic and environmental factors play 
important aetiological roles. Those 
who suffer from asthma, rhinocon-
junctivitis and eczema may also 
have a greater tendency to devel-
op other allergies such as food and 
drug allergies. More research is 
needed to understand the aetiolo-
gy of these allergic conditions. 
ALLERGY TO DRUGS, FOOD 
AND INSECT STINGS
 Allergy to drugs, food and insect 
stings may present as acute urti-
caria, angioedema, dyspnoea and 
other symptoms of anaphylaxis in 
the skin, gastrointestinal, respira-
tory or cardiovascular systems. 
Anaphylactic reactions, although 
not common, may be fatal within 
minutes. Immediate drug reac-
tions are seen most commonly 
with analgesics, antibiotics, radio-
contrast media and muscle relax-
ants. Food items that can cause 
allergy include shellfish, peanut 
and egg. 
PREVENTION AND TREATMENT 
Anaphylaxis can be effectively 
treated, if there is access to emer-
gency services including adrena-
line injections. Prevention strate-
gies include increased awareness 
of food and drug allergy, recording 
a history of drug allergy in all pa-
tients and stricter enforcement of 
food labelling laws. The majority of 
cases of asthma, rhinoconjunctivi-
tis, eczema, drug and food allergy 
can be diagnosed and managed 
in primary care, if there are func-
tioning health systems, including 
access to essential medicines. 
Deaths and hospitalization due to 
asthma in resource-constrained 
Shanthi Mendis  
WHO  
Geneva, Switzerland
CONTRIBUTION OF ALLERGY 
TO THE BURDEN OF 
NON-COMMUNICABLE DISEASES
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Contribution of allergy to the burden of non-communicable diseases
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Contribution of allergy to the burden of non-communicable diseases
settings are usually a consequence 
of weak health systems. The WHO 
global action plan for prevention 
and control of noncommunica-
ble diseases 2013-2020 provides 
many policy options to bridge the 
gaps in diagnosis and treatment 
of major noncommunicable dis-
eases, including asthma. Reducing 
premature mortality from chron-
ic respiratory diseases including 
asthma can contribute to the glob-
al target of reducing premature 
deaths due to major noncommu-
nicable diseases by 25% by 2025. 
KEY REFERENCES
1. Mallol J, Crane J, von Mutius E, 
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ISAAC Phase Three Study Group. 
The International Study of Asthma 
and Allergies in Childhood (ISAAC) 
Phase Three: a global synthe-
sis. Allergol Immunopathol (Madr). 
2013;41:73-85.
2. Global action plan for the preven-
tion and control of noncommuni-
cable disease 2013-2020 (WHA 
66.10). Geneva: World Health Or-
ganization; 2013.  http://apps.who.
int/gb/ebwha/pdf_files/WHA66/
A66_R10-en.pdf .
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s • The rapid increase in the prevalence of allergic diseases has 
driven Allergology as a medical specialty, and provided plentiful 
material for research
• The activities of the EAACI have been pivotal for prioritizing 
allergic diseases in the European political agenda
• The ‘Global Allergy and Asthma European Network (GA2LEN) 
developed into a EU flagship program bringing together an 
impressive number of European Institutions, resulting in 
hundreds of scientific publications and at least two ‘spin-off’ 
projects, MEDALL and PreDicta
• Following the proposal of the Polish EU Presidency in 2011, the 
European Council formally recognized the chronic respiratory 
diseases, including allergies, as major disease priorities
• The Written Declaration on the burden of allergic diseases 
achieved considerable interest and 178 Members of the 
European Parliament signed the Declaration
Allergy is a modern concept. De-
spite the occasional case reports, 
allergic diseases were rare just 
until a century ago. Since then 
and parallel to major changes in 
life-style, allergic diseases have 
become a major epidemic: in some 
countries, more than half of the 
population is already sensitized to 
allergens, while >30% suffer from 
one of more allergic diseases.
This rapid increase in prevalence 
has driven Allergology as a dis-
crete domain and medical special-
ty, and provided plentiful material 
for research, discovering the im-
munological basis and systemic 
nature of allergy and bringing to-
gether allergy with clinical immu-
nology. Allergy research remains 
a key need, for symptom control, 
understanding and prevention.
The study and practice of allergy 
started in Europe in the beginning 
of the 20th century, stemming 
from developed disciplines where 
allergic symptoms were more fre-
quent or more evident. Interesting-
ly, quite diverse schools developed 
in different countries, generating 
‘traditions’ with equally diverse 
prioritization and political direc-
tion in relation to allergy research 
and health services. Such diversity 
remains in Europe, where some 
nikolaos G. Papadopoulos  
University of Manchester 
Manchester, UK 
ALLERGIC DISEASES ON THE 
POLITICAL AGENDA2
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Allergic diseases on the political agenda
countries consider Allergology as 
a full medical specialty, while oth-
ers as a subspecialty; in some cas-
es there is no formal recognition, 
while integration with Immunology 
is equally diverse. Some countries, 
with the pioneering example of 
Finland, have established Nation-
al Programs in allergy and asthma, 
with tangible results.
The activities of the European 
Academy of Allergy and Clinical 
Immunology (EAACI) have been 
pivotal for prioritizing allergic 
diseases in the European political 
agenda. This has been achieved in 
several occasions, although not yet 
consistently. The support within 
the EU Framework Program (FP) 
6 of the ‘Global Allergy and Asth-
ma European Network (GA2LEN), 
was a notable success, following 
EAACI presence and lobbying in 
Brussels. GA2LEN developed into 
a EU flagship program and has 
achieved sustainability, bringing 
together an impressive number of 
European Institutions, resulting in 
hundreds of scientific publications 
and at least two ‘spin-off’ projects, 
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MEDALL and PreDicta, embedded 
in the FP7 framework (Figure 1).
Another milestone was the for-
mal recognition by the European 
Council of chronic respiratory dis-
eases, including allergies, as major 
disease priorities, after the pro-
posal of the Polish EU Presidency 
in 2011 (Figure 2).
Realising the need for consistent 
presence and involvement in EU 
and international political fora, 
EAACI has recently reinstated a 
Brussels Office. As the major part-
ner and backing force to a propos-
al by Members of the European 
Parliament (MEPs) for a Written 
Declaration on the burden of al-
lergic diseases, considerable inter-
est was generated and 178 MEPs 
signed the Declaration (Figure 3). 
Looking into the future, prioritiza-
tion of allergic diseases will come 
through partnerships with organi-
sations seeking similar goals in the 
field of health and research. It is 
clear that allergies share most of 
the major risk factors with other 
chronic non-communicable dis-
eases. A global approach, familiar 
to those who deal with allergy, 
needs to consider all chronic dis-
eases and the lifestyle chang-
es necessary to improve overall 
health of the population.
KEY REFERENCES
1. Calderon M, Demoly P, Gerth van 
Wijk R, Bousquet J, Sheikh A, Frew 
A et al EAACI: A European Decla-
ration on Immunotherapy. Design-
ing the future of allergen specific 
immunotherapy. Clin Transl Allergy 
2012;2:20.
2. Papadopoulos N, Agache I, Bavbek 
S, Bilo BM, Braido F, Cardona V et 
al. Research needs in allergy: an 
EAACI position paper, in collabo-
ration with EFA. Clin Transl Allergy 
2012;2:21.
3. Haahtela T, von Hertzen L, Mäkelä 
M, Hannuksela M; Allergy Pro-
gramme Working Group. Finnish 
Allergy Programme 2008-2018--
time to act and change the course. 
Allergy 2008;63:634-645.
4. Council of the European Union. 
Conclusion 16709/11.
5. European Parliament. Written 
Declaration 0022/2013 “Written 
declaration on recognising the bur-
den of allergic disease.
Figure 1 GA2LEN is both a result 
and a driver of the European research 
agenda in relation to allergies.
Figure 2 Prof. Nikolaos 
Papadopoulos addressing the Polish 
EU Presidency. The EU Council 
Conclusion suggested continuous 
investment in chronic respiratory 
diseases including allergies.
Figure 3 The EAACI Campaign supporting the Written Declaration on the 
burden of allergic diseases led to considerable appreciation among MEPs.
Allergic diseases on the political agenda
340
Global atlas oF allerGy
se
c
t
io
n
 h
 - 
To
w
ar
d
s 
a 
co
m
p
re
h
en
si
ve
 g
lo
b
al
 s
tr
at
eg
y 
fo
r 
th
e 
m
an
ag
em
en
t 
o
f a
lle
rg
ic
 d
is
ea
se
s • There is an unmet need to increase the accessibility to allergy 
and immunology services by those who need it delivered and by 
those who have the expertise to provide it
• No uniform policies and strategies for increasing accessibility to 
these services will be applicable in all circumstances
• Healthcare coverage and a source of usual care together, better 
satisfy this unmet need than either healthcare coverage or a 
source of usual care alone
• Patient centered medical homes with allergists serving as 
neighbor participants, coordinated care, timely referral to an 
allergist, and utilization of connect health options can improve 
and expand access to allergy and immunology care
The world is in the midst of an al-
lergy and asthma epidemic. This 
has resulted in an unmet need to 
increase in accessibility of aller-
gy services for those who need it 
delivered by those who have the 
expertise to provide it. Late di-
agnosis and wrong diagnosis of 
atopic disorders often results in 
increased morbidity, increased 
mortality, and increased resource 
utilization, all of which may re-
sult in suboptimal outcomes for 
patients, who suffer from these 
disorders and for institutions that 
are responsible for bearing much 
of the cost for managing these 
disorders. One of the fundamen-
tal questions that healthcare pro-
viders and institutions are pon-
dering is what strategies can be 
implemented to facilitate access 
to diagnosis and treatment of al-
lergic disorders in a timely manner 
that will decrease morbidity and 
mortality associated with allergic 
diseases, decrease resource utili-
zation associated with these dis-
eases, and improve quality of life 
for the individuals suffering from 
these allergic disorders.
VARIABILITY IN HEALTHCARE 
ACCESS AND COVERAGE
The highly affluent have few 
challenges accessing top quality 
Michael B. Foggs  
American College of Allergy, Asthma & Immunology 
Chicago, USA
POLICIES AND STRATEGIES TO 
FACILITATE ACCESS TO DIAGNOSIS 
AND TREATMENT FOR ALLERGIC 
DISEASES
3
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Policies and strategies to facilitate access to diagnosis and treatment for allergic diseases
healthcare. Access to asthma and 
allergy care will vary based on 
one’s socioeconomic status, based 
on the country within which one 
lives, and based on the availability 
of trained individuals to provide 
such care. The variable financial 
coverage for healthcare in dif-
ferent parts of the world make it 
clear that one size does not fit all, 
when it comes to healthcare de-
livery policies and strategies. Con-
sequently, no uniform policies and 
strategies will be universally appli-
cable to all people in all locations 
in the world. However, some basic 
principles may be universally ap-
plicable as strategies for improv-
ing access to healthcare in order 
to facilitate early diagnosis and 
early medical and environmental 
interventions for the treatment of 
allergic diseases. 
HEALTHCARE COVERAGE IS 
NOT EQUAL TO A SOURCE OF 
USUAL CARE
Several scholars have pointed out 
the importance of both health in-
surance, public or private, and a 
source of usual care as important 
facets of healthcare accessibili-
ty that are, in part, dependent on 
one’s socioeconomic status. There 
are obvious advantages of each. 
Consequently, any strategy to in-
crease access to allergy and im-
munology healthcare in order to 
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facilitate early diagnosis and early 
interventions should promote both 
healthcare coverage and a usual 
and consistent source of health-
care. Data indicate that, compared 
with patients having both health 
insurance and a regular source 
of care, insured patients without 
a usual source of care have high-
er rates of unmet medical needs 
and problems obtaining specialty 
care. The converse is very worthy 
of note. Having no health insur-
ance, but having a regular source 
of healthcare predicts a higher like-
lihood of being unable to get time-
ly urgent care, prescriptions, and 
needed health counseling. Getting 
specialty care has more to do with 
having a usual source of health-
care, (and with the characteristics 
of that usual source).
In many parts of the world, it has 
become clear that having public 
or private insurance does not nec-
essarily guarantee the ability to 
obtain needed allergy and immu-
nology services if there is no usual 
source of healthcare. 
Actual receipt of care is clearly 
more important than access to 
healthcare. Therefore, any policies 
and strategies to improve allergy 
and immunology healthcare servic-
es must ensure that these services 
are delivered and that non-aller-
gy specialists are educated about 
when such services are needed. 
The take home point is that health-
care coverage facilitates having a 
usual source of care, but it is the 
usual and regular source of care 
that can facilitate the provision of 
allergy and immunology services 
when they are needed.
WAYS TO IMPROVE AND 
ExPAND ACCESS
Despite their valiant efforts, 
healthcare researchers to date 
have not yet universally influenced 
policy makers to implement ideal 
strategies that will facilitate early 
diagnosis and early interventions 
for many allergic and immunologic 
diseases. Table 1 lists some useful 
approaches to improve access to 
allergy and immunology services. 
Table 2 itemizes some connected 
health options that could expand 
access to allergy and immunology 
care.
PATIENT CENTERED MEDICAL 
HOMES AND ACCOUNTABLE 
CARE ORGANIZATIONS
In the United States, there has 
been a grand movement towards 
patient centered medical homes 
(PCMH) governed by a primary 
care provider with allergists serv-
ing as neighbors to provide allergy 
and immunology services. Many 
PCMH operate under the auspic-
es of large medical agencies called 
accountable care organizations 
(ACOs). ACOs are healthcare de-
livery systems that implement 
a team approach to coordinat-
ed care and provide high-quality 
healthcare at lower cost for large 
populations.
KEY REFERENCES
1. Starfield Barbara. Access, primary 
care, and the medical home. Medi-
cal Care 2008;46:1015-1016.
2. Tillotson CJ, Wallace LS, Lesko SE, 
Angier H. The effect of health in-
surance and a usual source of care 
on a child’s receipt of health care. 
J Pediatr Health Care 2012;26:e25-
35.
3. Cook NL, Hicks LS, O’Malley J, 
Keegan T, Guadagnoli E, Landon 
BE. Access to specialty care and 
medical services in community 
health centers. Health Aff (Mill-
wood) 2007;26:1459-1468.
4. Shulkin DJ. The role of allergists 
in accountable care organizations. 
Ann Allergy, Asthma & Immunol 
2013;111:437-438.
5. Foggs MB, Fineman SM. Shifting 
Paradigms: “the times they are 
a-changin’.” Ann Allergy Asthma Im-
munol 2013;111:431-432.
6. Ein D, Foggs MB. Accountable Care 
Organizations and the Allergist: 
Challenges and Opportunities. J 
Allergy Clin Immunol Pract 2014;2: 
34-39.
Policies and strategies to facilitate access to diagnosis and treatment for allergic diseases
TABLE 1
Approaches to improve access to 
allergy and immunology services
1. Include allergists as neighbor 
participants to provide allergy 
and immunology services 
for complex cases in patient-
centered medical homes.
2. Use access to care “coordinators” 
to recruit allergy patients and 
to arrange and coordinate their 
allergy care.
3. Educate primary care providers 
about when referral to an allergist 
is necessary and encourage the 
concept of co-management of 
complex allergic diseases by 
these providers with allergists.
TABLE 2
Connected health options to expand 
access to allergy and immunology 
care
1. Utilize tele-health technology 
to allow allergists to provide 
selected allergy and immunology 
services virtually anywhere, 
including primary care provider 
offices, prisons, and remote areas.
2. Provide asthma screening and 
management via telemedicine 
video conferencing appointments.
3. Provide asthma and allergy 
monitoring and reporting via 
medical apps for smart phones 
and tablets.
4. Use web-based communication 
technology and portals to provide 
patients with automated alerts 
and important feedback after 
they have been diagnosed with 
asthma and allergic diseases.
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s • Reduce risk factors especially environmental pollutants, improve 
nutrition, physical activity, increase tolerance 
• Increase capacity building and improve health care delivery, 
increase accessibility and affordability to treatment 
• Raise the priority of allergic diseases at the level of governments, 
policy makers and the general public
• Establish and strengthen national policies and plans to promote 
interventions to treat and to reduce the burden of allergic 
diseases
• Support research that focuses on the increasing tolerance, early 
intervention and prevention and control of allergic diseases
A GLOBAL HEALTH PROBLEM
The prevalence of allergic dis-
eases is increasing worldwide, 
both in developed and developing 
countries, in parallel with other 
chronic noncommunicable dis-
eases (NCDs) and together com-
prise a major global public health 
challenge. The above include 
life-threatening anaphylaxis, food 
allergies, certain forms of asthma, 
rhinitis, conjunctivitis, angioede-
ma, urticaria, eczema, eosinophilic 
disorders, including eosinophilic 
esophagitis, and drug and insect 
allergies. This increase is espe-
cially problematic in children, who 
are bearing the greatest burden 
of this rising trend, which has oc-
curred over the last two decades. 
In addition, the complexity and se-
verity of allergic disorders, includ-
ing asthma, continues to increase, 
especially in children and young 
adults. 
This upsurge in the prevalence of 
allergies is seen as societies be-
come more affluent with change 
in life styles, dietary habits and 
better hygiene. Additional factors, 
like physical activity, nutrition, 
pollutants (both outdoor and in-
door air pollution), climate change 
reduced biodiversity, gene-envi-
ronmental interactions, epigenet-
Ruby Pawankar  
Nippon Medical School 
Tokyo, Japan
POLICIES AND STRATEGIES 
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Policies and strategies to reduce risk factors for allergic diseases
ic modulation and the microbiome 
all influence the immune system 
with chronic inflammation being 
the core underlying common fac-
tor (Figure 1). 
POLICIES AND STRATEGIES
The challenge to reduce the bur-
den of these diseases needs a 
multifactorial and multidiscipli-
nary approach involving several 
stakeholders including special-
ists, scientists, governments, pol-
icy makers, patients, the public, 
health care professionals as well 
as industry. 
Some simple interventions like 
physical exercise, a healthy diet 
and connection with the natural 
world and countryside are among 
potential ways to tackle this global 
health issue. Early interventional 
strategies through environmental 
control measures, evidence-based 
nutritional interventions that 
could potentially include pro-
biotics, prebiotics or Vitamin D 
etc, or interventions like aller-
gen immunotherapy that could 
strengthen immune tolerance are 
key elements for allergy preven-
tion (Figure 2). At the same time 
the complexity of allergic diseases 
and asthma as identified from new 
research highlights the need of a 
more stratified and personalized 
approach to treatment like the use 
of newly emerging biologics and 
biosimilars.
In addition, global epidemiological 
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Figure 1 Common risk factors for allergic diseases and noncommunicable diseases. (Reprinted from J Allergy Clin 
Immunol, 131/1, Prescott SL. Early-life environmental determinants of allergic diseases and the wider pandemic of inflammatory 
noncommunicable diseases, 23-30, Copyright 2013, with permission from Elsevier.)
Policies and strategies to reduce risk factors for allergic diseases
studies, increasing capacity build-
ing, increased global research on 
allergic diseases, especially on 
preventative strategies and early 
life interventions, collaborative 
action among academic organiza-
tions and inter-disciplinary cross 
talk, together with comprehen-
sive, well defined nationwide ac-
tion plans are needed. National ac-
tion plans should target to reduce 
the risk factors, especially envi-
ronmental pollution both outdoor 
and indoor, develop strategies to 
increase tolerance and improve 
nutrition and health. These action 
plans should be based on both 
scientific evidence and a broad 
clinical experience. The World 
Allergy Organization (WAO) has 
taken steps in this direction with 
the WAO White Book on Allergy, 
which provides a comprehensive 
view of the problem, includes re-
ports from its national member 
societies about the current state 
of allergy/immunology resources 
in their countries, and offers rec-
ommendations for action. 
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T cells
B cells
• SLIT
• SIT
NKT NK
DCs, macrophages,
monocytes, neutrophils,
mast cells, eosinophils, basophils
• Healthy diet
• Probiotics
• Physical exercise
• Connection
   with nature
Acquired immunity
• specific
• memory
• rearranged receptors
Innate immunity
• unspecific
• no conventional memory
• germline-encoded receptors
Figure 2 Induction of tolerance as a key strategy towards prevention. (From Haahtela T, Holgate S, Pawankar R,et al; WAO 
Special Committee on Climate Change and Biodiversity. The biodiversity hypothesis and allergic disease: world allergy position 
statement. World Allergy Organ J. 2013;6:3.; Reprinted with permission under the Creative Common Attribution License or 
equivalent)
Allergy 2012;2:21.
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• The first port of call for patients is usually the primary care or 
general practitioner (GP)
• GPs should determine whether the problem presented is allergic 
or non allergic in nature
• Most allergic disorders have the potential of being managed in 
primary care
• Stratification of severity should facilitate appropriate referral to 
specialists
• There is a need for further research into how care delivery can 
be optimised
The global population has crossed 
seven billion and increasing rap-
idly with just over 8.7 million 
physicians to meet their needs, 
with variability of less than 0.5 to 
64 physicians per 10,000 head of 
population. A conservative esti-
mate of the global prevalence of 
allergy in whatever form, is in the 
region of 20%: successive studies 
from differing locations all suggest 
that the prevalence is constantly 
increasing with little evidence of 
plateauing. The number of aller-
gists available to meet this chal-
lenge is not known but range be-
tween 1:17,000 (Czech Republic) 
and 1:50 million (Pakistan), with 
figure in the region of 1:1 million 
for countries such as France, Tur-
key and the UK. With the paucity 
of trained allergists in low- and 
middle-income countries, the im-
portance of the Primary Care Phy-
sician (PCP)/General Practitioner 
(GP) for diagnosis and manage-
ment of allergic diseases is greatly 
heightened (Figure 1). 
The first port of call for those who 
believe they are suffering from al-
lergy is usually the general practi-
tioner or family physician (Figure 
2).
The symptoms may be clear and 
straightforward, which facilitates 
THE ROLE OF PRIMARY 
CARE IN THE MANAGEMENT 
OF ALLERGIC DISEASES
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The role of primary care in the management of allergic diseases
ease of diagnosis and manage-
ment, but on the other hand may 
be more vague and poorly dif-
ferentiated. Furthermore, many 
syndromes have allergic (IgE 
mediated) as well as non allergic 
aetiology. Elucidating the patho-
physiology of the syndrome facil-
itates appropriate management, 
thus with regards to allergy man-
agement, the first critical step is 
to decide whether the presenting 
complaint(s) represents an allergic 
or a non allergic disorder.
In the primary care environment, 
many patients present with poor-
ly defined symptoms, but with a 
stated belief that their symptoms 
are due to an allergy; it is the task 
of the physician to determine 
whether there is any medical basis 
for these symptoms or whether 
the patients suffer from medically 
unexplained symptoms/somatisa-
tion. The actual prevalence of al-
lergic disease is considerably less 
than the number of patients who 
believe that they may have an al-
lergy. With regards to food allergy 
this difference amounts to some 
30% of people believing they have 
a food allergy with only in the re-
gion of 3% having this confirmed. 
Thus, with regards to allergy man-
agement the first critical step is 
to decide whether the presenting 
complaint represents an allergic 
disorder. The challenge facing 
GP’s is confounded further by var-
ious parties exploiting patient’s 
worries fears and anxieties, de-
ploying spurious investigations 
Dermot Ryan  
University of Edinburgh 
Edinburgh, UK
M. Osman Yusuf  
The Allergy & Asthma Institute 
Islamabad, Pakistan
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equipped with the skills to recog-
nise and manage straightforward 
allergy problems and to stratify 
them into those which may be 
safely and effectively managed in 
primary care, and also to identify 
those patients who need special-
ist assessment such as those who 
require challenge tests, allergen 
immunotherapy or management 
of anaphylaxis or food allergy.
The need and priorities for re-
search into best practices for diag-
nosis and management of allergy 
and asthma in primary care have 
been detailed by the International 
Primary Care Respiratory Group 
(IPCRG) in a global Delphi exercise 
and highlighted by the European 
Academy of Allergology & Clinical 
Immunology (EAACI) by the crea-
tion of a PC Interest Group.
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The role of primary care in the management of allergic diseases
Global Population 
7.2 bn
With allergy 
1.5 bn
Physicians  
~8.7 mn
Allergists?
Figure 1 A schematic of the global population, the numbers of allergy 
sufferers and the medically qualified staff to meet these needs.
Figure 2 Sources of Information for patients for diagnosis and management of 
allergic rhinitis. (Reproduced with permission from Scadding G, Richards D, Price M. 
Patient and physician perspectives on the impact and management of perennial and 
seasonal allergic rhinitis. Clin Otolaryngol Allied Sci 25:551–557, 2000.)
to confirm diagnosis and equally 
spurious remedies to rectify the 
identified problem.
The big challenge then is to pro-
vide a service to patients so that 
their needs may be met in the most 
appropriate and expeditious man-
ner. To facilitate this PCPs/GPs will 
need to be properly trained and 
GP
Magazine/newspaper articles
Pharmacist
Family
TV Advertisements
Friends
Press Advertisements
Others
None
No. of  subjects (%)
0 10 20 30 40
Seasonal Rhinitis
Perennial Rhinitis
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• The development of allergy expertise within the dietetic 
profession is in its infancy in many countries, while the allergy 
and asthma nurse are more and more acknowledged in their 
central role in patient care in Europe
• The cornerstone of the treatment of food allergy is the proper 
avoidance diet, eliminating only the demonstrated offending 
foods while keeping a balanced nutrition and avoiding 
unnecessary restrictions
• Over the past decades, allergy and asthma nurses have developed 
skills in allergy diagnostics, such as skin-prick testing, spirometry and 
food challenges. More recently, they were involved in clinical trials
• Allied Health professionals in allergy act as link and central point 
between patient, physician and other healthcare professionals 
to ensure that the patients fully understands their diagnosis and 
treatment and that communication between all parties is maintained
The EAACI has always support-
ed the involvement of Allied 
Health, and in 2010 the “EAACI 
Allied Health Interest Group” was 
formed. 
DIETITIANS
Within Europe, the development 
of allergy expertise within the di-
etetic profession is in its infancy 
in many countries. There clearly is 
a great need for more practically 
and scientifically trained allergy 
specialist dietitians.
The cornerstone of the treatment 
of food allergy is the avoidance 
diet. Therefore, dietary manage-
ment by the dietitian starts at 
the beginning of the diagnostic 
phase to ensure that an appropri-
ate avoidance diet is composed. 
In some countries dietitians are 
trained to take an allergy focused 
diet history with the aim to link 
symptoms to foods causing symp-
toms and to determine nutritional 
status and deficiencies (Figure 1). 
In other countries dietitians are 
only involved in the dietary man-
agement of avoidance diets. 
Avoidance diets can have a serious 
impact on quality of life and may 
lead to deficiencies and impaired 
growth due to extensive elimina-
tions (Figures 2 and 3). Nutritional 
THE ROLE OF ALLIED HEALTH 
IN THE MANAGEMENT OF 
ALLERGIC DISEASES
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The role of allied health in the management of allergic diseases
counselling by a dietitian is an es-
sential prerequisite to ensure op-
timal relief of symptoms, prevent 
inadvertent exposure, prevent un-
necessary avoidance, and support 
normal growth and development 
in children and to provide a healthy 
and balanced diet. In the dietary 
management plan, issues such as 
label reading, high-risk foods, eat-
ing out, school meals, day care, 
birthday parties, holidays, business 
and holiday travel and other social 
circumstances should also be ad-
dressed to limit the burden of the 
avoidance diet as much as possible. 
NURSES
The role of the allergy nurse is ex-
tremely important. Nurses are a 
valuable asset in chronic disease 
management, and with appro-
priate training and competency 
assessment can provide a high 
standard of care. Studies in asth-
ma and other chronic diseases 
have shown positive outcomes for 
patients and improvement in the 
management of a patient’s condi-
tion with the support of a clinical 
nurse specialist. Over the past 
decades, nurses have developed 
skills in allergy diagnostics, such 
Berber vlieg-Boerstra  
University of Amsterdam, 
The Netherlands
James Gardner  
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London, UK
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Royal Brompton & Harefield 
NHS Foundation Trust, 
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as skin prick testing, spirometry 
and food challenges. More recent-
ly competencies have been de-
veloped and are in-development 
in order to standardise care and 
practice. Nurse specialists in aller-
gy act as link and central point be-
tween patient, physician and other 
healthcare professionals to ensure 
that the patients fully understands 
their diagnosis and treatment and 
that communication between all 
parties is maintained. Many nur-
ses across the world are heavily 
involved into the implementation 
of treatment of allergic diseases. 
Increasingly they are also involved 
into allergy and asthma research. 
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The role of allied health in the management of allergic diseases
Questioning and 
linking
Symptom & atopic 
history
Food & simptoms
Foods eaten and 
avoided
Diet and Nutrition
Interpretation of 
History
Symptoms
Reported trigger 
foods
Cross-reactivity
Tests and 
Diagnosis
Test algorithm
Allergy and 
nutritional care 
plan
Management of 
Onward Referral
Dietary elimination 
diet
Commorbidities 
inflammation
↓ Specific nutrient intake
↓ Food intake
GH resistance
↓ IGF
Suppressed gonadotropin releasing hormone
Aversive
feeding
Reduced 
appetite
Modelling of parental 
dietary management 
strategies
Allergen 
avoidance may 
lead to nutrient 
deficiency
Parental 
anxiety leads to 
compensatory 
feeding
Poor growth
IL-6
TNF-α
Figure 3 Proposed model for the development of malnutrition in the allergic 
child. IGF, insulin-like growth factor, IL, interleukin; TNF, tumor necrosis factor. 
Figure 2 Summary of the most common food allergens excluded by the 
diet stratified by immunoglobulin (Ig)E, non-IgE and mixed IgE and non-IgE-
mediated food allergies. 
Figure 1 Allergy focused diet 
history tool for children and adults, 
currently under development by 
an Allied Health Task Force of 
the EAACI (red - wait and gather 
information; Amber  – get ready to go 
by linking that information together 
to formulate a potential diagnosis; 
Green - the way ahead is clear to 
undertake further relevant tests).
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• Patient organisations traditionally provide peer support, 
information and education for patients and their carers to cope 
with their disease
• Patient organisations revolutionised advocacy and consequently 
the political impact of patient organisations grows as they strive 
for action and change as indicated, with the inclusion of patient 
representatives in official bodies advising on health, care and 
research policies
• The concept of the patient as an ‘expert of experience’ has developed 
aiming to provide input into research and healthcare using his or her 
unique expertise – first-hand experience of a disease
• The EAACI Patient Organisation Committee offers a well-
organised and sustainable platform for communication and 
guidelines, enabling mutually beneficial interactions between 
patients and clinicians
Patient organisations traditional-
ly provide peer support, informa-
tion and education for patients to 
support their journey through the 
health care system. Patient organ-
isations aim to promote preven-
tion, and improve the quality of 
life for people affected by health 
conditions and for their families, 
through patient participation and 
empowerment.
The historic role for patient or-
ganisations in allergy, like in oth-
er diseases is to share patient’s 
experiences and nowadays this is 
still a crucial function. Today, this 
exchange is also expanded through 
partnerships to allergy health care 
professionals, like allergists, sec-
ond and primary care and support 
services like dieticians and policy 
makers at all levels. Within these 
partnerships, educational sessions 
are organised to help patients un-
derstand their condition and to 
empower them, so they can engage 
as a full partner in the societal ac-
tivities they want to activitely par-
ticipate in (Figures 1 and 2). 
Globalisation and information 
technology are a great oppor-
tunity and challenge for patient 
organisations. Patients increas-
ingly interact online and although 
many patient organisations still 
EAACI Patient Organisation Committee
THE ROLE OF PATIENT 
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The role of patient organisations in the management of allergic diseases
provide comprehensive and clear 
information on paper this is be-
ing supplemented with websites, 
videos, apps and social media. 
Here, patients and carers can get 
information and post their hopes 
for the near and distant future, 
while sharing their fears. Grasping 
this communication opportuni-
ty patient organisations revolu-
tionised advocacy (Figure 3) and 
consequently the political impact 
of patient organisations grows as 
they strive for action and change 
as indicated, with the inclusion of 
patient representatives in official 
bodies advising on health, care 
and research policies. 
Patient organisations are also 
playing an increasingly key role in 
funding national and internation-
al research. Public and patient in-
volvement in European projects 
has become a key requirement in 
decisions for funding. 
EAACI has installed a “Patient 
Organisation Committee” to en-
sure the input of allergic patients 
in their activities. This resulted 
for instance in the identification 
of patients’ needs for partnership 
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in clinical trials. Moreover, it led 
to a well-organised and sustaina-
ble platform for communication 
and guidelines, enabling mutually 
beneficial interactions between 
patients and clinicians. 
The concept of the patient as an 
‘expert of experience’ has devel-
oped. The expert patient aims to 
provide input into research and 
healthcare using his or her unique 
expertise – first-hand experience 
of a disease. Patient organisa-
tions have developed processes 
and methodologies to ensure that 
their members are fully prepared 
for involvement in areas like re-
search and clinical trials, while 
ensuring patients are available to 
participate wherever needed. We 
all need to work together as aller-
gy is a major public health prob-
lem!
KEY REFERENCES
1. de Wit MP, Berlo SE, Aanerud GJ, 
Aletaha D, Bijlsma JW, Croucher 
L et al. European League Against 
Rheumatism recommendations for 
the inclusion of patient represent-
atives in scientific projects. Ann 
Rheum Dis 2011;70:722-726.
2. Nahuis R, Boon WP. The impact 
of patient advocacy: the case of 
innovative breast cancer drug re-
imbursement. Sociol Health Illn 
2011;33:1-15.
3. Crevel RW, Baumert JL, Luccioli S, 
Baka A, Hattersley S, Hourihane JO 
et al. Translating reference doses 
into allergen management practice: 
Challenges for stakeholders. Food 
Chem Toxicol 2014;67C:277-287.
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Bavbek S, Bilo BM, Braido F, Cardo-
na V et al. Research needs in aller-
gy. Clin Transl Allergy 2012;2:21.
 
 
Avoiding triggers
Problems of intimacy
Self-esteem
Self-image
Tiredness
Irritability
Dealing with new environments indoors & out
Side-effects of medication & fear of them
Lack of information and education
?
QUALITY of LIFE
Stigma
Night awakenings
Always taking care
Always being prepared
Work/school absence
Choice of occupation
Doing exercise & enjoying sports
Managing & recovering exacerbations
Stigma
Cost of medication
Pregnancy
Fear of dying
Social isolation
Allergy as a chronic disease:
Figure 2 Adrenaline auto-injector training.
Figure 3 Patient representatives advocate for better allergy care at the EU 
Parliament.
Figure 1 Explaining to patients the concept of allergy as a chronic disease.
The role of patient organisations in the management of allergic diseases
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s • Allergic diseases are frequently under diagnosed and many 
patients tend to use unproven means to relieve their symptoms
• Pharmacists are often the first healthcare professionals seeing a 
person at risk of an allergic disease
• Many pharmacy-based studies demonstrated that pharmacists 
are able to identify, counsel and refer to a physician patients 
with previously undiagnosed chronic conditions, including type 
2 diabetes, cardiac diseases, COPD and uncontrolled asthma 
• Pharmacists can successfully provide screening for people at 
risk of allergic diseases and motivate at-risk subjects to consult a 
physician to receive an early and correct diagnosis and treatment
The symptoms of respiratory aller-
gies are distressing and negatively 
impact on the patient’s quality of 
life. However, many patients with 
respiratory allergy do not recog-
nise their condition and fail to con-
sult a physician. In a study of over 
9000 people in Europe, Bauchau 
et al. found that the prevalence of 
subjects with clinically confirm-
able allergic rhinitis ranged from 
17% in Italy to 29% in Belgium, 
with an overall prevalence of 23%. 
However, surprisingly, 45% of 
these subjects had not been previ-
ously diagnosed by a physician. 
Many patients tend to use unprov-
en means to relieve their symp-
toms, usually without a proper 
diagnosis. Given the availability of 
over-the-counter reliever medica-
tions for allergy symptoms, phar-
macists are often the first health-
care professionals seeing a person 
at risk of an allergic disease. Con-
sequently, they are in a good posi-
tion to identify patients at risk of 
allergy.
In this context, community phar-
macists can be considered a val-
uable component of the primary 
healthcare team, and can play a 
major role in the early identifica-
tion of the condition and guide pa-
tients to a correct diagnosis. Many 
THE ROLE OF PHARMACISTS 
IN MANAGING ALLERGIC 
DISEASES
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The role of pharmacists in managing allergic diseases
pharmacy-based studies demon-
strated that pharmacists are able 
to identify, counsel and refer to a 
physician, patients with previously 
undiagnosed conditions, including 
type 2 diabetes, cardiac diseases, 
COPD and uncontrolled asthma. 
Recently, the role of pharmacists 
in the early identification of cus-
tomers with respiratory allergy 
was evaluated in a pilot study, 
conducted by The European Fed-
eration of Allergy and Airways 
Diseases Patients Associations 
(EFA) in collaboration with the 
Pharmaceutical Group of the 
European Union, the Austrian 
Pharmacists Association and the 
Austrian Lungenunion. Between 
April and June 2013 (high allergy 
season in Austria), pharmacists in 
315 pharmacies in Vienna were 
invited to evaluate the allergy risk 
of customers with symptoms of 
respiratory allergy or asking for 
over-the-counter treatment for 
allergic symptoms, using the vali-
dated Allergy Screening Test ASF 
Questionnaire. A total of 2297 
questionnaires were completed. 
Of these 76% were at a moder-
ate-severe risk of allergy (Figure 
1), although only 35% of the total 
had been tested for allergy. Of the 
1486 participants that were nev-
er tested for allergy, 68% were at 
high risk of allergy (Figure 2) and 
57% “clearly felt unwell” because 
of their symptoms (Figure 3). 
Pharmacists advised 49% of their 
Maximin Liebl  
Pharmaceutical Group of the 
European Union, Bolzano, Italy
viktor Hafner  
Austrian Pharmasist 
Association, Austria
Otto Spranger  
Austrian Lungenunion, 
Wien, Austria
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customers to consult a physician 
for their allergic risk.
Screening and case detection are a 
part of prevention strategies that 
seek to identify and limit compli-
cations associated with chronic 
conditions. Screening for allergies 
may improve the quality of life of 
patients by promoting early diag-
nosis and appropriate treatment 
and therefore preventing exac-
erbations or life-threatening ep-
isodes due to severe anaphylaxis 
or severe asthma. Based on the 
results of the above pilot study, 
pharmacists can successfully pro-
vide screening for people at risk of 
allergic diseases. In addition, they 
can play a role in motivating at-
risk subjects to consult a physician 
to receive an early and correct di-
agnosis and treatment and overall 
improve patients’ quality of life.
KEY REFERENCES
1. Valovirta E, Ed. EFA Book on Res-
piratory Allergies 2011.
2. Bauchau V, Durham SR. Prevalence 
and rate of diagnosis of allergic rhi-
nitis in Europe. Eur Respir J 2004; 
24:758-764.
3. ARIA Guidelines for Pharmacists
4. Fathima M, Naik-Panvelkar P, Saini 
B, Armour CL. The role of commu-
nity pharmacists in screening and 
subsequent management of chron-
ic respiratory diseases: a systemat-
ic review. Pharmacy Practice 2013; 
11:228-245.
5. Fisher PE, Grabbe Y, Nolting H-D. 
Development and validation of a 
screening questionnaire for aller-
gy airway diseases (ASF Screening 
Questionnaire). Allergologie 2006; 
10:S393-402.
 
 
 
 
 
 
 
 
 
24%
76% No risk
Moderate-severe risk
Figure 1 Participants at a moderate-high risk of allergy (n. 2297) .
 
 
 
 
 
 
 
  
31.8%
68.2%
No risk
Moderate-severe risk
Figure 2 Risk of allergy in participants who never had allergy test (n.1486).
 
 
 
 
  
57.2%
42.8%
Moderate to severe feeling of 
illness
Almost no feeling of illness
Figure 3 Feeling of illness in participants who never had an allergy test (n. 
1486).
The role of pharmacists in managing allergic diseases
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s • Allergy affects around 25% of schoolchildren, most of them 
fortunately with mild symptoms
• Non severe cases can nevertheless have impaired school 
performance and quality of life
• Severe, potentially fatal, reactions can occur at school, especially 
in food allergic children
• Education of all school personnel on identification and prompt 
treatment of severe reactions is needed
• A safer school will be obtained through a collaborative network 
involving physicians, nurses, school personnel, and patients’ 
associations under the umbrella of an adequate legislation
Allergy is a systemic condition that 
can cause a variety of disorders, 
such as asthma, rhinoconjunc-
tivitis, dermatitis, urticaria and 
angioedema, digestive symptoms 
or anaphylaxis. The prevalence of 
allergic disorders is around 25% in 
schoolchildren in developed coun-
tries, and there is a rising prev-
alence in developing countries 
(Figure 1). Allergic children must 
face not only the same challenges 
in the school as their non-allergic 
peers but also added problems 
due to avoidance of triggers, their 
symptoms or to the treatment 
used for these. 
Exacerbations of asthma or atopic 
dermatitis, and sleep disturbances 
associated to them or to rhinitis 
lead to increased absenteeism. 
The sedating effects of drugs such 
as antihistamines or the lack of 
adequate night sleep repair can 
cause presenteeism, a state in 
which the child attends school, but 
is not able to focus and assimilate 
the learning objectives, causing a 
worse school performance. Aller-
gic children may seem “different” 
due to allergy signs, need to avoid 
allergy triggers or symptoms and 
thus become the target of teasing, 
bullying or isolation by peers, and 
teachers sometimes exclude aller-
Angel Mazon  
Children’s Hospital La Fe 
Valencia, Spain
THE ROLE OF SCHOOLS 
IN MANAGING ALLERGIC 
DISEASES 
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The role of schools in managing allergic diseases
Figure 1 One out of every four schoolchildren has an allergy. Which one is the 
allergic child in the photograph? A goal for the schools is to obtain a safe and 
friendly environment fully embracing the allergic child.
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Name:  
 
DOB:  
 
 
 
 
 
 
 
 
 
 
 
Emergency contact details: 
 
1) 
     ! 
 
2) 
     ! 
 
  
THIS CHILD HAS THE FOLLOWING ALLERGIES: 
 
 
 
 
 
Photo 
Keep your EpiPen device(s) at room temperature,  
do not refrigerate.  
For more information and to register for a free 
reminder alert service, go to www.epipen.co.uk 
 
Produced in conjunction with: 
 
       
 
!The British Society for Allergy & Clinical Immunology 
w w w .b sa c i . o rg         Approved Oct 2013 
 
Watch for signs of ANAPHYLAXIS 
(life-threatening allergic reaction): 
 
Mild-moderate allergic reaction: 
• Swollen lips, face or eyes 
• Itchy / tingling mouth 
• Hives or itchy skin rash 
 
ACTION: 
• Stay with the child, call for help if necessary 
• Give antihistamine:  
• Contact parent/carer 
 
• Abdominal pain or vomiting 
• Sudden change in behaviour 
(if vomited, can repeat dose) 
 
ChildÕs 
Weight:                   Kg 
AIRWAY:  Persistent cough, hoarse voice,  
difficulty swallowing, swollen tongue 
BREATHING:  Difficult or noisy breathing, 
 wheeze or persistent cough 
CONSCIOUSNESS:  Persistent dizziness / pale or floppy 
 suddenly sleepy, collapse, unconscious 
 
If ANY ONE of these signs are present: 
 
1. Lie child flat. If breathing is difficult, allow to sit 
2. Give EpiPen¨ or EpiPen¨ Junior 
3. Dial 999 for an ambulance* and say 
ANAPHYLAXIS (ÒANA-FIL-AX-ISÓ) 
If in doubt, give EpiPen¨ 
After giving Epipen: 
1. Stay with child, contact parent/carer 
2. Commence CPR if there are no signs of life 
3. If no improvement after 5 minutes, give a further EpiPen¨ 
or alternative adrenaline autoinjector device, if available 
 
 
 
*You can dial 999 from any phone, even if there is no credit left on a mobile. 
Medical observation in hospital is recommended after anaphylaxis. 
This is a medical document that can only be completed by the patient's treating health professional and cannot be 
altered without their permission.  
This plan has been prepared by: 
Hospital/Clinic:  
               !        Date: 
Additional instructions: 
 
 
 
 
 
Allergy Action Plan 
 
If wheezy, give 10 puffs salbutamol (blue inhaler) via spacer and dial 999
Figure 2 Example of a written personal plan with identification of the child, description of potential symptoms, and steps 
on how to proceed if these appear. (Accessed at www.bsaci.org/about/download-paediatric-allergy-action-plans?EID=26
293538&CID=4928446.)
The role of schools in managing allergic diseases
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gic children from certain activities 
for fear of a possible reaction. 
The most worrying problem for 
children with severe allergy is 
“life-threatening reactions”, as is 
the case for those with severe food 
allergy or severe asthma. For chil-
dren with food allergy data from 
registers of anaphylaxis report 
severe reactions, including death, 
occurring at school. Similarly, there 
are reports of death or life-threat-
ening symptoms from asthma in 
school premises or during school 
activities. 
Recommendations have thus 
been made to obtain a safer en-
vironment at schools. It is advo-
cated that every child with a se-
vere allergy is provided a written 
personal plan with instructions 
on how to act in the case of pre-
senting a reaction (Figure 2). An 
important pillar is the education 
of all school personnel (teachers, 
personnel working in canteens or 
playgrounds) regarding the pre-
vention, recognition and prompt 
treatment of severe allergic re-
actions. The preventive meas-
ures must be implemented also in 
school outings, sports, and leisure 
activities. 
To achieve this goal, the collabo-
ration between all stakeholders 
is warranted: healthcare profes-
sionals including school physicians 
and nurses, school personnel, par-
ents and families and associations 
of patients, all of them having an 
equal important role (Figure 3). 
There is an unmet need for legis-
lative changes to define the rights 
of the allergic children and also 
the duties and the protection of 
school personnel when acting ac-
cording to instructions provided 
by medical professionals. 
KEY REFERENCES
1. Asher MI, Montefort S, Björkstén 
B, Lai CKW, Strachan DP et al; 
and the ISAAC Phase Three Study 
Group. Worldwide time trends in 
the prevalence of symptoms of 
asthma, allergic rhinoconjunctivi-
tis, and eczema in childhood: ISAAC 
Phases One and Three repeat mul-
ticountry cross-sectional surveys. 
Lancet 2006;368:733-743.
2. Bock SA, Munoz-Forlang A, Samp-
son HA. Further fatalities caused 
by anaphylactic reactions to food, 
2001-2006. J Allergy Clin Immunol 
2006;119:1016-1018.
3. Murphy KR, Hopp RJ, Kittelson EB, 
Hansen G, Windle ML, Walburn 
JN. Life-threatening asthma and 
anaphylaxis in schools: a treat-
ment model for school-based pro-
grams. Ann Allergy Asthma Immunol 
2006;96:398–405. 
4. Muraro A, Clark A, Beyer K, Borre-
go LM, Borres M, Lødrup Carlsen K 
et al. The management of the aller-
gic child at school: EAACI/GA2LEN 
Task Force on the allergic child at 
school. Allergy 2010;65:681-689. 
Specialist
General Policy
National/EU
Patients
Associations
Risk child
at school
School nurse
and physician
Parents/
Guardians
School attitude
preparedness
Figure 3 A safe school environment for allergic children requires the joint action of all stakeholders, with specific roles 
that include raising awareness, education, prevention, treatment and legislation. 
The role of schools in managing allergic diseases
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• Most patient organizations work on the assumption that allergy 
sufferers are self-empowering and take responsibility for 
themselves
• Allergy sufferers and their families should have access to 
relevant, up-to-date and sound knowledge at the time and in the 
complexity, depth and form they need 
• Patients shall have the skills, life circumstances and support they 
need to live their lives as symptom-free as possible and with a 
consistently high quality of life
• Personalized measures are key for successful prevention and 
therapy of allergies
• The ideal mixture of mass media communication (online and 
print) and individual advising on a one-to-one or one-to-few 
basis together with online-based self-monitoring tools and 
personalized website surfaces can support patient-centered 
measures against the allergy epidemic
ALLERGY PATIENT 
ORGANIZATIONS
Patient organizations are most-
ly non-profit organizations that 
represent centre of excellence 
in the allergy field from a patient 
perspective. They seek visible 
public presence for the sake of 
creating awareness and carry al-
lergy-prevention, better patient 
care, quality of life-related mes-
sages to the population. Patient 
organizations are independent 
contact points for allergy sufferers 
and carers, but also for other in-
terested groups such as the media, 
companies, training centres, poli-
tics, authorities and associations. 
The services they offer range from 
advising individuals and training 
courses, self help groups through 
to prevention projects and cam-
paigns for the population at large. 
These offerings are often made 
possible by widespread national 
and international networks and 
close cooperations with leading 
experts and professional bodies in 
the relevant spheres.
AIMS
Patient organizations want aller-
gy sufferers and their families to 
have access to relevant, up-to-
date and sound knowledge at the 
time and in the complexity, depth 
Georg Schäppi  
Christine Kühne-Center for Allergy Research and Education 
Davos, Switzerland
COMPREHENSIVE ALLERGY 
MANAGEMENT PLAN. TOWARDS 
A PATIENT-CENTERED ATTITUDE 
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Comprehensive allergy management plan. Towards a patient-centered attitude 
and form they need it in their re-
spective situation. Sufferers shall 
have the skills, life circumstances 
and support they need to live their 
lives as symptom-free as possible 
and with a consistently high quali-
ty of life. The stakeholders in soci-
ety shall take on their share of re-
sponsibility for the health-related 
living conditions and quality of life 
of all humans.
SERVICES
To achieve these aims, patient or-
ganizations offer sufferers, carers 
and other groups very well estab-
lished services:
• high-quality documentation, 
publications and information
• expert advice
• interdisciplinary training cours-
es
• prevention and information 
campaigns on current topics
Therewith, organizations support 
the health and quality of life of al-
lergy sufferers, their families and 
potential sufferers and promote 
preventive action by a wide diver-
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sity of players. They campaign for 
high-quality, broadly accessible 
services: primary prevention with 
the focus on living conditions and 
lifestyle (Figure 1a); secondary 
prevention by improving skills 
(Figure 1b). Aided by modern qual-
ity development, they strive for 
best professional practice.
TOWARDS A PATIENT-
CENTERED ATTITUDE
In a global perspective, the num-
ber of sufferers steadily increas-
es. The diversity of known allergic 
diseases and allergens increases. 
At the same time, there is growing 
evidence that personalized meas-
ures are key for successful pre-
vention and therapy of allergies. 
In parallel to this, it is increasingly 
difficult to raise funds for patient 
organization activities. Today, al-
lergy patient organizations are 
heavily challenged by these facts. 
By choosing the ideal mixture of 
mass media communication (on-
line and print) and individual advis-
ing on a one-to-one or one-to-few 
basis (Figure 1c), this challenge 
has to be and will be mastered ef-
ficiently. In addition, online-based 
self-monitoring tools and person-
alized website surfaces can sup-
port patient-centered measures 
against the allergy epidemic.
KEY REFERENCES
1. Mohammad Y, Fink-Wagner AH, 
Nonikov D. Assets and needs of 
respiratory patient organizations: 
differences between developed 
and developing countries. J Thorac 
Dis 2013;5:914-918.
2. Worth A, Regent L, Levy M, Led-
ford C, East M, Sheikh A.Living 
with severe allergy: an Anaphylaxis 
Campaign national survey of young 
people. Clin Transl Allergy 2013;3:2.
3. Noerreslet M, Jemec GB, Traulsen 
JM. Involuntary autonomy: pa-
tients' perceptions of physicians, 
conventional medicines and risks 
in the management of atopic der-
matitis. Soc Sci Med 2009;69:1409-
1415. 
4. Rich M, Taylor SA, Chalfen R.Illness 
as a social construct: understand-
ing what asthma means to the pa-
tient to better treat the disease. Jt 
Comm J Qual Improv 2000;26:244-
253.
5. Licskai C, Sands TW, Ferrone M.De-
velopment and pilot testing of a 
mobile health solution for asthma 
self-management: asthma action 
plan smartphone application pilot 
study. Can Respir J 2013;20:301-
306.
a b
c
Figure 1 a - Implementing a healthy lifestyle as part of primary prevention; b - Developing the necessary skills to cope 
with the allergic disease; c - Expert individual advising on a one-to-one basis.
Comprehensive allergy management plan. Towards a patient-centered attitude 
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• Active collaboration between all national and international 
health workers including doctors, allied health, pharmacists, 
political and health authorities in addition to patient associations 
is needed to tackle the allergy epidemic
• Teachers and caregivers should be informed and trained in 
attitudes and behaviors to deal with allergy, both in prevention 
therapeutics, and should be actively involved in reducing 
exposure to tobacco smoke
• The undergraduate and postgraduate training of all healthcare 
professionals should improve their knowledge on allergic 
diseases
• Education, awareness and mobilization campaigns leaded by 
scientific societies will raise the standards for allergic diseases 
early diagnosis and efficient management 
Allergic diseases are a real non-in-
fectious epidemic of the last cen-
tury. The incidence of these dis-
eases increase continuously every 
year, affecting millions of human 
beings of all ages, from infancy 
to old age. Allergic diseases are 
chronic conditions that affect the 
quality of life of allergy sufferers 
physically, emotionally and social-
ly (Table 1). Sometimes the disease 
manifests itself in an acute form 
(asthma attack or anaphylactic re-
actions), which can lead to death.
These diseases carry significant 
health costs in different ways: 
direct and indirect, tangible and 
intangible. To achieve prevention, 
diagnosis and proper treatment of 
allergic diseases, it is essential that 
there is an active collaboration be-
tween all national and internation-
al health workers including doc-
tors, allied health, pharmacists, 
political and health authorities in 
addition to patient associations, 
who play an essential role. 
A significant proportion of indi-
viduals with allergy are under-
diagnosed, undertreated, and 
dissatisfied with their treatment. 
Addressing these shortcomings 
may help us to optimize allergy 
care and ultimately the patient's 
quality of life. 
Tomás Chivato Pérez  
University CEU San Pablo 
Madrid, Spain
SOCIAL MOBILIZATION 
FOR MANAGEMENT OF 
ALLERGIC DISEASES
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Social mobilization for management of allergic diseases
There is still a general lack of 
knowledge about major allergic 
diseases. Undoubtedly, there are 
clearly some aspects that can be 
improved, as described in table 2.
In nurseries, colleges and univer-
sities around the world billions 
of children and young people are 
educated. Many of these students 
are suffering from allergic diseas-
es. Teachers and caregivers should 
be informed and trained in atti-
tudes and behaviors to deal with 
allergy, both in prevention (e.g. 
food allergies), and in therapeu-
tics (e.g. asthma attacks induced 
by exercise). The consumption of 
tobacco products is still a major, 
unresolved problem in health ed-
ucation.
The training of all healthcare pro-
fessionals should improve their 
knowledge on allergic diseas-
es. Very few medical or nursing 
schools have Allergology as an 
undergraduate subject. Currently, 
there has been increased partici-
pation of teachers in considering 
Allergology as a relevant subject in 
the university. Similarly, it is very 
important to ensure that the spe-
cialty of Allergy is recognized in all 
countries within the postgraduate 
specialist training. GPs and pedia-
360
Global atlas oF allerGy
se
c
t
io
n
 h
 - 
To
w
ar
d
s 
a 
co
m
p
re
h
en
si
ve
 g
lo
b
al
 s
tr
at
eg
y 
fo
r 
th
e 
m
an
ag
em
en
t 
o
f a
lle
rg
ic
 d
is
ea
se
s
Social mobilization for management of allergic diseases
TABLE 1
Percentage of Patients (n=6236)a Experiencing Restrictions on Daily Life as a Result of Their Allergy
None of 
the Time
A Little of 
the Time
Some of 
the Time
Most of 
the Time
All the 
Time
Don’t Know/ 
No Answer
Patients suffer fromb
Poor concentration 53% 21% 17% 6% 2% 0%
Tiredness 36% 22% 23% 12% 6% 0%
Trouble sleeping  
through the night
47% 20% 20% 9% 4% 0%
Not at All A Little Somewhat Very Extremely Not
Restricted Restricted Restricted Restricted Restricted Relevant
Restrictions inc
Carrying heavy loads 51% 19% 13% 6% 3% 8%
Exercising 29% 24% 18% 9% 4% 15%
Gardening 32% 15% 13% 9% 7% 24%
Housework 54% 20% 11% 5% 2% 8%
Running up stairs 42% 21% 14% 8% 4% 11%
Spending time outdoors or in countryside 36% 21% 17% 12% 9% 5%
Visiting friends and relatives 62% 19% 11% 4% 2% 2%
Playing with children 56% 15% 7% 3% 1% 18%
Disagree 
Completely
Disagree Agree
Agree 
Completely
Not Rele-
vant
Don’t Know/ 
No Answer
Agreement with the followingd
Feel ill 38% 39% 17% 3% 3% 0%
Sometimes feel frustrated or angry be-
cause of the condition
29% 28% 31% 9% 3% 0%
Sometimes feel embarrassed about symp-
toms (runny nose, watery eyes)
31% 30% 27% 8% 4% 0%
Sometimes do not feel very attractive 
because of the condition
29% 28% 30% 9% 4% 0%
Convinced people are bothered by the 
attacks
36% 40% 13% 3% 8% 0%
Condition has negative impact on sex life 41% 36% 11% 2% 10% 0%
Condition affects ability to exercise 23% 31% 29% 7% 10% 0%
Condition makes it hard to be spontaneous 36% 38% 18% 3% 5% 0%
Do not mind taking medication when 
around other people
7% 12% 39% 25% 17% 0%
a Patients completing the second self-reporting questionnaire. b Question: Thinking about the last time you suffered from allergy, 
how much of the time did you experience the following symptoms? c Question: Please indicate for each of the activities listed 
below how restricted you felt by your allergy the last time you experienced symptoms. d Question: Please indicate for each of the 
statements below to what extent you agree or disagree. Reproduced with permission from Chivato T, Valovirta E, Dahl R,et al. 
Allergy, living and learning: diagnosis and treatment of allergic respiratory diseases in Europe. J Investig Allergol Clin Immunol. 
2012;22:168-79.
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tricians should be trained properly 
in order to perform early diagno-
sis and correct long-term manage-
ment of allergic diseases.
Although conventional mass me-
dia (TV, radio, press) and the Inter-
net pay increasingly more atten-
tion to allergic diseases, it is still 
the responsibility of all stakehold-
ers to ensure that adequate infor-
mation is available to all patients, 
families and caregivers.
Scientific societies are leading 
several education, awareness and 
mobilization campaigns. An exam-
ple of such kinds of initiative cam-
paigns are the immunotherapy, 
food allergy and allergy awareness 
carried out by the EAACI.
Being allergic diseases a major 
problem, awareness initiatives 
should be treated with equal im-
portance. For example, Global 
Alliance for Respiratory Diseases 
(GARD) activities are very impor-
tant as they pursue awareness 
through different competent au-
thorities from the World Health 
Organisation and Ministry of 
Health of countries.
Only by working together, can we 
make allergy and allergic diseases 
better known and in this way aller-
gic patients will receive the best 
care they deserve.
KEY REFERENCES
1. http://www.eaaci.org/eaacimedia/
campaigns.html
2. http://www.who.int/respiratory/
gard
3. Chivato T, Valovirta E, Dahl R, de 
Monchy J, Bloch Thomsen A, Palko-
nen S et al. Allergy, living and learn-
ing: diagnosis and treatment of 
allergic respiratory diseases in Eu-
rope. J Investig Allergol Clin Immunol 
2012;22:168-179.
4. Potter P , Warner J, Pawankar R, 
Kaliner M, Del Giacco S, Rosen-
wasser L; on behalf of the WAO 
Specialty and Training Council. 
Recommendations for Competen-
cy in Allergy Training for Under-
graduates Qualifying as Medical 
Practitioners: A Position Paper of 
the World Allergy Organization. J 
Investig Allergol Clin Immunol 2010; 
20:179-184.
5. Papadopoulos NG, Agache I, 
Bacbek S, Bilo BM, Braido F, Car-
dona V et al. Research needs in al-
lergy: an EAACI position paper, in 
collaboration with EFA. Clin Transl 
Allergy 2012;2:21.
Social mobilization for management of allergic diseases
TABLE 2
Key steps in improving management of allergic diseases
• Improved undergraduate and postgraduate training (including related spe-
cialities such as primary care, pediatrics, pneumology, ENT, dermatology) in 
allergology and clinical immunology
• Education, awareness and mobilization campaigns organized by the leading 
scientific societies in the field
• Joining forces into International Alliances such as iCAAL and GARD.  In-
volvement of competent authorities from the World Health Organisation to 
Ministry of Health in different countries
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s • In children, the health is best served by giving similar 
recommendations to every child, that is a balanced diet, physical 
activity and a close connection with the natural environment, 
whether he/she is allergic or not 
• Anti-smoking advice and legislation stopping smoking should be 
implemented since exposure to environmental tobacco smoke is 
still a major problem. Indoor and ambient air pollution should be 
tackled accordingly
• Modern, urbanized populations have lost factors balancing 
immune tolerance. The challenge is to gain the balance again 
and strengthen immune tolerance. The population should 
be encouraged to adopt sensible behaviors, getting rid of 
unnecessary diets, and consume diets that promote general 
health and immune balance
• Allergy should be addressed at a societal level: all healthcare 
providers, caregivers, kindergardens and schools personnel 
need to be provided with straightforward instructions to take 
care of allergic patients with mild symptoms
Strategies and recommendations 
for prevention of allergies have 
typically been quite restrictive 
based on relatively poor scientif-
ic evidence. New data imply that 
most children do not benefit in 
longer-term from avoidance di-
ets or by taking extra precautions 
to avoid environmental allergen 
exposure. In clinical practice, the 
avoidance of inhalant allergens 
like pollens, animal danders or 
mites is difficult, if not impossible. 
For example, mite allergens can be 
reduced in homes, but they can-
not be eradicated, and avoidance 
strategies to control mite allergies 
have been disappointing. 
In children, the health is best 
served by giving similar recom-
mendations to every child, that is 
a balanced diet, physical activity 
and a close connection with the 
natural environment, whether he/
she is allergic or not. This does not 
mean that the environment should 
not be improved in many ways. An-
ti-smoking advice and legislation 
stopping smoking should be imple-
mented since exposure of children 
to environmental tobacco smoke 
is still a major problem. Indoor 
and ambient air pollution should 
be tackled accordingly. Likewise, 
avoidance of potentially severe 
Tari Haahtela  
Helsinki University Hospital 
Helsinki, Finland
BEST BUYS FOR ALLERGY 
PREVENTION AND 
CONTROL
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Best buys for allergy prevention and control
symptom-causing agents is still, 
and should stay, in the armamen-
tarium of a competent allergist. 
It is becoming apparent, however, 
that modern, urbanized popula-
tions have lost factors balancing 
immune tolerance. Population 
growth, rapid urbanization, de-
struction of natural (green) are-
as, deforestation, and changes in 
nutrition and household water 
all contribute to reduced biodi-
versity. This may reduce interac-
tion between environmental and 
human microbiota, and immune 
dysfunction, impaired tolerance, 
and clinical disease may follow 
(Figure 1). The challenge is to gain 
the balance again and strengthen 
immune tolerance. A paradigm 
shift is taking place and affects 
especially prevention and prac-
tical guidance and education of 
patients. Everything people eat, 
drink, touch or breathe modulates 
their skin, gut and airway microbi-
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ome and keeps immune processes 
alert. Tolerance is an active pro-
cess, trained and tested by the en-
vironment on line.
The numbers of allergic individu-
als are so high that not all of them 
can receive specialist medical 
care. It is neither in society´s nor 
the patients’ interests to provide 
specialist treatment to large num-
bers of people with mild symp-
toms that can hardly be diagnosed 
as a disease. In the praxis of al-
lergy prevention and treatment 
over treatment is not uncommon. 
General practitioners and nurs-
es in primary care, in health care 
centers, well-baby clinics, and 
schools need to be provided with 
straightforward instructions to 
take care of patients with mild 
symptoms. The population should 
be encouraged to adopt sensible 
behaviors, getting rid of unneces-
sary diets, and consume diets that 
promote general health and im-
mune balance. 
The Finnish recommendations, 
along with the National Allergy 
Programme 2008-2018, are list-
ed as an example in Table 1. The 
messages have been well received 
both by health care profession-
als and allergic patients. The first 
experiences of the new mode are 
encouraging. 
Population explosion
(urbanization, change of life-style and nutrition)
Biodiversity loss
(both on macro- and microlevel)
Poor micorbiome, dysbiosis
(skin, gut, airways)
Immune dysfunction
(weak innate immunity)
Inflammatory 
dysresponse
(danger vs. nondanger,  
self vs nonself)
Clinical 
symptoms,
diseases
Biodiversity hypothesis
Figure 1 Population explosion has caused major changes in the interaction of humans with environment. Biodiversity 
loss both at macro- and micro-level is a major threat to humankind.
Best buys for allergy prevention and control
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TABLE 1
Practical advice to build-up and improve tolerance 
Primary prevention
• Support breastfeeding, solid foods from 4–6 months.
• Do not avoid environmental exposure unnecessarily (e.g. foods, pets).
• Strengthen immunity by increasing connection to natural environments.
• Strengthen immunity by regular physical exercise.
• Strengthen immunity by healthy diet (e.g. traditional Mediterranean or Baltic type).
• Use antibiotics only for true need, majority of microbes build-up healthy immune function.
• Probiotic bacteria in fermented food or other preparations may strengthen immune function.
• Do not smoke (e.g. smoking parents increase asthma risk in children).
Secondary and tertiary prevention
• Regular physical exercise is anti-inflammatory.
• Healthy diet is anti-inflammatory, (e.g. traditional Mediterranean or Baltic diet improves asthma control).
• Probiotic bacteria in fermented food or other preparations may be anti-inflammatory.
• Allergen specific immunotherapy:
  allergens as is (foods)
  sublingual tablets or drops (pollens, mites)
  subcutaneous injections (e.g. insect stings)
• Control early respiratory/skin inflammation with anti-inflammatory medication.
• Find treatment for long-term control.
• Do not smoke (e.g. asthma and allergy drugs do not have full effects in smokers).
KEY REFERENCES
1. Johansson SGO, Haahtela T (Eds.). 
Prevention of allergy and allergic 
asthma. World Allergy Organiza-
tion Project Report and Guidelines. 
Clinical Immunology and Allergy 
2004; 84:1-211.
2. Lødrup Carlsen KC, Roll S, Carls-
en KH, Mowinckel P, Wijga AH, 
Brunekreef B et al; GALEN WP 
1.5 ‘Birth Cohorts’ working group. 
Does pet ownership in infancy lead 
to asthma or allergy at school age? 
Pooled analysis of individual partic-
ipant data from 11 European birth 
cohorts. PLoS One 2012;7:e43214.
3. Wahn U. Considering 25 years 
of research on allergy preven-
tion--have we let ourselves down? 
Pediatr Allergy Immunol 2013; 
24:308-10.
4. Pelkonen AS, Kuitunen M, Dunder 
T, Reijonen T, Valovirta E, Mäkelä 
MJ; Finnish Allergy Programme. 
Allergy in children: practical rec-
ommendations of the Finnish Al-
lergy Programme 2008-2018 for 
prevention, diagnosis, and treat-
ment. Pediatr Allergy Immunol 2012; 
23:103-116.
5. Haahtela T, Holgate ST, Pawankar 
R, Akdis CA, Benjaponpitak S, Cara-
ballo L et al. WAO Special Commit-
tee on Climate Change and Biodi-
versity. The biodiversity hypothesis 
and allergic disease: world allergy 
organization position statement. 
World Allergy Organ J 2013;6:3.
6. Haahtela T, von Hertzen L, Mäkelä 
M, Hannuksela M; Allergy Pro-
gramme Working Group. Finnish 
Allergy Programme 2008-2018-- 
time to act and change the course. 
Allergy 2008;63:634-645. 
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• Implementation of any disease prevention or control programme 
always represents a great challenge
• Planning clear and simple objectives is crucial for success
• Involvement of all stakeholders is a good strategy
• Using innovative and successful communication tools to reach 
the target populations will help with the implementation
Allergic diseases are an epidemic 
in the modern society; therefore, 
there is an urgent need to coun-
teract their increase. As in other 
non-communicable chronic dis-
eases, strategies on prevention 
and control are being developed, 
focusing on promoting healthy 
lifestyles and early diagnosis and 
treatment. Nevertheless, imple-
mentation of these strategies re-
mains a challenge.
Barriers to implementation of pre-
vention and control programmes 
seem to be similar for many dis-
eases (Figure 1). Therefore, in 
order to improve dissemination 
and subsequent application, these 
should comply, among others, with 
the following characteristics: 
• Identification of risk factors and 
possible intervention measures
• Identify target populations
• Clear and simple objectives
• Realistic aims
• Design positive communication 
messages
• Measurable changes in appro-
priate indicators
• Involvement of all affected 
stakeholders (patients, society, 
healthcare system, health care 
professionals)
• Manageable costs
• Positive reinforcement through 
victòria Cardona  
Hospital Universitari Vall d’Hebron 
Barcelona, Spain
DEALING WITH THE 
IMPLEMENTATION GAP FOR ALLERGY 
PREVENTION AND CONTROL
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Dealing with the implementation gap for allergy prevention and control
communication of achieve-
ments
• Use of highly accepted commu-
nication channels (TV, internet, 
smartphones, social media)
As examples of such strategies, 
there are two programmes which 
have been developed, are imple-
mented and are achieving remark-
able success. In the field of allergy, 
the Finnish Allergy Programme 
2008-2018, lead by Dr. Tari Haate-
la, is achieving a reduction of the 
allergy burden with relatively 
simple means. This 10-year imple-
mentation programme is aimed to 
reduce burden of allergies both at 
the individual and societal levels 
(Figure 2). This is done by increas-
ing both immunological and psy-
chological tolerance and changing 
attitudes to support health in-
stead of over treatment of com-
mon and mild allergy symptoms. 
Severe forms of allergy are in spe-
cial focus, e.g. asthma attacks are 
prevented proactively by improv-
ing disease control with the help 
of guided self-management.
The second example is in the area 
of cardiovascular disease. Re-
search has proven that lifelong-ac-
quired behavior is unlikely to 
change, and therefore acquisition 
of healthy behaviors should begin 
as early in life as possible. A series 
of initiatives are being implement-
ed under the lead of the renowned 
cardiologist and researcher, Dr 
Valentin Fuster. An example of in-
novative tools to reach the target 
audience is the use a school-based 
program aiming at promoting 
health through a multilevel in-
tervention supported by Sesame 
Street materials and educational 
background. 
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s •Cultural beliefs
• Insufficient 
awareness
•Priorities
•Costs
• Insufficient coverage
• Suboptimal networks
•Costs 
•Priorities
•Scarce 
understanding of 
condition
•Suboptimal 
empowerment
•Costs
• Lack of knowledge
•Cultural beliefs
•Time constraints
•Priorities
Professionals Patients
SocietyHealth-care systems
Figure 1 Potential barriers for the implementation of disease prevention and control programmes.
Dealing with the implementation gap for allergy prevention and control
Figure 2 The key messages of the 
Finnish Allergy Programme 2008-
2018. (Reproduced with permission 
from Haahtela T, Valovirta E, Kauppi 
P, et al; Finnish Allergy Programme 
Group. The Finnish Allergy Programme 
2008-2018 - scientific rationale and 
practical implementation. Asia Pac 
Allergy.2012;2:275-279.)
KEY REFERENCES
1. Global Alliance against chronic res-
piratory diseases. http://www.who.
int/gard/publications/en/
2. Haahtela T, von Hertzen L, Mäkelä 
M, Hannuksela M; Allergy Pro-
gramme Working Group. Finnish 
Allergy Programme 2008-2018--
time to act and change the course.
Allergy 2008;63:634-645.
3. Haahtela T, Valovirta E, Kauppi P, 
Tommila E, Saarinen K, von Hertzen 
L, Mäkelä MJ; Finnish Allergy Pro-
gramme Group. The Finnish Allergy 
Programme 2008-2018 - scientific 
rationale and practical implemen-
tation. Asia Pac Allergy 2012;2:275-
279.
4. Peñalvo JL, Céspedes J, Fuster 
V. Sesame street: changing car-
diovascular risks for a lifetime. 
Semin Thorac Cardiovasc Surg 2012; 
24:238-240. 
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• Several measures have been advocated for primary, secondary 
and tertiary prevention of allergic diseases
• More funding for research for allergy prevention is needed 
• Support from policy makers for all levels of allergy prevention is 
warranted 
• Systematic health community plans will improve health care at 
all levels for secondary and tertiary prevention of allergic disease
The worldwide increase in allergic 
sensitisation and allergic diseases 
in recent decades may represent 
a prize we pay for improved liv-
ing-conditions, higher educational 
levels and modernised life style. 
Removing man from soil may il-
lustrate how human defence to-
wards environment shifted from 
protection towards harmful mi-
crobes to non-tolerance of harm-
less proteins. Our immune system 
must learn to live with new envi-
ronments including reduced con-
tact with microbial diversity, in-
creased exposures to xenobiotics 
and other harmful environmental 
products, sedentary life styles 
and altered and altered diets, or 
we must take steps to change our 
modern life style. Reduced epithe-
lial barriers, identified in asthma 
and atopic eczema, may enhance 
penetration of untoward environ-
mental agents to an un-balanced 
immune system. 
Primary prevention aims to pre-
vent allergic sensitisation and 
allergic disease, secondary pre-
vention to prevent further allergic 
diseases developing. Tertiary pre-
vention targets the person with 
allergic disease to obtain optimal 
disease control and reduce risk of 
disease deterioration. 
GENERATING RESOURCES 
FOR ALLERGY PREVENTION 
AND CONTROL
14
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Generating resources for allergy prevention and control
Recent decades have shown that 
development of allergic diseases 
starts early in life, even around 
conception or in pregnancy, and 
continue throughout life, exem-
plified by the direct association 
between tobacco smoke exposure 
and disease, and by the demon-
stration of methylation and his-
tone modification of gene ex-
pression by exposure to tobacco 
products. The role of nutritional 
factors in disease development, 
such as vitamin D and anti-oxi-
dants is unclear. 
Epidemiological evidence suggest 
that delayed food introduction in 
infancy may promote allergy rath-
er than tolerance. Thus, early oral 
introduction of food proteins in in-
fancy may provide a natural prima-
ry preventing strategy, although 
documentation of such a strategy 
is warranted. The use of microbial 
products in pregnancy or infancy 
for primary or secondary preven-
tion of allergy is suggested, but ef-
ficacy not proven. 
Tertiary prevention by immune 
tolerance induction is well doc-
umented for pollen and insect 
venom allergy through allergen 
immunotherapy. Oral immune tol-
erance appears promising to food 
allergens. 
Preventing maternal smoking 
in pregnancy can reduce asth-
ma incidence through several 
mechanisms, including epigenet-
ic effects by DNA-methylation. 
This includes reduced smoking 
among adolescents and women 
in childbearing age, including use 
of smoke-free tobacco (snus and 
e-cigarettes).
Kai-Håkon Carlsen Karin C. Lødrup Carlsen
University of Oslo and Oslo University Hospital 
Oslo, Norway
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KEY REFERENCES
1. von Hertzen LC, Laatikainen T, 
Makela MJ, Jousilahti P, Kosunen 
TU, Petays T et al. Infectious Bur-
den as a Determinant of Atopy - A 
Comparison between Adults in 
Finnish and Russian Karelia. Int 
Arch Allergy Immunol 2006;140:89-
95.
2. Strachan DP. Hay fever, hy-
giene, and household size. BMJ 
1989;299:1259-1260.
3. Breton CV, Byun HM, Wenten M, 
Pan F, Yang A, Gilliland FD. Pre-
natal tobacco smoke exposure af-
fects global and gene-specific DNA 
methylation. Am J Respir Crit Care 
Med 2009;180:462-467.
4. Flohr C, Mann J. New approaches to 
the prevention of childhood atopic 
dermatitis. Allergy 2014;69:56-61.
TABLE 1
Increased knowledge for primary and secondary prevention can be 
generated through research on
1. Mechanisms of allergy development
2. Tolerance induction and immune regulation after the instauration of aller-
gic sensitisation
3. Barrier defects in skin and the respiratory tract 
4. Human microbiota of different organ systems 
5. Early introduction of food allergens 
6. The link between atopic eczema and inhalant allergy
TABLE 2
Preventive strategies for combating allergy
• Remove or reduce early exposure to pollutants, including tobacco products 
and particulate air pollution 
• Strengthen research on allergy development and progression.
• Tolerance induction by early natural allergen exposure, immune therapy and 
natural exposure to microbial diversity 
• Early, correct diagnosis and treatment to obtain disease control and enable 
healthy living.
TABLE 3
Resources required for allergy prevention and control
• Creation of systematic health community plans to improve health care at all 
levels for secondary and tertiary prevention of allergic disease. 
• Support from policy makers for all preventive levels: reducing environmen-
tal exposures, funding research, ensuring natural habitats and encourage 
individuals to improve life style and avoid smoking exposure. 
Generating resources for allergy prevention and control
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• The Allergy Specialty is recognised as a full specialty in 14 Euro-
pean countries and as a subspecialty in another 8 and there are 
countries, where is not recognized at all
• Given the increasing incidence of allergic diseases of epidemic 
proportions, it is time to raise the standards of care and to allow 
access to modern treatment options
• Allergy as a full well-recognized speciality, harmonised training and 
an uniform framework for managing allergic diseases is advocated
• Comprehensive Multidisciplinary Allergy Centers are recom-
mended to coordinate optimal patient care and training of the 
health care professionals
Allergology or Allergology and 
Clinical Immunology is recognized 
as a full specialty in 13* countries 
(*In the Netherlands new special-
ists are trained as sub specialists in 
Internal medicine). It is a subspe-
cialty in 8 other European coun-
tries. Some countries also recog-
nize Pediatric Allergology as a full 
specialty or sub-specialty (Figure 
1). 
The spectrum of allergic diseases is 
broad and the number of causative 
agents is increasing. Often, aller-
gens cause symptoms in different 
organs simultaneously or sequen-
tially. Recently, several develop-
ments are challenging the role of 
healthcare providers in this disci-
pline. First, there has been a steady 
increase in knowledge about the 
immunological processes that play 
a role in allergic diseases. No longer 
can allergic diseases be seen as 
solely IgE mediated, but rather are 
based on a complex and variable 
interaction between cellular and 
humoral factors within and outside 
the immune system. The increase 
in knowledge has lead to changes 
in diagnostic and therapeutic pos-
sibilities (e.g., new forms of immu-
notherapy, component resolved di-
agnosis) and it is expected that this 
tendency will continue. Second, the 
STRENGTHENING THE 
SPECIALITY OF ALLERGOLOGY 
AND CLINICAL IMMUNOLOGY
15
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Strengthening the speciality of Allergology and Clinical Immunology
the role of environmental exposure 
(allergens and irritants) and the 
impact of primary and secondary 
prevention (benefits and risks of 
allergen avoidance, infant feeding, 
application of pro/prebiotics, risk 
of tobacco smoke, role of epigenet-
ics) are increasingly recognised as 
major players in the management 
of allergic diseases. Third, many ep-
idemiological surveys have shown 
that the number of allergic patients 
in Europe and other developed 
and developing countries have in-
creased dramatically, with one in 
three individuals being allergic. In 
addition, a notable proportion of 
individuals with respiratory aller-
gy in Europe are underdiagnosed, 
undertreated, and dissatisfied with 
their treatment. 
Considering all the challenges 
highlighted above it is time to 
raise the standards of care and al-
low access for the allergic patient 
to the most recent developments 
in allergy and clinical immunolo-
gy science. The EAACI together 
with The European Union of Med-
ical Specialists (UEMS) Section & 
Board on Allergology advocate a 
full Allergology specialty, formally 
recognised and structured. 
In order to set the standards for 
knowledge the EAACI-UEMS ex-
amination on Allergology was ini-
tiated several years ago.
A further goal is to harmonise the 
training of Allergists in Europe. In 
Jan G. R. de Monchy  
University of Groningen 
Groningen, The Netherlands
Jaques Gayraud  
Polyclinique de l’Ormeau 
Tarbes, France
370
Global atlas oF allerGy
se
c
t
io
n
 h
 - 
To
w
ar
d
s 
a 
co
m
p
re
h
en
si
ve
 g
lo
b
al
 s
tr
at
eg
y 
fo
r 
th
e 
m
an
ag
em
en
t 
o
f a
lle
rg
ic
 d
is
ea
se
s
order to achieve this, international 
visitations of training centres are 
being held by the UEMS Section 
& Board Allergology. Moreover 
standards for training have been 
set by the Core curriculum and 
Logbook on Allergology. 
Not only allergists, but also gen-
eral practioners and other med-
ical specialists take care of aller-
gic patients. In order to achieve a 
rational distribution of tasks and 
responsibilities of different care 
givers, recently ‘The Blueprint on 
Allergology’ was published in the 
journal Allergy. In this publication 
comprehensive Allergy Centers 
(Figure 2) are recommended to 
coordinate patient care, allergy 
and clinical immunology research 
and training activities. The Allergy 
Centre aims at optimizing efficien-
cy and increase quality at all levels.
KEY REFERENCES
1. Antó JM, Pinart M, Akdis M, Auf-
fray C, Bachert C, Basagaña X et al. 
Understanding the complexity of 
IgE related phenotypes from child-
hood to young adulthood: a Mecha-
nism of the Development of Allergy 
(MeDALL) seminar. J Allergy Clin Im-
munol 2012;129:943-954.
2. Law M, Morris JK, Wald N, Luczyn-
ska C, Burney P. Changes in atopy 
over a quarter of a century, based 
on cross sectional data at three 
time periods. BMJ 2005;330:1187-
1188.
3. Chivato T, Valovirta E, Dahl R, de 
Monchy J, Bloch Thomsen A, Palko-
nen S et al. Allergy, living and learn-
ing: Diagnosis and treatment of 
allergic respiratory diseases in Eu-
rope. Investig Allergol Clin Immunol 
2012;22:168-179.
4. Malling H-J, Gayraud J, Papageor-
giou-Saxoni P, Hornung B, Rosa-
do-Pinto J, Del Giacco SG. Ob-
jectives of training and specialty 
training core curriculum in Aller-
gology and clinical immunology. Al-
lergy 2004;59:579-588.
5. de Monchy JG, Demoly P, Akdis 
CA, Cardona V, Papadopoulos NG, 
Schmid-Grendelmeier P et al. Al-
lergology in Europe, the Blueprint. 
Allergy 2013;68:1211-1218.
SUBSPECIALITY:7
ITALY
PORTUGAL
SPAIN 
GREECE 
CZECH  REP.  
LITHUANIA
LUXEMBURG
CYPRUS
NETHERLANDS
SWITZERLAND
ROMANIA
UK
SWEDEN
SLOVAKIA
YES:14
NO:5
DENMARK         
SLOVENIA
AUSTRIA*
BELGIUM
IRELAND
POLAND
ESTONIA
CROATIA
FINLAND
FRANCE
GERMANY
HUNGARY 
Figure 1 Left: Map of Europe showing countries with a full speciality (green) and a sub-speciality (red) of Allergology.
Right: Table detailing individual countries.
Figure 2 The network within and around the Allergy Centre. A close collab-
oration between allergists working in the centre and in private practice, other 
medical specialists and general practitioners is advocated. Moreover the centre 
allows easy access to pharmaco-vigilance and international centres and is ideal-
ly situated for training and research. (GP = General practitioners, OBS = Organ 
Based Specialists eg. dermatologists, Occ. Phys. = Occupational Physicians)
Strengthening the speciality of Allergology and Clinical Immunology
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• The EAACI/UEMS Exam is a tool to improve, enhance and check 
knowledge in Allergology and Clinical Immunology offered 
annually since 2008
• The Exam comprises about 120 questions, revised annually 
from a question pool prepared by EAACI Task Force members 
and major European centres and is evaluated by professional 
institution (Institute for Medical Teaching, Bern) 
• All candidates receive a detailed summary of their tests and, if 
successful, a valued EACCI/UEMS certificate. The Exam does not 
replace or substitute currently existing national examinations 
regularly held by national bodies
HISTORICAL BACKGROUND
The idea of an EAACI examina-
tion in Allergy and Clinical Im-
munology goes back to some dis-
cussion in the excom-committee 
during 2006 and 2007. ‘The new 
Executive Committee (ExCom) 
members Werner Pichler from 
Bern, Switzerland and Gabriele 
Pauli from Strassbourg, France, 
proposed the idea of an common 
European Exam, and in particu-
lar some young ExCom members 
supported this “dream”. On the 
other side, the idea of an EAACI 
exam encountered some skepti-
cism, since allergy is handled quite 
differently by the various national 
societies, the rules to become an 
allergist/clinical immunologists 
differed quite widely and fear 
arose that by passing an European 
examination national regulations 
might be bypassed. After some 
internal discussion in the EAACI 
ExCom, and a positive outcome of 
the discussions with the UEMS in 
Göteborg in June 2007, where Jan 
de Monchy and Sergio del Giacco 
pushed the idea, both societies de-
cided to work on an EAACI-UEMS 
examination. Both EAACI and the 
allergy/clinical immunology sec-
tion at UEMS had already pub-
lished some common guidelines 
and a list of topics relevant for the 
EAACI-UEMS ExAM IN 
ALLERGOLOGY/CLINICAL 
IMMUNOLOGY
16
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EAACI-UEMS Exam in Allergology/Clinical Immunology
training in allergy and clinical im-
munology were already available 
both at national and international 
levels. 
The examination was conceived as 
a knowledge examination based 
on multiple choice questions. The 
topics should cover Allergy (70 %) 
and Immunology (30 %), the later 
including also some aspects of Ba-
sic Immunology. The decisive step 
for a successful examination was 
the recruitment of a specialised, 
professional institution (Institute 
for Medical Teaching, IML, Bern), 
which was specializing in creating 
and formulating exam questions 
and was already involved in other 
European examinations. Werner 
J Pichler and Gabriele Pauli co-
ordinated the first steps, created 
and collected questions (which 
turned out to be the biggest task) 
and adapted them for the Exam 
format. 
EAACI and UEMS coordinated 
their efforts and in 2007 pub-
lished their intention to organise 
an EAACI exam. The purpose of 
the exam was clarified (table 1). It 
was emphasized that passing this 
EAACI-UEMS examination was no 
license to practice in a country and 
this solved partly some concerns 
raised by National accreditation 
boards.
After creating and collecting al-
most 500 questions and careful 
selection of 100 questions for the 
Werner J. Pichler   
University Hospital of Bern 
Bern, Switzerland
Peter Schmid-Grendelmeier  
University Hospital of Zürich 
Zürich, Switzerland
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TABLE 1
Purpose of the EAACI-UEMS Knowledge Exam
• to booster the standards of Allergology/clinical Immunology in Europe; 
• to enhance the harmonization of the allergy training in Europe; 
• to provide an ability to compare oneself with the standard knowledge re-
quired from an allergologists in Europe, 
• in the future to provide help in the organization of national examinations 
(e.g. written examination on a European basis, oral examination on a nation-
al basis.
Figure 1 1st EAACI-UEMS Knowledge Exam was organized in 2008 in Barcelona.
EAACI-UEMS Exam in Allergology/Clinical Immunology
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exam, the first EAACI/UEMS ex-
amination took place in Barcelona 
in 2008 (figure 1). It was well or-
ganized and the participants came 
from more then 20 states, even 
from outside Europe. The ques-
tions were felt to be fair and 39 of 
41 participants passed.
After 2009 Peter Schmid-Gren-
delmeier was elected as respon-
sible for the examination. This 
choice guaranteed some conti-
nuity, as he was familiar with the 
IML, being a candidate y himself in 
2008. Moreover, the value of the 
examination has been approved 
by some national societies, which 
combined a local, oral examination 
with the EAACI-UEMS knowledge 
examination.
THE PRESENT AND FUTURE
Since 2010, each year 30-50 par-
ticipants took the examination. 
A further scope of the examina-
tion, to unify allergy teaching and 
standards in Europe, has also been 
approached. Regularly candidates 
come also from overseas such as 
Middle East, but also farer Asia, 
Africa or Latin America are partic-
ipating as it offers a good oppor-
tunity to enhance and check the 
personal knowledge in allergy and 
clinical immunology.
More than 200 candidates, mem-
bers of many National Societies, 
have already successfully passed 
the examination. The acceptance 
of this well structured and validat-
ed exam is rapidly increasing and 
Figure 1 The EAACI-UEMS Certificate of Excellence.
EAACI-UEMS Exam in Allergology/Clinical Immunology
it counts in an increasing number 
of nations as a sign of excellent 
knowledge in the field of allergy 
and clinical immunology.
The examination comprises ques-
tions, revised annually from a 
question pool, and many new 
questions are prepared by EAACI 
Task Force members and major Eu-
ropean centres. They are carefully 
evaluated by the EAACI Exam/
Knowledge Test Committee and 
also the IML and are continuously 
adapted to modern exam stand-
ard and techniques. A blueprint 
with relevant literature is avail-
able on the EAACI website. The 
180-minute exam contains about 
120 multiple-choice questions, 
currently all in English. Language 
dictionaries are permitted, and 
translations into other major lan-
guages foreseen. UEMS is strongly 
supporting the Exam, by promot-
ing and collaborating in the Exam 
TF. Both EAACI and recently also 
UEMS are offering financial sup-
port to enable on request reduced 
exam fees for candidates from low 
income areas.
All candidates receive a detailed 
summary of their tests and, if suc-
cessful, a valued EACCI/UEMS 
certificate (figure 2). The Knowl-
edge Test in Allergology/Clinical 
Immunology does not replace or 
substitute currently existing na-
tional examinations regularly held 
by national bodies. EAACI mem-
bers have the opportunity to use 
this Knowledge Test as a very use-
ful tool for self-evaluation. 
EAACI and UEMS are now proud 
of their successful exam. Even the 
skeptics have been convinced of 
its value. It proves to be a big step 
forward to better allergy training 
in Europe. 
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s • The main difficulties in the management of allergic diseases in 
developing countries are caused by insufficient level of health 
care, heterogeneous inhabitation and lack of educational 
programs for healthcare providers and patients
• A marked heterogeneity in prevalence is observed between 
countries or between regions within one country, highly 
dependent on environmental and social factors
• Management of allergic diseases is based on the availability of 
essential drugs and their financial affordability
More than 100 countries with al-
most 85% population of the world 
are considered to be developing 
countries (DCs). The main diffi-
culties in the management of al-
lergic diseases in DCs are caused 
by insufficient level of health care, 
heterogeneous inhabitation and 
lack of educational programs for 
healthcare providers and patients. 
A marked heterogeneity in preva-
lence is observed (Table 1). 
The prevalence of allergic diseas-
es and their severity is highly de-
pendent on environmental and 
social factors. Although it is hard 
to prove the association between 
high IgE levels and atopy in Africa 
because of wide-spread of parasit-
ic infections, reported prevalence 
rates from the ISAAC study that 
included 22 centers from 16 Afri-
can countries, varied for wheezing 
between 4–22 %, for allergic rhi-
noconjunctivitis between 7–27 %, 
and for eczema between 5–23 %. 
For some higher-income African 
urban centers, the rate of current 
wheezing was comparable to Eu-
ropean countries, and reflected an 
increase over the past decade. In 
general, the spread of allergic dis-
eases worldwide is positively as-
sociated with urbanization and the 
standards of living. One of the most 
MANAGING ALLERGIC 
DISEASES IN DEVELOPING 
COUNTRIES 
17
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Managing allergic diseases in developing countries
interesting findings of the ISAAC 
study was the striking difference in 
asthma prevalence in populations 
with similar genetic backgrounds 
from different environments. The 
prevalence of asthma was two 
times higher in Hong Kong, the 
most developed and westernized 
Chinese city, compared to Guang-
zhou located approximately 200 
km north-west. According to the 
ISAAC study the management of 
allergic diseases in DCs is based on 
the availability of essential drugs 
and their financial affordability. For 
example, chlorpheniramine and be-
clomethasone are part of the WHO 
essential drugs list, while allergen 
immunotherapy is listed as limited 
accessibility. 
In Russian Federation and other 
Commonwealth of Independent 
States (CIS) countries the network 
of specialized allergy centers pro-
vides sufficient care for allergic 
patients. Allergy and Clinical Im-
munology is a separate speciality. 
For the assessment of the preva-
lence of allergic diseases in Rus-
sian Federation, standard interna-
tional and European approaches 
are applied: ISAAC or ECRHS 
questionnaires, locally adopted 
questionnaires, skin tests, IgE 
measurement etc. Data on the 
prevalence of allergic diseases 
and allergens in Russian Federa-
tion is shown in Figures 1 and 2. 
The prevalence of allergic diseas-
es is influenced by climatic and ge-
ographical features of the region 
(Figure 1 and 2). International 
(ARIA, GINA) and local guidelines 
are applied in the management 
Musa R.  
Khaitov
Lyudmila v. 
 Luss
natalia I.  
Ilyna
Rakhim M. 
Khaitov
NRC Institute of Immunology FMBA 
Moscow, Russia 
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Managing allergic diseases in developing countries
TABLE 1
Prevalence of allergic diseases in some developing countries
Country Asthma
Allergic 
rhinitis
Eczema
Food 
Allergy
Authors
Vietnam, Hanoi  
(questionnaire)
5.6% Hoàng Thi Lâm, Bo Lundbäck 
et al., 2011
Iran 
(questionnaire)
3.9% (CI; 
3.2 to 4.7%)
Mohammadbeigi A, Hassanza-
deh J, Mousavizadeh A., 2011
China (questionnaire) 
Children 6-12 years 3.3% 9.8% 5.5%
Li F, Zhou Y, Li S, Jiang F et al., 
2011
Turkey (ques-
tionnaire)
Adults 29.6%,
Cingi C, Ozkiraz S. et al 2010
Children 11.5±3.3 years 11.5% 22.1% 10.7%
South Africa
Urban children 3.6% 17% P.C. Potter, 2009
Rural, children 6-7 years 0 0,8 – 14.9%
Children 13-14 years 1.4 – 39.7%
Rwanda(questionnaire) 
in Kigali Adults
8.9% Musafiri S, Brusselle G et al., 
2011
Republic of Ghana 11% Obeng BB, Yazdanbakhsh M, 
2011
Zimbabwe
Rural children 0.1% Keeley et al 1991
Urban children 3.2%
Brazil
Children 10-14 years 11% 33.2% Toledo MF, Rozov T, Leone C, 
2011Sao Paulo teenagers 6.8% 36.6 – 37.6% 16.2%
of allergic diseases, and access to 
specialized care is fully accessible 
for the whole population. 
KEY REFERENCES
1. Bousquet J, Ndiaye M, Ait-Khaled 
N, Annesi-Maesano I, Vignola AM. 
Management of chronic respirato-
ry and allergic diseases in develop-
ing countries. Focus on sub-Saha-
ran Africa. Allergy 2003;8:265-283.
2. Ait-Khaled N, Odhiambo J, Pearce 
N, Adjoh KS, Maesano IA, Benhab-
yles B et al. Prevalence of symp-
toms of asthma, rhinitis and ecze-
ma in 13- to 14-year-old children 
in Africa: the international study of 
asthma and allergies in childhood 
phase III. Allergy 2007;62:247–258.
3. Wong GW, Leung TF, Fok TF. ISAAC 
and risk factors for asthma in the 
Asia-Pacific. Paediatr Respir Rev 
2004;5:S163–S169.
4. Khaitov R, Bogova A, Ilyina N. Ep-
idemiology of allergic diseases in 
Russia. International review of al-
lergology and clinical immunology 
1999;1:5-12.
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Figure 1 The incidence of allergic diseases in Russian Federation.
Managing allergic diseases in developing countries
Figure 2 The most common allergens in Russian Federation.
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• One Health frames the complex interactions between human, 
animal and environmental health
• One Health is a unique approach to cope with allergies
• One Health also includes food safety and security, agriculture, 
water, sanitation and hygiene
• One Health focuses on equity and is key for human sustainable 
development
DEFINITION OF ONE HEALTH IN 
THE CONTExT OF ALLERGIES
Many emerging health issues are 
linked to increasing contact be-
tween humans and animals, the in-
dustrialization of food production, 
and environmental pollution. Ur-
banization, globalization, climate 
change, deforestation and other 
changes in land use, the creation 
and operation of large terrestrial 
and marine industrial food pro-
duction units, and microbial and 
chemical pollution of land and 
water sources have created new 
threats to the health of both ani-
mals and humans. These complex 
interactions impacting human 
health need integrative approach-
es to cope with. A promising ap-
proach, briefly introduced here, 
is the “One Health” concept. One 
Health frames the complex inter-
actions between human health, 
livestock, pet and wildlife health, 
ecosystems health, climate, agri-
culture, food systems, water and 
sanitation, and human develop-
ment (Figure 1).
RECENT DEVELOPMENTS IN 
ONE HEALTH
Whereas the “One Health” ap-
proach for many years was limit-
ed to an interdisciplinary collab-
oration in human and veterinary 
Walter J. Ammann  
Global Risk Forum GRF Davos 
Davos, Switzerland
THE “ONE HEALTH” 
CONCEPT AND ALLERGIC 
DISEASES
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The “One Health” concept and allergic diseases
medicine, with substantial added 
value in zoonoses control and 
related health service provision, 
One Health has evolved to a broad 
and holistic paradigm to include 
an ecological dimension, and most 
recently the economic and social 
dimension addressing equity, gov-
ernance, justice, livelihood, and 
welfare. One Health, thus has be-
gun to move beyond the status of 
a mere concept to become a truly 
global movement at the interface 
of science, society, policy and 
practice. This movement is deeply 
interdisciplinary and cross-sec-
torial and provides a fascinating, 
powerful framework that a variety 
of professional communities and 
social groups can adhere to (Fig-
ure 1). 
The One Health paradigm will 
be helpful in reversing the worst 
of current problems at the hu-
man-animal-environment and de-
velopment interface thus foster-
ing a more sustainable way of life 
on our planet (Figure 2). Keeping 
in mind that more than half of the 
worldwide population is living in 
urban areas and rural exodus con-
tinues to grow, One Health may 
become a crucial approach to suc-
cessfully cope with all the drivers 
and consequences in urbanization 
dynamics. 
Mitigating the impacts from 
threats like emerging pathogens, 
toxicant releases, climate change, 
and changes in the built environ-
ment requires pooling of global 
public health resources and ca-
pabilities across multiple disci-
plines. By collaboration among 
multiple sectors such as veteri-
nary medicine, human medicine, 
environment, wildlife, livestock, 
agriculture, water, sanitation and 
378
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hygiene, food security and public 
health, One Health can substan-
tially contribute to reduce existing 
and emerging global threats. 
KEY REFERENCES
1. Kahn LH, Kaplan B, Steele JH. Con-
fronting zoonoses through closer 
collaboration between medicine 
and veterinary medicine (as 'one 
medicine'). Veterinaria Italiana 
2007;43:5-19. 
2. The FAO-OIE-WHO Collaboration. 
A Tripartite Concept Note. April 
2010. http://web.oie.int/downld/
FINAL_CONCEPT_NOTE_Hanoi.
pdf. Accessed February 24, 2014.
3. Mackenzie SJ, Jeggo M, Richt J, 
Daszak P. (Eds.) One Health: The 
Human-Animal-Environment In-
terfaces in Emerging Infectious 
Diseases - Food Safety and Secu-
rity, and National Plans for Imple-
mentation of One Health Activi-
ties. Springer Berlin 2013, 235p.
4. Colbert M, Stiffler M, Ammann WJ 
(Eds.). GRF One Health Summit 
Davos 2012 – One Health – One 
Planet – One Future: Risks and 
Opportunities, Extracts from the 
Proceedings, OECD- GRF Davos, 
2012, 120 p.
Figure 1 The One Health paradigm at the human-animal-environment and development interface - a global movement 
at the coalescence of science, society, policy and practice, which is deeply interdisciplinary and cross-sectorial, and relates 
to an integrative health risk approach as an essential tool for an effective and efficient handling of health risks. (Ammann 
WJ, Colbert M, Rechkemmer A. One Health: Summary and Outlook, in Colbert M, Stiffler M, Ammann WJ (Eds.). GRF One 
Health Summit 2012 – One Health – One Planet – One Future: Risks and Opportunities, Extracts from the Proceedings, 
OECD- GRF Davos, p. 115 – 120).
Figure 2 The logo of the annual GRF 
Davos One Health Summits express-
ing the global One Health movement, 
fostering a more sustainable way of 
life on our planet (http://onehealth.
grforum.org/home/).
The “One Health” concept and allergic diseases
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• The concept of active and healthy ageing (AHA) is the process 
of optimizing opportunities for health to increase healthy life 
expectancy, healthy life years and quality of life for all people as 
they age
• Poor health is largely shaped by non-communicable diseases 
(NCDs) that share common risk and socio-economic factors, and 
cluster in co-morbidities
• Allergic diseases and asthma are the most common NCDs in chil-
dren and have been on the rise in recent decades. They represent 
a major cause of health care and socioeconomical burden
• Early life events play a fundamental role in health and on NCD 
development. AHA should be promoted very early in life
The broad concept of active and 
healthy ageing (AHA) is the pro-
cess of optimizing opportunities 
for health to increase healthy life 
expectancy, healthy life years and 
quality of life for all people as they 
age (http://www.who.int/ageing/
active_ageing/en/index.html). 
AHA allows people to realize their 
potential for physical, social (eco-
nomic, cultural, spiritual and civ-
ic affairs) and mental well being 
throughout the life course. The 
WHO report “Good Health adds 
to life years” (2012) approaches 
ageing from a life-course perspec-
tive and assumes that we age from 
the moment we are born (http://
whqlibdoc.who.int/hq/2012/
WHO_DCO_WHD_2012.2_eng.
pdf). 
AHA is a major societal chal-
lenge, common to all populations. 
Poor health is largely shaped 
by non-communicable diseases 
(NCDs), which share common risk 
and socio-economic factors, and 
cluster in co-morbidities. They are 
intertwined with ageing and rep-
resent a major cause of frailty. Ear-
ly life events play a fundamental 
role in health and on NCD devel-
opment. AHA should be promoted 
very early in life.
Allergic diseases and asthma, the 
ALLERGY AND ACTIVE AND 
HEALTHY AGEING19
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Allergy and active and healthy ageing
most common NCDs in children, 
have been on the rise in recent 
decades. They represent a ma-
jor cause of burden, school and 
work absenteeism. Children with 
asthma have a risk for COPD in 
adulthood. That is why the 2011 
Polish Presidency has made the 
prevention, early diagnosis and 
treatment of chronic respirato-
ry diseases in children a priority 
for the European Union's public 
health policy in order to reduce 
health inequalities across Euro-
pean societies. In its conclusions, 
the 3131st Council meeting of the 
EU invites member states to tack-
le the problems, which constitute 
the biggest risk factors that could 
trigger a chronic respiratory dis-
ease: tobacco smoke, poor indoor 
air quality and outdoor air pollu-
tion. Health education of children, 
parents and teachers is recognized 
as important in this regard, as well 
as training of health professionals. 
Allergic diseases and asthma oc-
cur very early in life and often per-
sist life-long. They impact physical, 
social (economic, cultural, spiritual 
and civic affairs) and mental 
well-being throughout the life 
course. Early diagnosis, preven-
tion and management of chronic 
respiratory diseases in children 
will help people to cope with their 
disease, to have a normal life and 
to age well.
Jean Bousquet   
University of Montpellier 
Montpellier, France
Boleslaw Samolinski  
Medical University of Warsaw 
Warsaw, Poland
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of childhood asthma and allergy 
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2012;67:726-731. 
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zat T, Anto JM, Blasi F, Neou A et al. 
Impact of early diagnosis and con-
trol of chronic respiratory diseases 
on active and healthy ageing. A de-
bate at the European Union Parlia-
ment. Allergy 2013;68:555-561. 
Figure 1 The concept of Good Health as promoted by the World Health Organisation.
Allergy and active and healthy ageing
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• The Internet has become a significant source of health 
information and support for both patients and doctors
• Information on allergy in internet can be sometimes misleading, 
non evidence-based and potentially dangerous
• Therefore, it is fundamental that both patients and doctors refer 
to accredited institutions websites, such as those created and/or 
endorsed by international scientific societies
• Apart from educational material, internet can provide patients 
platforms in which they may share their experiences with other 
patients or doctors
• Doctors may use internet also to improve their career, through 
scientific societies and/or journals websites
The Internet has become a signif-
icant source of health informa-
tion and support for patients with 
chronic conditions such as aller-
gy, and their caregivers, including 
health care professionals. Among 
the countless websites regarding 
allergic diseases, we can distin-
guish sites with high quality con-
tent from sites with low evidence 
grade and questionable informa-
tion. Therefore, it is important 
that both patients and doctors 
may count on few but trusted 
websites, which are certified by 
the world's most prestigious sci-
entific societies.
TRUSTED WEBSITES FOR 
PATIENTS
Probably the most interesting and 
comprehensive websites contain-
ing reliable informations on aller-
gies for patients, come from three 
of the most prestigious scientific 
societies in the field: EAACI (with 
it’s “Patients area”, see Figure 1 
upper-left quarter), ACAAI (with 
the website called “Allergist”, see 
Figure 1 upper-right quarter) and 
AAAAI (with the “Conditions and 
treatments” sub-section of its 
main website, see Figure 1 low-
er-left quarter) (see Box 1). 
“EAACI Patients Area” provides a 
large and comprehensive amount 
Enrico Heffler  
University of Torino 
Torino, Italy
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of information for patients, rang-
ing from the description of allergic 
diseases, their correct diagnostic 
work-up and treatment options, 
to information on how to inter-
pret, in a evidence-based manner, 
complementary and alternative 
medicine approaches to allergy, 
and to providing easy access to 
useful tools for allergic patients 
(i.e.: information on travelling with 
allergies or pregnancy and aller-
gy, the list of European and world 
wide patient associations, and a 
world-map of pollen counts). Both 
“EAACI Patients Area” and “Aller-
gist” provide interesting interac-
tive tools to let patients seek for 
symptoms or organ involvement 
to obtain information on possible 
allergic diseases which may ex-
plain their symptoms (“Think you 
have an allergy” and “Allergic and 
immunologic diseases & causes” 
for “EAACI Patiens Area”, “The vir-
tual allergist” for the AAAAI web-
site). A similar tool is available also 
on WAO and ACAAI websites, but 
the latter is limited to nasal com-
plaints (“My nasal journal”). An 
other website in which patients 
may find comprehensive informa-
tion on a specific aspect of aller-
gies, food allergy, is FARE (Food 
Allergy Research & Education).
One of the important patients’ 
need is to share their doubts/opin-
ion with expert doctors and with 
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other patients; an 
“Ask the expert” 
section is present 
in most of the pre-
viously mentioned 
websites, while 
discussion boards 
between patients 
are present in 
other websites as 
“AllergyUK”, “Aller-
gyChat” or “Health-
Boards”. Even if 
these websites cov-
er a patients’ need, 
it is important to re-
mind that they can-
not be considered 
a reliable source of 
scientific/correct 
information on allergies. This is 
one of the reasons that led scien-
tific societies as EAACI and AAAAI 
to publish their own Facebook 
pages in which evidence based in-
formation on allergy is spread to a 
larger audience.
TRUSTED WEBSITES FOR 
DOCTORS
Both experts in these field (special-
ists) and those who are in training 
(i.e.: residents) or more generalist 
doctors (i.e.: general practitioners) 
may need to seek for professional 
and scientific information on in-
ternet (see Box 2). 
As far as scientific update, doctors 
may count on institutional and 
universally recognized database 
such as “PubMed”, “EMBASE” or 
“Scopus” to seek scientific arti-
cles, or allergen database such as 
“Allergome”, “SDAP”, “Protall”, “All-
Fam” or “AllergenOnline”, or to a 
variety of allergy textbooks which 
are now available online.
Internet gives also the doctors 
the opportunity to easily improve 
their career through institution-
al websites collecting career/
jobs opportunity in the field (i.e: a 
specific sections into both EAACI 
and AAAAI websites, or specific 
databases into more generalist 
websites such as those of some 
prestigious scientific journals like 
NEJM, The Lancet, JACI, Allergy 
or JAMA).
KEY REFERENCES
1. D'Auria JP. All about asthma: top 
resources for children, adoles-
cents, and their families. J Pediatr 
Health Care 2013;27:e39-42.
2. Stewart M, Letourneau N, Masuda 
JR, Anderson S, Cicutto L, McGhan 
S et al. Support needs and prefer-
ences of young adolescents with 
asthma and allergies: "just no one 
really seems to understand". J Pedi-
atr Nurs 2012;27:479-490.
  BOX 1 – List of suggested internet resources for PATIENTS: 
 
INTERNATIONAL SCIENTIFIC SOCIETIES FOR PATIENTS: 
 
 
- “Patients Area” - EAACI (www.eaaci.org) 
- “Allergist”- ACAAI (www.acaai.org/allergist) 
- “AAAAI – Conditions and treatments” (www.aaaai.org/conditions-and-treatments.aspx) 
- “WAO – Patient resources” (www.worldallergy.org/patient-resources) 
- “FARE – Food Allergy Research & Education”: (www.foodallergy.org)    
DISCUSSION BOARDS ON ALLERGY: 
 
 
- “AllergyUK forum” (forum.allergyuk.org) 
- “AllergyChat” (www.allergychat.org/allergy_forum) 
- “Health Boards – Allergy” (www.healthboards.com/boards/allergies) 
  
BOX 2 – Main internet resources for DOCTORS: 
 
PRINCIPAL SCIENTIFIC ARTICLES DATABASES: 
 
 
- “PubMed” (www.ncbi.nlm.nih.gov/pubmed) 
- “EMBASE” (www.elsevier.com/online-tools/embase) 
- “Scopus” (www.scopus.com) 
 
ALLERGEN DATABASES: 
 
 
- “Allergome” (www.allergome.org) 
- “SDAP -  Structural Database of Allergenic Proteins” (fermi.utmb.edu) 
- “Protall” (www.ifr.ac.uk/protall/database.html) 
- “AllFam” (www.meduniwien.ac.at/allergens/allfam) 
- “AllergenOnline” (www.allergenonline.org) 
 
 
CAREER/JOB OPPORTUNITIES FOR ALLERGISTS: 
 
 
- “EAACI – Job center” (www.eaaci.org/resources/job-center.html) 
- “AAAAI - Career Connections Center” (careers.aaaai.org/home) 
- “ACAAI – Job source” (jobs.acaai.org) 
- “NEJM Career Center”  (www.nejmcareercenter.org) 
- “The Lancet Careers”  (jobs.thelancet.com) 
- “JAMA Career Center” (jama.careers.adicio.com)  
Allergy in internet
Figure 1 Screenshots of homepages of principal patients-targeted websites 
endorsed by the most prestigious international scientific societies in allergy and 
clinical immunology. 
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• In 2050 it is predicted that up 4 billion people in the world will 
suffer from asthma, allergic rhinitis and atopic dermatitis
• The burden of these prevalent allergic conditions, coupled with 
acquired and congenital immunodeficiencies and drug allergies, 
will negatively impact all communities and the overall world 
economy
• The American Academy of Allergy, Asthma & Immunology; 
the American College of Allergy, Asthma & Immunology; the 
European Academy of Allergy and Clinical Immunology; and 
the World Allergy Organization have formed a collaborative 
initiative termed the International Collaboration in Asthma, 
ALlergy and ImmunoLogy (iCAALL) 
• The aim of iCAAL is to coordinate communication about 
allergies, asthma, and immunologic diseases and to raise general 
awareness on a global level
• International consensus statements (ICONs) were developed 
to serve as reference tools for physicians and other health 
care professionals and as educational tools for policymakers 
and the general public. The ICONs combine the best scientific 
evidence with international expert consensus and are adaptable 
to circumstances in all countries worldwide, allowing for 
modifications based on the availability of regional diagnostic and 
therapeutic interventions
The prevalence of Allergic Dis-
eases and Asthma continues to 
increase worldwide. In 2050, the 
world’s population will likely reach 
9 to 10 billion, among which 2 to 
4 billion will suffer from allergic 
diseases, including asthma, aller-
gic rhinitis and atopic dermatitis. 
These conditions are compounded 
by a number of comorbidities. The 
burden of these prevalent, allergic 
conditions, coupled with acquired 
and congenital immunodeficien-
cies and drug allergies, will have a 
very strong adverse impact on all 
communities and will negatively 
affect the overall world economy.
To address these concerns and 
prepare for the resulting needs 
worldwide, the American Acad-
emy of Allergy, Asthma & Immu-
nology; the American College of 
Allergy, Asthma & Immunology; 
the European Academy of Allergy 
and Clinical Immunology; and the 
World Allergy Organization have 
formed a collaborative initiative 
termed the International Collab-
oration in Asthma, ALlergy and 
ImmunoLogy (iCAALL) (figures 1 
and 2). 
The mission of iCAALL is to en-
hance the coordinated commu-
nication of information about 
allergies, asthma, and immuno-
iCAALL: INTERNATIONAL 
COLLABORATION IN ASTHMA, 
ALLERGY AND IMMUNOLOGY
21
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iCAALL: International Collaboration in Asthma, Allergy and Immunology
logic diseases and to raise general 
awareness of these diseases on a 
global level. It will develop com-
munication and education tools 
for specialists, general practition-
ers, and other health care profes-
sionals and, ultimately, provide 
global information for the general 
public, patients, and policymakers. 
Ideally, this collaboration will re-
sult in a greater awareness about 
allergies, rhinitis, asthma, and im-
munologic diseases, resulting in 
more effective care for patients 
and increased allocation of re-
sources for research and patient 
Jan Lötval Denis Ledford Cezmi A. Akdis
iCAALL Chairs
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iCAALL: International Collaboration in Asthma, Allergy and Immunology
Figure 2 ICAALL Steering 
Committee 2011-2013 during 
the EAACI Annual Meeeting in 
Geneva June 2012. EAACI: Jan 
Lötvall, Cezmi A. Akdis, Nikolaos 
G. Papadopoulos, AAAAI: Dennis 
K. Ledford (iCAALL Chair), Thom-
as B. Casale, Wesley Burks, WAO: 
Richard F. Lockey, Ruby Pawankar, 
Lanny J. Rosenwasser: ACAAI: 
Dana V. Wallace, Stanley Fineman, 
Richard Weber. 
care, thus benefitting affected pa-
tients and the greater population.
The first project underway is the 
development of international 
consensus statements (ICONs) to 
serve as useful resources for phy-
sicians and other health care pro-
fessionals who treat patients with 
allergic and immunologic diseases. 
ICONs are also intended to edu-
cate policymakers about the im-
portance of providing resource al-
location to ensure optimal patient 
care and to sustain research. The 
ICONs combine the best scientif-
ic evidence with international ex-
pert consensus and are adaptable 
to circumstances in all countries 
worldwide, allowing for modifica-
tions based on the availability of 
regional diagnostic and therapeu-
tic interventions. 
KEY REFERENCES
1. Lotvall J, Pawankar R, Wallace DV, 
Akdis CA, Rosenwasser LJ, Weber 
RW et al. We call for iCAALL: Inter-
national Collaboration in Asthma, 
Allergy and Immunology. Allergy 
2012;67:449-450.
2. Burks AW, Tang M, Sicherer S, Mu-
raro A, Eigenmann PA, Ebisawa M 
et al. ICON: food allergy. J Allergy 
Clin Immunol 2012;129:906-920.
3. Papadopoulos NG, Arakawa H, 
Carlsen KH, Custovic A, Gern J, Le-
manske R, et al. International con-
sensus on (ICON) pediatric asthma. 
Allergy 2012;67:976-997.
4. Valent P, Klion AD, Rosenwasser 
LJ, Arock M, Bochner BS, Butter-
field JH et al. ICON: Eosinophil 
Disorders. World Allergy Organ J 
2012;5:174-181.
5. Lang DM, Aberer W, Bernstein JA, 
Chng HH, Grumach AS, Hide M et 
al. International consensus on he-
reditary and acquired angioede-
ma. Ann Allergy Asthma Immunol 
2012;109:395-402.
6. Demoly P, Adkinson NF, Brockow 
K, Castells M, Chiriac AM, Green-
berger PA et al. International 
Consensus on drug allergy. Allergy 
2014;69:420-437.
7. Routes J, Abinun M, Al-Herz W, 
Bustamante J, Condino-Neto A, 
De La Morena MT et al. ICON: The 
Early Diagnosis of Congenital Im-
munodeficiencies. J Clin Immunol 
2014;34:398-424.
Figure 1 Four International Societies joined forces into a global alliance against the heavy burden of allergic and immu-
nologic disease.
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• Allergy epidemic affects more than one billion patients with a 
global rise in prevalence, which may reach up to 4 billion affected 
individuals in 2050
• The already existing many unmet needs and a huge socioeconomic 
burden to health care systems is expected to substantially 
increase
• Effective policies and strategy development are needed at the 
global, regional and national level
• Efforts to overcome unmet needs should focus on 4 main 
directions: 
  Intensive research and development
  Improved patient care at the global level
  Increased public awareness
  Upgrade of the Allergy domain in the political agenda 
• A “Global Allergy Fight Strategy” should be developed
  All stakeholders should be involved 
  A multidisciplinary and scientific approach should be used
  The “One Health” concept should be integrated
  Next generation guidelines should be developed
  World Allergy Centers and integrated surveillance network 
should be established
  Existing know how from successful approaches in the past 
should be implemented and adapted to local conditions
With an epidemic rise during 
the last 60 years, today, allergic 
diseases are affecting the lives 
of more than one billion people 
worldwide, and their prevalence 
is expected to reach up to 4 billion 
in 2050. The prevalence of aller-
gic diseases and socioeconomic 
impact are particularly on the rise 
in urbanizing regions and globali-
zing world in association with en-
vironmental and lifestyle changes. 
Apart from individual suffering of 
patients, allergic diseases present 
a very high socioeconomic burden 
to health care systems and fami-
lies. In addition, patient care and 
access to diagnosis and treatment 
is inadequate in many developing 
regions and countries. Effective 
policies and strategy development 
are needed to fill this gap at the 
global, regional, national level (Ta-
ble 1). 
The efforts to overcome high 
numbers of unmet needs in al-
lergic diseases are described in 
“section H” and can be grouped in 
three directions:
A) Research and development 
should be synergized and pri-
oritized in order to achieve sus-
tainable results on prevention, 
biomarkers, curative treatment, 
anti-viral vaccines, and novel 
Cezmi A. Akdis  
Swiss Institute of Allergy and Asthma Research, University of Zurich 
Davos, Switzerland
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Vision and roadmap to fight with allergies
drug development. There are a 
number of barriers and obsta-
cles in grant giving bodies to be 
solved, particularly to support 
human immunology and allergy 
research (Table 2). 
B) Improved patient care at the 
global level requires a world-
wide approach to identify bar-
riers for prevention and cure, 
develop patient registries and 
next generation guidelines, im-
prove access to diagnosis and 
essential drugs in low income 
countries, implement full en-
vironment control, provide 
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Vision and roadmap to fight with allergies
psychological help directly and 
routinely without any need for 
consultation and implement 
every aspect of education of pa-
tients, primary care physicians 
and allied health personnel.
C) To increase the public aware-
ness, it is now essential to pub-
licly position allergic diseases 
and asthma as one of the most 
important causes of chron-
ic morbidity and health care 
burden. Allergy and asthma 
focused patient organizations 
should be immediately estab-
lished in all countries. A signif-
icant number of international 
alliances, societies, networks 
and academies are working on 
this. Intensive efforts should be 
performed at the level of local 
governments, United Nations, 
WHO, EU etc.
A worldwide strategy to fight and 
manage allergic diseases should 
be developed (Table 3).
A) All stakeholders including 
specialists, primary care phy-
sicians, nurses, dieticians, psy-
chologists, pharmacists, pa-
tient organizations, educators, 
industry, and policy makers 
should be involved. The roles 
of all stakeholders have been 
mentioned in detail in the previ-
ous chapters in section “H”.
B) The speciality of “Allergology” 
should be strengthened as a full 
specialty and should be world 
wide harmonized.
C) Modern global guidelines 
should be developed and im-
plemented for the management 
of allergic diseases, asthma and 
co-morbidities. The new gener-
ation guidelines should provide 
structured, multidisciplinary, 
region and environment-ori-
ented and individual patient-fo-
cused solutions, with full con-
siderations on differences 
across cultures.
D) There is substantial experience 
of already established strat-
egies and associations. We 
should avoid reinventing the 
wheel and utilize and imple-
ment the existing know how. 
For example, one of the most 
valuable experiences in our 
fight with allergies is the suc-
cess of the Finnish Allergy and 
Asthma Programmes. It is now 
fundamental to disseminate the 
Finnish experience to the whole 
world, collect feedback and fur-
ther improve. 
E) Global management of allergic 
diseases should be integrated 
TABLE 1
Efforts for increasing awareness in the political bodies for allergy and asthma 
• Global Allergy and Asthma European Network (GA2LEN) was established with the efforts of EAACI in 
2004 as an EU FP6 Network of Excellence. GA2LEN still continues as a non-profit network.
• Allergy was listed in the food and agriculture group in the EU research grants until 2007. EU accepted 
allergy as an important health problem in 2007 with the efforts of the EAACI and GA2LEN. 
• Allergy is not included in Horizons 2020 programme. Many attempts and several one day awareness 
meetings have been organized in the European Parliament and attended by patient organizations, 
EAACI leadership and members of the Parliament in Brussels during the recent years, which were 
specifically intensified during the last year.
• ICAALL: The American Academy of Allergy, Asthma & Immunology; the American College of Allergy, 
Asthma & Immunology; the European Academy of Allergy and Clinical Immunology; and the World 
Allergy Organization have formed a collaborative initiative termed the International Collaboration in 
Asthma, ALlergy and ImmunoLogy (iCAALL) in 2011. 12 International Consensus “on” (ICON) papers 
have been planned and 7 have been published so far.
• The results of the Finnish Allergy and Asthma Programmes demonstrated that allergy and asthma 
burden can be substantially decreased by relatively undemanding methods doable by every country 
(Chapter H12). This strategy is slowly being adapted to local conditions and implemented by some 
national health-care systems
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Vision and roadmap to fight with allergies
TABLE 2
Obstacles in research grants and grant giving bodies
• Lack of political awareness and low understanding and priority set-
ting for the allergy epidemics
• Curative approaches and research for prevention has not been so 
far efficiently supported 
• Small quantities of grants have been given to hypothesis-based 
research, although the real need is for large scale, non hypothesis 
based, in dept research, which is now possible with the novel devel-
opments in next generation DNA and RNA sequencing, exposome 
and epigenetic analysis and biomarkers
• Human research is receiving relatively less funding in many grant 
giving bodies compared to animal models
• Many major grant giving bodies had to decrease their budgets due 
to economical conditions in the US and Europe during the last years
TABLE 3
To do list for the global allergy fight strategy
• Accept allergies and asthma as a Global Public Health Problem
• Upgrade “Allergy” on the political agenda
• Perform research and develop strategies to reduce risk factors
• Appreciate the role of primary care, allied health personnel and 
pharmacists as the central link between patients and physicians 
and initiate global education programmes
• Develop intensive public education and awareness programmes
• Improve and disseminate the “Finnish Programmes”
• Increase research funds in general
• Prioritize prevention and curative treatments in research
• Generate resources for prevention and control
• Strengthen the specialty of “Allergology”
• Increase awareness on and implement  the “One Health” concept
• Harmonize and economize the educational and awareness activi-
ties of main associations through ICAALL
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with the “One Health” concept 
that acknowledges the syste-
mic interconnections of hu-
man, animal and environmental 
health in close relationship with 
food and water safety and secu-
rity. In an era of climate change, 
resource depletion, land de-
gradation, food insecurity and 
development challenges, an in-
tegrative approach is needed to 
ensure sustainable health. This 
concept strongly applies to all 
chronic inflammatory diseases, 
because of a strong scientific 
basis of epigenetic regulation of 
the disease genes with the influ-
ence of changing environment. 
Human health, animal health, 
plant health, healthy air, water 
and earth, food safety & secu-
rity are integrative components 
of the “One Health” concept.
F) A fully integrated World Aller-
gy and Asthma Network should 
be established with all national 
asthma centers and already es-
tablished networks, alliances, 
societies, academies aiming at 
worldwide allergy surveillance, 
strategy development and ed-
ucation. Prioritization of aller-
gies should take place more and 
more in the EU, United Nations, 
WHO and national political 
agendas. 
G) A multidisciplinary and scien-
tific approach is essential. 40 
scientists and clinicians from 
all around the world and vari-
ous fields of allergy and relat-
ed disciplines gathered under 
the sponsorship of the Chris-
tine Kühne - Center for Allergy 
Research and Education (CK-
CARE) for the 2nd Global Aller-
gy Forum from 16 to 19 June 
2013 in Davos, Switzerland. 
The participants representing 
major academies and socie-
ties formed working groups to 
discuss the actual most urgent 
problems. Role of environment, 
mechanisms of allergic inflam-
mation and protection, allergy 
prevention, allergy diagnosis 
and therapy as well as educa-
tion was particularly focused.
In a parallel action that brings 
together political bodies and 
scientists, representatives of 
the European Academy of Al-
lergy and Clinical Immunolo-
gy, the European Respiratory 
Society, the International Pri-
mary Care Respiratory Group, 
the Polish Allergy Society, the 
WHO Global Alliance against 
Chronic Respiratory Diseases, 
and the European Federation 
of Allergy and Airway Diseases 
Patients’ Associations were in-
vited by the Polish Minister of 
Health to convene and discuss 
how to prevent and control 
chronic respiratory diseases in 
children on Sept 20–21, 2011. 
These conclusions were adopt-
ed during an interministerial 
conference of the 27 EU Mem-
ber States,on Dec 2, 2011.
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Vision and roadmap to fight with allergies
The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organization active in the 
field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug 
allergy and anaphylaxis. Its scope covers both basic science and clinical medicine.
Since its establishment in 1956, EAACI has grown to become the largest medical association in Europe in the field 
of allergy and clinical immunology. Its membership currently includes nearly 7800 members from 121 countries, 
representing academicians, clinicians, and allied health professionals. In addition, EAACI includes 47 National 
Allergy Societies as members.
EAACI’s mission is to provide the most efficient platform for scientific communication and education in the field 
of allergy and immunology, ultimately striving to ease the lives of patients suffering from these diseases. EAACI 
is regarded as the primary source of expertise in Europe for all aspects of allergy. 
EAACI’s activities
• Fostering science through dedicated platforms Annual Congress, Focused Meetings, Guidelines and Position 
Papers
• Educating professionals (Allergy Schools; CME system; knowledge examination in allergy and clinical 
Immunology; Research and Clinical Fellowships)
• Disseminating knowledge through EAACI Journals (Allergy, Pediatric Allergy Immunology, Clinical and 
Translational Allergy, EAACI Newletter) and online communication platforms
• Advocating change and raising awareness among the European Union’s decision makers about the importance 
of allergy and clinical immunology and the opportunities to prevent and treat allergies through Public 
Campaigns and Public Declarations
Allergy today is a global public health concern of pandemic proportions and 
it requires immediate action. The European Academy of Allergy and Clinical 
Immunology called on all worldwide leaders to develop the “Global Atlas of 
Allergy”. 
The “Atlas” was written by an international group of 183 World leaders in 
allergy and asthma research and is aimed to highlight the burden of allergic 
diseases worldwide as of sufficient magnitude to warrant recognition 
as a priority in national health strategies; to describe mechanisms and 
risk factors and evaluate the best ways to prevent and control allergic 
diseases, to provide guidance on how to overcome barriers ahead such as 
poverty, poor education and infrastructure, low public health priority due 
to the importance of other illnesses and the lack of good worldwide valid 
epidemiologic data; to ensure that cost-effective management approaches, 
which have been proven to reduce morbidity and mortality are available to 
as many persons as possible with allergic diseases worldwide; to establish 
an action plan to manage resources for allergic diseases prevention and to 
prioritise funding for allergy research. 
A “Global Allergy Fight Strategy” should be developed, involving all 
stakeholders and targeting all aspects from optimal patient care and 
access to diagnosis and essential drug to innovative pathways for disease 
prevention  and future drug discovery.
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